<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>489</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">489</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Cost effectiveness analysis of evidence-based Finnish guidelines for antihypertensive interventions: A Markov model approach (Project record)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Costs and Cost Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Economic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><publisher><style face="normal" font="default" size="100%">Finnish Office for Health Care Technology Assessment (FinOHTA)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32002000895</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32002000895/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>490</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">490</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Eplerenone for the treatment of hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aldosterone Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Spironolactone [therapeutic use]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Coordinating Office for Health Technology Assessment (CCOHTA)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32003000844</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32003000844/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>491</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">491</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Management of moderately elevated blood pressure (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">HTA-32003001175</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32003001175/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>492</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">492</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Moderately elevated blood pressure (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><publisher><style face="normal" font="default" size="100%">Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32008100257</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32008100257/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>493</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">493</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Sildenafil citrate for adult pulmonary arterial hypertension - horizon scanning review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><publisher><style face="normal" font="default" size="100%">National Horizon Scanning Centre (NHSC)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32004000269</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32004000269/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>494</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">494</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Effectiveness of antihypertensive drugs in black people (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">12</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">African Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Ethnic Groups</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><publisher><style face="normal" font="default" size="100%">Centre for Reviews and Dissemination (CRD)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32004000834</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32004000834/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>495</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">495</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Moderately elevated blood pressure: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">HTA-32005000122</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32005000122/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>496</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">496</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Management of hypertension in adults in primary care (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">HTA-32004000779</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32004000779/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>497</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">497</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Lumbar subcutaneous shunt (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cerebrospinal Fluid Shunts</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrocephalus</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">HTA-32004000689</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32004000689/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>498</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">498</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Cost-effectiveness of different strategies for the treatment and monitoring of ocular hypertension and glaucoma (Project record)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Costs</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma [therapy] [economics]</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension [therapy] [economics] [drug effects]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">HTA-32005001072</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32005001072/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>499</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">499</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Diagnosis of renovascular hypertension - primary research (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Renovascular [diagnosis]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">Health Care Insurance Board / College voor Zorgverzekeringen (CVZ)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32005000525</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32005000525/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>500</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">500</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Aliskiren for hypertension: horizon scanning technology briefing (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">8</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">National Horizon Scanning Centre (NHSC)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32007000157</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32007000157/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>501</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">501</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Aliskiren (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">4</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Agency for Drugs and Technologies in Health (CADTH)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32007000068</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32007000068/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>502</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">502</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Hypertension: management of hypertension in adults in primary care (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">45</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [drug therapy] [therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">National Institute for Health and Clinical Excellence (NICE)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32006000737</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32006000737/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>503</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">503</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Sildenafil for pulmonary hypertension (Project record)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines [therapeutic use]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">HTA-32006001219</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32006001219/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>504</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">504</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Sildenafil for pulmonary hypertension after sclerodermy (Project record)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Scleroderma, Systemic [complications]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">HTA-32006001220</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32006001220/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>505</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">505</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Pulmonary thromboendarterectomy (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Endarterectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">Medical Services Advisory Committee (MSAC)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32008100129</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32008100129/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>506</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">506</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Ambrisentan (Volibris) for pulmonary arterial hypertension: horizon scanning technology briefing (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">8</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">National Horizon Scanning Centre (NHSC)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32007000482</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32007000482/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>507</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">507</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Moderately elevated blood pressure: a systematic review (update) (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Review Literature</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">Swedish Council on Technology Assessment in Health Care (SBU)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32007000261</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32007000261/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>508</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">508</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">derivatives</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [analogs &amp; derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">National Horizon Scanning Centre (NHSC)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000615</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000615/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>509</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">509</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Clevidipine (Cleviprex) for acute hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">National Horizon Scanning Centre (NHSC)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000527</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000527/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>510</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">510</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Aliskiren (Rasilez®) for the treatment of essential hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000412</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000412/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>511</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">511</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Ambrisentan (Volibris®) for pulmonary arterial hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylpropionates</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridazines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000413</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000413/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>512</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">512</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Intra-abdominal pressure monitoring with abviser (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Abdominal Cavity</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring, Physiologic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">Committee for New Health Technology Assessment (CNHTA)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010001304</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010001304/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>513</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">513</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Sildenafil (Revatio®) for the treatment of pulmonary arterial hypertension (WHO functional class II or III) to improve exercise capacity (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000385</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000385/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>514</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">514</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Use of diuretics for hypertension in patients with reduced renal function: a review of clinical effectiveness, safety, and guidelines (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diuretics</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Agency for Drugs and Technologies in Health (CADTH)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32011001154</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32011001154/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>515</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">515</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Sildenafil citrate (Revatio®) solution (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines</style></keyword><keyword><style face="normal" font="default" size="100%">Purines</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000368</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000368/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>516</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">516</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Valsartan (Diovan®) (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Valine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000364</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000364/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>517</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">517</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure monitoring chairs to identify hypertension: a review of the clinical effectiveness and guidelines (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Agency for Drugs and Technologies in Health (CADTH)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32011000935</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32011000935/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">1</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Twenty-four-hour ambulatory blood pressure monitoring in hypertension: an evidence-based analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring, Physiologic</style></keyword><keyword><style face="normal" font="default" size="100%">Office Visits</style></keyword><keyword><style face="normal" font="default" size="100%">White Coat Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">Health Quality Ontario</style></publisher><accession-num><style face="normal" font="default" size="100%">DARE-12012040120</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012040120/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>518</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">518</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Overview of the use of antihypertensive agents by adults covered by the Québec public prescription drug insurance plan (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Prescriptions</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Insurance, Health</style></keyword><keyword><style face="normal" font="default" size="100%">Quebec</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">L&apos;Institut national d&apos;excellence en sante et en services sociaux (INESSS)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000848</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000848/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>519</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">519</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Twenty-four-hour ambulatory blood pressure monitoring in hypertension: an evidence-based analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care (MAS)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000638</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000638/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>520</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">520</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Ramipril 2.5 mg/5 ml oral solution (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Ramipril</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000874</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000874/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>521</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">521</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Sildenafil (Revatio) 10mg/ml powder for oral suspension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines</style></keyword><keyword><style face="normal" font="default" size="100%">Purines</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000330</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000330/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">2</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><pages><style face="normal" font="default" size="100%">f5680</style></pages><volume><style face="normal" font="default" size="100%">347</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [etiology] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerular Filtration Rate [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Insufficiency, Chronic [complications] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013057159</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013057159/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>522</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">522</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Health-Related Quality of Life in two treatment pathways for primary open angle glaucoma and ocular hypertension: a randomised controlled trial of initial selective laser trabeculoplasty versus conventional medical therapy (Project record)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma, Open-Angle</style></keyword><keyword><style face="normal" font="default" size="100%">Laser Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Trabeculectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">Health Technology Assessment</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013001051</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013001051/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>523</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">523</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">European study of therapeutic hypothermia (32-35°C) for intracranial pressure reduction after traumatic brain injury (Eurotherm3235) (Project record)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Brain Injuries</style></keyword><keyword><style face="normal" font="default" size="100%">Hypothermia, Induced</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">Health Technology Assessment</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013001063</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013001063/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">3</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abela, R.</style></author><author><style face="normal" font="default" size="100%">Ivanova, S.</style></author><author><style face="normal" font="default" size="100%">Lidder, S.</style></author><author><style face="normal" font="default" size="100%">Morris, R.</style></author><author><style face="normal" font="default" size="100%">Hamilton, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">An analysis comparing open surgical and endovascular treatment of atherosclerotic renal artery stenosis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Vascular and Endovascular Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Vascular and Endovascular Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">666-675</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Angioplasty [adverse effects] [instrumentation] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis [complications] [mortality] [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Vessel Prosthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Vessel Prosthesis Implantation [adverse effects] [instrumentation] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Renovascular [etiology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Selection</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction [etiology] [mortality] [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Patency</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000457</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000457/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1078588409004110/1-s2.0-S1078588409004110-main.pdf?_tid=978f9052-1aea-11e5-ac37-00000aacb35f&amp;acdnat=1435203237_4941b35406736ecdf43722830f49e968</style></url></related-urls><pdf-urls><url>internal-pdf://2409000436/Abela-2009-An analysis comparing open surgical.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">4</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">AbuDagga, A.</style></author><author><style face="normal" font="default" size="100%">Resnick, H. E.</style></author><author><style face="normal" font="default" size="100%">Alwan, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Impact of blood pressure telemonitoring on hypertension outcomes: a literature review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Telemedicine and e-Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Telemedicine and e-Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">830-838</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitors</style></keyword><keyword><style face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style face="normal" font="default" size="100%">Diastole</style></keyword><keyword><style face="normal" font="default" size="100%">District of Columbia</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Systole</style></keyword><keyword><style face="normal" font="default" size="100%">Telemedicine [methods] [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013039831</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013039831/frame.html</style></url><url><style face="normal" font="default" size="100%">http://online.liebertpub.com/doi/pdfplus/10.1089/tmj.2010.0015</style></url></related-urls><pdf-urls><url>internal-pdf://0775321087/AbuDagga-2010-Impact of blood pressure telemon.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">5</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abuissa, H.</style></author><author><style face="normal" font="default" size="100%">Jones, P. G.</style></author><author><style face="normal" font="default" size="100%">Marso, S. P.</style></author><author><style face="normal" font="default" size="100%">O&apos;Keefe, J. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">821-826</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age of Onset</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Insulin Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005001337</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005001337/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0735109705012714/1-s2.0-S0735109705012714-main.pdf?_tid=9a9bb078-1aea-11e5-bbb7-00000aacb35d&amp;acdnat=1435203242_dc95f204047572c14647c0dff7332c60</style></url></related-urls><pdf-urls><url>internal-pdf://3099426549/Abuissa-2005-Angiotensin-converting enzyme inh.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">6</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aburto, N. J.</style></author><author><style face="normal" font="default" size="100%">Hanson, S.</style></author><author><style face="normal" font="default" size="100%">Gutierrez, H.</style></author><author><style face="normal" font="default" size="100%">Hooper, L.</style></author><author><style face="normal" font="default" size="100%">Elliott, P.</style></author><author><style face="normal" font="default" size="100%">Cappuccio, F. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><volume><style face="normal" font="default" size="100%">346:f1378</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Catecholamines [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Disease [metabolism] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [metabolism] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid Metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium, Dietary [administration &amp; dosage] [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [metabolism] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013018173</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013018173/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>7</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">7</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aburto, N. J.</style></author><author><style face="normal" font="default" size="100%">Ziolkovska, A.</style></author><author><style face="normal" font="default" size="100%">Hooper, L.</style></author><author><style face="normal" font="default" size="100%">Elliott, P.</style></author><author><style face="normal" font="default" size="100%">Cappuccio, F. P.</style></author><author><style face="normal" font="default" size="100%">Meerpohl, J. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of lower sodium intake on health: systematic review and meta-analyses (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><volume><style face="normal" font="default" size="100%">346:f1326</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [diet therapy] [metabolism] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Catecholamines [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy] [metabolism] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid Metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Public Health</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013018993</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013018993/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>524</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">524</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adler Alma, J.</style></author><author><style face="normal" font="default" size="100%">Taylor, Fiona</style></author><author><style face="normal" font="default" size="100%">Martin, Nicole</style></author><author><style face="normal" font="default" size="100%">Gottlieb, Sheldon</style></author><author><style face="normal" font="default" size="100%">Taylor Rod, S.</style></author><author><style face="normal" font="default" size="100%">Ebrahim, Shah</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reduced dietary salt for the prevention of cardiovascular disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009217</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: This is an update of a Cochrane review that was first published in 2011 of the effects of reducing dietary salt intake, through advice to reduce salt intake or low-sodium salt substitution, on mortality and cardiovascular events.Objectives: 1. To assess the long-term effects of advice and salt substitution, aimed at reducing dietary salt, on mortality and cardiovascular morbidity.2. To investigate whether a reduction in blood pressure is an explanatory factor in the effect of such dietary interventions on mortality and cardiovascular outcomes.Search methods: We updated the searches of CENTRAL (2013, Issue 4), MEDLINE (OVID, 1946 to April week 3 2013), EMBASE (OVID, 1947 to 30 April 2013) and CINAHL (EBSCO, inception to 1 April 2013) and last ran these on 1 May 2013. We also checked the references of included studies and reviews. We applied no language restrictions.Selection criteria: Trials fulfilled the following criteria: (1) randomised, with follow-up of at least six months, (2) the intervention was reduced dietary salt (through advice to reduce salt intake or low-sodium salt substitution), (3) participants were adults and (4) mortality or cardiovascular morbidity data were available. Two review authors independently assessed whether studies met these criteria.Data collection and analysis: A single author extracted data and assessed study validity, and a second author checked this. We contacted trial authors where possible to obtain missing information. We extracted events and calculated risk ratios (RRs) and 95% confidence intervals (CIs).Main results: Eight studies met the inclusion criteria: three in normotensives (n = 3518) and five in hypertensives or mixed populations of normo- and hypertensives (n = 3766). End of trial follow-up ranged from six to 36 months and the longest observational follow-up (after trial end) was 12.7 years.The risk ratios (RR) for all-cause mortality in normotensives were imprecise and showed no evidence of reduction (end of trial RR 0.67, 95% confidence interval (CI) 0.40 to 1.12, 60 deaths; longest follow-up RR 0.90, 95% CI 0.58 to 1.40, 79 deaths n=3518) or in hypertensives (end of trial RR 1.00, 95% CI 0.86 to 1.15, 565 deaths; longest follow-up RR 0.99, 95% CI 0.87 to 1.14, 674 deaths n=3085). There was weak evidence of benefit for cardiovascular mortality (hypertensives: end of trial RR 0.67, 95% CI 0.45 to 1.01, 106 events n=2656) and for cardiovascular events (hypertensives: end of trial RR 0.76, 95% CI 0.57 to 1.01, 194 events, four studies, n = 3397; normotensives: at longest follow-up RR 0.71, 95% CI 0.42 to 1.20, 200 events; hypertensives: RR 0.77, 95% CI 0.57 to 1.02, 192 events; pooled analysis of six trials RR 0.77, 95% CI 0.63 to 0.95, n = 5912). These findings were driven by one trial among retirement home residents that reduced salt intake in the kitchens of the homes, thereby not requiring individual behaviour change.Advice to reduce salt showed small reductions in systolic blood pressure (mean difference (MD) -1.15 mmHg, 95% CI -2.32 to 0.02 n=2079) and diastolic blood pressure (MD -0.80 mmHg, 95% CI -1.37 to -0.23 n=2079) in normotensives and greater reductions in systolic blood pressure in hypertensives (MD -4.14 mmHg, 95% CI -5.84 to -2.43 n=675), but no difference in diastolic blood pressure (MD -3.74 mmHg, 95% CI -8.41 to 0.93 n=675).Overall many of the trials failed to report sufficient detail to assess their potential risk of bias. Health-related quality of life was assessed in one trial in normotensives, which reported significant improvements in well-being but no data were presented.Authors&apos; conclusions: Despite collating more event data than previous systematic reviews of randomised controlled trials, there is insufficient power to confirm clinically important effects of dietary advice and salt substitution on cardiovascular mortality in normotensive or hypertensive populations. Our estimates of the clinical benefits from advice to reduce dietary salt are imprecise, but are larger than would be predicted from the small blood pressure reductio s achieved. Further well-powered studies would be needed to obtain more precise estimates. Our findings do not support individual dietary advice as a means of restricting salt intake. It is possible that alternative strategies that do not require individual behaviour change may be effective and merit further trials.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009217.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009217.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">8</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agarwal, R.</style></author><author><style face="normal" font="default" size="100%">Bills, J. E.</style></author><author><style face="normal" font="default" size="100%">Hecht, T. J.</style></author><author><style face="normal" font="default" size="100%">Light, R. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">29-38</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011000718</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011000718/frame.html</style></url><url><style face="normal" font="default" size="100%">http://hyper.ahajournals.org/content/57/1/29.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0111785436/Agarwal-2011-Role of home blood pressure monit.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">9</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agarwal, R.</style></author><author><style face="normal" font="default" size="100%">Sinha, A. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">860-866</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Dialysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009105366</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009105366/frame.html</style></url><url><style face="normal" font="default" size="100%">http://hyper.ahajournals.org/content/53/5/860.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0413194954/Agarwal-2009-Cardiovascular protection with an.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>10</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">10</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agarwal, R.</style></author><author><style face="normal" font="default" size="100%">Weir, M. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1692-1701</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amlodipine [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Complications [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Imidazoles [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Multivariate Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013029026</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013029026/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">11</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agarwal, V.</style></author><author><style face="normal" font="default" size="100%">Hans, N.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of allopurinol on blood pressure: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">435-442</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Allopurinol [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Gout Suppressants [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013030981</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013030981/frame.html</style></url><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/j.1751-7176.2012.00701.x/asset/jch701.pdf?v=1&amp;t=ibbmutb6&amp;s=ae5241dfbe117ba00a98323b17e2b1caf8ad33a4</style></url></related-urls><pdf-urls><url>internal-pdf://2794441895/Agarwal-2013-Effect of allopurinol on blood pr.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>525</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">525</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aguado, M. J.</style></author><author><style face="normal" font="default" size="100%">Llanos Mendez, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Immunisation against angiotensin II. A therapeutic vaccine against arterial hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">Andalusian Agency for Health Technology Assessment (AETSA)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32011000628</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32011000628/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>12</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">12</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aguiar, P. M.</style></author><author><style face="normal" font="default" size="100%">Balisa-Rocha, B. J.</style></author><author><style face="normal" font="default" size="100%">Brito, G. C.</style></author><author><style face="normal" font="default" size="100%">Silva, W. B.</style></author><author><style face="normal" font="default" size="100%">Machado, M.</style></author><author><style face="normal" font="default" size="100%">Lyra, D. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmaceutical care in hypertensive patients: a systematic literature review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Research In Social and Administrative Pharmacy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Research In Social and Administrative Pharmacy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">383-396</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceutical Services</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013008032</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013008032/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S1551741111001082/1-s2.0-S1551741111001082-main.pdf?_tid=a69cf396-1aea-11e5-b842-00000aacb35f&amp;acdnat=1435203262_d6415e03a6efe66ea7b005b599a25779</style></url></related-urls><pdf-urls><url>internal-pdf://0961859366/Aguiar-2012-Pharmaceutical care in hypertensiv.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">13</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aguilar-Olivos, N.</style></author><author><style face="normal" font="default" size="100%">Motola-Kuba, M.</style></author><author><style face="normal" font="default" size="100%">Candia, R.</style></author><author><style face="normal" font="default" size="100%">Arrese, M.</style></author><author><style face="normal" font="default" size="100%">Mendez-Sanchez, N.</style></author><author><style face="normal" font="default" size="100%">Uribe, M.</style></author><author><style face="normal" font="default" size="100%">Chavez-Tapia, N. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">420-428</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic alpha-Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Arrhythmia Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Carbazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatic Veins</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">Propranolol</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014039379</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014039379/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>14</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">14</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ahan, A.</style></author><author><style face="normal" font="default" size="100%">Zhang, R. X.</style></author><author><style face="normal" font="default" size="100%">Zhang, J. H.</style></author><author><style face="normal" font="default" size="100%">Zhao, J. M.</style></author><author><style face="normal" font="default" size="100%">Cao, J.</style></author><author><style face="normal" font="default" size="100%">Tai, Q. W.</style></author><author><style face="normal" font="default" size="100%">Ji, X. W.</style></author><author><style face="normal" font="default" size="100%">Wen, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Subtotal splenectomy versus total splenectomy for hepatic cirrhosis and portal hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">690-694</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Portal</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">Splenectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009107248</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009107248/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>526</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">526</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Al Hajeri, Amani</style></author><author><style face="normal" font="default" size="100%">Serjeant Graham, R.</style></author><author><style face="normal" font="default" size="100%">Fedorowicz, Zbys</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Inhaled nitric oxide for acute chest syndrome in people with sickle cell disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Anemia, Sickle Cell [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchodilator Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Respiration Disorders [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Cf</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006957</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Acute chest syndrome has been defined as a new infiltrate visible on chest radiograph associated with one or more symptoms, such as fever, cough, sputum production, tachypnoea, dyspnoea, or new-onset hypoxia. Symptoms and complications of this syndrome, whether of infectious or non-infectious origin, vary quite widely in people with sickle cell disease. Lung infection tends to predominate in children, whilst infarction appears more common in adults. However, these are often interrelated and may occur concurrently. The differences in clinical course and severity are suggestive of multiple causes for acute chest syndrome. Successful treatment depends principally on high-quality supportive care. The syndrome and its treatment have been extensively studied, but the response to antibiotics, anticoagulants, and other conventional therapies remains disappointing. The potential of inhaled nitric oxide as a treatment option has more recently provoked considerable interest. Nitric oxide appears to play a major role in both the regulation of vascular muscle tone at the cellular level and in platelet aggregation (clumping). Much of the pathophysiology of sickle cell disease is consistent with a mechanism of nitric oxide depletion and although there has been extensive research on the pathophysiology of acute chest syndrome, the possible therapeutic role of inhaled nitric oxide for acute chest syndrome in sickle cell disease is still to be determined.Objectives: To assess the effectiveness of inhaled nitric oxide for treating acute chest syndrome by comparing improvement in symptoms and clinical outcomes against standard care.Search methods: We searched The Group&apos;s Haemoglobinopathies Trials Register, which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. In July 2007 the following clinical trials registers were searched: ClinicalTrials.gov; the WHO International Clinical Trials Registry Platform; Current Controlled Trials; and Clinicaltrials.com.Most recent search of the Haemoglobinopathies Trials Register: 10 September 2010.Selection criteria: All randomised or quasi-randomised controlled trials of people with sickle cell disease suffering from acute chest syndrome, comparing the use of inhaled nitric oxide to placebo or standard care for any single or multiple treatment and over any time period.Data collection and analysis: No studies identified were eligible for inclusion.Main results: No studies identified were eligible for inclusion.Authors&apos; conclusions: There is a need for well-designed, adequately-powered randomised controlled trial to assess the benefits and risks of this form of treatment as an adjunct to established therapies.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006957/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006957</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">15</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alajmi, M.</style></author><author><style face="normal" font="default" size="100%">Mulgrew, A. T.</style></author><author><style face="normal" font="default" size="100%">Fox, J.</style></author><author><style face="normal" font="default" size="100%">Davidson, W.</style></author><author><style face="normal" font="default" size="100%">Schulzer, M.</style></author><author><style face="normal" font="default" size="100%">Mak, E.</style></author><author><style face="normal" font="default" size="100%">Ryan, C. F.</style></author><author><style face="normal" font="default" size="100%">Fleetham, J.</style></author><author><style face="normal" font="default" size="100%">Choi, P.</style></author><author><style face="normal" font="default" size="100%">Ayas, N. T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Lung</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lung</style></full-title></periodical><pages><style face="normal" font="default" size="100%">67-72</style></pages><volume><style face="normal" font="default" size="100%">185</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Continuous Positive Airway Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep Apnea, Obstructive [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007001365</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007001365/frame.html</style></url><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/768/art%253A10.1007%252Fs00408-006-0117-x.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00408-006-0117-x&amp;token2=exp=1435204285~acl=%2Fstatic%2Fpdf%2F768%2Fart%25253A10.1007%25252Fs00408-006-0117-x.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00408-006-0117-x*~hmac=dc10a468cce6522e9c73daa4d42f247abcf8ba12a054b578eeac4f94608f9672</style></url></related-urls><pdf-urls><url>internal-pdf://1049681413/Alajmi-2007-Impact of continuous positive airw.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">16</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Albillos, A.</style></author><author><style face="normal" font="default" size="100%">Banares, R.</style></author><author><style face="normal" font="default" size="100%">Gonzalez, M.</style></author><author><style face="normal" font="default" size="100%">Ripoll, C.</style></author><author><style face="normal" font="default" size="100%">Gonzalez, R.</style></author><author><style face="normal" font="default" size="100%">Catalina, M. V.</style></author><author><style face="normal" font="default" size="100%">Molinero, L. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1116-1126</style></pages><volume><style face="normal" font="default" size="100%">102</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Esophageal and Gastric Varices [etiology] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Hemorrhage [etiology] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatic Veins [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Portal Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Venous Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007001807</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007001807/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>527</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">527</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alhasso, Ammar</style></author><author><style face="normal" font="default" size="100%">Glazener Cathryn, M. A.</style></author><author><style face="normal" font="default" size="100%">Pickard, Robert</style></author><author><style face="normal" font="default" size="100%">N&apos;Dow James, M. O.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Adrenergic drugs for urinary incontinence in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic Agonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Clenbuterol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Midodrine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylpropanolamine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Incontinence [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Incontinence, Stress [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Incont</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD001842</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Adrenergic drugs have been used for the treatment of urinary incontinence. However, they have generally been considered to be ineffective or to have side effects which may limit their clinical use.Objectives: To determine the effectiveness of adrenergic agonists in the treatment of urinary incontinence in adults.Search methods: We searched the Cochrane Incontinence Group Specialised Trials Register (searched 15 September 2010) and the reference lists of relevant articles.Selection criteria: Randomised or quasi-randomised controlled trials in adults with urinary incontinence which included an adrenergic agonist drug in at least one arm of the trial.Data collection and analysis: Two reviewers independently assessed eligibility, trial quality and extracted data. Data were processed as described in the Cochrane Handbook for Systematic Reviews of Interventions.Main results: Twenty-two eligible randomised trials were identified, of which 11 were crossover trials. The trials included 1099 women with 673 receiving an adrenergic drug (phenylpropanolamine in 11 trials, midodrine in two, norepinephrine in three, clenbuterol in another three, terbutaline in one, eskornade in one and Ro 115-1240 in one). No trials included men.The limited evidence suggested that an adrenergic agonist drug is better than placebo in reducing the number of pad changes and incontinence episodes, as well as improving subjective symptoms. In two small trials, the drugs also appeared to be better than pelvic floor muscle training, possibly reflecting relative acceptability of the treatments to women but perhaps due to differential withdrawal of women from the trial groups. There was not enough evidence to evaluate the use of higher compared to lower doses of adrenergic agonists nor the relative merits of an adrenergic agonist drug compared with oestrogen, whether used alone or in combination.Over a quarter of women reported adverse effects. There were similar numbers of adverse effects with adrenergics, placebo or alternative drug treatment. However, when these were due to recognised adrenergic stimulation (insomnia, restlessness and vasomotor stimulation) they were only severe enough to stop treatment in 4% of women.Authors&apos; conclusions: There was weak evidence to suggest that use of an adrenergic agonist was better than placebo treatment. There was not enough evidence to assess the effects of adrenergic agonists when compared to or combined with other treatments. Further larger trials are needed to identify when adrenergics may be useful. Patients using adrenergic agonists may suffer from minor side effects, which sometimes cause them to stop treatment. Rare but serious side effects, such as cardiac arrhythmias and hypertension, have been reported.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001842.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001842.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>528</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">528</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Allison, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">BpTRU (TM) blood pressure monitor for use in a physician&apos;s office (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">4</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitors</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Physicians&apos; Offices</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Agency for Drugs and Technologies in Health (CADTH)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32006000883</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32006000883/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>17</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">17</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Al-Mallah, M.</style></author><author><style face="normal" font="default" size="100%">Khawaja, O.</style></author><author><style face="normal" font="default" size="100%">Sinno, M.</style></author><author><style face="normal" font="default" size="100%">Alzohaili, O.</style></author><author><style face="normal" font="default" size="100%">Abou Samra, B. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Cardiology Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cardiology Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">448-456</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolic Syndrome X [drug therapy] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010007568</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010007568/frame.html</style></url></related-urls><pdf-urls><url>internal-pdf://1662580886/Al-Mallah-2010-Do angiotensin converting enzym.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">18</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alviar, C. L.</style></author><author><style face="normal" font="default" size="100%">Devarapally, S.</style></author><author><style face="normal" font="default" size="100%">Nadkarni, G. N.</style></author><author><style face="normal" font="default" size="100%">Romero, J.</style></author><author><style face="normal" font="default" size="100%">Benjo, A. M.</style></author><author><style face="normal" font="default" size="100%">Javed, F.</style></author><author><style face="normal" font="default" size="100%">Doherty, B.</style></author><author><style face="normal" font="default" size="100%">Kang, H.</style></author><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of dual calcium channel blockade for the treatment of hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">287-297</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Dihydropyridines [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013027242</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013027242/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ajh.oxfordjournals.org/content/26/2/287.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2856923677/Alviar-2013-Efficacy and safety of dual calciu.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>19</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">19</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ambrosioni, E.</style></author><author><style face="normal" font="default" size="100%">Borghi, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective beta-blockers in the treatment of hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">High Blood Pressure and Cardiovascular Prevention</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">High Blood Pressure and Cardiovascular Prevention</style></full-title></periodical><pages><style face="normal" font="default" size="100%">27-35</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Atenolol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzopyrans [therapeutic use] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Bisoprolol [therapeutic use] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Ethanolamines [therapeutic use] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Metoprolol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005000924</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005000924/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>20</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">20</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">An, M. M.</style></author><author><style face="normal" font="default" size="100%">Zou, Z.</style></author><author><style face="normal" font="default" size="100%">Shen, H.</style></author><author><style face="normal" font="default" size="100%">Liu, P.</style></author><author><style face="normal" font="default" size="100%">Chen, M. L.</style></author><author><style face="normal" font="default" size="100%">Cao, Y. B.</style></author><author><style face="normal" font="default" size="100%">Jiang, Y. Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">813-821</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Autonomic Nervous System Diseases [chemically induced] [drug therapy] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Breast Neoplasms [chemically induced] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Carcinoma, Renal Cell [chemically induced] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [chemically induced] [drug therapy] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced] [epidemiology] [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-Analysis as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [chemically induced] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010006102</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010006102/frame.html</style></url><url><style face="normal" font="default" size="100%">http://download.springer.com/static/pdf/722/art%253A10.1007%252Fs00228-010-0815-4.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00228-010-0815-4&amp;token2=exp=1435204292~acl=%2Fstatic%2Fpdf%2F722%2Fart%25253A10.1007%25252Fs00228-010-0815-4.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs00228-010-0815-4*~hmac=abade6bff09f3c13a2ae04898b909642c9c64121cb314ba889a6c906a9b9fbd5</style></url></related-urls><pdf-urls><url>internal-pdf://1655436963/An-2010-Incidence and risk of significantly ra.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>21</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">21</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anderson, J. W.</style></author><author><style face="normal" font="default" size="100%">Liu, C.</style></author><author><style face="normal" font="default" size="100%">Kryscio, R. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure response to transcendental meditation: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">310-316</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [psychology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Meditation</style></keyword><keyword><style face="normal" font="default" size="100%">Quality Assurance, Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008104528</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008104528/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ajh.oxfordjournals.org/content/21/3/310.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://3028443916/Anderson-2008-Blood pressure response to trans.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>529</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">529</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andersson, B.</style></author><author><style face="normal" font="default" size="100%">Herlitz, H.</style></author><author><style face="normal" font="default" size="100%">Manhem, K.</style></author><author><style face="normal" font="default" size="100%">Zachrisson, K.</style></author><author><style face="normal" font="default" size="100%">Völz, S.</style></author><author><style face="normal" font="default" size="100%">Daxberg, E. L.</style></author><author><style face="normal" font="default" size="100%">Holmberg, Y.</style></author><author><style face="normal" font="default" size="100%">Samuelsson, O.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal sympathetic denervation in patients with therapy resistant hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Denervation</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">The Regional Health Technology Assessment Centre (HTA-centrum), Region Vastra Gotaland</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000119</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000119/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>22</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">22</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andraws, R.</style></author><author><style face="normal" font="default" size="100%">Brown, D. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials) (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1006-1012</style></pages><volume><style face="normal" font="default" size="100%">99</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007001188</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007001188/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0002914906025082/1-s2.0-S0002914906025082-main.pdf?_tid=b08a05ce-1aea-11e5-a747-00000aab0f6b&amp;acdnat=1435203279_5efeb8a2b42bb4042512cfbcdf34d2dd</style></url></related-urls><pdf-urls><url>internal-pdf://3910012706/Andraws-2007-Effect of inhibition of the renin.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>23</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">23</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ara, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A literature review of cardiovascular disease management programs in managed care populations (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Managed Care Pharmacy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Managed Care Pharmacy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">326-344</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperlipidemias [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Managed Care Programs [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005004802</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005004802/frame.html</style></url></related-urls><pdf-urls><url>internal-pdf://1250632682/Ara-2004-A literature review of cardiovascular.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>530</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">530</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arguedas Jose, Agustin</style></author><author><style face="normal" font="default" size="100%">Leiva, Viriam</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure targets for hypertension in patients with chronic renal disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008564</style></accession-num><abstract><style face="normal" font="default" size="100%">: This is the protocol for a review and there is no abstract. The objectives are as follows:Primary objective: To determine if there is a reduction in total mortality and morbidity associated with treatment of blood pressure to &quot;lower targets&quot; as compared with &quot;standard targets&quot; in the management of patients with chronic renal disease and elevated arterial blood pressure.  &quot;Lower targets&quot; are defined as blood pressure targets less than or equal to 130/80 mmHg.  &quot;Standard targets&quot; are defined as blood pressure targets less than or equal to 140-160 mmHg systolic and/or blood pressure targets less than or equal to 90-100 mmHg diastolic. Secondary objectives: To determine if there is a change in mean achieved systolic and diastolic blood pressure associated with &quot;lower targets&quot; as compared with &quot;standard targets&quot; in patients with chronic renal disease with elevated blood pressure.   To determine if there is a change in withdrawals due to adverse events with &quot;lower targets&quot; as compared with &quot;standard targets&quot;, in patients with chronic renal disease with elevated blood pressure. To determine if there is a change in mean decline in glomerular filtration rate with &quot;lower targets&quot; as compared with &quot;standard targets&quot;, in patients with chronic renal disease with elevated blood pressure.  </style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008564/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008564</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>531</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">531</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arguedas Jose, Agustin</style></author><author><style face="normal" font="default" size="100%">Leiva, Viriam</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure targets for hypertension in people with diabetes mellitus</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Angiopathies [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Diastole</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Values</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Systole</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008277</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: When treating elevated blood pressure (BP), doctors often want to know what blood pressure target they should try to achieve. The standard blood pressure target in clinical practice for some time has been less than 140 - 160/90 - 100 mmHg for the general population of people with elevated blood pressure. Several clinical guidelines published in recent years have recommended lower targets (less than 130/80 mmHg) for people with diabetes mellitus. It is not known whether attempting to achieve targets lower than the standard target reduces mortality and morbidity in those with elevated blood pressure and diabetes.Objectives: To determine if &apos;lower&apos; BP targets (any target less than 130/85 mmHg) are associated with reduction in mortality and morbidity compared with &apos;standard&apos; BP targets (less than 140 - 160/90 - 100 mmHg) in people with diabetes.Search methods: We searched the Database of Abstracts of Reviews of Effectiveness (DARE) and the Cochrane Database of Systematic Reviews for related reviews. We conducted electronic searches of the Hypertension Group Specialised Register (January 1946 - October 2013), the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 9), MEDLINE (January 1946 - October 2013), EMBASE (January 1974 - October 2013) and ClinicalTrials.gov. The most recent search was performed on October 4, 2013.Other search sources were the International Clinical Trials Registry Platform (WHO ICTRP), and reference lists of all papers and relevant reviews.Selection criteria: Randomized controlled trials comparing people with diabetes randomized to lower or to standard BP targets as previously defined, and providing data on any of the primary outcomes below.Data collection and analysis: Two review authors independently assessed and established the included trials and data entry. Primary outcomes were total mortality; total serious adverse events; myocardial infarction, stroke, congestive heart failure and end-stage renal disease. Secondary outcomes were achieved mean systolic and diastolic BP, and withdrawals due to adverse effects.Main results: We found five randomized trials, recruiting a total of 7314 participants and with a mean follow-up of 4.5 years. Only one trial (ACCORD) compared outcomes associated with &apos;lower&apos; (&lt; 120 mmHg) or &apos;standard&apos; (&lt; 140 mmHg) systolic blood pressure targets in 4734 participants. Despite achieving a significantly lower BP (119.3/64.4 mmHg vs 133.5/70.5 mmHg, P &lt; 0.0001), and using more antihypertensive medications, the only significant benefit in the group assigned to &apos;lower&apos; systolic blood pressure (SBP) was a reduction in the incidence of stroke: risk ratio (RR) 0.58, 95% confidence interval (CI) 0.39 to 0.88, P = 0.009, absolute risk reduction 1.1%. The effect of SBP targets on mortality was compatible with both a reduction and increase in risk: RR 1.05 CI 0.84 to 1.30, low quality evidence. Trying to achieve the &apos;lower&apos; SBP target was associated with a significant increase in the number of other serious adverse events: RR 2.58, 95% CI 1.70 to 3.91, P &lt; 0.00001, absolute risk increase 2.0%.Four trials (ABCD-H, ABCD-N, ABCD-2V, and a subgroup of HOT) specifically compared clinical outcomes associated with &apos;lower&apos; versus &apos;standard&apos; targets for diastolic blood pressure (DBP) in people with diabetes. The total number of participants included in the DBP target analysis was 2580. Participants assigned to &apos;lower&apos; DBP had a significantly lower achieved BP: 128/76 mmHg vs 135/83 mmHg, P &lt; 0.0001. There was a trend towards reduction in total mortality in the group assigned to the &apos;lower&apos; DBP target (RR 0.73, 95% CI 0.53 to 1.01), mainly due to a trend to lower non-cardiovascular mortality. There was no difference in stroke (RR 0.67, 95% CI 0.42 to 1.05), in myocardial infarction (RR 0.95, 95% CI 0.64 to 1.40) or in congestive heart failure (RR 1.06, 95% CI 0.58 to 1.92), low quality evidence. End-stage renal failure and total serious adverse events were not reported in any of the trials. A sensitivity analysis of trials comparing DBP targets &lt; 80 mmHg (as suggested in clinical guidelines) versus &lt; 90 mmHg showed similar results. There was a high risk of selection bias for every outcome analyzed in favor of the &apos;lower&apos; target in the trials included for the analysis of DBP targets.Authors&apos; conclusions: At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes. More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008277.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008277.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>532</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">532</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arguedas Jose, Agustin</style></author><author><style face="normal" font="default" size="100%">Perez Marco, I.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment blood pressure targets for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Diastole [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Standards</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004349</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: When treating elevated blood pressure, doctors need to know what blood pressure (BP) target they should try to achieve. The standard of clinical practice for some time has been ? 140 - 160/ 90 - 100 mmHg. New guidelines are recommending BP targets lower than this standard. It is not known whether attempting to achieve targets lower than the standard reduces mortality and morbidity.Objectives: To determine if lower BP targets (? 135/85 mmHg) are associated with reduction in mortality and morbidity as compared with standard BP targets (? 140-160/ 90-100 mmHg).Search methods: Electronic search of MEDLINE (1966-2008), EMBASE (1980-2008), and CENTRAL (up to June 2008); references from review articles, clinical guidelines, and clinical trials.Selection criteria: Randomized controlled trials comparing patients randomized to lower or to standard BP targets and providing data on any of the primary outcomes below.Data collection and analysis: Two reviewers (JAA, MIP) independently assessed the included trials and data entry. Primary outcomes were total mortality; total serious adverse events; total cardiovascular events; myocardial infarction, stroke, congestive heart failure and end stage renal disease. Secondary outcomes were achieved mean systolic and diastolic BP and withdrawals due to adverse effects.Main results: No trials comparing different systolic BP targets were found. Seven trials (22,089 subjects) comparing different diastolic BP targets were included. Despite a -4/-3 mmHg greater achieved reduction in systolic/diastolic BP, p&lt; 0.001, attempting to achieve &quot;lower targets&quot; instead of &quot;standard targets&quot; did not change total mortality (RR 0.92, 95% CI 0.86-1.15), myocardial infarction (RR 0.90, 95% CI 0.74-1.09), stroke (RR 0.99, 95% CI 0.79-1.25) , congestive heart failure (RR 0.88, 95% CI 0.59-1.32), major cardiovascular events (RR 0.94, 95% CI 0.83-1.07), or end-stage renal disease (RR 1.01, 95% CI 0.81-1.27). The net health effect of lower targets cannot be fully assessed due to lack of information regarding all total serious adverse events and withdrawals due to adverse effects in 6 of 7 trials. A sensitivity analysis in diabetic patients and in patients with chronic renal disease also did not show a reduction in any of the mortality and morbidity outcomes with lower targets as compared to standard targets.Authors&apos; conclusions: Treating patients to lower than standard BP targets, ?140-160/90-100 mmHg, does not reduce mortality or morbidity. Because guidelines are recommending even lower targets for diabetes mellitus and chronic renal disease, we are currently conducting systematic reviews in those groups of patients.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004349.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004349.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>533</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">533</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Atienza Merino, G.</style></author><author><style face="normal" font="default" size="100%">Maceira Rozas, M. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal sympathetic denervation as treatment of resistant hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney</style></keyword><keyword><style face="normal" font="default" size="100%">Sympathectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Galician Agency for Health Technology Assessment (AVALIA-T)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000089</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000089/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>24</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">24</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aucott, L.</style></author><author><style face="normal" font="default" size="100%">Poobalan, A.</style></author><author><style face="normal" font="default" size="100%">Smith, W. C.</style></author><author><style face="normal" font="default" size="100%">Avenell, A.</style></author><author><style face="normal" font="default" size="100%">Jung, R.</style></author><author><style face="normal" font="default" size="100%">Broom, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1035-1041</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension [etiology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity [complications] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005000408</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005000408/frame.html</style></url><url><style face="normal" font="default" size="100%">http://hyper.ahajournals.org/content/45/6/1035.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1743669885/Aucott-2005-Effects of weight loss in overweig.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">25</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aucott, L.</style></author><author><style face="normal" font="default" size="100%">Rothnie, H.</style></author><author><style face="normal" font="default" size="100%">McIntyre, L.</style></author><author><style face="normal" font="default" size="100%">Thapa, M.</style></author><author><style face="normal" font="default" size="100%">Waweru, C.</style></author><author><style face="normal" font="default" size="100%">Gray, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-term weight loss from lifestyle intervention benefits blood pressure: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">756-62</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009109434</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009109434/frame.html</style></url><url><style face="normal" font="default" size="100%">http://hyper.ahajournals.org/content/54/4/756.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2200402421/Aucott-2009-Long-term weight loss from lifesty.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>534</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">534</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Augustovski, F.</style></author><author><style face="normal" font="default" size="100%">Pichon Riviere, A.</style></author><author><style face="normal" font="default" size="100%">Alcaraz, A.</style></author><author><style face="normal" font="default" size="100%">Bardach, A.</style></author><author><style face="normal" font="default" size="100%">Ferrante, D.</style></author><author><style face="normal" font="default" size="100%">Garcia Marti, S.</style></author><author><style face="normal" font="default" size="100%">Glujovsky, D.</style></author><author><style face="normal" font="default" size="100%">Lopez, A.</style></author><author><style face="normal" font="default" size="100%">Regueiro, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prostacyclins (epoprostenol, iloprost, treprostinil and beraprost) for the management of primary pulmonary hypertension and pulmonary hypertension in collagen vascular disease (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Collagen Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Iloprost [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins I [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Diseases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">HTA-32005001241</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32005001241/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>535</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">535</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aung, KoKo</style></author><author><style face="normal" font="default" size="100%">Htay, Thwe</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Thiazide diuretics and the risk of hip fracture</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bone Density [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hip Fractures [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Postmenopause</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride Symporter Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005185</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Thiazide diuretics are one of the most commonly prescribed antihypertensive agents worldwide. Thiazides reduce urinary calcium excretion. Chronic ingestion of thiazides is associated with higher bone mineral density. It has been suggested that thiazides may prevent hip fracture. However, there are concerns that diuretics, by increasing the risk of fall in elderly, could potentially negate its beneficial effects on hip fracture.Objectives: To assess any association between the use of thiazide diuretics and the risk of hip fracture in adults.Search methods: We searched eligible studies up to December 2008 in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), International Pharmaceutical Abstracts, the Database of Abstracts of Review of Effects (DARE) and reference lists of previous reviews and included studies.Selection criteria: All randomized controlled trials and observational studies, which assessed the association between thiazide diuretic use and hip fracture.Data collection and analysis: Two review authors independently applied the selection criteria, extracted data and assessed risk of bias of each study selected.  The results were summarized descriptively and quantitatively. Cohort studies and case control studies were analysed separately.Main results: No randomized control trials were found. Twenty-one observational studies with nearly four hundred thousand participants were included. Six of them were cohort studies and 15 were case-control studies. Two cohort studies appear to involve the same cohort so there were only 5 unique ones. The risk of bias was assessed with the Newcastle-Ottawa Scale (NOS). Five cohort studies had low risk of bias and one had moderate risk of bias. Seven case control studies had low risk of bias and 8 had moderate risk of bias. Meta-analysis of cohort studies showed that thiazide use was associated with a reduction in risk of hip fracture by 24%, pooled RR 0.76 (95% CI 0.64-0.89; p = 0.0009). We chose not to provide a pooled summary statistics for case-control studies because of high heterogeneity (Tau2 = 0.03, I2 = 62%, p = 0.0008).Authors&apos; conclusions: Thiazides appear to reduce the risk of hip fracture based on observational studies. Randomized controlled trials are needed to confirm these findings.  </style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005185.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005185.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">26</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Avouac, J.</style></author><author><style face="normal" font="default" size="100%">Wipff, J.</style></author><author><style face="normal" font="default" size="100%">Kahan, A.</style></author><author><style face="normal" font="default" size="100%">Allanore, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of the Rheumatic Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of the Rheumatic Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">808-814</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Tolerance [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Scleroderma, Systemic [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009100110</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009100110/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ard.bmj.com/content/67/6/808.long</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>536</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">536</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bagga, Arvind</style></author><author><style face="normal" font="default" size="100%">Sinha, Aditi</style></author><author><style face="normal" font="default" size="100%">Pandey Ravindra, M.</style></author><author><style face="normal" font="default" size="100%">Schaefer, Franz</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive agents for children with chronic kidney disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010911</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:This review aims to look at the benefits and harms of therapy with antihypertensive agents in children with CKD.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010911/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010911</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>27</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">27</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bai, Y.</style></author><author><style face="normal" font="default" size="100%">Sun, L.</style></author><author><style face="normal" font="default" size="100%">Hu, S.</style></author><author><style face="normal" font="default" size="100%">Wei, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combination therapy in pulmonary arterial hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">157-165</style></pages><volume><style face="normal" font="default" size="100%">120</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Synergism</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [mortality] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphodiesterase 5 Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Endothelin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012009991</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012009991/frame.html</style></url></related-urls><pdf-urls><url>internal-pdf://1086115326/Bai-2011-Combination therapy in pulmonary arte.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">28</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baker, W. L.</style></author><author><style face="normal" font="default" size="100%">Smyth, L. R.</style></author><author><style face="normal" font="default" size="100%">Riche, D. M.</style></author><author><style face="normal" font="default" size="100%">Bourret, E. M.</style></author><author><style face="normal" font="default" size="100%">Chamberlin, K. W.</style></author><author><style face="normal" font="default" size="100%">White, W. B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">262-275.e9</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride Symporters</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014019446</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014019446/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">29</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baker, W. L.</style></author><author><style face="normal" font="default" size="100%">White, C. M.</style></author><author><style face="normal" font="default" size="100%">Coleman, C. I.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The impact of angiotensin II receptor blocker potency on the clinical outcomes of stroke, acute myocardial infarction, or death (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Formulary</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Formulary</style></full-title></periodical><pages><style face="normal" font="default" size="100%">581-590</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Fatal Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007003813</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007003813/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>30</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">30</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bakris, G.</style></author><author><style face="normal" font="default" size="100%">Sarafidis, P.</style></author><author><style face="normal" font="default" size="100%">Agarwal, R.</style></author><author><style face="normal" font="default" size="100%">Ruilope, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Review of blood pressure control rates and outcomes (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Society of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Society of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013071911</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013071911/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>31</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">31</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bakris, G. L.</style></author><author><style face="normal" font="default" size="100%">Weir, M. R.</style></author><author><style face="normal" font="default" size="100%">Secic, M.</style></author><author><style face="normal" font="default" size="100%">Campbell, B.</style></author><author><style face="normal" font="default" size="100%">Weis-McNulty, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Differential effects of calcium antagonist subclasses on markers of nephropathy progression (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Kidney International</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Kidney International</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1991-2002</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [classification] [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Nephropathies [drug therapy] [etiology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Dihydropyridines [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Renal [drug therapy] [etiology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria [drug therapy] [etiology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Animals[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004001130</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004001130/frame.html</style></url><url><style face="normal" font="default" size="100%">http://www.nature.com/ki/journal/v65/n6/pdf/4494501a.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2835646052/Bakris-2004-Differential effects of calcium an.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>32</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">32</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Balamuthusamy, S.</style></author><author><style face="normal" font="default" size="100%">Molnar, J.</style></author><author><style face="normal" font="default" size="100%">Adigopula, S.</style></author><author><style face="normal" font="default" size="100%">Arora, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">133-142</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [etiology] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009104792</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009104792/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>33</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">33</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Balk, E.</style></author><author><style face="normal" font="default" size="100%">Raman, G.</style></author><author><style face="normal" font="default" size="100%">Chung, M.</style></author><author><style face="normal" font="default" size="100%">Ip, S.</style></author><author><style face="normal" font="default" size="100%">Tatsioni, A.</style></author><author><style face="normal" font="default" size="100%">Alonso, A.</style></author><author><style face="normal" font="default" size="100%">Kupelnick, B.</style></author><author><style face="normal" font="default" size="100%">Chew, P.</style></author><author><style face="normal" font="default" size="100%">DeVine, D.</style></author><author><style face="normal" font="default" size="100%">Gilbert, S.</style></author><author><style face="normal" font="default" size="100%">Lau, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative effectiveness of management strategies for renal artery stenosis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">136</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty, Balloon</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Arteriosclerosis [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Healthcare Research and Quality</style></publisher><accession-num><style face="normal" font="default" size="100%">DARE-12007008013</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007008013/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>34</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">34</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Banach, M.</style></author><author><style face="normal" font="default" size="100%">Nikfar, S.</style></author><author><style face="normal" font="default" size="100%">Rahimi, R.</style></author><author><style face="normal" font="default" size="100%">Bielecka-Dabrowa, A.</style></author><author><style face="normal" font="default" size="100%">Pencina, M. J.</style></author><author><style face="normal" font="default" size="100%">Mikhailidis, D. P.</style></author><author><style face="normal" font="default" size="100%">Narkiewicz, K.</style></author><author><style face="normal" font="default" size="100%">Rysz, J.</style></author><author><style face="normal" font="default" size="100%">Ray, K. K.</style></author><author><style face="normal" font="default" size="100%">Abdollahi, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effects of statins on blood pressure in normotensive or hypertensive subjects: a meta-analysis of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013022592</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013022592/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>35</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">35</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Kamalakkannan, G.</style></author><author><style face="normal" font="default" size="100%">Parkar, S.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Fixed-dose combinations improve medication compliance: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">713-719</style></pages><volume><style face="normal" font="default" size="100%">120</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-HIV Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antitubercular Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Infections [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoglycemic Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Polypharmacy</style></keyword><keyword><style face="normal" font="default" size="100%">Tuberculosis [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007005994</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007005994/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>36</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">36</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Kumar, S.</style></author><author><style face="normal" font="default" size="100%">Kjeldsen, S. E.</style></author><author><style face="normal" font="default" size="100%">Makani, H.</style></author><author><style face="normal" font="default" size="100%">Grossman, E.</style></author><author><style face="normal" font="default" size="100%">Wetterslev, J.</style></author><author><style face="normal" font="default" size="100%">Gupta, A. K.</style></author><author><style face="normal" font="default" size="100%">Sever, P. S.</style></author><author><style face="normal" font="default" size="100%">Gluud, C.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324168 participants from randomised trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet Oncology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet Oncology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">65-82</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">dosage [adverse effects] [adverse effects] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011000671</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011000671/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>37</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">37</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Kumar, S.</style></author><author><style face="normal" font="default" size="100%">Lobach, I.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Circulation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2799-2810</style></pages><volume><style face="normal" font="default" size="100%">123</style></volume><number><style face="normal" font="default" size="100%">24</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Bayes Theorem</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose Intolerance [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011005754</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011005754/frame.html</style></url><url><style face="normal" font="default" size="100%">http://circ.ahajournals.org/content/123/24/2799.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1015267618/Bangalore-2011-Blood pressure targets in subje.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>38</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">38</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Kumar, S.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist? (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Congestive Heart Failure</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Congestive Heart Failure</style></full-title></periodical><pages><style face="normal" font="default" size="100%">107-115</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure</style></keyword><keyword><style face="normal" font="default" size="100%">Mineralocorticoid Receptor Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013035312</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013035312/frame.html</style></url><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/store/10.1111/chf.12011/asset/chf12011.pdf?v=1&amp;t=ibbmw9p6&amp;s=58549669d170ab776cfc0681292658443f701423</style></url></related-urls><pdf-urls><url>internal-pdf://2201080464/Bangalore-2013-When conventional heart failure.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">39</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Kumar, S.</style></author><author><style face="normal" font="default" size="100%">Volodarskiy, A.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Heart</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Heart</style></full-title></periodical><pages><style face="normal" font="default" size="100%">601-613</style></pages><volume><style face="normal" font="default" size="100%">99</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Bayes Theorem</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Artery Disease [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013025656</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013025656/frame.html</style></url><url><style face="normal" font="default" size="100%">http://heart.bmj.com/content/99/9/601.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0499448099/Bangalore-2013-Blood pressure targets in patie.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>40</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">40</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Kumar, S.</style></author><author><style face="normal" font="default" size="100%">Wetterslev, J.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><volume><style face="normal" font="default" size="100%">342:bmj.d2234</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011002545</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011002545/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>41</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">41</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Parkar, S.</style></author><author><style face="normal" font="default" size="100%">Grossman, E.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1254-1262</style></pages><volume><style face="normal" font="default" size="100%">100</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Atenolol [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Glucose</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [blood] [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Propranolol [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007003473</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007003473/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S000291490701332X/1-s2.0-S000291490701332X-main.pdf?_tid=d18af1f2-1aea-11e5-a74b-00000aacb35f&amp;acdnat=1435203334_2bc99b509dfd687211ee1cecf01fa5e6</style></url></related-urls><pdf-urls><url>internal-pdf://3334203894/Bangalore-2007-A meta-analysis of 94,492 patie.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>42</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">42</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Sawhney, S.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1482-1489</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">18</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiotonic Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [etiology] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009103787</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009103787/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0735109708027241/1-s2.0-S0735109708027241-main.pdf?_tid=d4b7d214-1aea-11e5-8bda-00000aab0f26&amp;acdnat=1435203339_4c38134166bf6966f2f18817991b49be</style></url></related-urls><pdf-urls><url>internal-pdf://2578907797/Bangalore-2008-Relation of beta-blocker-induce.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>43</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">43</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Wild, D.</style></author><author><style face="normal" font="default" size="100%">Parkar, S.</style></author><author><style face="normal" font="default" size="100%">Kukin, M.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1062-1072</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">13</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009100916</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009100916/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0735109708023127/1-s2.0-S0735109708023127-main.pdf?_tid=de034a88-1aea-11e5-b4ab-00000aacb35f&amp;acdnat=1435203355_cfb805c1eb89a961c2f9afa2480f9ed6</style></url></related-urls><pdf-urls><url>internal-pdf://2212447161/Bangalore-2008-Beta-blockers for primary preve.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>537</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">537</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barrington Keith, J.</style></author><author><style face="normal" font="default" size="100%">Finer, Neil</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Inhaled nitric oxide for respiratory failure in preterm infants</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchopulmonary Dysplasia [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature, Diseases [prevention &amp; control] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Insufficiency [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Salvage Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD000509</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Inhaled nitric oxide (iNO) is effective in term infants with hypoxic respiratory failure. The pathophysiology of respiratory failure and the potential risks of iNO differ substantially in preterm infants, necessitating study in this population.Objectives: To determine the effect of treatment with iNO on death, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), and neurodevelopmental disability in preterm newborn infants with respiratory disease.Search methods: Standard methods of the Cochrane Neonatal Review Group were used. MEDLINE, EMBASE, Healthstar and the Cochrane Central Register of Controlled Trials (The Cochrane Library) were searched covering the years from 1985 to 2010. In addition, the abstracts of the Pediatric Academic Societies were also searched.Selection criteria: Randomized and quasi-randomized studies in preterm infants with respiratory disease that compared the effects of iNO gas to control, with or without placebo were eligible.Data collection and analysis: Standard methods of the Cochrane Neonatal Review Group were used.Main results: Fourteen randomized controlled trials of inhaled nitric oxide therapy in preterm infants were found. The trials have been grouped post hoc into three categories depending on entry criteria; entry in the first three days of life based on oxygenation criteria, routine use in preterm babies with pulmonary disease, and later enrolment based on an increased risk of BPD. No overall analyses were performed.Nine trials of early rescue treatment of infants based on oxygenation criteria demonstrated no significant effect of iNO on mortality or BPD. Three studies with routine use of iNO in infants with pulmonary disease also demonstrated no significant reduction in death or BPD [typical RR 0.93 (95% CI 0.86 to 1.01)] although this small effect approached significance. Later treatment with iNO based on the risk of BPD (two trials) demonstrated no significant benefit for this outcome in analyses which are possible using summary data.There is no clear effect of iNO on the frequency of all grades of IVH or of severe IVH. Early rescue treatment was associated with a non-significant 20% increase in severe IVH.No effect on the incidence of neurodevelopmental impairment was found.Authors&apos; conclusions: iNO as rescue therapy for the very ill preterm infant does not appear to be effective. Early routine use of iNO in preterm infants with respiratory disease does not affect serious brain injury or improve survival without BPD. Later use of iNO to prevent BPD might be effective, but requires further study.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000509.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD000509.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>538</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">538</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bassler, Dirk</style></author><author><style face="normal" font="default" size="100%">Kreutzer, Karen</style></author><author><style face="normal" font="default" size="100%">McNamara, Patrick</style></author><author><style face="normal" font="default" size="100%">Kirpalani, Haresh</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Milrinone for persistent pulmonary hypertension of the newborn</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Milrinone [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Persistent Fetal Circulation Syndrome [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007802</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Persistent pulmonary hypertension of the newborn (PPHN) is a clinical syndrome characterized by suboptimal oxygenation as a result of sustained elevation in pulmonary vascular resistance after birth. Currently, the therapeutic mainstay for PPHN is optimal lung inflation and selective vasodilatation with inhaled nitric oxide (iNO). However, iNO is not available in all countries and not all infants will respond to iNO. Milrinone is a phosphodiesterase III inhibitor which induces pulmonary vasodilatation by its actions through a cyclic adenylate monophosphate mediated signaling pathway.Objectives: To assess efficacy and safety in infants with PPHN either treated with: milrinone compared with placebo or no treatment; milrinone compared with iNO; milrinone as an adjunct to iNO compared with iNO alone; milrinone compared with potential treatments for PPHN other than iNO.Search methods: We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 2, 2010), MEDLINE and EMBASE databases from their inception until January 2010. We searched the reference lists of potentially relevant studies without any language restriction.Selection criteria: Fully published randomized controlled trials (RCTs) and quasi-RCTs comparing milrinone with placebo, iNO or potential treatments other than iNO in neonates with PPHN were included if trials reported any clinical outcome.Data collection and analysis: We found no studies meeting the criteria for inclusion in this review.Main results: We found no studies meeting the criteria for inclusion in this review.Authors&apos; conclusions: The efficacy and safety of milrinone in the treatment of PPHN are not known and its use should be restricted within the context of RCTs. Such studies should address a comparison of milrinone with placebo (in clinical situations where iNO is not available) or, in well resourced countries, should compare milrinone with iNO or as an adjunct to iNO compared with iNO alone.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007802.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007802.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>539</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">539</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bath Philip, M. W.</style></author><author><style face="normal" font="default" size="100%">Krishnan, Kailash</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interventions for deliberately altering blood pressure in acute stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Time-to-Treatment [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD000039</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: It is unclear whether blood pressure should be altered actively during the acute phase of stroke. This is an update of a Cochrane review first published in 1997, and previously updated in 2001 and 2008.Objectives: To assess the clinical effectiveness of altering blood pressure in people with acute stroke, and the effect of different vasoactive drugs on blood pressure in acute stroke.Search methods: We searched the Cochrane Stroke Group Trials Register (last searched in February 2014), the Cochrane Database of Systematic reviews (CDSR) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, Issue 2), MEDLINE (Ovid) (1966 to May 2014), EMBASE (Ovid) (1974 to May 2014), Science Citation Index (ISI, Web of Science, 1981 to May 2014) and the Stroke Trials Registry (searched May 2014).Selection criteria: Randomised controlled trials of interventions that aimed to alter blood pressure compared with control in participants within one week of acute ischaemic or haemorrhagic stroke.Data collection and analysis: Two review authors independently applied the inclusion criteria, assessed trial quality and extracted data. The review authors cross-checked data and resolved discrepancies by discussion to reach consensus. We obtained published and unpublished data where available.Main results: We included 26 trials involving 17,011 participants (8497 participants were assigned active therapy and 8514 participants received placebo/control). Not all trials contributed to each outcome. Most data came from trials that had a wide time window for recruitment; four trials gave treatment within six hours and one trial within eight hours. The trials tested alpha-2 adrenergic agonists (A2AA), angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor antagonists (ARA), calcium channel blockers (CCBs), nitric oxide (NO) donors, thiazide-like diuretics, and target-driven blood pressure lowering. One trial tested phenylephrine.At 24 hours after randomisation oral ACEIs reduced systolic blood pressure (SBP, mean difference (MD) -8 mmHg, 95% confidence interval (CI) -17 to 1) and diastolic blood pressure (DBP, MD -3 mmHg, 95% CI -9 to 2), sublingual ACEIs reduced SBP (MD -12.00 mm Hg, 95% CI -26 to 2) and DBP (MD -2, 95%CI -10 to 6), oral ARA reduced SBP (MD -1 mm Hg, 95% CI -3 to 2) and DBP (MD -1 mm Hg, 95% CI -3 to 1), oral beta blockers reduced SBP (MD -14 mm Hg; 95% CI -27 to -1) and DBP (MD -1 mm Hg, 95% CI -9 to 7), intravenous (iv) beta blockers reduced SBP (MD -5 mm Hg, 95% CI -18 to 8) and DBP (-5 mm Hg, 95% CI -13 to 3), oral CCBs reduced SBP (MD -13 mmHg, 95% CI -43 to 17) and DBP (MD -6 mmHg, 95% CI -14 to 2), iv CCBs reduced SBP (MD -32 mmHg, 95% CI -65 to 1) and DBP (MD -13, 95% CI -31 to 6), NO donors reduced SBP (MD -12 mmHg, 95% CI -19 to -5) and DBP (MD -3, 95% CI -4 to -2) while phenylephrine, non-significantly increased SBP (MD 21 mmHg, 95% CI -13 to 55) and DBP (MD 1 mmHg, 95% CI -15 to 16).Blood pressure lowering did not reduce death or dependency either by drug class (OR 0.98, 95% CI 0.92 to 1.05), stroke type (OR 0.98, 95% CI 0.92 to 1.05) or time to treatment (OR 0.98, 95% CI 0.92 to 1.05). Treatment within six hours of stroke appeared effective in reducing death or dependency (OR 0.86, 95% CI 0.76 to 0.99) but not death (OR 0.70, 95% CI 0.38 to 1.26) at the end of the trial. Although death or dependency did not differ between people who continued pre-stroke antihypertensive treatment versus those who stopped it temporarily (worse outcome with continuing treatment, OR 1.06, 95% CI 0.91 to 1.24), disability scores at the end of the trial were worse in participants randomised to continue treatment (Barthel Index, MD -3.2, 95% CI -5.8, -0.6).Authors&apos; conclusions: There is insufficient evidence that lowering blood pressure during the acute phase of stroke improves functional outcome. It is reasonable to withhold blood pressure-lowering drugs until patients are medically and neurologically stable, and have suitable oral or enteral access, after which drugs can than be r introduced. In people with acute stroke, CCBs, ACEI, ARA, beta blockers and NO donors each lower blood pressure while phenylephrine probably increases blood pressure. Further trials are needed to identify which people are most likely to benefit from early treatment, in particular whether treatment started very early is beneficial.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000039.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD000039.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>540</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">540</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Batterink, Josh</style></author><author><style face="normal" font="default" size="100%">Stabler Sarah, N.</style></author><author><style face="normal" font="default" size="100%">Tejani Aaron, M.</style></author><author><style face="normal" font="default" size="100%">Fowkes Curt, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Spironolactone for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Spironolactone [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008169</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Spironolactone is an aldosterone antagonist, considered fourth line therapy for hypertension in patients already treated with multiple medications.Objectives: Primary: to determine the effect of spironolactone on patient mortality, morbidity, and to quantify the magnitude of blood pressure lowering effect of spironolactone monotherapy.Secondary: to determine the prevalence of adverse reactions observed with spironolactone monotherapy and to determine if there is a blood-pressure lowering dose response with spironolactone.Search methods: We searched the following databases: Cochrane Central Register of Controlled Trials (3rd Quarter 2009), MEDLINE (2005 - Sept. 2009), and EMBASE (2007 - Sept. 2009). References from retrieved studies were reviewed to identify any studies missed in the initial search. No language restrictions were applied.Selection criteria: We selected RCTs studying patients with primary hypertension. We excluded studies of patients with secondary or gestational hypertension, and studies where patients were receiving multiple antihypertensives.Data collection and analysis: Two reviewers independently reviewed the search results for studies meeting our criteria. Three reviewers extracted data and assessed trial quality using a standardized data extraction form. Data synthesis and analysis was performed using RevMan 5.Main results: Meta-analysis of the 5 cross-over studies found a reduction in SBP of 20.09 mmHg (95%CI:16.58-23.06,p&lt;0.00001) and a 6.75 mmHg (95%CI:4.8-8.69,p&lt;0.00001) reduction in DBP. These results were statistically significant and there was no evidence of heterogeneity between the studies. There may be a dose response effect with spironolactone up to 50 mg/day, but the confidence intervals around the mean end-of-study blood pressure for doses ranging 25-500 mg/day all overlapped. In other words, it appears that doses &gt;50mg/day do not produce further reductions in either SBP or DBP. One cross-over study found that spironolactone 25 mg/day did not statistically significantly change SBP or DBP compared to placebo, SBP: -9.9 (95%CI:-21.15,1.35); DBP -2.34 (95%CI:-7.92,3.06).Authors&apos; conclusions: From the limited available evidence, spironolactone appears to lower blood pressure compared to placebo to a similar degree in patients with primary (essential) hypertension when doses of 100-500 mg/day are given. A dose of 25 mg/day did not statistically significantly reduce systolic or diastolic blood pressure, compared to placebo. Given the lack of a dose-response, coupled with a possible increased risk in adverse events with higher doses, doses of 25 to 100 mg/day are reasonable. There is no evidence of the effect of spironolactone on clinical outcomes in hypertensive patients.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008169.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008169.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>541</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">541</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baumgart Daniel, C.</style></author><author><style face="normal" font="default" size="100%">MacDonald John, K.</style></author><author><style face="normal" font="default" size="100%">Feagan, Brian</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Colitis, Ulcerative [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Remission Induction</style></keyword><keyword><style face="normal" font="default" size="100%">Tacrolimus [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Ibd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007216</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: There are a limited number of treatment options for patients with refractory ulcerative colitis. Animal models of inflammatory bowel disease and uncontrolled studies in humans suggest that tacrolimus may be effective treatment for ulcerative colitis.Objectives: This review aims to evaluate the efficacy of tacrolimus for induction of remission in patients with corticosteroid refractory ulcerative colitis.Search methods: MEDLINE (PubMed), The Cochrane Central Register of Controlled Trials, the IBD/FBD review group specialized register and the ISI-Research Institute were searched (January 1997 to November 2007) to identify relevant studies all randomized trials.Selection criteria: Each author independently reviewed potentially relevant studies to determine eligibility based on the pre-specified criteria.Data collection and analysis: A data extraction form was developed and used to extract data from included studies. Two authors independently extracted data. Data were analyzed using Review Manager (RevMan 4.2.9). The primary outcomes were induction of remission and clinical improvement, as defined by the studies and expressed as a percentage of the patients randomized (intention to treat analysis).Main results: One randomized controlled trial comparing high target serum concentration and low target serum concentration tacrolimus versus placebo was identified and included in the review. Clinical remission was observed in 19% (4/21) of patients in the high target serum concentration group, in 9% (2/22) in the low target serum concentration group and in 5% (1/20) in the placebo group (OR 2.27; 95% CI 0.35 to 14.75). A statistically significant benefit for clinical improvement at two weeks was observed. Clinical improvement was observed in 62% (13/21) of patients in the high target serum concentration group, in 36% (8/22) in the low target serum concentration group and in 10% (2/20) in the placebo group (OR 8.66; 95% CI 1.79 to 42.00; RD 0.39; 95% CI 0.20 to 0.59; NNT = 3). Patients in the high serum target concentration group were significantly more likely than placebo patients to experience adverse events related to treatment (P = 0.043). Finger tremor (n = 6) was the most common adverse event in the tacrolimus group. Other adverse events included: gastroenteritis, sepsis, sleepiness, hot flush, headache, queasiness and stomach discomfort.Authors&apos; conclusions: Tacrolimus may be effective for short-term clinical improvement in patients with refractory ulcerative colitis. However, these results should be interpreted with caution due to the small number of patients enrolled in the trial and other study limitations. Insufficient treatment and follow-up intervals prevent any conclusions with regard to long term safety and efficacy. The use of tacrolimus in the clinical setting requires careful consideration of risks versus benefits as well as close monitoring for adverse events. More data from well designed and controlled studies are needed to determine the long-term efficacy and safety of tacrolimus.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007216/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007216</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>44</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">44</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bazzano, L. A.</style></author><author><style face="normal" font="default" size="100%">Khan, Z.</style></author><author><style face="normal" font="default" size="100%">Reynolds, K.</style></author><author><style face="normal" font="default" size="100%">He, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">417-423</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Gas Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Confidence Intervals</style></keyword><keyword><style face="normal" font="default" size="100%">Continuous Positive Airway Pressure [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Polysomnography</style></keyword><keyword><style face="normal" font="default" size="100%">Probability</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep Apnea Syndromes [complications] [diagnosis] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007002843</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007002843/frame.html</style></url><url><style face="normal" font="default" size="100%">http://hyper.ahajournals.org/content/50/2/417.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0599074581/Bazzano-2007-Effect of nocturnal nasal continu.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>45</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">45</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Becattini, C.</style></author><author><style face="normal" font="default" size="100%">Manina, G.</style></author><author><style face="normal" font="default" size="100%">Busti, C.</style></author><author><style face="normal" font="default" size="100%">Gennarini, S.</style></author><author><style face="normal" font="default" size="100%">Agnelli, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Thrombosis Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Thrombosis Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e51-e56</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [etiology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Embolism [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Resistance [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010006912</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010006912/frame.html</style></url><url><style face="normal" font="default" size="100%">http://ac.els-cdn.com/S0049384810000149/1-s2.0-S0049384810000149-main.pdf?_tid=d8266b22-1aea-11e5-bbb7-00000aacb35d&amp;acdnat=1435203345_7b42a73b987867a426b2fc16e19de701</style></url></related-urls><pdf-urls><url>internal-pdf://2877958845/Becattini-2010-Bosentan for chronic thromboemb.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>542</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">542</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Becla, L.</style></author><author><style face="normal" font="default" size="100%">Osinska, B.</style></author><author><style face="normal" font="default" size="100%">Malottki, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical effectiveness analysis of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension: a systematic review of randomised controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Iloprost [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Health Technology Assessment in Poland (AHTAPol)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32009100093</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32009100093/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>543</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">543</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bedenis, Rachel</style></author><author><style face="normal" font="default" size="100%">Stewart, Marlene</style></author><author><style face="normal" font="default" size="100%">Cleanthis, Marcus</style></author><author><style face="normal" font="default" size="100%">Robless, Peter</style></author><author><style face="normal" font="default" size="100%">Mikhailidis Dimitri, P.</style></author><author><style face="normal" font="default" size="100%">Stansby, Gerard</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cilostazol for intermittent claudication</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Intermittent Claudication [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Pentoxifylline [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Peripheral Vascular Diseases [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Aggregation Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Walking</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Pvd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003748</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Peripheral arterial disease (PAD) affects between 4% and 12% of people aged 55 to 70 years, and 20% of people over 70 years. A common complaint is intermittent claudication, characterised by pain in the legs or buttocks that occurs with exercise and which subsides with rest. Compared with age-matched controls, people with intermittent claudication have a three- to six-fold increase in cardiovascular mortality. Symptoms of intermittent claudication, walking distance, and quality of life can be improved by risk factor modification, smoking cessation, and a structured exercise programme. Antiplatelet treatment is beneficial in patients with intermittent claudication for the reduction of vascular events but has not previously been shown to influence claudication distance. This is an update of a review first published in 2007.Objectives: To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication.Search methods: For this update, the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched October 2013) and CENTRAL (2013, Issue 9).Selection criteria: Double-blind, randomised controlled trials (RCTs) of cilostazol versus placebo, or versus other antiplatelet agents in patients with stable intermittent claudication.Data collection and analysis: Two authors independently assessed trials for selection and independently extracted data. Disagreements were resolved by discussion. We performed the meta-analysis as a fixed-effect model with weighted mean differences (WMDs) and 95% confidence intervals (CIs) for continuous data, and odds ratios (ORs) with 95% CIs for dichotomous data.Main results: We included fifteen double-blind, RCTs comparing cilostazol with placebo, or medications currently known to increase walking distance e.g. pentoxifylline. There were a total of 3718 randomised participants with treatment durations ranging from six to 26 weeks. All participants had intermittent claudication secondary to PAD. Comparisons included cilostazol twice daily, with dosages of 50 mg, 100 mg and 150 mg compared with placebo, and cilostazol 100 mg, twice daily, compared with pentoxifylline 400 mg, three times daily. The methodological quality of the trials was generally low, with the majority being at an unclear risk for selection bias, performance bias, detection bias and other bias. Attrition bias was generally low, but reporting bias was high or unclear in the majority of the studies. For eight studies data were compatible for comparison by meta-analysis, but data for seven studies were too heterogenous to be pooled. For the studies included in the meta-analysis, for initial claudication distance (ICD - the distance walked on a treadmill before the onset of calf pain) there was an improvement in the cilostazol group for the 100 mg and 50 mg twice daily, compared with placebo (WMD 31.41 metres, 95% CI 22.38 to 40.45 metres; P &lt; 0.00001) and WMD 19.89 metres, 95% CI 9.44 to 30.34 metres; P = 0.0002), respectively. ICD was improved in the cilostazol group for the comparison of cilostazol 150 mg versus placebo and cilostazol 100 mg versus pentoxifylline, but only single studies were used for these analyses. Absolute claudication distance (ACD - the maximum distance walked on a treadmill) was significantly increased in participants taking cilostazol 100 mg and 50 mg twice daily, compared with placebo (WMD 43.12 metres, 95% CI 18.28 to 67.96 metres; P = 0.0007) and WMD 32.00 metres, 95% CI 14.17 to 49.83 metres; P = 0.0004), respectively. As with ICD, ACD was increased in participants taking cilostazol 150 mg versus placebo, but with only one study an association cannot be clearly determined. Two studies comparing cilostazol to pentoxifylline had opposing findings, resulting in an imprecise CI (WMD 13.42 metres (95% CI -43.51 to 70.35 metres; P = 0.64). Ankle brachial index (ABI) was lowered in the cilostaz l 100 mg group compared with placebo (WMD 0.06, 95% CI 0.04 to 0.08; P &lt; 0.00001). The single study evaluating ABI for the comparison of cilostazol versus pentoxifylline found no change in ABI.There was no association between treatment type and all-cause mortality for any of the treatment comparisons, but there were very few events, and therefore larger, adequately powered studies will be needed to assess if there is a relationship. Only one study evaluated individual cardiovascular events, and from this study there is no clear evidence of a difference between any of the treatment groups and risk of myocardial infarction or stroke. We evaluated adverse side effects, and in general cilostazol was associated with a higher odds of headache, diarrhoea, abnormal stool, dizziness and palpitations. We only reported quality of life measures descriptively as there was insufficient statistical detail within the studies to combine the results, although there was a possible indication in improvement of quality of life in the cilostazol treatment groups.Authors&apos; conclusions: Cilostazol has been shown to be of benefit in improving walking distance in people with intermittent claudication secondary to PAD. Although there is an increase in adverse side effects, they are generally mild and treatable. There is currently insufficient data on whether taking cilostazol results in a reduction of all-cause mortality and cardiovascular events or an improvement in quality of life. Future research into the effect of cilostazol on intermittent claudication should carefully consider comparability, sample size and homogeneity when designing a study.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003748.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003748.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>46</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">46</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beishon, L. C.</style></author><author><style face="normal" font="default" size="100%">Harrison, J. K.</style></author><author><style face="normal" font="default" size="100%">Harwood, R. H.</style></author><author><style face="normal" font="default" size="100%">Robinson, T. G.</style></author><author><style face="normal" font="default" size="100%">Gladman, J. R.</style></author><author><style face="normal" font="default" size="100%">Conroy, S. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The evidence for treating hypertension in older people with dementia: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dementia</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013064579</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013064579/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>544</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">544</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beletate, Vânia</style></author><author><style face="normal" font="default" size="100%">El Dib, Regina</style></author><author><style face="normal" font="default" size="100%">Atallah Álvaro, N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Zinc supplementation for the prevention of type 2 diabetes mellitus</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Endoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005525</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: The chronic hyperglycaemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels. The risk of developing type 2 diabetes increases with age, obesity, and lack of physical activity. Insulin resistance is a fundamental aspect of the aetiology of type 2 diabetes. Insulin resistance has been shown to be associated with atherosclerosis, hypertriglyceridaemia, glucose intolerance, dyslipidaemia, hyperuricaemia, hypertension and polycystic ovary syndrome. The mineral zinc plays a key role in the synthesis and action of insulin, both physiologically and in diabetes mellitus. Zinc seems to stimulate insulin action and insulin receptor tyrosine kinase activity.Objectives: To assess the effects of the zinc supplementation in the prevention of type 2 diabetes mellitus.Search methods: Studies were obtained from computerised searches of MEDLINE, EMBASE, LILACS and The Cochrane Library.Selection criteria: Studies were included if they had a randomised or quasi-randomised design and if they investigated zinc supplementation in adults living in the community, 18 years or older with insulin resistance (compared to placebo or no intervention).Data collection and analysis: Two authors selected relevant trials, assessed methodological quality and extracted data.Main results: Only one study met the inclusion criteria of this review. There were 56 normal glucose tolerant obese women (aged 25 to 45 years, body mass index 36.2 ± 2.3 kg/m2). Follow-up was four weeks. The outcomes measured were decrease of insulin resistance, anthropometric and diet parameters, leptin and insulin concentration, zinc concentration in the plasma and urine, lipid metabolism and fasting plasma glucose. There were no statistically significant differences favouring participants receiving zinc supplementation compared to placebo concerning any outcome measured by the study.Authors&apos; conclusions: There is currently no evidence to suggest the use of zinc supplementation in the prevention of type 2 diabetes mellitus. Future trials will have to standardise outcomes measures such as incidence of type 2 diabetes mellitus, decrease of the insulin resistance, quality of life, diabetic complications, all-cause mortality and costs.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005525.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005525.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>47</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">47</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bell, K. J.</style></author><author><style face="normal" font="default" size="100%">Hayen, A.</style></author><author><style face="normal" font="default" size="100%">Macaskill, P.</style></author><author><style face="normal" font="default" size="100%">Craig, J. C.</style></author><author><style face="normal" font="default" size="100%">Neal, B. C.</style></author><author><style face="normal" font="default" size="100%">Fox, K. M.</style></author><author><style face="normal" font="default" size="100%">Remme, W. J.</style></author><author><style face="normal" font="default" size="100%">Asselbergs, F. W.</style></author><author><style face="normal" font="default" size="100%">Gilst, W. H.</style></author><author><style face="normal" font="default" size="100%">MacMahon, S.</style></author><author><style face="normal" font="default" size="100%">Remuzzi, G.</style></author><author><style face="normal" font="default" size="100%">Ruggenenti, P.</style></author><author><style face="normal" font="default" size="100%">Teo, K. K.</style></author><author><style face="normal" font="default" size="100%">Irwig, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Monitoring initial response to angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">533-539</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010006621</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010006621/frame.html</style></url><url><style face="normal" font="default" size="100%">http://hyper.ahajournals.org/content/56/3/533.full.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://0095440920/Bell-2010-Monitoring initial response to angio.pdf</url></pdf-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>545</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">545</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beyer Fiona, R.</style></author><author><style face="normal" font="default" size="100%">Dickinson Heather, O.</style></author><author><style face="normal" font="default" size="100%">Nicolson, Donald</style></author><author><style face="normal" font="default" size="100%">Ford Gary, A.</style></author><author><style face="normal" font="default" size="100%">Mason, James</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combined calcium, magnesium and potassium supplementation for the management of primary hypertension in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium, Dietary [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Magnesium [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium, Dietary [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004805</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Previous research suggests that increasing dietary intakes of calcium, potassium or magnesium separately may reduce BP to a small degree over the short term. It is unclear whether increasing intakes of a combination of these minerals produces a larger reduction in BP.Objectives: To evaluate the effects of combined mineral supplementation as a treatment for primary hypertension in adults.Search methods: We searched the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, ISI Proceedings, ClinicalTrials.gov, Current Controlled Trials, CAB abstracts, and reference lists of systematic reviews, meta-analyses and randomised controlled trials (RCTs) included in the review. The search was unrestricted by language or publication status.Selection criteria: Inclusion criteria were: 1) RCTs of a parallel or crossover design comparing oral supplements comprising a combination of potassium, and/or calcium, and/or magnesium with placebo, no treatment, or usual care; 2) treatment and follow-up &gt;=8 weeks; 3) participants over 18 years old, with raised systolic blood pressure (SBP) &gt;=140 mmHg or diastolic blood pressure (DBP) &gt;=85 mmHg with no known primary cause; 4) SBP and DBP reported at end of follow-up. We excluded trials where participants were pregnant, or received antihypertensive medication which changed during the study.Data collection and analysis: Two reviewers independently extracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Random effects meta-analyses and sensitivity analyses were conducted.Main results: We included three RCTs (n=277) with 24-28 weeks follow-up. Three combinations of minerals were investigated: potassium-magnesium, calcium-magnesium, and calcium-potassium. One trial investigated combinations of calcium-magnesium and of calcium-potassium, and for each found a statistically non-significant increase in both SBP and DBP. All three trials investigated the potassium-magnesium combination. None of the trials provided mortality or morbidity data. The potassium-magnesium combination compared to control resulted in statistically non-significant reductions in both SBP (mean difference = -4.6 mmHg, 95% CI: -9.9 to 0.7) and DBP (mean difference = -3.8 mmHg, 95% CI: -9.5 to 1.8), although the results were heterogeneous (I2=68% and 85% for SBP and DBP respectively).A sensitivity analysis using alternative reported values which accounted for missing data had very little effect on DBP but resulted in a larger, statistically significant reduction in SBP (mean difference = -5.8 mmHg, 95% CI: -10.5 to -1.0).The quality of the trials was not well reported.Authors&apos; conclusions: We found no robust evidence that supplements of any combination of potassium, magnesium or calcium reduce mortality, morbidity or BP in adults. More trials are needed to investigate whether the combination of potassium &amp; magnesium is effective.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004805.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004805.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>546</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">546</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bheekie, Angeni</style></author><author><style face="normal" font="default" size="100%">Obikeze, Kenechukwu</style></author><author><style face="normal" font="default" size="100%">Nicolson, Ronald</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin converting enzyme inhibitor induced angioedema in patients with primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007437</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To determine the incidence of angioedema associated with ACE inhibitors versus placebo in the treatment of primary hypertension.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007437/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007437</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>48</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">48</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Birns, J.</style></author><author><style face="normal" font="default" size="100%">Morris, R.</style></author><author><style face="normal" font="default" size="100%">Donaldson, N.</style></author><author><style face="normal" font="default" size="100%">Kalra, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1907-1914</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006007356</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006007356/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>547</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">547</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bizzarro, Matthew</style></author><author><style face="normal" font="default" size="100%">Gross, Ian</style></author><author><style face="normal" font="default" size="100%">Barbosa Fabiano, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Defects, Congenital [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Diseases [congenital] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Postoperative Complications [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Anaesth</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005055</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Nitric oxide (NO) is a prevalent molecule in humans that is responsible for many physiologic activities including pulmonary vasodilation. An exogenous, inhaled form (iNO) exists that mimics this action without affecting systemic blood pressure. This therapy has been implemented in the treatment of pulmonary hypertension. This review examines the efficacy of iNO in the postoperative management of infants and children with congenital heart disease (CHD). The original review was published in 2005, updated in 2008 and again in 2014.Objectives: To compare the effects of postoperative administration of iNO versus placebo or conventional management, or both, on infants and children with CHD and pulmonary hypertension. The primary outcome was mortality. Secondary outcomes included length of hospital stay; neurodevelopmental disability; number of pulmonary hypertensive crises (PHTC); changes in mean pulmonary arterial pressure (MPAP), mean arterial pressure (MAP), and heart rate (HR); changes in oxygenation measured as the ratio of arterial oxygen tension (PaO2) to fraction of inspired oxygen (FiO2); and measurement of maximum methaemoglobin level as a marker of toxicity.Search methods: In this updated version we extended the CENTRAL search to 2013, Issue 12 of The Cochrane Library, and MEDLINE and EMBASE through to 1 December 2013. The original search was performed in July 2004 and again in November 2007. We included abstracts and all languages.Selection criteria: We included randomized and quasi-randomized controlled trials comparing iNO with placebo or conventional management, or both. Trials included only children with CHD requiring surgery complicated by pulmonary hypertension.Data collection and analysis: Two authors extracted data. Data were collected on mortality; number of PHTC; changes in MPAP, MAP, HR, and PaO2:FiO2; and maximum methaemoglobin level. Data on long-term mortality, neurodevelopmental disability, and length of hospital stay were unavailable. We performed subgroup analysis by method of control (placebo or conventional management).Main results: We reran the searches to December 2013 and identified three new studies. These three studies did not fulfil our inclusion criteria. Therefore, no new studies were included in this updated review. In total four randomized trials involving 210 participants were included in this review. We observed no differences in mortality (OR 1.67, 95% CI 0.38 to 7.30; P = 0.50); PHTC (OR 0.80, 95% CI 0.15 to 4.18; P = 0.79); changes in MPAP (treatment effect -2.94 mm Hg, 95% CI -9.28 to 3.40; P = 0.36), MAP (treatment effect -3.55 mm Hg, 95% CI -11.86 to 4.76; P = 0.40), HR (treatment effect 0.02 bpm, 95% CI -8.13 to 8.18; P = 1.00), or PaO2:FiO2 (mean difference 17.18, 95% CI -28.21 to 62.57; P = 0.46). There was a significant increase in the methaemoglobin level (mean difference 0.30%, 95% CI 0.24 to 0.36; P &lt; 0.00001) in patients treated with iNO, although levels did not reach toxicity levels. Data from long-term mortality, neurodevelopmental disability, and length of stay were not available. Two trials had a low risk of bias. Very low quality of the evidence was observed considering grading of the outcomes.Authors&apos; conclusions: We observed no differences with the use of iNO in the outcomes reviewed. No data were available for several clinical outcomes including long-term mortality and neurodevelopmental outcome. We found it difficult to draw valid conclusions given concerns regarding methodologic quality, sample size, and heterogeneity.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005055.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005055.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>49</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">49</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bliziotis, I. A.</style></author><author><style face="normal" font="default" size="100%">Destounis, A.</style></author><author><style face="normal" font="default" size="100%">Stergiou, G. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1289-1299</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Echocardiography</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Ventricles [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [pathology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012033315</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012033315/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>50</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">50</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blohm, D.</style></author><author><style face="normal" font="default" size="100%">Ploch, T.</style></author><author><style face="normal" font="default" size="100%">Apelt, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy of exercise therapy to reduce cardiometabolic risk factors in overweight and obese children and adolescents: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Deutsche Medizinische Wochenschrift</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Deutsche Medizinische Wochenschrift</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2631-2636</style></pages><volume><style face="normal" font="default" size="100%">137</style></volume><number><style face="normal" font="default" size="100%">50</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Dyslipidemias [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Therapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolic Syndrome X [etiology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Overweight [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013002710</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013002710/frame.html</style></url><url><style face="normal" font="default" size="100%">https://www.thieme-connect.com/DOI/DOI?10.1055/s-0032-1327333</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>548</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">548</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bolignano, Davide</style></author><author><style face="normal" font="default" size="100%">Palmer Suetonia, C.</style></author><author><style face="normal" font="default" size="100%">Navaneethan Sankar, D.</style></author><author><style face="normal" font="default" size="100%">Strippoli Giovanni, F. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Aldosterone antagonists for preventing the progression of chronic kidney disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperkalemia [chemically induced] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Mineralocorticoid Receptor Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007004</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Treatment with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is increasingly used to reduce proteinuria and retard the progression of chronic kidney disease (CKD). However, resolution of proteinuria may be incomplete with these therapies and the addition of an aldosterone antagonist may be added to further prevent progression of CKD. This is an update of a review first published in 2009.Objectives: To evaluate the effect of aldosterone antagonists (both selective (eplerenone) and non-selective (spironolactone)) alone or in combination with ACEi or ARB in adults who have CKD with proteinuria (nephrotic and non-nephrotic range) on: patient-centred endpoints including major cardiovascular events, hospitalisation and all-cause mortality; kidney function (proteinuria, glomerular filtration rate (GFR), serum creatinine, and need for renal replacement therapy; and adverse events (including gynaecomastia and hyperkalaemia).Search methods: For this update, we searched the Cochrane Renal Group&apos;s Specialised Register to 30 January 2013 using search terms relevant to this review.Selection criteria: We included randomised controlled trials (RCTs) and quasi-RCTs that compared aldosterone antagonists alone or in combination with ACEi or ARB (or both) with other anti-hypertensive strategies or placebo.Data collection and analysis: Two authors independently assessed study quality and extracted data. Data were summarised using random effects meta-analysis. We tested for heterogeneity in estimated treatment effects using the Cochran Q test and I² statistic. We expressed summary treatment estimates as a risk ratio (RR) for dichotomous outcomes together with their 95% confidence intervals (CI) and mean difference (MD) for continuous outcomes, or standardised mean difference (SMD) when different scales were used.Main results: We identified 27 studies (1549 participants) that were eligible for inclusion. These studies provided no data relating to aldosterone antagonists in addition to ACEi or ARB (or both) on patient-level outcomes including major cardiovascular events and mortality and progression to end-stage kidney disease (ESKD) requiring dialysis or transplantation.Compared with ACEi or ARB (or both), non-selective aldosterone antagonists (spironolactone) combined with ACEi or ARB (or both) significantly reduced 24-hour protein excretion (11 studies, 596 participants): SMD -0.61, 95% CI -1.08 to -0.13). There was a significant reduction in both systolic and diastolic blood pressure (BP) at the end of treatment with additional non-selective aldosterone antagonist therapy (systolic BP (10 studies, 556 participants): MD -3.44 mm Hg, 95% CI -5.05 to -1.83) (diastolic BP (9 studies, 520 participants): MD -1.73 mm Hg, 95% CI -2.83 to -0.62).However, we found that aldosterone antagonist treatment had imprecise effects at the end of treatment on GFR (9 studies, 528 participants; MD -2.55 mL/min/1.73 m², 95% CI -5.67 to 0.51), doubled the risk of hyperkalaemia (11 studies, 632 patients): RR 2.00, 95% CI 1.25 to 3.20; number needed to treat for an additional harmful outcome (NNTH): 7.2, 95% CI 3.4 to ?) and increased the risk of gynaecomastia compared to ACEi or ARB (or both) (4 studies, 281 patients): RR 5.14, 95% CI 1.14 to 23.23; NNTH: 14.1, 95% CI 8.7 to 37.3).Most studies enrolled few patients (range 12 to 268) and were powered to observe differences in surrogate end points rather than patient-focused outcomes. Nine studies had a cross-over design and the majority of studies did not adequately report study methods to assess methods and study quality.Authors&apos; conclusions: Aldosterone antagonists reduced proteinuria and blood pressure in adults who had mild to moderate CKD and were treated with ACEi or ARB (or both), but increase hyperkalaemia and gynaecomastia. Whether adding aldosterone antagonists to ACEi or ARB (or both) reduced the risk of major cardiovascular events or ESKD in this population is unknown.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007004.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007004.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>51</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">51</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bommel, E.</style></author><author><style face="normal" font="default" size="100%">Cleophas, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Potassium treatment for hypertension in patients with high salt intake: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Clinical Pharmacology and Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Clinical Pharmacology and Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">478-482</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diastole</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium, Dietary [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Systole</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012036804</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012036804/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>52</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">52</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bor-Seng-Shu, E.</style></author><author><style face="normal" font="default" size="100%">Figueiredo, E. G.</style></author><author><style face="normal" font="default" size="100%">Amorim, R. L.</style></author><author><style face="normal" font="default" size="100%">Teixeira, M. J.</style></author><author><style face="normal" font="default" size="100%">Valbuza, J. S.</style></author><author><style face="normal" font="default" size="100%">Oliveira, M. M.</style></author><author><style face="normal" font="default" size="100%">Panerai, R. B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Decompressive craniectomy: a meta-analysis of influences on intracranial pressure and cerebral perfusion pressure in the treatment of traumatic brain injury (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">589-596</style></pages><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Brain Injuries</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Decompressive Craniectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012043561</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012043561/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>53</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">53</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bortel, L. M.</style></author><author><style face="normal" font="default" size="100%">Fici, F.</style></author><author><style face="normal" font="default" size="100%">Mascagni, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Cardiovascular Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Cardiovascular Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35-44</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzopyrans [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Ethanolamines [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Losartan [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008104592</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008104592/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>549</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">549</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bosch-Capblanch, Xavier</style></author><author><style face="normal" font="default" size="100%">Abba, Katharine</style></author><author><style face="normal" font="default" size="100%">Prictor, Megan</style></author><author><style face="normal" font="default" size="100%">Garner, Paul</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Contracts between patients and healthcare practitioners for improving patients&apos; adherence to treatment, prevention and health promotion activities</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Patient Compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Physician-Patient Relations</style></keyword><keyword><style face="normal" font="default" size="100%">Consumer Participation</style></keyword><keyword><style face="normal" font="default" size="100%">Contracts [standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Health Promotion [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Commun</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004808</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Contracts are a verbal or written agreement that a patient makes with themselves, with healthcare practitioners, or with carers, where participants commit to a set of behaviours related to the care of a patient. Contracts aim to improve the patients&apos; adherence to treatment or health promotion programmes.Objectives: To assess the effects of contracts between patients and healthcare practitioners on patients&apos; adherence to treatment, prevention and health promotion activities, the stated health or behaviour aims in the contract, patient satisfaction or other relevant outcomes, including health practitioner behaviour and views, health status, reported harms, costs, or denial of treatment as a result of the contract.Search methods: We searched: the Cochrane Consumers and Communication Review Group&apos;s Specialised Register (in May 2004); the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library 2004, issue 1); MEDLINE 1966 to May 2004); EMBASE (1980 to May 2004); PsycINFO (1966 to May 2004); CINAHL (1982 to May 2004); Dissertation Abstracts. A: Humanities and Social Sciences (1966 to May 2004); Sociological Abstracts (1963 to May 2004); UK National Research Register (2000 to May 2004); and C2-SPECTR, Campbell Collaboration (1950 to May 2004).Selection criteria: We included randomised controlled trials comparing the effects of contracts between healthcare practitioners and patients or their carers on patient adherence, applied to diagnostic procedures, therapeutic regimens or any health promotion or illness prevention initiative for patients. Contracts had to specify at least one activity to be observed and a commitment of adherence to it. We included trials comparing contracts with routine care or any other intervention.Data collection and analysis: Selection and quality assessment of trials were conducted independently by two review authors; single data extraction was checked by a statistician. We present the data as a narrative summary, given the wide range of interventions, participants, settings and outcomes, grouped by the health problem being addressed.Main results: We included thirty trials, all conducted in high income countries, involving 4691 participants. Median sample size per group was 21. We examined the quality of each trial against eight standard criteria, and all trials were inadequate in relation to three or more of these standards. Trials evaluated contracts in addiction (10 trials), hypertension (4 trials), weight control (3 trials) and a variety of other areas (13 trials). Fifteen trials reported at least one outcome that showed statistically significant differences favouring the contracts group, six trials reported at least one outcome that showed differences favouring the control group and 26 trials reported at least one outcome without differences between groups. Effects on adherence were not detected when measured over longer periods.Authors&apos; conclusions: There is limited evidence that contracts can potentially contribute to improving adherence, but there is insufficient evidence from large, good quality studies to routinely recommend contracts for improving adherence to treatment or preventive health regimens.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004808.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004808.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>54</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">54</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boudville, N.</style></author><author><style face="normal" font="default" size="100%">Ramesh Prasad, G. V.</style></author><author><style face="normal" font="default" size="100%">Knoll, G.</style></author><author><style face="normal" font="default" size="100%">Muirhead, N.</style></author><author><style face="normal" font="default" size="100%">Thiessen-Philbrook, H.</style></author><author><style face="normal" font="default" size="100%">Yang, R. C.</style></author><author><style face="normal" font="default" size="100%">Rosas-Arellano, M. P.</style></author><author><style face="normal" font="default" size="100%">Housawi, A.</style></author><author><style face="normal" font="default" size="100%">Garg, A. X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis: risk for hypertension in living kidney donors (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">185-196</style></pages><volume><style face="normal" font="default" size="100%">145</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney</style></keyword><keyword><style face="normal" font="default" size="100%">Living Donors</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006008346</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006008346/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>55</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">55</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bradley, H. A.</style></author><author><style face="normal" font="default" size="100%">Wiysonge, C. S.</style></author><author><style face="normal" font="default" size="100%">Volmink, J. A.</style></author><author><style face="normal" font="default" size="100%">Mayosi, B. M.</style></author><author><style face="normal" font="default" size="100%">Opie, L. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">How strong is the evidence for use of beta-blockers as first-line therapy for hypertension: systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2131-2141</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006007739</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006007739/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">56</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bray, E. P.</style></author><author><style face="normal" font="default" size="100%">Holder, R.</style></author><author><style face="normal" font="default" size="100%">Mant, J.</style></author><author><style face="normal" font="default" size="100%">McManus, R. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">371-386</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010004653</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010004653/frame.html</style></url><url><style face="normal" font="default" size="100%">http://informahealthcare.com/doi/abs/10.3109/07853890.2010.489567</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>550</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">550</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brewster Lizzy, L. M.</style></author><author><style face="normal" font="default" size="100%">Kleijnen, Jos</style></author><author><style face="normal" font="default" size="100%">van Montfrans Gert, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">African Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Retraction of Publication as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005183</style></accession-num><abstract><style face="normal" font="default" size="100%">The editorial group and reviewers responsible for this previously published review have withdrawn it from publication.REASON FOR WITHDRAWAL This systematic review has been withdrawn temporarily (suspended) because of failure of the review authors and editorial group to agree on some aspects of the interpretation of the review results.  A revised version will be published in a future issue of The Cochrane Library.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005183.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005183.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>57</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">57</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brewster, L. M.</style></author><author><style face="normal" font="default" size="100%">Montfrans, G. A.</style></author><author><style face="normal" font="default" size="100%">Kleijnen, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review: antihypertensive drug therapy in black patients (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">614-627</style></pages><volume><style face="normal" font="default" size="100%">141</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic alpha-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">African Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 2 Receptor Blockers</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [ethnology] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sympatholytics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004006737</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004006737/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>58</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">58</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Briasoulis, A.</style></author><author><style face="normal" font="default" size="100%">Agarwal, V.</style></author><author><style face="normal" font="default" size="100%">Tousoulis, D.</style></author><author><style face="normal" font="default" size="100%">Stefanadis, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Heart</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Heart</style></full-title></periodical><pages><style face="normal" font="default" size="100%">317-323</style></pages><volume><style face="normal" font="default" size="100%">100</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013037618</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013037618/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>59</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">59</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Briasoulis, A.</style></author><author><style face="normal" font="default" size="100%">Agarwal, V.</style></author><author><style face="normal" font="default" size="100%">Valachis, A.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive effects of statins: a meta-analysis of prospective controlled studies (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">310-320</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypercholesterolemia [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013022398</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013022398/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>60</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">60</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brown, T.</style></author><author><style face="normal" font="default" size="100%">Avenell, A.</style></author><author><style face="normal" font="default" size="100%">Edmunds, L. D.</style></author><author><style face="normal" font="default" size="100%">Moore, H.</style></author><author><style face="normal" font="default" size="100%">Whittaker, V.</style></author><author><style face="normal" font="default" size="100%">Avery, L.</style></author><author><style face="normal" font="default" size="100%">Summerbell, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review of long-term lifestyle interventions to prevent weight gain and morbidity in adults (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Obesity Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Obesity Reviews</style></full-title></periodical><pages><style face="normal" font="default" size="100%">627-638</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Behavior Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Fat-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Reducing</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Food, Formulated</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolic Syndrome X [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Gain</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000054</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000054/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>61</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">61</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brownstein, J. N.</style></author><author><style face="normal" font="default" size="100%">Chowdhury, F. M.</style></author><author><style face="normal" font="default" size="100%">Norris, S. L.</style></author><author><style face="normal" font="default" size="100%">Horsley, T.</style></author><author><style face="normal" font="default" size="100%">Jack, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, X.</style></author><author><style face="normal" font="default" size="100%">Satterfield, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effectiveness of community health workers in the care of people with hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Preventive Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Preventive Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">435-447</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Community Health Services [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008103592</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008103592/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>62</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">62</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, M. S.</style></author><author><style face="normal" font="default" size="100%">Feldman, J. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">728-740</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Arteries</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiac Surgical Procedures</style></keyword><keyword><style face="normal" font="default" size="100%">dosage [pharmacology] [therapeutic use] [pharmacology] [therapeutic use] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010007438</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010007438/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>63</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">63</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, M. S.</style></author><author><style face="normal" font="default" size="100%">Staib, R. L.</style></author><author><style face="normal" font="default" size="100%">Wicks, L. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combination therapy in the management of pulmonary arterial hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">13-23</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">Supplement 179</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013022133</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013022133/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>551</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">551</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Burr, J. M.</style></author><author><style face="normal" font="default" size="100%">Botello-Pinzon, P.</style></author><author><style face="normal" font="default" size="100%">Takwoingi, Y.</style></author><author><style face="normal" font="default" size="100%">Hernández, R.</style></author><author><style face="normal" font="default" size="100%">Vazquez-Montes, M.</style></author><author><style face="normal" font="default" size="100%">Elders, A.</style></author><author><style face="normal" font="default" size="100%">Asaoka, R.</style></author><author><style face="normal" font="default" size="100%">Banister, K.</style></author><author><style face="normal" font="default" size="100%">Schoot, J.</style></author><author><style face="normal" font="default" size="100%">Fraser, C.</style></author><author><style face="normal" font="default" size="100%">King, A.</style></author><author><style face="normal" font="default" size="100%">Lemij, H.</style></author><author><style face="normal" font="default" size="100%">Sanders, R.</style></author><author><style face="normal" font="default" size="100%">Vernon, S.</style></author><author><style face="normal" font="default" size="100%">Tuulonen, A.</style></author><author><style face="normal" font="default" size="100%">Kotecha, A.</style></author><author><style face="normal" font="default" size="100%">Glasziou, P.</style></author><author><style face="normal" font="default" size="100%">Garway-Heath, D.</style></author><author><style face="normal" font="default" size="100%">Crabb, D.</style></author><author><style face="normal" font="default" size="100%">Vale, L.</style></author><author><style face="normal" font="default" size="100%">Azuara-Blanco, A.</style></author><author><style face="normal" font="default" size="100%">Perera, R.</style></author><author><style face="normal" font="default" size="100%">Ryan, M.</style></author><author><style face="normal" font="default" size="100%">Deeks, J.</style></author><author><style face="normal" font="default" size="100%">Cook, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Surveillance for ocular hypertension: an evidence synthesis and economic evaluation (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Population Surveillance</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">Health Technology Assessment</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000313</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000313/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>552</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">552</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cadth,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combination therapy for pulmonary arterial hypertension: a review of the clinical effectiveness (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphodiesterase 5 Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Agency for Drugs and Technologies in Health (CADTH)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000037</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000037/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>553</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">553</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cadth,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Azilsartan Medoxomil (Edarbi - Takeda Canada Inc.) indication: mild to moderate essential hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Benzimidazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Oxadiazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Agency for Drugs and Technologies in Health (CADTH)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32014000878</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32014000878/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>554</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">554</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cadth,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Azilsartan Medoxomil + Chlorthalidone (Edarbyclor- Takeda Canada Inc.) indication: severe hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Benzimidazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Chlorthalidone</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Oxadiazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Agency for Drugs and Technologies in Health (CADTH)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32014000873</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32014000873/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>555</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">555</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cadth,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Frequency of blood pressure measurements for children and adults: evidence-based guidelines (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Agency for Drugs and Technologies in Health (CADTH)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32014000910</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32014000910/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>64</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">64</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cai, L.</style></author><author><style face="normal" font="default" size="100%">Wu, Y.</style></author><author><style face="normal" font="default" size="100%">Wilson, R. F.</style></author><author><style face="normal" font="default" size="100%">Segal, J. B.</style></author><author><style face="normal" font="default" size="100%">Kim, M. T.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of childhood obesity prevention programs on blood pressure: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Circulation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Circulation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1832-1839</style></pages><volume><style face="normal" font="default" size="100%">129</style></volume><number><style face="normal" font="default" size="100%">18</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014015025</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014015025/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>65</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">65</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cai, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Laparoscopic versus open splenectomy for portal hypertension: a systematic review of comparative studies (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Surgical Innovation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Surgical Innovation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">442-447</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Portal</style></keyword><keyword><style face="normal" font="default" size="100%">Laparoscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Splenectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014011915</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014011915/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>66</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">66</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caielli, P.</style></author><author><style face="normal" font="default" size="100%">Frigo, A. C.</style></author><author><style face="normal" font="default" size="100%">Pengo, M. F.</style></author><author><style face="normal" font="default" size="100%">Rossitto, G.</style></author><author><style face="normal" font="default" size="100%">Maiolino, G.</style></author><author><style face="normal" font="default" size="100%">Seccia, T. M.</style></author><author><style face="normal" font="default" size="100%">Calo, L. A.</style></author><author><style face="normal" font="default" size="100%">Miotto, D.</style></author><author><style face="normal" font="default" size="100%">Rossi, G. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of atherosclerotic renovascular hypertension: review of observational studies and a meta-analysis of randomized clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Atherosclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Renal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014027897</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014027897/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>67</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">67</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Calvin, A. D.</style></author><author><style face="normal" font="default" size="100%">Aggarwal, N. R.</style></author><author><style face="normal" font="default" size="100%">Hassan Murad, M.</style></author><author><style face="normal" font="default" size="100%">Shi, Q.</style></author><author><style face="normal" font="default" size="100%">Elamin, M. B.</style></author><author><style face="normal" font="default" size="100%">Geske, J. B.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Balsells, M. M.</style></author><author><style face="normal" font="default" size="100%">Albuquerque, F. N.</style></author><author><style face="normal" font="default" size="100%">Lampropulos, J. F.</style></author><author><style face="normal" font="default" size="100%">Erwin, P. J.</style></author><author><style face="normal" font="default" size="100%">Smith, S. A.</style></author><author><style face="normal" font="default" size="100%">Montori, V. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetes Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diabetes Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2300-2306</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aspirin [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Angiopathies [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Observer Variation</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Prevention [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000552</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000552/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>556</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">556</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Campbell, Fiona</style></author><author><style face="normal" font="default" size="100%">Critchley Julia, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Fish oil supplements for the prevention and treatment of hypertension in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010021</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the effectiveness of fish oil supplements in reducing blood pressure in both normotensive and hypertensive populations.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010021/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010021</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>68</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">68</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Campbell, F.</style></author><author><style face="normal" font="default" size="100%">Dickinson, H. O.</style></author><author><style face="normal" font="default" size="100%">Critchley, J. A.</style></author><author><style face="normal" font="default" size="100%">Ford, G. A.</style></author><author><style face="normal" font="default" size="100%">Bradburn, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review of fish-oil supplements for the prevention and treatment of hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Preventive Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Preventive Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">107-120</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Fish Oils [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013014878</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013014878/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>69</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">69</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Canter, P. H.</style></author><author><style face="normal" font="default" size="100%">Ernst, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Insufficient evidence to conclude whether or not transcendental meditation decreases blood pressure: results of a systematic review of randomized clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2049-2054</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Meditation</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004006955</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004006955/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>70</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">70</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cappuccio, F. P.</style></author><author><style face="normal" font="default" size="100%">Kerry, S. M.</style></author><author><style face="normal" font="default" size="100%">Forbes, L.</style></author><author><style face="normal" font="default" size="100%">Donald, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure control by home monitoring: meta-analysis of randomised trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><pages><style face="normal" font="default" size="100%">145-148</style></pages><volume><style face="normal" font="default" size="100%">329</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Arteries [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Home Care Services</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004008571</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004008571/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">71</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carlberg, B.</style></author><author><style face="normal" font="default" size="100%">Samuelsson, O.</style></author><author><style face="normal" font="default" size="100%">Lindholm, L. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Atenolol in hypertension: is it a wise choice? (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1684-1689</style></pages><volume><style face="normal" font="default" size="100%">364</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Atenolol [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Atenolol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004006990</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004006990/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>72</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">72</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carlson, D. J.</style></author><author><style face="normal" font="default" size="100%">Dieberg, G.</style></author><author><style face="normal" font="default" size="100%">Hess, N. C.</style></author><author><style face="normal" font="default" size="100%">Millar, P. J.</style></author><author><style face="normal" font="default" size="100%">Smart, N. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Isometric exercise training for blood pressure management: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">327-334</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014017113</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014017113/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>73</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">73</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carter, B. L.</style></author><author><style face="normal" font="default" size="100%">Rogers, M.</style></author><author><style face="normal" font="default" size="100%">Daly, J.</style></author><author><style face="normal" font="default" size="100%">Zheng, S.</style></author><author><style face="normal" font="default" size="100%">James, P. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The potency of team-based care interventions for hypertension: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1748-1755</style></pages><volume><style face="normal" font="default" size="100%">169</style></volume><number><style face="normal" font="default" size="100%">19</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Nurse&apos;s Role</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Care Team</style></keyword><keyword><style face="normal" font="default" size="100%">Patient-Centered Care [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacists</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care [methods] [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009109344</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009109344/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>557</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">557</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castellanos Eddy, Ríos</style></author><author><style face="normal" font="default" size="100%">Seron, Pamela</style></author><author><style face="normal" font="default" size="100%">Gisbert Javier, P.</style></author><author><style face="normal" font="default" size="100%">Bonfill Cosp, Xavier</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in patients with portal hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Liver</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010180</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the benefits and harms of cyanoacrylate sclerotherapy compared with placebo,r no intervention or other endoscopic sclerotherapy procedures in acute gastric variceal bleeding and variceal band ligation with or without vasoactive drugs in patients with portal hypertension.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010180/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010180</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>74</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">74</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chan, C. C.</style></author><author><style face="normal" font="default" size="100%">Reid, C. M.</style></author><author><style face="normal" font="default" size="100%">Aw, T. J.</style></author><author><style face="normal" font="default" size="100%">Liew, D.</style></author><author><style face="normal" font="default" size="100%">Haas, S. J.</style></author><author><style face="normal" font="default" size="100%">Krum, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2332-2341</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclooxygenase 2 Inhibitors [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000781</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000781/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>558</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">558</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chan Kenneth, K.</style></author><author><style face="normal" font="default" size="100%">Lai, Peggy</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">First-line beta-blockers versus other antihypertensive medications for chronic type B aortic dissection</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Aneurysm, Dissecting [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Aortic Aneurysm, Thoracic [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010426</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Thoracic aortic dissection (TAD) is a severe and often lethal complication in people with hypertension. Current practice in the treatment of chronic type B aortic dissections is the use of beta-blockers as first-line therapy to decrease aortic wall stress. Other antihypertensive medications, such as calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), have been suggested for the medical therapy of type B TAD.Objectives: To assess the effects of first-line beta-blockers compared with other first-line antihypertensive drug classes for treating chronic type B TAD.Search methods: We searched the Database of Abstracts of Reviews of Effects (DARE) for related reviews. We searched the Hypertension Group Specialised Register (1946 to 26 January 2014), the Cochrane Central Register of Controlled Trials (2014, Issue 1), MEDLINE (1946 to 24 January 2014), MEDLINE In-Process, EMBASE (1974 to 24 January 2014) and ClinicalTrials.gov (to 26 January 2014).Selection criteria: We considered randomized controlled trials (RCTs) comparing different antihypertensive medications in the treatment of chronic type B TAD to be eligible for inclusion. Total mortality rate was the primary outcome of this review. Secondary outcomes included total non-fatal adverse events relating to TADs and number of people not requiring surgical treatment.Data collection and analysis: Two review authors (KC, PL) independently reviewed titles and abstracts and decided on studies to include based on the inclusion criteria. We resolved discrepancies between the two review authors by discussion.Main results: After a thorough review of the search results, we identified no studies that met the inclusion criteria.Authors&apos; conclusions: We did not find any RCTs that compared first-line beta-blockers with other first-line antihypertensive medications for the treatment of chronic type B TAD. Therefore, there is no RCT evidence to support the current guidelines recommending the use of beta-blockers. RCTs are required to assess the benefits and harms of beta-blockers and other antihypertensive medications as first-line treatment of chronic type B TAD.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010426.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010426.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>559</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">559</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chandrasekaran, Baskaran</style></author><author><style face="normal" font="default" size="100%">Arumugam, Ashokan</style></author><author><style face="normal" font="default" size="100%">Davis, Fiddy</style></author><author><style face="normal" font="default" size="100%">Kumaran, D. Senthil</style></author><author><style face="normal" font="default" size="100%">Chandrasharma, Bidhan</style></author><author><style face="normal" font="default" size="100%">Khundrakpam, Chinglembi</style></author><author><style face="normal" font="default" size="100%">Chanam, Lokeshowri</style></author><author><style face="normal" font="default" size="100%">Philipraj, S. Joseph</style></author><author><style face="normal" font="default" size="100%">Sanathombi Devi, Rajkumari</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Resistance exercise training for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008822</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the evidence for effectiveness of resistance exercise training in the management of hypertension when compared to aerobic exercise training, no exercise training or usual care.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008822/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008822</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>75</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">75</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chang, B. B.</style></author><author><style face="normal" font="default" size="100%">Wang, F.</style></author><author><style face="normal" font="default" size="100%">Xu, T. Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Q. Q.</style></author><author><style face="normal" font="default" size="100%">He, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, X. J.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Total flavones of Hippophae rhamnoides L. for essential hypertension: a systematic review of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1207-1213</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Flavonoids [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hippophae</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010001630</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010001630/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>76</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">76</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chang-Quan, H.</style></author><author><style face="normal" font="default" size="100%">Hui, W.</style></author><author><style face="normal" font="default" size="100%">Chao-Min, W.</style></author><author><style face="normal" font="default" size="100%">Zheng-Rong, W.</style></author><author><style face="normal" font="default" size="100%">Jun-Wen, G.</style></author><author><style face="normal" font="default" size="100%">Yong-Hong, L.</style></author><author><style face="normal" font="default" size="100%">Yan-You, L.</style></author><author><style face="normal" font="default" size="100%">Qing-Xiu, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1295-1305</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012000073</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012000073/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>77</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">77</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Charan, J.</style></author><author><style face="normal" font="default" size="100%">Goyal, J. P.</style></author><author><style face="normal" font="default" size="100%">Saxena, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Pollypill on cardiovascular parameters: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Cardiovascular Disease Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Cardiovascular Disease Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">92-97</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013048817</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013048817/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>560</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">560</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chaturvedi, Swasti</style></author><author><style face="normal" font="default" size="100%">Lipszyc Deborah, H.</style></author><author><style face="normal" font="default" size="100%">Licht, Christoph</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author><author><style face="normal" font="default" size="100%">Parekh, Rulan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacological interventions for hypertension in children</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008117</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Hypertension is a major risk factor for stroke, coronary artery disease and kidney damage in adults. There is a paucity of data on the long-term sequelae of persistent hypertension in children, but it is known that children with hypertension have evidence of end organ damage and are at risk of hypertension into adulthood. The prevalence of hypertension in children is rising, most likely due to a concurrent rise in obesity rates. In children with hypertension, non-pharmacological measures are often recommended as first-line therapy, but a significant proportion of children will eventually require pharmacological treatment to reduce blood pressure, especially those with evidence of end organ damage at presentation or during follow-up. A systematic review of the effects of antihypertensive agents in children has not previously been conducted.Objectives: To determine the dose-related effects of different classes of antihypertensive medications, as monotherapy compared to placebo; as combination therapy compared to placebo or a single medication; or in comparisons of various doses within the same class, on systolic or diastolic blood pressure (or both) in children with hypertension.Search methods: We searched the Cochrane Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 9), Ovid MEDLINE (1946 to October 2013), Ovid EMBASE (1974 to October 2013) and bibliographic citations.Selection criteria: The selection criteria were deliberately broad due to there being few clinical trials in children. We included randomised controlled trials (RCTs) of at least two weeks duration comparing antihypertensive agents either as monotherapy or combination therapy with either placebo or another medication, or comparing different doses of the same medication, in children with hypertension. Hypertension was defined as an average (over a minimum of three readings) systolic or diastolic blood pressure (or both) on the 95th percentile or above for age, height and gender. Data collection and analysis: Two authors independently selected relevant studies, extracted data and assessed risk of bias. We summarised data, where possible, using a random-effects model. Formal assessment of heterogeneity was not possible because of insufficient data.Main results: A total of 21 trials evaluated antihypertensive medications of various drug classes in 3454 hypertensive children with periods of follow-up ranging from three to 24 weeks. There were five RCTs comparing an antihypertensive drug directly with placebo, 12 dose-finding trials, two trials comparing calcium channel blockers with angiotensin receptor blockers, one trial comparing a centrally acting alpha blocker with a diuretic and one trial comparing an angiotensin-converting enzyme inhibitor with an angiotensin receptor blocker. No randomised trial was identified that evaluated the effectiveness of antihypertensive medications on target end organ damage. The trials were of variable quality and most were funded by pharmaceutical companies.Among the angiotensin receptor blockers, candesartan (one trial, n = 240), when compared to placebo, reduced systolic blood pressure by 6.50 mmHg (95% confidence interval (CI) -9.44 to -3.56) and diastolic blood pressure by 5.50 mmHg (95% CI -9.62 to -1.38) (low-quality evidence). High dose telmisartan (one trial, n = 76), when compared to placebo, reduced systolic blood pressure by -8.50 (95% CI -13.79 to -3.21) but not diastolic blood pressure (-4.80, 95% CI -9.50 to 0.10) (low-quality evidence). Beta blocker (metoprolol, one trial, n = 140), when compared with placebo , significantly reduced systolic blood pressure by 4.20 mmHg (95% CI -8.12 to -0.28) but not diastolic blood pressure (-3.20 mmHg 95% CI -7.12 to 0.72) (low-quality evidence). Beta blocker/diuretic combination (Bisoprolol/hydrochlorothiazide, one trial, n = 94)when compared with placebo , did not result in a significant reduction in systolic blood pressure (-4.0 mmHg, 95% CI -8.99 to -0.19) but did have an effect on diastolic blood pressure (-4.50 mmHg, 95% CI -8.26 to -0.74) (low-quality evidence). Calcium channel blocker (extended-release felodipine,one trial, n = 133) was not effective in reducing systolic blood pressure (-0.62 mmHg, 95% CI -2.97 to 1.73) or diastolic blood pressure (-1.86 mmHg, 95% CI -5.23 to 1.51) when compared with placebo. Further, there was no consistent dose response observed among any of the drug classes. The adverse events associated with the antihypertensive agents were mostly minor and included headaches, dizziness and upper respiratory infections.Authors&apos; conclusions: Overall, there are sparse data informing the use of antihypertensive agents in children, with outcomes reported limited to blood pressure and not end organ damage. The most data are available for candesartan, for which there is low-quality evidence of a modest lowering effect on blood pressure. We did not find evidence of a consistent dose response relationship for escalating doses of angiotensin receptor blockers, calcium channel blockers or angiotensin-converting enzyme inhibitors. All agents appear safe, at least in the short term.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008117.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008117.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>561</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">561</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chavez-Tapia Norberto, C.</style></author><author><style face="normal" font="default" size="100%">Barrientos-Gutierrez, Tonatiuh</style></author><author><style face="normal" font="default" size="100%">Tellez-Avila Felix, I.</style></author><author><style face="normal" font="default" size="100%">Soares-Weiser, Karla</style></author><author><style face="normal" font="default" size="100%">Uribe, Misael</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Hemorrhage [complications] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Cirrhosis [complications] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD002907</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Bacterial infections are a frequent complication in patients with cirrhosis and upper gastrointestinal bleeding. Antibiotic prophylaxis seems to decrease the incidence of bacterial infections. Oral antibiotics, active against enteric bacteria, have been commonly used as antibiotic prophylaxis in patients with cirrhosis and upper gastrointestinal bleeding. This is an update of a Cochrane review first published in 2002.Objectives: To assess the benefits and harms of antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding.Search methods: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index EXPANDED until June 2010. In addition, we handsearched the references of all identified studies.Selection criteria: Randomised clinical trials comparing different types of antibiotic prophylaxis with no intervention, placebo, or another antibiotic to prevent bacterial infections in cirrhotic patients with upper gastrointestinal bleeding.Data collection and analysis: Three authors independently assessed trial quality, risk of bias, and extracted data. We contacted study authors for additional information. Association measures were relative risk (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes.Main results: Twelve trials (1241 patients) evaluated antibiotic prophylaxis compared with placebo or no antibiotic prophylaxis. All trials were at risk of bias. Antibiotic prophylaxis compared with no intervention or placebo was associated with beneficial effects on mortality (RR 0.79, 95% CI 0.63 to 0.98), mortality from bacterial infections (RR 0.43, 95% CI 0.19 to 0.97), bacterial infections (RR 0.36, 95% CI 0.27 to 0.49), rebleeding (RR 0.53, 95% CI 0.38 to 0.74), days of hospitalisation (MD -1.91, 95% CI -3.80 to -0.02), bacteraemia (RR 0.25, 95% CI 0.15 to 0.40), pneumonia (RR 0.45, 95% CI 0.27 to 0.75), spontaneous bacterial peritonitis (RR 0.29, 95% CI 0.15 to 0.57), and urinary tract infections (RR 0.23, 95% CI 0.12 to 0.41). No serious adverse events were reported. The trials showed no significant heterogeneity of effects. Another five trials (650 patients) compared different antibiotic regimens. Data could not be combined as each trial used different antibiotic regimen. None of the examined antibiotic regimen was superior to the control regimen regarding mortality or bacterial infections.Authors&apos; conclusions: Prophylactic antibiotic use in patients with cirrhosis and upper gastrointestinal bleeding significantly reduced bacterial infections, and seems to have reduced all-cause mortality, bacterial infection mortality, rebleeding events, and hospitalisation length. These benefits were observed independently of the type of antibiotic used; thus, no specific antibiotic can be preferred. Therefore, antibiotic selection should be made considering local conditions such as bacterial resistance profile and treatment cost.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002907.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD002907.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>78</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">78</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cheema, E.</style></author><author><style face="normal" font="default" size="100%">Sutcliffe, P.</style></author><author><style face="normal" font="default" size="100%">Singer, D. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomised controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Community Pharmacy Services</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacists</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014040368</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014040368/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>79</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">79</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, G. J.</style></author><author><style face="normal" font="default" size="100%">Yang, M. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Effects of Calcium Channel Blockers in the Prevention of Stroke in Adults with Hypertension: A Meta-Analysis of Data from 273,543 Participants in 31 Randomized Controlled Trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Plos One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Plos One</style></full-title></periodical><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Confidence Intervals</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [drug therapy] [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013017088</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013017088/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>80</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">80</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, G. Z.</style></author><author><style face="normal" font="default" size="100%">Liu, W. H.</style></author><author><style face="normal" font="default" size="100%">Huo, J. P.</style></author><author><style face="normal" font="default" size="100%">Ma, X. Q.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of hand-assisted laparoscopic surgery and open surgery for portal hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">488-494</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hand-Assisted Laparoscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Laparotomy</style></keyword><keyword><style face="normal" font="default" size="100%">Postoperative Complications [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014003131</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014003131/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>562</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">562</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen Jenny, M. H.</style></author><author><style face="normal" font="default" size="100%">Heran Balraj, S.</style></author><author><style face="normal" font="default" size="100%">Perez Marco, I.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of drugs inhibiting the renin-angiotensin system as second-line therapy for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007188</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:Primary objective: To quantify the additional reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) of drugs inhibiting the renin-angiotensin system (RAS) as a second-line drug in hypertensive patients.Secondary objectives: 1. To determine the effects of second-line RAS inhibitor on variability of blood pressure. 2. To determine the effects of second-line RAS inhibitor on pulse pressure. 3. To quantify the effect of second-line RAS inhibitor on heart rate. 4. To quantify the effect of second-line RAS inhibitor on withdrawals due to adverse effects.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007188/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007188</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>563</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">563</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen Jenny, M. H.</style></author><author><style face="normal" font="default" size="100%">Heran Balraj, S.</style></author><author><style face="normal" font="default" size="100%">Perez Marco, I.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of calcium-channel blockers as second-line therapy for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007186</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:Primary objective: To quantify the additional reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) of calcium-channel blocker (CCB) therapy as a second-line drug in hypertensive patients.Secondary objectives: 1. To determine the effects of second-line CCB on variability of blood pressure. 2. To determine the effects of second-line CCB on pulse pressure. 3. To quantify the effect of second-line CCB on heart rate. 4. To quantify the effect of second-line CCB on withdrawals due to adverse effects.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007186/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007186</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>564</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">564</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen Jenny, M. H.</style></author><author><style face="normal" font="default" size="100%">Heran Balraj, S.</style></author><author><style face="normal" font="default" size="100%">Perez Marco, I.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007185</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Beta-blockers are one of the more commonly prescribed classes of anti-hypertensive drugs, both as first-line and second-line.Objectives: To quantify the effect on systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate and withdrawals due to adverse effects of beta-blocker therapy when given as a second-line drug in adult patients with primary hypertension.Search methods: CENTRAL (The Cochrane Library 2009, Issue 2), MEDLINE (1966-Aug 2009), EMBASE (1988-Aug 2009) and bibliographic citations of articles and reviews were searched.Selection criteria: Double-blind, randomized controlled trials comparing a beta-blocker in combination with a drug from another class of anti-hypertensive drugs compared with that drug alone for a duration of 3 to 12 weeks in patients with primary hypertension were included.Data collection and analysis: Two reviewers independently extracted the data and assessed trial quality of each included study.Main results: 20 double-blind RCTs evaluated the BP lowering efficacy of beta-blockers as second-line drug in 3744 hypertensive patients (baseline BP of 158/102 mmHg; mean duration of 7 weeks). The BP reduction from adding a beta-blocker as the second drug was estimated by comparing the difference in BP reduction between the combination and monotherapy groups. A reduction in BP was seen with adding a beta-blocker to thiazide diuretics or calcium channel blockers at doses as low as 0.25 times the manufacturer&apos;s recommended starting dose. The BP lowering efficacy of beta-blockers as a second drug was 6/4 mmHg at 1 times the starting dose and 8/6 mmHg at 2 times the starting dose. Beta-blockers reduced heart rate by 10 beats/min at 1 to 2 times the starting dose. Beta-blockers did not statistically significantly increase withdrawals due to adverse effects but this was likely due to the lack of reporting of this outcome in 35% of the included RCTs.Authors&apos; conclusions: Addition of a beta-blocker to diuretics or calcium-channel blockers reduces BP by 6/4mmHg at 1 times the starting dose and by 8/6 mmHg at 2 times the starting dose. When the blood pressure lowering effect of beta-blockers from this review was compared to that of thiazide diuretics from our previous review (Chen 2009), second-line beta-blockers reduce systolic BP to the same extent as second-line thiazide diuretics, but reduce diastolic BP to a greater degree. The different effect on diastolic BP means that beta-blockers have little or no effect on pulse pressure whereas thiazides cause a significant dose-related decrease in pulse pressure. This difference in the pattern of BP lowering with beta-blockers as compared to thiazides might be the explanation for the fact that beta-blockers appear to be less effective at reducing adverse cardiovascular outcomes than thiazide diuretics, particularly in older individuals.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007185.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007185.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>565</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">565</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen Jenny, M. H.</style></author><author><style face="normal" font="default" size="100%">Heran Balraj, S.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride Symporter Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Potassium Chloride Symporter Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007187</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Diuretics are widely prescribed for hypertension not only as a first-line drug but also as a second-line drug. Therefore, it is essential to determine the effects of diuretics on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAEs) when given as a second-line drug.Objectives: To quantify the additional reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) of diuretic therapy as a second-line drug in patients with primary hypertensionSearch methods: CENTRAL (The Cochrane Library 2008, Issue 2), MEDLINE (1966-July 2008), EMBASE (1988-July 2008) and bibliographic citations of articles and reviews were searched.Selection criteria: Double-blind, randomized, controlled trials evaluating the BP lowering efficacy of a diuretic in combination therapy with another class of anti-hypertensive drugs compared with the respective monotherapy (without a diuretic) for a duration of 3 to 12 weeks in patients with primary hypertension.Data collection and analysis: Two review authors independently extracted the data and assessed trial quality.Main results: Fifty-three double-blind RCTs evaluating a thiazide in 15129 hypertensive patients (baseline BP of 156/101 mmHg) were included. Hydrochlorothiazide was the thiazide used in 49/53 (92%) of the included studies. The additional BP reduction caused by the thiazide as a second drug was estimated by comparing the difference in BP reduction between the combination and monotherapy groups. Thiazides as a second-line drug reduced BP by 6/3 and 8/4 mmHg at doses of 1 and 2 times the manufacturer&apos;s recommended starting dose respectively. The BP lowering effect was dose related. The effect was similar to that obtained when thiazides are used as a single agent. Only 3 double-blind RCTs evaluating loop diuretics were identified. These RCTs showed a BP lowering effect of a starting dose of about 6/3 mmHg.Authors&apos; conclusions: Thiazides when given as a second-line drug have a dose related effect to lower blood pressure that is similar to when they are added as a first-line drug. This means that the BP lowering effect of thiazides is additive. Loop diuretics appear to have a similar blood pressure lowering effect as thiazides at 1 times the recommended starting dose. Because of the short duration of the trials and lack of reporting of adverse events, this review does not provide a good estimate of the incidence of adverse effects of diuretics given as a second-line drug.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007187.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007187.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>566</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">566</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Ning</style></author><author><style face="normal" font="default" size="100%">Zhou, Muke</style></author><author><style face="normal" font="default" size="100%">Yang, Mi</style></author><author><style face="normal" font="default" size="100%">Guo, Jian</style></author><author><style face="normal" font="default" size="100%">Zhu, Cairong</style></author><author><style face="normal" font="default" size="100%">Yang, Jie</style></author><author><style face="normal" font="default" size="100%">Wang, Yucai</style></author><author><style face="normal" font="default" size="100%">Yang, Xue</style></author><author><style face="normal" font="default" size="100%">He, Li</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Calcium channel blockers versus other classes of drugs for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride Symporter Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003654</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Calcium channel blockers (CCBs) are a relatively new antihypertensive class. The effect of first-line CCBs on the prevention of cardiovascular events, as compared with other antihypertensive drug classes, is unknown.Objectives: To determine whether CCBs used as first-line therapy for hypertension are different from other first-line drug classes in reducing the incidence of major adverse cardiovascular events.Search methods: Electronic searches of the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASEand the WHO-ISH Collaboration Register (up to May 2009) were performed. We also checked the references of published studies to identify additional trials.Selection criteria: Randomized controlled trial (RCT) comparing first-line CCBs with other antihypertensive classes, with at least 100 randomized hypertensive participants and with a follow-up of at least two years.Data collection and analysis: Two authors independently selected the included trials, evaluated the risk of bias and entered the data for analysis.Main results: Eighteen RCTs (14 dihydropyridines, 4 non-dihydropyridines) with a total of 141,807 participants were included. All-cause mortality was not different between first-line CCBs and any other first-line antihypertensive classes. CCBs reduced the following outcomes as compared to ?-blockers: total cardiovascular events (RR 0.84, 95% CI [0.77, 0.92]), stroke (RR 0.77, 95% CI [0.67, 0.88]) and cardiovascular mortality (RR 0.90, 95% CI [0.81, 0.99]). CCBs increased total cardiovascular events (RR 1.05 , 95% CI [1.00, 1.09], p = 0.03) and congestive heart failure events (RR 1.37, 95% CI [1.25, 1.51]) as compared to diuretics. CCBs reduced stroke (RR 0.89, 95% CI [0.80, 0.98]) as compared to ACE inhibitors and reduced stroke (RR 0.85, 95% CI [0.73, 0.99]) and MI (RR 0.83, 95% CI [0.72, 0.96]) as compared to ARBs. CCBs also increased congestive heart failure events as compared to ACE inhibitors (RR 1.16, 95% CI [1.06, 1.27]) and ARBs (RR 1.20, 95% CI [1.06, 1.36]). The other evaluated outcomes were not significantly different.Authors&apos; conclusions: Diuretics are preferred first-line over CCBs to optimize reduction of cardiovascular events. The review does not distinguish between CCBs, ACE inhibitors or ARBs, but does provide evidence supporting the use of CCBs over ?-blockers. Many of the differences found in the current review are not robust and further trials might change the conclusions. More well-designed RCTs studying the mortality and morbidity of patients taking CCBs as compared with other antihypertensive drug classes are needed for patients with different stages of hypertension, different ages, and with different co-morbidities such as diabetes.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003654.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003654.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>81</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">81</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, X. D.</style></author><author><style face="normal" font="default" size="100%">He, F. Q.</style></author><author><style face="normal" font="default" size="100%">Yang, L.</style></author><author><style face="normal" font="default" size="100%">Yu, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, Z. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Laparoscopic splenectomy with or without devascularization of the stomach for liver cirrhosis and portal hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">ANZ Journal of Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ANZ Journal of Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">122-128</style></pages><volume><style face="normal" font="default" size="100%">83</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Loss, Surgical</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Length of Stay</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Cirrhosis [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Splenectomy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Stomach [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013050711</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013050711/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>82</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">82</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Copeland, W. K.</style></author><author><style face="normal" font="default" size="100%">Vedanthan, R.</style></author><author><style face="normal" font="default" size="100%">Grant, E.</style></author><author><style face="normal" font="default" size="100%">Lee, J. E.</style></author><author><style face="normal" font="default" size="100%">Gu, D.</style></author><author><style face="normal" font="default" size="100%">Gupta, P. C.</style></author><author><style face="normal" font="default" size="100%">Ramadas, K.</style></author><author><style face="normal" font="default" size="100%">Inoue, M.</style></author><author><style face="normal" font="default" size="100%">Tsugane, S.</style></author><author><style face="normal" font="default" size="100%">Tamakoshi, A.</style></author><author><style face="normal" font="default" size="100%">Gao, Y. T.</style></author><author><style face="normal" font="default" size="100%">Yuan, J. M.</style></author><author><style face="normal" font="default" size="100%">Shu, X. O.</style></author><author><style face="normal" font="default" size="100%">Ozasa, K.</style></author><author><style face="normal" font="default" size="100%">Tsuji, I.</style></author><author><style face="normal" font="default" size="100%">Kakizaki, M.</style></author><author><style face="normal" font="default" size="100%">Tanaka, H.</style></author><author><style face="normal" font="default" size="100%">Nishino, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, C. J.</style></author><author><style face="normal" font="default" size="100%">Wang, R.</style></author><author><style face="normal" font="default" size="100%">Yoo, K. Y.</style></author><author><style face="normal" font="default" size="100%">Ahn, Y. O.</style></author><author><style face="normal" font="default" size="100%">Ahsan, H.</style></author><author><style face="normal" font="default" size="100%">Pan, W. H.</style></author><author><style face="normal" font="default" size="100%">Chen, C. S.</style></author><author><style face="normal" font="default" size="100%">Pednekar, M. S.</style></author><author><style face="normal" font="default" size="100%">Sauvaget, C.</style></author><author><style face="normal" font="default" size="100%">Sasazuki, S.</style></author><author><style face="normal" font="default" size="100%">Yang, G.</style></author><author><style face="normal" font="default" size="100%">Koh, W. P.</style></author><author><style face="normal" font="default" size="100%">Xiang, Y. B.</style></author><author><style face="normal" font="default" size="100%">Ohishi, W.</style></author><author><style face="normal" font="default" size="100%">Watanabe, T.</style></author><author><style face="normal" font="default" size="100%">Sugawara, Y.</style></author><author><style face="normal" font="default" size="100%">Matsuo, K.</style></author><author><style face="normal" font="default" size="100%">You, S. L.</style></author><author><style face="normal" font="default" size="100%">Park, S. K.</style></author><author><style face="normal" font="default" size="100%">Kim, D. H.</style></author><author><style face="normal" font="default" size="100%">Parvez, F.</style></author><author><style face="normal" font="default" size="100%">Chuang, S. Y.</style></author><author><style face="normal" font="default" size="100%">Ge, W.</style></author><author><style face="normal" font="default" size="100%">Rolland, B.</style></author><author><style face="normal" font="default" size="100%">McLerran, D.</style></author><author><style face="normal" font="default" size="100%">Sinha, R.</style></author><author><style face="normal" font="default" size="100%">Thornquist, M.</style></author><author><style face="normal" font="default" size="100%">Kang, D.</style></author><author><style face="normal" font="default" size="100%">Feng, Z.</style></author><author><style face="normal" font="default" size="100%">Boffetta, P.</style></author><author><style face="normal" font="default" size="100%">Zheng, W.</style></author><author><style face="normal" font="default" size="100%">He, J.</style></author><author><style face="normal" font="default" size="100%">Potter, J. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><pages><style face="normal" font="default" size="100%">f5446</style></pages><volume><style face="normal" font="default" size="100%">347</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Asia [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Asian Continental Ancestry Group [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [ethnology] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Disease [ethnology] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Far East [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [ethnology] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style [ethnology]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity [ethnology] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Smoking [ethnology] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [ethnology] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013057157</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013057157/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>567</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">567</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Yuanjing</style></author><author><style face="normal" font="default" size="100%">Fan, Zhiyu</style></author><author><style face="normal" font="default" size="100%">Liu, Hanmin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Calcium channel blockers for pulmonary arterial hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010066</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To evaluate the clinical effect of CCBs for patients with PAH.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010066/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010066</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>568</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">568</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Yuanjing</style></author><author><style face="normal" font="default" size="100%">Li, Ka</style></author><author><style face="normal" font="default" size="100%">Pu, Hongshan</style></author><author><style face="normal" font="default" size="100%">Wu, Taixiang</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Corticosteroids for pneumonia</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Ari</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007720</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Pneumonia is an acute inflammation of the lungs and treatments differ depending on the type and severity. Corticosteroids can influence immune regulation, carbohydrate metabolism, protein catabolism, electrolyte balance and stress response. However, the benefits of corticosteroids for patients with pneumonia remains unclear.Objectives: To assess the efficacy and safety of corticosteroids in the treatment of pneumonia.Search methods: We searched Cochrane Central Register of Controlled Clinical Trials (CENTRAL) (The Cochrane Library 2010, Issue 11) which contains the Cochrane Acute Respiratory Infections Group&apos;s Specialised Register, MEDLINE (1966 to December week 4, 2010), EMBASE (1974 to December 2010), the China National Knowledge Infrastructure (CNKI) (1978 to December 2010) and VIP (1986 to December 2010).Selection criteria: Randomised controlled trials (RCTs) assessing the effectiveness of corticosteroids for pneumonia.Data collection and analysis: Three review authors selected studies. We telephoned the trial authors to confirm the randomisation method used. We extracted and analysed the methodological details and data from the included studies.Main results: We included six studies including 437 participants in the review. Two studies were of high methodological quality and three were of poor quality. All studies involved small numbers of participants. Two small studies provided weak evidence that corticosteroids did not significantly reduce mortality (Peto odds ratio (OR) 0.26; 95% CI 0.05 to 1.37), but accelerated the resolution of symptoms or time to clinical stability, and decreased the rate of relapse of the disease. Steroids can improve the oxygenation and reduce the need for mechanical ventilation in severe pneumonia. There was no significant difference between treatment groups with regards to the time to discharge from the intensive care unit (ICU). There were insufficient data to report the time to pneumonia resolution and admission to ICU. Typical adverse events associated with corticosteroid therapy were infrequent.Authors&apos; conclusions: In most patients with pneumonia, corticosteroids are generally beneficial for accelerating the time to resolution of symptoms. However, evidence from the included studies was not strong enough to make any recommendations.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007720.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007720.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>83</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">83</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Meng, L.</style></author><author><style face="normal" font="default" size="100%">Shao, H.</style></author><author><style face="normal" font="default" size="100%">Yu, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">252-261</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013017435</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013017435/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>84</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">84</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y. F.</style></author><author><style face="normal" font="default" size="100%">Jowett, S.</style></author><author><style face="normal" font="default" size="100%">Barton, P.</style></author><author><style face="normal" font="default" size="100%">Malottki, K.</style></author><author><style face="normal" font="default" size="100%">Hyde, C.</style></author><author><style face="normal" font="default" size="100%">Gibbs, J. S.</style></author><author><style face="normal" font="default" size="100%">Pepke-Zaba, J.</style></author><author><style face="normal" font="default" size="100%">Fry-Smith, A.</style></author><author><style face="normal" font="default" size="100%">Roberts, J.</style></author><author><style face="normal" font="default" size="100%">Moore, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-296</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">49</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [economics]</style></keyword><keyword><style face="normal" font="default" size="100%">Iloprost [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Isoxazoles [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphodiesterase Inhibitors [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Purines [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Endothelin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Thiophenes [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000175</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000175/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>569</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">569</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y. F.</style></author><author><style face="normal" font="default" size="100%">Jowett, S.</style></author><author><style face="normal" font="default" size="100%">Barton, P.</style></author><author><style face="normal" font="default" size="100%">Malottki, K.</style></author><author><style face="normal" font="default" size="100%">Hyde, C.</style></author><author><style face="normal" font="default" size="100%">Gibbs, J. S. R.</style></author><author><style face="normal" font="default" size="100%">Pepke-Zaba, J.</style></author><author><style face="normal" font="default" size="100%">Fry-Smith, A.</style></author><author><style face="normal" font="default" size="100%">Roberts, J.</style></author><author><style face="normal" font="default" size="100%">Moore, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical and cost effectiveness of epoprostenol, iloprost, bosentan, sitaxentan, and sildenafil for the treatment of pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [economics]</style></keyword><keyword><style face="normal" font="default" size="100%">Iloprost [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Isoxazoles [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphodiesterase Inhibitors [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Purines [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Endothelin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Thiophenes [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">Health Technology Assessment</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32007000343</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32007000343/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>85</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">85</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cheng, J. W.</style></author><author><style face="normal" font="default" size="100%">Xi, G. L.</style></author><author><style face="normal" font="default" size="100%">Wei, R. L.</style></author><author><style face="normal" font="default" size="100%">Cai, J. P.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Current Therapeutic Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Therapeutic Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">335-350</style></pages><volume><style face="normal" font="default" size="100%">70</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Glaucoma, Open-Angle [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins F, Synthetic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009110011</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009110011/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>86</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">86</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cheung, B. M.</style></author><author><style face="normal" font="default" size="100%">Cheung, G. T.</style></author><author><style face="normal" font="default" size="100%">Lauder, I. J.</style></author><author><style face="normal" font="default" size="100%">Lau, C. P.</style></author><author><style face="normal" font="default" size="100%">Kumana, C. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">37-43</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006001555</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006001555/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>570</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">570</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cho, Gavin</style></author><author><style face="normal" font="default" size="100%">Hambleton Ian, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Erythrocyte Transfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Acute Chest Syndrome [etiology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Anemia, Sickle Cell [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [etiology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Cf</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008360</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Sickle cell disease can cause severe vaso-occlusive crises and dysfunction of most organ systems. The two most common chronic chest complications due to sickle cell disease are pulmonary hypertension and chronic sickle lung disease. These complications can lead to morbidity (such as reduced exercise tolerance) and increased mortality.Objectives: The aim of this review is to find out whether trials involving people with sickle cell disease that compare regular long-term blood transfusion regimens with an alternative treatment or no treatment show differences in the following:1. the incidence of chronic chest complications (chronic sickle lung disease or pulmonary hypertension); 2. the &apos;severity&apos; or progression of established chronic chest complications; 3. the mortality associated with chronic chest complications; and 4. unacceptable adverse events.Search methods: We searched the Group&apos;s Haemoglobinopathies Trials Register. Specific websites were also searched for information of ongoing or newly completed trials. The search included the reference lists of any randomised controlled trials identified using the above methods.Date of the most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Group&apos;s Haemoglobinopathies Trials Register: 22 July 2013.Selection criteria: We included randomized controlled trials. Trials that used quasi-randomized methods were to be included if sufficient evidence existed that the treatment and control groups were similar at baseline. Trials were eligible for inclusion if they investigated regular red blood cell transfusion regimens (either simple top-up or exchange transfusions) aimed at reducing the incidence, mortality, or objective measures of severity or progression of chronic chest complications (chronic sickle lung and pulmonary hypertension) among men or women of any age and with one of four common sickle cell disease genotypes, ie Hb SS, Sß0, SC, or Sß+. These interventions would be compared to an alternative treatment with the same aim or to no treatment.Data collection and analysis: No studies matching the selection criteria were found.Main results: No studies matching the selection criteria were found.Authors&apos; conclusions: There is a need for randomized controlled trials looking at the role of long-term transfusion therapy in pulmonary hypertension and chronic sickle lung disease. Due to the chronic nature of the conditions, such trials should aim to use a combination of objective and subjective measures to assess participants during an extended &apos;steady state&apos; baseline, and after the intervention.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008360.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008360.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>87</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">87</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chodosh, J.</style></author><author><style face="normal" font="default" size="100%">Morton, S. C.</style></author><author><style face="normal" font="default" size="100%">Mojica, W.</style></author><author><style face="normal" font="default" size="100%">Maglione, M.</style></author><author><style face="normal" font="default" size="100%">Suttorp, M. J.</style></author><author><style face="normal" font="default" size="100%">Hilton, L.</style></author><author><style face="normal" font="default" size="100%">Rhodes, S.</style></author><author><style face="normal" font="default" size="100%">Shekelle, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis: chronic disease self-management programs for older adults (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">427-438</style></pages><volume><style face="normal" font="default" size="100%">143</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobin A, Glycosylated [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Osteoarthritis [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Osteoarthritis [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Osteoarthritis [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Pain Measurement</style></keyword><keyword><style face="normal" font="default" size="100%">Program Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005008496</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005008496/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>571</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">571</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, Jung-In</style></author><author><style face="normal" font="default" size="100%">Sekhon, Gaurav</style></author><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Time course for blood pressure lowering of alpha blockers</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010083</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the temporal (hourly and 24-hour) effects of alpha-blockers for lowering ambulatory blood pressure in hypertension patients.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010083/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010083</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>88</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">88</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choi, S. B.</style></author><author><style face="normal" font="default" size="100%">Kim, H. J.</style></author><author><style face="normal" font="default" size="100%">Song, T. J.</style></author><author><style face="normal" font="default" size="100%">Ahn, H. S.</style></author><author><style face="normal" font="default" size="100%">Choi, S. Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">639-647</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Carcinoma, Hepatocellular</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014034641</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014034641/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>89</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">89</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chow, S. L.</style></author><author><style face="normal" font="default" size="100%">Chandran, V.</style></author><author><style face="normal" font="default" size="100%">Fazelzad, R.</style></author><author><style face="normal" font="default" size="100%">Johnson, S. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Lupus</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lupus</style></full-title></periodical><pages><style face="normal" font="default" size="100%">353-364</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [etiology] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Lupus Erythematosus, Systemic [complications] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012016815</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012016815/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>90</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">90</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cicero, A. F.</style></author><author><style face="normal" font="default" size="100%">Aubin, F.</style></author><author><style face="normal" font="default" size="100%">Azais-Braesco, V.</style></author><author><style face="normal" font="default" size="100%">Borghi, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">442-449</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Milk [chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Oligopeptides [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Animals[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013027245</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013027245/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>91</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">91</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Circelli, M.</style></author><author><style face="normal" font="default" size="100%">Nicolini, G.</style></author><author><style face="normal" font="default" size="100%">Egan, C. G.</style></author><author><style face="normal" font="default" size="100%">Cremonesi, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of delapril/indapamide compared to different ACE-inhibitor/hydrochlorothiazide combinations: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of General Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of General Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">725-734</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Indapamide</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013006348</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013006348/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>92</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">92</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Clark, C. E.</style></author><author><style face="normal" font="default" size="100%">Horvath, I. A.</style></author><author><style face="normal" font="default" size="100%">Taylor, R. S.</style></author><author><style face="normal" font="default" size="100%">Campbell, J. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Doctors record higher blood pressures than nurses: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e223-232</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Nurses</style></keyword><keyword><style face="normal" font="default" size="100%">Physicians</style></keyword><keyword><style face="normal" font="default" size="100%">White Coat Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014024228</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014024228/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>93</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">93</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Clark, C. E.</style></author><author><style face="normal" font="default" size="100%">Smith, L. F.</style></author><author><style face="normal" font="default" size="100%">Taylor, R. S.</style></author><author><style face="normal" font="default" size="100%">Campbell, J. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><volume><style face="normal" font="default" size="100%">341:c3995</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Bias (Epidemiology)</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Community Health Nursing [economics]</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [economics] [nursing] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Nurse&apos;s Practice Patterns [economics] [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010005893</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010005893/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>94</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">94</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Clark, C. E.</style></author><author><style face="normal" font="default" size="100%">Smith, L. F.</style></author><author><style face="normal" font="default" size="100%">Taylor, R. S.</style></author><author><style face="normal" font="default" size="100%">Campbell, J. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nurse-led interventions used to improve control of high blood pressure in people with diabetes: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetic Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diabetic Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">250-261</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [nursing] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Angiopathies [nursing] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [nursing] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Nurse&apos;s Practice Patterns [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011001596</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001596/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>572</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">572</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Clark Chris, E.</style></author><author><style face="normal" font="default" size="100%">Smith Lindsay, F. P.</style></author><author><style face="normal" font="default" size="100%">Glynn Liam, G.</style></author><author><style face="normal" font="default" size="100%">Taylor Rod, S.</style></author><author><style face="normal" font="default" size="100%">Campbell, John</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Allied health professional-led interventions for improving control of blood pressure in patients with hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009410</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows: To review the evidence base for allied health professional led interventions to improve the control of hypertension. To elucidate whether nurse or pharmacist prescribing is an important component of this complex intervention. To identify areas in need of further study.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009410/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009410</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>95</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">95</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Coeytaux, R. R.</style></author><author><style face="normal" font="default" size="100%">Schmit, K. M.</style></author><author><style face="normal" font="default" size="100%">Kraft, B.</style></author><author><style face="normal" font="default" size="100%">Kosinski, A. S.</style></author><author><style face="normal" font="default" size="100%">Mingo, A. M.</style></author><author><style face="normal" font="default" size="100%">Vann, L. M.</style></author><author><style face="normal" font="default" size="100%">Gilstrap, D. L.</style></author><author><style face="normal" font="default" size="100%">Hargett, C. W.</style></author><author><style face="normal" font="default" size="100%">Heidenfelder, B.</style></author><author><style face="normal" font="default" size="100%">Dolor, R. J.</style></author><author><style face="normal" font="default" size="100%">McCrory, D. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1055-1063</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphodiesterase Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014001194</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014001194/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>96</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">96</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Coleman, C. I.</style></author><author><style face="normal" font="default" size="100%">Baker, W. L.</style></author><author><style face="normal" font="default" size="100%">Kluger, J.</style></author><author><style face="normal" font="default" size="100%">White, C. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">622-629</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008104591</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008104591/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>573</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">573</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Colli, Agostino</style></author><author><style face="normal" font="default" size="100%">Gana Juan, Cristóbal</style></author><author><style face="normal" font="default" size="100%">Turner, Dan</style></author><author><style face="normal" font="default" size="100%">Yap, Jason</style></author><author><style face="normal" font="default" size="100%">Adams-Webber, Thomasin</style></author><author><style face="normal" font="default" size="100%">Ling Simon, C.</style></author><author><style face="normal" font="default" size="100%">Casazza, Giovanni</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Capsule endoscopy for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Capsule Endoscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Portal Vein</style></keyword><keyword><style face="normal" font="default" size="100%">Endoscopy, Digestive System</style></keyword><keyword><style face="normal" font="default" size="100%">Esophageal and Gastric Varices [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Diseases [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Venous Thrombosis [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008760</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Current guidelines recommend performance of oesophago-gastro-duodenoscopy at the time of diagnosis of hepatic cirrhosis to screen for oesophageal varices. These guidelines require people to undergo an unpleasant invasive procedure repeatedly with its attendant risks, despite the fact that half of the people do not have identifiable oesophageal varices 10 years after the initial diagnosis of cirrhosis. Video capsule endoscopy is a non-invasive test proposed as an alternative method for the diagnosis of oesophageal varices.Objectives: To determine the diagnostic accuracy of capsule endoscopy for the diagnosis of oesophageal varices in children or adults with chronic liver disease or portal vein thrombosis, irrespective of the aetiology. To investigate the accuracy of capsule endoscopy as triage or replacement of oesophago-gastro-duodenoscopy.Search methods: We searched the Cochrane Hepato-Biliary Group Diagnostic Test Accuracy Studies Register (October 2013), MEDLINE (Ovid SP) (1950 to October 2013), EMBASE (Ovid SP) (1980 to October 2013), ACP Journal Club (Ovid SP) (1991 to October 2013), Database of Abstracts of Reviews of Effects (DARE) (Ovid SP) (third quarter), Health Technology Assessment (HTA) (Ovid SP) (third quarter), NHS Economic Evaluation Database (NHSEED) (Ovid SP) (third quarter), and Science Citation Index Expanded (SCI-EXPANDED) (ISI Web of Knowledge) (1955 to October 2013). We applied no language or document type restrictions.Selection criteria: Studies that evaluated the diagnostic accuracy of capsule endoscopy for the diagnosis of oesophageal varices using oesophago-gastro-duodenoscopy as the reference standard in children or adults of any age, with chronic liver disease or portal vein thrombosis.Data collection and analysis: We followed the available guidelines provided in the Cochrane Handbook for Diagnostic Test of Accuracy Reviews. We calculated the pooled estimates of sensitivity and specificity using the bivariate model due to the absence of a negative correlation in the receiver operating characteristic (ROC) space and of a threshold effect.Main results: The search identified 16 eligible studies, in which only adults with cirrhosis were included. In one study, people with portal thrombosis were also included. We classified most of the studies at high risk of bias for the &apos;Participants selection&apos; and the &apos;Flow and timing&apos; domains. One study assessed the accuracy of capsule endoscopy for the diagnosis of large (high-risk) oesophageal varices. In the remaining15 studies that assessed the accuracy of capsule endoscopy for the diagnosis of oesophageal varices of any size in people with cirrhosis, 936 participants were included; the pooled estimate of sensitivity was 84.8% (95% confidence interval (CI) 77.3% to 90.2%) and of specificity 84.3% (95% CI 73.1% to 91.4%). Eight of these studies included people with suspected varices or people with already diagnosed or even treated varices, or both, introducing a selection bias. Seven studies including only people with suspected but unknown varices were at low risk of bias; the pooled estimate of sensitivity was 79.7% (95% CI 73.1% to 85.0%) and of specificity 86.1% (95% CI 64.5% to 95.5%). Six studies assessed the diagnostic accuracy of capsule endoscopy for the diagnosis of large oesophageal varices, associated with a higher risk of bleeding; the pooled sensitivity was 73.7% (95% CI 52.4% to 87.7%) and of specificity 90.5% (95% CI 84.1% to 94.4%). Two studies also evaluated the presence of red marks, which are another marker of high risk of bleeding; the estimates of sensitivity and specificity varied widely. Two studies obtained similar results with the use of a modified device as index test (string capsule). Due to the absence of data, we could not perform all planned subgroup analyses. Interobserver agreement in the interpretation of capsule endoscopy results and any adverse event attributable to capsule endoscopy were poorly assessed and reported. Only four studies evaluated the interobserver agreement in the interpretation of capsule ndoscopy results: the concordance was moderate. The participants&apos; preferences for capsule endoscopy or oesophago-gastro-duodenoscopy were reported differently but seemed in favour of capsule endoscopy in nine of 10 studies. In 10 studies, participants reported some minor discomfort on swallowing the capsule. Only one study identified other significant adverse events, including impaction of the capsule due to previously unidentified oesophageal strictures in two participants. No adverse events were reported as a consequence of the reference standard.Authors&apos; conclusions: We cannot support the use of capsule endoscopy as a triage test in adults with cirrhosis, administered before oesophago-gastro-duodenoscopy, despite the low incidence of adverse events and participant reports of being better tolerated. Thus, we cannot conclude that oesophago-gastro-duodenoscopy can be replaced by capsule endoscopy for the detection of oesophageal varices in adults with cirrhosis. We found no data assessing capsule endoscopy in children and in people with portal thrombosis.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008760.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008760.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>574</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">574</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Colquitt Jill, L.</style></author><author><style face="normal" font="default" size="100%">Pickett, Karen</style></author><author><style face="normal" font="default" size="100%">Loveman, Emma</style></author><author><style face="normal" font="default" size="100%">Frampton Geoff, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Surgery for weight loss in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Gastric Bypass [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Gastroplasty [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Ligation [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity, Morbid [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Endoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003641</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Bariatric (weight loss) surgery for obesity is considered when other treatments have failed. The effects of the available bariatric procedures compared with medical management and with each other are uncertain. This is an update of a Cochrane review first published in 2003 and most recently updated in 2009.Objectives: To assess the effects of bariatric surgery for overweight and obesity, including the control of comorbidities.Search methods: Studies were obtained from searches of numerous databases, supplemented with searches of reference lists and consultation with experts in obesity research. Date of last search was November 2013.Selection criteria: Randomised controlled trials (RCTs) comparing surgical interventions with non-surgical management of obesity or overweight or comparing different surgical procedures.Data collection and analysis: Data were extracted by one review author and checked by a second review author. Two review authors independently assessed risk of bias and evaluated overall study quality utilising the GRADE instrument.Main results: Twenty-two trials with 1798 participants were included; sample sizes ranged from 15 to 250. Most studies followed participants for 12, 24 or 36 months; the longest follow-up was 10 years. The risk of bias across all domains of most trials was uncertain; just one was judged to have adequate allocation concealment.All seven RCTs comparing surgery with non-surgical interventions found benefits of surgery on measures of weight change at one to two years follow-up. Improvements for some aspects of health-related quality of life (QoL) (two RCTs) and diabetes (five RCTs) were also found. The overall quality of the evidence was moderate. Five studies reported data on mortality, no deaths occurred. Serious adverse events (SAEs) were reported in four studies and ranged from 0% to 37% in the surgery groups and 0% to 25% in the no surgery groups. Between 2% and 13% of participants required reoperations in the five studies that reported these data.Three RCTs found that laparoscopic Roux-en-Y gastric bypass (L)(RYGB) achieved significantly greater weight loss and body mass index (BMI) reduction up to five years after surgery compared with laparoscopic adjustable gastric banding (LAGB). Mean end-of-study BMI was lower following LRYGB compared with LAGB: mean difference (MD) -5.2 kg/m² (95% confidence interval (CI) -6.4 to -4.0; P &lt; 0.00001; 265 participants; 3 trials; moderate quality evidence). Evidence for QoL and comorbidities was very low quality. The LRGYB procedure resulted in greater duration of hospitalisation in two RCTs (4/3.1 versus 2/1.5 days) and a greater number of late major complications (26.1% versus 11.6%) in one RCT. In one RCT the LAGB required high rates of reoperation for band removal (9 patients, 40.9%).Open RYGB, LRYGB and laparoscopic sleeve gastrectomy (LSG) led to losses of weight and/or BMI but there was no consistent picture as to which procedure was better or worse in the seven included trials. MD was -0.2 kg/m² (95% CI -1.8 to 1.3); 353 participants; 6 trials; low quality evidence) in favour of LRYGB.  No statistically significant differences in QoL were found (one RCT). Six RCTs reported mortality; one death occurred following LRYGB. SAEs were reported by one RCT and were higher in the LRYGB group (4.5%) than the LSG group (0.9%). Reoperations ranged from 6.7% to 24% in the LRYGB group and 3.3% to 34% in the LSG group. Effects on comorbidities, complications and additional surgical procedures were neutral, except gastro-oesophageal reflux disease improved following LRYGB (one RCT). One RCT of people with a BMI 25 to 35 and type 2 diabetes found laparoscopic mini-gastric bypass resulted in greater weight loss and improvement of diabetes compared with LSG, and had similar levels of complications.Two RCTs found that biliopancreatic diversion with duodenal switch (BDDS) resulted in greater weight loss than RYGB in morbidly obese patients. End-of-study mean BMI loss was greater following BDDS: MD -7.3 kg/m² (95% CI -9.3 to -5.4); P &lt; 0.00 01; 107 participants; 2 trials; moderate quality evidence). QoL was similar on most domains. In one study between 82% to 100% of participants with diabetes had a HbA1c of less than 5% three years after surgery. Reoperations were higher in the BDDS group (16.1% to 27.6%) than the LRYGB group (4.3% to 8.3%). One death occurred in the BDDS group.One RCT comparing laparoscopic duodenojejunal bypass with sleeve gastrectomy versus LRYGB found BMI, excess weight loss, and rates of remission of diabetes and hypertension were similar at 12 months follow-up (very low quality evidence). QoL, SAEs and reoperation rates were not reported. No deaths occurred in either group.One RCT comparing laparoscopic isolated sleeve gastrectomy (LISG) versus LAGB found greater improvement in weight-loss outcomes following LISG at three years follow-up (very low quality evidence). QoL, mortality and SAEs were not reported. Reoperations occurred in 20% of the LAGB group and in 10% of the LISG group.One RCT (unpublished) comparing laparoscopic gastric imbrication with LSG found no statistically significant difference in weight loss between groups (very low quality evidence).  QoL and comorbidities were not reported. No deaths occurred. Two participants in the gastric imbrication group required reoperation.Authors&apos; conclusions: Surgery results in greater improvement in weight loss outcomes and weight associated comorbidities compared with non-surgical interventions, regardless of the type of procedures used. When compared with each other, certain procedures resulted in greater weight loss and improvements in comorbidities than others. Outcomes were similar between RYGB and sleeve gastrectomy, and both of these procedures had better outcomes than adjustable gastric banding. For people with very high BMI, biliopancreatic diversion with duodenal switch resulted in greater weight loss than RYGB. Duodenojejunal bypass with sleeve gastrectomy and laparoscopic RYGB had similar outcomes, however this is based on one small trial. Isolated sleeve gastrectomy led to better weight-loss outcomes than adjustable gastric banding after three years follow-up. This was based on one trial only. Weight-related outcomes were similar between laparoscopic gastric imbrication and laparoscopic sleeve gastrectomy in one trial. Across all studies adverse event rates and reoperation rates were generally poorly reported. Most trials followed participants for only one or two years, therefore the long-term effects of surgery remain unclear.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003641.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003641.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>97</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">97</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Connell, P.</style></author><author><style face="normal" font="default" size="100%">Wolfe, C.</style></author><author><style face="normal" font="default" size="100%">McKevitt, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Preventing stroke: a narrative review of community interventions for improving hypertension control in black adults (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health and Social Care in the Community</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health and Social Care in the Community</style></full-title></periodical><pages><style face="normal" font="default" size="100%">165-187</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">African Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Awareness</style></keyword><keyword><style face="normal" font="default" size="100%">Community Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Cultural Competency</style></keyword><keyword><style face="normal" font="default" size="100%">Cultural Diversity</style></keyword><keyword><style face="normal" font="default" size="100%">Ethnic Groups</style></keyword><keyword><style face="normal" font="default" size="100%">Great Britain</style></keyword><keyword><style face="normal" font="default" size="100%">Health Education</style></keyword><keyword><style face="normal" font="default" size="100%">Health Knowledge, Attitudes, Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Health Promotion</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Program Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Social Marketing</style></keyword><keyword><style face="normal" font="default" size="100%">Social Support</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008103648</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008103648/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>575</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">575</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Coppin, Chris</style></author><author><style face="normal" font="default" size="100%">Le, Lyly</style></author><author><style face="normal" font="default" size="100%">Wilt Timothy, J.</style></author><author><style face="normal" font="default" size="100%">Kollmannsberger, Christian</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Targeted therapy for advanced renal cell carcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Carcinoma, Renal Cell [drug therapy] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Neoplasms [drug therapy] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006017</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Advanced renal cell carcinoma has been resistant to drug therapy of different types and new types of drug therapy are needed. Targeted agents inhibit known molecular pathways and have been tested in renal cancer for just over a decade.Objectives: 1) To provide a systematic and regularly updated review of randomized studies testing targeted agents in advanced renal cell cancer. 2) To identify the type and degree of clinical benefit of targeted agents over the prevailing standard of care.Search methods: Period of search: January 2000 to June 2010. 1) Electronic search of CENTRAL, MEDLINE and EMBASE databases. 2) Hand search of international cancer meeting abstracts.Selection criteria: Randomized, controlled studies, including a targeted agent in patients with advanced renal cell cancer reporting any pre-specified cancer outcome by allocation.Data collection and analysis: The majority of the standardized search and data extraction was conducted independently by two investigators with subsequent resolution of differences. Handsearching, quality of life and toxicity data extraction, most of the initial analysis, and risk of bias assessment, was carried out by one investigator and verified by additional authors as required. Twenty-five fully eligible studies tested thirteen different targeted agents in a total of 7484 patients with mostly Stage IV disease; 61% had not received prior systemic treatment. The majority of patients were good performance status (ECOG (Eastern Cooperative Oncology Group) 0 to 1). Most comparisons were each examined in only a single study. Risk of bias was considered low for studies that were placebo-controlled, had a primary outcome of overall survival, or that evaluated progression by independent radiologic reviewers unaware of the intervention allocation.Main results: Most progress has been made in patients with advanced renal cancer of the clear cell subtype, a condition with a clearly defined molecular pathology promoting angiogenesis. In systemically untreated patients, two approaches to angiogenesis inhibition have demonstrated benefit. Compared with interferon-alfa monotherapy, oral sunitinib improved multiple outcomes including overall survival (18% risk reduction for death; median survival improved from 21.8 to 26.4 months, P = 0.049) without correction for crossover) in patients with mostly good or moderate prognosis. In the same setting, two studies have shown that the addition of biweekly intravenous bevacizumab to interferon-alfa also improved the chance of major remission and prolonged progression-free survival. These two bevacizumab plus interferon studies each observed improved overall survival approaching statistical significance (each study observed a 14% risk reduction for death). Additional anti-angiogenesis agents, such as pazopanib and tivozanib, are in earlier stages of evaluation. After progression of clear cell disease on prior cytokine therapy, oral sorafenib results in a better quality of life than placebo. In patients with clear cell disease with progression on or within 6 months of first-line targeted therapy with sunitinib or sorafenib, the targeted oral mTOR (mammalian target of rapamycin) inhibitor everolimus resulted in prolonged disease-free survival without detriment to quality of life. Remissions were very infrequent and no improvement in overall survival was observed in this study where the majority of placebo-assigned patients received everolimus at disease progression. In untreated patients with unselected renal cancer histology and poor prognostic features, weekly intravenous temsirolimus, an mTOR inhibitor, improved outcomes compared with interferon-alfa (median overall survival improved from 7.3 to 10.9 months, P = 0.008). Of particular interest, an exploratory analysis observed a marked reduction in hazard for death in the non-clear cell subgroup. Combinations of targeted agents are being evaluated, but toxicity is problematic.Authors&apos; conclusions: Several agents with specified molecular targets have demonstrated clinically useful benefits over interferon-alfa, and also after either prior cytokine or initial anti-angiogenesis therapy. More research is required to fully establish the role of targeted agents in this condition.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006017.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006017.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>576</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">576</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Corio, M.</style></author><author><style face="normal" font="default" size="100%">Abraha, I.</style></author><author><style face="normal" font="default" size="100%">Lopatriello, S.</style></author><author><style face="normal" font="default" size="100%">Taddei, S.</style></author><author><style face="normal" font="default" size="100%">Nocco, U.</style></author><author><style face="normal" font="default" size="100%">Perrini, M. R.</style></author><author><style face="normal" font="default" size="100%">Filippi, C.</style></author><author><style face="normal" font="default" size="100%">Vassanelli, C.</style></author><author><style face="normal" font="default" size="100%">Jefferson, T.</style></author><author><style face="normal" font="default" size="100%">Cerbo, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal artery ablation in patients with treatment-resistant hypertension: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty, Balloon</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Renal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">Agenzia nazionale per i servizi sanitari regionali</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000650</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000650/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>577</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">577</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cormick, Gabriela</style></author><author><style face="normal" font="default" size="100%">Ciapponi, Agustín</style></author><author><style face="normal" font="default" size="100%">Mazzoni, Agustina</style></author><author><style face="normal" font="default" size="100%">Belizán José, M.</style></author><author><style face="normal" font="default" size="100%">Cafferata María, Luisa</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Calcium supplementation for prevention of primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010037</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the efficacy and safety of calcium supplementation versus placebo or control for reducing blood pressure in normotensive subjects.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010037/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010037</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>98</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">98</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cornelissen, V. A.</style></author><author><style face="normal" font="default" size="100%">Fagard, R. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of resistance training on resting blood pressure: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">251-259</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Rest</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Teaching</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Resistance [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006005073</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006005073/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>99</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">99</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cornelissen, V. A.</style></author><author><style face="normal" font="default" size="100%">Fagard, R. H.</style></author><author><style face="normal" font="default" size="100%">Coeckelberghs, E.</style></author><author><style face="normal" font="default" size="100%">Vanhees, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">950-958</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Tolerance [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen Consumption [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Values</style></keyword><keyword><style face="normal" font="default" size="100%">Resistance Training [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012000122</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012000122/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>100</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">100</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Costanzo, P.</style></author><author><style face="normal" font="default" size="100%">Perrone-Filardi, P.</style></author><author><style face="normal" font="default" size="100%">Petretta, M.</style></author><author><style face="normal" font="default" size="100%">Marciano, C.</style></author><author><style face="normal" font="default" size="100%">Vassallo, E.</style></author><author><style face="normal" font="default" size="100%">Gargiulo, P.</style></author><author><style face="normal" font="default" size="100%">Paolillo, S.</style></author><author><style face="normal" font="default" size="100%">Petretta, A.</style></author><author><style face="normal" font="default" size="100%">Chiariello, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1136-1151</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [drug therapy] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009107693</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009107693/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>101</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">101</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cramer, H.</style></author><author><style face="normal" font="default" size="100%">Haller, H.</style></author><author><style face="normal" font="default" size="100%">Lauche, R.</style></author><author><style face="normal" font="default" size="100%">Steckhan, N.</style></author><author><style face="normal" font="default" size="100%">Michalsen, A.</style></author><author><style face="normal" font="default" size="100%">Dobos, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review and meta-analysis of yoga for hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1146-1151</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Yoga</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014031243</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014031243/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>102</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">102</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cross, N. B.</style></author><author><style face="normal" font="default" size="100%">Webster, A. C.</style></author><author><style face="normal" font="default" size="100%">Masson, P.</style></author><author><style face="normal" font="default" size="100%">O&apos;Connell, P. J.</style></author><author><style face="normal" font="default" size="100%">Craig, J. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Transplantation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transplantation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7-18</style></pages><volume><style face="normal" font="default" size="100%">88</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerular Filtration Rate [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Graft Survival [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Transplantation [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009106946</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009106946/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>578</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">578</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cross Nicholas, B.</style></author><author><style face="normal" font="default" size="100%">Webster Angela, C.</style></author><author><style face="normal" font="default" size="100%">Masson, Philip</style></author><author><style face="normal" font="default" size="100%">O&apos;Connell Philip, J.</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive treatment for kidney transplant recipients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerular Filtration Rate [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Graft Rejection [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Graft Survival [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Transplantation [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003598</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: In some nontransplant populations, effects of different antihypertensive drug classes vary. Relative effects in kidney transplant recipients are uncertain.Objectives: To assess comparative effects of different classes of antihypertensive agents in kidney transplant recipients.Search methods: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, conference proceedings and reference lists of identified studies were searched.Selection criteria: Randomised controlled trials of any antihypertensive agent applied to kidney transplant recipients for at least two weeks were included.Data collection and analysis: Data was extracted by two investigators independently. Study quality, transplant outcomes and other patient centred outcomes were assessed using random effects meta-analysis. Risk ratios (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, both with 95% confidence intervals (CI) were calculated. Stratified analyses and meta-regression were used to investigate heterogeneity.Main results: We identified 60 studies, enrolling 3802 recipients. Twenty-nine studies (2262 participants) compared calcium channel blockers (CCB) to placebo/no treatment, 10 studies (445 participants) compared angiotensin converting enzyme inhibitors (ACEi) to placebo/no treatment and seven studies (405 participants) compared CCB to ACEi. CCB compared to placebo/no treatment (plus additional agents in either arm as required) reduced graft loss (RR 0.75, 95% CI 0.57 to 0.99) and improved glomerular filtration rate (GFR), (MD, 4.45 mL/min, 95% CI 2.22 to 6.68). Data on ACEi versus placebo/no treatment were inconclusive for GFR (MD -8.07 mL/min, 95% CI -18.57 to 2.43), and variable for graft loss, precluding meta-analysis. In direct comparison with CCB, ACEi decreased GFR (MD -11.48 mL/min, 95% CI -5.75 to -7.21), proteinuria (MD -0.28 g/24 h, 95% CI -0.47 to -0.10), haemoglobin (MD -12.96 g/L, 95% CI -5.72 to -10.21) and increased hyperkalaemia (RR 3.74, 95% CI 1.89 to 7.43). Graft loss data were inconclusive (RR 7.37, 95% CI 0.39 to 140.35). Other drug comparisons were compared in small numbers of participants and studies.Authors&apos; conclusions: These data suggest that CCB may be preferred as first line agents for hypertensive kidney transplant recipients. ACEi have some detrimental effects in kidney transplant recipients. More high quality studies reporting patient centred outcomes are required.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003598.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003598.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>103</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">103</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cucherat, M.</style></author><author><style face="normal" font="default" size="100%">Borer, J. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reduction of resting heart rate with antianginal drugs: review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">269-280</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angina Pectoris</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012035727</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012035727/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>104</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">104</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cucherat, M.</style></author><author><style face="normal" font="default" size="100%">Stalmans, I.</style></author><author><style face="normal" font="default" size="100%">Rouland, J. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Relative efficacy and safety of preservative-free Latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Glaucoma</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Glaucoma</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e69-e75</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma, Open-Angle</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins F, Synthetic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013041916</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013041916/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>105</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">105</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cutrona, S. L.</style></author><author><style face="normal" font="default" size="100%">Choudhry, N. K.</style></author><author><style face="normal" font="default" size="100%">Fischer, M. A.</style></author><author><style face="normal" font="default" size="100%">Servi, A.</style></author><author><style face="normal" font="default" size="100%">Liberman, J. N.</style></author><author><style face="normal" font="default" size="100%">Brennan, T. A.</style></author><author><style face="normal" font="default" size="100%">Shrank, W. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Modes of delivery for interventions to improve cardiovascular medication adherence (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Managed Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Managed Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">929-942</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Communication</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Directive Counseling</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoglycemic Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Discharge</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacies</style></keyword><keyword><style face="normal" font="default" size="100%">Prescription Drugs</style></keyword><keyword><style face="normal" font="default" size="100%">Professional-Patient Relations</style></keyword><keyword><style face="normal" font="default" size="100%">Telephone</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011000969</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011000969/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>106</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">106</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dahlof, B.</style></author><author><style face="normal" font="default" size="100%">Devereux, R. B.</style></author><author><style face="normal" font="default" size="100%">Kjeldsen, S. E.</style></author><author><style face="normal" font="default" size="100%">Lyle, P. A.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z.</style></author><author><style face="normal" font="default" size="100%">Edelman, J. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future? (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Blood Pressure</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Blood Pressure</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6-12</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [drug therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Control Groups</style></keyword><keyword><style face="normal" font="default" size="100%">Endpoint Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Values</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007001739</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007001739/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>107</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">107</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Daien, V.</style></author><author><style face="normal" font="default" size="100%">Duny, Y.</style></author><author><style face="normal" font="default" size="100%">Ribstein, J.</style></author><author><style face="normal" font="default" size="100%">Du Cailar, G.</style></author><author><style face="normal" font="default" size="100%">Mimran, A.</style></author><author><style face="normal" font="default" size="100%">Villain, M.</style></author><author><style face="normal" font="default" size="100%">Daures, J. P.</style></author><author><style face="normal" font="default" size="100%">Fesler, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of hypertension with renin-angiotensin system inhibitors and renal dysfunction: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">126-132</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012000290</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012000290/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">108</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dankbaar, J. W.</style></author><author><style face="normal" font="default" size="100%">Slooter, A. J.</style></author><author><style face="normal" font="default" size="100%">Rinkel, G. J.</style></author><author><style face="normal" font="default" size="100%">Schaaf, I. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Critical Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Critical Care</style></full-title></periodical><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Fluid Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodilution</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010006739</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010006739/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>579</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">579</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Danso-Appiah, Anthony</style></author><author><style face="normal" font="default" size="100%">Olliaro Piero, L.</style></author><author><style face="normal" font="default" size="100%">Donegan, Sarah</style></author><author><style face="normal" font="default" size="100%">Sinclair, David</style></author><author><style face="normal" font="default" size="100%">Utzinger, Jürg</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Drugs for treating Schistosoma mansoni infection</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Oxamniquine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Praziquantel [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Resins, Plant</style></keyword><keyword><style face="normal" font="default" size="100%">Schistosomiasis mansoni [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Schistosomicides [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Infectn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD000528</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Schistosoma mansoni is a parasitic infection common in the tropics and sub-tropics. Chronic and advanced disease includes abdominal pain, diarrhoea, blood in the stool, liver cirrhosis, portal hypertension, and premature death.Objectives: To evaluate the effects of antischistosomal drugs, used alone or in combination, for treating S. mansoni infection.Search methods: We searched MEDLINE, EMBASE and LILACS from inception to October 2012, with no language restrictions. We also searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2012) and mRCT. The reference lists of articles were reviewed and experts were contacted for unpublished studies.Selection criteria: Randomized controlled trials of antischistosomal drugs, used alone or in combination, versus placebo, different antischistosomal drugs, or different doses of the same antischistosomal drug for treating S. mansoni infection.Data collection and analysis: One author extracted data and assessed eligibility and risk of bias in the included studies, which were independently checked by a second author. We combined dichotomous outcomes using risk ratio (RR) and continuous data weighted mean difference (WMD); we presented both with 95% confidence intervals (CI). We assessed the quality of evidence using the GRADE approach.Main results: Fifty-two trials enrolling 10,269 participants were included. The evidence was of moderate or low quality due to the trial methods and small numbers of included participants.PraziquantelCompared to placebo, praziquantel 40 mg/kg probably reduces parasitological treatment failure at one month post-treatment (RR 3.13, 95% CI 1.03 to 9.53, two trials, 414 participants, moderate quality evidence). Compared to this standard dose, lower doses may be inferior (30 mg/kg: RR 1.52, 95% CI 1.15 to 2.01, three trials, 521 participants, low quality evidence; 20 mg/kg: RR 2.23, 95% CI 1.64 to 3.02, two trials, 341 participants, low quality evidence); and higher doses, up to 60 mg/kg, do not appear to show any advantage (four trials, 783 participants, moderate quality evidence).The absolute parasitological cure rate at one month with praziquantel 40 mg/kg varied substantially across studies, ranging from 52% in Senegal in 1993 to 92% in Brazil in 2006/2007.OxamniquineCompared to placebo, oxamniquine 40 mg/kg probably reduces parasitological treatment failure at three months (RR 8.74, 95% CI 3.74 to 20.43, two trials, 82 participants, moderate quality evidence). Lower doses than 40 mg/kg may be inferior at one month (30 mg/kg: RR 1.78, 95% CI 1.15 to 2.75, four trials, 268 participants, low quality evidence; 20 mg/kg: RR 3.78, 95% CI 2.05 to 6.99, two trials, 190 participants, low quality evidence), and higher doses, such as 60 mg/kg, do not show a consistent benefit (four trials, 317 participants, low quality evidence).These trials are now over 20 years old and only limited information was provided on the study designs and methods.Praziquantel versus oxamniquineOnly one small study directly compared praziquantel 40 mg/kg with oxamniquine 40 mg/kg and we are uncertain which treatment is more effective in reducing parasitological failure (one trial, 33 participants, very low quality evidence). A further 10 trials compared oxamniquine at 20, 30 and 60 mg/kg with praziquantel 40 mg/kg and did not show any marked differences in failure rate or percent egg reduction.Combination treatmentsWe are uncertain whether combining praziquantel with artesunate reduces failures compared to praziquantel alone at one month (one trial, 75 participants, very low quality evidence).Two trials also compared combinations of praziquantel and oxamniquine in different doses, but did not find statistically significant differences in failure (two trials, 87 participants).Other outcomes and analysesIn trials reporting clinical improvement evaluating lower doses (20 mg/kg and 30 mg/kg) against the standard 40 mg/kg for both praziquantel or oxamniquine, no dose effect was demonstrable in resolving abdominal pain, diarrhoea, bloo in stool, hepatomegaly, and splenomegaly (follow up at one, three, six, 12, and 24 months; three trials, 655 participants).Adverse events were not well-reported but were mostly described as minor and transient.In an additional analysis of treatment failure in the treatment arm of individual studies stratified by age, failure rates with 40 mg/kg of both praziquantel and oxamniquine were higher in children.Authors&apos; conclusions: Praziquantel 40 mg/kg as the standard treatment for S. mansoni infection is consistent with the evidence. Oxamniquine, a largely discarded alternative, also appears effective.Further research will help find the optimal dosing regimen of both these drugs in children.Combination therapy, ideally with drugs with unrelated mechanisms of action and targeting the different developmental stages of the schistosomes in the human host should be pursued as an area for future research.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000528.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD000528.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>109</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">109</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Davis, M. I.</style></author><author><style face="normal" font="default" size="100%">Filion, K. B.</style></author><author><style face="normal" font="default" size="100%">Zhang, D.</style></author><author><style face="normal" font="default" size="100%">Eisenberg, M. J.</style></author><author><style face="normal" font="default" size="100%">Afilalo, J.</style></author><author><style face="normal" font="default" size="100%">Schiffrin, E. L.</style></author><author><style face="normal" font="default" size="100%">Joyal, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology] [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney [innervation] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Sympathectomy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Animals[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013025355</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013025355/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>580</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">580</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Courten, Barbora</style></author><author><style face="normal" font="default" size="100%">Barber Melissa, N.</style></author><author><style face="normal" font="default" size="100%">Johnston Renea, V.</style></author><author><style face="normal" font="default" size="100%">Liew, Danny</style></author><author><style face="normal" font="default" size="100%">de Courten, Maximilian</style></author><author><style face="normal" font="default" size="100%">van Doornum, Sharon</style></author><author><style face="normal" font="default" size="100%">Reid, Christopher</style></author><author><style face="normal" font="default" size="100%">Buchbinder, Rachelle</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Muskel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007326</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To review the efficacy and safety of hypolipidemic and antihypertensive therapy in preventing cardiovascular events in rheumatoid arthritis.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007326/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007326</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>581</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">581</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Jongh, Thyra</style></author><author><style face="normal" font="default" size="100%">Gurol-Urganci, Ipek</style></author><author><style face="normal" font="default" size="100%">Vodopivec-Jamsek, Vlasta</style></author><author><style face="normal" font="default" size="100%">Car, Josip</style></author><author><style face="normal" font="default" size="100%">Atun, Rifat</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mobile phone messaging for facilitating self-management of long-term illnesses</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Reminder Systems</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Text Messaging</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Phones</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Commun</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007459</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Long-term illnesses affect a significant proportion of the population in developed and developing countries. Mobile phone messaging applications, such as Short Message Service (SMS) and Multimedia Message Service (MMS), may present convenient, cost-effective ways of supporting self-management and improving patients&apos; self-efficacy skills through, for instance, medication reminders, therapy adjustments or supportive messages.Objectives: To assess the effects of mobile phone messaging applications designed to facilitate self-management of long-term illnesses, in terms of impact on health outcomes and patients&apos; capacity to self-manage their condition. Secondary objectives include assessment of: user evaluation of the intervention; health service utilisation and costs; and possible risks and harms associated with the intervention.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL,The Cochrane Library 2009, Issue 2), MEDLINE (OvidSP) (January 1993 to June 2009), EMBASE (OvidSP) (January 1993 to June 2009), PsycINFO (OvidSP) (January 1993 to June 2009), CINAHL (EbscoHOST) (January 1993 to June 2009), LILACS (January 1993 to June 2009) and African Health Anthology (January 1993 to June 2009).We also reviewed grey literature (including trial registers) and reference lists of articles.Selection criteria: We included randomised controlled trials (RCTs), quasi-randomised controlled trials (QRCTs), controlled before-after (CBA) studies, or interrupted time series (ITS) studies with at least three time points before and after the intervention. We selected only studies where it was possible to assess the effects of mobile phone messaging independent of other technologies or interventions.Data collection and analysis: Two review authors independently assessed all studies against the inclusion criteria, with any disagreements resolved by a third review author. Study design features, characteristics of target populations, interventions and controls, and results data were extracted by two review authors and confirmed by a third. Primary outcomes of interest were health outcomes as a result of the intervention and capacity to self-manage long-term conditions. We also considered patients&apos; and providers&apos; evaluation of the intervention, perceptions of safety, health service utilisation and costs, and potential harms or adverse effects. The included studies were heterogeneous in type of condition addressed, intervention characteristics and outcome measures. Therefore, a meta-analysis to derive an overall effect size for the main outcome categories was not considered justified and findings are presented narratively.Main results: We included four randomised controlled trials involving 182 participants.For the primary outcome of health outcomes, including physiological measures, there is moderate quality evidence from two studies involving people with diabetes showing no statistical difference from text messaging interventions compared with usual care or email reminders for glycaemic control (HbA1c), the frequency of diabetic complications, or body weight. There is moderate quality evidence from one study of hypertensive patients that the mean blood pressure and the proportion of patients who achieved blood pressure control were not significantly different in the intervention and control groups, and that there was no statistically significant difference in mean body weight between the groups. There is moderate quality evidence from one study that asthma patients receiving a text messaging intervention experienced greater improvements on peak expiratory flow variability (mean difference (MD) -11.12, 95% confidence interval (CI) -19.56 to -2.68) and the pooled symptom score comprising four items (cough, night symptoms, sleep quality, and maximum tolerated activity) (MD -0.36, 95% CI -0.56 to -0.17) compared with the control group. However, the study found no significant differences between the groups in impact on forced vital capacity or forced expiratory flow in 1 second.For the primary outcome o capacity to self-manage the condition, there is moderate quality evidence from one study that diabetes patients receiving the text messaging intervention demonstrated improved scores on measures of self-management capacity (Self-Efficacy for Diabetes score (MD 6.10, 95% CI 0.45 to 11.75), Diabetes Social Support Interview pooled score (MD 4.39, 95% CI 2.85 to 5.92)), but did not show improved knowledge of diabetes. There is moderate quality evidence from three studies of the effects on treatment compliance. One study showed an increase in hypertensive patients&apos; rates of medication compliance in the intervention group (MD 8.90, 95% CI 0.18 to 17.62) compared with the control group, but in another study there was no statistically significant effect on rates of compliance with peak expiratory flow measurement in asthma patients. Text message prompts for diabetic patients initially also resulted in a higher number of blood glucose results sent back (46.0) than email prompts did (23.5).For the secondary outcome of participants&apos; evaluation of the intervention, there is very low quality evidence from two studies that patients receiving mobile phone messaging support reported perceived improvement in diabetes self-management, wanted to continue receiving messages, and preferred mobile phone messaging to email as a method to access a computerised reminder system.For the secondary outcome of health service utilisation, there is very low quality evidence from two studies. Diabetes patients receiving text messaging support made a comparable number of clinic visits and calls to an emergency hotline as patients without the support. For asthma patients the total number of office visits was higher in the text messaging group, whereas the number of hospital admissions was higher for the control group.Because of the small number of trials included, and the low overall number of participants, for any of the reviewed outcomes the quality of the evidence can at best be considered moderate.Authors&apos; conclusions: We found some, albeit very limited, indications that in certain cases mobile phone messaging interventions may provide benefit in supporting the self-management of long-term illnesses. However, there are significant information gaps regarding the long-term effects, acceptability, costs, and risks of such interventions. Given the enthusiasm with which so-called mHealth interventions are currently being implemented, further research into these issues is needed. </style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007459.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007459.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>110</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">110</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Desch, S.</style></author><author><style face="normal" font="default" size="100%">Schmidt, J.</style></author><author><style face="normal" font="default" size="100%">Kobler, D.</style></author><author><style face="normal" font="default" size="100%">Sonnabend, M.</style></author><author><style face="normal" font="default" size="100%">Eitel, I.</style></author><author><style face="normal" font="default" size="100%">Sareban, M.</style></author><author><style face="normal" font="default" size="100%">Rahimi, K.</style></author><author><style face="normal" font="default" size="100%">Schuler, G.</style></author><author><style face="normal" font="default" size="100%">Thiele, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of cocoa products on blood pressure: systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">97-103</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Cacao [chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Diastole</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoids [analysis]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Systole</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000691</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000691/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>582</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">582</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Desroches, Sophie</style></author><author><style face="normal" font="default" size="100%">Lapointe, Annie</style></author><author><style face="normal" font="default" size="100%">Ratté, Stéphane</style></author><author><style face="normal" font="default" size="100%">Gravel, Karine</style></author><author><style face="normal" font="default" size="100%">Légaré, France</style></author><author><style face="normal" font="default" size="100%">Turcotte, Stéphane</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interventions to enhance adherence to dietary advice for preventing and managing chronic diseases in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Patient Compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease [prevention &amp; control] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Counseling [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet Therapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Dietetics [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Health Education [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Commun</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008722</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: It has been recognized that poor adherence can be a serious risk to the health and wellbeing of patients, and greater adherence to dietary advice is a critical component in preventing and managing chronic diseases.Objectives: To assess the effects of interventions for enhancing adherence to dietary advice for preventing and managing chronic diseases in adults.Search methods: We searched the following electronic databases up to 29 September 2010: The Cochrane Library (issue 9 2010), PubMed, EMBASE (Embase.com), CINAHL (Ebsco) and PsycINFO (PsycNET) with no language restrictions. We also reviewed: a) recent years of relevant conferences, symposium and colloquium proceedings and abstracts; b) web-based registries of clinical trials; and c) the bibliographies of included studies.Selection criteria: We included randomized controlled trials that evaluated interventions enhancing adherence to dietary advice for preventing and managing chronic diseases in adults. Studies were eligible if the primary outcome was the client?s adherence to dietary advice. We defined &apos;client&apos; as an adult participating in a chronic disease prevention or chronic disease management study involving dietary advice.Data collection and analysis: Two review authors independently assessed the eligibility of the studies. They also assessed the risk of bias and extracted data using a modified version of the Cochrane Consumers and Communication Review Group data extraction template. Any discrepancies in judgement were resolved by discussion and consensus, or with a third review author. Because the studies differed widely with respect to interventions, measures of diet adherence, dietary advice, nature of the chronic diseases and duration of interventions and follow-up, we conducted a qualitative analysis. We classified included studies according to the function of the intervention and present results in a narrative table using vote counting for each category of intervention.Main results: We included 38 studies involving 9445 participants. Among studies that measured diet adherence outcomes between an intervention group and a control/usual care group, 32 out of 123 diet adherence outcomes favoured the intervention group, 4 favoured the control group whereas 62 had no significant difference between groups (assessment was impossible for 25 diet adherence outcomes since data and/or statistical analyses needed for comparison between groups were not provided). Interventions shown to improve at least one diet adherence outcome are: telephone follow-up, video, contract, feedback, nutritional tools and more complex interventions including multiple interventions. However, these interventions also shown no difference in some diet adherence outcomes compared to a control/usual care group making inconclusive results about the most effective intervention to enhance dietary advice. The majority of studies reporting a diet adherence outcome favouring the intervention group compared to the control/usual care group in the short-term also reported no significant effect at later time points. Studies investigating interventions such as a group session, individual session, reminders, restriction and behaviour change techniques reported no diet adherence outcome showing a statistically significant difference favouring the intervention group. Finally, studies were generally of short duration and low quality, and adherence measures varied widely.Authors&apos; conclusions: There is a need for further, long-term, good-quality studies using more standardized and validated measures of adherence to identify the interventions that should be used in practice to enhance adherence to dietary advice in the context of a variety of chronic diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008722.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008722.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>583</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">583</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Diao, Diana</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author><author><style face="normal" font="default" size="100%">Cundiff David, K.</style></author><author><style face="normal" font="default" size="100%">Gueyffier, Francois</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacotherapy for mild hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Disease [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006742</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: People with no previous cardiovascular events or cardiovascular disease represent a primary prevention population. The benefits and harms of treating mild hypertension in primary prevention patients are not known at present. This review examines the existing randomised controlled trial (RCT) evidence.Objectives: Primary objective: To quantify the effects of antihypertensive drug therapy on mortality and morbidity in adults with mild hypertension (systolic blood pressure (BP) 140-159 mmHg and/or diastolic BP 90-99 mmHg) and without cardiovascular disease.Search methods: We searched The Cochrane Central Register of Controlled Trials (CENTRAL) 2013 Issue 9, MEDLINE (1946 to October 2013), EMBASE (1974 to October 2013), ClinicalTrials.gov (all dates to October 2013), and reference lists of articles. The Cochrane Database of Systematic Reviews and the Database of Abstracts of Reviews of Effectiveness (DARE) were searched for previous reviews and meta-analyses of anti-hypertensive drug treatment compared to placebo or no treatment trials until the end of 2011.Selection criteria: RCTs of at least 1 year duration.Data collection and analysis: The outcomes assessed were mortality, stroke, coronary heart disease (CHD), total cardiovascular events (CVS), and withdrawals due to adverse effects.Main results: Of 11 RCTs identified 4 were included in this review, with 8,912 participants. Treatment for 4 to 5 years with antihypertensive drugs as compared to placebo did not reduce total mortality (RR 0.85, 95% CI 0.63, 1.15). In 7,080 participants treatment with antihypertensive drugs as compared to placebo did not reduce coronary heart disease (RR 1.12, 95% CI 0.80, 1.57), stroke (RR 0.51, 95% CI 0.24, 1.08), or total cardiovascular events (RR 0.97, 95% CI 0.72, 1.32). Withdrawals due to adverse effects were increased by drug therapy (RR 4.80, 95%CI 4.14, 5.57), Absolute risk increase (ARI) 9%.Authors&apos; conclusions: Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) have not been shown to reduce mortality or morbidity in RCTs. Treatment caused 9% of patients to discontinue treatment due to adverse effects. More RCTs are needed in this prevalent population to know whether the benefits of treatment exceed the harms.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006742.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006742.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>584</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">584</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dickinson Heather, O.</style></author><author><style face="normal" font="default" size="100%">Beyer Fiona, R.</style></author><author><style face="normal" font="default" size="100%">Ford Gary, A.</style></author><author><style face="normal" font="default" size="100%">Nicolson, Donald</style></author><author><style face="normal" font="default" size="100%">Campbell, Fiona</style></author><author><style face="normal" font="default" size="100%">Cook Julia, V.</style></author><author><style face="normal" font="default" size="100%">Mason, James</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Relaxation therapies for the management of primary hypertension in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Relaxation Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004935</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Lifestyle interventions are often recommended as initial treatment for mild hypertension, but the efficacy of relaxation therapies is unclear.Objectives: To evaluate the effects of relaxation therapies on cardiovascular outcomes and blood pressure in people with elevated blood pressure.Search methods: We searched the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, ISI Proceedings, ClinicalTrials.gov, Current Controlled Trials and reference lists of systematic reviews, meta-analyses and randomised controlled trials (RCTs) included in the review.Selection criteria: Inclusion criteria: RCTs of a parallel design comparing relaxation therapies with no active treatment, or sham therapy; follow-up ?8 weeks; participants over 18 years, with raised systolic blood pressure (SBP) ?140 mmHg or diastolic blood pressure (DBP) ?85 mmHg); SBP and DBP reported at end of follow-up. Exclusion criteria: participants were pregnant; participants received antihypertensive medication which changed during the trial.Data collection and analysis: Two reviewers independently extracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Random effects meta-analyses and sensitivity analyses were conducted.Main results: 29 RCTs, with eight weeks to five years follow-up, met our inclusion criteria; four were excluded from the primary meta-analysis because of inadequate outcome data. The remaining 25 trials assessed 1,198 participants, but adequate randomisation was confirmed in only seven trials and concealment of allocation in only one. Only one trial reported deaths, heart attacks and strokes (one of each). Meta-analysis indicated that relaxation resulted in small, statistically significant reductions in SBP (mean difference: -5.5 mmHg, 95% CI: -8.2 to -2.8, I2 =72%) and DBP (mean difference: -3.5 mmHg, 95% CI: -5.3 to -1.6, I2 =75%) compared to control. The substantial heterogeneity between trials was not explained by duration of follow-up, type of control, type of relaxation therapy or baseline blood pressure.The nine trials that reported blinding of outcome assessors found a non-significant net reduction in blood pressure (SBP mean difference: -3.2 mmHg, 95% CI: -7.7 to 1.4, I2 =69%) associated with relaxation. The 15 trials comparing relaxation with sham therapy likewise found a non-significant reduction in blood pressure (SBP mean difference: -3.5 mmHg, 95% CI: -7.1 to 0.2, I2 =63%).Authors&apos; conclusions: In view of the poor quality of included trials and unexplained variation between trials, the evidence in favour of causal association between relaxation and blood pressure reduction is weak. Some of the apparent benefit of relaxation was probably due to aspects of treatment unrelated to relaxation.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004935.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004935.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>585</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">585</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dickinson Heather, O.</style></author><author><style face="normal" font="default" size="100%">Nicolson, Donald</style></author><author><style face="normal" font="default" size="100%">Campbell, Fiona</style></author><author><style face="normal" font="default" size="100%">Beyer Fiona, R.</style></author><author><style face="normal" font="default" size="100%">Mason, James</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Potassium supplementation for the management of primary hypertension in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dietary Supplements [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium, Dietary [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004641</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Epidemiological evidence on the effects of potassium on blood pressure is inconsistent.Objectives: To evaluate the effects of potassium supplementation on health outcomes and blood pressure in people with elevated blood pressure.Search methods: We searched the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, ISI Proceedings, ClinicalTrials.gov, Current Controlled Trials, CAB abstracts, and reference lists of systematic reviews, meta-analyses and randomised controlled trials (RCTs) included in the review.Selection criteria: Inclusion criteria were: 1) RCTs of a parallel or crossover design comparing oral potassium supplements with placebo, no treatment, or usual care; 2) treatment and follow-up &gt;=8 weeks; 3) participants over 18 years, with raised systolic blood pressure (SBP) &gt;=140 mmHg or diastolic blood pressure (DBP) &gt;=85 mmHg); 4) SBP and DBP reported at end of follow-up. We excluded trials where: participants were pregnant; received antihypertensive medication which changed during the study; or potassium supplementation was combined with other interventions.Data collection and analysis: Two reviewers independently extracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Random effects meta-analyses and sensitivity analyses were conducted.Main results: Six RCT&apos;s (n=483), with 8-16 weeks follow-up, met our inclusion criteria. Meta-analysis of five trials (n=425) with adequate data indicated that potassium supplementation compared to control resulted in a large but statistically non-significant reductions in SBP (mean difference: -11.2, 95% CI: -25.2 to 2.7) and DBP (mean difference: -5.0, 95% CI: -12.5 to 2.4). The substantial heterogeneity between trials was not explained by potassium dose, quality of trials or baseline blood pressure.Excluding one trial in an African population with very high baseline blood pressure resulted in smaller overall reductions in blood pressure (SBP mean difference: -3.9, 95% CI: -8.6 to 0.8; DBP mean difference: -1.5, 95% CI: -6.2 to 3.1). Further sensitivity analysis restricted to two high quality trials (n=138) also found non-significant reductions in blood pressure (SBP mean difference: -7.1, 95% CI: -19.9 to 5.7; DBP mean difference: -5.5, 95% CI: -14.5 to 3.5).Authors&apos; conclusions: Potassium supplementation has no statistically significant effect on blood pressure. Due to small number of participants in the two high quality trials, the short duration of follow-up, and the unexplained heterogeneity between trials, the evidence about the effect of potassium supplementation on blood pressure is not conclusive. Further high quality RCTs of longer duration are required to clarify whether potassium supplementation can reduce blood pressure and improve health outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004641.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004641.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>586</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">586</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dickinson Heather, O.</style></author><author><style face="normal" font="default" size="100%">Nicolson, Donald</style></author><author><style face="normal" font="default" size="100%">Campbell, Fiona</style></author><author><style face="normal" font="default" size="100%">Cook Julia, V.</style></author><author><style face="normal" font="default" size="100%">Beyer Fiona, R.</style></author><author><style face="normal" font="default" size="100%">Ford Gary, A.</style></author><author><style face="normal" font="default" size="100%">Mason, James</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Magnesium supplementation for the management of primary hypertension in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dietary Supplements [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Magnesium [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004640</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Epidemiological evidence on the effects of magnesium on blood pressure is inconsistent. Metabolic and experimental studies suggest that magnesium may have a role in the regulation of blood pressure.Objectives: To evaluate the effects of magnesium supplementation as treatment for primary hypertension in adults.Search methods: We searched the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, ISI Proceedings, ClinicalTrials.gov, Current Controlled Trials, CAB abstracts, and reference lists of systematic reviews, meta-analyses and randomised controlled trials (RCTs) included in the review.Selection criteria: Inclusion criteria were: 1) RCTs of a parallel or crossover design comparing oral magnesium supplementation with placebo, no treatment, or usual care; 2) treatment and follow-up ?8 weeks; 3) participants over 18 years old, with raised systolic blood pressure (SBP) ?140 mmHg or diastolic blood pressure (DBP) ?85 mmHg; 4) SBP and DBP reported at end of follow-up. We excluded trials where: participants were pregnant; received antihypertensive medication which changed during the study; or magnesium supplementation was combined with other interventions.Data collection and analysis: Two reviewers independently abstracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Random effects meta-analyses and sensitivity analyses were conducted.Main results: Twelve RCTs (n=545) with eight to 26 weeks follow-up met our inclusion criteria. The results of the individual trials were heterogeneous. Combining all trials, participants receiving magnesium supplements as compared to control did not significantly reduce SBP (mean difference: -1.3 mmHg, 95% CI: -4.0 to 1.5, I2=67%), but did statistically significantly reduce DBP (mean difference: -2.2 mmHg, 95% CI: -3.4 to -0.9, I2=47%). Sensitivity analyses excluding poor quality trials yielded similar results. Sub-group analyses and meta-regression indicated that heterogeneity between trials could not be explained by dose of magnesium, baseline blood pressure or the proportion of males among the participants.Authors&apos; conclusions: In view of the poor quality of included trials and the heterogeneity between trials, the evidence in favour of a causal association between magnesium supplementation and blood pressure reduction is weak and is probably due to bias. This is because poor quality studies generally tend to over-estimate the effects of treatment. Larger, longer duration and better quality double-blind placebo controlled trials are needed to assess the effect of magnesium supplementation on blood pressure and cardiovascular outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004640.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004640.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>587</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">587</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dickinson Heather, O.</style></author><author><style face="normal" font="default" size="100%">Nicolson, Donald</style></author><author><style face="normal" font="default" size="100%">Cook Julia, V.</style></author><author><style face="normal" font="default" size="100%">Campbell, Fiona</style></author><author><style face="normal" font="default" size="100%">Beyer Fiona, R.</style></author><author><style face="normal" font="default" size="100%">Ford Gary, A.</style></author><author><style face="normal" font="default" size="100%">Mason, James</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Calcium supplementation for the management of primary hypertension in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium, Dietary [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004639</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Metabolic studies suggest calcium may have a role in the regulation of blood pressure. Some epidemiological studies reported people with a higher intake of calcium tend to have lower blood pressure. Previous systematic reviews and meta-analyses reached conflicting conclusions about whether oral calcium supplementation can reduce blood pressure.Objectives: To evaluate the effects of oral calcium supplementation as a treatment for primary hypertension in adults.Search methods: We searched the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, ISI Proceedings, ClinicalTrials.gov, Current Controlled Trials, CAB abstracts, and reference lists of systematic reviews, meta-analyses and randomised controlled trials (RCTs) included in the review.Selection criteria: Inclusion criteria were: 1) RCTs comparing oral calcium supplementation with placebo, no treatment, or usual care; 2) treatment and follow-up ?8 weeks; 3) participants over 18 years old, with raised systolic blood pressure (SBP) ?140 mmHg or diastolic blood pressure (DBP) ?85 mmHg; 4) SBP and DBP reported at end of follow-up. We excluded trials where: participants were pregnant; received antihypertensive medication which changed during the study; or calcium supplementation was combined with other interventions.Data collection and analysis: Two reviewers independently abstracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Random effects meta-analyses and sensitivity analyses were conducted.Main results: We included 13 RCTs (n=485), with between eight and 15 weeks follow-up. The results of the individual trials were heterogeneous. Combining all trials, participants receiving calcium supplementation as compared to control had a statistically significant reduction in SBP (mean difference: -2.5 mmHg, 95% CI: -4.5 to -0.6, I2 = 42%), but not DBP (mean difference: -0.8 mmHg, 95% CI: -2.1 to 0.4, I2 = 48%). Sub-group analyses indicated that heterogeneity between trials could not be explained by dose of calcium or baseline blood pressure. Heterogeneity was reduced when poor quality trials were excluded. The one trial reporting adequate concealment of allocation and the one trial reporting adequate blinding yielded results consistent with the primary meta-analysis.Authors&apos; conclusions: Due to poor quality of included trials and heterogeneity between trials, the evidence in favour of causal association between calcium supplementation and blood pressure reduction is weak and is probably due to bias. This is because poor quality studies generally tend to over-estimate the effects of treatment. Larger, longer duration and better quality double-blind placebo controlled trials are needed to assess the effect of calcium supplementation on blood pressure and cardiovascular outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004639.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004639.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>111</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">111</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dickinson, H. O.</style></author><author><style face="normal" font="default" size="100%">Campbell, F.</style></author><author><style face="normal" font="default" size="100%">Beyer, F. R.</style></author><author><style face="normal" font="default" size="100%">Nicolson, D. J.</style></author><author><style face="normal" font="default" size="100%">Cook, J. V.</style></author><author><style face="normal" font="default" size="100%">Ford, G. A.</style></author><author><style face="normal" font="default" size="100%">Mason, J. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Relaxation therapies for the management of primary hypertension in adults: a Cochrane review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">809-820</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [psychology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Relaxation Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009101876</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009101876/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>112</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">112</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dickinson, H. O.</style></author><author><style face="normal" font="default" size="100%">Mason, J. M.</style></author><author><style face="normal" font="default" size="100%">Nicolson, D. J.</style></author><author><style face="normal" font="default" size="100%">Campbell, F.</style></author><author><style face="normal" font="default" size="100%">Beyer, F. R.</style></author><author><style face="normal" font="default" size="100%">Cook, J. V.</style></author><author><style face="normal" font="default" size="100%">Williams, B.</style></author><author><style face="normal" font="default" size="100%">Ford, G. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">215-233</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administrative Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium, Dietary [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Fish Oils [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">Magnesium [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006001560</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006001560/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>113</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">113</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ding, Q.</style></author><author><style face="normal" font="default" size="100%">Yu, J.</style></author><author><style face="normal" font="default" size="100%">Li, N. Y.</style></author><author><style face="normal" font="default" size="100%">Chang, P.</style></author><author><style face="normal" font="default" size="100%">Lin, X.</style></author><author><style face="normal" font="default" size="100%">Wang, Q. Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, X. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of calcium channel blockers and angiotensin converting enzyme inhibitors on the left ventricular hypertrophy in Chinese hypertensive patients: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">436-444</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertrophy, Left Ventricular</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Dysfunction, Left</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012025341</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012025341/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>114</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">114</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dobarro, D.</style></author><author><style face="normal" font="default" size="100%">Schreiber, B. E.</style></author><author><style face="normal" font="default" size="100%">Handler, C.</style></author><author><style face="normal" font="default" size="100%">Beynon, H.</style></author><author><style face="normal" font="default" size="100%">Denton, C. P.</style></author><author><style face="normal" font="default" size="100%">Coghlan, J. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">278-285</style></pages><volume><style face="normal" font="default" size="100%">111</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [etiology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default" size="100%">Sarcoidosis, Pulmonary [complications] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate [trends]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">World Health</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013007464</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013007464/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">115</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dobre, M.</style></author><author><style face="normal" font="default" size="100%">Demirjian, S.</style></author><author><style face="normal" font="default" size="100%">Sehgal, A. R.</style></author><author><style face="normal" font="default" size="100%">Navaneethan, S. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Urology and Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Urology and Nephrology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">175-184</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis, Differential</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatorenal Syndrome [diagnosis] [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Cirrhosis [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Lypressin [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011002943</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011002943/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">116</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dong, J. Y.</style></author><author><style face="normal" font="default" size="100%">Qin, L. Q.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Arigoni, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Heart Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">959-965</style></pages><volume><style face="normal" font="default" size="100%">162</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Arginine [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012000051</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012000051/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>117</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">117</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dong, J. Y.</style></author><author><style face="normal" font="default" size="100%">Szeto, I. M.</style></author><author><style face="normal" font="default" size="100%">Makinen, K.</style></author><author><style face="normal" font="default" size="100%">Gao, Q.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Qin, L. Q.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of probiotic fermented milk on blood pressure: a meta-analysis of randomised controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1188-1194</style></pages><volume><style face="normal" font="default" size="100%">110</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Cultured Milk Products</style></keyword><keyword><style face="normal" font="default" size="100%">Fermentation</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Animals[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013037475</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013037475/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>118</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">118</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dong, J. Y.</style></author><author><style face="normal" font="default" size="100%">Tong, X.</style></author><author><style face="normal" font="default" size="100%">Wu, Z. W.</style></author><author><style face="normal" font="default" size="100%">Xun, P. C.</style></author><author><style face="normal" font="default" size="100%">He, K.</style></author><author><style face="normal" font="default" size="100%">Qin, L. Q.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of soya protein on blood pressure: a meta-analysis of randomised controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">317-326</style></pages><volume><style face="normal" font="default" size="100%">106</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Soybean Proteins [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Soybeans [chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011006200</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011006200/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>119</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">119</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doulton, T. W.</style></author><author><style face="normal" font="default" size="100%">He, F. J.</style></author><author><style face="normal" font="default" size="100%">MacGregor, G. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">880-886</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005000127</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005000127/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>588</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">588</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doyle Lex, W.</style></author><author><style face="normal" font="default" size="100%">Ehrenkranz Richard, A.</style></author><author><style face="normal" font="default" size="100%">Halliday Henry, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Early (&lt; 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchopulmonary Dysplasia [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Dexamethasone [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Glucocorticoids [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrocortisone [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Low Birth Weight</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Distress Syndrome, Newborn [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD001146</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Chronic lung disease remains a major problem in neonatal intensive care units. Persistent inflammation in the lungs is the most likely underlying pathogenesis. Corticosteroids have been used to either prevent or treat chronic lung disease because of their potent anti-inflammatory effects.Objectives: To examine the relative benefits and adverse effects of postnatal corticosteroids commenced within the first seven days of life to preterm infants at risk of developing chronic lung disease.Search methods: We sought randomised controlled trials (RCTs) of postnatal corticosteroid therapy from the Cochrane Central Register of Controlled Trials (CENTRAL, 2013, Issue 8), MEDLINE (1966 to August 2013), handsearching paediatric and perinatal journals, and by examining previous review articles and information received from practising neonatologists. We contacted authors of all studies, where possible, to confirm details of reported follow-up studies, or to obtain any information about long-term follow-up where none had been reported.Selection criteria: We selected RCTs of postnatal corticosteroid treatment within the first seven days of life (early) in high-risk preterm infants for this review. Most studies evaluated the use of dexamethasone but we also included studies that assessed hydrocortisone, even if it was used primarily to manage hypotension.Data collection and analysis: We extracted and analysed data regarding clinical outcomes that included mortality, chronic lung disease, death or chronic lung disease, failure to extubate, complications during the primary hospitalisation, and long-term health outcomes.Main results: Twenty-nine RCTs enrolling a total of 3750 participants were eligible for inclusion in this review. The overall risk for bias was probably low as all were randomised controlled trials, and most trials have used rigorous methods. There were significant benefits for the following outcomes: lower rates of failure to extubate and decreased risks of chronic lung disease at both 28 days and 36 weeks&apos; postmenstrual age, death or chronic lung disease at 28 days and 36 weeks&apos; postmenstrual age, patent ductus arteriosus and ROP, including severe ROP. There were no significant differences in the rates of neonatal or subsequent mortality, infection, severe intraventricular haemorrhage, periventricular leukomalacia, necrotising enterocolitis or pulmonary haemorrhage. Gastrointestinal bleeding and intestinal perforation were important adverse effects. The risks of hyperglycaemia, hypertension, hypertrophic cardiomyopathy and growth failure were also increased. In the 12 trials that reported late outcomes, several adverse neurological effects were found at follow-up examinations, including developmental delay (not defined), cerebral palsy and abnormal neurological examination. However, major neurosensory disability was not significantly increased, either overall in the seven studies where this outcome could be determined, or in the two individual studies where the rates of cerebral palsy or abnormal neurological examination were significantly increased. Moreover, the rates of the combined outcomes of death or cerebral palsy, or of death or major neurosensory disability, were not significantly increased. Dexamethasone was used in most studies (n = 20); only nine studies used hydrocortisone. In subgroup analyses by type of corticosteroid, most of the beneficial and harmful effects were attributable to dexamethasone; hydrocortisone had little effect on any outcomes except for an increase in intestinal perforation and a borderline reduction in patent ductus arteriosus.Authors&apos; conclusions: The benefits of early postnatal corticosteroid treatment (? 7 days), particularly dexamethasone, may not outweigh the adverse effects of this treatment. Although early corticosteroid treatment facilitates extubation and reduces the risk of chronic lung disease and patent ductus arteriosus, it causes short-term adverse effects including gastrointestinal bleeding, intestinal perforation, hyperglycaemia, hypertension, hypertrophic cardiomyopathy and growth failure. Long-term follow-up studies report an increased risk of abnormal neurological examination and cerebral palsy. However, the methodological quality of the studies determining long-term outcomes is limited in some cases; the surviving children have been assessed predominantly before school age, and no study has been sufficiently powered to detect important adverse long-term neurosensory outcomes. There is a compelling need for the long-term follow-up and reporting of late outcomes, especially neurological and developmental outcomes, among surviving infants who participated in all randomised trials of early postnatal corticosteroid treatment. Hydrocortisone in the doses and regimens used in the reported RCTs has few beneficial or harmful effects and cannot be recommended for the prevention of chronic lung disease.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001146.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001146.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>589</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">589</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doyle Lex, W.</style></author><author><style face="normal" font="default" size="100%">Ehrenkranz Richard, A.</style></author><author><style face="normal" font="default" size="100%">Halliday Henry, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Late (&gt; 7 days) postnatal corticosteroids for chronic lung disease in preterm infants</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Dexamethasone [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Glucocorticoids [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature, Diseases [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Diseases [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD001145</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Many preterm infants who survive go on to develop chronic lung disease. This is probably due to persistent inflammation in the lungs. Corticosteroids have powerful anti-inflammatory effects and have been used to treat established chronic lung disease. However, it is unclear whether any beneficial effects outweigh the adverse effects of these drugs.Objectives: To determine the relative benefits and adverse effects associated with late (&gt; 7 days) postnatal systemic corticosteroid treatment compared with control (placebo or nothing) in the preterm infant with evolving or established chronic lung disease.Search methods: We sought randomised controlled trials (RCTs) of postnatal corticosteroid therapy from the Cochrane Central Register of Controlled Trials (CENTRAL 2013, Issue 8), MEDLINE (1966 through August 2013), handsearching paediatric and perinatal journals, and by examining previous review articles and information received from practising neonatologists. When possible, we contacted authors of all studies to confirm details of reported follow-up studies or to obtain any information about long-term follow-up where none had been reported.Selection criteria: We selected RCTs of postnatal corticosteroid treatment initiated after seven days after birth in preterm infants with evolving or established chronic lung disease for this review.Data collection and analysis: We extracted and analysed data regarding clinical outcomes including mortality, chronic lung disease, death or chronic lung disease, failure to extubate, complications in the primary hospitalisation, and long-term health outcomesMain results: Twenty-one RCTs enrolling a total of 1424 participants were eligible for this review. All were randomised controlled trials, but the methods for random allocation were not always clear. Allocation concealment, blinding of the intervention and blinding of the outcome assessments were mostly satisfactory. Late steroid treatment was associated with a reduction in neonatal mortality (at 28 days), but not mortality at discharge or latest reported age. Benefits of delayed steroid treatment included reductions in failure to extubate by three, seven or 28 days, chronic lung disease at both 28 days and 36 weeks&apos; postmenstrual age, need for late rescue treatment with dexamethasone, discharge on home oxygen, and death or chronic lung disease at both 28 days and 36 weeks&apos; postmenstrual age. There was a trend towards an increase in risk of infection and gastrointestinal bleeding, but not necrotising enterocolitis. Short-term adverse affects included hyperglycaemia, glycosuria and hypertension. There was an increase in severe retinopathy of prematurity, but no significant increase in blindness. There was a trend towards a reduction in severe intraventricular haemorrhage, but only 247 infants were enrolled in five studies reporting this outcome. The trends to an increase in cerebral palsy or abnormal neurological examination were partly offset by a trend in the opposite direction in death before late follow-up. The combined rate of death or cerebral palsy was not significantly different between steroid and control groups. Major neurosensory disability, and the combined rate of death or major neurosensory disability, were not significantly different between steroid and control groups. There were no substantial differences between groups for other outcomes in later childhood, including respiratory health or function, blood pressure or growth, although there were fewer with a clinically important reduction in the forced expired volume in one second (FEV1) on respiratory function testing.Authors&apos; conclusions: The benefits of late corticosteroid therapy may not outweigh actual or potential adverse effects. Although there continues to be concern about an increased incidence of adverse neurological outcomes in infants treated with postnatal steroids, this review of postnatal corticosteroid treatment for chronic lung disease initiated after seven days of age suggests that late therapy may reduce neonatal mortality without significan ly increasing the risk of adverse long-term neurodevelopmental outcomes. However, the methodological quality of the studies determining the long-term outcome is limited in some cases; in some studies the surviving children have only been assessed before school age, when some important neurological outcomes cannot be determined with certainty, and no study was sufficiently powered to detect increased rates of important adverse long-term neurosensory outcomes. Given the evidence of both benefits and harms of treatment, and the limitations of the evidence at present, it appears prudent to reserve the use of late corticosteroids for infants who cannot be weaned from mechanical ventilation and to minimise the dose and duration of any course of treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001145.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001145.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">120</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Du, B.</style></author><author><style face="normal" font="default" size="100%">Cui, W. P.</style></author><author><style face="normal" font="default" size="100%">Xu, G. L.</style></author><author><style face="normal" font="default" size="100%">Sun, G. Q.</style></author><author><style face="normal" font="default" size="100%">Wu, G. D.</style></author><author><style face="normal" font="default" size="100%">Qu, R.</style></author><author><style face="normal" font="default" size="100%">Lin, S. M.</style></author><author><style face="normal" font="default" size="100%">Liu, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Qin, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A meta-analysis of the efficacy and safety of arotinolol in the treatment of Chinese patients with essential hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">African Journal of Pharmacy and Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">African Journal of Pharmacy and Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">36-42</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012006504</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012006504/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>121</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">121</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dubourg, J.</style></author><author><style face="normal" font="default" size="100%">Javouhey, E.</style></author><author><style face="normal" font="default" size="100%">Geeraerts, T.</style></author><author><style face="normal" font="default" size="100%">Messerer, M.</style></author><author><style face="normal" font="default" size="100%">Kassai, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ultrasonography of optic nerve sheath diameter for detection of raised intracranial pressure: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Intensive Care Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Intensive Care Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1059-1068</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [physiopathology] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Myelin Sheath [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Optic Nerve [physiopathology] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012035011</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012035011/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>590</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">590</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dutta, Debarati</style></author><author><style face="normal" font="default" size="100%">Sule, Medha</style></author><author><style face="normal" font="default" size="100%">Ray, Amita</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Epidural therapy for the treatment of severe pre-eclampsia in non labouring women</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Preg</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009540</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:The objective of this review is to assess, from the best available evidence, the effect of the extended use of epidural therapy alone, and then compare it with other methods, which include intravenous magnesium sulphate, anticonvulsants other than magnesium sulphate, with or without use of the antihypertensive drugs and adjuncts in the treatment of severe pre-eclampsia, and to assess its effect on maternal and perinatal outcomes. Here, we will only consider the use of epidural anaesthesia in the management of severe pre-eclampsia in the antepartum period and not as pain relief in labour. </style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009540/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009540</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>122</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">122</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eastridge, D. K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">An integrative review of interventions to reduce peripheral arterial disease risk factors in African Americans (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Vascular Nursing</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Vascular Nursing</style></full-title></periodical><pages><style face="normal" font="default" size="100%">31-45</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">African Americans [ethnology] [genetics] [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Complications [complications] [ethnology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperlipidemias [complications] [ethnology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [ethnology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Peripheral Vascular Diseases [ethnology] [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Reduction Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">United States [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009107270</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009107270/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>591</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">591</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ebrahim, Shah</style></author><author><style face="normal" font="default" size="100%">Taylor, Fiona</style></author><author><style face="normal" font="default" size="100%">Ward, Kirsten</style></author><author><style face="normal" font="default" size="100%">Beswick, Andrew</style></author><author><style face="normal" font="default" size="100%">Burke, Margaret</style></author><author><style face="normal" font="default" size="100%">Davey Smith, George</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Multiple risk factor interventions for primary prevention of coronary heart disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Coronary Disease [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Counseling</style></keyword><keyword><style face="normal" font="default" size="100%">Health Promotion</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD001561</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Multiple risk factor interventions using counselling and educational methods assumed to be efficacious and cost-effective in reducing coronary heart disease (CHD) mortality and morbidity and that they should be expanded. Trials examining risk factor changes have cast doubt on the effectiveness of these interventions.Objectives: To assess the effects of multiple risk factor interventions for reducing total mortality, fatal and non-fatal events from CHD and cardiovascular risk factors among adults assumed to be without prior clinical evidence CHD..Search methods: We updated the original search BY SEARCHING CENTRAL (2006, Issue 2), MEDLINE (2000 to June 2006) and EMBASE (1998 to June 2006), and checking bibliographies.Selection criteria: Randomised controlled trials of more than six months duration using counselling or education to modify more than one cardiovascular risk factor in adults from general populations, occupational groups or specific risk factors (i.e. diabetes, hypertension, hyperlipidaemia, obesity).Data collection and analysis: Two authors extracted data independently. We expressed categorical variables as odds ratios (OR) with 95% confidence intervals (CI). Where studies published subsequent follow-up data on mortality and event rates, we updated these data.Main results: We found 55 trials (163,471 participants) with a median duration of 12 month follow up. Fourteen trials (139,256 participants) with reported clinical event endpoints, the pooled ORs for total and CHD mortality were 1.00 (95% CI 0.96 to 1.05) and 0.99 (95% CI 0.92 to 1.07), respectively. Total mortality and combined fatal and non-fatal cardiovascular events showed benefits from intervention when confined to trials involving people with hypertension (16 trials) and diabetes (5 trials): OR 0.78 (95% CI 0.68 to 0.89) and OR 0.71 (95% CI 0.61 to 0.83), respectively. Net changes (weighted mean differences) in systolic and diastolic blood pressure (53 trials) and blood cholesterol (50 trials) were -2.71 mmHg (95% CI -3.49 to -1.93), -2.13 mmHg (95% CI -2.67 to -1.58 ) and -0.24 mmol/l (95% CI -0.32 to -0.16), respectively. The OR for reduction in smoking prevalence (20 trials) was 0.87 (95% CI 0.75 to 1.00). Marked heterogeneity (I2 &gt; 85%) for all risk factor analyses was not explained by co-morbidities, allocation concealment, use of antihypertensive or cholesterol-lowering drugs, or by age of trial.Authors&apos; conclusions: Interventions using counselling and education aimed at behaviour change do not reduce total or CHD mortality or clinical events in general populations but may be effective in reducing mortality in high-risk hypertensive and diabetic populations. Risk factor declines were modest but owing to marked unexplained heterogeneity between trials, the pooled estimates are of dubious validity. Evidence suggests that health promotion interventions have limited use in general populations.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001561.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001561.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>123</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">123</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Echouffo-Tcheugui, J. B.</style></author><author><style face="normal" font="default" size="100%">Batty, G. D.</style></author><author><style face="normal" font="default" size="100%">Kivimaki, M.</style></author><author><style face="normal" font="default" size="100%">Kengne, A. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk models to predict hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Plos One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Plos One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e67370</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013041342</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013041342/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>124</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">124</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elley, C. R.</style></author><author><style face="normal" font="default" size="100%">Gupta, A. K.</style></author><author><style face="normal" font="default" size="100%">Webster, R.</style></author><author><style face="normal" font="default" size="100%">Selak, V.</style></author><author><style face="normal" font="default" size="100%">Jun, M.</style></author><author><style face="normal" font="default" size="100%">Patel, A.</style></author><author><style face="normal" font="default" size="100%">Rodgers, A.</style></author><author><style face="normal" font="default" size="100%">Thom, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The efficacy and tolerability of &apos;polypills&apos;: meta-analysis of randomised controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Plos One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Plos One</style></full-title></periodical><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Hypolipidemic Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013003627</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013003627/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>125</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">125</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ellinger, S.</style></author><author><style face="normal" font="default" size="100%">Reusch, A.</style></author><author><style face="normal" font="default" size="100%">Stehle, P.</style></author><author><style face="normal" font="default" size="100%">Helfrich, H. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Epicatechin ingested via cocoa products reduces blood pressure in humans: A nonlinear regression model with a Bayesian approach (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1365-1377</style></pages><volume><style face="normal" font="default" size="100%">95</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bayes Theorem</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cacao [chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Catechin [administration &amp; dosage] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts [administration &amp; dosage] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012029061</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012029061/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>126</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">126</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elliott, H. L.</style></author><author><style face="normal" font="default" size="100%">Meredith, P. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Thrapeutic equivalence in the treatment of hypertension: can lercanidipine and nifedipine GITS be considered to be interchangeable? (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">507-513</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dihydropyridines</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Nifedipine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014041867</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014041867/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>592</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">592</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">El-Zammar Diala, N.</style></author><author><style face="normal" font="default" size="100%">Chen Jenny, M. H.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering effect of diuretics as second line therapy for primary hypertension in crossover trials</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008279</style></accession-num><abstract><style face="normal" font="default" size="100%">: This is the protocol for a review and there is no abstract. The objectives are as follows:Primary objective: To quantify the additional reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) of diuretics as second-line therapy in patients with primary hypertension based on cross-over trials. Secondary objectives: To quantify the effects of a second-line diuretic on heart rate (HR). To quantify the effects of a second-line diuretic on withdrawals due to adverse effects (WDAE).</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008279/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008279</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>593</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">593</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Emengo, H.</style></author><author><style face="normal" font="default" size="100%">Clifton, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evidence note: What is the clinical and cost effectiveness of treatment with renal denervation for patients with resistant hypertension? (Project record)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Catheter Ablation</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Scotland</style></keyword><keyword><style face="normal" font="default" size="100%">Sympathectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">NHS Quality Improvement Scotland (NHS QIS)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000493</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000493/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>127</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">127</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eyawo, O.</style></author><author><style face="normal" font="default" size="100%">Nachega, J.</style></author><author><style face="normal" font="default" size="100%">Lefebvre, P.</style></author><author><style face="normal" font="default" size="100%">Meyer, D.</style></author><author><style face="normal" font="default" size="100%">Rachlis, B.</style></author><author><style face="normal" font="default" size="100%">Lee, C. W.</style></author><author><style face="normal" font="default" size="100%">Kelly, S.</style></author><author><style face="normal" font="default" size="100%">Mills, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Ophthalmology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Ophthalmology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">447-456</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Glaucoma</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma, Open-Angle</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010002675</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010002675/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>128</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">128</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fahey, T.</style></author><author><style face="normal" font="default" size="100%">Schroeder, K.</style></author><author><style face="normal" font="default" size="100%">Ebrahim, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">875-882</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">520</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Delivery of Health Care [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Family Practice [education]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Program Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Psychiatric Status Rating Scales</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006003215</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006003215/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>129</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">129</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fan, J. Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of backrest position on intracranial pressure and cerebral perfusion pressure in individuals with brain injury: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Neuroscience Nursing</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Neuroscience Nursing</style></full-title></periodical><pages><style face="normal" font="default" size="100%">278-288</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bed Rest [methods] [nursing] [standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries [complications] [nursing] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Nursing Research</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Intensive Care [methods] [standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [etiology] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring, Physiologic [instrumentation] [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Posture</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design [standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sample Size</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004005366</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004005366/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>130</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">130</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fang, Z. L.</style></author><author><style face="normal" font="default" size="100%">Shen, G.</style></author><author><style face="normal" font="default" size="100%">Hu, S. L.</style></author><author><style face="normal" font="default" size="100%">Xu, T. J.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, L.</style></author><author><style face="normal" font="default" size="100%">Xu, W. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Rosiglitazone in treating type 2 diabetes mellitus with essential hypertension patients: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1012-1020</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoglycemic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Thiazolidinediones</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011006592</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011006592/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>131</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">131</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Feldon, S. E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Visual outcomes comparing surgical techniques for management of severe idiopathic intracranial hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Neurosurgical Focus</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurosurgical Focus</style></full-title></periodical><pages><style face="normal" font="default" size="100%">E6</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cerebrospinal Fluid Shunts [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [complications] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Ventriculoperitoneal Shunt</style></keyword><keyword><style face="normal" font="default" size="100%">Vision Disorders [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008103229</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008103229/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>132</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">132</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ferrario, C. M.</style></author><author><style face="normal" font="default" size="100%">Flack, J. M.</style></author><author><style face="normal" font="default" size="100%">Strobeck, J. E.</style></author><author><style face="normal" font="default" size="100%">Smits, G.</style></author><author><style face="normal" font="default" size="100%">Peters, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Therapeutic Advances in Cardiovascular Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Therapeutic Advances in Cardiovascular Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5-16</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiography, Impedance [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Decision Making</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">United States [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010002373</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010002373/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>594</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">594</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Finer, Neil</style></author><author><style face="normal" font="default" size="100%">Barrington Keith, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nitric oxide for respiratory failure in infants born at or near term</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Insufficiency [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD000399</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Nitric oxide is a major endogenous regulator of vascular tone. Inhaled nitric oxide gas has been investigated as a treatment for persistent pulmonary hypertension of the newborn.Objectives: To determine whether treatment of hypoxaemic term and near-term newborn infants with inhaled nitric oxide (iNO) improves oxygenation and reduces the rates of death, the requirement for extracorporeal membrane oxygenation (ECMO), or affects long term neurodevelopmental outcomes.Search methods: Electronic and hand searching of pediatric/neonatal literature and personal data files. In addition we contacted the principal investigators of articles which have been published as abstracts to ascertain the necessary information.Selection criteria: Randomized and quasi-randomized studies of inhaled nitric oxide in term and near term infants with hypoxic respiratory failure. Clinically relevant outcomes, including death, requirement for ECMO, and oxygenation.Data collection and analysis: Trial reports were analysed for methodologic quality using the criteria of the Cochrane Neonatal Review Group. Results of mortality, oxygenation, short term clinical outcomes (particularly need for ECMO), and long term developmental outcomes were tabulated.Statistics: For categorical outcomes, typical estimates for relative risk and risk difference were calculated. For continuous variables, typical estimates for weighted mean difference were calculated. 95% confidence intervals were used. A fixed effect model was assumed for meta-analysis.Main results: Fourteen eligible randomized controlled studies were found in term and near term infants with hypoxia. Seven of the trials compared iNO to control (placebo or standard care without iNO) in infants with moderate or severe severity of illness scores. Four of the trials compared iNO to control, but allowed back up treatment with iNO if the infants continued to satisfy the same criteria for severity of illness after a defined period of time. Two trials enrolled infants with moderate severity of illness score (OI or AaDO2) and randomized to immediate iNO treatment or iNO treatment only if they deteriorated to more severe criteria. One trial studied only infants with congenital diaphragmatic hernia (Ninos 1997), and one trial enrolled both preterm and term infants (Mercier 1998), but reported the majority of the results separately for the two groups.Inhaled nitric oxide appears to improve outcome in hypoxaemic term and near term infants by reducing the incidence of the combined endpoint of death or need for ECMO. The reduction seems to be entirely a reduction in need for ECMO; mortality is not reduced. Oxygenation improves in approximately 50% of infants receiving nitric oxide. The Oxygenation Index decreases by a (weighted) mean of 15.1 within 30 to 60 minutes after commencing therapy and PaO2 increases by a mean of 53 mmHg. Whether infants have clear echocardiographic evidence of persistent pulmonary hypertension of the newborn (PPHN) or not does not appear to affect outcome.The outcome of infants with diaphragmatic hernia was not improved; indeed there is a suggestion that outcome was slightly worsened.The incidence of disability, incidence of deafness and infant development scores are all similar between tested survivors who received nitric oxide or not.Authors&apos; conclusions: On the evidence presently available, it appears reasonable to use inhaled nitric oxide in an initial concentration of 20 ppm for term and near term infants with hypoxic respiratory failure who do not have a diaphragmatic hernia.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000399.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD000399.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>595</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">595</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Forsyth Rob, J.</style></author><author><style face="normal" font="default" size="100%">Wolny, Susanne</style></author><author><style face="normal" font="default" size="100%">Rodrigues, Beryl</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Routine intracranial pressure monitoring in acute coma</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Coma [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring, Physiologic [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Inj</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD002043</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Studies in traumatic encephalopathy first led to the insight that the damage seen was not just due to direct consequences of the primary injury. A significant, and potentially preventable, contribution to the overall morbidity arose from secondary hypoxic-ischaemic damage. Brain swelling accompanied by raised intracranial pressure (ICP) resulted in inadequate cerebral perfusion with well-oxygenated blood. Detection of raised ICP could be useful in alerting clinicians to the need to improve cerebral perfusion, with consequent reductions in brain injury.Objectives: To determine whether routine ICP monitoring in all acute cases of severe coma reduces the risk of all-cause mortality or severe disability at final follow-up.Search methods: We searched the Cochrane Injuries Group&apos;s Specialised Register (searched 7 April 2009), CENTRAL (The Cochrane Library 2009, Issue 1), MEDLINE 1950 to March week 4 2009, EMBASE 1980 to week 14 March 2009, CINAHL 1982 to March 2009, ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) 1970 to March 2009, Conference Proceedings Citation Index- Science (CPCI-S) 1990 to March 2009, PubMed (searched 7 April 2009, limit; added in last 6 months). The searches were last updated in April 2009.Selection criteria: All randomised controlled studies of real-time ICP monitoring by invasive or semi-invasive means in acute coma (traumatic or non-traumatic aetiology) versus no ICP monitoring (that is, clinical assessment of ICP).Data collection and analysis: Primary outcome measures were all-cause mortality and severe disability at the end of the follow-up period.Main results: No studies meeting the selection criteria have been identified to date.Authors&apos; conclusions: There are no data from randomised controlled trials that can clarify the role of ICP monitoring in acute coma.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002043.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD002043.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>596</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">596</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foster, Gill</style></author><author><style face="normal" font="default" size="100%">Taylor Stephanie, J. C.</style></author><author><style face="normal" font="default" size="100%">Eldridge, Sandra</style></author><author><style face="normal" font="default" size="100%">Ramsay, Jean</style></author><author><style face="normal" font="default" size="100%">Griffiths Chris, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Self-management education programmes by lay leaders for people with chronic conditions</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Program Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Participation</style></keyword><keyword><style face="normal" font="default" size="100%">Peer Group</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Self-Help Groups</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Commun</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005108</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Lay-led self-management programmes are becoming widespread in the attempt to promote self-care for people with chronic conditions.Objectives: To assess systematically the effectiveness of lay-led self-management programmes for people with chronic conditions.Search methods: We searched: the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 2005, Issue 1), MEDLINE (January 1986 to May 2006), EMBASE (January 1986 to June 2006), AMED (January 1986 to June 2006), CINAHL (January 1986 to June 2006), DARE (1994 to July 2006, National Research Register (2000 to July 2006), NHS Economic Evaluations Database (1994 to July 2006), PsycINFO (January 1986 to June 2006), Science Citation Index (January 1986 to July 2006), reference lists and forward citation tracking of included studies. We contacted principal investigators and experts in the field. There were no language restrictions.Selection criteria: Randomised controlled trials (RCTs) comparing structured lay-led self-management education programmes for chronic conditions against no intervention or clinician-led programmes.Data collection and analysis: Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information. Results of RCTs were pooled using a random-effects model with standardised mean differences (SMDs) or weighted mean differences (WMDs) for continuous outcomes.Main results: We included seventeen trials involving 7442 participants. The interventions shared similar structures and components but studies showed heterogeneity in conditions studied, outcomes collected and effects. There were no studies of children and adolescents, only one study provided data on outcomes beyond six months, and only two studies reported clinical outcomes.Primary outcomesHealth status: There was a small, statistically-significant reduction in: pain (11 studies, SMD -0.10 (95% confidence interval (CI) -0.17 to -0.04)); disability (8 studies, SMD -0.15 (95% CI -0.25 to -0.05); and fatigue (7 studies, SMD -0.16 (95% CI -0.23 to -0.09); and small, statistically-significant improvement in depression (6 studies, SMD -0.16 95% CI -0.24 to -0.07). There was a small (but not statistically- or clinically-significant) improvement in psychological well-being (5 studies; SMD -0.12 (95% CI -0.33 to 0.09)); but no difference between groups for health-related quality of life (3 studies; WMD -0.03 (95% CI -0.09 to 0.02). Six studies showed a statistically-significant improvement in self-rated general health (WMD -0.20 (95% CI -0.31 to -0.10).Health behaviours: 7 studies showed a small, statistically-significant increase in self-reported aerobic exercise (SMD -0.20 (95% CI -0.27 to -0.12)) and a moderate increase in cognitive symptom management (4 studies, WMD -0.55 ( 95% CI -0.85 to -0.26)).Healthcare use: There were no statistically-significant differences between groups in physician or general practitioner attendance (9 studies; SMD -0.03 (95% CI -0.09 to 0.04)). There were also no statistically-significant differences between groups for days/nights spent in hospital (6 studies; WMD -0.32 (95% CI -0.71 to 0.07)).Self-efficacy: (confidence to manage condition) showed a small statistically-significant improvement (10 studies): SMD -0.30, 95% CI -0.41 to -0.19.No adverse events were reported in any of the studies.Authors&apos; conclusions: Lay-led self-management education programmes may lead to small, short-term improvements in participants&apos; self-efficacy, self-rated health, cognitive symptom management, and frequency of aerobic exercise. There is currently no evidence to suggest that such programmes improve psychological health, symptoms or health-related quality of life, or that they significantly alter healthcare use. Future research on such interventions should explore longer term outcomes, their effect on clinical measures of disease and their potential role in children and adolescents.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005108.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005108.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>133</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">133</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fox, B. D.</style></author><author><style face="normal" font="default" size="100%">Shimony, A.</style></author><author><style face="normal" font="default" size="100%">Langleben, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1177-1182</style></pages><volume><style face="normal" font="default" size="100%">108</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Transplantation [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011006739</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011006739/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>597</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">597</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Frank, W.</style></author><author><style face="normal" font="default" size="100%">Konta, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hypertension guidelines and their effects on the health system (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Delivery of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32005001399</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32005001399/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>134</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">134</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fretheim, A.</style></author><author><style face="normal" font="default" size="100%">Odgaard-Jensen, J.</style></author><author><style face="normal" font="default" size="100%">Brors, O.</style></author><author><style face="normal" font="default" size="100%">Madsen, S.</style></author><author><style face="normal" font="default" size="100%">Njolstad, I.</style></author><author><style face="normal" font="default" size="100%">Norheim, O. F.</style></author><author><style face="normal" font="default" size="100%">Svilaas, A.</style></author><author><style face="normal" font="default" size="100%">Kristiansen, I. S.</style></author><author><style face="normal" font="default" size="100%">Thurmer, H.</style></author><author><style face="normal" font="default" size="100%">Flottorp, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">Article Number 33</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [epidemiology] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Prevention [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [epidemiology] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012027711</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012027711/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>135</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">135</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fridley, J.</style></author><author><style face="normal" font="default" size="100%">Foroozan, R.</style></author><author><style face="normal" font="default" size="100%">Sherman, V.</style></author><author><style face="normal" font="default" size="100%">Brandt, M. L.</style></author><author><style face="normal" font="default" size="100%">Yoshor, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Bariatric surgery for the treatment of idiopathic intracranial hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Neurosurgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Neurosurgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">34-39</style></pages><volume><style face="normal" font="default" size="100%">114</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bariatric Surgery [adverse effects] [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [etiology] [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity [complications] [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Visual Fields [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011001242</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001242/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>136</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">136</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Funakoshi, T.</style></author><author><style face="normal" font="default" size="100%">Latif, A.</style></author><author><style face="normal" font="default" size="100%">Galsky, M. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">601-611</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antineoplastic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013024411</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013024411/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>137</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">137</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fung, A. T.</style></author><author><style face="normal" font="default" size="100%">Reid, S. E.</style></author><author><style face="normal" font="default" size="100%">Jones, M. P.</style></author><author><style face="normal" font="default" size="100%">Healey, P. R.</style></author><author><style face="normal" font="default" size="100%">McCluskey, P. J.</style></author><author><style face="normal" font="default" size="100%">Craig, J. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Ophthalmology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Ophthalmology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">62-68</style></pages><volume><style face="normal" font="default" size="100%">91</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Topical</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma, Open-Angle [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins F, Synthetic [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins F, Synthetic [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins F, Synthetic [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Quinoxalines [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Quinoxalines [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Quinoxalines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007000583</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007000583/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>598</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">598</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gaitskell, Kezia</style></author><author><style face="normal" font="default" size="100%">Martinek, Igor</style></author><author><style face="normal" font="default" size="100%">Bryant, Andrew</style></author><author><style face="normal" font="default" size="100%">Kehoe, Sean</style></author><author><style face="normal" font="default" size="100%">Nicum, Shibani</style></author><author><style face="normal" font="default" size="100%">Morrison, Jo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiogenesis inhibitors for the treatment of ovarian cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Antineoplastic Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Indoles [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Pathologic [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Ovarian Neoplasms [blood supply] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Paclitaxel [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Fusion Proteins [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Gynaeca</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007930</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Many women with ovarian cancer eventually develop resistance to conventional chemotherapy drugs, and so novel agents are being developed to target specific molecular pathways. One such class of drugs inhibits angiogenesis (the development of new blood vessels), which is essential for tumour growth. It is important to establish whether the addition of these new drugs to conventional chemotherapy regimens improves survival, and what the side-effects may be.Objectives: To compare the effectiveness and toxicities of angiogenesis inhibitors in the treatment of ovarian cancer.Search methods: We sought to identify completed randomised controlled trials (RCTs) by searching The Cochrane Gynaecological Cancer Review Group&apos;s Trial Register, The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 10), MEDLINE and EMBASE (1990 to October 2010). We also searched registers of clinical trials, and contacted investigators of completed and ongoing trials for further information.Selection criteria: Randomised controlled studies comparing angiogenesis inhibitors with either standard chemotherapy or no treatment, in women with ovarian cancer.Data collection and analysis: Two independent authors carried out data collection and extraction. We used a random-effects model for pooling data.Main results: We did not find any fully-published, completed RCTs of angiogenesis inhibitors that met our inclusion criteria. We identified five abstracts of completed RCTs of four different angiogenesis-inhibiting agents, with a total of 3701 participants.Meta-analysis of two trials found no statistically significant difference in overall survival (OS) between women with newly-diagnosed advanced ovarian cancer who received concurrent and maintenance bevacizumab compared to those who received chemotherapy (carboplatin and paclitaxel) alone. However, women who received concurrent and maintenance bevacizumab had their risk of disease progression reduced by a quarter (hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.68 to 0.83; P &lt; 0.001); they also had a significantly increased risk of severe gastrointestinal adverse events, moderate or severe hypertension and severe bleeding.One trial also compared chemotherapy to concurrent (but not maintenance bevacizumab), and found no statistically significant difference in OS or progression-free survival (PFS).  However, the women who received bevacizumab had a significantly higher risk of moderate or severe hypertension.A three-armed RCT, of paclitaxel alone or with low- or high-dose AMG 386, in women with recurrent ovarian cancer, found no statistically significant difference in OS. However, women who received low-dose AMG 386 had a third less risk of disease progression than those who received placebo (HR 0.57, 95% CI 0.36 to 0.91; P = 0.02). The trial found no evidence of increased adverse events in the intervention arms.Two relatively small RCTs (one of VEGF-Trap, the other of BIBF 1120) found no evidence of either significant survival benefit or increased severe adverse events, compared to placebo, but they both lacked statistical power. All five trials had unclear risk of bias, largely because they have only been published in abstract form, and thus many methodological details are unclear. We identified twelve suitable ongoing trials.Authors&apos; conclusions: There is, as yet, no fully-published RCT evidence for the efficacy or safety of angiogenesis inhibitors for the treatment of ovarian cancer, but some preliminary results are available from five trials. There is some evidence from a meta-analysis of two trials that the addition of concurrent and maintenance bevacizumab to standard chemotherapy may reduce the risk of disease progression, in women with newly-diagnosed advanced ovarian cancer. There is also some evidence from a single trial that low-dose AMG 386 may reduce the risk of disease progression in women with recurrent ovarian cancer. However, there is currently no evidence that angiogenesis inhibitors improve OS, nor is there enough evidence to jus ify the routine use of angiogenesis inhibitors in treating women with ovarian cancer. We eagerly await both the more detailed results of these five completed trials, and the preliminary results of the several ongoing trials.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007930.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007930.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>138</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">138</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gallagher, H.</style></author><author><style face="normal" font="default" size="100%">Lusignan, S.</style></author><author><style face="normal" font="default" size="100%">Harris, K.</style></author><author><style face="normal" font="default" size="100%">Cates, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Quality-improvement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e258-e265</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">575</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiologic Methods</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome and Process Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Insufficiency, Chronic [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011000389</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011000389/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>139</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">139</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gao, D.</style></author><author><style face="normal" font="default" size="100%">Ning, N.</style></author><author><style face="normal" font="default" size="100%">Niu, X.</style></author><author><style face="normal" font="default" size="100%">Wei, J.</style></author><author><style face="normal" font="default" size="100%">Sun, P.</style></author><author><style face="normal" font="default" size="100%">Hao, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Aliskiren vs angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">613-621</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011002894</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011002894/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>599</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">599</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garg Sushil, K.</style></author><author><style face="normal" font="default" size="100%">Ahuja, Vineet</style></author><author><style face="normal" font="default" size="100%">Sankar Mari, Jeeva</style></author><author><style face="normal" font="default" size="100%">Kumar, Atul</style></author><author><style face="normal" font="default" size="100%">Moss Alan, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Curcumin for maintenance of remission in ulcerative colitis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Colitis, Ulcerative [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Curcumin [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Maintenance Chemotherapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Mesalamine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfasalazine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Ibd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008424</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Ulcerative colitis (UC) is a chronic inflammatory condition of the colon characterized by episodes of disease activity and symptom-free remission.There is paucity of evidence regarding the efficacy and safety of complementary or alternative medicines for the management of UC. Curcumin, an anti-inflammatory agent, has been used in many chronic inflammatory conditions such as rheumatoid arthritis, esophagitis and post-surgical inflammation. The efficacy of this agent for maintenance of remission in patients with UC has not been systematically evaluated.Objectives: The primary objective was to systematically review the efficacy and safety of curcumin for maintenance of remission in UC.Search methods: A computer-assisted literature search of MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Inflammatory Bowel Disease Specialized Trial Register was performed on July 11, 2012 to identify relevant publications. Proceedings from major gastroenterology meetings and references from published articles were also searched to identify additional studies.Selection criteria: Randomized placebo-controlled trials (RCT) of curcumin for maintenance of remission in UC were included. Studies included patients (of any age) who were in remission at the time of recruitment. Co-interventions were allowed.Data collection and analysis: Two authors independently extracted data and assessed the methodological quality of the included studies using the Cochrane risk of bias tool. Data were analyzed using Review Manager (RevMan 5.1). We calculated the relative risk (RR) and 95% confidence interval (95% CI) for each dichotomous outcome. For continuous outcomes we calculated the mean difference (MD) and 95% CI.Main results: Only one trial (89 patients) fulfilled the inclusion criteria. This trial randomized 45 patients to curcumin and 44 patients to placebo. All patients received treatment with sulfasalazine or mesalamine. The study was rated as low risk of bias. Curcumin was administered orally in a dose of 2 g/day for six months. Fewer patients relapsed in the curcumin group than the placebo group at six months. Four per cent of patients in the curcumin group relapsed at six months compared to 18% of patients in the placebo group (RR 0.24, 95% CI 0.05 to 1.09; P = 0.06). There was no statistically significant difference in relapse rates at 12 months. Twenty-two per cent of curcumin patients relapsed at 12 months compared to 32% of placebo patients (RR 0.70, 95% CI 0.35 to 1.40; P = 0.31). A total of nine adverse events were reported in seven patients. These adverse events included sensation of abdominal bulging, nausea, transient hypertension, and transient increase in the number of stools. The authors did not report which treatment group the patients who experienced adverse events belonged to. The clinical activity index (CAI) at six months was significantly lower in the curcumin group compared to the placebo group (1.0 + 2.0 versus 2.2 + 2.3; MD -1.20, 95% CI -2.14 to -0.26). The endoscopic index (EI) at six months was significantly lower in the curcumin group than in the placebo group (0.8 + 0.6 versus 1.6 + 1.6; MD -0.80, 95% CI -1.33 to -0.27).Authors&apos; conclusions: Curcumin may be a safe and effective therapy for maintenance of remission in quiescent UC when given as adjunctive therapy along with mesalamine or sulfasalazine. However, further research in the form of a large scale methodologically rigorous randomized controlled trial is needed to confirm any possible benefit of curcumin in quiescent UC.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008424.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008424.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>140</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">140</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gargiulo, P.</style></author><author><style face="normal" font="default" size="100%">Petretta, M.</style></author><author><style face="normal" font="default" size="100%">Bruzzese, D.</style></author><author><style face="normal" font="default" size="100%">Cuocolo, A.</style></author><author><style face="normal" font="default" size="100%">Prastaro, M.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amore, C.</style></author><author><style face="normal" font="default" size="100%">Vassallo, E.</style></author><author><style face="normal" font="default" size="100%">Savarese, G.</style></author><author><style face="normal" font="default" size="100%">Marciano, C.</style></author><author><style face="normal" font="default" size="100%">Paolillo, S.</style></author><author><style face="normal" font="default" size="100%">Filardi, P. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Myocardial perfusion scintigraphy and echocardiography for detecting coronary artery disease in hypertensive patients: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Nuclear Medicine and Molecular Imaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Nuclear Medicine and Molecular Imaging</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2040-2049</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Coronary Artery Disease [complications] [physiopathology] [radionuclide imaging] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Echocardiography [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Perfusion Imaging [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Physiological</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011007190</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011007190/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>600</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">600</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garjón, Javier</style></author><author><style face="normal" font="default" size="100%">Azparren, Ana</style></author><author><style face="normal" font="default" size="100%">Elizondo José, J.</style></author><author><style face="normal" font="default" size="100%">Gaminde, Idoia</style></author><author><style face="normal" font="default" size="100%">Ariz Mª, José</style></author><author><style face="normal" font="default" size="100%">Erviti, Juan</style></author><author><style face="normal" font="default" size="100%">Saiz Luis, Carlos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Monotherapy versus combination therapy used as first-line therapy for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010316</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To determine if there are differences in clinical outcomes between monotherapy and combination therapy when used as initial treatment for primary hypertension.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010316/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010316</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>601</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">601</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garner Sarah, E.</style></author><author><style face="normal" font="default" size="100%">Fidan, Dogan</style></author><author><style face="normal" font="default" size="100%">Frankish Ruth, R.</style></author><author><style face="normal" font="default" size="100%">Maxwell, Lara</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Rofecoxib for osteoarthritis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclooxygenase Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Lactones [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Approval</style></keyword><keyword><style face="normal" font="default" size="100%">Osteoarthritis [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Muskel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005115</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Editor&apos;s note: The anti-inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long-term use (greater than 18 months) could increase the risk of heart attack and stroke. Further information is available at www.vioxx.com.Osteoarthritis is a chronic disease of the joints, characterised by joint pain, stiffness and loss of physical function. Its onset is age-related and occurs usually between the ages of 50 and 60. It is the commonest cause of disability in those aged over 65, with OA of the knee and/or hip affecting over 20 per cent of the elderly population.Objectives: To establish the efficacy and safety of rofecoxib in the management of OA by systematic review of available evidence.Search methods: We searched the following databases up to August 2004: MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register, National Research Register, NHS Economic Evaluation Database, Health Technology Assessment Database. The bibliographies of retrieved papers and content experts were consulted for additional references.Selection criteria: All eligible randomised controlled trials (RCTs) were included. No unpublished RCTs were included in this edition of the review.Data collection and analysis: Data were abstracted independently by two reviewers. A validated checklist was used to score the quality of the RCTs. Comparable trials were pooled using fixed effects model.Main results: Twenty-six RCTs were included. The comparators were placebo, diclofenac, ibuprofen, naproxen, nimesulide, nabumetone, paracetamol, celecoxib and Arthrotec. The evidence reviewed indicated that rofecoxib was more effective than placebo (patient global response RR 1.75 95% CI: 1.35, 2.26) but was associated with more adverse events (RR 1.32 95% CI 1.11, 1.56). There were no consistent differences in efficacy between rofecoxib and any of the active comparators at equivalent doses. Endoscopic studies indicated that compared to ibuprofen 800mg three times a day, rofecoxib caused fewer erosions and gastric ulcers at doses of 25mg and 50mg; the difference in duodenal ulcers was evident only at a dose of 25mg. Rofecoxib 50mg also caused more endoscopically observed ulcers greater than rofecoxib 25mg (RR 2.48 CI: 1.21, 5.11). Very few of the trials reported overall rates of GI adverse events although rofecoxib was found to cause fewer GI events than naproxen. Only one of the nine trials comparing rofecoxib to celecoxib reported on the overall rates of GI events and this was a comparison of the higher recommended dose of rofecoxib with the lower recommended dose of celecoxib. Similarly, the three trials in older hypertensive patients that examined the cardiovascular safety of rofecoxib and celecoxib used non-comparable doses; the results of these studies indicated that rofecoxib caused more patients to have oedema and a clinically significant increase in systolic blood pressure. This difference between rofecoxib and celecoxib was not evident in studies conducted in more general populations.Authors&apos; conclusions: Rofecoxib was voluntarily withdrawn from global markets in October 2004 therefore there are no implications for practice concerning its use. There remains a number of questions over both the benefits and risks associated with Cox II selective agents and further work is ongoing.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005115/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005115</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>602</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">602</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Geeganage, Chamila</style></author><author><style face="normal" font="default" size="100%">Bath Philip, M. W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Vasoactive drugs for acute stroke</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin [adverse effects] [analogs &amp; derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobins [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypotension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Injections, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasoconstrictor Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD002839</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: It is unclear whether blood pressure (BP) should be altered actively during the acute phase of stroke.Objectives: To assess the effect of lowering or elevating BP in people with acute stroke, and the effect of different vasoactive drugs on BP in acute stroke.Search methods: We searched the Cochrane Stroke Group Trials Register (last searched June 2009), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2009), MEDLINE (1966 to October 2009), EMBASE (1980 to October 2009), and Science Citation Index (1981 to October 2009).Selection criteria: Randomised trials of interventions that would be expected, on pharmacological grounds, to alter BP in patients within one week of the onset of acute stroke.Data collection and analysis: Two review authors independently applied the trial inclusion criteria, assessed trial quality, and extracted data.Main results: We identified 131 trials involving in excess of 18,000 patients; a further 13 trials are ongoing. We obtained data for 43 trials (7649 patients). Among BP-lowering trials, beta receptor antagonists lowered BP (early systolic BP (SBP) mean difference (MD) -6.1 mmHg, 95% CI -11.4 to -0.9; late SBP MD -4.9 mmHg, 95% CI -10.2 to 0.4; late diastolic BP (DBP) MD -4.5 mmHg, 95% CI -7.8 to -1.2). Oral calcium channel blockers (CCB) lowered BP (late SBP MD -3.2 mmHg, 95% CI -5.4 to -1.1; early DBP MD -2.5, 95% CI -5.6 to 0.7; late DBP MD -2.1, 95% CI -3.5 to -0.7). Nitric oxide donors lowered BP (early SBP MD -10.3 mmHg, 95% CI -17.6 to -3.0). Prostacyclin lowered BP (late SBP MD, -7.7 mmHg, 95% CI -15.6 to 0.2; late DBP MD -3.9 mmHg, 95% CI -8.1 to 0.4). Among BP-increasing trials, diaspirin cross-linked haemoglobin (DCLHb) increased BP (early SBP MD 15.3 mmHg, 95% CI 4.0 to 26.6; late SBP MD 15.9 mmHg, 95% CI 1.8 to 30.0). None of the drug classes significantly altered outcome apart from DCLHb which increased combined death or dependency (odds ratio (OR) 5.41, 95% CI 1.87 to 15.64).Authors&apos; conclusions: There is not enough evidence to evaluate reliably the effect of altering BP on outcome after acute stroke. However, treatment with DCLHb was associated with poor clinical outcomes. Beta receptor antagonists, CCBs, nitric oxide, and prostacyclin each lowered BP during the acute phase of stroke. In contrast, DCLHb increased BP.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002839.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD002839.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>141</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">141</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Geeganage, C. M.</style></author><author><style face="normal" font="default" size="100%">Bath, P. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Relationship between therapeutic changes in blood pressure and outcomes in acute stroke: a metaregression (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">775-781</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [contraindications]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [diagnosis] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009109435</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009109435/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>142</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">142</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Geleijnse, J. M.</style></author><author><style face="normal" font="default" size="100%">Kok, F. J.</style></author><author><style face="normal" font="default" size="100%">Grobbee, D. E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">471-480</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium, Dietary [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium, Dietary [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003001396</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003001396/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>143</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">143</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Geng, D. F.</style></author><author><style face="normal" font="default" size="100%">Jin, D. M.</style></author><author><style face="normal" font="default" size="100%">Wu, W.</style></author><author><style face="normal" font="default" size="100%">Xu, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, J. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: a meta-analysis of 59,862 patients (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">236-242</style></pages><volume><style face="normal" font="default" size="100%">155</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose Intolerance [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012011955</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012011955/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>144</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">144</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Geng, X.</style></author><author><style face="normal" font="default" size="100%">Cui, W.</style></author><author><style face="normal" font="default" size="100%">Yang, X. H.</style></author><author><style face="normal" font="default" size="100%">Xie, R. Q.</style></author><author><style face="normal" font="default" size="100%">Zhang, J. D.</style></author><author><style face="normal" font="default" size="100%">Zheng, H. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The efficacy of antihypertensive treatment on diabetes mellitus or impaired glucose tolerance patients with blood pressure below 140/90 mm Hg: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">875-879</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose Intolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose Metabolism Disorders [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013065640</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013065640/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>603</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">603</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gewaily, Dina</style></author><author><style face="normal" font="default" size="100%">Greenberg Paul, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Macular Edema [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Retinal Vein Occlusion [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Steroids [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Eyes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007324</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Central retinal vein occlusion (CRVO) is a common retinal vascular abnormality associated with conditions such as hypertension, diabetes, glaucoma, and a wide variety of hematologic disorders. Macular edema (ME) represents an important vision-threatening complication of CRVO. There is no proven treatment; laser photocoagulation is not effective in treating cystoid macular edema secondary to CRVO. Intravitreal steroids, such as triamcinolone acetonide, have been utilized to treat macular edema stemming from a variety of etiologies and may represent a treatment option for CRVO-ME.Objectives: The objective of this review was to explore the effectiveness and safety of intravitreal steroids in the treatment of CRVO-ME.Search methods: We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2008), MEDLINE (January 1950 to November 2008) and EMBASE (January 1980 to November 2008). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 5 November 2008. For all included primary studies, we used The Science Citation Index and manually reviewed reference lists to identify other possible relevant trials. We contacted researchers in the field, currently working on a randomized controlled trial (RCT) on this topic (The Standard Care versus Corticosteroid for Retinal Vein Occlusion - SCORE study), for information on additional current, past, or unpublished trials.Selection criteria: We considered RCTs that compared intravitreal steroids of any dosage/duration to observation in the treatment of CRVO-ME for inclusion in this review. We focused on studies that included individuals of any age or gender with unilateral or bilateral disease, with a minimum of six months follow up. Secondarily we considered non-randomized studies with the same criteria for description of evidence, however we did not conduct a separate electronic search for finding all non-randomized studies.Data collection and analysis: We found no RCTs that met the inclusion criteria after independent and duplicate review of the search results.Main results: We found no relevant RCTs and therefore performed no meta-analysis. Evidence from non-randomized studies is reported in this review.Authors&apos; conclusions: There is inadequate evidence for the use of intravitreal steroids for CRVO-ME due to a paucity of RCTs and well-designed observational studies on the topic; therefore, it is still an experimental procedure.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007324.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007324.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>604</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">604</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ghamami, Niousha</style></author><author><style face="normal" font="default" size="100%">Chiang Sandy Hsiang, Yu</style></author><author><style face="normal" font="default" size="100%">Dormuth, Colin</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Time course for blood pressure lowering of dihydropyridine calcium channel blockers</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Circadian Rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">Dihydropyridines [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010052</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Calcium channel blockers are a heterogeneous class of drugs, including dihydropyridine and non-dihydropyridine subgroups, commonly used in the treatment of hypertension. A systematic review of the 24-hour time course of the blood pressure-lowering effect has not been published.Objectives: To assess how much variation there is in hourly systolic and diastolic blood pressure lowering by dihydropyridine calcium channel blockers over a 24-hour period in people with hypertension aged 18 years or over, with baseline systolic blood pressure of at least 140 mmHg or diastolic blood pressure of at least 90 mmHg, or both.Search methods: We performed electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2014), MEDLINE (1946 to February 2014), EMBASE (1974 to February 2014), and ClinicalTrials.gov (to February 2014). We also screened references of published studies and reviews to identify additional trials.Selection criteria: We included all randomized, placebo-controlled trials assessing the hourly effects of dihydropyridine calcium channel blockers by ambulatory blood pressure monitoring in adults with hypertension with a follow-up of at least three weeks.Data collection and analysis: Two authors independently selected the included trials, evaluated the risk of bias, and analyzed the data.Main results: We included 16 randomized controlled trials of dihydropyridine calcium channel blockers in this systematic review, with 2768 randomized participants. Drugs studied included amlodipine, lercanidipine, mandipine, nifedipine, and felodipine (all administered once daily) and nicardipine (administered twice daily). We analyzed and presented data by hour post dose. The blood pressure-lowering effect was stable over time; there were no clinically important differences in blood pressure-lowering effect of calcium channel blockers between each hour for either systolic blood pressure (estimated mean hourly differences ranged between 9.45 mmHg and 13.2 mmHg) or diastolic blood pressure (estimated mean hourly differences ranged between 5.85 mmHg and 8.5 mmHg). However, there was a moderate risk of bias for this finding. Once-daily dihydropyridine calcium channel blockers appeared to lower blood pressure by a relatively constant amount throughout the 24-hour dosing interval.Authors&apos; conclusions: Six dihydropyridine calcium channel blockers studied in this review lowered blood pressure by a relatively similar amount each hour over the course of 24 hours. The benefits and harms of this pattern of blood pressure lowering are unknown. Further trials are needed with accurate recording of time of drug intake and with reporting of standard deviation of blood pressure at each hour. We did not attempt to assess adverse effects in this review due to the lack of reporting and the short duration of follow-up.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010052.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010052.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>145</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">145</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giannakoulas, G.</style></author><author><style face="normal" font="default" size="100%">Mouratoglou, S. A.</style></author><author><style face="normal" font="default" size="100%">Gatzoulis, M. A.</style></author><author><style face="normal" font="default" size="100%">Karvounis, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. A systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">618-623</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Arginine</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Markers</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Defects, Congenital</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Natriuretic Peptides</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014032995</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014032995/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>146</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">146</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Glynn, L. G.</style></author><author><style face="normal" font="default" size="100%">Murphy, A. W.</style></author><author><style face="normal" font="default" size="100%">Smith, S. M.</style></author><author><style face="normal" font="default" size="100%">Schroeder, K.</style></author><author><style face="normal" font="default" size="100%">Fahey, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Self-monitoring and other non-pharmacological interventions to improve the management of hypertension in primary care: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e476-e488</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">581</style></number><keywords><keyword><style face="normal" font="default" size="100%">administration</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Community Pharmacy Services [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Delivery of Health Care [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Education, Medical, Continuing</style></keyword><keyword><style face="normal" font="default" size="100%">General Practice [education] [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [nursing] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011001948</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001948/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>605</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">605</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Glynn Liam, G.</style></author><author><style face="normal" font="default" size="100%">Murphy Andrew, W.</style></author><author><style face="normal" font="default" size="100%">Smith Susan, M.</style></author><author><style face="normal" font="default" size="100%">Schroeder, Knut</style></author><author><style face="normal" font="default" size="100%">Fahey, Tom</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interventions used to improve control of blood pressure in patients with hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Education, Medical, Continuing</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005182</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Patients with high blood pressure (hypertension) in the community frequently fail to meet treatment goals - a condition labelled as &quot;uncontrolled&quot; hypertension. The optimal way to organize and deliver care to hypertensive patients has not been clearly identified.Objectives: To determine the effectiveness of interventions to improve control of blood pressure in patients with hypertension. To evaluate the effectiveness of reminders on improving the follow-up of patients with hypertension.Search methods: All-language search of all articles (any year) in the Cochrane Controlled Trials Register (CCTR) and Medline; and Embase from January 1980.Selection criteria: Randomized controlled trials (RCTs) of patients with hypertension that evaluated the following interventions: (1) self-monitoring (2) educational interventions directed to the patient (3) educational interventions directed to the health professional (4) health professional (nurse or pharmacist) led care (5) organisational interventions that aimed to improve the delivery of care (6) appointment reminder systemsOutcomes assessed were: (1) mean systolic and diastolic blood pressure (2) control of blood pressure (3) proportion of patients followed up at clinicData collection and analysis: Two authors extracted data independently and in duplicate and assessed each study according to the criteria outlined by the Cochrane Handbook.Main results: 72 RCTs met our inclusion criteria. The methodological quality of included studies varied. An organized system of regular review allied to vigorous antihypertensive drug therapy was shown to reduce systolic blood pressure (weighted mean difference (WMD) -8.0 mmHg, 95% CI: -8.8 to -7.2 mmHg) and diastolic blood pressure (WMD -4.3 mmHg, 95% CI: -4.7 to -3.9 mmHg) for three strata of entry blood pressure, and all-cause mortality at five years follow-up (6.4% versus 7.8%, difference 1.4%) in a single large RCT- the Hypertension Detection and Follow-Up study. Other interventions had variable effects. Self-monitoring was associated with moderate net reduction in systolic blood pressure (WMD -2.5 mmHg, 95% CI: -3.7 to -1.3 mmHg) and diastolic blood pressure (WMD -1.8 mmHg, 95% CI: -2.4 to -1.2 mmHg). RCTs of educational interventions directed at patients or health professionals were heterogeneous but appeared unlikely to be associated with large net reductions in blood pressure by themselves. Nurse or pharmacist led care may be a promising way forward, with the majority of RCTs being associated with improved blood pressure control and mean SBP and DBP but these interventions require further evaluation. Appointment reminder systems also require further evaluation due to heterogeneity and small trial numbers, but the majority of trials increased the proportion of individuals who attended for follow-up (odds ratio 0.41, 95% CI 0.32 to 0.51) and in two small trials also led to improved blood pressure control, odds ratio favouring intervention 0.54 (95% CI 0.41 to 0.73).Authors&apos; conclusions: Family practices and community-based clinics need to have an organized system of regular follow-up and review of their hypertensive patients. Antihypertensive drug therapy should be implemented by means of a vigorous stepped care approach when patients do not reach target blood pressure levels. Self-monitoring and appointment reminders may be useful adjuncts to the above strategies to improve blood pressure control but require further evaluation.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005182.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005182.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>606</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">606</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gois Pedro Henrique, França</style></author><author><style face="normal" font="default" size="100%">Souza Edison Regio de, Moraes</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacotherapy for hyperuricemia in hypertensive patients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Allopurinol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperuricemia [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Uricosuric Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008652</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: High blood pressure represents a major public health problem. Worldwide, approximately one fourth of the adult population has hypertension. Epidemiological and experimental studies suggest a linkage between hyperuricemia and hypertension. Hyperuricemia affects 25-40 % of patients with untreated hypertension. A much lower prevalence has been reported in normotensives or in the general population. However, whether lowering serum uric acid (SUA) might lower blood pressure (BP) is an unanswered question.Objectives: To determine whether uric acid lowering agents reduce BP in patients with primary hypertension.Search methods: Electronic searches of the following sources were performed without language restriction: Cochrane Hypertension Group Specialised Register (1946 to May 2012), Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, 2012 Issue 4), MEDLINE (1946 to May 2012), EMBASE (1974 to May 2012), LILACS (1982 to July 2012), Scirus and ClinicalTrials.gov. Authors of relevant papers were also contacted regarding further published and unpublished work.Selection criteria: To be included in this review, the studies had to meet the following criteria: 1) Randomised or quasi-randomised with a group assigned to receive a uric acid lowering agent and another group assigned to receive placebo; 2) Double-blind, single-blind or open label; 3) Parallel or crossover trial; 4) For crossover trial, a washout period of at least two weeks; 5) Minimum treatment duration of four weeks; 6) Participants with diagnosis of essential hypertension and hyperuricemia, serum uric acid greater than 6 in women, 7 in men and 5.5 in children/adolescents; 7) Outcome measures includes change in casual or ambulatory, systolic or diastolic blood pressure.Data collection and analysis: Two independent reviewers collected the data using a data extraction form. Disagreements were resolved by discussion. Risk of bias was accessed by the Cochrane Collaboration Risk of Bias Tool.Main results: Three hundred and thirty-six abstracts were examined. One study (enrolling hypertensive and hyperuricemic patients) met the inclusion criteria for the review and was independently rated by both authors. No other studies were identified by the supplementary searches. The study identified as eligible for this review was a randomised controlled trial conducted in the USA (FEIG 2008 ) . This well designed double-blind, placebo-controlled, crossover trial randomised 30 adolescents (11-17 years), newly diagnosed stage 1 primary hypertension and with SUA &gt; 6mg/dl, to receive allopurinol 200 mg twice daily for 4 weeks, and placebo for 4 weeks, with a 2 week washout period between treatments. Casual BP during the allopurinol phase decreased - 6.9 mmHg (95 % CI, - 4.5 to - 9.3), systolic, and - 5.1 mmHg (95 % CI, - 2.5 to - 7.8), diastolic, versus during the placebo phase, - 2.0 mmHg (95 % CI, 0.3 to - 4.3) systolic and - 2.4 mmHg (95 % CI, 0.2 to - 4.1) diastolic. For the secondary outcome (change in 24 ambulatory BP), change in systolic BP with allopurinol was - 6.3 mmHg (95 % CI, - 3.8 to - 8.9), systolic, and - 4.6 mmHg (95% CI, - 2.4 to - 6.8), diastolic, and with placebo, 0.8 mmHg (95 % CI, 3.4 to - 2.9) systolic and - 0.3 mmHg (95 % CI, 2.3 to - 2.1) diastolic. P-value results ranged from 0.004 to 0.05. No participant dropout occurred and no adverse effects were seen in patients treated with allopurinol.Authors&apos; conclusions: Meta-analysis was not possible in this systematic review. In the one study that matched the inclusion criteria allopurinol decreased &quot;in office&quot; and ambulatory systolic and diastolic BP. Because there was only one included RCT, the number of patients providing data on pharmacotherapy for hyperuricemia in hypertension is small and restricted to adolescents with recently diagnosed mild essential hypertension. Hence, there is insufficient evidence to recommend the use of allopurinol or other hypouricemic drugs as an initial or adjuvant treatment of hypertension and more RCTs are needed.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008652.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008652.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>607</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">607</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gong, Yan</style></author><author><style face="normal" font="default" size="100%">Christensen, Erik</style></author><author><style face="normal" font="default" size="100%">Gluud, Christian</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cyclosporin A for primary biliary cirrhosis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cyclosporine [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Cirrhosis, Biliary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005526</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Cyclosporin A has been used for patients with primary biliary cirrhosis, but the therapeutic responses in randomised clinical trials have been heterogeneous.Objectives: To assess the beneficial and harmful effects of cyclosporin A for patients with primary biliary cirrhosis.Search methods: Relevant randomised clinical trials were identified by searching The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, The Chinese Biomedical Database, and LILACS, and manual searches of bibliographies to June 2006. We contacted authors of trials and the company producing cyclosporin A.Selection criteria: Randomised clinical trials comparing cyclosporin A with placebo, no intervention, or another drug were included irrespective of blinding, language, year of publication, and publication status.Data collection and analysis: Our primary outcomes were mortality, and mortality or liver transplantation. Dichotomous outcomes were reported as relative risk (RR) and if appropriate, Peto odds ratio with 95% confidence interval (CI). Continuous outcomes were reported as weighted mean difference (WMD) or standardised mean difference (SMD). We examined intervention effects by random-effects and fixed-effect models.Main results: We identified three trials with 390 patients that compared cyclosporin A versus placebo. Two of them were assessed methodologically adequate with low-bias risk. Cyclosporin A did not significantly reduce mortality risk (RR 0.92, 95% CI 0.59 to 1.45), and mortality or liver transplantation (RR 0.85, 95% CI 0.60 to 1.20). Cyclosporin A significantly improved pruritus (SMD -0.38, 95% CI -0.63 to -0.14), but not fatigue. Cyclosporin A significantly reduced alanine aminotransferase (WMD -41 U/L, 95% CI -63 to -18) and increased serum albumin level (WMD 1.66 g/L, 95% CI 0.26 to 3.05). Significantly more patients experienced adverse events in the cyclosporin A group than in the placebo group, especially renal dysfunction (Peto odds ratio 5.56, 95% CI 2.52 to 12.27) and hypertension (SMD 0.88, 95% CI 0.27 to 1.48).Authors&apos; conclusions: We found no evidence supporting or refuting that cyclosporin A may delay death, death or liver transplantation, or progression of primary biliary cirrhosis. Cyclosporin A caused more adverse events than placebo, like renal dysfunction and hypertension. We do not recommend the use of cyclosporin A outside randomised clinical trials.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005526.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005526.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>608</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">608</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gorricho, Javier</style></author><author><style face="normal" font="default" size="100%">Garjón, Javier</style></author><author><style face="normal" font="default" size="100%">Celaya Mª, Concepción</style></author><author><style face="normal" font="default" size="100%">Muruzábal, Lourdes</style></author><author><style face="normal" font="default" size="100%">Montoya, Rodolfo</style></author><author><style face="normal" font="default" size="100%">López Andrés, Antonio</style></author><author><style face="normal" font="default" size="100%">Malón Mª del, Mar</style></author><author><style face="normal" font="default" size="100%">Saiz Luis, Carlos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure targets for the treatment of patients with hypertension and cardiovascular disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010315</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To determine if &apos;lower&apos; blood pressure targets (? 135/85 mmHg) are associated with reduction in mortality and morbidity as compared with &apos;standard&apos; blood pressure targets (? 140-160/ 90-100 mmHg) in the treatment of patients with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular occlusive disease).</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010315/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010315</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>147</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">147</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gosain, P.</style></author><author><style face="normal" font="default" size="100%">Garimella, P. S.</style></author><author><style face="normal" font="default" size="100%">Hart, P. D.</style></author><author><style face="normal" font="default" size="100%">Agarwal, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal sympathetic denervation for treatment of resistant hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">75-84</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney [innervation]</style></keyword><keyword><style face="normal" font="default" size="100%">Sympathectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013007379</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013007379/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>148</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">148</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Graudal, N. A.</style></author><author><style face="normal" font="default" size="100%">Hubeck-Graudal, T.</style></author><author><style face="normal" font="default" size="100%">Jurgens, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of low-sodium diet vs high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane review) (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-15</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">African Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Aldosterone [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Catecholamines [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Triglycerides [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012000285</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012000285/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>609</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">609</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Graudal Niels, Albert</style></author><author><style face="normal" font="default" size="100%">Hubeck-Graudal, Thorbjorn</style></author><author><style face="normal" font="default" size="100%">Jurgens, Gesche</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">African Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Aldosterone [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [radiation effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Catecholamines [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy] [ethnology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Triglycerides [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004022</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: In spite of more than 100 years of investigations the question of reduced sodium intake as a health prophylaxis initiative is still unsolved.Objectives: To estimate the effects of low sodium versus high sodium intake on systolic and diastolic blood pressure (SBP and DBP), plasma or serum levels of renin, aldosterone, catecholamines, cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides.Search methods: PUBMED, EMBASE and Cochrane Central and reference lists of relevant articles were searched from 1950 to July 2011.Selection criteria: Studies randomizing persons to low sodium and high sodium diets were included if they evaluated at least one of the above outcome parameters.Data collection and analysis: Two authors independently collected data, which were analysed with Review Manager 5.1.Main results: A total of 167 studies were included in this 2011 update.The effect of sodium reduction in normotensive Caucasians was SBP -1.27 mmHg (95% CI: -1.88, -0.66; p=0.0001), DBP -0.05 mmHg (95% CI: -0.51, 0.42; p=0.85). The effect of sodium reduction in normotensive Blacks was SBP -4.02 mmHg (95% CI:-7.37, -0.68; p=0.002), DBP -2.01 mmHg (95% CI:-4.37, 0.35; p=0.09). The effect of sodium reduction in normotensive Asians was SBP -1.27 mmHg (95% CI: -3.07, 0.54; p=0.17), DBP -1.68 mmHg (95% CI:-3.29, -0.06; p=0.04). The effect of sodium reduction in hypertensive Caucasians was SBP -5.48 mmHg (95% CI: -6.53, -4.43; p&lt;0.00001), DBP -2.75 mmHg (95% CI: -3.34, -2.17; p&lt;0.00001). The effect of sodium reduction in hypertensive Blacks was SBP -6.44 mmHg (95% CI:-8.85, -4.03; p=0.00001), DBP -2.40 mmHg (95% CI:-4.68, -0.12; p=0.04). The effect of sodium reduction in hypertensive Asians was SBP -10.21 mmHg (95% CI:-16.98, -3.44; p=0.003), DBP -2.60 mmHg (95% CI: -4.03, -1.16; p=0.0004).In plasma or serum there was a significant increase in renin (p&lt;0.00001), aldosterone (p&lt;0.00001), noradrenaline (p&lt;0.00001), adrenaline (p&lt;0.0002), cholesterol (p&lt;0.001) and triglyceride (p&lt;0.0008) with low sodium intake as compared with high sodium intake. In general the results were similar in studies with a duration of at least 2 weeks.Authors&apos; conclusions: Sodium reduction resulted in a 1% decrease in blood pressure in normotensives, a 3.5% decrease in hypertensives, a significant increase in plasma renin, plasma aldosterone, plasma adrenaline and plasma noradrenaline, a 2.5% increase in cholesterol, and a 7% increase in triglyceride. In general, these effects were stable in studies lasting for 2 weeks or more.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004022.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004022.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>610</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">610</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Green Carolyn, J.</style></author><author><style face="normal" font="default" size="100%">Maclure, Malcolm</style></author><author><style face="normal" font="default" size="100%">Fortin Patricia, M.</style></author><author><style face="normal" font="default" size="100%">Ramsay Craig, R.</style></author><author><style face="normal" font="default" size="100%">Aaserud, Morten</style></author><author><style face="normal" font="default" size="100%">Bardal, Stan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmaceutical policies: effects of restrictions on reimbursement</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Drug Costs</style></keyword><keyword><style face="normal" font="default" size="100%">Health Care Costs [legislation &amp; jurisprudence]</style></keyword><keyword><style face="normal" font="default" size="100%">Health Services [utilization]</style></keyword><keyword><style face="normal" font="default" size="100%">Insurance, Pharmaceutical Services [legislation &amp; jurisprudence]</style></keyword><keyword><style face="normal" font="default" size="100%">Prescription Drugs [economics] [supply &amp; distribution]</style></keyword><keyword><style face="normal" font="default" size="100%">Process Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Reimbursement Mechanisms [legislation &amp; jurisprudence]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Epoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008654</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Public policy makers and benefit plan managers need to restrain rising pharmaceutical drug costs while preserving access and optimizing health benefits.Objectives: To determine the effects of a pharmaceutical policy restricting the reimbursement of selected medications on drug use, health care utilization, health outcomes and costs (expenditures).Search methods: We searched the 14 major bibliographic databases and websites (to January 2009).Selection criteria: Included were studies of pharmaceutical policies that restrict coverage and reimbursement of selected drugs or drug classes, often using additional patient specific information related to health status or need. We included randomised controlled trials, non-randomised controlled trials, interrupted time series (ITS) analyses, repeated measures studies and controlled before-after studies set in large care systems or jurisdictions.Data collection and analysis: Two authors independently extracted data and assessed study limitations. Quantitative re-analysis of time series data was undertaken for studies with sufficient data.Main results: We included 29 ITS analyses (12 were controlled) investigating policies targeting 11 drug classes for restriction. Participants were most often senior citizens or low income adult populations, or both, in publically subsidized or administered pharmaceutical benefit plans. Impact of policies varied by drug class and whether restrictions were implemented or relaxed. When policies targeted gastric-acid suppressant and non-steroidal anti-inflammatory drug classes, decreased drug use and substantial savings on drugs occurred immediately and for up to two years afterwards, with no increase in the use of other health services (6 studies). Targeting second generation antipsychotic drugs increased treatment discontinuity and the use of other health services without reducing overall drug expenditures (2 studies). Relaxing restrictions for reimbursement of antihypertensives and statins increased appropriate use and decreased overall drug expenditures. Two studies which measured health outcomes directly were inconclusive.Authors&apos; conclusions: Implementing restrictions to coverage and reimbursement of selected medications can decrease third-party drug spending without increasing the use of other health services (6 studies). Relaxing reimbursement rules for drugs used for secondary prevention can also remove barriers to access. Policy design, however, needs to be based on research quantifying the harm and benefit profiles of target and alternative drugs to avoid unwanted health system and health effects. Health impact evaluation should be conducted where drugs are not interchangeable. Impacts on health equity, relating to the fair and just distribution of health benefits in society (sustainable access to publically financed drug benefits for seniors and low income populations, for example), also require explicit measurement. </style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008654/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008654</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>149</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">149</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Greenhalgh, J.</style></author><author><style face="normal" font="default" size="100%">Dickson, R.</style></author><author><style face="normal" font="default" size="100%">Dundar, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effects of biofeedback for the treatment of essential hypertension: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-79</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">46</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biofeedback, Psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [psychology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009110246</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009110246/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>611</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">611</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Greenhalgh, J.</style></author><author><style face="normal" font="default" size="100%">Dickson, R.</style></author><author><style face="normal" font="default" size="100%">Dundar, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effects of biofeedback for the treatment of essential hypertension: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biofeedback, Psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [psychology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">Health Technology Assessment</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32007000895</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32007000895/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>612</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">612</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grimm, C.</style></author><author><style face="normal" font="default" size="100%">Koeberlein, J.</style></author><author><style face="normal" font="default" size="100%">Wiosna, W.</style></author><author><style face="normal" font="default" size="100%">Kresimon, J.</style></author><author><style face="normal" font="default" size="100%">Kiencke, P.</style></author><author><style face="normal" font="default" size="100%">Rychlik, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">New-onset diabetes and antihypertensive treatment (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32011000458</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32011000458/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>150</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">150</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grossman, E.</style></author><author><style face="normal" font="default" size="100%">Laudon, M.</style></author><author><style face="normal" font="default" size="100%">Zisapel, N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Vascular Health and Risk Management</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Vascular Health and Risk Management</style></full-title></periodical><pages><style face="normal" font="default" size="100%">577-584</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Circadian Rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">Delayed-Action Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Melatonin [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012005840</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012005840/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>151</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">151</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grossman, E.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Are calcium antagonists beneficial in diabetic patients with hypertension? (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">44-49</style></pages><volume><style face="normal" font="default" size="100%">116</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004009244</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004009244/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>152</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">152</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grosso, A. M.</style></author><author><style face="normal" font="default" size="100%">Bodalia, P. N.</style></author><author><style face="normal" font="default" size="100%">MacAllister, R. J.</style></author><author><style face="normal" font="default" size="100%">Hingorani, A. D.</style></author><author><style face="normal" font="default" size="100%">Moon, J. C.</style></author><author><style face="normal" font="default" size="100%">Scott, M. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">253-263</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Costs</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [economics]</style></keyword><keyword><style face="normal" font="default" size="100%">Losartan [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Quality-Adjusted Life Years</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles [economics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011001912</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001912/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>153</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">153</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guo, L.</style></author><author><style face="normal" font="default" size="100%">Liu, Y. J.</style></author><author><style face="normal" font="default" size="100%">Xie, Z. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">638-645</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Defects, Congenital</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014024529</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014024529/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>154</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">154</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guo, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, L. L.</style></author><author><style face="normal" font="default" size="100%">Zheng, B.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Cao, X. J.</style></author><author><style face="normal" font="default" size="100%">Pi, Y.</style></author><author><style face="normal" font="default" size="100%">Li, B. H.</style></author><author><style face="normal" font="default" size="100%">Li, J. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The C825T polymorphism of the G-Protein beta3 subunit gene and its association with hypertension and stroke: an ppdated meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Plos One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Plos One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e65863</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013035968</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013035968/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>155</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">155</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guo, X.</style></author><author><style face="normal" font="default" size="100%">Zhou, B.</style></author><author><style face="normal" font="default" size="100%">Nishimura, T.</style></author><author><style face="normal" font="default" size="100%">Teramukai, S.</style></author><author><style face="normal" font="default" size="100%">Fukushima, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical effect of qigong practice on essential hypertension: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Alternative and Complementary Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Alternative and Complementary Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">27-37</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Breathing Exercises</style></keyword><keyword><style face="normal" font="default" size="100%">Confidence Intervals</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008103939</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008103939/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>613</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">613</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guo, Zhen</style></author><author><style face="normal" font="default" size="100%">Wu, Zongying</style></author><author><style face="normal" font="default" size="100%">Wang, Yang</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antacids [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Esophageal and Gastric Varices [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Hemorrhage [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Cirrhosis [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005443</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Ruptured gastroesophageal varices are the most severe and frequent cause of gastrointestinal bleeding in cirrhotic patients, leading to death in 5% to 8% of patients during the first 48 hours and oesophagogastric varices account for 60% to 80% of first bleeding in patients with portal hypertension. Antacids are often used for emergency treatment of bleeding oesophageal varices in patients with cirrhosis of the liver.Objectives: To evaluate the beneficial and harmful effects of antacids for preventing oesophagogastric bleeding and rebleeding.Search methods: We planned to identify relevant randomised clinical trials by searching The Cochrane Hepato-Biliary Group Controlled Trials Register (June 2007), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 2, 2007), MEDLINE (1950 to June 2007), EMBASE (Excerpta Medica Database) (1980 to June 2007), and the Science Citation Index Expanded (SCI-EXPANDED) (1945 to June 2007). Additional randomised trials were sought from the reference lists of the trials found and reviews identified by the electronic searches.Selection criteria: We planned to include randomised clinical trials.Data collection and analysis: We planned to summarise data using Cochrane Collaboration methodologies.Main results: We could not find any randomised clinical trials on antacids for preventing oesophagogastric variceal bleeding and bleeding in cirrhotic patients.Authors&apos; conclusions: It is not possible to determine whether antacids are beneficial or harmful for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients since randomised clinical trials investigating this question are lacking.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005443.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005443.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>156</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">156</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guo-Zhou, C.</style></author><author><style face="normal" font="default" size="100%">Wu-Hua, L.</style></author><author><style face="normal" font="default" size="100%">Jin-Peng, H.</style></author><author><style face="normal" font="default" size="100%">Xiao-Quan, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of hand-assisted laparoscopic surgery and open surgery for portal hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Academiae Medicinae Sinicae</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Academiae Medicinae Sinicae</style></full-title></periodical><pages><style face="normal" font="default" size="100%">488-494</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal</style></keyword><keyword><style face="normal" font="default" size="100%">Laparoscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013064541</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013064541/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>157</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">157</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, A. K.</style></author><author><style face="normal" font="default" size="100%">Arshad, S.</style></author><author><style face="normal" font="default" size="100%">Poulter, N. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">399-407</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination</style></keyword><keyword><style face="normal" font="default" size="100%">dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Compliance [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Safety Management</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010001505</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010001505/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>158</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">158</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, R.</style></author><author><style face="normal" font="default" size="100%">Connolly, E. S.</style></author><author><style face="normal" font="default" size="100%">Mayer, S.</style></author><author><style face="normal" font="default" size="100%">Elkind, M. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hemicraniectomy for massive middle cerebral artery territory infarction: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title></periodical><pages><style face="normal" font="default" size="100%">539-543</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Edema [etiology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Craniotomy</style></keyword><keyword><style face="normal" font="default" size="100%">Decompression, Surgical</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Infarction, Middle Cerebral Artery [complications] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [etiology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004000303</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004000303/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>159</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">159</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gwer, S.</style></author><author><style face="normal" font="default" size="100%">Gatakaa, H.</style></author><author><style face="normal" font="default" size="100%">Mwai, L.</style></author><author><style face="normal" font="default" size="100%">Idro, R.</style></author><author><style face="normal" font="default" size="100%">Newton, C. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The role for osmotic agents in children with acute encephalopathies: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Pediatrics</style></full-title></periodical><volume><style face="normal" font="default" size="100%">10:23</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Diseases [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics, Osmotic [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glycerol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Isotonic Solutions [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Mannitol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Saline Solution, Hypertonic [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010007426</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010007426/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>160</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">160</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ha, V.</style></author><author><style face="normal" font="default" size="100%">Sievenpiper, J. L.</style></author><author><style face="normal" font="default" size="100%">Souza, R. J.</style></author><author><style face="normal" font="default" size="100%">Chiavaroli, L.</style></author><author><style face="normal" font="default" size="100%">Wang, D. D.</style></author><author><style face="normal" font="default" size="100%">Cozma, A. I.</style></author><author><style face="normal" font="default" size="100%">Mirrahimi, A.</style></author><author><style face="normal" font="default" size="100%">Yu, M. E.</style></author><author><style face="normal" font="default" size="100%">Carleton, A. J.</style></author><author><style face="normal" font="default" size="100%">Dibuono, M.</style></author><author><style face="normal" font="default" size="100%">Jenkins, A. L.</style></author><author><style face="normal" font="default" size="100%">Leiter, L. A.</style></author><author><style face="normal" font="default" size="100%">Wolever, T. M.</style></author><author><style face="normal" font="default" size="100%">Beyene, J.</style></author><author><style face="normal" font="default" size="100%">Kendall, C. W.</style></author><author><style face="normal" font="default" size="100%">Jenkins, D. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of fructose on blood pressure: a systematic review and meta-analysis of controlled feeding trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">787-795</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Carbohydrates [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Fructose [adverse effects] [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012016875</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012016875/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>161</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">161</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hagins, M.</style></author><author><style face="normal" font="default" size="100%">States, R.</style></author><author><style face="normal" font="default" size="100%">Selfe, T.</style></author><author><style face="normal" font="default" size="100%">Innes, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effectiveness of yoga for hypertension: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">649836</style></pages><volume><style face="normal" font="default" size="100%">2013</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Yoga</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013034614</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013034614/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>614</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">614</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hahn, Seokyung</style></author><author><style face="normal" font="default" size="100%">Choi Hyun, Jin</style></author><author><style face="normal" font="default" size="100%">Soll, Roger</style></author><author><style face="normal" font="default" size="100%">Dargaville Peter, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lung lavage for meconium aspiration syndrome in newborn infants</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Meconium Aspiration Syndrome [mortality] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Surfactants [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003486</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Meconium aspiration syndrome (MAS) can occur when a newborn infant inhales a mixture of meconium and amniotic fluid into the lungs around the time of delivery. Other than supportive measures, little effective therapy is available. Lung lavage may be a potentially effective treatment for MAS by virtue of removing meconium from the airspaces and altering the natural course of the disease.Objectives: To evaluate the effects of lung lavage on morbidity and mortality in newborn infants with MAS.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE, and EMBASE up to December 2012; previous reviews including cross-references, abstracts, and conference proceedings; and expert informants. We contacted authors directly to obtain additional data. We used the following subject headings and text words: meconium aspiration, pulmonary surfactants, fluorocarbons, bronchoalveolar lavage, lung lavage, pulmonary lavage.Selection criteria: Randomised controlled trials that evaluated the effects of lung lavage in infants with MAS, including those intubated for the purpose of lavage. Lung lavage was defined as any intervention in which fluid is instilled into the lung that is followed by an attempt to remove it by suctioning and/or postural drainage.Data collection and analysis: The review authors extracted from the reports of the clinical trial, data regarding clinical outcomes, including mortality, requirement for extracorporeal membrane oxygenation (ECMO), pneumothorax, duration of mechanical ventilation and oxygen therapy, length of hospital stay, indices of pulmonary function, and adverse effects of lavage. Data analysis was done in accordance with the standards of the Cochrane Neonatal Review Group.Main results: Only four small randomised controlled trials fulfilled the selection criteria. For one of these trials, no data are available for the control group. Two studies compared lavage using diluted surfactant with standard care. Meta-analysis of these two studies did not show a significant effect on mortality (typical relative risk 0.42, 95% confidence interval [CI] 0.12 to 1.46; typical risk difference -0.10, 95% CI -0.24 to 0.04) or the use of ECMO (typical relative risk 0.27, 95% CI 0.04 to 1.86; typical risk difference -0.15, 95% CI -0.35 to 0.04). For the composite outcome of death or use of ECMO, a significant effect favoured the lavage group (typical relative risk 0.33, 95% CI 0.11 to 0.96; typical risk difference -0.19, 95% CI -0.34 to -0.03; number needed to benefit [NNTB] 5). No other benefits were reported. The other published study compared surfactant lavage followed by a surfactant bolus with surfactant bolus therapy alone in MAS complicated by pulmonary hypertension. No significant improvements in mortality, pneumothorax, duration of mechanical ventilation. or duration of hospitalisation were observed.Authors&apos; conclusions: In infants with meconium aspiration syndrome, lung lavage with diluted surfactant may be beneficial, but additional controlled clinical trials of lavage therapy should be conducted to confirm the treatment effect, to refine the method of lavage treatment, and to compare lavage treatment with other approaches, including surfactant bolus therapy. Long-term outcomes should be evaluated in further clinical trials.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003486.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003486.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>615</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">615</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Halliday Henry, L.</style></author><author><style face="normal" font="default" size="100%">Ehrenkranz Richard, A.</style></author><author><style face="normal" font="default" size="100%">Doyle Lex, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Glucocorticoids [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature, Diseases [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Diseases [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Steroids</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD001144</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Corticosteroids have been used late in the neonatal period to treat chronic lung disease (CLD) in preterm babies, and early to try to prevent it. CLD is likely to be the result of persisting inflammation in the lung and the use of powerful anti-inflammatory drugs like dexamethasone has some rationale. Early use tends to be associated with increased adverse effects so that studies of moderately early treatment (7-14 days postnatal) might have the dual benefits of fewer side effects and onset of action before chronic inflammation is established.Objectives: To determine if moderately early (7-14 days) postnatal corticosteroid treatment vs control (placebo or nothing) is of benefit in the prevention and/or treatment of early chronic lung disease in the preterm infant.Search methods: Randomised controlled trials of postnatal corticosteroid therapy were sought from the Oxford Database of Perinatal Trials, Cochrane Database of Controlled Trials, MEDLINE (1966 - October 2002), hand searching paediatric and perinatal journals, examining previous review articles and information received from practicing neonatologists. Authors of all studies were contacted, where possible, to confirm details of reported follow-up studies, or to obtain any information about long-term follow-up where none had been reported.Selection criteria: Randomised controlled trials of postnatal corticosteroid treatment from 7-14 days of birth in high risk preterm infants were selected for this review.Data collection and analysis: Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, or need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, hypertrophic cardiomyopathy, pneumothorax, severe intraventricular haemorrhage (IVH), necrotizing enterocolitis (NEC), gastrointestinal bleeding, and severe retinopathy of prematurity (ROP)), and long term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 4.1.Main results: Seven studies enrolling a total of 669 participants were eligible for inclusion in this review. Moderately early steroid treatment (vs placebo or nothing) reduced mortality by 28 days, chronic lung disease at 28 days and 36 weeks, and death or chronic lung disease at 28 days or 36 weeks. Earlier extubation was facilitated. There was no significant effect on the rates of pneumothorax, severe ROP, or NEC. Adverse effects included hypertension, hyperglycaemia, gastrointestinal bleeding, hypertrophic cardiomyopathy and infection. Steroid-treated infants were less likely to need late rescue with dexamethasone. There were limited data from four studies of long term follow-up; these did not show evidence of an increase in adverse neurological outcomes.Authors&apos; conclusions: Moderately early corticosteroid therapy (started at 7-14 days) reduces neonatal mortality and CLD, but at the cost of important short term adverse effects. Limited evidence concerning long term effects is provided by the trials included in this review. The methodological quality of the studies determining the long-term outcome is limited in some cases, the children have been assessed predominantly before school age, and no study has been sufficiently powered to detect important adverse long-term neurosensory outcomes. Therefore, given the risk:benefit ratio of short-term effects and the limited long-term follow-up data, it seems appropriate to reserve moderately early corticosteroid treatment to infants who cannot be weaned from mechanical ventilation and to minimise the dose and duration of any course of therapy. More research is urgently needed, including long term follow-up of survivors included in previous and any future trials, before the benefits and risks of postnatal steroid treatment, including initiation at 7-14 days, can be reliably assessed (See DART study; Doyle 2000a).</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001144/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001144</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>162</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">162</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hamer, M.</style></author><author><style face="normal" font="default" size="100%">Taylor, A.</style></author><author><style face="normal" font="default" size="100%">Steptoe, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effect of acute aerobic exercise on stress related blood pressure responses: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Biological Psychology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biological Psychology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">183-190</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Psychological [psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006000435</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006000435/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>616</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">616</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Han, SeungHye</style></author><author><style face="normal" font="default" size="100%">Patil Susheel, P.</style></author><author><style face="normal" font="default" size="100%">Robinson Karen, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacotherapy for hypertension in adults with obstructive sleep apnea</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007666</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the blood pressure lowering efficacy of oral antihypertensive medication from different drug classes as compared to placebo from randomized controlled trials in adult patients with primary hypertension and obstructive sleep apnea. To compare the blood pressure lowering efficacy of different classes of antihypertensive medication from randomized controlled trials in adult patients with primary hypertension and obstructive sleep apnea.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007666/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007666</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>163</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">163</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Harel, Z.</style></author><author><style face="normal" font="default" size="100%">Gilbert, C.</style></author><author><style face="normal" font="default" size="100%">Wald, R.</style></author><author><style face="normal" font="default" size="100%">Bell, C.</style></author><author><style face="normal" font="default" size="100%">Perl, J.</style></author><author><style face="normal" font="default" size="100%">Juurlink, D.</style></author><author><style face="normal" font="default" size="100%">Beyene, J.</style></author><author><style face="normal" font="default" size="100%">Shah, P. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><volume><style face="normal" font="default" size="100%">344:e42</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Kidney Injury [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Amides [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperkalemia [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012000469</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012000469/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>617</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">617</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hartley, Louise</style></author><author><style face="normal" font="default" size="100%">Flowers, Nadine</style></author><author><style face="normal" font="default" size="100%">Lee Myeong, Soo</style></author><author><style face="normal" font="default" size="100%">Ernst, Edzard</style></author><author><style face="normal" font="default" size="100%">Rees, Karen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tai chi for primary prevention of cardiovascular disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Vasc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010366</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Stress and a sedentary lifestyle are major determinants of cardiovascular disease (CVD). As tai chi involves exercise and can help in stress reduction, it may be effective in the primary prevention of CVD.Objectives: To determine the effectiveness of tai chi for the primary prevention of CVD.Search methods: We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 11, 2013); MEDLINE (Ovid) (1946 to November week 3, 2013); EMBASE Classic + EMBASE (Ovid) (1947 to 6 December 2013); Web of Science (Thomson Reuters) (1970 to 6 December 2013); PsycINFO (Ovid) (1806 to December week 1, 2013); Database of Abstracts of Reviews of Effects (DARE); Health Technology Assessment Database and Health Economics Evaluations Database (Issue 4, 2013). We also searched the Allied and complementary Medicine Database (AMED) and OpenGrey (inception to October 2012) and several Asian databases. We searched trial registers and reference lists of reviews for further studies. We applied no language restrictions.Selection criteria: Randomised controlled trials of tai chi lasting at least three months involving healthy adults or adults at high risk of CVD. The comparison group was no intervention or minimal intervention. The outcomes of interest were CVD clinical events and CVD risk factors. We excluded trials involving multifactorial lifestyle interventions or focusing on weight loss to avoid confounding.Data collection and analysis: Two review authors independently selected trials for inclusion, abstracted the data and assessed the risk of bias.Main results: We identified 13 small trials (1520 participants randomised) and three ongoing trials. All studies had at least one domain with unclear risk of bias, and some studies were at high risk of bias for allocation concealment (one study) and selective reporting (two studies). Duration and style of tai chi differed between trials. Seven studies recruited 903 healthy participants, the other studies recruited people with borderline hypertension or hypertension, elderly people at high risk of falling, and people with hypertension with liver and kidney yin deficiency syndrome.No studies reported on cardiovascular mortality, all-cause mortality or non-fatal events as most studies were short term (all studies had follow-up of one year or less). There was also considerable heterogeneity between studies, which meant that it was not possible to combine studies statistically for cardiovascular risk (I2 statistic for systolic blood pressure (SBP) was 96%, for diastolic blood pressure (DBP) 96%, for total cholesterol 96%, low-density lipoprotein-cholesterol (LDL-C) 95%, high-density lipoprotein-cholesterol (HDL-C) 98%, triglycerides 75%). Nine trials measured blood pressure, six individual trials found reductions in SBP (reductions ranged from -22.0 mmHg (95% confidence interval (CI) -26.3 to -17.7) to -11.5 mmHg (95% CI -21.5 to -1.46)), two trials found no clear evidence of a difference (however, CIs were wide and an increase or decrease in SBP cannot be ruled out), and one trial found an increase in SBP with tai chi (increase 5.2 mmHg, 95% CI 3.73 to 6.67). A similar pattern was seen for DBP: three trials found a reduction in DBP (reductions ranged from -12.2 mmHg (95% CI -15.8 to -8.7) to -4.43 mmHg (95% CI -7.14 to -1.72)) and three trials found no clear evidence of a difference, however again with wide CIs. Three trials reported lipid levels and two found reductions in total cholesterol, LDL-C and triglycerides (total cholesterol reductions ranged from -1.30 mmol/L (95% CI -1.57 to -1.03) to -0.50 mmol/L (95% CI -0.74 to -0.26): LDL-C reductions ranged from -0.76 mmol/L (95% CI -0.93 to -0.59) to -0.59 mmol/L (95% CI -0.80 to -0.38): triglyceride reductions ranged from -0.46 mmol/L (95% CI -0.62 to -0.30) to -0.37 mmol/L (95% CI -0.67 to-0.07)) and increased HDL-C with the intervention (HDL-C increases ranged from 0.61 mmol/L (95% CI 0.51 to 0.71) to 0.16 mmol/L (95% CI 0.02 to 0.30)), while the third study found no clear eviden e of a difference between groups on lipid levels. Quality of life was measured in one trial: tai chi improved quality of life at three months. None of the included trials reported on adverse events, costs or occurrence of type 2 diabetes.Authors&apos; conclusions: There are currently no long-term trials examining tai chi for the primary prevention of CVD. Due to the limited evidence available currently no conclusions can be drawn as to the effectiveness of tai chi on CVD risk factors. There was some suggestion of beneficial effects of tai chi on CVD risk factors but this was not consistent across all studies. There was considerable heterogeneity between the studies included in this review and studies were small and at some risk of bias. Results of the ongoing trials will add to the evidence base but additional longer-term, high-quality trials are needed.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010366.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010366.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>164</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">164</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hassan, A.</style></author><author><style face="normal" font="default" size="100%">Alison, J.</style></author><author><style face="normal" font="default" size="100%">Redfern, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Exercise in pulmonary hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Physical Therapy Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Physical Therapy Reviews</style></full-title></periodical><pages><style face="normal" font="default" size="100%">19-24</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011003055</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011003055/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>165</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">165</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayashino, Y.</style></author><author><style face="normal" font="default" size="100%">Jackson, J. L.</style></author><author><style face="normal" font="default" size="100%">Fukumori, N.</style></author><author><style face="normal" font="default" size="100%">Nakamura, F.</style></author><author><style face="normal" font="default" size="100%">Fukuhara, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetes Research and Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diabetes Research and Clinical Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">349-360</style></pages><volume><style face="normal" font="default" size="100%">98</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [blood] [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Angiopathies [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hypercholesterolemia [complications] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Lipoproteins [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013001754</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013001754/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>618</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">618</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Biofeedback for the treatment of hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biofeedback (Psychology)</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32006000982</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32006000982/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>619</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">619</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal stenting for treatment of renal stenosis in patients with hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Renovascular</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32009100536</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32009100536/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>620</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">620</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Selective laser trabeculoplasty (SLT) using the Selecta 7000 (Lumenis Inc.) for treatment of primary open-angle glaucoma and ocular hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma, Open-Angle</style></keyword><keyword><style face="normal" font="default" size="100%">Laser Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Trabeculectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32009100545</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32009100545/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>621</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">621</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nonstimulant medications for attention-deficit hyperactivity disorder (ADHD) in children: Atomoxetine (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic Uptake Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Antidepressive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Attention Deficit Disorder with Hyperactivity</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000016</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000016/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>622</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">622</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nonstimulant medications for attention-deficit hyperactivity disorder (ADHD) in adults: Atomoxetine (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic Uptake Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Antidepressive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Attention Deficit Disorder with Hyperactivity</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000013</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000013/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>623</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">623</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nonstimulant medications for attention-deficit hyperactivity disorder (ADHD) in adults: antidepressants and antihypertensives (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antidepressive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Attention Deficit Disorder with Hyperactivity</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000012</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000012/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>624</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">624</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nonstimulant medications for attention-deficit hyperactivity disorder (ADHD) in children: antihypertensives (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Attention Deficit Disorder with Hyperactivity</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000015</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000015/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>625</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">625</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pulmonary thromboendarterectomy for treatment of pulmonary hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Endarterectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Embolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32009100526</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32009100526/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>626</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">626</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">RESPeRATE (InterCure Ltd.) device to lower blood pressure (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Respiration</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32009100537</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32009100537/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>627</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">627</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Inhaled nitric oxide for the treatment of persistent pulmonary hypertension in term and near-term newborns (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide</style></keyword><keyword><style face="normal" font="default" size="100%">Persistent Fetal Circulation Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32009100654</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32009100654/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>628</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">628</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pulmonary thromboendarterectomy for treatment of pulmonary hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Endarterectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Embolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000275</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000275/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>629</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">629</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hayes,</style></author><author><style face="normal" font="default" size="100%">Inc,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin receptor 1 (AGTR1) c.*86A&gt;C (1166A&gt;C, A1166C) polymorphism testing for essential hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">HAYES, Inc</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000563</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000563/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>166</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">166</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, B.</style></author><author><style face="normal" font="default" size="100%">Zhang, F.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Tang, C.</style></author><author><style face="normal" font="default" size="100%">Lin, G.</style></author><author><style face="normal" font="default" size="100%">Du, J.</style></author><author><style face="normal" font="default" size="100%">Jin, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Circulation Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Circulation Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1458-1464</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-Analysis as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010006047</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010006047/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>630</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">630</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He Feng, J.</style></author><author><style face="normal" font="default" size="100%">Li, Jiafu</style></author><author><style face="normal" font="default" size="100%">MacGregor Graham, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of longer-term modest salt reduction on blood pressure</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aldosterone [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [blood] [diet therapy] [ethnology]</style></keyword><keyword><style face="normal" font="default" size="100%">Lipids [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Norepinephrine [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004937</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: A reduction in salt intake lowers blood pressure (BP) and, thereby, reduces cardiovascular risk. A recent meta-analysis by Graudal implied that salt reduction had adverse effects on hormones and lipids which might mitigate any benefit that occurs with BP reduction. However, Graudal&apos;s meta-analysis included a large number of very short-term trials with a large change in salt intake, and such studies are irrelevant to the public health recommendations for a longer-term modest reduction in salt intake. We have updated our Cochrane meta-analysis.  Objectives: To assess (1) the effect of a longer-term modest reduction in salt intake (i.e. of public health relevance) on BP and whether there was a dose-response relationship; (2) the effect on BP by sex and ethnic group; (3) the effect on plasma renin activity, aldosterone, noradrenaline, adrenaline, cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides.Search methods: We searched MEDLINE, EMBASE, Cochrane Hypertension Group Specialised Register, Cochrane Central Register of Controlled Trials, and reference list of relevant articles.Selection criteria: We included randomised trials with a modest reduction in salt intake and duration of at least 4 weeks.Data collection and analysis: Data were extracted independently by two reviewers. Random effects meta-analyses, subgroup analyses and meta-regression were performed.Main results: Thirty-four trials (3230 participants) were included. Meta-analysis showed that the mean change in urinary sodium (reduced salt vs usual salt) was -75 mmol/24-h (equivalent to a reduction of 4.4 g/d salt), the mean change in BP was -4.18 mmHg (95% CI: -5.18 to -3.18, I 2=75%) for systolic and -2.06 mmHg (95% CI: -2.67 to -1.45, I 2=68%) for diastolic BP. Meta-regression showed that age, ethnic group, BP status (hypertensive or normotensive) and the change in 24-h urinary sodium were all significantly associated with the fall in systolic BP, explaining 68% of the variance between studies. A 100 mmol reduction in 24 hour urinary sodium (6 g/day salt) was associated with a fall in systolic BP of 5.8 mmHg (95%CI: 2.5 to 9.2, P=0.001) after adjusting for age, ethnic group and BP status. For diastolic BP, age, ethnic group, BP status and the change in 24-h urinary sodium explained 41% of the variance between studies. Meta-analysis by subgroup showed that, in hypertensives, the mean effect was -5.39 mmHg (95% CI: -6.62 to -4.15, I 2=61%) for systolic and -2.82 mmHg (95% CI: -3.54 to -2.11, I 2=52%) for diastolic BP. In normotensives, the mean effect was -2.42 mmHg (95% CI: -3.56 to -1.29, I 2=66%) for systolic and -1.00 mmHg (95% CI: -1.85 to -0.15, I 2=66%) for diastolic BP. Further subgroup analysis showed that the decrease in systolic BP was significant in both whites and blacks, men and women. Meta-analysis of hormone and lipid data showed that the mean effect was 0.26 ng/ml/hr (95% CI: 0.17 to 0.36, I 2=70%) for plasma renin activity, 73.20 pmol/l (95% CI: 44.92 to 101.48, I 2=62%) for aldosterone, 31.67 pg/ml (95% CI: 6.57 to 56.77, I 2=5%) for noradrenaline, 6.70 pg/ml (95% CI: -0.25 to 13.64, I 2=12%) for adrenaline, 0.05 mmol/l (95% CI: -0.02 to 0.11, I 2=0%) for cholesterol, 0.05 mmol/l (95% CI: -0.01 to 0.12, I 2=0%) for LDL, -0.02 mmol/l (95% CI: -0.06 to 0.01, I 2=16%) for HDL, and 0.04 mmol/l (95% CI: -0.02 to 0.09, I 2=0%) for triglycerides.Authors&apos; conclusions: A modest reduction in salt intake for 4 or more weeks causes significant and, from a population viewpoint, important falls in BP in both hypertensive and normotensive individuals, irrespective of sex and ethnic group. With salt reduction, there is a small physiological increase in plasma renin activity, aldosterone and noradrenaline. There is no significant change in lipid levels. These results provide further strong support for a reduction in population salt intake. This will likely lower population BP and, thereby, reduce cardiovascular disease. Additionally, our analysis demonstrates a significant association between the reduction n 24-h urinary sodium and the fall in systolic BP, indicating the greater the reduction in salt intake, the greater the fall in systolic BP. The current recommendations to reduce salt intake from 9-12 to 5-6 g/d will have a major effect on BP, but are not ideal. A further reduction to 3 g/d will have a greater effect and should become the long term target for population salt intake.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004937.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004937.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>167</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">167</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, F. J.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Macgregor, G. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><volume><style face="normal" font="default" size="100%">346:f1325</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aldosterone [metabolism] [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Markers [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control] [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy] [prevention &amp; control] [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Lipids [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Norepinephrine [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Public Health</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary [administration &amp; dosage] [adverse effects] [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013018994</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013018994/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>168</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">168</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, F. J.</style></author><author><style face="normal" font="default" size="100%">MacGregor, G. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Importance of salt in determining blood pressure in children: meta-analysis of controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">861-869</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [methods] [trends]</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary [administration &amp; dosage] [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006007740</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006007740/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>169</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">169</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">He, Y. M.</style></author><author><style face="normal" font="default" size="100%">Yang, X. J.</style></author><author><style face="normal" font="default" size="100%">Zhao, X.</style></author><author><style face="normal" font="default" size="100%">Cheng, X. J.</style></author><author><style face="normal" font="default" size="100%">Xu, H. F.</style></author><author><style face="normal" font="default" size="100%">Qian, Y. X.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Beta-blockers in heart failure: benefits of beta-blockers according to varying male proportions of study patients (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">505-511</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Bisoprolol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Carbazoles [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [drug therapy] [epidemiology] [mortality] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">Metoprolol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Propanolamines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012039269</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012039269/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>170</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">170</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hebert, P. R.</style></author><author><style face="normal" font="default" size="100%">Coffey, C. S.</style></author><author><style face="normal" font="default" size="100%">Byrne, D. W.</style></author><author><style face="normal" font="default" size="100%">Scott, T. A.</style></author><author><style face="normal" font="default" size="100%">Fagard, R. H.</style></author><author><style face="normal" font="default" size="100%">Rottman, J. N.</style></author><author><style face="normal" font="default" size="100%">Murray, K. T.</style></author><author><style face="normal" font="default" size="100%">Oates, J. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of elderly hypertensive patients with epithelial sodium channel inhibitors combined with a thiazide diuretic reduces coronary mortality and sudden cardiac death (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Society of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Society of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">355-365</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Epithelial Sodium Channel</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium</style></keyword><keyword><style face="normal" font="default" size="100%">Tachycardia, Ventricular</style></keyword><keyword><style face="normal" font="default" size="100%">Thiazides</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009100588</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009100588/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>171</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">171</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helman, D. L.</style></author><author><style face="normal" font="default" size="100%">Brown, A. W.</style></author><author><style face="normal" font="default" size="100%">Jackson, J. L.</style></author><author><style face="normal" font="default" size="100%">Shorr, A. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Analyzing the short-term effect of placebo therapy in pulmonary arterial hypertension: potential implications for the design of future clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chest</style></full-title></periodical><pages><style face="normal" font="default" size="100%">764-772</style></pages><volume><style face="normal" font="default" size="100%">132</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008009029</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008009029/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>631</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">631</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heran Balraj, S.</style></author><author><style face="normal" font="default" size="100%">Chen Jenny, M. H.</style></author><author><style face="normal" font="default" size="100%">Wang Josh, J.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amiloride [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Channel Blockers [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Triamterene [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008167</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Potassium-sparing diuretics, which block the epithelial sodium channel (ENaC), are widely prescribed for hypertension as a second-line drug in patients taking other diuretics (e.g. thiazide diuretics) and much less commonly prescribed as monotherapy. Therefore, it is essential to determine the effects of ENaC blockers on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAEs) when given as a first-line or second-line therapy.Objectives: To quantify the dose-related reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) of ENaC blocker therapy as a first-line or second-line drug in patients with primary hypertension.Search methods: We searched CENTRAL (The Cochrane Library 2012), MEDLINE (1950 to August 2012), EMBASE (1980 to August 2012) and reference lists of articles.Selection criteria: Double-blind, randomized, controlled trials in patients with primary hypertension that evaluate, for a duration of 3 to 12 weeks, the BP lowering efficacy of: 1) fixed-dose monotherapy with an ENaC blocker compared with placebo; or 2) an ENaC blocker in combination with another class of anti-hypertensive drugs compared with the respective monotherapy (without an ENaC blocker).Data collection and analysis: Two authors independently assessed the risk of bias and extracted data. Study authors were contacted for additional information. WDAE information was also collected from the trials.Main results: No trials evaluating the BP lowering efficacy of ENaC blockers as monotherapy in patients with primary hypertension were identified. Only 6 trials evaluated the BP lowering efficacy of low doses of amiloride and triamterene as a second drug in 496 participants with a baseline BP of 151/102 mm Hg. The additional BP reduction caused by the ENaC blocker as a second drug was estimated by comparing the difference in BP reduction between the combination and monotherapy groups. The addition of low doses of amiloride and triamterene in these trials did not reduce BP. An estimate of the dose-related BP lowering efficacy for ENaC blockers was not possible because of a lack of trial data at higher doses.Authors&apos; conclusions: ENaC blockers do not have a statistically or clinically significant BP lowering effect at low doses but trials at higher doses are not available. The review did not provide a good estimate of the incidence of harms associated with ENaC blockers.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008167.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008167.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>632</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">632</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heran Balraj, S.</style></author><author><style face="normal" font="default" size="100%">Galm Brandon, P.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of alpha blockers for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic alpha-Antagonists [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004643</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Alpha blockers are occasionally prescribed for hypertension so it is important to determine and compare their effects on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAE).Objectives: To quantify the dose-related systolic and/or diastolic BP lowering efficacy of alpha blockers versus placebo in the treatment of primary hypertension.Search methods: For the updated review, we searched CENTRAL (The Cochrane Library 2012, Issue 4), MEDLINE (1946 to May 2012), EMBASE (1980 to May 2012) and reference lists of articles.Selection criteria: Double-blind, randomized, controlled trials evaluating the BP lowering efficacy of fixed-dose monotherapy with an alpha blocker compared with placebo for a duration of 3 to 12 weeks in patients with primary hypertension.Data collection and analysis: Two authors independently assessed the risk of bias and extracted data. Study authors were contacted for additional information. WDAE information was collected from the trials.Main results: Only 10 trials evaluated the dose-related trough BP lowering efficacy of 4 different alpha blockers in 1175 participants with a baseline BP of 155/101 mm Hg. The data do not suggest that any one alpha blocker is better or worse at lowering BP. The best but unsatisfactory estimate of the trough BP lowering efficacy for alpha blockers is -8/-5 mmHg.Authors&apos; conclusions: Based on the limited number of published RCTs, the BP lowering effect of alpha blockers is modest; the estimate of the magnitude of trough BP lowering of -8/-5 mmHg is likely an overestimate. There are no clinically meaningful BP lowering differences between different alpha blockers. The review did not provide a good estimate of the incidence of harms associated with alpha blockers because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004643.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004643.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>633</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">633</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heran Balraj, S.</style></author><author><style face="normal" font="default" size="100%">Wong Michelle, M. Y.</style></author><author><style face="normal" font="default" size="100%">Heran Inderjit, K.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003823</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAE).Objectives: To quantify the dose-related systolic and/or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension.Search methods: We searched CENTRAL (The Cochrane Library 2007, Issue 1), MEDLINE (1966 to February 2007), EMBASE (1988 to February 2007) and reference lists of articles.Selection criteria: Double-blind, randomized, controlled trials evaluating the BP lowering efficacy of fixed-dose monotherapy with an ACE inhibitor compared with placebo for a duration of 3 to 12 weeks in patients with primary hypertension.Data collection and analysis: Two authors independently assessed the risk of bias and extracted data. Study authors were contacted for additional information. WDAE information was collected from the trials.Main results: Ninety two trials evaluated the dose-related trough BP lowering efficacy of 14 different ACE inhibitors in 12 954 participants with a baseline BP of 157/101 mm Hg. The data do not suggest that any one ACE inhibitor is better or worse at lowering BP. A dose of 1/8 or 1/4 of the manufacturer&apos;s maximum recommended daily dose (Max) achieved a BP lowering effect that was 60 to 70% of the BP lowering effect of Max. A dose of 1/2 Max achieved a BP lowering effect that was 90% of Max. ACE inhibitor doses above Max did not significantly lower BP more than Max. Combining the effects of 1/2 Max and higher doses gives an estimate of the average trough BP lowering efficacy for ACE inhibitors as a class of drugs of -8 mm Hg for SBP and -5 mm Hg for DBP. ACE inhibitors reduced BP measured 1 to 12 hours after the dose by about 11/6 mm Hg.Authors&apos; conclusions: There are no clinically meaningful BP lowering differences between different ACE inhibitors. The BP lowering effect of ACE inhibitors is modest; the magnitude of trough BP lowering at one-half the manufacturers&apos; maximum recommended dose and above is -8/-5 mm Hg. Furthermore, 60 to 70% of this trough BP lowering effect occurs with recommended starting doses. The review did not provide a good estimate of the incidence of harms associated with ACE inhibitors because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials. </style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003823.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003823.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>634</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">634</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heran Balraj, S.</style></author><author><style face="normal" font="default" size="100%">Wong Michelle, M. Y.</style></author><author><style face="normal" font="default" size="100%">Heran Inderjit, K.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003822</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Angiotensin receptor blockers (ARBs) are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAE).Objectives: To quantify the dose-related systolic and/or diastolic BP lowering efficacy of ARBs versus placebo in the treatment of primary hypertension.Search methods: We searched CENTRAL (The Cochrane Library 2007, Issue 1), MEDLINE (1966 to February 2007), EMBASE (1988 to February 2007) and reference lists of articles.Selection criteria: Double-blind, randomized, controlled trials evaluating the BP lowering efficacy of fixed-dose monotherapy with an ARB compared with placebo for a duration of 3 to 12 weeks in patients with primary hypertension.Data collection and analysis: Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information. WDAE information was collected from the trials.Main results: Forty six RCTs evaluated the dose-related trough BP lowering efficacy of 9 ARBs in 13 451 participants with a baseline BP of 156/101 mm Hg. The data do not suggest that any one ARB is better or worse at lowering BP. A dose of 1/8 or 1/4 of the manufacturers? maximum recommended daily dose (Max) achieved a BP lowering effect that was 60 to 70% of the BP lowering effect of Max. A dose of 1/2 Max achieved a BP lowering effect that was 80% of Max. ARB doses above Max did not significantly lower BP more than Max. Due to evidence of publication bias, the largest trials provide the best estimate of the trough BP lowering efficacy for ARBs as a class of drugs: -8 mm Hg for SBP and -5 mm Hg for DBP. ARBs reduced BP measured 1 to 12 hours after the dose by about 12/7 mm Hg.Authors&apos; conclusions: The evidence from this review suggests that there are no clinically meaningful BP lowering differences between available ARBs. The BP lowering effect of ARBs is modest and similar to ACE inhibitors as a class; the magnitude of average trough BP lowering for ARBs at maximum recommended doses and above is -8/-5 mmHg.  Furthermore, 60 to 70% of this trough BP lowering effect occurs with recommended starting doses. The review did not provide a good estimate of the incidence of harms associated with ARBs because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003822.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003822.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>635</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">635</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hermanowski, T.</style></author><author><style face="normal" font="default" size="100%">Kowalik, E.</style></author><author><style face="normal" font="default" size="100%">Jakubczyk, M.</style></author><author><style face="normal" font="default" size="100%">Niewada, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of pulmonary arterial hypertension in Poland - current practice. Survey results (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Data Collection</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Iloprost [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Poland</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Health Technology Assessment in Poland (AHTAPol)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32009100095</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32009100095/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>636</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">636</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hermanowski, T.</style></author><author><style face="normal" font="default" size="100%">Kowalik, E.</style></author><author><style face="normal" font="default" size="100%">Jakubczyk, M.</style></author><author><style face="normal" font="default" size="100%">Niewada, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Use of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension in Poland. Budget impact analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Costs and Cost Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Iloprost [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Poland</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Health Technology Assessment in Poland (AHTAPol)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32009100094</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32009100094/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>637</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">637</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ho Jacqueline, J.</style></author><author><style face="normal" font="default" size="100%">Rasa, Ganesa</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Magnesium sulfate for persistent pulmonary hypertension of the newborn</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Magnesium Sulfate [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Persistent Fetal Circulation Syndrome [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005588</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Persistent pulmonary hypertension of the newborn (PPHN) occurs in approximately 1.9 per 1000 newborns and may be more frequent in developing countries. There is strong evidence for the use of inhaled nitric oxide (iNO) and extracorporeal membrane oxygenation (ECMO) in the treatment of PPHN. However, many developing countries do not have access or the technical expertise required for these expensive therapies. Magnesium sulfate is a potent vasodilator and hence has the potential to reduce the high pulmonary arterial pressures associated with PPHN. If magnesium sulfate were found to be effective in the treatment of PPHN, this could be a cost effective and potentially life-saving therapy.Objectives: To evaluate the use of magnesium sulfate compared with placebo or standard ventilator management alone, sildenafil infusion, adenosine infusion, or inhaled nitric oxide on mortality or the use of backup iNO or ECMO in term and near-term newborns (&gt; 34 weeks gestational age) with PPHN.Search methods: The standard search strategy of the Cochrane Neonatal Review Group (CNRG) was used. No language restrictions was applied. The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 1, 2006) and MEDLINE (1966 to April 20, 2007) were searched for relevant randomized and quasi-randomized trials. In addition the reference lists of retrieved articles were reviewed and known experts were contacted to obtain unpublished data. This search was updated in December 2009.Selection criteria: All randomised or quasi-random studies were eligible where one of the treatment groups received magnesium sulfate for PPHN.Data collection and analysis: Standard methods of the Cochrane Collaboration and the CNRG were used, including independent assessment of trial quality and extraction of data by each author.Main results: No eligible trials were foundAuthors&apos; conclusions: On the basis of the current lack of evidence, the use of magnesium sulphate cannot be recommended in the treatment of PPHN. Randomised controlled trials are recommended.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005588.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005588.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>638</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">638</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ho Meghan, J.</style></author><author><style face="normal" font="default" size="100%">Bellusci, Anthony</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Bias (Epidemiology)</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquinone [analogs &amp; derivatives] [deficiency] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007435</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Studies have shown that coenzyme Q10 deficiency is associated with cardiovascular disease. Hypertension is a commonly measured surrogate marker for non-fatal and fatal cardiovascular endpoints such as heart attacks and strokes. Clinical trials have suggested that coenzyme Q10 supplementation can effectively lower blood pressure (BP).Objectives: To determine the blood pressure lowering effect of coenzyme Q10 in primary hypertension.Search methods: The Cochrane Central Register of Controlled Trials (2009 Issue 2), MEDLINE (1966 -May 2008), EMBASE (1982 - May 2008), and CINAHL (1970 - May 2008) as well as the reference lists of articles were searched for relevant clinical trials in any language.Selection criteria: Double-blind, randomized, placebo-controlled parallel or crossover trials evaluating the BP lowering efficacy of coenzyme Q10 for a duration of at least 3 weeks in patients with primary hypertension.Data collection and analysis: The primary author independently assessed the risk of bias and extracted the data. The second author verified data extraction.Main results: Three clinical trials with a total of 96 participants were evaluated for the effects of coenzyme Q10 on blood pressure compared to placebo. Treatment with coenzyme Q10 in subjects with systolic BP (SBP) &gt; 140 mmHg or diastolic BP (DBP) &gt; 90 mmHg resulted in mean decreases in SBP of 11 mmHg (95% CI 8, 14) and DBP of 7 mmHg (95% CI 5, 8).Authors&apos; conclusions: Due to the possible unreliability of some of the included studies, it is uncertain whether or not coenzyme Q10 reduces blood pressure in the long-term management of primary hypertension.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007435.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007435.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>172</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">172</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hodge, W. G.</style></author><author><style face="normal" font="default" size="100%">Lachaine, J.</style></author><author><style face="normal" font="default" size="100%">Steffensen, I.</style></author><author><style face="normal" font="default" size="100%">Murray, C.</style></author><author><style face="normal" font="default" size="100%">Barnes, D.</style></author><author><style face="normal" font="default" size="100%">Foerster, V.</style></author><author><style face="normal" font="default" size="100%">Ducruet, T.</style></author><author><style face="normal" font="default" size="100%">Morrison, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Ophthalmology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Ophthalmology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7-12</style></pages><volume><style face="normal" font="default" size="100%">92</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins, Synthetic [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins F, Synthetic [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Quinoxalines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Thiophenes [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008005094</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008005094/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>173</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">173</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hodgkinson, J.</style></author><author><style face="normal" font="default" size="100%">Mant, J.</style></author><author><style face="normal" font="default" size="100%">Martin, U.</style></author><author><style face="normal" font="default" size="100%">Guo, B.</style></author><author><style face="normal" font="default" size="100%">Hobbs, F. D.</style></author><author><style face="normal" font="default" size="100%">Deeks, J. J.</style></author><author><style face="normal" font="default" size="100%">Heneghan, C.</style></author><author><style face="normal" font="default" size="100%">Roberts, N.</style></author><author><style face="normal" font="default" size="100%">McManus, R. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><volume><style face="normal" font="default" size="100%">342:d3621</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Health Facilities</style></keyword><keyword><style face="normal" font="default" size="100%">Home Care Services</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011003883</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011003883/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>639</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">639</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hodson Elisabeth, M.</style></author><author><style face="normal" font="default" size="100%">Willis Narelle, S.</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Corticosteroid therapy for nephrotic syndrome in children</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glucocorticoids [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Nephrotic Syndrome [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Prednisone [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnenediones [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD001533</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: In nephrotic syndrome (NS) protein leaks from the blood to the urine through the glomeruli resulting in hypoproteinaemia and generalised oedema. While the majority of children with NS respond to corticosteroids, 70% experience a relapsing course. Corticosteroids have reduced the mortality rate to around 3%. However corticosteroids have well recognised potentially serious adverse effects such as obesity, poor growth, hypertension, diabetes mellitus and osteoporosis.Objectives: To determine the benefits and harms of corticosteroid regimens in preventing relapse in children with steroid sensitive NS (SSNS).Search methods: We searched CENTRAL, Cochrane Renal Group Specialised Register, MEDLINE and EMBASE without language restriction, reference lists of articles and contact with known investigators.Selection criteria: Randomised controlled trials performed in children (three months to 18 years) in their initial or subsequent episode of SSNS, comparing different durations, total doses or other dose strategies using any corticosteroid agent, with outcome data at six months or more.Data collection and analysis: Two authors independently assessed trial quality and extracted data. Results were expressed as risk ratio (RR) with 95% confidence intervals (CI) or mean difference (MD). Meta-regression was used to explore potential between-study differences due to baseline risk of relapse, study quality and interventions.Main results: Twenty four trials were identified. Six trials comparing two months of prednisone or prednisolone with three months or more in the first episode showed longer duration significantly reduced the risk of relapse at 12 to 24 months (RR 0.70, 95% CI 0.58 to 0.84). There was an inverse linear relationship between treatment duration and risk of relapse (RR = 1.26 - 0.112 duration; P = 0.03). Four trials showed that six months of prednisone was more effective than three months in reducing the risk for relapse (RR 0.57; 95% CI 0.45 to 0.71). Deflazacort was significantly more effective in maintaining remission than prednisone in children who frequently relapsed in a single study (RR 0.44, 95% CI 0.25 to 0.78). There were no increases in adverse events.Authors&apos; conclusions: Children in their first episode of SSNS should be treated for at least three months with an increase in benefit for up to seven months of treatment. For a baseline risk for relapse following the first episode of 60% with two months of therapy, daily prednisone or prednisolone given for four weeks followed by alternate-day therapy for six months would reduce the number of children relapsing by 33%.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001533.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001533.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>640</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">640</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hodson Elisabeth, M.</style></author><author><style face="normal" font="default" size="100%">Willis Narelle, S.</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Growth hormone for children with chronic kidney disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Body Height [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Growth Disorders [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Human Growth Hormone [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003264</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Growth retardation is a common complication of chronic kidney disease (CKD) in children and is of concern to families. Recombinant human growth hormone (rhGH) treatment has been used to help short children with CKD attain a height more in keeping with their age group. However there are concerns about the long-term benefits of rhGH in significantly improving adult height as well as concerns about potential adverse effects (deterioration in native kidney function, increased acute rejection in kidney transplant recipients, benign intracranial hypertension).Objectives: To evaluate the benefits and harms of rhGH treatment in children with CKD.Search methods: Randomised controlled trials (RCTs) were identified from the Cochrane Renal Group&apos;s Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 12, 2011), MEDLINE (from 1966), EMBASE (from 1980), article reference lists and through contact with local and international experts in the field.Date of last search: December 29, 2011Selection criteria: RCTs were included if they were carried out in children aged zero to 18 years, diagnosed with CKD, who were pre-dialysis, on dialysis or post-transplant; if they compared rhGH treatment with placebo/no treatment or two doses of rhGH treatments; and if they included height outcomes.Data collection and analysis: Two authors independently assessed studies for risk of bias and extracted data from eligible studies. Data was pooled using a random effects model with calculation of mean difference (MD) for continuous outcomes with 95% confidence intervals (CI).Main results: Sixteen studies (enrolling 809 children) were identified. Risk of bias assessment indicated that study quality was poor or poorly reported with only four and five studies respectively reporting adequate allocation concealment or blinding of study participants and investigators. Treatment with rhGH (28 IU/m²/wk) compared with placebo or no specific therapy resulted in a significant increase in height standard deviation score (HSDS) at one year (8 studies, 391 children: MD 0.82, 95% CI 0.56 to 1.07), and a significant increase in height velocity at six months (2 studies, 27 children: MD 2.85 cm/6 mo, 95% CI 2.22 to 3.48) and one year (7 studies, 287 children: MD 3.88 cm/y, 95% CI 3.32 to 4.44). Height velocity, though reduced, remained significantly greater than untreated children during the second year of therapy (1 study, 82 children: MD 2.30 cm/y, 95% CI 1.39 to 3.21). Compared to the 14 IU/m²/wk group, there was a 1.18 cm/y increase in height velocity in the 28 IU/m²/wk group (3 studies, 150 children: 1.18 cm/y, 95% CI 0.52 to 1.84) . The frequency of reported side effects of rhGH was generally similar to that of the control group.Authors&apos; conclusions: One year of 28 IU/m²/wk rhGH in children with CKD resulted in a 3.88 cm increase in height velocity above that of untreated patients. Studies were too short to determine if continuing treatment resulted in an increase in final adult height.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003264.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003264.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>641</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">641</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Holdgate, Anna</style></author><author><style face="normal" font="default" size="100%">Pollock, Tamara</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nonsteroidal anti-inflammatory drugs (NSAIDS) versus opioids for acute renal colic</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Analgesics, Opioid [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Colic [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Diseases [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004137</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Renal colic is a common cause of acute severe pain. Both opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended for treatment, but the relative efficacy of these drugs is uncertain.Objectives: To examine the benefits and disadvantages of NSAIDs and opioids for the management of pain in acute renal colic.Search methods: We searched the Cochrane Renal Group&apos;s specialised register, the Cochrane Central Register of Randomised Controlled Trials (CENTRAL - The Cochrane Library, MEDLINE, EMBASE and handsearched reference lists of retrieved articles.Selection criteria: Randomised controlled trials (RCTs) comparing any opioid with any NSAID, regardless of dose or route of administration were included.Data collection and analysis: Data was extracted and quality assessed independently by two reviewers, with differences resolved by discussion. Dichotomous outcomes are reported as risk ratio (RR) and measurements on continuous scales are reported as mean differences (MD) with 95% confidence intervals. Subgroup analysis by study quality, drug type and drug route have been performed where possible to explore reasons for heterogeneity.Main results: Twenty trials from nine countries with a total of 1613 participants were identified. Both NSAIDs and opioids lead to clinically significant falls in patient-reported pain scores. Due to unexplained heterogeneity these results could not be pooled although 10/13 studies reported lower pain scores in patients receiving NSAIDs. Patients treated with NSAIDs were significantly less likely to require rescue medication (RR 0.75, 95% CI 0.61 to 0.93, P = 0.007), though most of these trials used pethidine. The majority of trials showed a higher incidence of adverse events in patients treated with opioids, but there was significant heterogeneity between studies so the results could not be pooled. There was significantly less vomiting in patients treated with NSAIDs (RR 0.35, 95% CI 0.23 to 0.53, P &lt; 0.00001). In particular, patients receiving pethidine had a much higher rate of vomiting compared with patients receiving NSAIDs. Gastrointestinal bleeding and renal impairment were not reported.Authors&apos; conclusions: Both NSAIDs and opioids can provide effective analgesia in acute renal colic. Opioids are associated with a higher incidence of adverse events, particularly vomiting. Given the high rate of vomiting associated with the use of opioids, particularly pethidine, and the greater likelihood of requiring further analgesia, we recommend that if an opioid is to be used it should not be pethidine.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004137.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004137.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>174</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">174</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Honrubia, F.</style></author><author><style face="normal" font="default" size="100%">Garcia-Sanchez, J.</style></author><author><style face="normal" font="default" size="100%">Polo, V.</style></author><author><style face="normal" font="default" size="100%">Martinez De La Casa, J. M.</style></author><author><style face="normal" font="default" size="100%">Soto, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Ophthalmology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Ophthalmology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">316-321</style></pages><volume><style face="normal" font="default" size="100%">93</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cloprostenol [adverse effects] [analogs &amp; derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Conjunctival Diseases [chemically induced] [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">derivatives [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperemia [chemically induced] [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins, Synthetic [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins F, Synthetic [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009103839</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009103839/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>642</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">642</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hooper, Lee</style></author><author><style face="normal" font="default" size="100%">Bartlett, Christopher</style></author><author><style face="normal" font="default" size="100%">Davey Smith, George</style></author><author><style face="normal" font="default" size="100%">Ebrahim, Shah</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Advice to reduce dietary salt for prevention of cardiovascular disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003656</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Restricting sodium intake in hypertensive patients over short periods of time reduces blood pressure. Long term effects (on mortality, morbidity or blood pressure) of advice to reduce salt in patients with elevated or normal blood pressure are unclear.Objectives: To assess in adults the long term effects (mortality, cardiovascular events, blood pressure, quality of life, weight, urinary sodium excretion, other nutrients and use of anti-hypertensive medications) of advice to restrict dietary sodium using all relevant randomised controlled trials.Search methods: The Cochrane Library, MEDLINE, EMBASE, bibliographies of included studies and related systematic reviews were searched for unconfounded randomised trials in healthy adults aiming to reduce sodium intake over at least 6 months. Attempts were made to trace unpublished or missed studies and authors of all included trials were contacted. There were no language restrictions.Selection criteria: Inclusion decisions were independently duplicated and based on the following criteria: 1) randomisation was adequate; 2) there was a usual or control diet group; 3) the intervention aimed to reduce sodium intake; 4) the intervention was not multifactorial; 5) the participants were not children, acutely ill, pregnant or institutionalised; 6) follow-up was at least 26 weeks; 7) data on any of the outcomes of interest were available.Data collection and analysis: Decisions on validity and data extraction were made independently by two reviewers, disagreements were resolved by discussion or if necessary by a third reviewer. Random effects meta-analysis, sub-grouping, sensitivity analysis and meta-regression were performed.Main results: Three trials in normotensives (n=2326), five in untreated hypertensives (n=387) and three in treated hypertensives (n=801) were included, with follow up from six months to seven years. The large, high quality (and therefore most informative) studies used intensive behavioural interventions.Deaths and cardiovascular events were inconsistently defined and reported; only 17 deaths equally distributed between intervention and control groups occurred. Systolic and diastolic blood pressures were reduced at 13 to 60 months in those given low sodium advice as compared with controls (systolic by 1.1 mm Hg, 95% CI 1.8 to 0.4, diastolic by 0.6 mm hg, 95% CI 1.5 to -0.3), as was urinary 24 hour sodium excretion (by 35.5 mmol/ 24 hours, 95% CI 47.2 to 23.9). Degree of reduction in sodium intake and change in blood pressure were not related. People on anti-hypertensive medications were able to stop their medication more often on a reduced sodium diet as compared with controls, while maintaining similar blood pressure control.Authors&apos; conclusions: Intensive interventions, unsuited to primary care or population prevention programmes, provide only minimal reductions in blood pressure during long-term trials. Further evaluations to assess effects on morbidity and mortality outcomes are needed for populations as a whole and for patients with elevated blood pressure.A low sodium diet may help in maintenance of lower blood pressure following withdrawal of antihypertensives. If this is confirmed, with no increase in cardiovascular events, then targeting of comprehensive dietary and behavioural programmes in patients with elevated blood pressure requiring drug treatment would be justified.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003656.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003656.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>643</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">643</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hooper, Lee</style></author><author><style face="normal" font="default" size="100%">Summerbell Carolyn, D.</style></author><author><style face="normal" font="default" size="100%">Thompson, Rachel</style></author><author><style face="normal" font="default" size="100%">Sills, Deirdre</style></author><author><style face="normal" font="default" size="100%">Roberts Felicia, G.</style></author><author><style face="normal" font="default" size="100%">Moore Helen, J.</style></author><author><style face="normal" font="default" size="100%">Davey Smith, George</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reduced or modified dietary fat for preventing cardiovascular disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Fat-Restricted [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Fats [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Fats, Unsaturated [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Triglycerides [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD002137</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Reduction and modification of dietary fats have differing effects on cardiovascular risk factors (such as serum cholesterol), but their effects on important health outcomes are less clear.Objectives: To assess the effect of reduction and/or modification of dietary fats on mortality, cardiovascular mortality, cardiovascular morbidity and individual outcomes including myocardial infarction, stroke and cancer diagnoses in randomised clinical trials of at least 6 months duration.Search methods: For this review update, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE, were searched through to June 2010. References of Included studies and reviews were also checked.Selection criteria: Trials fulfilled the following criteria: 1) randomised with appropriate control group, 2) intention to reduce or modify fat or cholesterol intake (excluding exclusively omega-3 fat interventions), 3) not multi factorial, 4) adult humans with or without cardiovascular disease, 5) intervention at least six months, 6) mortality or cardiovascular morbidity data available.Data collection and analysis: Participant numbers experiencing health outcomes in each arm were extracted independently in duplicate and random effects meta-analyses, meta-regression, sub-grouping, sensitivity analyses and funnel plots were performed.Main results: This updated review suggested that reducing saturated fat by reducing and/or modifying dietary fat reduced the risk of cardiovascular events by 14% (RR 0.86, 95% CI 0.77 to 0.96, 24 comparisons, 65,508 participants of whom 7% had a cardiovascular event, I2 50%). Subgrouping suggested that this reduction in cardiovascular events was seen in studies of fat modification (not reduction - which related directly to the degree of effect on serum total and LDL cholesterol and triglycerides), of at least two years duration and in studies of men (not of women). There were no clear effects of dietary fat changes on total mortality (RR 0.98, 95% CI 0.93 to 1.04, 71,790 participants) or cardiovascular mortality (RR 0.94, 95% CI 0.85 to 1.04, 65,978 participants). This did not alter with sub-grouping or sensitivity analysis.Few studies compared reduced with modified fat diets, so direct comparison was not possible.Authors&apos; conclusions: The findings are suggestive of a small but potentially important reduction in cardiovascular risk on modification of dietary fat, but not reduction of total fat, in longer trials. Lifestyle advice to all those at risk of cardiovascular disease and to lower risk population groups, should continue to include permanent reduction of dietary saturated fat and partial replacement by unsaturates. The ideal type of unsaturated fat is unclear.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002137.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD002137.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>644</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">644</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Horjus Deborah, L.</style></author><author><style face="normal" font="default" size="100%">Oudman, Inge</style></author><author><style face="normal" font="default" size="100%">van Montfrans Gert, A.</style></author><author><style face="normal" font="default" size="100%">Brewster Lizzy, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Creatine and creatine analogues in hypertension and cardiovascular disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Creatine [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Creatine Kinase [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Targeted Therapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Ischemia [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphocreatine [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005184</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: The creatine kinase system, the central regulatory system of cellular energy metabolism, provides ATP in situ at ATP-ases involved in ion transport and muscle contraction. Furthermore, the enzyme system provides relative protection from tissue ischaemia and acidosis. The system could therefore be a target for pharmacologic intervention.Objectives: To systematically evaluate evidence regarding the effectiveness of interventions directly targeting the creatine kinase system as compared to placebo control in adult patients with essential hypertension or cardiovascular disease.Search methods: Electronic databases searched: Medline (1950 - Feb 2011), Embase (up to Feb 2011), the Cochrane Controlled Trials Register (issue 3, Aug 2009), Latin-American/Caribbean databank Lilacs; references from textbooks and reviews; contact with experts and pharmaceutical companies; and searching the Internet. There was no language restriction.Selection criteria: Randomized controlled trials comparing creatine, creatine phosphate, or cyclocreatine (any route, dose or duration of treatment) with placebo; in adult patients with essential hypertension, heart failure, or myocardial infarction. We did not include papers on the short-term use of creatine during cardiac surgery.Data collection and analysis: The outcomes assessed were death, total myocardial infarction (fatal or non-fatal), hospitalizations for congestive heart failure, change in ejection fraction, and changes in diastolic and systolic blood pressure in mm Hg or as percent change.Main results: Full reports or abstracts from 1164 papers were reviewed, yielding 11 trials considering treatment with creatine or creatine analogues in 1474 patients with heart failure, ischemic heart disease or myocardial infarction. No trial in patients with hypertension was identified. Eleven trials (1474 patients, 35 years or older) comparing add-on therapy of the creatine-based drug on standard treatment to placebo control in patients with heart failure (6 trials in 1226 / 1474 patients ), or acute myocardial infarction (4 trials in 220 / 1474 patients) or 1 in ischemic heart disease (28 / 1474 patients) were identified. The drugs used were either creatine, creatine phosphate (orally, intravenously, or intramuscular) or phosphocreatinine. In the trials considering heart failure all three different compounds were studied; creatine orally (Gordon 1995, Kuethe 2006), creatine phosphate via intravenous infusion (Ferraro 1996, Grazioli 1992), and phosphocreatinine orally (Carmenini 1994, Maggi 1990). In contrast, the acute myocardial infarction trials studied intravenous creatine phosphate only. In the ischemic heart disease trial (Pedone 1984) creatine phosphate was given twice daily through an intramuscular injection to outpatients and through an intravenous infusion to inpatients. The duration of the study intervention was shorter for the acute patients, from a two hour intravenous infusion of creatine phosphate in acute myocardial infarction (Ruda 1988, Samarenko 1987), to six months in patients with heart failure on oral phosphocreatinine therapy (Carmenini 1994). In the acute myocardial infarction patients the follow-up period varied from the acute treatment period (Ruda 1988) to 28 days after start of the symptoms (Samarenko 1987) or end of the hospitalization period (Zochowski 1994). In the other trials there was no follow-up after discontinuation of treatment, except for Gordon 1995 which followed the patients until four days after stopping the intervention.Only two out of four trials in patients with acute myocardial infarction reported mortality outcomes, with no significant effect of creatine or creatine analogues (RR 0.73, CI: 0.22 - 2.45). In addition, there was no significance on the progression of myocardial infarction or improvement on ejection fraction. The main effect of the interventions seems to be on improvement of dysrhythmia.Authors&apos; conclusions: This review found inconclusive evidence to decide on the use of creatine analogues in clinical practice. In particular, it is ot clear whether there is an effect on mortality, progression of myocardial infarction and ejection fraction, while there is some evidence that dysrhythmia and dyspnoea might improve. However, it is not clear which analogue, dose, route of administration, and duration of therapy is most effective. Moreover, given the small sample size of the discussed trials and the heterogeneity of the population included in these reports, larger clinical studies are needed to confirm these observations.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005184.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005184.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>175</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">175</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Horvath, K.</style></author><author><style face="normal" font="default" size="100%">Jeitler, K.</style></author><author><style face="normal" font="default" size="100%">Siering, U.</style></author><author><style face="normal" font="default" size="100%">Stich, A. K.</style></author><author><style face="normal" font="default" size="100%">Skipka, G.</style></author><author><style face="normal" font="default" size="100%">Gratzer, T. W.</style></author><author><style face="normal" font="default" size="100%">Siebenhofer, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">571-580</style></pages><volume><style face="normal" font="default" size="100%">168</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Appetite Depressants [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclobutanes [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Lactones [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008008117</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008008117/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>645</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">645</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hróbjartsson, Asbjørn</style></author><author><style face="normal" font="default" size="100%">Gøtzsche Peter, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Placebo interventions for all clinical conditions</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Placebo Effect</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Pain [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Refusal to Treat</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Commun</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003974</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Placebo interventions are often claimed to substantially improve patient-reported and observer-reported outcomes in many clinical conditions, but most reports on effects of placebos are based on studies that have not randomised patients to placebo or no treatment. Two previous versions of this review from 2001 and 2004 found that placebo interventions in general did not have clinically important effects, but that there were possible beneficial effects on patient-reported outcomes, especially pain. Since then several relevant trials have been published.Objectives: Our primary aims were to assess the effect of placebo interventions in general across all clinical conditions, and to investigate the effects of placebo interventions on specific clinical conditions. Our secondary aims were to assess whether the effect of placebo treatments differed for patient-reported and observer-reported outcomes, and to explore other reasons for variations in effect.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library Issue 4, 2007), MEDLINE (1966 to March 2008), EMBASE (1980 to March 2008), PsycINFO (1887 to March 2008) and Biological Abstracts (1986 to March 2008). We contacted experts on placebo research, and read references in the included trials.Selection criteria: We included randomised placebo trials with a no-treatment control group investigating any health problem.Data collection and analysis: Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information. Trials with binary data were summarised using relative risk (a value of less than 1 indicates a beneficial effect of placebo), and trials with continuous outcomes were summarised using standardised mean difference (a negative value indicates a beneficial effect of placebo).Main results: Outcome data were available in 202 out of 234 included trials, investigating 60 clinical conditions. We regarded the risk of bias as low in only 16 trials (8%), five of which had binary outcomes.In 44 studies with binary outcomes (6041 patients), there was moderate heterogeneity (P &lt; 0.001; I2 45%) but no clear difference in effects between small and large trials (symmetrical funnel plot). The overall pooled effect of placebo was a relative risk of 0.93 (95% confidence interval (CI) 0.88 to 0.99). The pooled relative risk for patient-reported outcomes was 0.93 (95% CI 0.86 to 1.00) and for observer-reported outcomes 0.93 (95% CI 0.85 to 1.02). We found no statistically significant effect of placebo interventions in four clinical conditions that had been investigated in three trials or more: pain, nausea, smoking, and depression, but confidence intervals were wide. The effect on pain varied considerably, even among trials with low risk of bias.In 158 trials with continuous outcomes (10,525 patients), there was moderate heterogeneity (P &lt; 0.001; I2 42%), and considerable variation in effects between small and large trials (asymmetrical funnel plot). It is therefore a questionable procedure to pool all the trials, and we did so mainly as a basis for exploring causes for heterogeneity. We found an overall effect of placebo treatments, standardised mean difference (SMD) -0.23 (95% CI -0.28 to -0.17). The SMD for patient-reported outcomes was -0.26 (95% CI -0.32 to -0.19), and for observer-reported outcomes, SMD -0.13 (95% CI -0.24 to -0.02). We found an effect on pain, SMD -0.28 (95% CI -0.36 to -0.19)); nausea, SMD -0.25 (-0.46 to -0.04)), asthma (-0.35 (-0.70 to -0.01)), and phobia (SMD -0.63 (95% CI -1.17 to -0.08)). The effect on pain was very variable, also among trials with low risk of bias. Four similarly-designed acupuncture trials conducted by an overlapping group of authors reported large effects (SMD -0.68 (-0.85 to -0.50)) whereas three other pain trials reported low or no effect (SMD -0.13 (-0.28 to 0.03)). The pooled effect on nausea was small, but consistent. The effects on phobia and asthma were very uncertain due to high risk of bias. There was no statist cally significant effect of placebo interventions in the seven other clinical conditions investigated in three trials or more: smoking, dementia, depression, obesity, hypertension, insomnia and anxiety, but confidence intervals were wide.Meta-regression analyses showed that larger effects of placebo interventions were associated with physical placebo interventions (e.g. sham acupuncture), patient-involved outcomes (patient-reported outcomes and observer-reported outcomes involving patient cooperation), small trials, and trials with the explicit purpose of studying placebo. Larger effects of placebo were also found in trials that did not inform patients about the possible placebo intervention.Authors&apos; conclusions: We did not find that placebo interventions have important clinical effects in general. However, in certain settings placebo interventions can influence patient-reported outcomes, especially pain and nausea, though it is difficult to distinguish patient-reported effects of placebo from biased reporting. The effect on pain varied, even among trials with low risk of bias, from negligible to clinically important. Variations in the effect of placebo were partly explained by variations in how trials were conducted and how patients were informed.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003974.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003974.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>176</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">176</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hudon, C.</style></author><author><style face="normal" font="default" size="100%">Fortin, M.</style></author><author><style face="normal" font="default" size="100%">Soubhi, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Single risk factor interventions to promote physical activity among patients with chronic diseases: systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Canadian Family Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Canadian Family Physician</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1130-1137</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [diagnosis] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [diagnosis] [rehabilitation]</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperlipidemias [diagnosis] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Intervention Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Diseases [diagnosis] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity [diagnosis] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Physical Fitness [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009100610</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009100610/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>177</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">177</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hughes, D.</style></author><author><style face="normal" font="default" size="100%">Ladas, E.</style></author><author><style face="normal" font="default" size="100%">Rooney, D.</style></author><author><style face="normal" font="default" size="100%">Kelly, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Massage therapy as a supportive care intervention for children with cancer (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Oncology Nursing Forum</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Oncology Nursing Forum</style></full-title></periodical><pages><style face="normal" font="default" size="100%">431-442</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anxiety [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Child Psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Constipation [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Depression [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Feasibility Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Massage [methods] [nursing] [psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [complications] [immunology] [nursing] [psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Nurse&apos;s Role</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Evaluation Research</style></keyword><keyword><style face="normal" font="default" size="100%">Oncology Nursing [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Pain [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Pediatric Nursing [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Psychoneuroimmunology</style></keyword><keyword><style face="normal" font="default" size="100%">Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Social Support</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Psychological [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008104200</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008104200/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>646</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">646</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hughes Richard, A. C.</style></author><author><style face="normal" font="default" size="100%">van Doorn Pieter, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Corticosteroids for Guillain-Barré syndrome</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenocorticotropic Hormone [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glucocorticoids [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Guillain-Barre Syndrome [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Methylprednisolone [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Prednisolone [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neuromusc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD001446</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Guillain-Barré syndrome (GBS) is an acute paralysing disease caused by inflammation of the peripheral nerves, which corticosteroids would be expected to benefit.Objectives: To examine the ability of corticosteroids to hasten recovery and reduce the long-term morbidity from GBS.Search methods: We searched The Cochrane Neuromuscular Disease Group Specialized Register (1 November 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 4), CENTRAL (2011, Issue 4), MEDLINE (January 1966 to October 2011) and EMBASE (January 1980 to October 2011).Selection criteria: We included randomised controlled trials (RCTs) or quasi-RCTs of any form of corticosteroid or adrenocorticotrophic hormone in GBS. Our primary outcome was change in disability grade on a seven-point scale after four weeks. Secondary outcomes included time from randomisation until recovery of unaided walking, time from randomisation until discontinuation of ventilation (for those ventilated), death, death or disability (inability to walk without aid) after 12 months, relapse, and adverse events.Data collection and analysis: Two authors extracted the data independently.Main results: No new trials were discovered in the new searches in June 2009 or November 2011. Six trials with 587 participants provided data for the primary outcome. According to moderate quality evidence, the disability grade change after four weeks in the corticosteroid groups was not significantly different from that in the control groups, mean difference (MD) 0.36 less improvement (95% confidence intervals (CI) 0.16 more to 0.88 less improvement). In four trials of oral corticosteroids with 120 participants in total, there was significantly less improvement after four weeks with corticosteroids than without corticosteroids, MD 0.82 disability grades less improvement (95% CI 0.17 to 1.47). In two trials with a combined total of 467 participants, there was no significant difference, MD 0.17 (95% CI -0.06 to 0.39) of a disability grade more improvement after four weeks with intravenous corticosteroids. According to moderate to high quality evidence, there were no significant differences between the corticosteroid-treated and the control groups in any of the secondary efficacy outcomes. Diabetes was significantly more common and hypertension significantly much less common in the corticosteroid-treated participants.Authors&apos; conclusions: According to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome. According to low quality evidence oral corticosteroids delay recovery. Diabetes requiring insulin was significantly more common and hypertension less common with corticosteroids.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001446.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001446.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>178</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">178</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hur, M. H.</style></author><author><style face="normal" font="default" size="100%">Lee, M. S.</style></author><author><style face="normal" font="default" size="100%">Kim, C.</style></author><author><style face="normal" font="default" size="100%">Ernst, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Aromatherapy for treatment of hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Evaluation in Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Evaluation in Clinical Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">37-41</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aromatherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012002843</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012002843/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>179</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">179</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hussain, S. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Progestogen-only pills and high blood pressure: is there an association? A literature review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Contraception</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contraception</style></full-title></periodical><pages><style face="normal" font="default" size="100%">89-97</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptives, Oral, Combined [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Progestins [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">PubMed</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004000447</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004000447/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>647</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">647</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iared, Wagner</style></author><author><style face="normal" font="default" size="100%">Mourão José, Eduardo</style></author><author><style face="normal" font="default" size="100%">Puchnick, Andrea</style></author><author><style face="normal" font="default" size="100%">Soma, Fernando</style></author><author><style face="normal" font="default" size="100%">Shigueoka David, Carlos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angioplasty versus stenting for subclavian artery stenosis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Subclavian Steal Syndrome [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Pvd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008461</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: There is insufficient evidence to guide stent usage following angioplasty in subclavian artery stenosis. This is an update of a review first published in 2011.Objectives: The aim of this review was to determine whether stenting is more effective than angioplasty alone for stenosis of the subclavian artery.Search methods: For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched February 2014) and CENTRAL (2014, Issue 1). There was no restriction on language.Selection criteria: Randomised controlled trials of endovascular treatment of subclavian artery lesions comparing angioplasty alone and stent implantation.Data collection and analysis: Two authors independently evaluated studies to assess eligibility. Discrepancies were resolved by discussion. If there was no agreement, the third author was asked to assess the study for inclusion.Main results: To date we have not identified any completed or ongoing randomised controlled trials comparing percutaneous transluminal angioplasty and stenting for subclavian artery stenosis.Authors&apos; conclusions: There is currently insufficient evidence to determine whether stenting is more effective than angioplasty alone for stenosis of the subclavian artery.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008461.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008461.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>648</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">648</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im, Gesundheitswesen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation of the benefits and harms of non-drug treatment strategies in patients with essential hypertension: weight reduction (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss [physiology]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32007000036</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32007000036/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>180</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">180</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iordanous, Y.</style></author><author><style face="normal" font="default" size="100%">Seymour, N.</style></author><author><style face="normal" font="default" size="100%">Young, A.</style></author><author><style face="normal" font="default" size="100%">Johnson, J.</style></author><author><style face="normal" font="default" size="100%">Iansavichus, A. V.</style></author><author><style face="normal" font="default" size="100%">Cuerden, M. S.</style></author><author><style face="normal" font="default" size="100%">Gill, J. S.</style></author><author><style face="normal" font="default" size="100%">Poggio, E.</style></author><author><style face="normal" font="default" size="100%">Garg, A. X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Recipient outcomes for expanded criteria living kidney donors: the disconnect between current evidence and practice (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Transplantation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Transplantation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1558-1573</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Graft Survival</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Living Donors</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Tissue and Organ Procurement [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009107319</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009107319/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>649</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">649</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IqwiG,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Different antihypertensive drugs as first-line therapy in patients with essential hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000644</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000644/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>650</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">650</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IqwiG,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reduction of salt intake in essential hypertension - rapid report (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000654</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000654/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>651</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">651</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IqwiG,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increase of physical activity in essential hypertension - rapid report (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32011000005</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32011000005/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>652</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">652</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IqwiG,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Drug treatment of hypertension - update search (rapid report) (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32011000002</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32011000002/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>653</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">653</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IqwiG,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cessation of smoking in essential hypertension - Rapid report (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Smoking</style></keyword><keyword><style face="normal" font="default" size="100%">Smoking Cessation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000383</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000383/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>654</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">654</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IqwiG,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Stress-coping interventions in essential hypertension - Rapid report (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adaptation, Psychological</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Psychological</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000382</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000382/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>655</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">655</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IqwiG,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Benefit assessment of non-drug treatment strategies in patients with essential hypertension: special diets without the primary aim of reducing weight or salt intake - rapid report (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diet, Reducing</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000385</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000385/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>656</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">656</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IqwiG,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Benefit assessment of long-term lowering of blood pressure to levels in the lower normal range in patients with diabetes mellitus - rapid report (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000386</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000386/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>657</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">657</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IqwiG,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reduction of alcohol consumption in essential hypertension - Rapid report (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alcohol Drinking</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000381</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000381/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>658</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">658</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IqwiG,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Macitentan: assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrimidines</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32014000721</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32014000721/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>181</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">181</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ishikawa, J.</style></author><author><style face="normal" font="default" size="100%">Carroll, D. J.</style></author><author><style face="normal" font="default" size="100%">Kuruvilla, S.</style></author><author><style face="normal" font="default" size="100%">Schwartz, J. E.</style></author><author><style face="normal" font="default" size="100%">Pickering, T. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">856-864</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Ambulatory Care Facilities</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Circadian Rhythm [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009101416</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009101416/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>182</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">182</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iyer, S.</style></author><author><style face="normal" font="default" size="100%">Naganathan, V.</style></author><author><style face="normal" font="default" size="100%">McLachlan, A. J.</style></author><author><style face="normal" font="default" size="100%">Couteur, D. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Medication withdrawal trials in people aged 65 years and older: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs and Aging</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs and Aging</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1021-1031</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug-Related Side Effects and Adverse Reactions</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceutical Preparations [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Psychotropic Drugs [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Substance Withdrawal Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009101728</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009101728/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>183</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">183</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jaana, M.</style></author><author><style face="normal" font="default" size="100%">Pare, G.</style></author><author><style face="normal" font="default" size="100%">Sicotte, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hypertension home telemonitoring: current evidence and recommendations for future studies (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Disease Management and Health Outcomes</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Disease Management and Health Outcomes</style></full-title></periodical><pages><style face="normal" font="default" size="100%">19-31</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Telemedicine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007009162</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007009162/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>184</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">184</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jager, R. D.</style></author><author><style face="normal" font="default" size="100%">Aiello, L. P.</style></author><author><style face="normal" font="default" size="100%">Patel, S. C.</style></author><author><style face="normal" font="default" size="100%">Cunningham, E. T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Risks of intravitreous injection: a comprehensive review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Retina</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Retina</style></full-title></periodical><pages><style face="normal" font="default" size="100%">676-698</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cataract [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Endophthalmitis [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Eye Diseases [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Eye Hemorrhage [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Injections [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Iritis [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceutical Preparations [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Retinal Detachment [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Uveitis [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Vitreous Body</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004001947</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004001947/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>185</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">185</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Janda, S.</style></author><author><style face="normal" font="default" size="100%">Shahidi, N.</style></author><author><style face="normal" font="default" size="100%">Gin, K.</style></author><author><style face="normal" font="default" size="100%">Swiston, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Heart</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Heart</style></full-title></periodical><pages><style face="normal" font="default" size="100%">612-622</style></pages><volume><style face="normal" font="default" size="100%">97</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiac Catheterization</style></keyword><keyword><style face="normal" font="default" size="100%">Echocardiography, Doppler</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiologic Methods</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [diagnosis] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011002753</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011002753/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>186</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">186</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jang, Y.</style></author><author><style face="normal" font="default" size="100%">Yoo, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Self-management programs based on the social cognitive theory for Koreans with chronic disease: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Contemporary Nurse</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contemporary Nurse</style></full-title></periodical><pages><style face="normal" font="default" size="100%">147-59</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease [psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [psychology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [psychology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Psychological</style></keyword><keyword><style face="normal" font="default" size="100%">Republic of Korea</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Self Efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012026487</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012026487/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>187</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">187</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Janssen, I.</style></author><author><style face="normal" font="default" size="100%">LeBlanc, A. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review of the health benefits of physical activity and fitness in school-aged children and youth (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Behavioral Nutrition and Physical Activity</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Behavioral Nutrition and Physical Activity</style></full-title></periodical><volume><style face="normal" font="default" size="100%">7:40</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bone Density</style></keyword><keyword><style face="normal" font="default" size="100%">Depressive Disorder, Major</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hypercholesterolemia</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolic Syndrome X</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity</style></keyword><keyword><style face="normal" font="default" size="100%">Physical Fitness</style></keyword><keyword><style face="normal" font="default" size="100%">Wounds and Injuries</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010005701</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010005701/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>659</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">659</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jaturapatporn, Darin</style></author><author><style face="normal" font="default" size="100%">Isaac Mokhtar Gad El Kareem, Nasr</style></author><author><style face="normal" font="default" size="100%">McCleery, Jenny</style></author><author><style face="normal" font="default" size="100%">Tabet, Naji</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer Disease [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclooxygenase 2 Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glucocorticoids [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006378</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Alzheimer?s disease (AD) is the most common form of dementia. The incidence of AD rises exponentially with age and its prevalence will increase significantly worldwide in the next few decades. Inflammatory processes have been suspected in the pathogenesis of the disease.Objectives: To review the efficacy and side effects of aspirin, steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of AD, compared to placebo.Search methods: We searched ALOIS: the Cochrane Dementia and Cognitive Improvement Group?s Specialized Register on 12 April 2011 using the terms: aspirin OR &quot;cyclooxygenase 2 inhibitor&quot; OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR &quot;anti-inflammatory&quot; OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR NSAIDS OR NSAID. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (including MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS), numerous trial registries (including national, international and pharmacuetical registries) and grey literature sources.Selection criteria: All randomised controlled trials assessing the efficacy of aspirin, steroidal and non-steroidal anti-inflammatory drugs in AD.Data collection and analysis: One author assessed risk of bias of each study and extracted data. A second author verified data selection.Main results: Our search identified 604 potentially relevant studies. Of these, 14 studies (15 interventions) were RCTs and met our inclusion criteria. The numbers of participants were 352, 138 and 1745 for aspirin, steroid and NSAIDs groups, respectively. One selected study comprised two separate interventions. Interventions assessed in these studies were grouped into four categories: aspirin (three interventions), steroids (one intervention), traditional NSAIDs (six interventions), and selective cyclooxygenase-2 (COX-2) inhibitors (five interventions). All studies were evaluated for internal validity using a risk of bias assessment tool. The risk of bias was low for five studies, high for seven studies, and unclear for two studies.There was no significant improvement in cognitive decline for aspirin, steroid, traditional NSAIDs and selective COX-2 inhibitors. Compared to controls, patients receiving aspirin experienced more bleeding while patients receiving steroid experienced more hyperglycaemia, abnormal lab results and face edema. Patients receiving NSAIDs experienced nausea, vomiting, elevated creatinine, elevated LFT and hypertension. A trend towards higher death rates was observed among patients treated with NSAIDS compared with placebo and this was somewhat higher for selective COX-2 inhibitors than for traditional NSAIDs.Authors&apos; conclusions: Based on the studies carried out so far, the efficacy of aspirin, steroid and NSAIDs (traditional NSAIDs and COX-2 inhibitors) is not proven. Therefore, these drugs cannot be recommended for the treatment of AD.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006378.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006378.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>188</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">188</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jayalath, V. H.</style></author><author><style face="normal" font="default" size="100%">Souza, R. J.</style></author><author><style face="normal" font="default" size="100%">Sievenpiper, J. L.</style></author><author><style face="normal" font="default" size="100%">Ha, V.</style></author><author><style face="normal" font="default" size="100%">Chiavaroli, L.</style></author><author><style face="normal" font="default" size="100%">Mirrahimi, A.</style></author><author><style face="normal" font="default" size="100%">Buono, M.</style></author><author><style face="normal" font="default" size="100%">Bernstein, A. M.</style></author><author><style face="normal" font="default" size="100%">Leiter, L. A.</style></author><author><style face="normal" font="default" size="100%">Kris-Etherton, P. M.</style></author><author><style face="normal" font="default" size="100%">Vuksan, V.</style></author><author><style face="normal" font="default" size="100%">Beyene, J.</style></author><author><style face="normal" font="default" size="100%">Kendall, C. W.</style></author><author><style face="normal" font="default" size="100%">Jenkins, D. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of dietary pulses on blood pressure: a systematic review and meta-analysis of controlled feeding trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">56-64</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Fabaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013053570</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013053570/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>660</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">660</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jenks, Sara</style></author><author><style face="normal" font="default" size="100%">Yeoh Su, Ern</style></author><author><style face="normal" font="default" size="100%">Conway Bryan, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Balloon angioplasty, with and without stenting, versus medical therapy for hypertensive patients with renal artery stenosis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty, Balloon</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Pvd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD002944</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Atherosclerotic renal artery stenosis is the most common cause of secondary hypertension. Balloon angioplasty with stenting is widely used for the treatment of hypertensive patients with renal artery stenosis but the effectiveness of this procedure in treating hypertension, improving renal function and preventing adverse cardiovascular and renal events remains uncertain. This is an update, to include the results of recent, important large trials, of a review first published in 2003.Objectives: To compare the effectiveness of balloon angioplasty (with and without stenting) with medical therapy for the treatment of atherosclerotic renal artery stenosis in patients with hypertension. The following outcomes were compared: blood pressure control, renal function, frequency of cardiovascular and renal adverse events, presence or absence of restenosis of the renal artery, side effects of medical therapy, numbers and defined daily doses of antihypertensive drugs.Search methods: For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched May 2014) and CENTRAL (2014, Issue 4). Bibliographies were also reviewed and trial authors were contacted for more information.Selection criteria: Randomised controlled trials (RCTs) comparing balloon angioplasty with medical therapy in hypertensive patients with haemodynamically significant renal artery stenosis (greater than 50% reduction in luminal diameter) and with a minimum follow-up of six months.Data collection and analysis: Data were extracted independently on trial design, participants, interventions and outcome measures. A formal meta-analysis was completed to assess the effect on blood pressure, renal function and cardiovascular and renal adverse events. Peto&apos;s odds ratios (ORs) and corresponding 95% confidence intervals (CI) for dichotomous outcomes and mean differences (MD) and corresponding 95% CIs for continuous variables were calculated.Main results: Eight RCTs involving 2222 participants with renal artery stenosis were included in the review. The overall quality of evidence included in this review was moderate. Limited pooling of results was possible due to the variable presentation of some of the trial outcomes. Meta-analysis of the four studies reporting change in diastolic blood pressure (BP) found a small improvement in diastolic BP in the angioplasty group (MD -2.00 mmHg; 95% CI -3.72 to -0.27) whilst the meta-analysis of the five studies reporting change in systolic BP did not find any evidence of significant improvement (MD -1.07 mmHg; 95% CI -3.45 to 1.30). There was no significant effect on renal function as measured by serum creatinine (MD -7.99 µmol/L; 95% CI -22.6 to 6.62). Meta-analysis of the three studies that reported the mean number of antihypertensive drugs found a small decrease in antihypertensive drug requirements for the angioplasty group (MD -0.18; 95% CI -0.34 to -0.03). Repeat angiography was only performed on a small number of participants in a single trial and it was therefore not possible to comment on restenosis of the renal artery following balloon angioplasty. Based on the results of the seven studies that reported cardiovascular and renal clinical outcomes there were no differences in cardiovascular (OR 0.91; 95% CI 0.75 to 1.11) or renal adverse events (OR 1.02; 95% CI 0.75 to 1.38) between the angioplasty and medical treatment groups. A small number of procedural complications of balloon angioplasty were reported (haematoma at the site of catheter insertion (6.5%), femoral artery pseudoaneurysm (0.7%), renal artery or kidney perforation or dissection (2.5%) as well as peri-procedural deaths (0.4%)). No side effects of medical therapy were reported.Authors&apos; conclusions: The available data are insufficient to conclude that revascularisation in the form of balloon angioplasty, with or without stenting, is superior to medical therapy for the treatment of atherosclerotic renal artery stenosis in patients with hypertension. However, balloon angioplasty resu ts in a small improvement in diastolic blood pressure and a small reduction in antihypertensive drug requirements. Balloon angioplasty appears safe and results in similar numbers of cardiovascular and renal adverse events to medical therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002944.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD002944.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>661</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">661</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jin, Zhichao</style></author><author><style face="normal" font="default" size="100%">He, Jia</style></author><author><style face="normal" font="default" size="100%">Xie, Feng</style></author><author><style face="normal" font="default" size="100%">Liu, Shijian</style></author><author><style face="normal" font="default" size="100%">Zhou, Xiao-Hua</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin converting enzyme (ACE) gene polymorphism (ACEI/D) in hypertensive adults with ACE inhibitor-induced cough</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010310</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:The objective of this review is to evaluate the influence of polymorphisms of ACE gene on ACE inhibitor-induced cough in adults with primary hypertension.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010310/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010310</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>189</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">189</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Johnson, S. R.</style></author><author><style face="normal" font="default" size="100%">Brode, S. K.</style></author><author><style face="normal" font="default" size="100%">Mielniczuk, L. M.</style></author><author><style face="normal" font="default" size="100%">Granton, J. T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Dual therapy in IPAH and SSc-PAH. A qualitative systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Respiratory Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Respiratory Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">730-739</style></pages><volume><style face="normal" font="default" size="100%">106</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphodiesterase 5 Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins, Synthetic [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Endothelin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Scleroderma, Systemic [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012017824</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012017824/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>190</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">190</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Johnson, S. R.</style></author><author><style face="normal" font="default" size="100%">Mehta, S.</style></author><author><style face="normal" font="default" size="100%">Granton, J. T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Respiratory Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Respiratory Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">999-1004</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anticoagulants [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [blood] [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">International Normalized Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Warfarin [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007001096</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007001096/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>191</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">191</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Juraschek, S. P.</style></author><author><style face="normal" font="default" size="100%">Guallar, E.</style></author><author><style face="normal" font="default" size="100%">Appel, L. J.</style></author><author><style face="normal" font="default" size="100%">Miller, E. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1079-1088</style></pages><volume><style face="normal" font="default" size="100%">95</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Ascorbic Acid [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamins [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012023684</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012023684/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>662</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">662</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kahan, T.</style></author><author><style face="normal" font="default" size="100%">Dahlgren, H.</style></author><author><style face="normal" font="default" size="100%">Faire, U.</style></author><author><style face="normal" font="default" size="100%">Hedblad, B.</style></author><author><style face="normal" font="default" size="100%">Hjemdahl, P.</style></author><author><style face="normal" font="default" size="100%">Lindholm, L.</style></author><author><style face="normal" font="default" size="100%">Manheim, K.</style></author><author><style face="normal" font="default" size="100%">Persson, M.</style></author><author><style face="normal" font="default" size="100%">Ranzlov, E.</style></author><author><style face="normal" font="default" size="100%">Svardsudd, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Moderately elevated blood pressure (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">Swedish Council on Technology Assessment in Health Care (SBU)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000478</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000478/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>192</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">192</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kaiser, T.</style></author><author><style face="normal" font="default" size="100%">Florack, C.</style></author><author><style face="normal" font="default" size="100%">Stephan, U.</style></author><author><style face="normal" font="default" size="100%">Sawicki, P. T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Should BP targets be lower in diabetic patients with microalbuminuria or nephropathy: a systematic review of randomised controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Diabetes and Vascular Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Diabetes and Vascular Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">278-281</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Retinopathy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004005160</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004005160/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>193</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">193</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kamel, H.</style></author><author><style face="normal" font="default" size="100%">Navi, B. B.</style></author><author><style face="normal" font="default" size="100%">Nakagawa, K.</style></author><author><style face="normal" font="default" size="100%">Hemphill, J. C.</style></author><author><style face="normal" font="default" size="100%">Ko, N. U.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Critical Care Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Critical Care Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">554-559</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diuretics, Osmotic [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Mannitol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Saline Solution, Hypertonic [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011002010</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011002010/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>663</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">663</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kandler Michael, R.</style></author><author><style face="normal" font="default" size="100%">Mah Greg, T.</style></author><author><style face="normal" font="default" size="100%">Tejani Aaron, M.</style></author><author><style face="normal" font="default" size="100%">Stabler Sarah, N.</style></author><author><style face="normal" font="default" size="100%">Salzwedel Douglas, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hydralazine for essential hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydralazine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004934</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950&apos;s. Although it has largely been replaced by newer antihypertensive drugs with more acceptable tolerability profiles, hydralazine is still widely used in developing countries due to its lower cost. A review of its relative effectiveness compared to placebo on surrogate and clinical outcomes is justified.Objectives: To quantify the effect of hydralazine compared to placebo in randomized controlled trials (RCTs) on all cause mortality, cardiovascular mortality, serious adverse events, myocardial infarctions, strokes, withdrawals due to adverse effects and blood pressure in patients with primary hypertension.Search methods: We searched the following databases: Cochrane Central Register of Controlled Trials (2011, Issue 3), MEDLINE (1948-August 2011), International Pharmaceutical Abstracts (1970-June 2009) and EMBASE (1980-August 2011). Bibliographic citations from retrieved studies were also reviewed. No language restrictions were applied.Selection criteria: We selected RCTs studying the effect of oral hydralazine compared to oral placebo in patients with primary hypertension. We excluded studies of patients with secondary hypertension or gestational hypertension.Data collection and analysis: Two reviewers independently extracted data and assessed trial quality using the risk of bias tool. Data synthesis and analysis was performed using RevMan 5.Main results: The search strategy did not yield any randomized controlled trials comparing hydralazine to placebo for inclusion in this review. There is insufficient evidence to conclude on the effects of hydralazine versus placebo on mortality, morbidity, withdrawals due to adverse effects, serious adverse events, or systolic and diastolic blood pressure. Some of the adverse effects related to hydralazine that have been reported in the literature include reflex tachycardia, hemolytic anemia, vasculitis, glomerulonephritis, and a lupus-like syndrome.Authors&apos; conclusions: Hydralazine may reduce blood pressure when compared to placebo in patients with primary hypertension, however this data is based on before and after studies, not RCTs. Furthermore, its effect on clinical outcomes remains uncertain.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004934.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004934.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>664</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">664</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kanthapillai, Parthipan</style></author><author><style face="normal" font="default" size="100%">Walters, E. Haydn</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phosphodiesterase 5 inhibitors for pulmonary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">3&apos;,5&apos;-Cyclic-GMP Phosphodiesterases [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Purines</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003562</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Pulmonary Hypertension (PH) can be either of unknown aetiology (primary pulmonary hypertension (PPH)) or due to a known underlying cause (secondary pulmonary hypertension (SPH). Pulmonary arteriolar vasoconstriction is considered to be an important characteristic of PH. Therapies which aim to vasodilate are used to treat pulmonary hypertension.Objectives: To determine the clinical efficacy of sildenafil, a vasodilator which works through inhibition of the enzyme phosphodiesterase type V (PDE5I), administered via any route to people with pulmonary hypertension in primary or secondary forms.Search methods: MEDLINE, EMBASE and CENTRAL were searched with pre-defined search terms. Searches were current as of October 2006.Selection criteria: Randomised controlled trials were considered for inclusion in the review. We included studies which assessed the effects of sildenafil in participants with PPH and SPH.Data collection and analysis: Two reviewers independently assessed and extracted data from clinical trials. Data were entered in RevMan Analyses 1.0.2. Continuous data were pooled with an estimate on either WMD (weighted mean difference) or SMD (standardised mean difference) scales. Dichotomous data were pooled and a RR (relative risk) was calculated.Main results: Four studies recruiting 77 participants met the inclusion criteria of the review. Two studies assessed the acute effects of sildenafil. Two small crossover study assessed the effects of long term administration. The &apos;acute effect&apos; studies indicated that sildenafil has a pulmonary vasodilatory effect. The two crossover studies showed improvement in symptoms. One study showed improvement in fatigue domains from a validated health status questionnaire. Both crossover studies reported that the drug was well tolerated.Authors&apos; conclusions: The validity of the observed effects is undermined by small participant numbers and inadequate exploration of the different disease etiologies. The effects on long term outcome such as NYHA functional class, symptoms, mortality and exercise capacity require further validation. More studies of adequate size are required before the long term effects of sildenafil on clinically important outcomes can be established.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003562.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003562.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>194</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">194</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karkos, C. D.</style></author><author><style face="normal" font="default" size="100%">Menexes, G. C.</style></author><author><style face="normal" font="default" size="100%">Patelis, N.</style></author><author><style face="normal" font="default" size="100%">Kalogirou, T. E.</style></author><author><style face="normal" font="default" size="100%">Giagtzidis, I. T.</style></author><author><style face="normal" font="default" size="100%">Harkin, D. W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review and meta-analysis of abdominal compartment syndrome after endovascular repair of ruptured abdominal aortic aneurysms (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Vascular Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Vascular Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">829-842</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aortic Aneurysm, Abdominal [mortality] [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Aortic Rupture [mortality] [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Vessel Prosthesis Implantation [adverse effects] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Decompression, Surgical</style></keyword><keyword><style face="normal" font="default" size="100%">Drainage</style></keyword><keyword><style face="normal" font="default" size="100%">Endovascular Procedures [adverse effects] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Intra-Abdominal Hypertension [diagnosis] [etiology] [mortality] [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Nonlinear Dynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Reoperation</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014008089</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014008089/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>195</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">195</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karkos, C. D.</style></author><author><style face="normal" font="default" size="100%">Sutton, A. J.</style></author><author><style face="normal" font="default" size="100%">Bown, M. J.</style></author><author><style face="normal" font="default" size="100%">Sayers, R. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A meta-analysis and metaregression analysis of factors influencing mortality after endovascular repair of ruptured abdominal aortic aneurysms (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Vascular and Endovascular Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Vascular and Endovascular Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">775-786</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Aortic Aneurysm, Abdominal [mortality] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Aortic Rupture [mortality] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Vessel Prosthesis Implantation</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Intra-Abdominal Hypertension [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011007499</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011007499/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>665</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">665</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karpe Krishna, M.</style></author><author><style face="normal" font="default" size="100%">Talaulikar Girish, S.</style></author><author><style face="normal" font="default" size="100%">Walters, Giles</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006750</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:This review aims to look at the benefits and harms of calcineurin inhibitor tapering or withdrawal in terms of graft function and loss, incidence of acute rejection episodes, treatment-related side effects (hypertension, hyperlipidaemia) and mortality.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006750/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006750</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>196</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">196</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Katout, M.</style></author><author><style face="normal" font="default" size="100%">Zhu, H.</style></author><author><style face="normal" font="default" size="100%">Rutsky, J.</style></author><author><style face="normal" font="default" size="100%">Shah, P.</style></author><author><style face="normal" font="default" size="100%">Brook, R. D.</style></author><author><style face="normal" font="default" size="100%">Zhong, J.</style></author><author><style face="normal" font="default" size="100%">Rajagopalan, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">130-139</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biomimetic Materials</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013069731</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013069731/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>666</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">666</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kawaguchi, Atsushi</style></author><author><style face="normal" font="default" size="100%">Isayama, Tetsuya</style></author><author><style face="normal" font="default" size="100%">Mori, Rintaro</style></author><author><style face="normal" font="default" size="100%">Minami, Hirotaka</style></author><author><style face="normal" font="default" size="100%">Yang, Ying</style></author><author><style face="normal" font="default" size="100%">Tamura, Masanori</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hydralazine in infants with persistent hypoxemic respiratory failure</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anoxia [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydralazine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Insufficiency [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009449</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Most deaths of infants with chronic lung disease (CLD) are caused by respiratory failure, unremitting pulmonary artery hypertension (PAH) with cor pulmonale, or infection. Although the exact prevalence of PAH in infants with CLD is unknown, infants with CLD and severe PAH have a high mortality rate. Except for oxygen supplementation, no specific interventions have been established as effective in the treatment for PAH in premature infants with CLD. Little has been proven regarding the clinical efficacy of vasodilators and concerns remain regarding adverse effects.Objectives: To review current evidence for the benefits and harms of hydralazine therapy to infants with persistent hypoxemic respiratory failure.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE via PubMed and EMBASE, and other clinical trials registries through November 2011 using the standard search strategy of the Cochrane Neonatal Review Group. We searched these databases using a strategy combining a variation of the Cochrane highly sensitive search strategy for identifying randomised trials in MEDLINE; sensitivity-maximising version with selected MeSH and free-text terms: hydralazine, vasodilator agent, antihypertensive agent, heart diseases, lung diseases, respiratory tract diseases, infant, and randomised controlled trial.Selection criteria: We considered only randomised controlled trials and quasi-randomised trials for inclusion. We included low birth weight (LBW) infants with persistent hypoxemic respiratory failure who were treated with any type of hydralazine therapy.Data collection and analysis: Two review authors independently assessed trial quality according to pre-specified criteria.Main results: We found no studies meeting the criteria for inclusion in this review.Authors&apos; conclusions: There was insufficient evidence to determine the safety and efficacy of hydralazine in LBW infants with persistent hypoxemic respiratory failure. Since hydralazine is inexpensive and potentially beneficial, randomised controlled trials are recommended. Such trials are particularly needed in settings where other medications such as sildenafil, inhaled nitric oxide (iNO), or extracorporeal membrane oxygenation (ECMO) are not available.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009449.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009449.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>197</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">197</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khalesi, S.</style></author><author><style face="normal" font="default" size="100%">Sun, J.</style></author><author><style face="normal" font="default" size="100%">Buys, N.</style></author><author><style face="normal" font="default" size="100%">Jamshidi, A.</style></author><author><style face="normal" font="default" size="100%">Nikbakht-Nasrabadi, E.</style></author><author><style face="normal" font="default" size="100%">Khosravi-Boroujeni, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Green tea catechins and blood pressure: a systematic review and meta-analysis of randomised controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1299-1311</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Beverages</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Catechin</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Tea</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014034741</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014034741/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>667</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">667</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khasraw, Mustafa</style></author><author><style face="normal" font="default" size="100%">Ameratunga Malaka, S.</style></author><author><style face="normal" font="default" size="100%">Grant, Robin</style></author><author><style face="normal" font="default" size="100%">Wheeler, Helen</style></author><author><style face="normal" font="default" size="100%">Pavlakis, Nick</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antiangiogenic therapy for high-grade glioma</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Gynaeca</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008218</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: The most common primary brain tumours in adults are gliomas. Gliomas span a spectrum from low to high-grade and are graded pathologically on a scale of one to four according to the World Health Organization (WHO) classification. High-grade glioma (HGG) carries a poor prognosis. Grade IV glioma is known as glioblastoma (GBM) and carries a median survival in treated patients of about 15 months. GBMs are rich in blood vessels (i.e. highly vascular) and in a protein known as vascular endothelial growth factor (VEGF), which promotes new blood vessel formation (the process of angiogenesis). Antiangiogenic agents inhibit the process of new blood vessel formation and promote regression of existing vessels. Several antiangiogenic agents have been investigated in clinical trials in newly diagnosed and recurrent HGG, showing promising preliminary results. This review was undertaken to report on the benefits and harms associated with the use of antiangiogenic agents in the treatment of HGGs.Objectives: To evaluate the efficacy and toxicity of antiangiogenic therapy in patients with high-grade glioma. This intervention can be used in two broad groups of patients: those with first diagnosis as part of &apos;adjuvant&apos; therapy, and those with recurrent or progressive disease. Comparisons will include the following.? Treatment with antiangiogenic therapy versus placebo.? Treatment (such as chemotherapy or chemoradiotherapy) with antiangiogenic therapy added versus the same treatment without the addition of antiangiogenic therapy.Search methods: Searches were conducted to identify published and unpublished Randomised Controlled Trials (RCTs) starting in 2000; the following databases were searched: the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 3, 2014; MEDLINE to April 2014 and EMBASE to April 2014. Proceedings of relevant oncology conferences since 2000 were handsearched.Selection criteria: RCTs evaluating the use of antiangiogenic therapy versus control treatment without antiangiogenic therapy in the treatment of HGG.Data collection and analysis: Review authors screened the search results and reviewed the abstracts of potentially relevant articles before retrieving the full text of eligible articles.Main results: After a comprehensive literature search, seven eligible RCTs were identified (total of 2987 participants). Significant design heterogeneity was noted in the included studies, especially in the response assessment criteria used. All eligible studies were restricted to GBMs, and no eligible studies evaluated other HGGs. Four studies were available only in abstract form. We have reserved an overall assessment of the quality of the evidence until the final study publications are received. The three studies that have been published in full were judged to have low risk of bias. The seven trials of 2987 participants included in this systematic review did not show improvement in OS with the addition of antiangiogenic therapy (pooled hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.86 to 1.02; P value 0.16). However, pooled analysis of PFS from six studies (2847 participants) showed improvement in PFS with the addition of antiangiogenic therapy (HR 0.74, 95% CI 0.68 to 0.81; P value &lt; 0.00001). Bevacizumab was the antiangiogenic therapy more likely to yield favourable results. Pooled HR for PFS for bevacizumab studies (three studies with 1712 participants) was significant at 0.66 (95% CI 0.59 to 0.74; P value &lt; 0.00001), and this was reflected in the lower hazard ratio reported in the pooled analysis of bevacizumab studies compared with the overall analysis. Nevertheless, this finding was not significant for OS (HR 0.92, 95% CI 0.83 to 1.02; P value 0.12). Similar to trials of antiangiogenic therapies in other solid tumours, adverse events related to this class of therapy included hypertension and proteinuria, poor wound healing and the potential for thromboembolic events, although generally, the occurrence of grade 3 events of this kind was low (&lt; 14.1%), consistent with reported findings of studie of bevacizumab in other tumours.Authors&apos; conclusions: In patients with newly diagnosed GBM, the use of antiangiogenic therapy does not improve survival, despite evidence of improved progression-free survival. Thus at this time, evidence is insufficient to support the use of antiangiogenic therapy in patients with newly diagnosed GBM on the basis of effects on survival.Bevacizumab may confer a progression-free survival benefit in GBM; however evidence in favour of using other antiangiogenic therapies in recurrent GBM is insufficient.Although bevacizumab appears to prolong progression-free survival in newly diagnosed and recurrent GBM, the impact of this on quality of life remains unclear.Adequately powered, randomised, placebo-controlled studies of bevacizumab in recurrent GBM (or HGG) are needed.Not addressed here is whether subsets of patients with newly diagnosed GBM may benefit from antiangiogenic therapies and whether these therapies are useful in other high-grade glioma histologies.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008218.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008218.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>668</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">668</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khemani Robinder, G.</style></author><author><style face="normal" font="default" size="100%">Randolph, Adrienne</style></author><author><style face="normal" font="default" size="100%">Markovitz, Barry</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Ventilator Weaning</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Dexamethasone [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Respiration Disorders [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Respiration, Artificial [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Sounds [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD001000</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Post-extubation stridor may prolong length of stay in the intensive care unit, particularly if airway obstruction is severe and re-intubation proves necessary. Some clinicians use corticosteroids to prevent or treat post-extubation stridor, but corticosteroids may be associated with adverse effects ranging from hypertension to hyperglycaemia, so a systematic assessment of the efficacy of this therapy is indicated.Objectives: To determine whether corticosteroids are effective in preventing or treating post-extubation stridor in critically ill infants, children, or adults.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and reference lists of articles. The most recent searches were conducted in January 2011.Selection criteria: Randomized controlled trials comparing administration of corticosteroids by any route with placebo in infants, children, or adults receiving mechanical ventilation via an endotracheal tube in an intensive care unit.Data collection and analysis: Three review authors independently assessed trial quality and extracted data.Main results: Eleven trials involving 2301 people were included: six in adults, two in neonates, three in children. All but one examined use of steroids for the prevention of post-extubation stridor; the remaining one concerned treatment of existing post-extubation stridor in children. Patients were drawn from heterogeneous medical/surgical populations. Dexamethasone given intravenously at least once prior to extubation was the most common steroid regimen utilized (uniformly in neonates and children). In neonates the two studies found heterogeneous results, with no overall statistically significant reduction in post extubation stridor (RR 0.42; 95% CI 0.07 to 2.32). One of these studies was on high-risk patients treated with multiple doses of steroids around the time of extubation, and this study showed a significant reduction in stridor. In children, the two studies were clinically heterogeneous. One study included children with underlying airway abnormalities and the other excluded this group. Prophylactic corticosteroids tended to reduce reintubation and significantly reduced post-extubation stridor in the study that included children with underlying airway abnormalities (N = 62) but not in the study that excluded these children (N = 153). In six adult studies (total N = 1953), the use of prophylactic corticosteroid administration did not significantly reduce the risk of re-intubation (RR 0.48; 95% CI 0.19 to 1.22). While there was a significant reduction in the incidence of post extubation stridor (RR 0.47; 95% CI 0.22 to 0.99), there was significant heterogeneity (I2=81%, X2=26.36, df=5, p&lt;0.0001). Subgroup analysis revealed that post extubation stridor could be reduced in adults with a high likelihood of post extubation stridor when corticosteroids were administered as multiple doses begun 12-24 hours prior to extubation compared to single doses closer to extubation; the test for interaction for multiple versus single doses indicated RRR 0.22 (95% CI 0.10 to 0.47) for stridor with multiple doses. Side effects were uncommon and could not be aggregated.Authors&apos; conclusions: Using corticosteroids to prevent (or treat) stridor after extubation has not proven effective for neonates or children. However, given the consistent trends towards benefit, this intervention does merit further study, particularly for high risk children or neonates. In adults, multiple doses of corticosteroids begun 12-24 hours prior to extubation do appear beneficial for patients with a high likelihood of post extubation stridor.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001000.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001000.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>198</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">198</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, L. W.</style></author><author><style face="normal" font="default" size="100%">Zhu, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Acupuncture for essential hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Alternative Therapies in Health and Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Alternative Therapies in Health and Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">18-29</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acupuncture Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010002948</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010002948/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>199</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">199</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. M.</style></author><author><style face="normal" font="default" size="100%">Jee, S. H.</style></author><author><style face="normal" font="default" size="100%">Nam, C. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Obesity Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Obesity Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1116-1123</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Appetite Depressants [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclobutanes [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Energy Metabolism [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004003221</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004003221/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>200</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">200</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kizilirmak, P.</style></author><author><style face="normal" font="default" size="100%">Berktas, M.</style></author><author><style face="normal" font="default" size="100%">Uresin, Y.</style></author><author><style face="normal" font="default" size="100%">Yildiz, O. B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The efficacy and safety of triple vs dual combination of angiotensin ii receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">193-200</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [administration &amp; dosage] [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage] [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [administration &amp; dosage] [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [administration &amp; dosage] [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013017240</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013017240/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>201</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">201</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klingbeil, A. U.</style></author><author><style face="normal" font="default" size="100%">Schneider, M.</style></author><author><style face="normal" font="default" size="100%">Martus, P.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author><author><style face="normal" font="default" size="100%">Schmieder, R. E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">41-46</style></pages><volume><style face="normal" font="default" size="100%">115</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [classification] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Ventricles [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertrophy, Left Ventricular [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003001611</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003001611/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>669</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">669</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Knijnenburg Sebastiaan, L.</style></author><author><style face="normal" font="default" size="100%">Mulder Renée, L.</style></author><author><style face="normal" font="default" size="100%">Schouten-Van Meeteren Antoinette, Y. N.</style></author><author><style face="normal" font="default" size="100%">Bökenkamp, Arend</style></author><author><style face="normal" font="default" size="100%">Blufpand, Hester</style></author><author><style face="normal" font="default" size="100%">van Dulmen-den Broeder, Eline</style></author><author><style face="normal" font="default" size="100%">Veening Margreet, A.</style></author><author><style face="normal" font="default" size="100%">Kremer Leontien, C. M.</style></author><author><style face="normal" font="default" size="100%">Jaspers Monique, W. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Survivors</style></keyword><keyword><style face="normal" font="default" size="100%">Antineoplastic Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Carboplatin [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cisplatin [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerular Filtration Rate [drug effects] [physiology] [radiation effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypophosphatemia [epidemiology] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Ifosfamide [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Magnesium Deficiency [epidemiology] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Nephrectomy [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria [epidemiology] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Radiotherapy [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Insufficiency, Chronic [epidemiology] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Childca</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008944</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Great improvements in diagnostics and treatment for malignant disease in childhood have led to a major increase in survival. However, childhood cancer survivors (CCS) are at great risk for developing adverse effects caused by multimodal treatment for their malignancy. Nephrotoxicity is one of these known (acute) side effects of several treatments, including cisplatin, carboplatin, ifosfamide, radiotherapy and nephrectomy, and can cause glomerular filtration rate impairment, proteinuria, tubulopathy and hypertension. However, evidence about the long-term effects of these treatments on renal function remains inconclusive. To reduce the number of (long-term) nephrotoxic events in CCS, it is important to know the risk of, and risk factors for, early and late renal adverse effects, so that ultimately treatment and screening protocols can be adjusted.Objectives: To evaluate existing evidence on the effects of potentially nephrotoxic treatment modalities on the prevalence of and associated risk factors for renal dysfunction in survivors treated for childhood cancer with a median or mean survival of at least one year after cessation of treatment, where possible in comparison with healthy controls or CCS treated without potentially nephrotoxic treatment.Search methods: We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 4, 2011), MEDLINE/PubMed (from 1945 to December 2011) and EMBASE/Ovid (from 1980 to December 2011).Selection criteria: With the exception of case reports, case series and studies including fewer than 20 participants, we included studies with all study designs that reported on renal function (one year or longer after cessation of treatment) in children and adults who were treated for a paediatric malignancy (aged 18 years or younger at diagnosis) with cisplatin, carboplatin, ifosfamide, radiation including the kidney region and/or a nephrectomy.Data collection and analysis: Two review authors independently performed study selection, risk of bias assessment and data extraction using standardised data collection forms. Analyses were performed according to the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions.Main results: The search strategy identified 5504 studies, of which 5138 were excluded on the basis of title and/or abstract. The full-text screening of the remaining 366 articles resulted in the inclusion of 57 studies investigating the prevalence of and sometimes also risk factors for early and late renal adverse effects of treatment for childhood cancer. The 57 studies included at least 13,338 participants of interest for this study, of whom at least 6516 underwent renal function testing. The prevalence of renal adverse effects ranged from 0% to 84%. This variation may be due to diversity in included malignancies, prescribed treatments, reported outcome measurements and the methodological quality of available evidence.Chronic kidney disease/renal insufficiency (as defined by the authors of the original studies) was reported in 10 of 57 studies. The prevalence of chronic kidney disease ranged between 0.5% and 70.4% in the 10 studies and between 0.5% and 18.8% in the six studies that specifically investigated Wilms&apos; tumour survivors treated with a unilateral nephrectomy.A decreased (estimated) glomerular filtration rate was present in 0% to 50% of all assessed survivors (32/57 studies). Total body irradiation; concomitant treatment with aminoglycosides, vancomycin, amphotericin B or cyclosporin A; older age at treatment and longer interval from therapy to follow-up were significant risk factors reported in multivariate analyses. Proteinuria was present in 0% to 84% of all survivors (17/57 studies). No study performed multivariate analysis to assess risk factors for proteinuria.Hypophosphataemia was assessed in seven studies. Reported prevalences ranged between 0% and 47.6%, but four of seven studies found a prevalence of 0%. No studies assessed risk factors for hypophosphataemia using m ltivariate analysis. The prevalence of impairment of tubular phosphate reabsorption was mostly higher (range 0% to 62.5%; 11/57 studies). Higher cumulative ifosfamide dose, concomitant cisplatin treatment, nephrectomy and longer follow-up duration were significant risk factors for impaired tubular phosphate reabsorption in multivariate analyses.Treatment with cisplatin and carboplatin was associated with a significantly lower serum magnesium level in multivariate analysis, and the prevalence of hypomagnesaemia ranged between 0% and 37.5% in the eight studies investigating serum magnesium.Hypertension was investigated in 24 of the 57 studies. Reported prevalences ranged from 0% to 18.2%. A higher body mass index was the only significant risk factor noted in more than one multivariate analysis. Other reported factors that significantly increased the risk of hypertension were use of total body irradiation, abdominal irradiation, acute kidney injury, unrelated or autologous stem cell donor type, growth hormone therapy and older age at screening. Previous infection with hepatitis C significantly decreased the risk of hypertension.Because of the profound heterogeneity of the studies, it was not possible to perform any meta-analysis.Authors&apos; conclusions: The prevalence of renal adverse events after treatment with cisplatin, carboplatin, ifosfamide, radiation therapy involving the kidney region and/or nephrectomy ranged from 0% to 84%. With currently available evidence, it was not possible to draw any conclusions with regard to prevalence of and risk factors for renal adverse effects. Future studies should focus on adequate study design and reporting and should deploy multivariate risk factor analysis to correct for possible confounding. Until more evidence becomes available, CCS should be enrolled into long-term follow-up programmes to monitor their renal function and blood pressure.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008944.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008944.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>202</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">202</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kollias, A.</style></author><author><style face="normal" font="default" size="100%">Stergiou, G. S.</style></author><author><style face="normal" font="default" size="100%">Dolan, E.</style></author><author><style face="normal" font="default" size="100%">O&apos;Brien, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ambulatory arterial stiffness index: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Atherosclerosis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">291-301</style></pages><volume><style face="normal" font="default" size="100%">224</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Arteries [drug effects] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [diagnosis] [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Pulse Wave Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Stiffness [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012045959</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012045959/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>203</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">203</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Korenstein, D.</style></author><author><style face="normal" font="default" size="100%">Wisnivesky, J. P.</style></author><author><style face="normal" font="default" size="100%">Wyer, P.</style></author><author><style face="normal" font="default" size="100%">Adler, R.</style></author><author><style face="normal" font="default" size="100%">Ponieman, D.</style></author><author><style face="normal" font="default" size="100%">McGinn, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The utility of B-type natriuretic peptide in the diagnosis of heart failure in the emergency department: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Emergency Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Emergency Medicine</style></full-title></periodical><volume><style face="normal" font="default" size="100%">7:6</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biological Markers [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Disease [blood] [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Dyspnea [blood] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Emergency Service, Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [blood] [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Natriuretic Peptide, Brain [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Peptide Fragments [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007003098</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007003098/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>204</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">204</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kostis, W. J.</style></author><author><style face="normal" font="default" size="100%">Lutgarde, T.</style></author><author><style face="normal" font="default" size="100%">Richart, T.</style></author><author><style face="normal" font="default" size="100%">Kostis, J. B.</style></author><author><style face="normal" font="default" size="100%">Staessen, J. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure-lowering medications (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1060-1068</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Dysfunction, Left [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012043226</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012043226/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>205</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">205</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kowal-Bielecka, O.</style></author><author><style face="normal" font="default" size="100%">Avouac, J.</style></author><author><style face="normal" font="default" size="100%">Pittrow, D.</style></author><author><style face="normal" font="default" size="100%">Huscher, D.</style></author><author><style face="normal" font="default" size="100%">Behrens, F.</style></author><author><style face="normal" font="default" size="100%">Denton, C. P.</style></author><author><style face="normal" font="default" size="100%">Foeldvari, I.</style></author><author><style face="normal" font="default" size="100%">Humbert, M.</style></author><author><style face="normal" font="default" size="100%">Matucci-Cerinic, M.</style></author><author><style face="normal" font="default" size="100%">Nash, P.</style></author><author><style face="normal" font="default" size="100%">Opitz, C. F.</style></author><author><style face="normal" font="default" size="100%">Rubin, L. J.</style></author><author><style face="normal" font="default" size="100%">Seibold, J. R.</style></author><author><style face="normal" font="default" size="100%">Strand, V.</style></author><author><style face="normal" font="default" size="100%">Furst, D. E.</style></author><author><style face="normal" font="default" size="100%">Distler, O.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the expert panel on outcomes measures in pulmonary arterial hypertension related to systemic sclerosis (EPOSS) (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Rheumatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Rheumatology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2419-2427</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Disability Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Scleroderma, Systemic [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012006979</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012006979/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>670</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">670</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krogsbøll Lasse, T.</style></author><author><style face="normal" font="default" size="100%">Jørgensen Karsten, Juhl</style></author><author><style face="normal" font="default" size="100%">Grønhøj Larsen, Christian</style></author><author><style face="normal" font="default" size="100%">Gøtzsche Peter, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">General health checks in adults for reducing morbidity and mortality from disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Health Status Indicators</style></keyword><keyword><style face="normal" font="default" size="100%">Morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Screening [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Prevention [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Epoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009009</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: General health checks are common elements of health care in some countries. These aim to detect disease and risk factors for disease with the purpose of reducing morbidity and mortality. Most of the commonly used screening tests offered in general health checks have been incompletely studied. Also, screening leads to increased use of diagnostic and therapeutic interventions, which can be harmful as well as beneficial. It is, therefore, important to assess whether general health checks do more good than harm.Objectives: We aimed to quantify the benefits and harms of general health checks with an emphasis on patient-relevant outcomes such as morbidity and mortality rather than on surrogate outcomes such as blood pressure and serum cholesterol levels.Search methods: We searched The Cochrane Library, the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Effective Practice and Organisation of Care (EPOC) Trials Register, MEDLINE, EMBASE, Healthstar, CINAHL, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform (ICTRP) to July 2012. Two authors screened titles and abstracts, assessed papers for eligibility and read reference lists. One author used citation tracking (Web of Knowledge) and asked trialists about additional studies.Selection criteria: We included randomised trials comparing health checks with no health checks in adults unselected for disease or risk factors. We did not include geriatric trials. We defined health checks as screening general populations for more than one disease or risk factor in more than one organ system.Data collection and analysis: Two authors independently extracted data and assessed the risk of bias in the trials. We contacted authors for additional outcomes or trial details when necessary. For mortality outcomes we analysed the results with random-effects model meta-analysis, and for other outcomes we did a qualitative synthesis as meta-analysis was not feasible.Main results: We included 16 trials, 14 of which had available outcome data (182,880 participants). Nine trials provided data on total mortality (155,899 participants, 11,940 deaths), median follow-up time nine years, giving a risk ratio of 0.99 (95% confidence interval (CI) 0.95 to 1.03). Eight trials provided data on cardiovascular mortality (152,435 participants, 4567 deaths), risk ratio 1.03 (95% CI 0.91 to 1.17) and eight trials on cancer mortality (139,290 participants, 3663 deaths), risk ratio 1.01 (95% CI 0.92 to 1.12). Subgroup and sensitivity analyses did not alter these findings.We did not find an effect on clinical events or other measures of morbidity but one trial found an increased occurrence of hypertension and hypercholesterolaemia with screening and one trial found an increased occurence of self-reported chronic disease. One trial found a 20% increase in the total number of new diagnoses per participant over six years compared to the control group. No trials compared the total number of prescriptions, but two out of four trials found an increased number of people using antihypertensive drugs. Two out of four trials found small beneficial effects on self-reported health, but this could be due to reporting bias as the trials were not blinded. We did not find an effect on admission to hospital, disability, worry, additional visits to the physician, or absence from work, but most of these outcomes were poorly studied. We did not find useful results on the number of referrals to specialists, the number of follow-up tests after positive screening results, or the amount of surgery.Authors&apos; conclusions: General health checks did not reduce morbidity or mortality, neither overall nor for cardiovascular or cancer causes, although the number of new diagnoses was increased. Important harmful outcomes, such as the number of follow-up diagnostic procedures or short term psychological effects, were often not studied or reported and many trials had methodological problems. With the large number of participants and deaths included, the long follow-up periods used, and consider ng that cardiovascular and cancer mortality were not reduced, general health checks are unlikely to be beneficial.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009009.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009009.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>671</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">671</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kulasekaran, Karthikeyan</style></author><author><style face="normal" font="default" size="100%">Sargent Philip, H.</style></author><author><style face="normal" font="default" size="100%">Flenady, Vicki</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Milrinone for the treatment of cardiac dysfunction in neonates</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004952</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:The primary objective is to assess the safety and efficacy of milrinone (with or without concomitant use of other inotropes) compared with placebo or no treatment for the treatment of neonates with cardiac dysfunction.Sub group analysis will be undertaken if data permit to identify the effects of milrinone in subgroups according to Gestational age: preterm &lt;32 weeks gestation Aetiology for dysfunction: associated with or secondary to pulmonary hypertension Type of dysfunction: diastolic dysfunction - diagnosed using Tissue doppler measurement of Ew/Aw &lt;1 Dosage regimen: continuous infusion of high dose (&gt;0.5 mcg/kg/min), low dose (&lt;0.5 mcg/kg/min) Concomitant inotropes: milrinone used as the single agent in the treatment of cardiac dysfunction (i.e. without the use of concomitant inotropes)</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004952/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004952</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>206</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">206</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kumbhani, D. J.</style></author><author><style face="normal" font="default" size="100%">Bavry, A. A.</style></author><author><style face="normal" font="default" size="100%">Harvey, J. E.</style></author><author><style face="normal" font="default" size="100%">Souza, R.</style></author><author><style face="normal" font="default" size="100%">Scarpioni, R.</style></author><author><style face="normal" font="default" size="100%">Bhatt, D. L.</style></author><author><style face="normal" font="default" size="100%">Kapadia, S. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Heart Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">622-630.e1</style></pages><volume><style face="normal" font="default" size="100%">161</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty, Balloon</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Creatinine [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction [physiopathology] [surgery] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011002148</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011002148/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>207</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">207</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kunutsor, S. K.</style></author><author><style face="normal" font="default" size="100%">Apekey, T. A.</style></author><author><style face="normal" font="default" size="100%">Steur, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Epidemiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">205-221</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biological Markers [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [blood] [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin D [administration &amp; dosage] [analogs &amp; derivatives] [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013032315</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013032315/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>208</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">208</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kunutsor, S. K.</style></author><author><style face="normal" font="default" size="100%">Burgess, S.</style></author><author><style face="normal" font="default" size="100%">Munroe, P. B.</style></author><author><style face="normal" font="default" size="100%">Khan, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Vitamin D and high blood pressure: causal association or epiphenomenon? (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-14</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [blood] [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Mendelian Randomization Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin D [blood] [genetics] [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014020847</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014020847/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>209</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">209</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuti, E. L.</style></author><author><style face="normal" font="default" size="100%">Baker, W. L.</style></author><author><style face="normal" font="default" size="100%">White, C. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Current Medical Research and Opinion</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Medical Research and Opinion</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1239-1244</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007002414</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007002414/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>210</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">210</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuwana, M.</style></author><author><style face="normal" font="default" size="100%">Watanabe, H.</style></author><author><style face="normal" font="default" size="100%">Matsuoka, N.</style></author><author><style face="normal" font="default" size="100%">Sugiyama, N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ Open</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e003113</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Connective Tissue Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013047861</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013047861/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>211</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">211</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lai, L. T.</style></author><author><style face="normal" font="default" size="100%">Danesh-Meyer, H. V.</style></author><author><style face="normal" font="default" size="100%">Kaye, A. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Visual outcomes and headache following interventions for idiopathic intracranial hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1670-1678</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Headache</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014041908</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014041908/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>212</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">212</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lakhan, S. E.</style></author><author><style face="normal" font="default" size="100%">Sapko, M. T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Archives of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Archives of Medicine</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Reduction Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000034</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000034/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>213</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">213</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lambers Heerspink, H. J.</style></author><author><style face="normal" font="default" size="100%">Ninomiya, T.</style></author><author><style face="normal" font="default" size="100%">Zoungas, S.</style></author><author><style face="normal" font="default" size="100%">Zeeuw, D.</style></author><author><style face="normal" font="default" size="100%">Grobbee, D. E.</style></author><author><style face="normal" font="default" size="100%">Jardine, M. J.</style></author><author><style face="normal" font="default" size="100%">Gallagher, M.</style></author><author><style face="normal" font="default" size="100%">Roberts, M. A.</style></author><author><style face="normal" font="default" size="100%">Cass, A.</style></author><author><style face="normal" font="default" size="100%">Neal, B.</style></author><author><style face="normal" font="default" size="100%">Perkovic, V.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1009-1015</style></pages><volume><style face="normal" font="default" size="100%">373</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Causality</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology] [etiology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Dialysis [adverse effects] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009103420</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009103420/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>214</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">214</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Landman, G. W.</style></author><author><style face="normal" font="default" size="100%">Hateren, K. J.</style></author><author><style face="normal" font="default" size="100%">Dijk, P. R.</style></author><author><style face="normal" font="default" size="100%">Logtenberg, S. J.</style></author><author><style face="normal" font="default" size="100%">Houweling, S. T.</style></author><author><style face="normal" font="default" size="100%">Groenier, K. H.</style></author><author><style face="normal" font="default" size="100%">Bilo, H. J.</style></author><author><style face="normal" font="default" size="100%">Kleefstra, N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy of device-guided breathing for hypertension in blinded, randomized, active-controlled trials: a meta-analysis of individual patient data (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Breathing Exercises</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014058465</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014058465/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>672</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">672</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lane Deirdre, A.</style></author><author><style face="normal" font="default" size="100%">Lip Gregory, Y. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of hypertension in peripheral arterial disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Intermittent Claudication [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Peripheral Vascular Diseases [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Pvd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003075</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Peripheral arterial disease (PAD) causes considerable morbidity and mortality. Hypertension is a risk factor for PAD. Treatment for hypertension must be compatible with the symptoms of PAD. Controversy regarding the effects of beta-adrenoreceptor blockade for hypertension in patients with PAD has led many physicians to stop prescribing beta-adrenoreceptor blockers. Little is known about the effects of other classes of anti-hypertensive drugs in the presence of PAD. This is the second update of a Cochrane review first published in 2003.Objectives: To determine the effects of anti-hypertensive drugs in patients with both raised blood pressure and symptomatic PAD in terms of the rate of cardiovascular events and death, symptoms of claudication and critical leg ischaemia, and progression of atherosclerotic PAD as measured by ankle brachial index (ABI) changes and the need for revascularisation (reconstructive surgery or angioplasty) or amputation.Search methods: For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Cochrane Peripheral Vascular Diseases Group Specialised Register (last searched March 2013) and CENTRAL (2013, Issue 2).Selection criteria: Randomised controlled trials (RCTs) of at least one anti-hypertensive treatment against placebo or two anti-hypertensive medications against each other, with interventions lasting at least one month. Trials had to include patients with symptomatic PAD.Data collection and analysis: Data were extracted by one author (DAL) and checked by the other (GYHL). Potentially eligible studies were excluded when the results presentation prevented adequate extraction of data and enquiries to authors did not yield raw data.Main results: Eight RCTs were included with a total of 3610 PAD patients. Four studies compared a recognised class of anti-hypertensive treatment with placebo and four studies compared two anti-hypertensive treatments with each other. Studies were not pooled due to the variation of the comparisons and the outcomes presented. Overall the quality of the available evidence was unclear, primarily as a result of a lack of detail in the study reports on the randomisation and blinding procedures and incomplete outcome data. Two studies compared angiotensin converting enzyme (ACE) inhibitors against placebo. In one study there was a significant reduction in the number of cardiovascular events in patients receiving ramipril (odds ratio (OR) 0.72, 95% confidence interval (CI) 0.58 to 0.91; n = 1725). In the second trial using perindopril (n = 52) there was a marginal increase in claudication distance but no change in ABI and a reduction in maximum walking distance. A trial comparing the calcium antagonist verapamil versus placebo in patients undergoing angioplasty (n = 96) suggested that verapamil reduced restenosis (per cent diameter stenosis (± SD) 48.0% ± 11.5 versus 69.6% ± 12.2; P &lt; 0.01), although this was not reflected in the maintenance of a high ABI (0.76 ± 0.10 versus 0.72 ± 0.08 for verapamil versus placebo). Another study (n = 80) demonstrated no significant difference in arterial intima-media thickness (IMT) in men receiving the thiazide diuretic hydrochlorothiazide (HCTZ) compared to those receiving the alpha-adrenoreceptor blocker doxazosin (-0.12 ± 0.14 mm and -0.08 ± 0.13 mm, respectively; P = 0.66). A study (n = 36) comparing telmisartan to placebo found a significant improvement in maximum walking distance at 12 months with telmisartan (median (interquartile range (IQR)) 191 m (157 to 226) versus 103 m (76 to 164); P &lt; 0.001) but no differences in ABI (median (IQR) 0.60 (0.60 to 0.77) versus 0.52 (0.48 to 0.67)) or arterial IMT (median (IQR) 0.08 cm (0.07 to 0.09) versus 0.09 cm (0.08 to 0.10)). Two studies compared the beta-adrenoreceptor blocker nebivolol with either the thiazide diuretic HCTZ or with metoprolol. Both studies found no significant differences in intermittent or absolute claudication distance, ABI, or all-cause mortality between the anti-hypertensives. A subgroup analysis of</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003075.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003075.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>215</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">215</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lassere, M. N.</style></author><author><style face="normal" font="default" size="100%">Johnson, K. R.</style></author><author><style face="normal" font="default" size="100%">Schiff, M.</style></author><author><style face="normal" font="default" size="100%">Rees, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES) (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Medical Research Methodology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Medical Research Methodology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">27</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biological Markers [analysis]</style></keyword><keyword><style face="normal" font="default" size="100%">Biometry</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Endpoint Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiologic Methods</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Likelihood Functions</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [mortality] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Threshold Limit Values</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012047851</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012047851/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>216</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">216</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lattanzi, S.</style></author><author><style face="normal" font="default" size="100%">Silvestrini, M.</style></author><author><style face="normal" font="default" size="100%">Provinciali, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Elevated blood pressure in the acute phase of stroke and the role of angiotensin receptor blockers (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Hypertension</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2013:941783</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitors</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013013413</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013013413/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>673</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">673</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Law, M.</style></author><author><style face="normal" font="default" size="100%">Wald, N.</style></author><author><style face="normal" font="default" size="100%">Morris, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Health Policy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><publisher><style face="normal" font="default" size="100%">Health Technology Assessment</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32003001160</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32003001160/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>217</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">217</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Law, M. R.</style></author><author><style face="normal" font="default" size="100%">Morris, J. K.</style></author><author><style face="normal" font="default" size="100%">Wald, N. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><volume><style face="normal" font="default" size="100%">338:b1665</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Disease [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009105015</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009105015/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>218</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">218</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Law, M. R.</style></author><author><style face="normal" font="default" size="100%">Wald, N. J.</style></author><author><style face="normal" font="default" size="100%">Morris, J. K.</style></author><author><style face="normal" font="default" size="100%">Jordan, R. E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1427-1431</style></pages><volume><style face="normal" font="default" size="100%">326</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Ischemia [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003008462</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003008462/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>219</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">219</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lawrence Gould, A.</style></author><author><style face="normal" font="default" size="100%">Unniachan, S.</style></author><author><style face="normal" font="default" size="100%">Wu, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">163-172</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amlodipine</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Losartan</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014009693</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014009693/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>220</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">220</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lazaridis, C.</style></author><author><style face="normal" font="default" size="100%">Neyens, R.</style></author><author><style face="normal" font="default" size="100%">Bodle, J.</style></author><author><style face="normal" font="default" size="100%">DeSantis, S. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">High-osmolarity saline in neurocritical care: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Critical Care Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Critical Care Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1353-1360</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Brain Edema [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Critical Care [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Critical Illness [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Infusions, Intravenous</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [complications] [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Mannitol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Saline Solution, Hypertonic [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013022136</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013022136/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>674</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">674</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leas, B.</style></author><author><style face="normal" font="default" size="100%">Umscheid, C. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Postpartum management of hypertensive disorders (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Postpartum Period</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">Center for Evidence-based Practice (CEP)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32011000533</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32011000533/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>221</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">221</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Kim, S. Y.</style></author><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. J.</style></author><author><style face="normal" font="default" size="100%">Lee, H.</style></author><author><style face="normal" font="default" size="100%">Park, H. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Acupuncture for lowering blood pressure: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">122-128</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acupuncture Therapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009102698</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009102698/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>222</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">222</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, L. L.</style></author><author><style face="normal" font="default" size="100%">Watson, M. C.</style></author><author><style face="normal" font="default" size="100%">Mulvaney, C. A.</style></author><author><style face="normal" font="default" size="100%">Tsai, C. C.</style></author><author><style face="normal" font="default" size="100%">Lo, S. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effect of walking intervention on blood pressure control: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Nursing Studies</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Nursing Studies</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1545-1561</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Walking</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011000358</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011000358/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>675</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">675</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, Ling-Ling</style></author><author><style face="normal" font="default" size="100%">Watson, Michael</style></author><author><style face="normal" font="default" size="100%">Mulvaney, Caroline</style></author><author><style face="normal" font="default" size="100%">Salzwedel Douglas, M.</style></author><author><style face="normal" font="default" size="100%">Chan Edwin, S. Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Walking for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008823</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To determine the effect of walking as a lifestyle physical activity intervention on: Systolic blood pressure in hypertensive adults Systolic blood pressure in pre-hypertensive adults Systolic blood pressure in hypertensive adults Systolic blood pressure in pre-hypertensive adults</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008823/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008823</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>223</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">223</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, M.</style></author><author><style face="normal" font="default" size="100%">Saver, J. L.</style></author><author><style face="normal" font="default" size="100%">Hong, K. S.</style></author><author><style face="normal" font="default" size="100%">Hao, Q.</style></author><author><style face="normal" font="default" size="100%">Ovbiagele, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Does achieving an intensive versus usual blood pressure level prevent stroke? (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Neurology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">133-140</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [epidemiology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [methods] [trends]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [epidemiology] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012006744</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012006744/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>224</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">224</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, M. S.</style></author><author><style face="normal" font="default" size="100%">Choi, T. Y.</style></author><author><style face="normal" font="default" size="100%">Shin, B. C.</style></author><author><style face="normal" font="default" size="100%">Kim, J. I.</style></author><author><style face="normal" font="default" size="100%">Nam, S. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cupping for hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical and Experimental Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical and Experimental Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">423-425</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acupuncture Points</style></keyword><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010007847</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010007847/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>225</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">225</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, M. S.</style></author><author><style face="normal" font="default" size="100%">Lee, E. N.</style></author><author><style face="normal" font="default" size="100%">Kim, J. I.</style></author><author><style face="normal" font="default" size="100%">Ernst, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tai chi for lowering resting blood pressure in the elderly: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Evaluation in Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Evaluation in Clinical Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">818-824</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Tai Ji</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010005340</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010005340/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>226</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">226</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, M. S.</style></author><author><style face="normal" font="default" size="100%">Pittler, M. H.</style></author><author><style face="normal" font="default" size="100%">Guo, R.</style></author><author><style face="normal" font="default" size="100%">Ernst, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Qigong for hypertension: a systematic review of randomized clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1525-1532</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Breathing Exercises</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Waiting Lists</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007002560</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007002560/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>227</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">227</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, Y. H.</style></author><author><style face="normal" font="default" size="100%">Song, G. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Korean Journal of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Korean Journal of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">701-707</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013071939</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013071939/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>228</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">228</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Levi Marpillat, N.</style></author><author><style face="normal" font="default" size="100%">Macquin-Mavier, I.</style></author><author><style face="normal" font="default" size="100%">Tropeano, A. I.</style></author><author><style face="normal" font="default" size="100%">Bachoud-Levi, A. C.</style></author><author><style face="normal" font="default" size="100%">Maison, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1073-1082</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013019170</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013019170/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>229</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">229</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Levine, C. B.</style></author><author><style face="normal" font="default" size="100%">Fahrbach, K. R.</style></author><author><style face="normal" font="default" size="100%">Frame, D.</style></author><author><style face="normal" font="default" size="100%">Connelly, J. E.</style></author><author><style face="normal" font="default" size="100%">Estok, R. P.</style></author><author><style face="normal" font="default" size="100%">Stone, L. R.</style></author><author><style face="normal" font="default" size="100%">Ludensky, V.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of amlodipine on systolic blood pressure (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35-57</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Amlodipine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Complications</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003008420</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003008420/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>230</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">230</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, D. Z.</style></author><author><style face="normal" font="default" size="100%">Zhou, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, Y. N.</style></author><author><style face="normal" font="default" size="100%">Ma, Y. T.</style></author><author><style face="normal" font="default" size="100%">Li, X. M.</style></author><author><style face="normal" font="default" size="100%">Yu, J.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Zhai, H.</style></author><author><style face="normal" font="default" size="100%">Lao, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Acupuncture for essential hypertension: a meta-analysis of randomized sham-controlled clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">279478</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acupuncture Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014023527</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014023527/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>676</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">676</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li Edmond, C. K.</style></author><author><style face="normal" font="default" size="100%">Heran Balraj, S.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Diseases [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypotension</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009096</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension (systolic blood pressure &gt; 140 mmHg or diastolic blood pressure &gt; 90 mmHg). However, while ACE inhibitors have been shown to reduce mortality and morbidity in placebo-controlled trials, ARBs have not. Therefore, a comparison of the efficacies of these two drug classes in primary hypertension for preventing total mortality and cardiovascular events is important.Objectives: To compare the effects of ACE inhibitors and ARBs on total mortality and cardiovascular events, and their rates of withdrawals due to adverse effects (WDAEs), in people with primary hypertension.Search methods: We searched the Cochrane Hypertension Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the World Health Organization (WHO) International Clinical Trials Registry Platform, and the ISI Web of Science up to July 2014. We contacted study authors for missing and unpublished information, and also searched the reference lists of relevant reviews for eligible studies.Selection criteria: We included randomized controlled trials enrolling people with uncontrolled or controlled primary hypertension with or without other risk factors. Included trials must have compared an ACE inhibitor and an ARB in a head-to-head manner, and lasted for a duration of at least one year. If background blood pressure lowering agents were continued or added during the study, the protocol to do so must have been the same in both study arms.Data collection and analysis: We used standard methodological procedures expected by The Cochrane Collaboration.Main results: Nine studies with 11,007 participants were included. Of the included studies, five reported data on total mortality, three reported data on total cardiovascular events, and four reported data on cardiovascular mortality. No study separately reported cardiovascular morbidity. In contrast, eight studies contributed data on WDAE. Included studies were of good to moderate quality. There was no evidence of a difference between ACE inhibitors and ARBs for total mortality (risk ratio (RR) 0.98; 95% confidence interval (CI) 0.88 to 1.10), total cardiovascular events (RR 1.07; 95% CI 0.96 to 1.19), or cardiovascular mortality (RR 0.98; 95% CI 0.85 to 1.13). Conversely, a high level of evidence indicated a slightly lower incidence of WDAE for ARBs as compared with ACE inhibitors (RR 0.83; 95% CI 0.74 to 0.93; absolute risk reduction (ARR) 1.8%, number needed to treat for an additional beneficial outcome (NNTB) 55 over 4.1 years), mainly attributable to a higher incidence of dry cough with ACE inhibitors. The quality of the evidence for mortality and cardiovascular outcomes was limited by possible publication bias, in that several studies were initially eligible for inclusion in this review, but had no extractable data available for the hypertension subgroup. To this end, the evidence for total mortality was judged to be moderate, while the evidence for total cardiovascular events was judged to be low by the GRADE approach.Authors&apos; conclusions: Our analyses found no evidence of a difference in total mortality or cardiovascular outcomes for ARBs as compared with ACE inhibitors, while ARBs caused slightly fewer WDAEs than ACE inhibitors. Although ACE inhibitors have shown efficacy in these outcomes over placebo, our results cannot be used to extrapolate the same conclusion for ARBs directly, which have not been studied in placebo-controlled trials for hypertension. Thus, the substitution of an ARB for an ACE inhibitor, while supported by evidence on grounds of tolerability, must be made in consideration of the weaker evidence for the efficacy of ARBs regarding mortality and morbidity outcomes compared with ACE inhibitors. Additionally, our data mostly derives from participants with existing clinical sequelae of hypertension, and it would be useful to have data from asymptomatic people to increase the generalizability of this review. Unpublished subgroup data of hypertensive participants in existing trials comparing ACE inhibitors and ARBs needs to be made available for this purpose.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009096.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009096.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>677</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">677</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Li</style></author><author><style face="normal" font="default" size="100%">McGee Richard, G.</style></author><author><style face="normal" font="default" size="100%">Isbister, Geoff</style></author><author><style face="normal" font="default" size="100%">Webster Angela, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interventions for the symptoms and signs resulting from jellyfish stings</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cnidaria</style></keyword><keyword><style face="normal" font="default" size="100%">Acetic Acid [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Bites and Stings [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Cryotherapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Cubozoa</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Hot Temperature [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrozoa</style></keyword><keyword><style face="normal" font="default" size="100%">Pain Management [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Papain [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium, Dietary [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Animals[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Sympt</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009688</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Jellyfish envenomations are common amongst temperate coastal regions and vary in severity depending on the species. Stings result in a variety of symptoms and signs, including pain, dermatological reactions and, in some species, Irukandji syndrome (including abdominal/back/chest pain, tachycardia, hypertension, sweating, piloerection, agitation and sometimes cardiac complications). Many treatments have been suggested for the symptoms and signs of jellyfish stings. However, it is unclear which interventions are most effective.Objectives: To determine the benefits and harms associated with the use of any intervention, in both adults and children, for the treatment of jellyfish stings, as assessed from randomised trials.Search methods: We searched the following electronic databases in October 2012 and again in October 2013: the Cochrane Central Register of Controlled Trials (CENTRAL;The Cochrane Library, Issue 9, 2013); MEDLINE via Ovid SP (1948 to 22 October 2013); EMBASE via Ovid SP (1980 to 21 October 2013); and Web of Science (all databases; 1899 to 21 October 2013). We also searched reference lists from eligible studies and guidelines, conference proceedings and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and contacted content experts to identify trials.Selection criteria: We included randomised controlled trials that compared any intervention(s) to active and/or non-active controls for the treatment of symptoms and signs of jellyfish sting envenomation. No language, publication date or publication status restrictions were applied.Data collection and analysis: Two review authors independently conducted study selection and data extraction and assessed risk of bias using a standardised form. Disagreements were resolved by consensus with a third review author when necessary.Main results: We included seven trials with a total of 435 participants. Three trials focused on Physalia (Bluebottle) jellyfish, one trial on Carukia jellyfish and three on Carybdea alata (Hawaiian box) jellyfish. Two ongoing trials were identified.Six of the seven trials were judged as having high risk of bias. Blinding was not feasible in four of the included trials because of the nature of the interventions. A wide range of interventions were assessed across trials, and a wide range of outcomes were measured. We reported results from the two trials for which data were available and reported the effects of interventions according to our definition of primary or secondary outcomes.Hot water immersion was superior to ice packs in achieving clinically significant (at least 50%) pain relief at 10 minutes (one trial, 96 participants, risk ratio (RR) 1.66, 95% confidence interval (CI) 1.01 to 2.72; low-quality evidence) and 20 minutes (one trial, 88 participants, RR 2.66, 95% CI 1.71 to 4.15; low-quality evidence). No statistically significant differences between hot water immersion and ice packs were demonstrated for dermatological outcomes.Treatment with vinegar or Adolph&apos;s meat tenderizer compared with hot water made skin appear worse (one trial, 25 participants, RR 0.31, 95% CI 0.14 to 0.72; low-quality evidence).Adverse events due to treatment were not reported in any trial.Authors&apos; conclusions: This review located a small number of trials that assessed a variety of different interventions applied in different ways and in different settings. Although heat appears to be an effective treatment for Physalia (Bluebottle) stings, this evidence is based on a single trial of low-quality evidence. It is still unclear what type of application, temperature, duration of treatment and type of water (salt or fresh) constitute the most effective treatment. In addition, these results may not apply to other species of jellyfish with different envenomation characteristics. Future research should further assess the most effective interventions using standardised research methodology.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009688.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009688.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>678</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">678</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Lun</style></author><author><style face="normal" font="default" size="100%">Tian Jin, Hui</style></author><author><style face="normal" font="default" size="100%">Yang, KeHu</style></author><author><style face="normal" font="default" size="100%">Zhang, Peng</style></author><author><style face="normal" font="default" size="100%">Jia Wen, Qin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">CCR5 Receptor Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">HIV-1 [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-HIV Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Antibodies [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Infections [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Viral [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Hiv</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008439</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: PRO 140 (a humanized form of the PA14 antibody, a monoclonal CCR5 antibody) inhibits CCR5-tropic (R5) type 1 human immunodeficiency virus (HIV). This may be an effective new treatment with the potential to address the limitations of currently available therapies for HIV-infected patients.Objectives: We aimed to assess the efficacy, safety, clinical disease progression and immunologic (CD4 count/percentage) and virologic (plasma HIV RNA viral load) markers of PRO 140 for HIV-infected patients in randomized controlled trials (RCTs) and quasi-randomized controlled trials (quasi-RCTs).Search methods: We searched databases including The Cochrane Central Register of Controlled Trials (The Cochrane Library 2014, Issue 4), MEDLINE (PubMed, January 1966 to April 2014), EMBASE (January 1978 to April 2014) and ISI Web of Knowledge (January 1966 to April 2014), online trials registries and other sources. We also screened the reference lists of related literature and eligible studies, and presentations from major HIV/AIDS (human immunodeficiency virus/acquired immunodeficiency syndrome) conferences.Selection criteria: We included RCTs and quasi-RCTs comparing PRO 140 with placebo or other antiretroviral drugs, or different doses of PRO 140 for individuals infected with HIV.Data collection and analysis: Two reviewers (L Li and JH Tian) independently screened all retrieved citations and selected eligible studies. Two authors (P Zhang and WQ Jia) independently extracted data. Any disagreements when selecting studies and extracting data were adjudicated by the review mentor (KH Yang). We used Review Manager (RevMan) software for statistical analysis based on an intention-to-treat analysis. We examined heterogeneity using the Chi2 statistic. We regarded I2 estimates greater than 50% as moderate or high levels of heterogeneity. According to the level of heterogeneity, we used either a fixed or random-effects model.If significant heterogeneity existed and the reasons could not be found, we reported the results qualitatively.Main results: We included three trials comparing PRO 140 with placebo in adult patients with HIV infection. Our review indicates that PRO 140 may offer significant dose-dependent HIV-1 RNA suppression with tolerable side effects. PRO 140 2 mg/kg, 5 mg/kg, 10 mg/kg, 162 mg weekly, 324 mg biweekly, and 324 mg weekly showed statistically significant differences in the changes of HIV-1 RNA levels. HIV-1 RNA levels were reduced by intravenous (IV) infusion of PRO 140 2 mg/kg or 5 mg/kg on day 10, 5 mg/kg or 10 mg/kg on day 12, 162 mg weekly, 324 mg biweekly, or 324 mg weekly on day 22. PRO 140 2 mg/kg, 5 mg/kg, 10 mg/kg, 162 mg weekly, 324 mg biweekly, and 324 mg weekly demonstrated greater antiviral response. PRO 140 324 mg weekly, 5 mg/kg, and 10 mg/kg showed more patients with ? 400 copies/mL HIV-1 RNA. Only PRO 140 5 mg/kg showed greater change in CD4+ cell count on day eight. Headache, lymphadenopathy, diarrhoea, fatigue, hypertension, nasal congestion and pruritus were reported to be the most frequent adverse events.Authors&apos; conclusions: Limited evidence from three small trials suggests that PRO 140 might demonstrate potent, short-term, dose-dependent, highly significant antiviral activity. However, as the evidence is insufficient, recommendations cannot yet be made. Larger, longer-term, double-blind RCTs are required to provide conclusive evidence.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008439.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008439.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>231</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">231</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, T.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Zang, W.</style></author><author><style face="normal" font="default" size="100%">Geng, N.</style></author><author><style face="normal" font="default" size="100%">Ma, S.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Current Medical Research and Opinion</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Medical Research and Opinion</style></full-title></periodical><pages><style face="normal" font="default" size="100%">889-899</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013047152</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013047152/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>232</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">232</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Zhu, Y.</style></author><author><style face="normal" font="default" size="100%">Liang, X.</style></author><author><style face="normal" font="default" size="100%">Meng, H.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, D.</style></author><author><style face="normal" font="default" size="100%">Guo, H.</style></author><author><style face="normal" font="default" size="100%">Shi, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Niacinamide</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylurea Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014019116</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014019116/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>233</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">233</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Chao, J. Q.</style></author><author><style face="normal" font="default" size="100%">Song, L.</style></author><author><style face="normal" font="default" size="100%">Zong, M. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Influence of health education on medicine-taking compliance of Chinese hypertensive patients: a Bayesian meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">211-215</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Health Education</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014040238</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014040238/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>234</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">234</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Qian, Y.</style></author><author><style face="normal" font="default" size="100%">Lu, X. Z.</style></author><author><style face="normal" font="default" size="100%">Yang, B.</style></author><author><style face="normal" font="default" size="100%">Chen, M.</style></author><author><style face="normal" font="default" size="100%">Yang, Z. J.</style></author><author><style face="normal" font="default" size="100%">Cao, K. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Bradykinin beta2 receptor ?58T/C gene polymorphism and essential hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Plos One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Plos One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e43068</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Frequency</style></keyword><keyword><style face="normal" font="default" size="100%">Genes, Dominant</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Bradykinin B2 [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013018096</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013018096/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>679</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">679</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, Shih-Wei</style></author><author><style face="normal" font="default" size="100%">Wu Shi, Qi</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of clonidine for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008284</style></accession-num><abstract><style face="normal" font="default" size="100%">: This is the protocol for a review and there is no abstract. The objectives are as follows:Primary objective: To quantify the dose-related effect of various doses of clonidine on systolic and diastolic blood pressure versus placebo in patients with primary hypertension.Secondary objectives: To quantify the dose-related effect of clonidine on heart rate. To determine the effect of clonidine on pulse pressure. To determine the effect of clonidine on blood pressure variability. To quantify the effect of clonidine withdrawals due to adverse effects.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008284/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008284</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>235</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">235</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lindholm, L. H.</style></author><author><style face="normal" font="default" size="100%">Carlberg, B.</style></author><author><style face="normal" font="default" size="100%">Samuelsson, O.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Should beta blockers remain first choice in the treatment of primary hypertension: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1545-1553</style></pages><volume><style face="normal" font="default" size="100%">366</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Atenolol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005008553</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005008553/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>680</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">680</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lip Gregory, Y. H.</style></author><author><style face="normal" font="default" size="100%">Felmeden Dirk, C.</style></author><author><style face="normal" font="default" size="100%">Dwivedi, Girish</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antiplatelet agents and anticoagulants for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anticoagulants [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Aggregation Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Thromboembolism [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Ticlopidine [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Warfarin [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003186</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Elevated systemic blood pressure results in high intravascular pressure but the main complications, coronary heart disease (CHD), ischaemic strokes and peripheral vascular disease (PVD), are related to thrombosis rather than haemorrhage. Some complications related to elevated blood pressure, heart failure or atrial fibrillation, are themselves associated with stroke and thromboembolism. Therefore it is important to investigate if antithrombotic therapy may be useful in preventing thrombosis-related complications in patients with elevated blood pressure.Objectives: To conduct a systematic review of the role of antiplatelet therapy and anticoagulation in patients with high blood pressure, including those with elevations in both systolic and diastolic blood pressure, isolated elevations of either systolic or diastolic blood pressure, to address the following hypotheses: (i) antiplatelet agents reduce total deaths and/or major thrombotic events when compared to placebo or other active treatment; and (ii) oral anticoagulants reduce total deaths and/or major thromboembolic events when compared to placebo or other active treatment.Search methods: Electronic databases (MEDLINE, EMBASE, DARE, CENTRAL, Hypertension Group specialised register) were searched up to January 2011. The reference lists of papers resulting from the electronic searches and abstracts from national and international cardiovascular meetings were hand-searched to identify missed or unpublished studies. Relevant authors of studies were contacted to obtain further data.Selection criteria: Randomised controlled trials (RCTs) in patients with elevated blood pressure were included if they were of at least 3 months in duration and compared antithrombotic therapy with control or other active treatment.Data collection and analysis: Data were independently collected and verified by two reviewers. Data from different trials were pooled where appropriate.Main results: Four trials with a combined total of 44,012 patients met the inclusion criteria and are included in this review. Acetylsalicylic acid (ASA) did not reduce stroke or &apos;all cardiovascular events&apos; compared to placebo in primary prevention patients with elevated blood pressure and no prior cardiovascular disease. In one large trial ASA taken for 5 years reduced myocardial infarction (ARR 0.5%, NNT 200), increased major haemorrhage (ARI 0.7%, NNT 154), and did not reduce all cause mortality or cardiovascular mortality. In one trial there was no significant difference between ASA and clopidogrel for the composite endpoint of stroke, myocardial infarction or vascular death. In two small trials warfarin alone or in combination with ASA did not reduce stroke or coronary events. The ATC meta-analysis of antiplatelet therapy for secondary prevention in patients with elevated blood pressure reported an absolute reduction in vascular events of 4.1% as compared to placebo. Data on the 10,600 patients with elevated blood pressure from the 29 individual trials included in the ATC meta-analysis was requested but could not be obtained.Authors&apos; conclusions: Antiplatelet therapy with ASA for primary prevention in patients with elevated blood pressure provides a benefit, reduction in myocardial infarction, which is negated by a harm of similar magnitude, increase in major haemorrhage.The benefit of antiplatelet therapy for secondary prevention in patients with elevated blood pressure is many times greater than the harm.Benefit has not been demonstrated for warfarin therapy alone or in combination with aspirin in patients with elevated blood pressure. Ticlopidine, clopidogrel and newer antiplatelet agents such as prasugrel and ticagrelor have not been sufficiently evaluated in patients with high blood pressure. Newer antithrombotic oral drugs such as dabigatran, rivaroxaban, apixaban and endosaban are yet to be tested in patients with high blood pressure.Further trials of antithrombotic therapy including with newer agents and complete documentation of all benefits and harms are required in patients with elevat d blood pressure.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003186.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003186.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>681</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">681</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Chao</style></author><author><style face="normal" font="default" size="100%">Chen, Junmin</style></author><author><style face="normal" font="default" size="100%">Gao, Yanqiu</style></author><author><style face="normal" font="default" size="100%">Deng, Bao</style></author><author><style face="normal" font="default" size="100%">Liu, Kunshen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Endothelin receptor antagonists for pulmonary arterial hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Endothelin Receptor Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004434</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Pulmonary arterial hypertension is a devastating disease, which leads to right heart failure and premature death. Recent evidence suggests that endothelin receptor antagonists may be promising drugs in the treatment of pulmonary arterial hypertension.Objectives: To evaluate the efficacy of endothelin receptor antagonists in pulmonary arterial hypertension.Search methods: We searched CENTRAL (Cochrane Central Register of Controlled Trials), MEDLINE, EMBASE, and the reference section of retrieved articles. Searches are current as of January 2012.Selection criteria: We included randomised trials (RCTs) and quasi-randomised trials involving patients with pulmonary arterial hypertension.Data collection and analysis: Five review authors independently selected studies, assessed study quality and extracted data.Main results: We included 12 randomised controlled trials involving 1471 patients. All the trials were of relatively short duration (12 weeks to six months). After treatment, patients treated with endothelin receptor antagonists could walk on average 33.71 metres (95% confidence interval (CI) 24.90 to 42.52 metres) further than those treated with placebo in a six-minute walk test. Endothelin receptor antagonists improved more patients&apos; World Health Organization/New York Heart Association (WHO/NYHA) functional class status than placebo (odds ratio (OR) 1.60; 95% CI 1.20 to 2.14), and reduced the odds of functional class deterioration compared with placebo (OR 0.26; 95% CI 0.16 to 0.42). There was a reduction in mortality that did not reach statistical significance on endothelin receptor antagonists (OR 0.57; 95% CI 0.26 to 1.24), and limited data suggest that endothelin receptor antagonists improve the Borg dyspnoea score and cardiopulmonary haemodynamics in symptomatic patients. Hepatic toxicity was not common, and endothelin receptor antagonists were well tolerated in this population. However, several cases of irreversible liver failure caused by sitaxsentan have been reported that led to license holder for sitaxsentan to withdraw the product from all markets worldwide.Authors&apos; conclusions: Endothelin receptor antagonists can increase exercise capacity, improve WHO/NYHA functional class, prevent WHO/NYHA functional class deterioration, reduce dyspnoea and improve cardiopulmonary haemodynamic variables in patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III. However, there was only a trend towards endothelin receptor antagonists reducing mortality in patients with pulmonary arterial hypertension. Efficacy data are strongest in those with idiopathic pulmonary hypertension. The irreversible liver failure caused by sitaxsentan and its withdrawal from global markets emphasise the importance of hepatic monitoring in patients treated with endothelin receptor antagonists.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004434.pub5/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004434.pub5</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>236</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">236</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, C. F.</style></author><author><style face="normal" font="default" size="100%">Gu, Y. T.</style></author><author><style face="normal" font="default" size="100%">Wang, H. Y.</style></author><author><style face="normal" font="default" size="100%">Fang, N. Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Gamma-glutamyltransferase level and risk of hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Plos One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Plos One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e48878</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biological Markers [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">gamma-Glutamyltransferase [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012056050</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012056050/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>237</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">237</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, F.</style></author><author><style face="normal" font="default" size="100%">Qiu, M.</style></author><author><style face="normal" font="default" size="100%">Zhai, S. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Current Therapeutic Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Therapeutic Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-29</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amlodipine [adverse effects] [analogs &amp; derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacokinetics] [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">derivatives [pharmacokinetics] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Stereoisomerism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010004299</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010004299/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>238</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">238</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, S.</style></author><author><style face="normal" font="default" size="100%">Dunford, S. D.</style></author><author><style face="normal" font="default" size="100%">Leung, Y. W.</style></author><author><style face="normal" font="default" size="100%">Brooks, D.</style></author><author><style face="normal" font="default" size="100%">Thomas, S. G.</style></author><author><style face="normal" font="default" size="100%">Eysenbach, G.</style></author><author><style face="normal" font="default" size="100%">Nolan, R. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reducing blood pressure with internet-based interventions: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Canadian Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Canadian Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">613-621</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Counseling</style></keyword><keyword><style face="normal" font="default" size="100%">Health Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Internet</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013024680</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013024680/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>239</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">239</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, S. Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, X. J.</style></author><author><style face="normal" font="default" size="100%">Cai, H.</style></author><author><style face="normal" font="default" size="100%">Yang, L. Y.</style></author><author><style face="normal" font="default" size="100%">Ding, X. N.</style></author><author><style face="normal" font="default" size="100%">Chang, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis on influence of different doses of atorvastatin on carotid atherosclerosis in Chinese (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Jilin University (Medicine Edition)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Jilin University (Medicine Edition)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">313-317</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Heptanoic Acids</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrroles</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013025680</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013025680/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>240</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">240</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, K.</style></author><author><style face="normal" font="default" size="100%">Kou, X.</style></author><author><style face="normal" font="default" size="100%">Han, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Zeng, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Plos One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Plos One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e70111</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Amlodipine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013046358</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013046358/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>241</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">241</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Ma, W.</style></author><author><style face="normal" font="default" size="100%">Zhang, P.</style></author><author><style face="normal" font="default" size="100%">He, S.</style></author><author><style face="normal" font="default" size="100%">Huang, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Stilbenes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014026496</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014026496/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>242</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">242</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Yan, R.</style></author><author><style face="normal" font="default" size="100%">Song, A.</style></author><author><style face="normal" font="default" size="100%">Niu, X.</style></author><author><style face="normal" font="default" size="100%">Cao, C.</style></author><author><style face="normal" font="default" size="100%">Wei, J.</style></author><author><style face="normal" font="default" size="100%">Dong, X.</style></author><author><style face="normal" font="default" size="100%">Gao, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">268-278</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides</style></keyword><keyword><style face="normal" font="default" size="100%">Amlodipine</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013071986</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013071986/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>682</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">682</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu Zhao, Lan</style></author><author><style face="normal" font="default" size="100%">Li George, Q.</style></author><author><style face="normal" font="default" size="100%">Bensoussan, Alan</style></author><author><style face="normal" font="default" size="100%">Kiat, Hosen</style></author><author><style face="normal" font="default" size="100%">Chan, Kelvin</style></author><author><style face="normal" font="default" size="100%">Liu Jian, Ping</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chinese herbal medicines for hypertriglyceridaemia</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Gemfibrozil [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertriglyceridemia [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypolipidemic Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Endoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009560</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Hypertriglyceridaemia is associated with many diseases including atherosclerosis, diabetes, hypertension and chylomicronaemia. Chinese herbal medicines have been used for a long time as lipid-lowering agents.Objectives: To assess the effects and safety of Chinese herbal medicines for hypertriglyceridaemia.Search methods: We searched a number of databases including The Cochrane Library, MEDLINE, EMBASE and several Chinese databases (all until May 2012).Selection criteria: Randomised controlled trials in participants with hypertriglyceridaemia comparing Chinese herbal medicines with placebo, no treatment, and pharmacological or non-pharmacological interventions.Data collection and analysis: Two review authors independently extracted data and assessed the risk of bias. Any disagreement was resolved by discussion and a decision was achieved based on consensus. We assessed trials for risk of bias against key criteria: random sequence generation, allocation concealment, blinding of participants, incomplete outcome data, selective outcome reporting and other sources of bias.Main results: We included three randomised trials with 170 participants. Ninety participants were randomised to the Chinese herbal medicines groups and 80 to the comparator groups with numbers ranging from 50 to 60 participants per trial. The duration of treatment varied from four to six weeks. All the included trials were conducted in China and published in Chinese. Overall, the risk of bias of included trials was unclear. There were no outcome data in any of the trials on death from any cause, cardiovascular or cerebrovascular events, health-related quality of life, or costs.Three different herbal medicines, including Zhusuan Huoxue decoction, Huoxue Huayu Tongluo decoction, and Chushi Huayu decoction were evaluated. All three trials investigating Chinese herbal medicines treatment alone (two studies) or in combination with gemfibrozil (one study) reported results on serum triglyceride (TG) in favour of the herbal treatment. We did not perform a meta-analysis due to significant clinical heterogeneity between the studies.No relevant differences in adverse effects occurred and no serious adverse events were noted.Authors&apos; conclusions: The present systematic review suggests that Chinese herbal medicines may have positive effects on hypertriglyceridaemia. The trials did not report serious adverse effects following Chinese herbal medicines treatment. However, based on an unclear risk of bias in included studies and lack of patient-important long-term outcomes, no definite conclusion could be reached.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009560.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009560.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>683</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">683</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu Zhao, Lan</style></author><author><style face="normal" font="default" size="100%">Liu Jian, Ping</style></author><author><style face="normal" font="default" size="100%">Zhang Anthony, Lin</style></author><author><style face="normal" font="default" size="100%">Wu, Qiong</style></author><author><style face="normal" font="default" size="100%">Ruan, Yao</style></author><author><style face="normal" font="default" size="100%">Lewith, George</style></author><author><style face="normal" font="default" size="100%">Visconte, Denise</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chinese herbal medicines for hypercholesterolemia</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypercholesterolemia [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Endoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008305</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Hypercholesterolemia is an important key contributory factor for ischemic heart disease and is associated with age, high blood pressure, a family history of hypercholesterolemia, and diabetes. Chinese herbal medicines have been used for a long time as lipid-lowering agents.Objectives: To assess the effects of Chinese herbal medicines on hypercholesterolemia.Search methods: We searched the following databases: The Cochrane Library (issue 8, 2010), MEDLINE (until July 2010), EMBASE (until July 2010 ), Chinese BioMedical Database (until July 2010), Traditional Chinese Medical Literature Analysis and Retrieval System (until July 2010), China National Knowledge Infrastructure (until July 2010), Chinese VIP Information (until July 2010), Chinese Academic Conference Papers Database and Chinese Dissertation Database (until July 2010), and Allied and Complementary Medicine Database (until July 2010).Selection criteria: We considered randomized controlled clinical trials in hypercholesterolemic participants comparing Chinese herbal medicines with placebo, no treatment, and pharmacological or non-pharmacological interventions.Data collection and analysis: Two review authors independently extracted data and assessed the risk of bias. We resolved any disagreements with this assessment through discussion and a decision was achieved based by consensus. We assessed trials for the risk of bias against key criteria: random sequence generation, allocation concealment, blinding of participants, incomplete outcome data, selective outcome reporting and other sources of bias.Main results: We included 22 randomized trials (2130 participants). The mean treatment duration was 2.3 ± 1.3 months (ranging from one to six months). Twenty trials were conducted in China and 18 trials were published in Chinese. Overall, the risk of bias of included trials was high or unclear. Five different herbal medicines were evaluated in the included trials, which compared herbs with conventional medicine in six comparisons (20 trials), or placebo (two trials). There were no outcome data in any of the trials on cardiovascular events and death from any cause. One trial each reported well-being (no significant differences) and economic costs. No serious adverse events were observed. Xuezhikang was the most commonly used herbal formula investigated. A significant effect on total cholesterol (two trial, 254 participants) was shown in favor of Xuezhikang when compared with inositol nicotinate (mean difference (MD) -0.90 mmol/L, 95% confidence interval (CI) -1.13 to -0.68) .Authors&apos; conclusions: Some herbal medicines may have cholesterol-lowering effects. Our findings have to be interpreted with caution due to high or unclear risk of bias of the included trials.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008305.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008305.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>243</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">243</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ljungman, C.</style></author><author><style face="normal" font="default" size="100%">Mortensen, L.</style></author><author><style face="normal" font="default" size="100%">Kahan, T.</style></author><author><style face="normal" font="default" size="100%">Manhem, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of mild to moderate hypertension by gender perspective: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Women&apos;s Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Women&apos;s Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1049-1062</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009109744</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009109744/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>244</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">244</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lu, G. C.</style></author><author><style face="normal" font="default" size="100%">Cheng, J. W.</style></author><author><style face="normal" font="default" size="100%">Zhu, K. M.</style></author><author><style face="normal" font="default" size="100%">Ma, X. J.</style></author><author><style face="normal" font="default" size="100%">Shen, F. M.</style></author><author><style face="normal" font="default" size="100%">Su, D. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review of angiotensin receptor blockers in preventing stroke (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3876-3878</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II [antagonists &amp; inhibitors] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [drug therapy] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Angiotensin [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [drug therapy] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000996</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000996/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>245</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">245</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lu, Z.</style></author><author><style face="normal" font="default" size="100%">Cao, S.</style></author><author><style face="normal" font="default" size="100%">Chai, Y.</style></author><author><style face="normal" font="default" size="100%">Liang, Y.</style></author><author><style face="normal" font="default" size="100%">Bachmann, M.</style></author><author><style face="normal" font="default" size="100%">Suhrcke, M.</style></author><author><style face="normal" font="default" size="100%">Song, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effectiveness of interventions for hypertension care in the community: a meta-analysis of controlled studies in China (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Health Services Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Health Services Research</style></full-title></periodical><volume><style face="normal" font="default" size="100%">12:216</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Community Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013002399</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013002399/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>684</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">684</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lueck Christian, J.</style></author><author><style face="normal" font="default" size="100%">McIlwaine Gawn, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interventions for idiopathic intracranial hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Eyes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003434</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Idiopathic intracranial hypertension occurs throughout the world with an estimated incidence of one to three per 100,000 population per year. It occurs most commonly in obese young women but the cause is unknown. It presents a significant threat to sight and is associated with severe morbidity, in the form of headaches in most cases. Several different treatments have been proposed ranging from relatively conservative measures such as diuretic therapy to more invasive treatments such as optic nerve sheath fenestration, stenting of cerebral venous sinuses, or lumbo-peritoneal shunting.Objectives: The objective of this review was to assess the effects of various forms of treatment for idiopathic intracranial hypertension with a view to producing an evidence-based treatment strategy.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library, Issue 4, 2008), MEDLINE (January 1950 to December 2008) and EMBASE (January 1980 to December 2008). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 10 December 2008.Selection criteria: We included only randomised controlled trials in which any intervention used to treat idiopathic intracranial hypertension had been compared to placebo or to another form of treatment in people with a clinical diagnosis of idiopathic intracranial hypertension.Data collection and analysis: Both authors independently assessed the search results for trials to be included in the review. Discrepancies were resolved by discussion. Since no trials met our inclusion criteria, no assessment of quality or meta-analysis was undertaken.Main results: No randomised controlled trials were found that met the inclusion criteria.Authors&apos; conclusions: There is insufficient information to generate an evidence-based management strategy for idiopathic intracranial hypertension. There is inadequate information regarding which treatments are truly beneficial and which are potentially harmful. Properly designed and executed trials are needed.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003434.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003434.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>246</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">246</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luo, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhou, Q.</style></author><author><style face="normal" font="default" size="100%">Gao, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Association of endothelial nitric oxide synthase (eNOS) G894T polymorphism with high altitude pulmonary edema susceptibility: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Wilderness and Environmental Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Wilderness and Environmental Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">270-274</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style face="normal" font="default" size="100%">Altitude</style></keyword><keyword><style face="normal" font="default" size="100%">Altitude Sickness [enzymology] [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Association Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Linkage</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [enzymology] [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Nitric Oxide Synthase Type III [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012052799</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012052799/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>247</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">247</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lv, J.</style></author><author><style face="normal" font="default" size="100%">Ehteshami, P.</style></author><author><style face="normal" font="default" size="100%">Sarnak, M. J.</style></author><author><style face="normal" font="default" size="100%">Tighiouart, H.</style></author><author><style face="normal" font="default" size="100%">Jun, M.</style></author><author><style face="normal" font="default" size="100%">Ninomiya, T.</style></author><author><style face="normal" font="default" size="100%">Foote, C.</style></author><author><style face="normal" font="default" size="100%">Rodgers, A.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Strippoli, G. F.</style></author><author><style face="normal" font="default" size="100%">Perkovic, V.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">CMAJ: Canadian Medical Association Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CMAJ: Canadian Medical Association Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">949-957</style></pages><volume><style face="normal" font="default" size="100%">185</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Insufficiency, Chronic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013046152</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013046152/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>248</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">248</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lv, J.</style></author><author><style face="normal" font="default" size="100%">Neal, B.</style></author><author><style face="normal" font="default" size="100%">Ehteshami, P.</style></author><author><style face="normal" font="default" size="100%">Ninomiya, T.</style></author><author><style face="normal" font="default" size="100%">Woodward, M.</style></author><author><style face="normal" font="default" size="100%">Rodgers, A.</style></author><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">MacMahon, S.</style></author><author><style face="normal" font="default" size="100%">Turnbull, F.</style></author><author><style face="normal" font="default" size="100%">Hillis, G.</style></author><author><style face="normal" font="default" size="100%">Chalmers, J.</style></author><author><style face="normal" font="default" size="100%">Perkovic, V.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">PLOS Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLOS Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e1001293</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [drug therapy] [pathology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular System [drug effects] [pathology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney [drug effects] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Diseases [drug therapy] [pathology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012042268</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012042268/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>685</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">685</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lv, Jicheng</style></author><author><style face="normal" font="default" size="100%">Perkovic, Vlado</style></author><author><style face="normal" font="default" size="100%">Foote Celine, V.</style></author><author><style face="normal" font="default" size="100%">Craig Maria, E.</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author><author><style face="normal" font="default" size="100%">Strippoli Giovanni, F. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive agents for preventing diabetic kidney disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Albuminuria [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Nephropathies [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004136</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Various blood pressure-lowering agents, and particularly inhibitors of the renin-angiotensin system (RAS), are widely used for people with diabetes to prevent the onset of diabetic kidney disease (DKD) and adverse cardiovascular outcomes. This is an update of a Cochrane review first published in 2003 and updated in 2005.Objectives: This systematic review aimed to assess the benefits and harms of blood pressure lowering agents in people with diabetes mellitus and a normal amount of albumin in the urine (normoalbuminuria).Search methods: In January 2011 we searched the Cochrane Renal Group&apos;s Specialised Register through contact with the Trials Search Co-ordinator.Selection criteria: Randomised controlled trials (RCTs) comparing any antihypertensive agent with placebo or another agent in hypertensive or normotensive patients with diabetes and no kidney disease (albumin excretion rate &lt; 30 mg/d) were included.Data collection and analysis: Two investigators independently extracted data on kidney and other patient-relevant outcomes (all-cause mortality and serious cardiovascular events), and assessed study quality. Analysis was by a random effects model was applied to analyse results which were expressed as risk ratio (RR) and 95% confidence intervals (CI).Main results: We identified 26 studies that enrolling 61,264 participants. Angiotensin-converting enzyme inhibitors (ACEi) reduced the risk of new onset of microalbuminuria, macroalbuminuria or both when compared to placebo (8 studies, 11,906 patients: RR 0.71, 95% CI 0.56 to 0.89), with similar benefits in people with and without hypertension (P = 0.74), and when compared to calcium channel blockers (5 studies, 1253 participants: RR 0.60, 95% CI 0.42 to 0.85). ACEi reduced the risk of death when compared to placebo (6 studies, 11,350 participants: RR 0.84, 95% CI 0.73 to 0.97). No effect was observed for angiotensin receptor blockers (ARB) when compared to placebo for new microalbuminuria, macroalbuminuria or both (5 studies, 7653 participants: RR 0.90, 95% CI 0.68 to 1.19) or death (5 studies, 7653 participants: RR 1.12, 95% CI 0.88 to 1.41); however, meta-regression suggested possible benefits from ARB for preventing kidney disease in high risk patients. There was a trend towards benefit from use of combined ACEi and ARB for prevention of DKD compared with ACEi alone (2 studies, 4171 participants: RR 0.88, 95% CI 0.78 to 1.00).The risk of cough was significantly increased with ACEi when compared to placebo (6 studies, 11,791 patients: RR 1.84, 95% CI 1.24 to 2.72), however there was no significant difference in the risk of headache or hyperkalaemia. There was no significant difference in the risk of cough, headache or hyperkalaemia when ARB was to placebo. On average risk of bias was judged to be either low (27% to 69%) or unclear (i.e. no information available) (8% to 73%). Blinding of participants, incomplete outcome data and selective reporting were judged to be high in 23%, 31% and 31% of studies, respectively.Authors&apos; conclusions: ACEi were found to prevent new onset DKD and death in normoalbuminuric people with diabetes, and could therefore be used in this population. More data are needed to clarify the role of ARB and other drug classes in preventing DKD.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004136.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004136.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>249</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">249</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lv, Y.</style></author><author><style face="normal" font="default" size="100%">Zou, Z.</style></author><author><style face="normal" font="default" size="100%">Chen, G. M.</style></author><author><style face="normal" font="default" size="100%">Jia, H. X.</style></author><author><style face="normal" font="default" size="100%">Zhong, J.</style></author><author><style face="normal" font="default" size="100%">Fang, W. W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Blood Pressure Monitoring</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Blood Pressure Monitoring</style></full-title></periodical><pages><style face="normal" font="default" size="100%">195-204</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amlodipine [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">dosage [adverse effects] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010006128</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010006128/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>250</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">250</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Macchia, A.</style></author><author><style face="normal" font="default" size="100%">Marchioli, R.</style></author><author><style face="normal" font="default" size="100%">Tognoni, G.</style></author><author><style face="normal" font="default" size="100%">Scarano, M.</style></author><author><style face="normal" font="default" size="100%">Marfisi, R.</style></author><author><style face="normal" font="default" size="100%">Tavazzi, L.</style></author><author><style face="normal" font="default" size="100%">Rich, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Heart Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">245-257</style></pages><volume><style face="normal" font="default" size="100%">159</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010001903</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010001903/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>251</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">251</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Machado, M.</style></author><author><style face="normal" font="default" size="100%">Bajcar, J.</style></author><author><style face="normal" font="default" size="100%">Guzzo, G. C.</style></author><author><style face="normal" font="default" size="100%">Einarson, T. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Sensitivity of patient outcomes to pharmacist interventions - Part II: systematic review and meta-analysis in hypertension management (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1770-1781</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">administration</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Community Pharmacy Services [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacists</style></keyword><keyword><style face="normal" font="default" size="100%">Professional Role</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008009150</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008009150/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>686</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">686</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">MacKay-Lyons, Marilyn</style></author><author><style face="normal" font="default" size="100%">Thornton, Marianne</style></author><author><style face="normal" font="default" size="100%">Ruggles, Tim</style></author><author><style face="normal" font="default" size="100%">Che, Marion</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Non-pharmacological interventions for preventing secondary vascular events after stroke or transient ischemic attack</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008656</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Stroke is the second leading cause of death among adults worldwide. Individuals who have suffered a stroke are at high risk of having another stroke likely leading to greater disability and institutionalization. Non-pharmacological interventions may have a role to play in averting a second stroke.Objectives: To determine the effectiveness of multi-modal programs of non-pharmacological interventions compared with usual care in preventing secondary vascular events and reducing vascular risk factors after stroke or transient ischemic attack (TIA).Search methods: We searched the Cochrane Stroke Group Trials Register (September 2012); The Cochrane Library databases CENTRAL, CDSR, DARE, HTA and NHS EED (2012 Issue 2); MEDLINE (1950 to February 2012); EMBASE (1974 to February 2012); CINAHL (1982 to February 2012); SPORTDiscus (1800 to February 2012); PsycINFO (1887 to February 2012) and Web of Science (1900 to February 2012). We also searched PEDro, OT Seeker, OpenSIGLE, REHABDATA and Dissertation Abstracts (February 2012). In an effort to identify further published, unpublished and ongoing trials we searched trials registers, scanned reference lists, and contacted authors and researchers.Selection criteria: We included randomized controlled trials evaluating the use of non-pharmacological interventions that included components traditionally used in cardiac rehabilitation (CR) programs in adults with stroke or TIA. Primary outcomes were a cluster of second stroke or myocardial infarction or vascular death. Secondary outcomes were (1) secondary vascular events: second stroke, myocardial infarction, and vascular death, as well as (2) vascular risk factors: blood pressure, body weight, lipid profile, insulin resistance and tobacco use. We also recorded adverse events such as exercise-related musculoskeletal injuries or cardiovascular events.Data collection and analysis: Two review authors independently scanned titles and abstracts and independently screened full reports of studies that were potentially relevant. At each stage, we compared results. The two review authors resolved disagreements through discussion or by involving a third review author.Main results: We identified one study, involving 48 participants, of a 10-week CR program for patients post-stroke that met the inclusion criteria. The results of this completed pilot trial show that patients post-stroke had significantly greater improvement in cardiac risk score in the CR group (13.4 ± 10.1 to 12.4 ± 10.5, P value &lt; 0.05) when compared with usual care (9.4 ± 6.7 to 15.0 ± 6.1, P value &lt; 0.05). In addition, five trials, which are ongoing, will likely meet the inclusion criteria for this review once completed.Authors&apos; conclusions: There is limited applicable evidence. Therefore, no implications for practice can be drawn. Further research is required and several trials are underway, the findings of which are anticipated to contribute to the body of evidence.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008656.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008656.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>687</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">687</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mah Greg, T.</style></author><author><style face="normal" font="default" size="100%">Tejani Aaron, M.</style></author><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Methyldopa for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Methyldopa [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003893</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Methyldopa is a centrally acting antihypertensive agent, which was commonly used in the 1970&apos;s and 80&apos;s for blood pressure control. Its use at present has largely been replaced by antihypertensive drug classes with less side effects, but it is still used in developing countries due to its low cost. A review of its relative effectiveness compared to placebo on surrogate and clinical outcomes is justified.Objectives: To quantify the effect of methyldopa compared to placebo in randomized controlled trials (RCTs) on all cause mortality, cardiovascular mortality, serious adverse events, myocardial infarctions, strokes, withdrawals due to adverse effects and blood pressure in patients with primary hypertension.Search methods: We searched the following databases: Cochrane Central Register of Controlled Trials (1960-June 2009), MEDLINE (2005-June 2009), and EMBASE (2007-June 2009). Bibliographic citations from retrieved studies were also reviewed. No language restrictions were applied.Selection criteria: We selected RCTs studying patients with primary hypertension. We excluded studies of patients with secondary hypertension or gestational hypertension.Data collection and analysis: Two reviewers independently extracted data and assessed trial quality using the risk of bias tool. Data synthesis and analysis was performed using RevMan 5. Data for blood pressure were combined using the generic inverse variance method.Main results: Twelve trials (N=595) met the inclusion criteria for this review. None of these studies evaluated the effects of methyldopa compared to placebo on mortality and morbidity outcomes. Data for withdrawals due to adverse effects were not reported in a way that permitted meaningful meta-analysis. Data from six of the twelve trials (N=231) were combined to evaluate the blood pressure lowering effects of methyldopa compared to placebo. This meta-analysis shows that methyldopa at doses ranging from 500-2250 mg daily lowers systolic and diastolic blood pressure by a mean of 13 (95%CI 6-20) / 8 (95% CI 4-13) mmHg. Overall, the risk of bias was considered moderate.Authors&apos; conclusions: Methyldopa lowers blood pressure to varying degrees compared to placebo for patients with primary hypertension. Its effect on clinical outcomes, however, remains uncertain.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003893.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003893.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>252</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">252</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mahmoodi, B. K.</style></author><author><style face="normal" font="default" size="100%">Matsushita, K.</style></author><author><style face="normal" font="default" size="100%">Woodward, M.</style></author><author><style face="normal" font="default" size="100%">Blankestijn, P. J.</style></author><author><style face="normal" font="default" size="100%">Cirillo, M.</style></author><author><style face="normal" font="default" size="100%">Ohkubo, T.</style></author><author><style face="normal" font="default" size="100%">Rossing, P.</style></author><author><style face="normal" font="default" size="100%">Sarnak, M. J.</style></author><author><style face="normal" font="default" size="100%">Stengel, B.</style></author><author><style face="normal" font="default" size="100%">Yamagishi, K.</style></author><author><style face="normal" font="default" size="100%">Yamashita, K.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Coresh, J.</style></author><author><style face="normal" font="default" size="100%">Jong, P. E.</style></author><author><style face="normal" font="default" size="100%">Astor, B. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1649-1661</style></pages><volume><style face="normal" font="default" size="100%">380</style></volume><number><style face="normal" font="default" size="100%">9854</style></number><keywords><keyword><style face="normal" font="default" size="100%">Albuminuria [etiology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerular Filtration Rate [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [mortality] [physiopathology] [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [mortality] [physiopathology] [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012043231</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012043231/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>253</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">253</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mahtani, K. R.</style></author><author><style face="normal" font="default" size="100%">Nunan, D.</style></author><author><style face="normal" font="default" size="100%">Heneghan, C. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Device-guided breathing exercises in the control of human blood pressure: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">852-860</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Breathing Exercises</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment and Supplies</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Systole</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012021145</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012021145/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>254</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">254</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maier, P. C.</style></author><author><style face="normal" font="default" size="100%">Funk, J.</style></author><author><style face="normal" font="default" size="100%">Schwarzer, G.</style></author><author><style face="normal" font="default" size="100%">Antes, G.</style></author><author><style face="normal" font="default" size="100%">Falck-Ytter, Y. T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><pages><style face="normal" font="default" size="100%">134</style></pages><volume><style face="normal" font="default" size="100%">331</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Glaucoma, Open-Angle [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma, Open-Angle [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005008315</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005008315/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>255</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">255</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maimaris, W.</style></author><author><style face="normal" font="default" size="100%">Paty, J.</style></author><author><style face="normal" font="default" size="100%">Perel, P.</style></author><author><style face="normal" font="default" size="100%">Legido-Quigley, H.</style></author><author><style face="normal" font="default" size="100%">Balabanova, D.</style></author><author><style face="normal" font="default" size="100%">Nieuwlaat, R.</style></author><author><style face="normal" font="default" size="100%">McKee, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">PLOS Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLOS Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e1001490</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013048237</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013048237/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>256</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">256</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Makani, H.</style></author><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Romero, J.</style></author><author><style face="normal" font="default" size="100%">Wever-Pinzon, O.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">128-135</style></pages><volume><style face="normal" font="default" size="100%">124</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">dosage [adverse effects] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Edema [chemically induced] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Refusal</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011001575</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001575/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>257</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">257</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Makani, H.</style></author><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author><author><style face="normal" font="default" size="100%">Supariwala, A.</style></author><author><style face="normal" font="default" size="100%">Romero, J.</style></author><author><style face="normal" font="default" size="100%">Argulian, E.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Heart Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1732-1742</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">26</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Losartan</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013051165</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013051165/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>258</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">258</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Makarounas-Kirchmann, K.</style></author><author><style face="normal" font="default" size="100%">Glover-Koudounas, S.</style></author><author><style face="normal" font="default" size="100%">Ferrari, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1652-1663</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Dihydropyridines [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Edema [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000643</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000643/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>259</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">259</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mallareddy, M.</style></author><author><style face="normal" font="default" size="100%">Parikh, C. R.</style></author><author><style face="normal" font="default" size="100%">Peixoto, A. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of angiotensin-converting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">398-403</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Arteries [drug effects] [physiopathology] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Brachial Artery [drug effects] [physiopathology] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Arteries [drug effects] [physiopathology] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Femoral Artery [drug effects] [physiopathology] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Radial Artery [drug effects] [physiopathology] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006004173</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006004173/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>260</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">260</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mancia, G.</style></author><author><style face="normal" font="default" size="100%">Parati, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Office compared with ambulatory blood pressure in assessing response to anti hypertensive treatment: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">435-445</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Physicians&apos; Offices</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004000791</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004000791/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>261</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">261</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Manisty, C. H.</style></author><author><style face="normal" font="default" size="100%">Hughes, A. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">79-92</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [classification] [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Aorta [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Brachial Artery [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Systole [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013002546</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013002546/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>262</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">262</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marshall, I. J.</style></author><author><style face="normal" font="default" size="100%">Wolfe, C. D.</style></author><author><style face="normal" font="default" size="100%">McKevitt, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lay perspectives on hypertension and drug adherence: systematic review of qualitative research (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e3953</style></pages><volume><style face="normal" font="default" size="100%">345</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage] [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Health Knowledge, Attitudes, Practice [ethnology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [ethnology] [psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Intention</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence [ethnology] [psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Qualitative Research</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Psychological [complications] [ethnology]</style></keyword><keyword><style face="normal" font="default" size="100%">World Health</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012031565</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012031565/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>688</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">688</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martí-Carvajal Arturo, J.</style></author><author><style face="normal" font="default" size="100%">Agreda-Pérez Luis, H.</style></author><author><style face="normal" font="default" size="100%">Solà, Ivan</style></author><author><style face="normal" font="default" size="100%">Simancas-Racines, Daniel</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anemia [blood] [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Arthritis, Rheumatoid [blood] [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Erythropoietin [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hematinics [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobin A [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Muskel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD000332</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disorder that mainly affects the small joints of the hands and feet. Erythropoiesis-stimulating agents have been used to treat anemia, one of the extra-articular manifestations of RA. Although anemia is less of a problem now because of the reduction in inflammation due to disease-modifying antirheumatic drugs (DMARDs), it could still be an issue in countries where DMARDs are not yet accessible.Objectives: We assessed the clinical benefits and harms of erythropoiesis-stimulating agents for anemia in rheumatoid arthritis.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (issue 7 2012), Ovid MEDLINE and Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations (1948 to 7 August 2012), OVID EMBASE (1980 to 7 August 2012), LILACS (1982 to 7 August 2012), the Clinical Trials Search Portal of the World Health Organization, reference lists of the retrieved publications and review articles. We did not apply any language restrictions.Selection criteria: We included randomized controlled trials (RCTs) in patients aged 16 years or over, with a diagnosis of rheumatoid arthritis affected by anemia. We considered health-related quality of life, fatigue and safety as the primary outcomes.Data collection and analysis: Two authors independently performed trial selection, risk of bias assessment, and data extraction. We estimated difference in means with 95% confidence intervals (CIs) for continuous outcomes. We estimated risk ratios with 95% CIs for binary outcomes.Main results: We included three RCTs with a total of 133 participants. All trials compared human recombinant erythropoietin (EPO), for different durations (8, 12 and 52 weeks), versus placebo. All RCTs assessed health-related quality of life. All trials had high or unclear risk of bias for most domains, and were sponsored by the pharmaceutical industry. Two trials administered EPO by a subcutaneous route while the other used an intravenous route.We decided not to pool results from trials, due to inconsistencies in the reporting of results.Health-related quality of life: subcutaneous EPO ? one trial with 70 patients at 52 weeks showed a statistically significant difference in improvement of patient global assessment (median and interquartile range 3.5 (1.0 to 6.0) compared with placebo 4.5 (2.0 to 7.5) (P = 0.027) on a VAS scale (0 to 10)). The other shorter term trials (12 weeks with subcutaneous EPO and eight weeks with intravenous administration) did not find statistically significant differences between treatment and control groups in health-related quality of life outcomes.Change in hemoglobin: both trials of subcutaneous EPO showed a statistically significant difference in increasing hemoglobin levels; (i) at  52 weeks (one trial, 70 patients), intervention hemoglobin level (median 134, interquartile range 110 to 158 g/litre) compared with the placebo group level (median 112, interquartile range; 86 to 128 g/litre) (P = 0.0001); (ii) at  12 weeks (one trial, 24 patients) compared with placebo (difference in means 8.00, 95% CI 7.43 to 8.57). Intravenous EPO at eight weeks showed no statistically significant difference in increasing hematocrit level for EPO versus placebo (difference in means 4.69, 95% CI -0.17 to 9.55; P = 0.06).Information on withdrawals due to adverse events was not reported in two trials, and one trial found no serious adverse events leading to withdrawals. None of the trials reported withdrawals due to high blood pressure, or to lack of efficacy or to fatigue.Authors&apos; conclusions: We found conflicting evidence for erythropoiesis-stimulating agents to increase quality of life and hemoglobin level by treating anemia in patients with rheumatoid arthritis. However, this conclusion is based on randomized controlled trials with a high risk of bias, and relies on trials assessing human recombinant erythropoietin (EPO). The safety profile of EPO is unclear. Future trials assessing erythropoiesis-stimulating agents for nemia in rheumatoid arthritis should be conducted by independent researchers and reported according to the CONSORT statements. Trials should be based on Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) and The Patient-Centered Outcomes Research Institute (PCORI) approaches for combining both clinician and patient perspectives.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000332.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD000332.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>689</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">689</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martinez, L.</style></author><author><style face="normal" font="default" size="100%">Paladio, N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ambrisentan (Volibris) in the treatment of pulmonary arterial hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylpropionates</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridazines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">Catalan Agency for Health Information, Assessment and Quality (CAHIAQ) - formerly CAHTA</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010000734</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010000734/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>263</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">263</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mason, J. M.</style></author><author><style face="normal" font="default" size="100%">Dickinson, H. O.</style></author><author><style face="normal" font="default" size="100%">Nicolson, D. J.</style></author><author><style face="normal" font="default" size="100%">Campbell, F.</style></author><author><style face="normal" font="default" size="100%">Ford, G. A.</style></author><author><style face="normal" font="default" size="100%">Williams, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1777-1781</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride Symporter Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005004685</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005004685/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>690</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">690</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mason, Martina</style></author><author><style face="normal" font="default" size="100%">Welsh Emma, J.</style></author><author><style face="normal" font="default" size="100%">Smith, Ian</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Drug therapy for obstructive sleep apnoea in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep Apnea, Obstructive [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003002</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: The treatment of choice for moderate to severe obstructive sleep apnoea (OSA) is continuous positive airways pressure (CPAP) applied via a mask during sleep. However, this is not tolerated by all individuals and its role in mild OSA is not proven. Drug therapy has been proposed as an alternative to CPAP in some patients with mild to moderate sleep apnoea and could be of value in patients intolerant of CPAP. A number of mechanisms have been proposed by which drugs could reduce the severity of OSA. These include an increase in tone in the upper airway dilator muscles, an increase in ventilatory drive, a reduction in the proportion of rapid eye movement (REM) sleep, an increase in cholinergic tone during sleep, an increase in arousal threshold, a reduction in airway resistance and a reduction in surface tension in the upper airway.Objectives: To determine the efficacy of drug therapies in the specific treatment of sleep apnoea.Search methods: We searched the Cochrane Airways Group Specialised Register of trials. Searches were current as of July 2012.Selection criteria: Randomised, placebo controlled trials involving adult patients with confirmed OSA. We excluded trials if continuous positive airways pressure, mandibular devices or oxygen therapy were used. We excluded studies investigating treatment of associated conditions such as excessive sleepiness, hypertension, gastro-oesophageal reflux disease and obesity.Data collection and analysis: We used standard methodological procedures recommended by The Cochrane Collaboration.Main results: Thirty trials of 25 drugs, involving 516 participants, contributed data to the review. Drugs had several different proposed modes of action and the results were grouped accordingly in the review. Each of the studies stated that the participants had OSA but diagnostic criteria were not always explicit and it was possible that some patients with central apnoeas may have been recruited.Acetazolamide, eszopiclone, naltrexone, nasal lubricant (phosphocholinamine) and physiostigmine were administered for one to two nights only. Donepezil in patients with and without Alzheimer&apos;s disease, fluticasone in patients with allergic rhinitis, combinations of ondansetrone and fluoxetine and paroxetine were trials of one to three months duration, however most of the studies were small and had methodological limitations. The overall quality of the available evidence was low.The primary outcomes for the systematic review were the apnoea hypopnoea index (AHI) and the level of sleepiness associated with OSA, estimated by the Epworth Sleepiness Scale (ESS). AHI was reported in 25 studies and of these 10 showed statistically significant reductions in AHI.Fluticasone in patients with allergic rhinitis was well tolerated and reduced the severity of sleep apnoea compared with placebo (AHI 23.3 versus 30.3; P &lt; 0.05) and improved subjective daytime alertness. Excessive sleepiness was reported to be altered in four studies, however the only clinically and statistically significant change in ESS of -2.9 (SD 2.9; P = 0.04) along with a small but statistically significant reduction in AHI of -9.4 (SD 17.2; P = 0.03) was seen in patients without Alzheimer&apos;s disease receiving donepezil for one month. In 23 patients with mild to moderate Alzheimer&apos;s disease donepezil led to a significant reduction in AHI (donepezil 20 (SD 15) to 9.9 (SD 11.5) versus placebo 23.2 (SD 26.4) to 22.9 (SD 28.8); P = 0.035) after three months of treatment but no reduction in sleepiness was reported. High dose combined treatment with ondansetron 24 mg and fluoxetine 10 mg showed a 40.5% decrease in AHI from the baseline at treatment day 28. Paroxetine was shown to reduce AHI compared to placebo (-6.10 events/hour; 95% CI -11.00 to -1.20) but failed to improve daytime symptoms.Promising results from the preliminary mirtazapine study failed to be reproduced in the two more recent multicentre trials and, moreover, the use of mirtazapine was associated with significant weight gain and sleepiness. Few data were presented on the long-te m tolerability of any of the compounds used.Authors&apos; conclusions: There is insufficient evidence to recommend the use of drug therapy in the treatment of OSA. Small studies have reported positive effects of certain agents on short-term outcomes. Certain agents have been shown to reduce the AHI in largely unselected populations with OSA by between 24% and 45%. For donepezil and fluticasone, studies of longer duration with a larger population and better matching of groups are required to establish whether the change in AHI and impact on daytime symptoms are reproducible. Individual patients had more complete responses to particular drugs. It is possible that better matching of drugs to patients according to the dominant mechanism of their OSA will lead to better results and this also needs further study.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003002.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003002.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>691</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">691</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matchar, D. B.</style></author><author><style face="normal" font="default" size="100%">McCrory, D. C.</style></author><author><style face="normal" font="default" size="100%">Orlando, L. A.</style></author><author><style face="normal" font="default" size="100%">Patel, M. R.</style></author><author><style face="normal" font="default" size="100%">Patel, U. D.</style></author><author><style face="normal" font="default" size="100%">Patwardhan, M. B.</style></author><author><style face="normal" font="default" size="100%">Powers, B.</style></author><author><style face="normal" font="default" size="100%">Samsa, G. P.</style></author><author><style face="normal" font="default" size="100%">Gray, R. N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative effectiveness of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs) for treating essential hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Healthcare Research and Quality (AHRQ)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010001626</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010001626/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>264</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">264</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matchar, D. B.</style></author><author><style face="normal" font="default" size="100%">McCrory, D. C.</style></author><author><style face="normal" font="default" size="100%">Orlando, L. A.</style></author><author><style face="normal" font="default" size="100%">Patel, M. R.</style></author><author><style face="normal" font="default" size="100%">Patel, U. D.</style></author><author><style face="normal" font="default" size="100%">Patwardhan, M. B.</style></author><author><style face="normal" font="default" size="100%">Powers, B.</style></author><author><style face="normal" font="default" size="100%">Samsa, G. P.</style></author><author><style face="normal" font="default" size="100%">Gray, R. N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">16-29</style></pages><volume><style face="normal" font="default" size="100%">148</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008008049</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008008049/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>692</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">692</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mathew Joseph, L.</style></author><author><style face="normal" font="default" size="100%">El Dib, Regina</style></author><author><style face="normal" font="default" size="100%">Mathew Preethy, J.</style></author><author><style face="normal" font="default" size="100%">Boxall Elizabeth, H.</style></author><author><style face="normal" font="default" size="100%">Brok, Jesper</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">DNA, Viral [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatitis B [immunology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatitis B e Antigens [immunology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatitis B Surface Antigens [immunology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatitis B Vaccines [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006481</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: The benefits and harms of hepatitis B vaccination in persons not previously exposed to hepatitis B infection or with unknown exposure status have not been established.Objectives: To assess the benefits and harms of hepatitis B vaccination in people not previously exposed to hepatitis B infection or with unknown exposure status.Search methods: Trials were identified from The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, Science Citation Index Expanded (last search, March 2007). Additionally, we contacted experts and vaccine manufacturers, and read through reference lists for eligible trials.Selection criteria: Randomised clinical trials comparing hepatitis B vaccine versus placebo, no intervention, or another vaccine in persons not previously exposed to hepatitis B (HBsAg negative) or with unknown exposure status.Data collection and analysis: The primary outcome was hepatitis B infection (detecting HBsAg, HBeAg, HBV DNA, or anti-HBc). Secondary outcomes were lack of sero-protection, antibody titre, clinical complications, adverse events, lack of compliance, and cost-effectiveness. Dichotomous outcomes were reported as relative risk (RR) with 95% confidence interval (CI), using intention-to-treat analysis assuming an unfavourable event for missing data. Sensitivity analyses based on methodological quality (risk of bias), available data analysis, intention-to-treat analysis assuming a favourable event for missing data, best-case scenario, and worst-case scenario were conducted.Main results: Twelve trials were eligible. All had high risk of bias and reporting was inconsistent. Hepatitis B vaccine did not show a clear effect on the risk of developing HBsAg (RR 0.96, 95% CI 0.89 to 1.03, 4 trials, 1230 participants) and anti-HBc (RR 0.81, 95% CI 0.61 to 1.07; 4 trials, 1230 participants, random-effects) when data were analysed using intention-to-treat analysis assuming an unfavourable event for missing data. Analysis based on data of available participants showed reduced risk of developing HBsAg (RR 0.12, 95% CI 0.03 to 0.44, 4 trials, 576 participants) and anti-HBc (RR 0.36, 95% CI 0.17 to 0.76, 4 trials, 576 participants, random-effects). Intention-to-treat analysis assuming favourable outcome for missing data showed similar reduction in risk. Hepatitis B vaccination had an unclear effect on the risk of lacking protective antibody levels (RR 0.57, 95% CI 0.26 to 1.27, 3 trials, 1210 participants, random-effects). Development of adverse events was sparsely reported.Authors&apos; conclusions: In people not previously exposed to hepatitis B, vaccination has unclear effect on the risk of developing infection, as compared to no vaccination. The risk of lacking protective antibody levels as well as serious and non-serious adverse events appear comparable among recipients and non-recipients of hepatitis B vaccine.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006481.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006481.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>265</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">265</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mazzaro, C. C.</style></author><author><style face="normal" font="default" size="100%">Klostermann, F. C.</style></author><author><style face="normal" font="default" size="100%">Erbano, B. O.</style></author><author><style face="normal" font="default" size="100%">Schio, N. A.</style></author><author><style face="normal" font="default" size="100%">Guarita-Souza, L. C.</style></author><author><style face="normal" font="default" size="100%">Olandoski, M.</style></author><author><style face="normal" font="default" size="100%">Faria-Neto, J. R.</style></author><author><style face="normal" font="default" size="100%">Baena, C. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Dietary interventions and blood pressure in Latin America ? systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Diet Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Latin America</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014024409</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014024409/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>266</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">266</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McAlister, F. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Heart Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">505-514</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Observer Variation</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012011755</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012011755/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>267</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">267</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McBrien, K.</style></author><author><style face="normal" font="default" size="100%">Rabi, D. M.</style></author><author><style face="normal" font="default" size="100%">Campbell, N.</style></author><author><style face="normal" font="default" size="100%">Barnieh, L.</style></author><author><style face="normal" font="default" size="100%">Clement, F.</style></author><author><style face="normal" font="default" size="100%">Hemmelgarn, B. R.</style></author><author><style face="normal" font="default" size="100%">Tonelli, M.</style></author><author><style face="normal" font="default" size="100%">Leiter, L. A.</style></author><author><style face="normal" font="default" size="100%">Klarenbach, S. W.</style></author><author><style face="normal" font="default" size="100%">Manns, B. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">E1-e8</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose Intolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012035427</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012035427/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>268</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">268</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McCrory, D. C.</style></author><author><style face="normal" font="default" size="100%">Coeytaux, R. R.</style></author><author><style face="normal" font="default" size="100%">Schmit, K. M.</style></author><author><style face="normal" font="default" size="100%">Kraft, B.</style></author><author><style face="normal" font="default" size="100%">Kosinski, A. S.</style></author><author><style face="normal" font="default" size="100%">Mingo, A. M.</style></author><author><style face="normal" font="default" size="100%">Vann, L. M.</style></author><author><style face="normal" font="default" size="100%">Gilstrap, D. L.</style></author><author><style face="normal" font="default" size="100%">Hargett, C. W.</style></author><author><style face="normal" font="default" size="100%">Lugogo, N. L.</style></author><author><style face="normal" font="default" size="100%">Heidenfelder, B. L.</style></author><author><style face="normal" font="default" size="100%">Posey, R.</style></author><author><style face="normal" font="default" size="100%">Irvine, R. J.</style></author><author><style face="normal" font="default" size="100%">Wing, L.</style></author><author><style face="normal" font="default" size="100%">Pendergast, K.</style></author><author><style face="normal" font="default" size="100%">Dolor, R. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pulmonary arterial hypertension: screening, management, and treatment (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Healthcare Research and Quality</style></publisher><accession-num><style face="normal" font="default" size="100%">DARE-12013022189</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013022189/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>693</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">693</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McCrory, D. C.</style></author><author><style face="normal" font="default" size="100%">Coeytaux, R. R.</style></author><author><style face="normal" font="default" size="100%">Schmit, K. M.</style></author><author><style face="normal" font="default" size="100%">Kraft, B.</style></author><author><style face="normal" font="default" size="100%">Kosinski, A. S.</style></author><author><style face="normal" font="default" size="100%">Mingo, A. M.</style></author><author><style face="normal" font="default" size="100%">Vann, L. M.</style></author><author><style face="normal" font="default" size="100%">Gilstrap, D. L.</style></author><author><style face="normal" font="default" size="100%">Hargett, C. W.</style></author><author><style face="normal" font="default" size="100%">Lugogo, N. L.</style></author><author><style face="normal" font="default" size="100%">Heidenfelder, B. L.</style></author><author><style face="normal" font="default" size="100%">Posey, R.</style></author><author><style face="normal" font="default" size="100%">Irvine, R. J.</style></author><author><style face="normal" font="default" size="100%">Wing, L.</style></author><author><style face="normal" font="default" size="100%">Pendergast, K.</style></author><author><style face="normal" font="default" size="100%">Dolor, R. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pulmonary arterial hypertension: screening, management, and treatment (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Catheterization, Swan-Ganz</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Artery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">HTA-32006001029</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32006001029/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>694</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">694</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McGuinness, Bernadette</style></author><author><style face="normal" font="default" size="100%">Todd, Stephen</style></author><author><style face="normal" font="default" size="100%">Passmore, Peter</style></author><author><style face="normal" font="default" size="100%">Bullock, Roger</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer Disease [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition Disorders [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia, Vascular [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004034</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: This is an update of a previous review (McGuinness 2006).Hypertension and cognitive impairment are prevalent in older people. Hypertension is a direct risk factor for vascular dementia (VaD) and recent studies have suggested hypertension impacts upon prevalence of Alzheimer&apos;s disease (AD). Therefore does treatment of hypertension prevent cognitive decline?Objectives: To assess the effects of blood pressure lowering treatments for the prevention of dementia and cognitive decline in patients with hypertension but no history of cerebrovascular disease.Search methods: The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group, The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS as well as many trials databases and grey literature sources were searched on 13 February 2008 using the terms: hypertens$ OR anti-hypertens$.Selection criteria: Randomized, double-blind, placebo controlled trials in which pharmacological or non-pharmacological interventions to lower blood pressure were given for at least six months.Data collection and analysis: Two independent reviewers assessed trial quality and extracted data. The following outcomes were assessed: incidence of dementia, cognitive change from baseline, blood pressure level, incidence and severity of side effects and quality of life.Main results: Four trials including 15,936 hypertensive subjects were identified. Average age was 75.4 years. Mean blood pressure at entry across the studies was 171/86 mmHg. The combined result of the four trials reporting incidence of dementia indicated no significant difference between treatment and placebo (236/7767 versus 259/7660, Odds Ratio (OR) = 0.89, 95% CI 0.74, 1.07) and there was considerable heterogeneity between the trials. The combined results from the three trials reporting change in Mini Mental State Examination (MMSE) did not indicate a benefit from treatment (Weighted Mean Difference (WMD) = 0.42, 95% CI 0.30, 0.53). Both systolic and diastolic blood pressure levels were reduced significantly in the three trials assessing this outcome (WMD = -10.22, 95% CI -10.78, -9.66 for systolic blood pressure, WMD = -4.28, 95% CI -4.58, -3.98 for diastolic blood pressure). Three trials reported adverse effects requiring discontinuation of treatment and the combined results indicated no significant difference (OR = 1.01, 95% CI 0.92, 1.11). When analysed separately, however, more patients on placebo in Syst Eur 1997 were likely to discontinue treatment due to side effects; the converse was true in SHEP 1991. Quality of life data could not be analysed in the four studies. Analysis of the included studies in this review was problematic as many of the control subjects received antihypertensive treatment because their blood pressures exceeded pre-set values. In most cases the study became a comparison between the study drug against a usual antihypertensive regimen.Authors&apos; conclusions: There is no convincing evidence from the trials identified that blood pressure lowering in late-life prevents the development of dementia or cognitive impairment in hypertensive patients with no apparent prior cerebrovascular disease. There were significant problems identified with analysing the data, however, due to the number of patients lost to follow-up and the number of placebo patients who received active treatment. This introduced bias. More robust results may be obtained by conducting a meta-analysis using individual patient data.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004034.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004034.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>269</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">269</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McRae, M. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Is vitamin C an effective antihypertensive supplement: a review and analysis of the literature (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Chiropractic Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Chiropractic Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">60-64</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Ascorbic Acid [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006008564</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006008564/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>270</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">270</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McRae, M. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">High-dose folic acid supplementation effects on endothelial function and blood pressure in hypertensive patients: a meta-analysis of randomized controlled clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Chiropractic Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Chiropractic Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">15-24</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular</style></keyword><keyword><style face="normal" font="default" size="100%">Folic Acid [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009105618</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009105618/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>271</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">271</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meredith, P. A.</style></author><author><style face="normal" font="default" size="100%">Murray, L. S.</style></author><author><style face="normal" font="default" size="100%">McInnes, G. T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">525-531</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Losartan [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010005740</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010005740/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>272</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">272</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author><author><style face="normal" font="default" size="100%">Makani, H.</style></author><author><style face="normal" font="default" size="100%">Benjo, A.</style></author><author><style face="normal" font="default" size="100%">Romero, J.</style></author><author><style face="normal" font="default" size="100%">Alviar, C.</style></author><author><style face="normal" font="default" size="100%">Bangalore, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">590-600</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory [methods] [standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011001327</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001327/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>695</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">695</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Michael, Mini</style></author><author><style face="normal" font="default" size="100%">Elliott Elizabeth, J.</style></author><author><style face="normal" font="default" size="100%">Ridley Greta, F.</style></author><author><style face="normal" font="default" size="100%">Hodson Elisabeth, M.</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cyclophosphamide [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hemolytic-Uremic Syndrome [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulins, Intravenous [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Mycophenolic Acid [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Plasma Exchange</style></keyword><keyword><style face="normal" font="default" size="100%">Purpura, Thrombotic Thrombocytopenic [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003595</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are related conditions with similar clinical features of variable severity. Survival of patients with HUS and TTP has improved greatly over the past two decades with improved supportive care for patients with HUS and by the use of plasma exchange (PE) with fresh frozen plasma (FFP) for patients with TTP. Separate pathogenesis of these two disorders has become more evident, but management overlaps.Objectives: To evaluate the benefits and harms of different interventions for HUS and TTP separately, in patients of all ages.Search methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), conference proceedings, reference lists of articles and text books and contact with investigators were used to identify relevant studies.Selection criteria: Randomised controlled trials (RCTs) evaluating any interventions for HUS or TTP in patients of all ages.Data collection and analysis: Three authors independently extracted data and evaluated study reporting quality using standard Cochrane criteria. Analysis was undertaken using a random effects model and results expressed as risk ratio (RR) and 95% confidence intervals (CI).Main results: For TTP, we found six RCTs (331 participants) evaluating PE with FFP as the control. Interventions tested included antiplatelet therapy (APT) plus PE with FFP, FFP transfusion and PE with cryosupernatant plasma (CSP). Two studies compared plasma infusion (PI) to PE with FFP and showed a significant increase in failure of remission at two weeks (RR 1.48, 95% 1.12 to 1.96) and all-cause mortality (RR 1.91, 95% 1.09 to 3.33) in the PI group. Seven RCTs were undertaken in children with HUS. None of the assessed interventions used (FFP transfusion, heparin with or without urokinase or dipyridamole, shiga toxin binding protein and steroids) were superior to supportive therapy alone, for all-cause mortality, neurological/extrarenal events, renal biopsy changes, proteinuria or hypertension at the last follow-up visit. Bleeding was significantly higher in those receiving anticoagulation therapy compared to supportive therapy alone (RR 25.89, 95% CI 3.67 to 182.83).Authors&apos; conclusions: PE with FFP is still the most effective treatment available for TTP. For patients with HUS, supportive therapy including dialysis is still the most effective treatment. All studies in HUS have been conducted in the diarrhoeal form of the disease. There were no RCTs evaluating the effectiveness of any interventions on patients with atypical HUS who have a more chronic and relapsing course.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003595.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003595.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>696</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">696</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Michelessi, Manuele</style></author><author><style face="normal" font="default" size="100%">Lindsley, Kristina</style></author><author><style face="normal" font="default" size="100%">Yu, Tsung</style></author><author><style face="normal" font="default" size="100%">Li, Tianjing</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Eyes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD011366</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:The objectives of this review are to examine the comparative effectiveness and safety of different glaucoma fixed combination therapies and monotherapies in eyes with primary open angle glaucoma or ocular hypertension and to provide relative rankings of these treatments.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011366/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD011366</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>273</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">273</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mick, E.</style></author><author><style face="normal" font="default" size="100%">McManus, D. D.</style></author><author><style face="normal" font="default" size="100%">Goldberg, R. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Neuropsychopharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Neuropsychopharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">534-541</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aging</style></keyword><keyword><style face="normal" font="default" size="100%">Attention Deficit Disorder with Hyperactivity [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Central Nervous System Stimulants [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Tachycardia [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012034074</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012034074/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>274</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">274</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Montero, D.</style></author><author><style face="normal" font="default" size="100%">Roche, E.</style></author><author><style face="normal" font="default" size="100%">Martinez-Rodriguez, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The impact of aerobic exercise training on arterial stiffness in pre- and hypertensive subjects: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">361-368</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Stiffness</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014025194</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014025194/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>275</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">275</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Montero, D.</style></author><author><style face="normal" font="default" size="100%">Walther, G.</style></author><author><style face="normal" font="default" size="100%">Benamo, E.</style></author><author><style face="normal" font="default" size="100%">Perez-Martin, A.</style></author><author><style face="normal" font="default" size="100%">Vinet, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of exercise training on arterial function in type 2 diabetes mellitus: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Sports Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sports Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1191-1199</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Smooth, Vascular</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013046535</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013046535/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>697</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">697</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Montero, Nuria</style></author><author><style face="normal" font="default" size="100%">Webster Angela, C.</style></author><author><style face="normal" font="default" size="100%">Royuela, Ana</style></author><author><style face="normal" font="default" size="100%">Zamora, Javier</style></author><author><style face="normal" font="default" size="100%">Crespo Barrio, Marta</style></author><author><style face="normal" font="default" size="100%">Pascual, Julio</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007669</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Pancreas or kidney-pancreas transplantation improves survival and quality of life for people with type 1 diabetes mellitus and kidney failure. Immunosuppression after transplantation is associated with complications. Steroids have adverse effects on cardiovascular risk factors such as hypertension, hyperglycaemia or hyperlipidaemia, increase risk of infection, obesity, cataracts, myopathy, bone metabolism alterations, dermatologic problems and cushingoid appearance. Whether avoiding steroids changes outcomes is unclear.Objectives: We aimed to assess the safety and efficacy of steroid early withdrawal (treatment for less than 14 days after transplantation), late withdrawal (after 14 days after transplantation) or steroid avoidance in patients receiving a pancreas (including a vascularized organ) alone (PTA), simultaneous with a kidney (SPK) or after kidney transplantation (PAK).Search methods: We searched the Cochrane Renal Group&apos;s Specialised Register (to 18 June 2014) through contact with the Trials&apos; Search Co-ordinator. We handsearched: reference lists of nephrology textbooks, relevant studies, recent publications and clinical practice guidelines; abstracts from international transplantation society scientific meetings; and sent emails and letters seeking information about unpublished or incomplete studies to known investigators.Selection criteria: We included randomised controlled trials (RCTs) or cohort studies of steroid avoidance (including early withdrawal) versus steroid maintenance or versus late withdrawal in pancreas or pancreas with kidney transplant recipients. We defined steroid avoidance as complete avoidance of steroid immunosuppression, early steroid withdrawal as steroid treatment for less than 14 days after transplantation and late withdrawal as steroid withdrawal after 14 days after transplantation.Data collection and analysis: Two authors independently assessed the retrieved titles and abstracts, and where necessary the full text reports to determine which studies satisfied the inclusion criteria. Authors of included studies were contacted to obtain missing information. Statistical analyses were performed using random effects models and results expressed as risk ratio (RR) or mean difference (MD) with 95% confidence interval (CI). Cohort studies were not meta-analysed, but their findings summarised descriptively.Main results: Three RCTs enrolling 144 participants met our inclusion criteria. Two compared steroid avoidance versus late steroid withdrawal and one compared late steroid withdrawal versus steroid maintenance. All studies included SPK and only one also included PTA. All studies had an overall moderate risk of bias and presented only short-term results (six to 12 months). Two studies (89 participants) compared steroid avoidance or early steroid withdrawal versus late steroid withdrawal. There was no clear evidence of an impact on mortality (2 studies, 89 participants: RR 1.64, 95% CI 0.21 to 12.75), risk of kidney loss censored for death (2 studies, 89 participants: RR 0.35, 95% CI 0.04 to 3.09), risk of pancreas loss censored for death (2 studies, 89 participants: RR 1.05, 95% CI 0.36 to 3.04), or acute kidney rejection (1 study, 49 participants: RR 2.08, 95% CI 0.20 to 21.50), however results were uncertain and consistent with no difference or important benefit or harm of steroid avoidance/early steroid withdrawal. The study that compared late steroid withdrawal versus steroid maintenance observed no deaths, no graft loss or acute kidney rejection at six months in either group and reported uncertain effects on acute pancreas rejection (RR 0.88, 95% CI 0.06 to 13.35). Of the possible adverse effects only infection was reported by one study. There were significantly more UTIs reported in the late withdrawal group compared to the steroid avoidance group (1 study, 25 patients: RR 0.41, 95% CI 0.26 to 0.66).We also identified 13 cohort studies and one RCT which randomised tacrolimus versus cyclosporin. These studies in general showed that steroid-sparing and withdrawal strategies had benefits in lowering HbAc1 and risk of infections (BK virus and CMV disease) and improved blood pressure control without increasing the risk of rejection. However, two studies found an increased incidence of acute pancreas rejection (HR 2.8, 95% CI 0.89 to 8.81, P = 0.066 in one study and 43.3% in the steroid withdrawal group versus 9.3% in the steroid maintenance, P &lt; 0.05 at three years in the other) and one study found an increased incidence of acute kidney rejection (18.7% in the steroid withdrawal group versus 2.8% in the steroid maintenance, P &lt; 0.05) at three years.Authors&apos; conclusions: There is currently insufficient evidence for the benefits and harms of steroid withdrawal in pancreas transplantation in the three RCTs (144 patients) identified. The results showed uncertain results for short-term risk of rejection, mortality, or graft survival in steroid-sparing strategies in a very small number of patients over a short period of follow-up. Overall the data was sparse, so no firm conclusions are possible. Moreover, the 13 observational studies findings generally concur with the evidence found in the RCTs.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007669.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007669.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>698</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">698</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moraa, Irene</style></author><author><style face="normal" font="default" size="100%">Sturman, Nancy</style></author><author><style face="normal" font="default" size="100%">McGuire, Treasure</style></author><author><style face="normal" font="default" size="100%">van Driel Mieke, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Heliox for croup in children</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Airway Obstruction [etiology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Airway Resistance [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Croup [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Dexamethasone [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Epinephrine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Helium [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen Inhalation Therapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Ari</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006822</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Croup is thought to be triggered by a viral infection and is characterised by respiratory distress due to upper airway inflammation and swelling of the subglottic mucosa in children. Mostly it is mild and transient and resolves with supportive care. In moderate to severe cases, treatment with corticosteroids and nebulised epinephrine (adrenaline) is required. Corticosteroids improve symptoms but it takes time for a full effect to be achieved. In the interim, the child is at risk of further deterioration. This may rarely result in respiratory failure necessitating emergency intubation and ventilation. Nebulised epinephrine may result in dose-related adverse effects including tachycardia, arrhythmias and hypertension and its benefit may be short-lived. Helium-oxygen (heliox) inhalation has shown therapeutic benefit in initial treatment of acute respiratory syncytial virus (RSV) bronchiolitis and may prevent morbidity and mortality in ventilated neonates. Heliox has been used during emergency transport of children with severe croup and anecdotal evidence suggests that heliox relieves respiratory distress.Objectives: To examine the effect of heliox on relieving symptoms and signs of croup, as determined by a croup score (a tool for measuring the severity of croup). To examine the effect of croup on rates of admission or intubation (or both), through comparisons of heliox with placebo or any active intervention(s) in children with croup.Search methods: We searched CENTRAL 2013, Issue 10, MEDLINE (1950 to October week 5, 2013), EMBASE (1974 to November 2013), CINAHL (1982 to November 2013), Web of Science (1955 to November 2013) and LILACS (1982 to November 2013). In addition, we searched two clinical trials registries: the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and clinicaltrials.gov (searched 12 November 2013).Selection criteria: Randomised controlled trials (RCTs) and quasi-RCTs comparing the effect of helium-oxygen mixtures with placebo or any active intervention(s) in children with croup.Data collection and analysis: Two review authors independently identified and assessed citations for inclusion. A third review author resolved disagreements. We assessed included trials for allocation concealment, blinding of intervention, completeness of outcome data, selective outcome reporting and other potential sources of bias. We reported mean differences for continuous data and odds ratios for dichotomous data. We descriptively reported data not suitable for statistical analysis.Main results: We included three RCTs with a total of 91 participants. One study compared heliox 70%/30% with 30% humidified oxygen administered for 20 minutes in children with mild croup and found no statistically significant differences in the overall change in croup scores between heliox and the comparator. In another study, children with moderate to severe croup were administered intramuscular dexamethasone 0.6 mg/kg and either heliox 70%/30% with one to two doses of nebulised saline, or 100% oxygen with one to two doses of nebulised racaemic epinephrine for three hours. In this study, the heliox group&apos;s croup scores improved significantly more at all time points from 90 minutes onwards. However, overall there were no significant differences in croup scores between the groups after four hours using repeated measures analysis. In a third study, children with moderate croup all received one dose of oral dexamethasone 0.3 mg/kg with heliox 70%/30% for 60 minutes in the intervention group and no treatment in the comparator. There was a statistically significant difference in croup scores at 60 minutes in favour of heliox but no significant difference after 120 minutes. It was not possible to pool outcomes because the included studies compared different interventions and reported different outcomes. No adverse events were reported.Authors&apos; conclusions: There is some evidence to suggest a short-term benefit of heliox inhalation in children with moderate to severe croup who have been administered o al or intramuscular dexamethasone. In one study, the benefit appeared to be similar to a combination of 100% oxygen with nebulised epinephrine. In another study there was a slight change in croup scores between heliox and controls, with unclear clinical significance. In another study in mild croup, the benefit of humidified heliox was equivalent to that of 30% humidified oxygen, suggesting that heliox is not indicated in this group of patients provided that 30% oxygen is available. Adequately powered RCTs comparing heliox with standard treatments are needed to further assess the role of heliox in children with moderate to severe croup.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006822.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006822.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>699</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">699</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">More, Kiran</style></author><author><style face="normal" font="default" size="100%">Athalye-Jape, Gayatri</style></author><author><style face="normal" font="default" size="100%">Rao Shripada, C.</style></author><author><style face="normal" font="default" size="100%">Patole Sanjay, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010531</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the efficacy and safety of ETRA in the treatment of PPHN in full-term and late preterm infants. To assess the efficacy and safety of selective (which block only the ETA receptors) and non-selective (which block both ETA and ETB receptors) ETRA separately.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010531/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010531</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>276</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">276</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morgado, M. P.</style></author><author><style face="normal" font="default" size="100%">Morgado, S. R.</style></author><author><style face="normal" font="default" size="100%">Mendes, L. C.</style></author><author><style face="normal" font="default" size="100%">Pereira, L. J.</style></author><author><style face="normal" font="default" size="100%">Castelo-Branco, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Health-System Pharmacy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Health-System Pharmacy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">241-253</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceutical Services [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011001772</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001772/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>277</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">277</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morgado, M. P.</style></author><author><style face="normal" font="default" size="100%">Rolo, S. A.</style></author><author><style face="normal" font="default" size="100%">Castelo-Branco, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy of aliskiren/hydrochlorothiazide combination for the treatment of hypertension: a meta-analytical approach (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Open Cardiovascular Medicine Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open Cardiovascular Medicine Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6-14</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011006692</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011006692/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>700</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">700</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morris Norman, R.</style></author><author><style face="normal" font="default" size="100%">Kermeen Fiona, D.</style></author><author><style face="normal" font="default" size="100%">Holland Anne, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Exercise-based rehabilitation programmes for pulmonary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD011285</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the efficacy and safety of exercise-based rehabilitation for people with PH.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011285/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD011285</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>278</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">278</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mukai, J.</style></author><author><style face="normal" font="default" size="100%">Tada, H.</style></author><author><style face="normal" font="default" size="100%">Miura, M.</style></author><author><style face="normal" font="default" size="100%">Mohri, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis-based examination regarding the efficacy of angiotensin II receptor blockers and calcium channel blockers in borderline diabetes and diabetes patients (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the Pharmaceutical Society of Japan</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the Pharmaceutical Society of Japan</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1213-1223</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Body Weight</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [drug therapy] [metabolism] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Insulin Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid Metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">MEDLINE</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011005125</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011005125/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>279</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">279</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mulay, A. V.</style></author><author><style face="normal" font="default" size="100%">Hussain, N.</style></author><author><style face="normal" font="default" size="100%">Fergusson, D.</style></author><author><style face="normal" font="default" size="100%">Knoll, G. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1748-1756</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Calcineurin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Graft Rejection [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Sirolimus [therapeutic use]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005000838</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005000838/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>701</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">701</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mulrow Cynthia, D.</style></author><author><style face="normal" font="default" size="100%">Chiquette, Elaine</style></author><author><style face="normal" font="default" size="100%">Angel, L.</style></author><author><style face="normal" font="default" size="100%">Grimm, Richard</style></author><author><style face="normal" font="default" size="100%">Cornell, John</style></author><author><style face="normal" font="default" size="100%">Summerbell Carolyn, D.</style></author><author><style face="normal" font="default" size="100%">Anagnostelis Betsy, B.</style></author><author><style face="normal" font="default" size="100%">Brand, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Dieting to reduce body weight for controlling hypertension in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diet, Reducing</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD000484</style></accession-num><abstract><style face="normal" font="default" size="100%">The authors have requested this review to be withdrawn. Authors are unable to update the review. This is one of the conditions for publishing the review. New authors are being sought to update this review.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000484.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD000484.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>702</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">702</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mundy, L.</style></author><author><style face="normal" font="default" size="100%">Hiller, J. E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal sympathetic denervation for the treatment of resistant hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Denervation</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney</style></keyword><keyword><style face="normal" font="default" size="100%">Sympathectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Sympathetic Nervous System</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010001660</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010001660/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>703</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">703</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mundy, L.</style></author><author><style face="normal" font="default" size="100%">Merlin, T.</style></author><author><style face="normal" font="default" size="100%">Parrella, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">RESPeRATE (TM): self guided breathing device for the treatment of hypertension in the home. Horizon Scanning Prioritising Summary - Volume 5 (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Ambulatory Care</style></keyword><keyword><style face="normal" font="default" size="100%">Breathing Exercises</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><publisher><style face="normal" font="default" size="100%">Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32006000606</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32006000606/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>704</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">704</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mundy, L.</style></author><author><style face="normal" font="default" size="100%">Parrella, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Frequent home visits by nurses for hypertensive patients. Horizon Scanning Prioritising Summary - Volume 7 (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Home Care Services</style></keyword><keyword><style face="normal" font="default" size="100%">House Calls</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [nursing]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><publisher><style face="normal" font="default" size="100%">Adelaide Health Technology Assessment (AHTA) on behalf of National Horizon Scanning Unit (HealthPACT and MSAC)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32006000632</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32006000632/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>705</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">705</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author><author><style face="normal" font="default" size="100%">Fortin Patricia, M.</style></author><author><style face="normal" font="default" size="100%">Bassett, Ken</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of renin inhibitors for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007066</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Hypertension is a chronic condition associated with an increased risk of mortality and morbidity. The renin-angiotensin-aldosterone system is an important target site for five antihypertensive drug classes: beta blockers, renin inhibitors, ACE inhibitors, angiotensin receptor blockers (ARBs) and aldosterone inhibitors. Renin is the enzyme responsible for converting angiotensinogen to angiotensin I, which is then converted to angiotensin II. Renin inhibitors prevent the formation of both angiotensin I and angiotensin II . Renin inhibitors do not affect kinin metabolism and may produce fewer adverse effects than ACE inhibitors such as dry cough or angioedema.Objectives: To quantify the dose-related blood pressure lowering efficacy of renin inhibitors versus placebo in the treatment of primary hypertension.Search methods: We searched the following databases for randomised, double blind, placebo-controlled trials of renin inhibitors: Medline (1966-June 2011), EMBASE (1988-June 2011), Cochrane CENTRAL, the Hypertension Group Specialised Register and bibliographic citations from retrieved references. No language restrictions were applied.Selection criteria: Study design had to meet the following criteria: double-blinded, placebo-controlled; random allocation to a specific dose of renin inhibitor group and parallel placebo group; duration of follow-up of at least three weeks.Data collection and analysis: Two reviewers independently extracted data and assessed trial quality using risk of bias tables. Disagreements were resolved by discussion or a third reviewer. Data synthesis and analyses were done using the Cochrane Review Manager software, RevMan 5.1. Data for continuous variables were combined using a weighted mean difference method and dichotomous variables were analysed using relative risk with 95% CI.Main results: Eight trials met the inclusion criteria. Six trials (N=3694) in the original review and two additional trials comparing the renin inhibitor, aliskiren (N=3393), to placebo (N=1623 ) met the inclusion criteria for this updated review. Aliskiren was the only renin inhibitor studied in these studies. The meta-analysis shows that aliskiren has a dose-related systolic/diastolic blood pressure lowering effect as compared to placebo: aliskiren 75 mg -2.6/-2.1 mm Hg, aliskiren 150 mg -5.6/-2.9 mm Hg, aliskiren 300 mg -7.9/-4.8, aliskiren 600 mg -11.4/-6.6 mm Hg. Aliskiren 300 mg significantly lowered both SBP and DBP as compared to aliskiren150 mg (SBP:-2.97 (95% CI -3.50, -1.90) and DBP: -1.86 (95% CI -2.39, -1.33). Aliskiren has no effect on blood pressure variability. No data was available to assess the effect of aliskiren on heart rate and pulse pressure. This review found weak evidence that with short-term use, aliskiren does not increase withdrawals due to adverse effects as compared to placebo.Authors&apos; conclusions: Aliskiren has a dose-related blood pressure lowering effect better than placebo. This effect is similar to that determined for ACE inhibitors and ARBs.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007066.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007066.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>706</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">706</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author><author><style face="normal" font="default" size="100%">Nazer, Mark</style></author><author><style face="normal" font="default" size="100%">Bassett, Ken</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003824</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Hypertension is a modifiable cardiovascular risk factor. Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity, the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review. It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects.Objectives: To determine the dose-related decrease in systolic and/or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension. Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium, uric acid, creatinine, glucose and lipids.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 1), Ovid MEDLINE (1946 to February 2014), Ovid EMBASE (1974 to February 2014) and ClinicalTrials.gov.Selection criteria: We included double-blind, randomized controlled trials (RCTs) comparing fixed-dose thiazide diuretic monotherapy with placebo for a duration of 3 to 12 weeks in the treatment of adult patients with primary hypertension.Data collection and analysis: Two authors independently screened articles, assessed trial eligibility, extracted data and determined risk of bias. We combined data for continuous variables using a mean difference (MD) and for dichotomous outcomes we calculated the relative risk ratio (RR) with 95% confidence interval (CI).Main results: We included 60 randomized, double-blind trials that evaluated the dose-related trough blood pressure-lowering efficacy of six different thiazide diuretics in 11,282 participants treated for a mean duration of eight weeks. The mean age of the participants was 55 years and baseline blood pressure was 158/99 mmHg. Adequate blood pressure-lowering efficacy data were available for hydrochlorothiazide, chlorthalidone and indapamide. We judged 54 (90%) included trials to have unclear or high risk of bias, which impacted on our confidence in the results for some of our outcomes.In 33 trials with a baseline blood pressure of 155/100 mmHg, hydrochlorothiazide lowered blood pressure based on dose, with doses of 6.25 mg, 12.5 mg, 25 mg and 50 mg/day lowering blood pressure compared to placebo by 4 mmHg (95% CI 2 to 6, moderate-quality evidence)/2 mmHg (95% CI 1 to 4, moderate-quality evidence), 6 mmHg (95% CI 5 to 7, high-quality evidence)/3 mmHg (95% CI 3 to 4, high-quality evidence), 8 mmHg (95% CI 7 to 9, high-quality evidence)/3 mmHg (95% CI 3 to 4, high-quality evidence) and 11 mmHg (95% CI 6 to 15, low-quality evidence)/5 mmHg (95% CI 3 to 7, low-quality evidence), respectively.Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available: bendrofluazide, chlorthalidone, cyclopenthiazide, metolazone or indapamide.In seven trials with a baseline blood pressure of 163/88 mmHg, chlorthalidone at doses of 12.5 mg to 75 mg/day reduced average blood pressure compared to placebo by 12.0 mmHg (95% CI 10 to 14, low-quality evidence)/4 mmHg (95% CI 3 to 5, low-quality evidence).In 10 trials with a baseline blood pressure of 161/98 mmHg, indapamide at doses of 1.0 mg to 5.0 mg/day reduced blood pressure compared to placebo by 9 mmHg (95% CI 7 to 10, low-quality evidence)/4 (95% CI 3 to 5, low-quality evidence).We judged the maximal blood pressure-lowering effect of the different thiazides to be similar. Overall, thiazides reduced average blood pressure compared to placebo by 9 mmHg (95% CI 9 to 10, high-quality evidence)/4 mmHg (95% CI 3 to 4, high-quality evidence).Thiazides as a class have a greater effect on systolic than on diastolic blood pressure, therefore thiazides lower pulse pressure by 4 mmHg to 6 mmHg, an amount that is greater than the 3 mmHg seen with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and renin in ibitors, and the 2 mmHg seen with non-selective beta-blockers. This is based on an informal indirect comparison of results observed in other Cochrane reviews on ACE inhibitors, ARBs and renin inhibitors compared with placebo, which used similar inclusion/exclusion criteria to the present review.Thiazides reduced potassium, increased uric acid and increased total cholesterol and triglycerides. These effects were dose-related and were least for hydrochlorothiazide. Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides. There is a high risk of bias in the metabolic data. This review does not provide a good assessment of the adverse effects of these drugs because there was a high risk of bias in the reporting of withdrawals due to adverse effects.Authors&apos; conclusions: This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect. The mean blood pressure-lowering effect over the dose range 6.25 mg, 12.5 mg, 25 mg and 50 mg/day is 4/2 mmHg, 6/3 mmHg, 8/3 mmHg and 11/5 mmHg, respectively. For other thiazide drugs, the lowest doses studied lowered blood pressure maximally and higher doses did not lower it more. Due to the greater effect on systolic than on diastolic blood pressure, thiazides lower pulse pressure by 4 mmHg to 6 mmHg. This exceeds the mean 3 mmHg pulse pressure reduction achieved by ACE inhibitors, ARBs and renin inhibitors, and the 2 mmHg pulse pressure reduction with non-selective beta-blockers as shown in other Cochrane reviews, which compared these antihypertensive drug classes with placebo and used similar inclusion/exclusion criteria.Thiazides did not increase withdrawals due to adverse effects in these short-term trials but there is a high risk of bias for that outcome. Thiazides reduced potassium, increased uric acid and increased total cholesterol and triglycerides.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003824.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003824.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>707</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">707</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author><author><style face="normal" font="default" size="100%">Rezapour, Pouria</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author><author><style face="normal" font="default" size="100%">Bassett, Ken</style></author><author><style face="normal" font="default" size="100%">Jauca Ciprian, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of loop diuretics for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Potassium Chloride Symporter Inhibitors [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003825</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity. Loop diuretics are indicated and used as antihypertensive drugs but a systematic review of their blood pressure lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from randomized controlled trial evidence has not been conducted.Objectives: To determine the dose related decrease in systolic and/or diastolic blood pressure as well as adverse events leading to patient withdrawal and adverse biochemical effects (serum potassium, uric acid, creatinine, glucose and lipids profile) due to loop diuretics versus placebo control in the treatment of patients with primary hypertension.Search methods: Medline (1946-February 2012), EMBASE (1974-February 2012), CENTRAL (issue 2, 2012) and bibliographic citations were searched.Selection criteria: Double blind randomized placebo controlled trials of at least 3 weeks duration comparing loop diuretic with a placebo in patients with primary hypertension defined as BP &gt;140/90 mmHg at baseline were included.Data collection and analysis: Two authors independently assessed the risk of bias and extracted data. Weighted mean difference and a fixed effects model were used to combine continuous outcome data. The drop outs due to adverse effects was analysed using relative risk ratio.Main results: Nine trials evaluated the dose-related blood pressure lowering efficacy of five drugs within the loop diuretics class (furosemide 40 to 60mg, cicletanine 100 to 150 mg, piretanide 3 to 6 mg, indacrinone enantiomer -2.5 to -10.0/+80 mg and etozolin 200 mg) in 460 patients with baseline blood pressure of 162/103 mmHg for a mean duration of 8.8 weeks. The best estimate of systolic/diastolic blood pressure lowering efficacy of loop diuretics was -7.9 (-10.5, -5.4) mmHg/ -4.4 (-5.6, -2.8) mmHg . Withdrawals due to adverse effects and serum biochemical changes did not show a significant difference.The 2012 updated search resulted in no additional new trials meeting the minimum inclusion criteria.Authors&apos; conclusions: Based on the limited number of published RCTs, the systolic/diastolic blood pressure lowering effect of loop diuretics is modest (-8/-4 mmHg) and is likely an overestimate due to the high risk of bias in the included studies. There are no clinically meaningful BP lowering differences between different drugs within the loop diuretic class. The dose ranging effects of loop diuretics could not be evaluated. The review did not provide a good estimate of the incidence of harms associated with loop diuretics because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003825.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003825.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>708</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">708</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author><author><style face="normal" font="default" size="100%">Tejani Aaron, M.</style></author><author><style face="normal" font="default" size="100%">Bassett, Ken</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacotherapy for hypertension in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Withholding Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD000028</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Elevated blood pressure (known as hypertension) increases with age, and most rapidly over age 60.  Systolic hypertension is more strongly associated with cardiovascular disease than diastolic hypertension, and occurs more commonly in older people.  It is important to know the benefits and harms of antihypertensive treatment of hypertension in this age group.Objectives: To quantify antihypertensive drug effect on overall mortality, cardiovascular mortality and morbidity and withdrawal due to adverse effects in people 60 years and older with mild to moderate systolic or diastolic hypertension.Search methods: Updated search of electronic database of EMBASE, CENTRAL, MEDLINE until Dec 2008; previous search of two Japanese databases (1973-1995) and WHO-ISH Collaboration register (August 1997); references from reviews, trials and previously published meta-analyses; and experts.Selection criteria: Randomized controlled trials of at least one year duration in hypertensive elders (at least 60 years old) comparing antihypertensive drug therapy with placebo or no treatment and providing morbidity and mortality data.Data collection and analysis: Outcomes assessed were total mortality (including cardiovascular, coronary heart disease and cerebrovascular mortality); total cardiovascular morbidity and mortality (representing combined coronary heart disease and cerebrovascular morbidity and mortality); and withdrawal due to adverse events.Main results: Fifteen trials (24,055 subjects ? 60 years) with moderate to severe hypertension were identified.  These trials mostly evaluated first-line thiazide diuretic therapy for a mean duration of treatment of 4.5 years. Treatment reduced total mortality, RR 0.90 (0.84, 0.97); event rates per 1000 participants reduced from 116 to 104.  Treatment also reduced total cardiovascular morbidity and mortality, RR 0.72 (0.68, 0.77); event rates per 1000 participants reduced from 149 to 106. In the three trials restricted to persons with isolated systolic hypertension the benefit was similar. In very elderly patients ? 80 years the reduction in total cardiovascular mortality and morbidity was similar RR 0.75 [0.65, 0.87] however, there was no reduction in total mortality, RR 1.01 [0.90, 1.13].  Withdrawals due to adverse effects were increased with treatment, RR 1.71 [1.45, 2.00].Authors&apos; conclusions: Treating healthy persons (60 years or older) with moderate to severe systolic and/or diastolic hypertension reduces all cause mortality and cardiovascular morbidity and mortality. The decrease in all cause mortality was limited to persons 60 to 80 years of age.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000028.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD000028.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>709</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">709</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author><author><style face="normal" font="default" size="100%">Tejani Aaron, M.</style></author><author><style face="normal" font="default" size="100%">Labeit Alexander, Michael</style></author><author><style face="normal" font="default" size="100%">Salzwedel Douglas, M.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacotherapy for hypertension in non-elderly adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008276</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:Primary objective:1. To quantify antihypertensive drug effect on overall mortality in people 18 to 59 years with mild to moderate systolic or diastolic hypertension.Secondary objectives:2. To quantify antihypertensive drug effect on cardiovascular mortality and morbidity in people 18 to 59 years with mild to moderate systolic or diastolic hypertension.3. To quantify withdrawal due adverse effects.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008276/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008276</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>280</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">280</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Musini, V. M.</style></author><author><style face="normal" font="default" size="100%">Fortin, P. M.</style></author><author><style face="normal" font="default" size="100%">Bassett, K.</style></author><author><style face="normal" font="default" size="100%">Wright, J. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">495-502</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Angioedema [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cough [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">dosage [adverse effects] [adverse effects] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009108085</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009108085/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>710</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">710</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muzevic, Dario</style></author><author><style face="normal" font="default" size="100%">Splavski, Bruno</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Lund concept for severe traumatic brain injury</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Microcirculation [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Inj</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010193</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Severe traumatic brain injury is a significant cause of morbidity and mortality. Treatment strategies in management of such injuries are directed to the prevention of secondary brain ischaemia, as a consequence of disturbed post-traumatic cerebral blood flow. They are usually concerned with avoiding high intracranial pressure (ICP) or adequate cerebral perfusion pressure (CPP). An alternative to this conventional treatment is the Lund concept, which emphasises a reduction in microvascular pressures.Objectives: To assess the role of the Lund concept versus other treatment modalities such as ICP-targeted therapy, CPP-targeted therapy or other possible treatment strategies in the management of severe traumatic brain injury.Search methods: We searched the Cochrane Injuries Group&apos;s Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL; Issue 10, 2013), MEDLINE (OvidSP), EMBASE (OvidSP), CINAHL Plus (EBSCO Host), ISI Web of Science (SCI-EXPANDED and CPCI-S) and trials registries. We searched the reference lists of relevant studies and published reviews found with our search. The most recent search was 5 November 2013.Selection criteria: Randomised controlled trials (RCTs, level 1 evidence) exploring the efficacy of the Lund concept in the treatment of traumatic brain injury.Data collection and analysis: Two review authors independently selected papers and made decisions about the eligibility of potentially relevant studies.Main results: We found no studies that met the inclusion criteria for this review.Authors&apos; conclusions: There is no evidence that the Lund concept is a preferable treatment option in the management of severe traumatic brain injury.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010193.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010193.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>281</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">281</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Naderi, S. H.</style></author><author><style face="normal" font="default" size="100%">Bestwick, J. P.</style></author><author><style face="normal" font="default" size="100%">Wald, D. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">882-887</style></pages><volume><style face="normal" font="default" size="100%">125</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Anticholesteremic Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Costs</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Prescriptions [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Aggregation Inhibitors [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Prevention [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Self Administration</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride Symporter Inhibitors [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012042498</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012042498/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>282</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">282</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nakao, M.</style></author><author><style face="normal" font="default" size="100%">Yano, E.</style></author><author><style face="normal" font="default" size="100%">Nomura, S.</style></author><author><style face="normal" font="default" size="100%">Kuboki, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure-lowering effects of biofeedback treatment in hypertension: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">37-46</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biofeedback (Psychology)</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003000717</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003000717/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>283</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">283</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Newman-Casey, P. A.</style></author><author><style face="normal" font="default" size="100%">Weizer, J. S.</style></author><author><style face="normal" font="default" size="100%">Heisler, M.</style></author><author><style face="normal" font="default" size="100%">Lee, P. P.</style></author><author><style face="normal" font="default" size="100%">Stein, J. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review of educational interventions to improve glaucoma medication adherence (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Seminars in Ophthalmology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Seminars in Ophthalmology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">191-201</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Acceptance of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013029032</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013029032/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>711</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">711</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ng, Geraldine</style></author><author><style face="normal" font="default" size="100%">da Silva, Orlando</style></author><author><style face="normal" font="default" size="100%">Ohlsson, Arne</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Albuterol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Beclomethasone [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature, Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003214</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Chronic lung disease (CLD) occurs frequently in preterm infants. Bronchodilators have the potential effect of dilating small airways with muscle hypertrophy. Increase in compliance and tidal volume and decrease in pulmonary resistance have been documented with use of bronchodilators in studies of pulmonary mechanics in infants with CLD. Therefore, it is possible that bronchodilators might have a role in the prevention and treatment of CLD.Objectives: To determine the effect of bronchodilators given either prophylactically or as treatment for CLD on mortality and other complications of prematurity in preterm infants at risk for or having CLD.Search methods: For this update of the review, searches of The Cochrane Library, Issue 3, 2012; MEDLINE 1966; EMBASE; CINAHL; personal files and reference lists of identified trials were performed in March 2012. In addition Web of Science and abstracts from the Annual meetings of the Pediatric Academic Societies were searched electronically from 2000 to 2012 on PAS Abstracts2viewTM. No language restrictions were applied.Selection criteria: Randomised controlled trials involving preterm infants were eligible for inclusion. Initiation of bronchodilator therapy had to occur within two weeks of birth for prevention of CLD. For treatment of CLD, treatment had to be initiated before discharge from the neonatal unit. The intervention had to include the administration of a bronchodilator either by nebulisation, metered dose inhaler (with or without a spacer device), intravenously or orally versus placebo or no intervention. Eligible studies had to include at least one of the predefined clinical outcomes (mortality, CLD, number of days on oxygen, number of days on ventilator, patent ductus arteriosus (PDA), pulmonary interstitial emphysema (PIE), pneumothorax, any grade of intraventricular haemorrhage (IVH), necrotising enterocolitis (NEC), sepsis and adverse effects of bronchodilators. Adverse effects of bronchodilators included hypokalaemia, tachycardia, cardiac arrhythmias, tremor, hypertension and hyperglycaemia).Data collection and analysis: We used the standard method described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Two investigators extracted and assessed all data for each study. We reported risk ratio (RR) and risk difference (RD) with 95% confidence intervals (CI) for dichotomous outcomes and weighted mean difference (WMD) for continuous data.Main results: In this update we identified four randomised controlled trials investigating the effects of bronchodilators in preterm infants. None of these studies fulfilled our inclusion criterion that clinical outcomes should be reported. One eligible study was previously found dealing with prevention of CLD; this study used salbutamol and enrolled 173 infants. No eligible studies were found dealing with treatment of CLD. Prophylaxis with salbutamol did not show a statistically significant difference in mortality (RR 1.08; 95% CI 0.50 to 2.31; RD 0.01; 95% CI -0.09 to 0.11) or CLD (RR 1.03; 95% CI 0.78 to 1.37; RD 0.02; 95% CI -0.13 to 0.17). No statistically significant differences were seen in other complications associated with CLD or preterm birth. No side effects due to salbutamol were commented on in this study.Authors&apos; conclusions: There are insufficient data to reliably assess the use of salbutamol for the prevention of CLD. Further clinical trials are necessary to assess the role of salbutamol or other bronchodilator agents in prophylaxis or treatment of CLD. Researchers studying the effects of bronchodilators in preterm infants should include relevant clinical outcomes in addition to pulmonary mechanical outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003214.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003214.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>712</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">712</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ngamjarus, Chetta</style></author><author><style face="normal" font="default" size="100%">Pattanittum, Porjai</style></author><author><style face="normal" font="default" size="100%">Somboonporn, Charoonsak</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Roselle for hypertension in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Rumex</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007894</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Hypertension is considered a serious health problem worldwide. Controlling and lowering blood pressure have a significant benefit to the hypertensive patients because hypertension is a risk factor for stroke, heart disease and cardiovascular disease. A tropical plant called Roselle, or Red Sorrel in English-speaking countries, has been used both as a thirst-quenching drink and for medical purposes.Objectives: To explore the effect of Roselle on blood pressure in hypertensive adult patients.Search methods: The following databases were searched (Date of most recent search was September 2009): - Cochrane Database of Systematic Reviews (2nd Quarter 2009) - DARE (2nd Quarter 2009) - Ovid MEDLINE (1950 to Present with Daily Update) - EMBASE (1980 to 2009 Week 22) - AMED (1985 to May 2009) - EBSCO CINAHL - BIOSIS (1969 to 2008) - AGRICOLA (1970 to May 2009) - Food Science and Technology Abstract (1969 to 2009 June Week 1) - International Pharmaceutical Abstracts - International Bibliographic Information on Dietary Supplements - Clinical Trials.gov and Current Controlled Trials - OpenSIGLE - Hand searching of journals - ISI Web of KnowledgeSelection criteria: We sought randomised control trials (RCTs) evaluating use of any forms of Roselle with placebo or no treatment in hypertensive patients. Change in trough and/or peak systolic and diastolic blood pressure were primary outcomes. Secondary outcomes were withdrawals due to adverse effects, change of pulse pressure and change of heart rate.Data collection and analysis: Two review authors (C Ngamjarus, CN and P Pattanittum, PP) independently scanned titles and abstracts, as well as independently screened the full reports of the potentially relevant studies. At each stage, the results were compared and disagreements were solved by discussion.Main results: No studies were identified that met the inclusion criteria. However, one abstract of an ongoing study is likely to meet the inclusion criteria, when completed.Authors&apos; conclusions: There is insufficient evidence to support the benefit of Roselle for either controlling or lowering blood pressure in patients with hypertension. Based on the information of this review, there is a clear need to develop well-designed studies to assess the efficacy of Roselle on hypertensive patients.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007894.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007894.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>284</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">284</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nguyen, T. T.</style></author><author><style face="normal" font="default" size="100%">Kaufman, J. S.</style></author><author><style face="normal" font="default" size="100%">Whitsel, E. A.</style></author><author><style face="normal" font="default" size="100%">Cooper, R. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">911-917</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">African Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Data Interpretation, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Ethnic Groups</style></keyword><keyword><style face="normal" font="default" size="100%">European Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009109004</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009109004/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>285</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">285</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ni, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Huang, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effect of pharmaceutical care programs on blood pressure control in individuals with hypertension: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pharmacy Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pharmacy Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">292-296</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceutical Services</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009110420</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009110420/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>713</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">713</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nicolau, I.</style></author><author><style face="normal" font="default" size="100%">Dendukuri, N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal denervation for resistant hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Denervation</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Technology Assessment Unit of the McGill University Health Centre (MUHC)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000679</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000679/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>286</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">286</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nicolson, D. J.</style></author><author><style face="normal" font="default" size="100%">Dickinson, H. O.</style></author><author><style face="normal" font="default" size="100%">Campbell, F.</style></author><author><style face="normal" font="default" size="100%">Mason, J. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lifestyle interventions or drugs for patients with essential hypertension: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2043-2048</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004006956</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004006956/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>287</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">287</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nieuwstraten, C.</style></author><author><style face="normal" font="default" size="100%">Labiris, N. R.</style></author><author><style face="normal" font="default" size="100%">Holbrook, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic overview of drug interactions with antidepressant medications (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Canadian Journal of Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Canadian Journal of Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">300-316</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cytochrome P-450 Enzyme System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Depressive Disorder, Major [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Interactions</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy [adverse effects] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypericum</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Monoamine Oxidase Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin Syndrome [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin Uptake Inhibitors [therapeutic use]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006002321</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006002321/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>288</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">288</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niu, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The relationship between natriuretic peptide precursor a gene T2238C polymorphism and hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">653698</style></pages><volume><style face="normal" font="default" size="100%">2011</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Atrial Natriuretic Factor</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012051349</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012051349/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>289</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">289</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niu, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation of transforming growth factor beta-1 gene 869T/C polymorphism with hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">934265</style></pages><volume><style face="normal" font="default" size="100%">2011</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012051365</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012051365/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>290</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">290</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niu, X. W.</style></author><author><style face="normal" font="default" size="100%">Xu, H.</style></author><author><style face="normal" font="default" size="100%">He, S. L.</style></author><author><style face="normal" font="default" size="100%">Chen, D.</style></author><author><style face="normal" font="default" size="100%">Yan, D.</style></author><author><style face="normal" font="default" size="100%">He, Z. Y.</style></author><author><style face="normal" font="default" size="100%">Yao, Y. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Carvedilol versus metoprolol for primary hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">963-970</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Carbazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Metoprolol</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014021249</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014021249/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>291</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">291</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nixon, R. M.</style></author><author><style face="normal" font="default" size="100%">Muller, E.</style></author><author><style face="normal" font="default" size="100%">Lowy, A.</style></author><author><style face="normal" font="default" size="100%">Falvey, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">766-775</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzoates [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Biphenyl Compounds [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Imidazoles [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Losartan [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Valine [administration &amp; dosage] [analogs &amp; derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009104656</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009104656/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>714</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">714</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nkansah, Nancy</style></author><author><style face="normal" font="default" size="100%">Mostovetsky, Olga</style></author><author><style face="normal" font="default" size="100%">Yu, Christine</style></author><author><style face="normal" font="default" size="100%">Chheng, Tami</style></author><author><style face="normal" font="default" size="100%">Beney, Johnny</style></author><author><style face="normal" font="default" size="100%">Bond Christine, M.</style></author><author><style face="normal" font="default" size="100%">Bero, Lisa</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of outpatient pharmacists&apos; non-dispensing roles on patient outcomes and prescribing patterns</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Ambulatory Care</style></keyword><keyword><style face="normal" font="default" size="100%">Community Pharmacy Services</style></keyword><keyword><style face="normal" font="default" size="100%">Delivery of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Professional Role</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacists</style></keyword><keyword><style face="normal" font="default" size="100%">Physician&apos;s Practice Patterns</style></keyword><keyword><style face="normal" font="default" size="100%">Prescription Drugs [supply &amp; distribution] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Epoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD000336</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: The roles of pharmacists in patient care have expanded from the traditional tasks of dispensing medications and providing basic medication counseling to working with other health professionals and the public. Multiple reviews have evaluated the impact of pharmacist-provided patient care on health-related outcomes. Prior reviews have primarily focused on in-patient settings. This systematic review focuses on services provided by outpatient pharmacists in community or ambulatory care settings. This is an update of the Cochrane review published in 2000.Objectives: To examine the effect of outpatient pharmacists&apos; non-dispensing roles on patient and health professional outcomes.Search methods: This review has been split into two phases. For Phase I, we searched the Cochrane Effective Practice and Organisation of Care (EPOC) Group Specialised Register (January 1966 through March 2007). For Phase II, we searched MEDLINE/EMBASE (January 1966 through March 2008). The Phase I results are reported in this review; Phase II will be summarized in the next update.Selection criteria: Randomized controlled trials comparing 1. Pharmacist services targeted at patients versus services delivered by other health professionals; 2. Pharmacist services targeted at patients versus the delivery of no comparable service; 3. Pharmacist services targeted at health professionals versus services delivered by other health professionals; 4. Pharmacist services targeted at health professionals versus the delivery of no comparable service.Data collection and analysis: Two authors independently reviewed studies for inclusion, extracted data, and assessed risk of bias of included studies.Main results: Forty-three studies were included; 36 studies were pharmacist interventions targeting patients and seven studies were pharmacist interventions targeting health professionals. For comparison 1, the only included study showed a significant improvement in systolic blood pressure for patients receiving medication management from a pharmacist compared to usual care from a physician. For comparison 2, in the five studies evaluating process of care outcomes, pharmacist services reduced the incidence of therapeutic duplication and decreased the total number of medications prescribed. Twenty-nine of 36 studies reported clinical and humanistic outcomes. Pharmacist interventions resulted in improvement in most clinical outcomes, although these improvements were not always statistically significant. Eight studies reported patient quality of life outcomes; three studies showed improvement in at least three subdomains. For comparison 3, no studies were identified meeting the inclusion criteria. For comparison 4, two of seven studies demonstrated a clear statistically significant improvement in prescribing patterns.Authors&apos; conclusions: Only one included study compared pharmacist services with other health professional services, hence we are unable to draw conclusions regarding comparisons 1 and 3. Most included studies supported the role of pharmacists in medication/therapeutic management, patient counseling, and providing health professional education with the goal of improving patient process of care and clinical outcomes, and of educational outreach visits on physician prescribing patterns. There was great heterogeneity in the types of outcomes measured across all studies. Therefore a standardized approach to measure and report clinical, humanistic, and process outcomes for future randomized controlled studies evaluating the impact of outpatient pharmacists is needed. Heterogeneity in study comparison groups, outcomes, and measures makes it challenging to make generalised statements regarding the impact of pharmacists in specific settings, disease states, and patient populations.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000336.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD000336.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>292</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">292</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nordmann, A. J.</style></author><author><style face="normal" font="default" size="100%">Woo, K.</style></author><author><style face="normal" font="default" size="100%">Parkes, R.</style></author><author><style face="normal" font="default" size="100%">Logan, A. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Balloon angioplasty or medical therapy for hypertensive patients with atherosclerotic renal artery stenosis: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">44-50</style></pages><volume><style face="normal" font="default" size="100%">114</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty, Balloon</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Arteriosclerosis [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003000378</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003000378/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>715</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">715</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Novikova, Natalia</style></author><author><style face="normal" font="default" size="100%">Cluver, Catherine</style></author><author><style face="normal" font="default" size="100%">Koopmans Corine, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Preg</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009273</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the benefits and risks of a policy of planned delivery versus a policy of expectant management of women with hypertensive disorders, at or near term.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009273/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009273</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>293</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">293</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Oakeshott, P.</style></author><author><style face="normal" font="default" size="100%">Kerry, S.</style></author><author><style face="normal" font="default" size="100%">Austin, A.</style></author><author><style face="normal" font="default" size="100%">Cappuccio, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Is there a role for nurse-led blood pressure management in primary care (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Family Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Family Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">469-473</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Disease Management</style></keyword><keyword><style face="normal" font="default" size="100%">Family Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Great Britain [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology] [nursing]</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Nursing</style></keyword><keyword><style face="normal" font="default" size="100%">State Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003001778</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003001778/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>294</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">294</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ogedegbe, G.</style></author><author><style face="normal" font="default" size="100%">Schoenthaler, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review of the effects of home blood pressure monitoring on medication adherence (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">174-180</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Compliance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006003534</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006003534/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>295</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">295</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Omboni, S.</style></author><author><style face="normal" font="default" size="100%">Guarda, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Impact of home blood pressure telemonitoring and blood pressure control: a meta-analysis of randomized controlled studies (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">989-998</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Diastole</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Office Visits</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Systole</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011005548</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011005548/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>716</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">716</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Orozco Leonardo, J.</style></author><author><style face="normal" font="default" size="100%">Buchleitner Ana, Maria</style></author><author><style face="normal" font="default" size="100%">Gimenez-Perez, Gabriel</style></author><author><style face="normal" font="default" size="100%">Roqué i Figuls, Marta</style></author><author><style face="normal" font="default" size="100%">Richter, Bernd</style></author><author><style face="normal" font="default" size="100%">Mauricio, Didac</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Exercise or exercise and diet for preventing type 2 diabetes mellitus</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Combined Modality Therapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Endoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003054</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: The incidence of type 2 diabetes is associated with the &apos;Westernised lifestyle&apos;, mainly in terms of dietary habits and physical activity. Thus an intensive diet and exercise intervention might prevent or delay the appearance of diabetes in persons at high risk.Objectives: To assess the effects of exercise or exercise and diet for preventing type 2 diabetes mellitus.Search methods: We searched The Cochrane Library, MEDLINE, EMBASE, CINAHL, LILACS, SocioFile, databases of ongoing trials and reference lists of relevant reviews.Selection criteria: Studies were included if they were randomised controlled trials of exercise and diet interventions of at least six month duration and reported diabetes incidence in people at risk for type 2 diabetes.Data collection and analysis: Two authors independently assessed trial quality and extracted data. Study authors were contacted to obtain missing data. Data on diabetes incidence and secondary outcomes were analysed by means of random-effects meta-analysis.Main results: We included eight trials that had an exercise plus diet (2241 participants) and a standard recommendation arm (2509 participants). Two studies had a diet only (167 participants) and exercise only arm (178 participants). Study duration ranged from one to six years. Overall, exercise plus diet interventions reduced the risk of diabetes compared with standard recommendations (RR 0.63, 95% CI 0.49 to 0.79). This had also favourable effects on weight and body mass index reduction, waist-to-hip ratio and waist circumference. However, statistical heterogeneity was very high for these outcomes. Exercise and diet interventions had a very modest effect on blood lipids. However, this intervention improved systolic and diastolic blood pressure levels (weighted mean difference -4 mmHg, 95% CI -5 to -2 and -2 mmHg, 95% CI -3 to -1, respectively). No statistical significant effects on diabetes incidence were observed when comparing exercise only interventions either with standard recommendations or with diet only interventions. No study reported relevant data on diabetes and cardiovascular related morbidity, mortality and quality of life.Authors&apos; conclusions: Interventions aimed at increasing exercise combined with diet are able to decrease the incidence of type 2 diabetes mellitus in high risk groups (people with impaired glucose tolerance or the metabolic syndrome). There is a need for studies exploring exercise only interventions and studies exploring the effect of exercise and diet on quality of life, morbidity and mortality, with special focus on cardiovascular outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003054.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003054.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>296</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">296</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Owen, A.</style></author><author><style face="normal" font="default" size="100%">Wiles, J.</style></author><author><style face="normal" font="default" size="100%">Swaine, I.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of isometric exercise on resting blood pressure: a meta analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">796-800</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Isometric Contraction</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle, Skeletal [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Rest</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010008265</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010008265/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>717</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">717</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pádua Laryssa Maria, Siqueira</style></author><author><style face="normal" font="default" size="100%">Garcia Lucas, Cezar</style></author><author><style face="normal" font="default" size="100%">Rubira Claudio, Jose</style></author><author><style face="normal" font="default" size="100%">de Oliveira Carvalho Paulo, Eduardo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Stent placement versus surgery for coarctation of the thoracic aorta</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Aortic Coarctation [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Pvd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008204</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Coarctation of the aorta (CoA) accounts for 5% to 7% of congenital heart disease, with an incidence of 0.3 to 0.4 per 1000 live births. Surgery was the only choice of therapy for CoA until 1982 when balloon angioplasty became an available alternative for its treatment. Re-coarctation, aneurysm and aortic dissection remain the disadvantages of both treatments. To avoid those disadvantages, in 1990 endovascular stents were introduced for native coarctation and re-coarctation and since then they have become an alternative approach to surgical repair. The best approach to treat the CoA, whether open surgery or by stent placement, is not clear.Objectives: To analyze the effectiveness and safety of stent placement compared with open surgery in patients with coarctation of the thoracic aorta.Search methods: The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched September 2011) and CENTRAL (2011, Issue 3). We also searched MEDLINE, EMBASE, CINAHL, AMED, Web of Science and LILACS (last searched in September 2011). We evaluated the located references and applied the inclusion criteria to selected studies. There was no restriction on language.Selection criteria: Randomized or quasi-randomized controlled clinical trials that compared patients with CoA undergoing open surgery or stent placement.Data collection and analysis: The review authors independently assessed the studies identified for eligibility for inclusion. We excluded studies after a consensus meeting.Main results: All identified studies were screened and had the selection criteria applied to the title and abstract. In total, we selected five studies for full-text analysis. After detailed evaluation, we excluded all studies because there was no comparison between stent placement and open surgery.Authors&apos; conclusions: There is insufficient evidence with regards to the best treatment for coarctation of the thoracic aorta. This review suggests a need to perform a randomized controlled clinical trial with emphasis on the allocation method, evaluation of primary outcomes, size and quality of the sample, and long-term follow-up.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008204.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008204.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>297</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">297</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Padwal, R.</style></author><author><style face="normal" font="default" size="100%">Laupacis, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive therapy and incidence of type 2 diabetes (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetes Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diabetes Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">247-255</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004000192</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004000192/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>298</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">298</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Padwal, R.</style></author><author><style face="normal" font="default" size="100%">Majumdar, S. R.</style></author><author><style face="normal" font="default" size="100%">Johnson, J. A.</style></author><author><style face="normal" font="default" size="100%">Varney, J.</style></author><author><style face="normal" font="default" size="100%">McAlister, F. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review of drug therapy to delay or prevent type 2 diabetes (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetes Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diabetes Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">736-744</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Obesity Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoglycemic Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Lactones [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005009496</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005009496/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>718</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">718</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palmer Suetonia, C.</style></author><author><style face="normal" font="default" size="100%">Saglimbene, Valeria</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author><author><style face="normal" font="default" size="100%">Navaneethan Sankar, D.</style></author><author><style face="normal" font="default" size="100%">Strippoli Giovanni, F. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Darbepoetin for the anaemia of chronic kidney disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anemia [drug therapy] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Erythropoietin [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hematinics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Polyethylene Glycols [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Insufficiency, Chronic [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009297</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Erythropoiesis-stimulating agents are used to treat anaemia in people with chronic kidney disease (CKD). Several agents are available including epoetin alfa or beta as well as agents with a longer duration of action, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta.Objectives: To assess the benefits and harms of darbepoetin alfa to treat anaemia in adults and children with CKD (stages 3 to 5, 5D, and kidney transplant recipients).Search methods: We searched the Cochrane Renal Group&apos;s Specialised Register (to 13 January 2014) through contact with the Trials&apos; Search Co-ordinator using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE and EMBASE.Selection criteria: We included randomised controlled trials of any darbepoetin alfa treatment of at least three months duration in adults or children with CKD (any stage).Data collection and analysis: Data were extracted by two independent investigators. Patient-centred outcomes (need for blood transfusion, iron therapy, progression of kidney disease, total and cardiovascular mortality, cardiovascular events, cancer, hypertension, seizures, and health-related quality of life) and other outcomes (haemoglobin levels) were assessed using random effects meta-analysis. We calculated risk ratios for dichotomous outcomes and mean differences for continuous outcomes, both with 95% confidence intervals.Main results: We identified 32 studies comprising 9414 participants; 21 studies in 8328 participants could be included in our meta-analyses. One study (4038 participants) compared darbepoetin alfa to placebo, 16 studies (2955 participants) compared darbepoetin alfa to epoetin alfa or beta, four studies (1198 participants) compared darbepoetin alfa to methoxy polyethylene glycol-epoetin beta, three studies (420 participants) compared more frequent with less frequent darbepoetin alfa administration and four studies (303 participants) compared intravenous with subcutaneous darbepoetin alfa administration.In a single large study, darbepoetin alfa reduced the need for blood transfusion and iron therapy compared with placebo in adults with CKD stage 3 to 5, but had little or no effect on survival, increased risks of hypertension, and had uncertain effects on quality of life. Data comparing darbepoetin alfa with epoetin alfa or beta or methoxy polyethylene glycol-epoetin beta were sparse and inconclusive. Comparisons of differing dosing schedules and routes of administration were compared in small numbers of participants and studies. Evidence for treatment effects of darbepoetin alfa were particularly limited for children with CKD, adults with CKD stage 5D, and recipients of a kidney transplant.Studies included in this review were generally at high or unclear risk of bias for all items (random sequence generation, allocation concealment, incomplete outcome data, blinding of participants and personnel, blinding of outcome assessment, selective outcome reporting, intention to treat analysis and other sources of bias). One large study comparing darbepoetin alfa with placebo was at low risk of bias for most items assessed.Authors&apos; conclusions: Data suggest that darbepoetin alfa effectively reduces need for blood transfusions in adults with CKD stage 3 to 5, but has little or no effect on mortality or quality of life. The effects of darbepoetin alfa in adults with CKD stage 5D and kidney transplant recipients and children with CKD remain uncertain as do the relative benefits and harms of darbepoetin alfa compared with other ESAs (epoetin alfa or beta and methoxy polyethylene glycol-epoetin beta).</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009297.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009297.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>719</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">719</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palmer Suetonia, C.</style></author><author><style face="normal" font="default" size="100%">Saglimbene, Valeria</style></author><author><style face="normal" font="default" size="100%">Mavridis, Dimitris</style></author><author><style face="normal" font="default" size="100%">Salanti, Georgia</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author><author><style face="normal" font="default" size="100%">Tonelli, Marcello</style></author><author><style face="normal" font="default" size="100%">Wiebe, Natasha</style></author><author><style face="normal" font="default" size="100%">Strippoli Giovanni, F. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010590</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Several erythropoiesis-stimulating agents (ESAs) are available for treating anaemia in people with chronic kidney disease (CKD). Their relative efficacy (preventing blood transfusions and reducing fatigue and breathlessness) and safety (mortality and cardiovascular events) are unclear due to the limited power of head-to-head studies.Objectives: To compare the efficacy and safety of ESAs (epoetin alfa, epoetin beta, darbepoetin alfa, or methoxy polyethylene glycol-epoetin beta, and biosimilar ESAs, against each other, placebo, or no treatment) to treat anaemia in adults with CKD.Search methods: We searched the Cochrane Renal Group&apos;s Specialised Register to 11 February 2014 through contact with the Trials&apos; Search Co-ordinator using search terms relevant to this review.Selection criteria: Randomised controlled trials (RCTs) that included a comparison of an ESA (epoetin alfa, epoetin beta, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta, or biosimilar ESA) with another ESA, placebo or no treatment in adults with CKD and that reported prespecified patient-relevant outcomes were considered for inclusion.Data collection and analysis: Two independent authors screened the search results and extracted data. Data synthesis was performed by random-effects pairwise meta-analysis and network meta-analysis. We assessed for heterogeneity and inconsistency within meta-analyses using standard techniques and planned subgroup and meta-regression to explore for sources of heterogeneity or inconsistency. We assessed our confidence in treatment estimates for the primary outcomes within network meta-analysis (preventing blood transfusions and all-cause mortality) according to adapted GRADE methodology as very low, low, moderate, or high.Main results: We identified 56 eligible studies involving 15,596 adults with CKD. Risks of bias in the included studies was generally high or unclear for more than half of studies in all of the risk of bias domains we assessed; no study was low risk for allocation concealment, blinding of outcome assessment and attrition from follow-up. In network analyses, there was moderate to low confidence that epoetin alfa (OR 0.18, 95% CI 0.05 to 0.59), epoetin beta (OR 0.09, 95% CI 0.02 to 0.38), darbepoetin alfa (OR 0.17, 95% CI 0.05 to 0.57), and methoxy polyethylene glycol-epoetin beta (OR 0.15, 95% CI 0.03 to 0.70) prevented blood transfusions compared to placebo. In very low quality evidence, biosimilar ESA therapy was possibly no better than placebo for preventing blood transfusions (OR 0.27, 95% CI 0.05 to 1.47) with considerable imprecision in estimated effects. We could not discern whether all ESAs were similar or different in their effects on preventing blood transfusions and our confidence in the comparative effectiveness of different ESAs was generally very low. Similarly, the comparative effects of ESAs compared with another ESA, placebo or no treatment on all-cause mortality were imprecise.All proprietary ESAs increased the odds of hypertension compared to placebo (epoetin alfa OR 2.31, 95% CI 1.27 to 4.23; epoetin beta OR 2.57, 95% CI 1.23 to 5.39; darbepoetin alfa OR 1.83, 95% CI 1.05 to 3.21; methoxy polyethylene glycol-epoetin beta OR 1.96, 95% CI 0.98 to 3.92), while the effect of biosimilar ESAs on developing hypertension was less certain (OR 1.18, 95% CI 0.47 to 2.99). Our confidence in the comparative effects of ESAs on hypertension was low due to considerable imprecision in treatment estimates. The comparative effects of all ESAs on cardiovascular mortality, myocardial infarction (MI), stroke, and vascular access thrombosis were uncertain and network analyses for major cardiovascular events, end-stage kidney disease (ESKD), fatigue and breathlessness were not possible. Effects of ESAs on fatigue were described heterogeneously in the available studies in ways that were not useable for analyses.Authors&apos; conclusions: In the CKD setting, there is currently insufficient evidence to suggest the superiority of any ESA formulation based on available safety and efficacy data. Direc ly comparative data for the effectiveness of different ESA formulations based on patient-centred outcomes (such as quality of life, fatigue, and functional status) are sparse and poorly reported and current research studies are unable to inform care. All proprietary ESAs (epoetin alfa, epoetin beta, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta) prevent blood transfusions but information for biosimilar ESAs is less conclusive. Comparative treatment effects of different ESA formulations on other patient-important outcomes such as survival, MI, stroke, breathlessness and fatigue are very uncertain.For consumers, clinicians and funders, considerations such as drug cost and availability and preferences for dosing frequency might be considered as the basis for individualising anaemia care due to lack of data for comparative differences in clinical benefits and harms.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010590.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010590.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>299</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">299</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pan, G.</style></author><author><style face="normal" font="default" size="100%">Zhou, X.</style></author><author><style face="normal" font="default" size="100%">Zhao, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Cardiovascular Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cardiovascular Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Atrial Fibrillation</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014022005</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014022005/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>720</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">720</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pande, Sami</style></author><author><style face="normal" font="default" size="100%">Hiller Janet, E.</style></author><author><style face="normal" font="default" size="100%">Nkansah, Nancy</style></author><author><style face="normal" font="default" size="100%">Bero, Lisa</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Costs and Cost Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Health Promotion [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Health Services [utilization]</style></keyword><keyword><style face="normal" font="default" size="100%">Health Status</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceutical Services [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Professional Role</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Epoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010398</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: The role of pharmacists has expanded beyond dispensing and packaging over the past two decades, and now includes ensuring rational use of drugs, improving clinical outcomes and promoting health status by working with the public and other healthcare professionals.Objectives: To examine the effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries.Search methods: Studies were identified by electronically searching the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (February 2010), MEDLINE (1949 to February 2010), Scopus (1960 to March 2010) and International Pharmaceutical Abstracts (1970 to January 2010) databases. An update of this review is currently ongoing. The search was re-run September 2012 and the potentially relevant studies are awaiting classification.Selection criteria: Randomised controlled trials, non-randomised controlled trials, controlled before-after studies and interrupted time series analyses comparing 1. pharmacist-provided non-dispensing services targeted at patients versus (a) the same services provided by other healthcare professionals, (b) the same services provided by untrained health workers, and (c) usual care; and 2. pharmacist-provided non-dispensing services targeted at healthcare professionals versus (a) the same services provided by other healthcare professionals, (b) the same services provided by untrained health workers, and (c) usual care in low- and middle-income countries. The research sites must have been located in low or middle income countries according to World Bank Group 2009 at the time of the study, regardless of the location or the origin of the researchers.            Data collection and analysis: Two authors independently reviewed studies for inclusion in the review. Two review authors independently extracted data for each study. Risk of bias of the included studies was also assessed independently by two authors.Main results: Twelve studies comparing pharmacist-provided services versus usual care were included in this review. Of the 12 studies, seven were from lower middle income countries and five were from upper middle income countries. Eleven studies examined pharmacist-provided services targeted at patients and one study evaluated pharmacist interventions targeted at healthcare professionals. Pharmacist-provided services targeting patients resulted in a small improvement of clinical outcomes such as blood pressure (-25 mm Hg/-6 mm Hg and -4.56 mm Hg/-2.45 mm Hg), blood glucose (-39.84 mg/dl and -16.16 mg/dl), blood cholesterol (-25.7 mg/dl)/ triglyceride levels (-80.1 mg/dl) and asthma outcomes (peak expiratory flow rate 1.76 l/min). Moreover, there was a small improvement in the quality of life, although four studies did not report the effect size explicitly. Health service utilisation, such as rate of hospitalisation and general practice and emergency room visits, was also found to be reduced by the patient targeted pharmacist-provided services. A single study examined the effect of patient targeted pharmacist interventions on medical expenses and the cost was found to be reduced. A single study that examined pharmacist services that targeted healthcare professionals demonstrated a very small impact on asthma symptom scores. No studies assessing the impact of pharmacist-provided non-dispensing services that targeted healthcare professionals reported health service utilisation and cost outcomes. Overall, five studies did not adequately report the numerical data for outcomes but instead reported qualitative statements about results, which prevented an estimation of the effect size.Studies for the comparison of patient targeted services provided by pharmacists versus the same services provided by other healthcare professionals or untrained healthcare workers were not found. Similarly, studies for the comparison of healthcare professional targeted services provided by pharmacists versus the same services provided by other h althcare professionals or untrained healthcare workers were not found.Authors&apos; conclusions: Pharmacist-provided services that target patients may improve clinical outcomes such as management of high glucose levels among diabetic patients, management of blood pressure and cholesterol levels and may improve the quality of life of patients with chronic conditions such as diabetes, hypertension and asthma. Pharmacist services may reduce health service utilisation such as visits to general practitioners and hospitalisation rates. We are uncertain about the effect of educational sessions by pharmacists for healthcare professionals due to the imprecision of a single study included in this review. Similarly, conclusions could not be drawn for health service utilisation and costs due to lack of evidence on interventions delivered by pharmacists to healthcare professionals. These results were heterogenous in the types of outcomes measured, clinical conditions and approaches to measurement of outcomes, and require cautious interpretation. All eligible studies were from middle income countries and the results may not be applicable to low income countries.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010398/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010398</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>721</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">721</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paramothayan, N. Shanthi</style></author><author><style face="normal" font="default" size="100%">Lasserson Toby, J.</style></author><author><style face="normal" font="default" size="100%">Wells, Athol</style></author><author><style face="normal" font="default" size="100%">Walters, E. Haydn</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prostacyclin for pulmonary hypertension in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD002994</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Primary pulmonary hypertension (PPH) is progressive, resulting in right ventricular failure. Pulmonary hypertension can be idiopathic or associated with other conditions. Prostacyclin is a potent vasodilator and inhibitor of platelet aggregation, and can be given orally, subcutaneously, intravenously or inhaled via a nebuliser.Objectives: To determine the efficacy of prostacyclin or one of its analogues in idiopathic primary pulmonary hypertension.Search methods: Electronic searches were carried out in CENTRAL, MEDLINE and EMABSE with pre-specified terms. Searches were current as of July 2006.Selection criteria: Two reviewers selected randomised controlled trials (RCTs) involving adults with pulmonary hypertension for inclusion.Data collection and analysis: Study quality was assessed and data extracted independently by two reviewers. Outcomes were analysed as continuous and dichotomous outcomes. We sub-grouped data where possible by aetiology of PH (PPH, PH secondary to connective tissue disorder or mixed populations).Main results: Nine RCTs of mixed duration (3 days-52 weeks), recruiting 1175 participants were included (NYHA functional classes II-IV). Intravenous prostacyclin versus usual care (four studies) : There were significant improvements in exercise capacity of around 90 metres, cardiopulmonary haemodynamics and NYHA functional class over 3 days-12 weeks. Effects were consistent in primary and secondary pulmonary hypertension. Oral prostacyclin versus placebo (two studies) : Short-term data (3-6 months) indicated that there was a significant improvement in exercise capacity, but data from one study of 52 weeks reported no significant difference at 12 months. No significant differences were observed for any other outcome. Subcutaneous treprostinil versus placebo (two studies, 8-12 weeks): One large study reported a significant median improvement in exercise capacity of around 16 metres. Cardiopulmonary haemodynamics and symptom scores favoured treprostinil. Infusion site pain and withdrawals due to adverse events were more frequent with treprostinil. Inhaled prostacyclin versus placebo (one study, 12 weeks): There was a significant increase in exercise capacity of approximately 36 metres. Treatment led to better symptom scores and functional class status than with placebo. Subgroup analyses reported by individual studies showed a better exercise capacity in participants with PPH, than those participants with PH secondary to other diseases. Side effects and adverse events were common in the studies.Authors&apos; conclusions: There is evidence that intravenous prostacyclin in addition to conventional therapy at tolerable doses optimised by titration, can confer some short-term benefits (up to 12 weeks of treatment) in exercise capacity, NYHA functional class and cardiopulmonary haemodynamics. There is also some evidence that patients with more severe disease based upon NYHA functional class showed a greater response to treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002994.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD002994.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>722</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">722</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paravastu Sharath Chandra, Vikram</style></author><author><style face="normal" font="default" size="100%">Mendonca Derick, A.</style></author><author><style face="normal" font="default" size="100%">Da Silva, Anthony</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Beta blockers for peripheral arterial disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Atenolol [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Intermittent Claudication [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Metoprolol [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Peripheral Vascular Diseases [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Pindolol [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Propranolol [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Regional Blood Flow [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Walking</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Pvd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005508</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Beta (?) blockers are indicated for use in coronary artery disease (CAD). However, optimal therapy for people with CAD accompanied by intermittent claudication has been controversial because of the presumed peripheral haemodynamic consequences of beta blockers, leading to worsening symptoms of intermittent claudication. This is an update of a review first published in 2008.Objectives: To quantify the potential harmful effects of beta blockers on maximum walking distance, claudication distance, calf blood flow, calf vascular resistance and skin temperature when used in patients with peripheral arterial disease (PAD).Search methods: For this update, the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched March 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, 2013, Issue 2).Selection criteria: Randomised controlled trials (RCTs) evaluating the role of both selective (?1) and non-selective (?1 and ?2) beta blockers compared with placebo. We excluded trials that compared different types of beta blockers.Data collection and analysis: Primary outcome measures were claudication distance in metres, time to claudication in minutes and maximum walking distance in metres and minutes (as assessed by treadmill).Secondary outcome measures included calf blood flow (mL/100 mL/min), calf vascular resistance and skin temperature (ºC).Main results: We included six RCTs that fulfilled the above criteria, with a total of 119 participants. The beta blockers studied were atenolol, propranolol, pindolol and metoprolol. All trials were of poor quality with the drugs administered over a short time (10 days to two months). None of the primary outcomes were reported by more than one study. Similarly, secondary outcome measures, with the exception of vascular resistance (as reported by three studies), were reported, each by only one study. Pooling of such results was deemed inappropriate. None of the trials showed a statistically significant worsening effect of beta blockers on time to claudication, claudication distance and maximal walking distance as measured on a treadmill, nor on calf blood flow, calf vascular resistance and skin temperature, when compared with placebo. No reports described adverse events associated with the beta blockers studied.Authors&apos; conclusions: Currently, no evidence suggests that beta blockers adversely affect walking distance, calf blood flow, calf vascular resistance and skin temperature in people with intermittent claudication. However, because of the lack of large published trials, beta blockers should be used with caution, if clinically indicated.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005508.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005508.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>723</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">723</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parent Mathias, Veronica</style></author><author><style face="normal" font="default" size="100%">Rueda, José-Ramón</style></author><author><style face="normal" font="default" size="100%">Solà, Ivan</style></author><author><style face="normal" font="default" size="100%">Bonfill Cosp, Xavier</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Alcohol intake reduction for controlling hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010022</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the effects of interventions to reduce alcohol intake for controlling hypertension in hypertensive people.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010022/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010022</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>300</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">300</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Park, I. U.</style></author><author><style face="normal" font="default" size="100%">Taylor, A. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Family Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Family Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">444-452</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">African Americans [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Asian Continental Ancestry Group [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [ethnology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Continental Population Groups</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Ethnic Groups</style></keyword><keyword><style face="normal" font="default" size="100%">European Continental Ancestry Group [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Hispanic Americans [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [ethnology]</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Research Subjects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">World Health</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007003464</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007003464/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>301</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">301</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Park, J.</style></author><author><style face="normal" font="default" size="100%">Song, J. H.</style></author><author><style face="normal" font="default" size="100%">Park, D. A.</style></author><author><style face="normal" font="default" size="100%">Lee, J. S.</style></author><author><style face="normal" font="default" size="100%">Lee, S. D.</style></author><author><style face="normal" font="default" size="100%">Oh, Y. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Korean Medical Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Korean Medical Science</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1200-1206</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Disease, Chronic Obstructive</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013050409</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013050409/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>724</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">724</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pascual, Julio</style></author><author><style face="normal" font="default" size="100%">Zamora, Javier</style></author><author><style face="normal" font="default" size="100%">Galeano, Cristina</style></author><author><style face="normal" font="default" size="100%">Royuela, Ana</style></author><author><style face="normal" font="default" size="100%">Quereda, Carlos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Steroid avoidance or withdrawal for kidney transplant recipients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Graft Rejection [immunology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Graft Survival [drug effects] [immunology]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppression</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Transplantation [immunology] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Steroids [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005632</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Steroid-sparing strategies have been attempted during the last two decades in order to avoid morbidity in kidney transplant recipients. Previous systematic reviews of steroid withdrawal after kidney transplantation have shown significant increases in acute rejection and an increase in graft failure rates. Steroid avoidance in kidney transplantation is increasingly attempted and the possible benefits or harms have never been a subject of a systematic review.Objectives: To assess the safety and efficacy of steroid withdrawal or avoidance in patients receiving a kidney transplant.Search methods: We searched CENTRAL, MEDLINE and EMBASE, references lists and abstracts from international transplantation society scientific meetings.Selection criteria: Randomised controlled studies (RCTs) of steroid avoidance or withdrawal were included providing that one treatment arm consisted in steroid avoidance or withdrawal and intention-to-treat rates of acute rejection and graft failure were clearly established after steroid avoidance or use or withdrawal or continuation. Observational studies were tabulated.Data collection and analysis: Two authors independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and results expressed as risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI).Main results: We included 30 RCTs (5949 participants). Steroid-sparing strategies showed no effect on mortality or graft loss including death. Patients on any steroid-sparing strategy showed a higher risk of graft loss excluding death than those with conventional steroid use (RR 1.23, 95% CI 1.00 to 1.52), especially in those not receiving MMF/Myf or everolimus (RR 1.70, 95% CI 1.00 to 2.90). Acute rejection was more frequent with a steroid-sparing strategy (RR 1.27, 95% CI 1.14 to 1.40) and more frequent after steroid withdrawal or avoidance when compared with standard steroid treatment when cyclosporin (CsA) was used. Steroid-sparing and withdrawal strategies showed benefits in reducing antihypertensive drug need, serum cholesterol, antihyperlipidaemic drug need, new-onset diabetes after transplantation (NODAT) requiring any treatment and cataracts. Steroid avoidance did not alter serum cholesterol, but was associated with less frequent NODAT requiring any treatment. Cardiovascular events were reduced with steroid avoidance. Reduced antihypertensive drug need and serum cholesterol were similar with CsA or tacrolimus (TAC). Reduced antihyperlipidaemic drug need was only evident with TAC, whereas the reduction in NODAT requiring any treatment was only evident with CsA. Infection was lower in steroid-sparing patients using CsA (RR 0.88, 95% CI 0.78 to 1.00). NODAT requiring any treatment was less frequent with steroid avoidance than with steroid withdrawal.Authors&apos; conclusions: This review confirms that steroid avoidance and steroid withdrawal strategies in kidney transplantation are not associated with increased mortality or graft loss despite an increase in acute rejection. These immunosuppression strategies may allow safe steroid avoidance or elimination a few days after kidney transplantation if antibody induction treatment is prescribed or after three to six months if such induction is not used.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005632.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005632.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>725</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">725</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pass, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Agents for pulmonary hypertension (TCR) (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><publisher><style face="normal" font="default" size="100%">University Healthsystem Consortium</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32006001061</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32006001061/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>726</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">726</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pattanittum, Porjai</style></author><author><style face="normal" font="default" size="100%">Ngamjarus, Chetta</style></author><author><style face="normal" font="default" size="100%">Somboonporn, Charoonsak</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cordyceps sinensis for hypertension in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008894</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the effectiveness and adverse effects of Cordyceps Sinensis (CDS) on blood pressure compared to placebo or no treatment in hypertensive patients.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008894/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008894</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>727</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">727</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Penninga, Luit</style></author><author><style face="normal" font="default" size="100%">Møller Christian, H.</style></author><author><style face="normal" font="default" size="100%">Gustafsson, Finn</style></author><author><style face="normal" font="default" size="100%">Gluud, Christian</style></author><author><style face="normal" font="default" size="100%">Steinbrüchel Daniel, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Immunosuppressive T-cell antibody induction for heart transplant recipients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Heart Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal [immunology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antilymphocyte Serum [immunology]</style></keyword><keyword><style face="normal" font="default" size="100%">Graft Rejection [immunology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin G [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppression [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Muromonab-CD3 [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Interleukin-2 [antagonists &amp; inhibitors] [immunology]</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Fusion Proteins [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes [immunology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008842</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Heart transplantation has become a valuable and well-accepted treatment option for end-stage heart failure. Rejection of the transplanted heart by the recipient&apos;s body is a risk to the success of the procedure, and life-long immunosuppression is necessary to avoid this. Clear evidence is required to identify the best, safest and most effective immunosuppressive treatment strategy for heart transplant recipients. To date, there is no consensus on the use of immunosuppressive antibodies against T-cells for induction after heart transplantation.Objectives: To review the benefits, harms, feasibility and tolerability of immunosuppressive T-cell antibody induction versus placebo, or no antibody induction, or another kind of antibody induction for heart transplant recipients.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 11, 2012), MEDLINE (Ovid) (1946 to November Week 1 2012), EMBASE (Ovid) (1946 to 2012 Week 45), ISI Web of Science (14 November 2012); we also searched two clinical trial registers and checked reference lists in November 2012.Selection criteria: We included all randomised clinical trials (RCTs) assessing immunosuppressive T-cell antibody induction for heart transplant recipients. Within individual trials, we required all participants to receive the same maintenance immunosuppressive therapy.Data collection and analysis: Two authors extracted data independently. RevMan analysis was used for statistical analysis of dichotomous data with risk ratio (RR), and of continuous data with mean difference (MD), both with 95% confidence intervals (CI). Methodological components were used to assess risks of systematic errors (bias). Trial sequential analysis was used to assess the risks of random errors (play of chance). We assessed mortality, acute rejection, infection, Cytomegalovirus (CMV) infection, post-transplantation lymphoproliferative disorder, cancer, adverse events, chronic allograft vasculopathy, renal function, hypertension, diabetes mellitus, and hyperlipidaemia.Main results: In this review, we included 22 RCTs that investigated the use of T-cell antibody induction, with a total of 1427 heart-transplant recipients. All trials were judged to be at a high risk of bias. Five trials, with a total of 606 participants, compared any kind of T-cell antibody induction versus no antibody induction; four trials, with a total of 576 participants, compared interleukin-2 receptor antagonist (IL-2 RA) versus no induction; one trial, with 30 participants, compared monoclonal antibody (other than IL-2 RA) versus no antibody induction; two trials, with a total of 159 participants, compared IL-2 RA versus monoclonal antibody (other than IL-2 RA) induction; four trials, with a total of 185 participants, compared IL-2 RA versus polyclonal antibody induction; seven trials, with a total of 315 participants, compared monoclonal antibody (other than IL-2 RA) versus polyclonal antibody induction; and four trials, with a total of 162 participants, compared polyclonal antibody induction versus another kind, or dose of polyclonal antibodies.No significant differences were found for any of the comparisons for the outcomes of mortality, infection, CMV infection, post-transplantation lymphoproliferative disorder, cancer, adverse events, chronic allograft vasculopathy, renal function, hypertension, diabetes mellitus, or hyperlipidaemia. Acute rejection occurred significantly less frequently when IL-2 RA induction was compared with no induction (93/284 (33%) versus 132/292 (45%); RR 0.73; 95% CI 0.59 to 0.90; I2 57%) applying the fixed-effect model. No significant difference was found when the random-effects model was applied (RR 0.73; 95% CI 0.46 to 1.17; I2 57%). In addition, acute rejection occurred more often statistically when IL-2 RA induction was compared with polyclonal antibody induction (24/90 (27%) versus 10/95 (11%); RR 2.43; 95% CI 1.01 to 5.86; I2 28%). For all of these differences in acute rejection, trial sequential alpha-spending boundaries were not crossed and t e required information sizes were not reached when trial sequential analysis was performed, indicating that we cannot exclude random errors.We observed some occasional significant differences in adverse events in some of the comparisons, however definitions of adverse events varied between trials, and numbers of participants and events in these outcomes were too small to allow definitive conclusions to be drawn.Authors&apos; conclusions: This review shows that acute rejection might be reduced by IL-2 RA compared with no induction, and by polyclonal antibody induction compared with IL-2 RA, though trial sequential analyses cannot exclude random errors, and the significance of our observations depended on the statistical model used. Furthermore, this review does not show other clear benefits or harms associated with the use of any kind of T-cell antibody induction compared with no induction, or when one type of T-cell antibody is compared with another type of antibody. The number of trials investigating the use of antibodies against T-cells for induction after heart transplantation is small, and the number of participants and outcomes in these RCTs is limited. Furthermore, the included trials are at a high risk of bias. Hence, more RCTs are needed to assess the benefits and harms of T-cell antibody induction for heart-transplant recipients. Such trials ought to be conducted with low risks of systematic and random error.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008842.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008842.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>728</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">728</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Penninga, Luit</style></author><author><style face="normal" font="default" size="100%">Penninga Elisabeth, I.</style></author><author><style face="normal" font="default" size="100%">Møller Christian, H.</style></author><author><style face="normal" font="default" size="100%">Iversen, Martin</style></author><author><style face="normal" font="default" size="100%">Steinbrüchel Daniel, A.</style></author><author><style face="normal" font="default" size="100%">Gluud, Christian</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bronchiolitis Obliterans [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclosporine [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Graft Rejection [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Immune Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppression [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Transplantation [immunology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Tacrolimus [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008817</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Lung transplantation is a well-accepted treatment for people with most end-stage lung diseases. Although both tacrolimus and cyclosporin are used as primary immunosuppressive agents in lung transplant recipients, it is unclear which of these drugs is better in reducing rejection and death without causing adverse effects.Objectives: To assess the benefits and harms of tacrolimus versus cyclosporin for primary immunosuppression in lung transplant recipients.Search methods: We searched the Cochrane Renal Group&apos;s Specialised Register to 10 April 2013 through contact with the Trials Search Co-ordinator using search terms relevant to this review. We also searched Science Citation Index Expanded and the Transplant Library to 20 April 2013.Selection criteria: We included all randomised controlled trials (RCT) that compared any dose and duration of administration of tacrolimus versus cyclosporin as primary immunosuppressive treatment in lung transplant recipients. Our selection criteria required that all included patients received the same additional immunosuppressive therapy within each study.Data collection and analysis: Three authors extracted data. For dichotomous data we used risk ratio (RR) and used mean difference (MD) for continuous data, each with 95% confidence intervals (CI). Methodological components of the included studies were used to assess risk of systematic errors (bias). Trial sequential analysis was used to assess risk of random errors (play of chance).Main results: We included three studies that enrolled a total of 413 adult patients that compared tacrolimus with microemulsion or oral solution cyclosporin. All studies were found to be at high risk of bias. Tacrolimus seemed to be significantly superior to cyclosporin regarding the incidence of bronchiolitis obliterans syndrome (RR 0.46, 95% CI 0.29 to 0.74), lymphocytic bronchitis score (MD -0.60, 95% CI -1.04 to -0.16), treatment withdrawal (RR 0.27, 95% CI 0.16 to 0.46), and arterial hypertension (RR 0.67, 95% CI 0.50 to 0.89). However, the finding for arterial hypertension was not confirmed when analysed using a random-effects model (RR 0.54, 95% CI 0.17 to 1.73). Furthermore, trial sequential analysis found that none of the meta-analyses reached the required information sizes and cumulative Z-curves did not cross trial sequential monitoring boundaries. Diabetes mellitus occurred more frequently among people in the tacrolimus group compared with the cyclosporin group when the fixed-effect model was applied (RR 4.24, 95% CI 1.58 to 11.40), but no difference was found when the random-effects model was used for analysis (RR 4.43, 95% CI 0.75 to 26.05). Again, trial sequential analysis found that the required information threshold was not reached and cumulative Z-curve did not cross the trial sequential monitoring boundary. No significant difference between treatment groups was observed regarding mortality (RR 1.06, 95% CI 0.75 to 1.49), incidence of acute rejection (RR 0.89, 95% CI 0.77 to 1.03), numbers of infections/100 patient-days (MD -0.15, 95% CI -0.30 to 0.00), cancer (RR 0.21, 95% CI 0.04 to 1.16), kidney dysfunction (RR 1.41, 95% CI 0.93 to 2.14), kidney failure (RR 1.57, 95% CI 0.28 to 8.94), neurotoxicity (RR 7.06, 95% CI 0.37 to 135.19), and hyperlipidaemia (RR 0.60, 95% CI 0.30 to 1.20). Trial sequential analysis showed the required information thresholds were not reached for any of these outcome measures.Authors&apos; conclusions: Tacrolimus may be superior to cyclosporin regarding bronchiolitis obliterans syndrome, lymphocytic bronchitis, treatment withdrawal, and arterial hypertension, but may be inferior regarding development of diabetes. No difference in mortality and acute rejection was observed between patients treated with tacrolimus and cyclosporin. There were few studies comparing tacrolimus and cyclosporin after lung transplantation, and the numbers of patients and events in the included studies were limited. Furthermore, the included studies were deemed to be at high risk of bias. Hence, more RCTs are needed to assess the re ults of the present review. Such studies ought to be conducted with low risks of systematic errors (bias) and of random errors (play of chance).</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008817.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008817.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>729</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">729</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Penninga, Luit</style></author><author><style face="normal" font="default" size="100%">Wettergren, André</style></author><author><style face="normal" font="default" size="100%">Wilson Colin, H.</style></author><author><style face="normal" font="default" size="100%">Chan, An-Wen</style></author><author><style face="normal" font="default" size="100%">Steinbrüchel Daniel, A.</style></author><author><style face="normal" font="default" size="100%">Gluud, Christian</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Liver</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010253</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Liver transplantation is an established treatment option for end-stage liver failure. To date, no consensus has been reached on the use of immunosuppressive T-cell antibody induction for preventing rejection after liver transplantation.Objectives: To assess the benefits and harms of immunosuppressive T-cell specific antibody induction compared with placebo, no induction, or another type of T-cell specific antibody induction for prevention of acute rejection in liver transplant recipients.Search methods: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Science Citation Index Expanded, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) until September 2013.Selection criteria: Randomised clinical trials assessing immunosuppression with T-cell specific antibody induction compared with placebo, no induction, or another type of antibody induction in liver transplant recipients. Our inclusion criteria stated that participants within each included trial should have received the same maintenance immunosuppressive therapy. We planned to include trials with all of the different types of T-cell specific antibodies that are or have been used for induction (ie., polyclonal antibodies (rabbit of horse antithymocyte globulin (ATG), or antilymphocyte globulin (ALG)), monoclonal antibodies (muromonab-CD3, anti-CD2, or alemtuzumab), and interleukin-2 receptor antagonists (daclizumab, basiliximab, BT563, or Lo-Tact-1)).Data collection and analysis: We used RevMan analysis for statistical analysis of dichotomous data with risk ratio (RR) and of continuous data with mean difference (MD), both with 95% confidence intervals (CIs). We assessed the risk of systematic errors (bias) using bias risk domains with definitions. We used trial sequential analysis to control for random errors (play of chance). We presented outcome results in a summary of findings table.Main results: We included 19 randomised clinical trials with a total of 2067 liver transplant recipients. All 19 trials were with high risk of bias. Of the 19 trials, 16 trials were two-arm trials, and three trials were three-arm trials. Hence, we found 25 trial comparisons with antibody induction agents: interleukin-2 receptor antagonist (IL-2 RA) versus no induction (10 trials with 1454 participants); monoclonal antibody versus no induction (five trials with 398 participants); polyclonal antibody versus no induction (three trials with 145 participants); IL-2 RA versus monoclonal antibody (one trial with 87 participants); and IL-2 RA versus polyclonal antibody (two trials with 112 participants). Thus, we were able to compare T-cell specific antibody induction versus no induction (17 trials with a total of 1955 participants). Overall, no difference in mortality (RR 0.91; 95% CI 0.64 to 1.28; low-quality of evidence), graft loss including death (RR 0.92; 95% CI 0.71 to 1.19; low-quality of evidence), and adverse events ((RR 0.97; 95% CI 0.93 to 1.02; low-quality evidence) outcomes was observed between any kind of T-cell specific antibody induction compared with no induction when the T-cell specific antibody induction agents were analysed together or separately. Acute rejection seemed to be reduced when any kind of T-cell specific antibody induction was compared with no induction (RR 0.85, 95% CI 0.75 to 0.96; moderate-quality evidence), and when trial sequential analysis was applied, the trial sequential monitoring boundary for benefit was crossed before the required information size was obtained. Furthermore, serum creatinine was statistically significantly higher when T-cell specific antibody induction was compared with no induction (MD 3.77 ?mol/L, 95% CI 0.33 to 7.21; low-quality evidence), as well as when polyclonal T-cell specific antibody induction was compared with no induction, but this small difference was not clinically significant. We found no statistically significant differences for any of the remaining predefined o tcomes - infection, cytomegalovirus infection, hepatitis C recurrence, malignancy, post-transplant lymphoproliferative disease, renal failure requiring dialysis, hyperlipidaemia, diabetes mellitus, and hypertension - when the T-cell specific antibody induction agents were analysed together or separately. Limited data were available for meta-analysis on drug-specific adverse events such as haematological adverse events for antithymocyte globulin. No data were found on quality of life.When T-cell specific antibody induction agents were compared with another type of antibody induction, no statistically significant differences were found for mortality, graft loss, and acute rejection for the separate analyses. When interleukin-2 receptor antagonists were compared with polyclonal T-cell specific antibody induction, drug-related adverse events were less common among participants treated with interleukin-2 receptor antagonists (RR 0.23, 95% CI 0.09 to 0.63; low-quality evidence), but this was caused by the results from one trial, and trial sequential analysis could not exclude random errors. We found no statistically significant differences for any of the remaining predefined outcomes: infection, cytomegalovirus infection, hepatitis C recurrence, malignancy, post-transplant lymphoproliferative disease, renal failure requiring dialysis, hyperlipidaemia, diabetes mellitus, and hypertension. No data were found on quality of life.Authors&apos; conclusions: The effects of T-cell antibody induction remain uncertain because of the high risk of bias of the randomised clinical trials, the small number of randomised clinical trials reported, and the limited numbers of participants and outcomes in the trials. T-cell specific antibody induction seems to reduce acute rejection when compared with no induction. No other clear benefits or harms were associated with the use of any kind of T-cell specific antibody induction compared with no induction, or when compared with another type of T-cell specific antibody. Hence, more randomised clinical trials are needed to assess the benefits and harms of T-cell specific antibody induction compared with placebo, and compared with another type of antibody, for prevention of rejection in liver transplant recipients. Such trials ought to be conducted with low risks of systematic error (bias) and low risk of random error (play of chance).</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010253.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010253.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>730</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">730</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Penninga, Luit</style></author><author><style face="normal" font="default" size="100%">Wettergren, André</style></author><author><style face="normal" font="default" size="100%">Wilson Colin, H.</style></author><author><style face="normal" font="default" size="100%">Chan, An-Wen</style></author><author><style face="normal" font="default" size="100%">Steinbrüchel Daniel, A.</style></author><author><style face="normal" font="default" size="100%">Gluud, Christian</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antibody induction versus corticosteroid induction for liver transplant recipients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Liver</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010252</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Liver transplantation is an established treatment option for end-stage liver failure. To date, no consensus has been reached on the use of immunosuppressive T-cell specific antibody induction compared with corticosteroid induction of immunosuppression after liver transplantation.Objectives: To assess the benefits and harms of T-cell specific antibody induction versus corticosteroid induction for prevention of acute rejection in liver transplant recipients.Search methods: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Science Citation Index Expanded, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) on 30 September 2013 together with reference checking, citation searching, contact with trial authors and pharmaceutical companies to identify additional trials.Selection criteria: We included all randomised clinical trials assessing immunosuppression with T-cell specific antibody induction versus corticosteroid induction in liver transplant recipients. Our inclusion criteria stated that participants within each included trial should have received the same maintenance immunosuppressive therapy.Data collection and analysis: We used RevMan for statistical analysis of dichotomous data with risk ratio (RR) and of continuous data with mean difference (MD), both with 95% confidence intervals (CIs). We assessed risk of systematic errors (bias) using bias risk domains with definitions. We used trial sequential analysis to control for random errors (play of chance).Main results: We included 10 randomised trials with a total of 1589 liver transplant recipients, which studied the use of T-cell specific antibody induction versus corticosteroid induction. All trials were with high risk of bias. We compared any kind of T-cell specific antibody induction versus corticosteroid induction in 10 trials with 1589 participants, including interleukin-2 receptor antagonist induction versus corticosteroid induction in nine trials with 1470 participants, and polyclonal T-cell specific antibody induction versus corticosteroid induction in one trial with 119 participants.Our analyses showed no significant differences regarding mortality (RR 1.01, 95% CI 0.72 to 1.43), graft loss (RR 1.12, 95% CI 0.82 to 1.53) and acute rejection (RR 0.84, 95% CI 0.70 to 1.00), infection (RR 0.96, 95% CI 0.85 to 1.09), hepatitis C virus recurrence (RR 0.89, 95% CI 0.79 to 1.00), malignancy (RR 0.59, 95% CI 0.13 to 2.73), and post-transplantation lymphoproliferative disorder (RR 1.00, 95% CI 0.07 to 15.38) when any kind of T-cell specific antibody induction was compared with corticosteroid induction (all low-quality evidence). Cytomegalovirus infection was less frequent in patients receiving any kind of T-cell specific antibody induction compared with corticosteroid induction (RR 0.50, 95% CI 0.33 to 0.75; low-quality evidence). This was also observed when interleukin-2 receptor antagonist induction was compared with corticosteroid induction (RR 0.55, 95% CI 0.37 to 0.83; low-quality evidence), and when polyclonal T-cell specific antibody induction was compared with corticosteroid induction (RR 0.21, 95% CI 0.06 to 0.70; low-quality evidence). However, when trial sequential analysis regarding cytomegalovirus infection was applied, the required information size was not reached. Furthermore, diabetes mellitus occurred less frequently when T-cell specific antibody induction was compared with corticosteroid induction (RR 0.45, 95% CI 0.34 to 0.60; low-quality evidence), when interleukin-2 receptor antagonist induction was compared with corticosteroid induction (RR 0.45, 95% CI 0.35 to 0.61; low-quality evidence), and when polyclonal T-cell specific antibody induction was compared with corticosteroid induction (RR 0.12, 95% CI 0.02 to 0.95; low-quality evidence). When trial sequential analysis was applied, the trial sequential monitoring boundary for benefit was crossed. We found no subgroup differences for type of interleukin-2 receptor antagonist (basiliximab versus daclizumab). Four trials reported on adverse events. However, no differences between trial groups were noted. Limited data were available for meta-analysis on drug-specific adverse events such as haematological adverse events for antithymocyte globulin. No data were available on quality of life.Authors&apos; conclusions: Because of the low quality of the evidence, the effects of T-cell antibody induction remain uncertain. T-cell specific antibody induction seems to reduce diabetes mellitus and may reduce cytomegalovirus infection when compared with corticosteroid induction. No other clear benefits or harms were associated with the use of T-cell specific antibody induction compared with corticosteroid induction. For some analyses, the number of trials investigating the use of T-cell specific antibody induction after liver transplantation is small, and the numbers of participants and outcomes in these randomised trials are limited. Furthermore, the included trials are heterogeneous in nature and have applied different types of T-cell specific antibody induction therapy. All trials were at high risk of bias. Hence, additional randomised clinical trials are needed to assess the benefits and harms of T-cell specific antibody induction compared with corticosteroid induction for liver transplant recipients. Such trials ought to be conducted with low risks of systematic error and of random error.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010252.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010252.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>731</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">731</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez Marco, I.</style></author><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacological interventions for hypertensive emergencies</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Emergencies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003653</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Hypertensive emergencies, marked hypertension associated with acute end-organ damage, are life-threatening conditions. Many anti-hypertensive drugs have been used in these clinical settings. The benefits and harms of such treatment and the best first-line treatment are not known.Objectives: To answer the following two questions using randomized controlled trials (RCTs): 1) does anti-hypertensive drug therapy as compared to placebo or no treatment affect mortality and morbidity in patients presenting with a hypertensive emergency? 2) Does one first-line antihypertensive drug class as compared to another antihypertensive drug class affect mortality and morbidity in these patients?Search methods: Electronic sources: MEDLINE, EMBASE, Cochrane clinical trial register. In addition, we searched for references in review articles and trials. We attempted to contact trialists. Most recent search August 2007.Selection criteria: All unconfounded, truly randomized trials that compare an antihypertensive drug versus placebo, no treatment, or another antihypertensive drug from a different class in patients presenting with a hypertensive emergency.Data collection and analysis: Quality of concealment allocation was scored. Data on randomized patients, total serious adverse events, all-cause mortality, non-fatal cardiovascular events, withdrawals due to adverse events, length of follow-up, blood pressure and heart rate were extracted independently and cross checked.Main results: Fifteen randomized controlled trials (representing 869 patients) met the inclusion criteria. Two trials included a placebo arm. All studies (except one) were open-label trials. Seven drug classes were evaluated in those trials: nitrates (9 trials), ACE-inhibitors (7), diuretics (3), calcium channel blockers (6), alpha-1 adrenergic antagonists (4), direct vasodilators (2) and dopamine agonists (1). Mortality event data were reported in 7 trials. No meta-analysis was performed for clinical outcomes, due to insufficient data. The pooled effect of 3 different anti-hypertensive drugs in one placebo-controlled trial showed a statistically significant greater reduction in both systolic [WMD -13, 95%CI -19,-7] and diastolic [WMD -8, 95%CI, -12,-3] blood pressure with antihypertensive therapy.Authors&apos; conclusions: There is no RCT evidence demonstrating that anti-hypertensive drugs reduce mortality or morbidity in patients with hypertensive emergencies. Furthermore, there is insufficient RCT evidence to determine which drug or drug class is most effective in reducing mortality and morbidity. There were some minor differences in the degree of blood pressure lowering when one class of antihypertensive drug is compared to another. However, the clinical significance is unknown. RCTs are needed to assess different drug classes to determine initial and longer term mortality and morbidity outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003653.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003653.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>732</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">732</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez Marco, I.</style></author><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Nitrates [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006743</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Acute cardiovascular events represent a therapeutic challenge. Blood pressure lowering drugs are commonly used and recommended in the early phase of these settings. This review analyses randomized controlled trial (RCT) evidence for this approach.Objectives: To determine the effect of immediate and short-term administration of anti-hypertensive drugs on all-cause mortality, total non-fatal serious adverse events (SAE) and blood pressure, in patients with an acute cardiovascular event, regardless of blood pressure at the time of enrollment.Search methods: MEDLINE, EMBASE, and Cochrane clinical trial register from Jan 1966 to February 2009 were searched. Reference lists of articles were also browsed. In case of missing information from retrieved articles, authors were contacted.Selection criteria: Randomized controlled trials (RCTs) comparing anti-hypertensive drug with placebo or no treatment administered to patients within 24 hours of the onset of an acute cardiovascular event.Data collection and analysis: Two reviewers independently extracted data and assessed risk of bias. Fixed effects model with 95% confidence intervals (CI) were used. Sensitivity analyses were also conducted.Main results: Sixty-five RCTs (N=166,206) were included, evaluating four classes of anti-hypertensive drugs: ACE inhibitors (12 trials), beta-blockers (20), calcium channel blockers (18) and nitrates (18). Acute stroke was studied in 6 trials (all involving CCBs). Acute myocardial infarction was studied in 59 trials. In the latter setting immediate nitrate treatment (within 24 hours) reduced all-cause mortality during the first 2 days (RR 0.81, 95%CI [0.74,0.89], p&lt;0.0001). No further benefit was observed with nitrate therapy beyond this point. ACE inhibitors did not reduce mortality at 2 days (RR 0.91,95%CI [0.82, 1.00]), but did after 10 days (RR 0.93, 95%CI [0.87,0.98] p=0.01). No other blood pressure lowering drug administered as an immediate treatment or short-term treatment produced a statistical significant mortality reduction at 2, 10 or ?30 days. There was not enough data studying acute stroke, and there were no RCTs evaluating other acute cardiovascular events.Authors&apos; conclusions: Nitrates reduce mortality (4-8 deaths prevented per 1000) at 2 days when administered within 24 hours of symptom onset of an acute myocardial infarction. No mortality benefit was seen when treatment continued beyond 48 hours. Mortality benefit of immediate treatment with ACE inhibitors post MI at 2 days did not reach statistical significance but the effect was significant at 10 days (3-5 deaths prevented per 1000). There is good evidence for lack of a mortality benefit with immediate or short-term treatment with beta-blockers and calcium channel blockers for acute myocardial infarction.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006743.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006743.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>302</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">302</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez, M. I.</style></author><author><style face="normal" font="default" size="100%">Musini, V. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">596-607</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Emergencies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009100400</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009100400/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>303</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">303</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pewsner, D.</style></author><author><style face="normal" font="default" size="100%">Juni, P.</style></author><author><style face="normal" font="default" size="100%">Egger, M.</style></author><author><style face="normal" font="default" size="100%">Battaglia, M.</style></author><author><style face="normal" font="default" size="100%">Sundstrom, J.</style></author><author><style face="normal" font="default" size="100%">Bachmann, L. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><pages><style face="normal" font="default" size="100%">711</style></pages><volume><style face="normal" font="default" size="100%">335</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Electrocardiography [standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Forecasting</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertrophy, Left Ventricular [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Professional Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007008438</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007008438/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>733</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">733</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pichon Riviere, A.</style></author><author><style face="normal" font="default" size="100%">Augustovski, F.</style></author><author><style face="normal" font="default" size="100%">Garcia Marti, S.</style></author><author><style face="normal" font="default" size="100%">Alcaraz, A.</style></author><author><style face="normal" font="default" size="100%">Glujovsky, D.</style></author><author><style face="normal" font="default" size="100%">Lopez, A.</style></author><author><style face="normal" font="default" size="100%">Rey-Ares, L.</style></author><author><style face="normal" font="default" size="100%">Bardach, A.</style></author><author><style face="normal" font="default" size="100%">Ciapponi, A.</style></author><author><style face="normal" font="default" size="100%">Dehese, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Actualization: radiofrequency sympathetic denervation of the renal arteries for refractory arterial hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery</style></keyword><keyword><style face="normal" font="default" size="100%">Sympathectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Sympathetic Nervous System</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Institute for Clinical Effectiveness and Health Policy (IECS)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32014000256</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32014000256/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>734</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">734</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pichon-Riviere, A.</style></author><author><style face="normal" font="default" size="100%">Augustovski, F.</style></author><author><style face="normal" font="default" size="100%">Garcia Marti, S.</style></author><author><style face="normal" font="default" size="100%">Bardach, A.</style></author><author><style face="normal" font="default" size="100%">Galante, J.</style></author><author><style face="normal" font="default" size="100%">Lopez, A.</style></author><author><style face="normal" font="default" size="100%">Regueiro, A.</style></author><author><style face="normal" font="default" size="100%">Glujovsky, D.</style></author><author><style face="normal" font="default" size="100%">Aruj, P.</style></author><author><style face="normal" font="default" size="100%">Calcagno, J.</style></author><author><style face="normal" font="default" size="100%">Linetzky, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prostacyclins (epoprostenol, iloprost, treprostinil and beraprost) for the management of primary pulmonary hypertension and pulmonary hypertension in collagen vascular disease (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">derivatives [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [analogs &amp; derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Iloprost [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">Institute for Clinical Effectiveness and Health Policy (IECS)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32009100104</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32009100104/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>304</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">304</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pierdomenico, S. D.</style></author><author><style face="normal" font="default" size="100%">Cuccurullo, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">876-881</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertrophy, Left Ventricular [complications] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Reduction Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010006296</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010006296/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>305</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">305</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pierdomenico, S. D.</style></author><author><style face="normal" font="default" size="100%">Pierdomenico, A. M.</style></author><author><style face="normal" font="default" size="100%">Cuccurullo, C.</style></author><author><style face="normal" font="default" size="100%">Mancini, M.</style></author><author><style face="normal" font="default" size="100%">Carlo, S.</style></author><author><style face="normal" font="default" size="100%">Cuccurullo, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cardiac events in hypertensive patients with renal artery stenosis treated with renal angioplasty or drug therapy: meta-analysis of randomized trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1209-1214</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Creatinine [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction [complications] [drug therapy] [surgery] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012050698</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012050698/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>735</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">735</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pohar, R.</style></author><author><style face="normal" font="default" size="100%">Clark, M.</style></author><author><style face="normal" font="default" size="100%">Spry, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Drugs for pulmonary arterial hypertension: a systematic review of the clinical-effectiveness of combination therapy (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Agency for Drugs and Technologies in Health (CADTH)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32010001776</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010001776/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>736</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">736</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pohl, Annette</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Modes of administration of antibiotics for symptomatic severe urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents, Urinary [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003237</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Urinary tract infection (UTI), worldwide, is a major source of disease in children and adults. As it may have long-term consequences such as kidney failure and hypertension, it is important to treat patients with UTI adequately. Although standard management of severe UTI usually means intravenous (IV) therapy, at least initially, there are studies showing that oral therapy may also be effective.Objectives: To assess whether the mode of administration of antibiotic therapy for severe UTI has an effect on cure rate, reinfection rate and kidney scarring.Search methods: The Cochrane Renal Group&apos;s specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL, in The Cochrane Library), MEDLINE and EMBASE were searched. No language restriction was applied. Reference lists of relevant articles and reviews were checked for additional studies and authors of relevant articles/abstracts were contacted for further information.Selection criteria: All randomised controlled trials (RCTs) comparing different modes of antibiotic application for patients with severe UTI (children and adults) were considered.Data collection and analysis: Study quality was assessed and data extracted. Statistical analyses were performed using the random effects model and the results expressed as risk ratio (RR) for dichotomous outcomes or mean difference (MD) for continuous data with 95% confidence intervals (CI).Main results: Fifteen RCTs (1743 patients) were included. Studies compared oral versus parenteral treatment (1), oral versus switch treatment (initial intravenous (IV) or intramuscular (IM) therapy followed by oral therapy) (5), switch versus parenteral treatment (6) and single dose parenteral followed by oral therapy versus oral (1) or switch therapy (3). There was a variety of short-term and long-term outcomes, but no pooled outcomes showed significant differences. Most included studies were small though and there were few outcomes for combination in a meta-analysis.Authors&apos; conclusions: There is no evidence suggesting that oral antibiotic therapy is less effective for treatment of severe UTI than parenteral or initial parenteral therapy. The results of this review suggest that the mode of application does not determine therapeutic success.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003237.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003237.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>306</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">306</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Posadzki, P.</style></author><author><style face="normal" font="default" size="100%">Cramer, H.</style></author><author><style face="normal" font="default" size="100%">Kuzdzal, A.</style></author><author><style face="normal" font="default" size="100%">Lee, M. S.</style></author><author><style face="normal" font="default" size="100%">Ernst, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Yoga for hypertension: a systematic review of randomized clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">511-522</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Yoga</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014038678</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014038678/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>737</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">737</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Potter, J.</style></author><author><style face="normal" font="default" size="100%">Mistri, A.</style></author><author><style face="normal" font="default" size="100%">Brodie, F.</style></author><author><style face="normal" font="default" size="100%">Chernova, J.</style></author><author><style face="normal" font="default" size="100%">Wilson, E.</style></author><author><style face="normal" font="default" size="100%">Jagger, C.</style></author><author><style face="normal" font="default" size="100%">James, M.</style></author><author><style face="normal" font="default" size="100%">Ford, G.</style></author><author><style face="normal" font="default" size="100%">Robinson, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Controlling Hypertension and Hypotension Immediately Post-Stroke (CHHIPS) - a randomised controlled trial (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypotension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Labetalol [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Lisinopril [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [complications] [mortality] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">Health Technology Assessment</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32009100031</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32009100031/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>307</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">307</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Powers, B. J.</style></author><author><style face="normal" font="default" size="100%">Coeytaux, R. R.</style></author><author><style face="normal" font="default" size="100%">Dolor, R. J.</style></author><author><style face="normal" font="default" size="100%">Hasselblad, V.</style></author><author><style face="normal" font="default" size="100%">Patel, U. D.</style></author><author><style face="normal" font="default" size="100%">Yancy, W. S.</style></author><author><style face="normal" font="default" size="100%">Gray, R. N.</style></author><author><style face="normal" font="default" size="100%">Julian Irvine, R.</style></author><author><style face="normal" font="default" size="100%">Kendrick, A. S.</style></author><author><style face="normal" font="default" size="100%">Sanders, G. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: Much more data, little new information (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">716-729</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">Protease Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Renin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012031972</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012031972/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>738</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">738</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Price, Jackie</style></author><author><style face="normal" font="default" size="100%">Leng Gillian, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Steroid sex hormones for lower limb atherosclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Arteriosclerosis [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Intermittent Claudication [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemia [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Leg [blood supply]</style></keyword><keyword><style face="normal" font="default" size="100%">Peripheral Vascular Diseases [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Testosterone [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Pvd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD000188</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: There is accumulating evidence that steroid sex hormones have a beneficial effect on a number of risk factors for peripheral arterial disease.Objectives: The objective of this review was to determine whether exogenous steroid sex hormones are an effective treatment for patients with lower limb atherosclerosis.Search methods: For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched August 2012) and CENTRAL 2012, Issue 7. There were no language restrictions.Selection criteria: We selected randomised or quasi-randomised controlled trials of steroid sex hormones in patients with lower limb atherosclerosis.Data collection and analysis: Both authors extracted data and assessed trial quality independently. Whenever possible investigators were contacted to obtain information needed for the review that could not be found in published reports.Main results: Four trials appeared to meet the inclusion criteria, but one was excluded because of poor methodology. The three remaining trials compared testosterone treatment with placebo in a total of 109 subjects with intermittent claudication or critical leg ischaemia. The most recent trial to meet the inclusion criteria dated from 1971. No trials were available which investigated the potentially beneficial effects of oestrogenic hormones in women with lower limb atherosclerosis.Testosterone therapy produced no significant improvement in tests of walking distance or in a variety of other objective tests for peripheral arterial disease, including venous filling time, muscle blood flow and plethysmography. The relative risk for subjective improvement in symptoms using the combined trial results was also non-significant (relative risk (RR) 1.10, 95% confidence interval (CI) 0.81 to 1.48).Authors&apos; conclusions: There is no evidence to date that short-term testosterone treatment is beneficial in subjects with lower limb atherosclerosis. However, this might reflect limited data rather than the lack of a real effect.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000188.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD000188.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>308</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">308</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Proia, K. K.</style></author><author><style face="normal" font="default" size="100%">Thota, A. B.</style></author><author><style face="normal" font="default" size="100%">Njie, G. J.</style></author><author><style face="normal" font="default" size="100%">Finnie, R. K.</style></author><author><style face="normal" font="default" size="100%">Hopkins, D. P.</style></author><author><style face="normal" font="default" size="100%">Mukhtar, Q.</style></author><author><style face="normal" font="default" size="100%">Pronk, N. P.</style></author><author><style face="normal" font="default" size="100%">Zeigler, D.</style></author><author><style face="normal" font="default" size="100%">Kottke, T. E.</style></author><author><style face="normal" font="default" size="100%">Rask, K. J.</style></author><author><style face="normal" font="default" size="100%">Lackland, D. T.</style></author><author><style face="normal" font="default" size="100%">Brooks, J. F.</style></author><author><style face="normal" font="default" size="100%">Braun, L. T.</style></author><author><style face="normal" font="default" size="100%">Cooksey, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Team-based care and improved blood pressure control: a community guide systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">86-99</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Delivery of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Nurses</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Care Team</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacists</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014039262</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014039262/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>309</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">309</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Psaty, B. M.</style></author><author><style face="normal" font="default" size="100%">Lumley, T.</style></author><author><style face="normal" font="default" size="100%">Furberg, C. D.</style></author><author><style face="normal" font="default" size="100%">Schellenbaum, G.</style></author><author><style face="normal" font="default" size="100%">Pahor, M.</style></author><author><style face="normal" font="default" size="100%">Alderman, M. H.</style></author><author><style face="normal" font="default" size="100%">Weiss, N. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Jama</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Jama</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2534-2544</style></pages><volume><style face="normal" font="default" size="100%">289</style></volume><number><style face="normal" font="default" size="100%">19</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic alpha-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Angiotensin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003008394</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003008394/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>310</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">310</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Punal, J.</style></author><author><style face="normal" font="default" size="100%">Lema, L. V.</style></author><author><style face="normal" font="default" size="100%">Sanhez-Guisande, D.</style></author><author><style face="normal" font="default" size="100%">Ruano-Ravina, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical effectiveness and quality of life of conventional haemodialysis versus short daily haemodialysis: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Nephrology Dialysis Transplantation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nephrology Dialysis Transplantation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2634-2646</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anemia [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Catheters, Indwelling [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Erythropoietin [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertrophy, Left Ventricular [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Nutritional Status</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Dialysis [adverse effects] [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009100520</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009100520/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>739</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">739</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qamar, Nashat</style></author><author><style face="normal" font="default" size="100%">Bray Emma, P.</style></author><author><style face="normal" font="default" size="100%">Glynn Liam, G.</style></author><author><style face="normal" font="default" size="100%">Fahey, Tom</style></author><author><style face="normal" font="default" size="100%">Mant, Jonathan</style></author><author><style face="normal" font="default" size="100%">Holder Roger, L.</style></author><author><style face="normal" font="default" size="100%">McManus, Richard</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Self-monitoring for improving control of blood pressure in patients with hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010311</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:The objective of this review is to determine the effect of SBPM in adults with hypertension on blood pressure control as compared to OBPM or usual care.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010311/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010311</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>311</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">311</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qi, W. X.</style></author><author><style face="normal" font="default" size="100%">He, A. N.</style></author><author><style face="normal" font="default" size="100%">Shen, Z.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Incidence and risk of hypertension with a novel multitargeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">348-357</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antineoplastic Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Protein Kinase Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013024698</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013024698/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>312</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">312</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qi, W. X.</style></author><author><style face="normal" font="default" size="100%">Lin, F.</style></author><author><style face="normal" font="default" size="100%">Sun, Y. J.</style></author><author><style face="normal" font="default" size="100%">Tang, L. N.</style></author><author><style face="normal" font="default" size="100%">He, A. N.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author><author><style face="normal" font="default" size="100%">Shen, Z.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Chemotherapy and Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cancer Chemotherapy and Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">431-439</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inhibitors [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrimidines [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Vascular Endothelial Growth Factor [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013014944</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013014944/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>313</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">313</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qi, W. X.</style></author><author><style face="normal" font="default" size="100%">Shen, Z.</style></author><author><style face="normal" font="default" size="100%">Lin, F.</style></author><author><style face="normal" font="default" size="100%">Sun, Y. J.</style></author><author><style face="normal" font="default" size="100%">Min, D. L.</style></author><author><style face="normal" font="default" size="100%">Tang, L. N.</style></author><author><style face="normal" font="default" size="100%">He, A. N.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">919-930</style></pages><volume><style face="normal" font="default" size="100%">75</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antineoplastic Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced] [complications] [diagnosis] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Quinazolines [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013018284</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013018284/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>314</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">314</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qi, W. X.</style></author><author><style face="normal" font="default" size="100%">Shen, Z.</style></author><author><style face="normal" font="default" size="100%">Tang, L. N.</style></author><author><style face="normal" font="default" size="100%">Yao, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Drug Investigation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Drug Investigation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">231-240</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antineoplastic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Vascular Endothelial Growth Factor</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014011970</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014011970/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>315</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">315</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qian, Z. G.</style></author><author><style face="normal" font="default" size="100%">Ke, M.</style></author><author><style face="normal" font="default" size="100%">Huang, G.</style></author><author><style face="normal" font="default" size="100%">Zou, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of latanoprost versus travoprost for primary open-angle glaucoma and ocular hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">965-970</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma, Open-Angle [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins F, Synthetic [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011005712</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011005712/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>316</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">316</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qin, L. Q.</style></author><author><style face="normal" font="default" size="100%">Xu, J. Y.</style></author><author><style face="normal" font="default" size="100%">Dong, J. Y.</style></author><author><style face="normal" font="default" size="100%">Zhao, Y.</style></author><author><style face="normal" font="default" size="100%">Bladeren, P.</style></author><author><style face="normal" font="default" size="100%">Zhang, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lactotripeptides intake and blood pressure management: a meta-analysis of randomised controlled clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition, Metabolism and Cardiovascular Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition, Metabolism and Cardiovascular Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">395-402</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Milk</style></keyword><keyword><style face="normal" font="default" size="100%">Oligopeptides</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013020618</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013020618/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>317</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">317</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qin, Y. W.</style></author><author><style face="normal" font="default" size="100%">Peng, J.</style></author><author><style face="normal" font="default" size="100%">Liang, B. Y.</style></author><author><style face="normal" font="default" size="100%">Su, L.</style></author><author><style face="normal" font="default" size="100%">Chen, Q.</style></author><author><style face="normal" font="default" size="100%">Xie, J. J.</style></author><author><style face="normal" font="default" size="100%">Gu, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The A930G polymorphism of P22phox (CYBA) gene but not C242T variation is associated with hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Plos One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Plos One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e82465</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">NADPH Oxidase</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014000240</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014000240/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>318</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">318</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Qiu, M. T.</style></author><author><style face="normal" font="default" size="100%">Lin, F. Q.</style></author><author><style face="normal" font="default" size="100%">Fu, S. K.</style></author><author><style face="normal" font="default" size="100%">Zhang, H. B.</style></author><author><style face="normal" font="default" size="100%">Li, H. H.</style></author><author><style face="normal" font="default" size="100%">Zhang, L. M.</style></author><author><style face="normal" font="default" size="100%">Li, Q.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combination of low-dose bupivacaine and opioids provides satisfactory analgesia with less intraoperative hypotension for spinal anesthesia in cesarean section (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">CNS Neuroscience and Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CNS Neuroscience and Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">426-432</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Analgesia, Obstetrical [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Analgesics, Opioid [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anesthesia, Spinal</style></keyword><keyword><style face="normal" font="default" size="100%">Bupivacaine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Databases, Bibliographic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Postoperative Complications [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012023653</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012023653/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>740</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">740</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rada, Gabriel</style></author><author><style face="normal" font="default" size="100%">Capurro, Daniel</style></author><author><style face="normal" font="default" size="100%">Pantoja, Tomas</style></author><author><style face="normal" font="default" size="100%">Corbalán, Javiera</style></author><author><style face="normal" font="default" size="100%">Moreno, Gladys</style></author><author><style face="normal" font="default" size="100%">Letelier Luz, M.</style></author><author><style face="normal" font="default" size="100%">Vera, Claudio</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Non-hormonal interventions for hot flushes in women with a history of breast cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acupuncture Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Amines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Breast Neoplasms [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Clonidine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclohexanecarboxylic Acids [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Excitatory Amino Acid Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Homeopathy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hot Flashes [etiology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Field Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Norepinephrine [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Relaxation Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin E [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamins [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">gamma-Aminobutyric Acid [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Breastca</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004923</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Hot flushes are common in women with a history of breast cancer. Hormonal therapies are known to reduce these symptoms but are not recommended in women with a history of breast cancer due to their potential adverse effects. The efficacy of non-hormonal therapies is still uncertain.Objectives: To assess the efficacy of non-hormonal therapies in reducing hot flushes in women with a history of breast cancer.Search methods: We searched the Cochrane Breast Cancer Group Specialised Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE, LILACS, CINAHL, PsycINFO (August 2008) and WHO ICTRP Search Portal. We handsearched reference lists of reviews and included articles, reviewed conference proceedings and contacted experts.Selection criteria: Randomized controlled trials (RCTs) comparing non-hormonal therapies with placebo or no therapy for reducing hot flushes in women with a history of breast cancer.Data collection and analysis: Two authors independently selected potentially relevant studies, decided upon their inclusion and extracted data on participant characteristics, interventions, outcomes and the risk of bias of included studies.Main results: Sixteen RCTs met our inclusion criteria. We included six studies on selective serotonin (SSRI) and serotonin-norepinephrine (SNRI) reuptake inhibitors, two on clonidine, one on gabapentin, two each on relaxation therapy and homeopathy, and one each on vitamin E, magnetic devices and acupuncture. The risk of bias of most studies was rated as low or moderate. Data on continuous outcomes were presented inconsistently among studies, which precluded the possibility of pooling the results. Three pharmacological treatments (SSRIs and SNRIs, clonidine and gabapentin) reduced the number and severity of hot flushes. One study assessing vitamin E did not show any beneficial effect. One of two studies on relaxation therapy showed a significant benefit. None of the other non-pharmacological therapies had a significant benefit. Side-effects were inconsistently reported.Authors&apos; conclusions: Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004923.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004923.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>319</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">319</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Radhakrishnan, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The efficacy of tailored interventions for self-management outcomes of type 2 diabetes, hypertension or heart disease: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Advanced Nursing</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Advanced Nursing</style></full-title></periodical><pages><style face="normal" font="default" size="100%">496-510</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [nursing] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Health Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Diseases [nursing] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [nursing] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Care Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012026479</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012026479/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>320</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">320</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rahnavardi, M.</style></author><author><style face="normal" font="default" size="100%">Yan, T. D.</style></author><author><style face="normal" font="default" size="100%">Cao, C.</style></author><author><style face="normal" font="default" size="100%">Vallely, M. P.</style></author><author><style face="normal" font="default" size="100%">Bannon, P. G.</style></author><author><style face="normal" font="default" size="100%">Wilson, M. K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Thoracic and Cardiovascular Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Thoracic and Cardiovascular Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">435-445</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Endarterectomy [adverse effects] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [etiology] [mortality] [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Selection</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Artery [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Embolism [complications] [mortality] [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012010556</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012010556/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>321</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">321</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ranpura, V.</style></author><author><style face="normal" font="default" size="100%">Pulipati, B.</style></author><author><style face="normal" font="default" size="100%">Chu, D.</style></author><author><style face="normal" font="default" size="100%">Zhu, X.</style></author><author><style face="normal" font="default" size="100%">Wu, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">460-468</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010003841</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010003841/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>322</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">322</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rashid, P.</style></author><author><style face="normal" font="default" size="100%">Leonardi-Bee, J.</style></author><author><style face="normal" font="default" size="100%">Bath, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2741-2748</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Reduction Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003002315</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003002315/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>323</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">323</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reboldi, G.</style></author><author><style face="normal" font="default" size="100%">Gentile, G.</style></author><author><style face="normal" font="default" size="100%">Angeli, F.</style></author><author><style face="normal" font="default" size="100%">Ambrosio, G.</style></author><author><style face="normal" font="default" size="100%">Mancia, G.</style></author><author><style face="normal" font="default" size="100%">Verdecchia, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1253-1269</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Complications</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Infarction [complications] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011003989</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011003989/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>741</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">741</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rees, Karen</style></author><author><style face="normal" font="default" size="100%">Stowe, Rebecca</style></author><author><style face="normal" font="default" size="100%">Patel, Smitaa</style></author><author><style face="normal" font="default" size="100%">Ives, Natalie</style></author><author><style face="normal" font="default" size="100%">Breen, Kieran</style></author><author><style face="normal" font="default" size="100%">Ben-Shlomo, Yoav</style></author><author><style face="normal" font="default" size="100%">Clarke Carl, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Anti-hypertensive drugs as disease-modifying agents for Parkinson&apos;s disease: evidence from observational studies and clinical trials</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson Disease [drug therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Prevention [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Movement</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008535</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Current treatment for Parkinson&apos;s disease (PD) is focused on relieving symptoms, at present there is nothing that is widely accepted to halt or slow disease progression. Potential neuroprotective or disease modifying agents have been identified from preclinical studies. One such group of compounds are anti-hypertensive drugs.Objectives: 1) Do anti-hypertensive drugs prevent the onset of PD? (primary prevention)2) Are anti-hypertensive drugs disease modifying agents in PD, do they slow the progression of disease once PD is established? (secondary prevention)3) What are the adverse effects of taking anti-hypertensive drugs for patients with PD?Search methods: Electronic databases including trial registers were searched, complemented with handsearching of conference proceedings and searching the citations of key articles (updated May 2011). Authors were contacted, to provide additional information, where necessary.Selection criteria: For the primary prevention review, primary prevention trials and observational studies (cohort and case control studies) were sought. Participants were free of PD when exposure to anti-hypertensive drugs was assessed. For the secondary prevention review, clinical trials in patients with well defined PD were sought. Two people independently selected studies for inclusion using predetermined criteria.Data collection and analysis: Data were abstracted from the source papers and methodological quality was assessed independently by two review authors. Results for both reviews were dealt with descriptively.Main results: Two cohort studies and four case control studies met the inclusion criteria for the primary prevention review. The two cohort studies found no effect of exposure to calcium channel blockers on the risk of developing PD. Three case control studies looked at the effects of exposure to calcium channel blockers and beta blockers on the risk of developing PD but the assessment periods of exposure were markedly different prior to PD onset, and different subclasses of drugs were examined, so results were not comparable. A protective effect of centrally acting calcium channel blockers was found in one study.Two trials and one ongoing trial met the inclusion criteria for the secondary prevention review. Each completed trial examined a different class of anti-hypertensive drug. The ongoing trial is examining the effects of the calcium channel blocker isradipine on motor symptoms and disease progression. It follows an earlier tolerability study. The results are due in the year 2012.Adverse effects were noted in all included trials and included intolerability to the drugs and worsening PD symptoms.Authors&apos; conclusions: There is currently a lack of evidence for the use of antihypertensive drugs for either the primary or secondary prevention of PD. More observational studies are required to identify potential drugs to go forward for safety and tolerability studies in people with early PD. The results of the ongoing trial will help inform further research.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008535.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008535.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>742</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">742</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reid, Sharon</style></author><author><style face="normal" font="default" size="100%">Cawthon Peggy, M.</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author><author><style face="normal" font="default" size="100%">Samuels Joshua, A.</style></author><author><style face="normal" font="default" size="100%">Molony Donald, A.</style></author><author><style face="normal" font="default" size="100%">Strippoli Giovanni, F. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Non-immunosuppressive treatment for IgA nephropathy</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anticoagulants [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Combined Modality Therapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Fish Oils [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerulonephritis, IGA [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Phenytoin [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Preparations [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Platelet Aggregation Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Tonsillectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003962</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: IgA nephropathy (IgAN) is the most common primary glomerular disease with approximately 30% to 40% of patients progressing to end-stage kidney disease (ESKD) within 20 years. The most common regimens include immunosuppressive agents, however the risks of long-term treatment often outweigh the potential benefits. Non-immunosuppressive options, including fish oils, anticoagulants, antihypertensive agents and tonsillectomy have also been examined but not reviewed systematically.Objectives: To assess the benefits and harms of non-immunosuppressive treatments for treating IgAN in adults and children.Search methods: In July 2010 we searched the Cochrane Renal Group&apos;s specialised register, CENTRAL (in The Cochrane Library), MEDLINE (from 1966) and EMBASE (from 1980). We also searched reference lists of included studies, review articles and contacted local and international experts.Selection criteria: Randomised controlled trials (RCTs) of non-immunosuppressive agents in adults and children with biopsy-proven IgAN were included.Data collection and analysis: Two authors independently reviewed search results, extracted data and assessed study quality. Results were expressed as mean differences (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes with 95% confidence intervals (CI) using a random-effects model.Main results: We included 56 studies (2838 participants). Antihypertensive agents were the most beneficial non-immunosuppressive intervention for IgAN. The antihypertensives examined were predominantly angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or combinations of both, versus other antihypertensives and other agents. The benefits of antihypertensive agents, particularly inhibitors of the renin angiotensin system, appear to potentially outweigh the harms in patients with IgAN. The benefits are largely manifest as a reduction in proteinuria, a surrogate outcome. There is no evidence that treatment with any of the antihypertensive agents evaluated affect major renal and/or cardiovascular endpoints or long-term mortality risk beyond the benefit that arises from controlling hypertension in patients with IgAN. The RCT evidence is insufficiently robust to demonstrate efficacy for any of the other non-immunosuppressive therapies evaluated here.Authors&apos; conclusions: IgAN remains a disease in search of adequately powered RCTs to reliably inform clinical practice. More and better evidence is needed to understand the magnitude of benefit and the possible risks of anti-hypertensive or more specifically of ACEi/ARB therapy alone or in combination and which specific types of patients with the IgAN might have the greatest potential for benefit. For other non-immunosuppressive therapies, where neither benefit nor significant harm has yet to be demonstrated, there remains some justification for further exploration of the potential benefits.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003962.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003962.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>324</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">324</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reinhart, K. M.</style></author><author><style face="normal" font="default" size="100%">Coleman, C. I.</style></author><author><style face="normal" font="default" size="100%">Teevan, C.</style></author><author><style face="normal" font="default" size="100%">Vachhani, P.</style></author><author><style face="normal" font="default" size="100%">White, C. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1766-1771</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Data Interpretation, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Garlic</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Preparations [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009102538</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009102538/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>743</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">743</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reinhart, Marcia</style></author><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author><author><style face="normal" font="default" size="100%">Salzwedel Douglas, M.</style></author><author><style face="normal" font="default" size="100%">Dormuth, Colin</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">First-line diuretics versus other classes of antihypertensive drugs for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008161</style></accession-num><abstract><style face="normal" font="default" size="100%">: This is the protocol for a review and there is no abstract. The objectives are as follows:Primary objective: To compare in head-to-head trials the effect of first-line diuretic drugs versus other classes of antihypertensive drugs on morbidity, mortality and drop-outs due to adverse drug effects in patients with hypertension.Secondary objectives: To compare the percentage of patients requiring dose titration, addition of a second or third drug, and switching to other therapy in the same trials.To compare the blood pressure lowering efficacy in the two groups in the same trials.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008161.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008161.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>325</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">325</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ricci, C.</style></author><author><style face="normal" font="default" size="100%">Gaeta, M.</style></author><author><style face="normal" font="default" size="100%">Rausa, E.</style></author><author><style face="normal" font="default" size="100%">Macchitella, Y.</style></author><author><style face="normal" font="default" size="100%">Bonavina, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Early impact of bariatric surgery on type II diabetes, hypertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6,587 patients (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Obesity Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Obesity Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bariatric Surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperlipidemias</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013066676</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013066676/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>326</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">326</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Richy, F. F.</style></author><author><style face="normal" font="default" size="100%">Laurent, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Blood Pressure</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Blood Pressure</style></full-title></periodical><pages><style face="normal" font="default" size="100%">54-59</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amlodipine [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Ankle</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dihydropyridines [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Edema [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-Analysis as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011001476</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001476/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>327</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">327</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ried, K.</style></author><author><style face="normal" font="default" size="100%">Frank, O. R.</style></author><author><style face="normal" font="default" size="100%">Stocks, N. P.</style></author><author><style face="normal" font="default" size="100%">Fakler, P.</style></author><author><style face="normal" font="default" size="100%">Sullivan, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of garlic on blood pressure: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Cardiovascular Disorders</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Cardiovascular Disorders</style></full-title></periodical><volume><style face="normal" font="default" size="100%">8:13</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Garlic</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Preparations [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008105574</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008105574/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>744</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">744</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ried, Karin</style></author><author><style face="normal" font="default" size="100%">Sullivan Thomas, R.</style></author><author><style face="normal" font="default" size="100%">Fakler, Peter</style></author><author><style face="normal" font="default" size="100%">Frank Oliver, R.</style></author><author><style face="normal" font="default" size="100%">Stocks Nigel, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of cocoa on blood pressure</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cacao [chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonols [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008893</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: High blood pressure is an important risk factor for cardiovascular disease attributing to about 50% of cardiovascular events worldwide and 37% of cardiovascular related deaths in Western populations. Epidemiological studies suggest that cocoa rich products reduce the risk of cardiovascular disease. Flavanols found in cocoa have been shown to increase the formation of endothelial nitric oxide which promotes vasodilation and therefore blood pressure reduction. Previous meta-analyses have shown that cocoa-rich foods may reduce blood pressure. Recently additional trials had conflicting results.Objectives: To determine the effect of flavanol-rich chocolate or cocoa products on blood pressure in people with or without hypertension.Search methods: We searched the following electronic databases from inception to November 2011: Cochrane Hypertension Group Specialised Register, CENTRAL, MEDLINE and EMBASE. In addition we searched international trial registries, and the reference lists of review articles and included trials.Selection criteria: Randomised controlled trials (RCT) investigating the effects of chocolate or cocoa products on systolic and diastolic blood pressure in adults for a minimum of two weeks duration.Data collection and analysis: Two authors independently extracted data and assessed the risk of bias in each trial in consultation with a third author. Random effects meta-analyses on all studies fitting the inclusion criteria were conducted using Review Manager version 5.1 and Stata version 12. Heterogeneity was explored by subgroup analyses and univariate meta-regression analysis of several variables including dosage of flavanol content (total or monomers) in chocolate or cocoa products, blinding, baseline blood pressure, theobromine content, sugar content, body-mass-index (BMI), duration and age.Main results: Twenty studies met the inclusion criteria. Meta-analyses of the 20 studies involving 856 mainly healthy participants revealed a statistically significant blood pressure reducing effect of flavanol-rich cocoa products compared with control in short-term trials of 2-18 weeks duration: Mean difference SBP (95%CI): -2.77 (-4.72, -0.82) mm Hg, p=0.005, n=20; mean difference DBP (95%CI): - 2.20 (-3.46, -0.93) mm Hg, p=0.006, n=19 available for DBP.Trials provided participants with 30-1080 mg of flavanols (mean=545.5 mg) in 3.6-105 g of cocoa products per day in the active intervention group. In half of the trials (n=10) the active group consumed 500-750 mg of flavanols per day. The control group received either a flavanol-free product (n=12) or a low-flavanol containing cocoa powder (6.4 and 41 mg flavanols, n=8). Subgroup meta-analysis of trials with a flavanol-free control group revealed a significant blood pressure reducing effect, in contrast to trials using a low-flavanol product in the control group. This analysis may have been confounded by trial duration and the level of blinding of participants.Trial duration was short (mean 4.4 weeks, range 2-8 weeks, n=19, and one trial of 18 weeks). A significant blood pressure reducing effect was evident in trials of 2 weeks duration (n=9), but not in trials of &gt;2 weeks duration (n=11). It is important to note that seven out of the nine trials (78%) of 2 weeks duration also had a flavanol-free control group. Therefore, subgroup analysis by duration might be confounded by flavanol dosage used in the control groups, and the level of blinding of participants.Adverse effects including gastrointestinal complaints and distaste of the trial product were reported by 5% of patients in the active cocoa intervention group and 1% of patients in the control groups.Authors&apos; conclusions: Flavanol-rich chocolate and cocoa products may have a small but statistically significant effect in lowering blood pressure by 2-3 mm Hg in the short term.Our findings are limited by the heterogeneity between trials, which was explored by univariate meta-regression and subgroup analyses. Subgroup meta-analysis of trials using a flavanol-free control group revealed a significant bl od pressure reducing effect of cocoa, whereas analysis of trials using a low-flavanol control product did not. While it appears that shorter trials of 2 weeks duration were more effective, analysis may be confounded by type of control and unblinding of participants, as the majority of 2-week trials also used a flavanol-free control and unblinding of participants. Results of these and other subgroup analyses based on, for example, age of participants, should be interpreted with caution and need to be confirmed or refuted in trials using direct randomized comparison.Long-term trials investigating the effect of cocoa products are needed to determine whether or not blood pressure is reduced on a chronic basis by daily ingestion of cocoa. Furthermore, long-term trials investigating the effect of cocoa on clinical outcomes are also needed to assess whether cocoa has an effect on cardiovascular events and to assess potential adverse effects associated with chronic ingestion of cocoa products.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008893.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008893.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>328</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">328</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rival, G.</style></author><author><style face="normal" font="default" size="100%">Lacasse, Y.</style></author><author><style face="normal" font="default" size="100%">Martin, S.</style></author><author><style face="normal" font="default" size="100%">Bonnet, S.</style></author><author><style face="normal" font="default" size="100%">Provencher, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of pulmonary arterial hypertension specific therapies on health-related quality of life: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chest</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014021191</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014021191/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>329</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">329</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Robbins, C. L.</style></author><author><style face="normal" font="default" size="100%">Dietz, P. M.</style></author><author><style face="normal" font="default" size="100%">Bombard, J.</style></author><author><style face="normal" font="default" size="100%">Tregear, M.</style></author><author><style face="normal" font="default" size="100%">Schmidt, S. M.</style></author><author><style face="normal" font="default" size="100%">Tregear, S. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lifestyle interventions for hypertension and dyslipidemia among women of reproductive age (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Preventing Chronic Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Preventing Chronic Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">A123</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Dyslipidemias [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Reproductive Health</style></keyword><keyword><style face="normal" font="default" size="100%">United States [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Women&apos;s Health</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012011444</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012011444/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>745</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">745</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Robert, Nadège</style></author><author><style face="normal" font="default" size="100%">Wong Gavin, W. K.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of cyclosporine on blood pressure</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclosporine [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007893</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Cyclosporine is an immunosuppressive agent used for different autoimmune diseases. The official Canadian indications for cyclosporine are solid organ transplantation, bone marrow transplantation, psoriasis, rheumatoid arthritis and nephritic syndrome (e-CPS 2008). The expanding range of indications for cyclosporine therapy will lead to more patients receiving chronic therapy with possible side effects, hypertension being one of the most common. Therefore it is essential to know the magnitude of increase of blood pressure (BP) associated with cyclosporine in order to appropriately manage patients receiving the drug.Objectives: The primary objective of this systematic review is to evaluate the effect of cyclosporine on blood pressure, compared to placebo in randomized trials.Search methods: We searched The Cochrane Central Register of Controlled Trials (CENTRAL) and bibliographic databases, including MEDLINE (2000-2008) and EMBASE (1980-2008).Selection criteria: Selection was made using double-blind, randomized, controlled trials comparing cyclosporine to placebo. All patients treated with cyclosporine were included without restriction by type of disease or by age and sex.Data collection and analysis: Blood pressure measurements in any setting and by any means were acceptable including the auscultatory or oscillometric method with a preference for the sitting position. Mean blood pressure results were entered as mean change from placebo and standard error of the mean (SEM). If blood pressure data was provided at different times after the initiation of cyclosporine therapy the weighted mean BP change from placebo from all measurements was used.Main results: The search yielded 1340 citations, of which 17 trials met the inclusion criteria. We created dose-ranges according to the usual dose administration recommended by the manufacturer and allocated the 17 included trials to the corresponding dose-range. The results demonstrate a highly statistically significant increase in blood pressure associated with cyclosporine. There appears to be a dose-related effect with lower doses (1-4 mg/kg/d) increasing mean BP by an average of 5 mmHg and higher doses (&gt;10 mg/kg/d) increasing mean BP by 11 mmHg on average. Furthermore in 3 trials the effect appears to be similar after a single dose as with chronic therapy.Authors&apos; conclusions: Cyclosporine statistically significantly increases blood pressure compared to placebo in a dose-related fashion. The magnitude of increase in blood pressure is clinically significant and increases the risk of stroke, myocardial infarction, heart failure and other adverse cardiovascular events associated with elevated BP. Consequently prescribers should try to find the lowest effective dose in all patients receiving cyclosporine chronically.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007893.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007893.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>746</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">746</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roberts, Ian</style></author><author><style face="normal" font="default" size="100%">Sydenham, Emma</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Barbiturates for acute traumatic brain injury</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Barbiturates [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries [complications] [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Central Nervous System Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypotension [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Inj</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD000033</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Raised intracranial pressure (ICP) is an important complication of severe brain injury, and is associated with high mortality. Barbiturates are believed to reduce ICP by suppressing cerebral metabolism, thus reducing cerebral metabolic demands and cerebral blood volume. However, barbiturates also reduce blood pressure and may, therefore, adversely effect cerebral perfusion pressure.Objectives: To assess the effects of barbiturates in reducing mortality, disability and raised ICP in people with acute traumatic brain injury. To quantify any side effects resulting from the use of barbiturates.Search methods: The following electronic databases were searched on 26 September 2012: CENTRAL (The Cochrane Library), MEDLINE (Ovid SP), PubMed, EMBASE (Ovid SP), PsycINFO (Ovid SP), PsycEXTRA (Ovid SP), ISI Web of Science: Science Citation Index and Conference Proceedings Citation Index-Science. Searching was not restricted by date, language or publication status. We also searched the reference lists of the included trials and review articles. We contacted researchers for information on ongoing studies.Selection criteria: Randomised controlled trials of one or more of the barbiturate class of drugs, where study participants had clinically diagnosed acute traumatic brain injury of any severity.Data collection and analysis: Two review authors screened the search results, extracted data and assessed the risk of bias in the trials.Main results: Data from seven trials involving 341 people are included in this review.For barbiturates versus no barbiturate, the pooled risk ratio (RR) of death from three trials was 1.09 (95% confidence interval (CI) 0.81 to 1.47). Death or disability, measured using the Glasgow Outcome Scale was assessed in two trials, the RR with barbiturates was 1.15 (95% CI 0.81 to 1.64). Two trials examined the effect of barbiturate therapy on ICP. In one, a smaller proportion of patients in the barbiturate group had uncontrolled ICP (68% versus 83%); the RR for uncontrolled ICP was 0.81 (95% CI 0.62 to 1.06). In the other, mean ICP was also lower in the barbiturate group. Barbiturate therapy results in an increased occurrence of hypotension (RR 1.80; 95% CI 1.19 to 2.70). For every four patients treated, one developed clinically significant hypotension. Mean body temperature was significantly lower in the barbiturate group.In one study of pentobarbital versus mannitol there was no difference in death between the two study groups (RR 1.21; 95% CI 0.75 to 1.94). Pentobarbital was less effective than mannitol for control of raised ICP (RR 1.75; 95% CI 1.05 to 2.92).In one study the RR of death with pentobarbital versus thiopental was 1.78 (95% CI 1.03 to 3.08) in favour of thiopental. Fewer people had uncontrollable ICP with thiopental (RR 1.64; 95% CI 1.03 to 2.60). There was no significant difference in the effects of pentobarbital versus thiopental for death or disability, measured using the Glasgow Outcome Scale (RR 1.31; 95% CI 0.88 to 1.94), or hypotension (RR 0.95; 95% CI 0.81 to 1.12).Authors&apos; conclusions: There is no evidence that barbiturate therapy in patients with acute severe head injury improves outcome. Barbiturate therapy results in a fall in blood pressure in one in four patients. This hypotensive effect will offset any ICP lowering effect on cerebral perfusion pressure.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000033.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD000033.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>747</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">747</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Robertson, Lindsay</style></author><author><style face="normal" font="default" size="100%">Atallah, Edmond</style></author><author><style face="normal" font="default" size="100%">Stansby, Gerard</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Aortic Aneurysm, Abdominal [complications] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Metoprolol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Pvd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010447</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in patients with atherosclerotic occlusive arterial disease. However, the role of prophylaxis in patients with abdominal aortic aneurysm (AAA) remains unclear. Several studies have shown that despite successful repair, those with AAA have a poorer rate of survival than healthy controls. People with AAA have an increased prevalence of coronary heart disease and risk of cardiovascular events. Despite this association, little is known about the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA.Objectives: To determine the long-term effectiveness of antiplatelet, antihypertensive or lipid-lowering medication in reducing mortality and cardiovascular events in people with abdominal aortic aneurysm (AAA).Search methods: The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched April 2013) and CENTRAL (2013, Issue 3). Reference lists of relevant articles were also checked.Selection criteria: Randomised controlled trials in which people with AAA were randomly allocated to one prophylactic treatment versus another, a different regimen of the same treatment, a placebo, or no treatment were eligible for inclusion in this review. Primary outcomes included all-cause mortality and cardiovascular mortality.Data collection and analysis: Selection of the studies, quality assessment and data extraction were completed independently by two review authors. Any disagreements were resolved by discussion. Only one study was included in the review, therefore meta-analysis could not be performed.Main results: One randomised controlled study was included in the review. A subgroup of 227 patients with AAA received either metoprolol (N = 111) or placebo (N = 116). There was no clear evidence that metoprolol reduced all-cause mortality (odds ratio (OR) 0.17, 95% confidence interval (CI) 0.02 to 1.41), cardiovascular death (OR 0.20, 95% CI 0.02 to 1.76), AAA-related death (OR 1.05, 95% CI 0.06 to 16.92) or increased nonfatal cardiovascular events (OR 1.44, 95% CI 0.58 to 3.57) 30 days postoperatively. Furthermore, at six months postoperatively, estimated effects were compatible with benefit and harm for all-cause mortality (OR 0.71, 95% CI 0.26 to 1.95), cardiovascular death (OR 0.73, 95% CI 0.23 to 2.39) and nonfatal cardiovascular events (OR 1.41, 95% CI 0.59 to 3.35). Adverse drug effects were reported for the whole study population and were not available for the subgroup of participants with AAA. The study was deemed to be at a generally low risk of bias.Authors&apos; conclusions: Due to the limited number of trials, there is insufficient evidence to draw any conclusions about the effectiveness of cardiovascular prophylaxis in reducing mortality and cardiovascular events in people with AAA. Further good-quality randomised controlled trials examining many types of prophylaxis with long-term follow-up are required before firm conclusions can be made.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010447.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010447.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>330</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">330</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rosenfeldt, F. L.</style></author><author><style face="normal" font="default" size="100%">Haas, S. J.</style></author><author><style face="normal" font="default" size="100%">Krum, H.</style></author><author><style face="normal" font="default" size="100%">Hadj, A.</style></author><author><style face="normal" font="default" size="100%">Ng, K.</style></author><author><style face="normal" font="default" size="100%">Leong, J. Y.</style></author><author><style face="normal" font="default" size="100%">Watts, G. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">297-306</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Coenzymes [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style face="normal" font="default" size="100%">derivatives [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Ubiquinone [adverse effects] [analogs &amp; derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamins [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007001307</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007001307/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>331</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">331</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rosero Arenas, M. A.</style></author><author><style face="normal" font="default" size="100%">Rosero Arenas, E.</style></author><author><style face="normal" font="default" size="100%">Portaceli Arminana, M. A.</style></author><author><style face="normal" font="default" size="100%">Garcia Garcia, M. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Usefulness of phyto-oestrogens in reduction of blood pressure: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Atencion Primaria</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Atencion Primaria</style></full-title></periodical><pages><style face="normal" font="default" size="100%">177-186</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Diastole [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Phytoestrogens [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Soy Foods</style></keyword><keyword><style face="normal" font="default" size="100%">Systole [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008105895</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008105895/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>332</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">332</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roshanov, P. S.</style></author><author><style face="normal" font="default" size="100%">Misra, S.</style></author><author><style face="normal" font="default" size="100%">Gerstein, H. C.</style></author><author><style face="normal" font="default" size="100%">Garg, A. X.</style></author><author><style face="normal" font="default" size="100%">Sebaldt, R. J.</style></author><author><style face="normal" font="default" size="100%">Mackay, J. A.</style></author><author><style face="normal" font="default" size="100%">Weise-Kelly, L.</style></author><author><style face="normal" font="default" size="100%">Navarro, T.</style></author><author><style face="normal" font="default" size="100%">Wilczynski, N. L.</style></author><author><style face="normal" font="default" size="100%">Haynes, R. B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Computerized clinical decision support systems for chronic disease management: a decision-maker-researcher partnership systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Implementation Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Implementation Science</style></full-title></periodical><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">92</style></number><keywords><keyword><style face="normal" font="default" size="100%">administration</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Cooperative Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Decision Making</style></keyword><keyword><style face="normal" font="default" size="100%">Decision Support Systems, Clinical [instrumentation] [organization &amp; administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Dyslipidemias</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring, Physiologic [instrumentation] [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Disease, Chronic Obstructive</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011006654</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011006654/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>748</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">748</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rosito, Guido</style></author><author><style face="normal" font="default" size="100%">Stein Airton, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Statins for preventing major vascular events in people with hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004933</style></accession-num><abstract><style face="normal" font="default" size="100%">: This is the protocol for a review and there is no abstract. The objectives are as follows:Primary Objective: To determine if statins, as compared to placebo or no treatment, reduce major vascular endpoints (such as total and cardiovascular mortality, stroke and myocardial infarction) in patients with elevated blood pressure.Secondary Objectives: To determine the magnitude of the effect of statins on systolic and diastolic blood pressure in patients with elevated blood pressure. To determine the magnitude of the effect of statin on plasma lipids (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) in patients with elevated blood pressure. To determine the rate of withdrawal due to adverse effects with statins as compared to placebo or no treatment in patients with elevated blood pressure.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004933.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004933.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>333</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">333</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rossi, A.</style></author><author><style face="normal" font="default" size="100%">Dikareva, A.</style></author><author><style face="normal" font="default" size="100%">Bacon, S. L.</style></author><author><style face="normal" font="default" size="100%">Daskalopoulou, S. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The impact of physical activity on mortality in patients with high blood pressure: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1277-1288</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [mortality] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012033309</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012033309/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>334</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">334</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rossi, A. M.</style></author><author><style face="normal" font="default" size="100%">Moullec, G.</style></author><author><style face="normal" font="default" size="100%">Lavoie, K. L.</style></author><author><style face="normal" font="default" size="100%">Gour-Provencal, G.</style></author><author><style face="normal" font="default" size="100%">Bacon, S. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The evolution of a Canadian Hypertension Education Program recommendation: the impact of resistance training on resting blood pressure in adults as an example (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Canadian Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Canadian Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">622-627</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Canada</style></keyword><keyword><style face="normal" font="default" size="100%">Health Education</style></keyword><keyword><style face="normal" font="default" size="100%">Health Planning Guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Resistance Training</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013019401</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013019401/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>335</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">335</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roush, G. C.</style></author><author><style face="normal" font="default" size="100%">Holford, T. R.</style></author><author><style face="normal" font="default" size="100%">Guddati, A. K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1110-1117</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [chemically induced] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Chlorthalidone [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012027860</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012027860/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>336</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">336</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruzicka, M.</style></author><author><style face="normal" font="default" size="100%">Hiremath, S.</style></author><author><style face="normal" font="default" size="100%">Steiner, S.</style></author><author><style face="normal" font="default" size="100%">Helis, E.</style></author><author><style face="normal" font="default" size="100%">Szczotka, A.</style></author><author><style face="normal" font="default" size="100%">Baker, P.</style></author><author><style face="normal" font="default" size="100%">Fodor, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">What is the feasibility of implementing effective sodium reduction strategies to treat hypertension in primary care settings? A systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1388-1394</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014024140</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014024140/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>337</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">337</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ryerson, C. J.</style></author><author><style face="normal" font="default" size="100%">Nayar, S.</style></author><author><style face="normal" font="default" size="100%">Swiston, J. R.</style></author><author><style face="normal" font="default" size="100%">Sin, D. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Respiratory Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Respiratory Research</style></full-title></periodical><volume><style face="normal" font="default" size="100%">11:12</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphodiesterase 5 Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Endothelin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010003765</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010003765/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>338</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">338</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sadaka, F.</style></author><author><style face="normal" font="default" size="100%">Veremakis, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Therapeutic hypothermia for the management of intracranial hypertension in severe traumatic brain injury: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Injury</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brain Injury</style></full-title></periodical><pages><style face="normal" font="default" size="100%">899-908</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">7-8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Brain Injuries [complications] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Critical Care [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypothermia, Induced [methods] [trends]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [etiology] [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012031095</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012031095/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>749</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">749</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saenz, Antonio</style></author><author><style face="normal" font="default" size="100%">Fernandez-Esteban, Inmaculada</style></author><author><style face="normal" font="default" size="100%">Mataix, Angel</style></author><author><style face="normal" font="default" size="100%">Ausejo Segura, Monica</style></author><author><style face="normal" font="default" size="100%">Roqué i Figuls, Marta</style></author><author><style face="normal" font="default" size="100%">Moher, David</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Metformin monotherapy for type 2 diabetes mellitus</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoglycemic Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Metformin [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Endoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD002966</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Metformin is an anti-hyperglycaemic agent used for the treatment of type 2 diabetes mellitus. Type 2 diabetes may present long-term complications: micro- (retinopathy, nephropathy and neuropathy) and macrovascular (stroke, myocardial infarction and peripheral vascular disease). Two meta-analyses have been published before, although only secondary outcomes were assessed.Objectives: To assess the effects of metformin monotherapy on mortality, morbidity, quality of life, glycaemic control, body weight, lipid levels, blood pressure, insulinaemia, and albuminuria in patients with type 2 diabetes mellitus.Search methods: Studies were obtained from computerised searches of multiple electronic databases and hand searches of reference lists of relevant trials identified.Selection criteria: Trials fulfilling the following inclusion criteria: Diabetes mellitus type 2, metformin versus any other oral intervention, assessment of relevant clinical outcome measures, use of random allocation.Data collection and analysis: Two reviewers extracted data, using a standard data extraction form. Data were summarised under a random effects model. Dichotomous data were expressed as relative risk. We calculated the risk difference (RD), and the Number Needed to Treat, when it was possible. We collected data of mean and standard deviation from changes to baseline. However many trials reported end point data. This limitation lead to the expression of the results as standardised mean differences (SMD) and an overall SMD was calculated. Heterogeneity was tested for using the Z score and the I-squared statistic. Subgroup, sensitivity analysis and meta-regression were used to explore heterogeneity.Main results: We included for analysis 29 trials with 37 arms (5259 participants), comparing metformin (37 arms and 2007 participants) with sulphonylureas (13 and 1167), placebo (12 and 702), diet (three and 493), thiazolidinediones (three and 132), insulin (two and 439), meglitinides (two and 208), and glucosidase inhibitors (two and 111). Nine studies reported data on primary outcomes. Obese patients allocated to intensive blood glucose control with metformin showed a greater benefit than chlorpropamide, glibenclamide, or insulin for any diabetes-related outcomes (P = 0.009), and for all-cause mortality (P = 0.03). Obese participants assigned to intensive blood glucose control with metformin showed a greater benefit than overweight patients on conventional treatment for any diabetes-related outcomes (P = 0.004), diabetes-related death (P = 0.03), all-cause mortality (P = 0.01), and myocardial infarction (P = 0.02). Patients assigned to metformin monotherapy showed a significant benefit for glycaemia control, weight, dyslipidaemia, and diastolic blood pressure. Metformin presents a strong benefit for HbA1c when compared with placebo and diet; and a moderated benefit for: glycaemia control, LDL cholesterol, and BMI or weight when compared with sulphonylureas.Authors&apos; conclusions: Metformin may be the first therapeutic option in the diabetes mellitus type 2 with overweight or obesity, as it may prevent some vascular complications, and mortality. Metformin produces beneficial changes in glycaemia control, and moderated in weight, lipids, insulinaemia and diastolic blood pressure. Sulphonylureas, alpha-glucosidase inhibitors, thiazolidinediones, meglitinides, insulin, and diet fail to show more benefit for glycaemia control, body weight, or lipids, than metformin.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002966.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD002966.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>750</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">750</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sahuquillo, Juan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Decompressive craniectomy for the treatment of refractory high intracranial pressure in traumatic brain injury</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Brain Injuries [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Craniotomy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Decompression, Surgical [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Inj</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003983</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: High intracranial pressure (ICP) is the most frequent cause of death and disability after a severe traumatic brain injury (TBI). High ICP is usually treated with general maneuvers (normothermia, sedation, etc.) and a set of first-line therapeutic measures (moderate hypocapnia, mannitol, etc.). When these measures fail to control high ICP, second-line therapies are initiated. Of these, barbiturates, hyperventilation, moderate hypothermia, or removal of a variable amount of skull bone (decompressive craniectomy) are used.Objectives: To assess the effects of secondary decompressive craniectomy on outcomes and quality of life for patients with severe TBI in whom conventional medical therapeutic measures have failed to control a raised ICP.Search methods: We searched the following electronic databases: Cochrane Injuries Group Specialised Register, CENTRAL (The Cochrane Library), MEDLINE, PubMed, EMBASE, ZETOC, CINAHL, and Controlled Trials metaRegister (www.controlled-trials.com/mrct/search). We searched the Internet using Google Scholar (http://scholar.google.com) and handsearched relevant conference proceedings. We also contacted experts in the field and authors of included studies. The searches were last conducted in May 2008.Selection criteria: Randomized or quasi-randomized studies assessing patients over the age of 12 months with severe TBI who underwent decompressive craniectomy to control ICP refractory to conventional medical treatments.Data collection and analysis: The electronic search and handsearching results were examined for reports of potentially relevant trials, which were then retrieved in full. The selection criteria were applied, data extraction performed, and studies assessed for methodological quality.Main results: We found only one trial with 27 participants, conducted in a pediatric population. Decompressive craniectomy was associated with a risk ratio (RR) for death of 0.54 (95% CI 0.17 to 1.72) and a RR of 0.54 (95% CI 0.29 to 1.01) for an unfavorable outcome (death, vegetative status, or severe disability 6 to 12 months after injury). To date, no results are available to confirm or refute the effectiveness of decompressive craniectomy in adults.Authors&apos; conclusions: There is no evidence from randomized controlled trials that supports the routine use of secondary decompressive craniectomy to reduce unfavorable outcomes in adults with severe TBI and refractory high ICP. In the study with a pediatric population, decompressive craniectomy reduced the risk of death and unfavorable outcomes. Despite the wide CI for death and the small sample size of this one identified study, the treatment may be justified in patients below the age of 18 years when maximal medical treatment has failed to control ICP. There are two ongoing randomized controlled trials of decompressive craniectomy (RescueICP and DECRA) that will allow further conclusions on the efficacy of this procedure in adults.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003983.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003983.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>339</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">339</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saksena, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Computer-based education for patients with hypertension: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Education Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Education Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">236-245</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Computer-Assisted Instruction</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010007461</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010007461/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>751</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">751</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saldanha Ian, J.</style></author><author><style face="normal" font="default" size="100%">Akinyede, Oluwaseun</style></author><author><style face="normal" font="default" size="100%">McKoy Naomi, A.</style></author><author><style face="normal" font="default" size="100%">Robinson Karen, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Lung Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Graft Rejection [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppressive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Cf</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009421</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: For patients with cystic fibrosis and advanced pulmonary damage, lung transplantation is an available and viable option. However, graft rejection is an important potential consequence after lung transplantation. Immunosuppressive therapy is needed to prevent episodes of graft rejection and thus subsequently reduce morbidity and mortality in this population. There are a number of classes of immunosuppressive drugs which act on different components of the immune system. There is considerable variability in the use of immunosuppressive agents after lung transplantation in cystic fibrosis. While much of the research in immunosuppressive drug therapy has focused on the general population of lung transplant recipients, little is known about the comparative effectiveness and safety of these agents in patients with cystic fibrosis.Objectives: To assess the effects of individual drugs or combinations of drugs compared to placebo or other individual drugs or combinations of drugs in preventing rejection following lung transplantation in patients with cystic fibrosis.Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register and scanned references of the potentially eligible study. We also searched the www.clinicaltrials.gov trials registry to obtain information on unpublished and ongoing studies.Date of latest search: 22 August 2013.Selection criteria: Randomised and quasi-randomised studies.Data collection and analysis: We independently assessed the studies identified from our searches for inclusion in the review. Should eligible studies be identified and included in future updates of the review, we will independently extract data and assess the risk of bias.Main results: While two studies met our inclusion criteria, we did not include them in the review because the investigators of the studies did not report any information specific to patients with cystic fibrosis. Our attempts to obtain this information have not yet been successful. We will include any provided data in future updates of the review.Authors&apos; conclusions: The lack of currently available evidence makes it impossible to make conclusions about the comparative efficacy and safety of the various immunosuppressive drugs among patients with cystic fibrosis after lung transplantation. A recent Cochrane review comparing tacrolimus with cyclosporine in all patients with lung transplantation (not restricted to patients with cystic fibrosis) reported no significant difference in mortality and risk of acute rejection. However, tacrolimus use was associated with lower risk of broncholitis obliterans syndrome and arterial hypertension and higher risk of diabetes mellitus. It should be noted that this review contained only a small number of included studies (n = 3) with a high risk of bias. Additional randomised studies are required to provide evidence for the benefit and safety of the use of immunosuppressive therapy among patients with cystic fibrosis after lung transplantation.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009421.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009421.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>340</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">340</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salehi-Abargouei, A.</style></author><author><style face="normal" font="default" size="100%">Maghsoudi, Z.</style></author><author><style face="normal" font="default" size="100%">Shirani, F.</style></author><author><style face="normal" font="default" size="100%">Azadbakht, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases - incidence: a systematic review and meta-analysis on observational prospective studies (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">611-618</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Disease [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Health Promotion</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013021387</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013021387/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>752</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">752</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salpeter Shelley, R.</style></author><author><style face="normal" font="default" size="100%">Ormiston Thomas, M.</style></author><author><style face="normal" font="default" size="100%">Salpeter Edwin, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cardioselective beta-blockers for chronic obstructive pulmonary disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Disease, Chronic Obstructive [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003566</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Beta-blocker therapy has a proven mortality benefit in patients with hypertension, heart failure and coronary artery disease, as well as during the perioperative period. These drugs have traditionally been considered contraindicated in patients with chronic obstructive pulmonary disease (COPD).Objectives: To assess the effect of cardioselective beta-blockers on respiratory function of patients with COPD.Search methods: A comprehensive search of the Cochrane Airways Group Specialised Register (derived from systematic searches of CENTRAL, MEDLINE, EMBASE and CINAHL) was carried out to identify randomised blinded controlled trials from 1966 to August 2010. We did not exclude trials on the basis of language.Selection criteria: Randomised, blinded, controlled trials of single dose or longer duration that studied the effects of cardioselective beta-blockers on the forced expiratory volume in one second (FEV1) or symptoms in patients with COPD.Data collection and analysis: Two independent reviewers extracted data from the selected articles, reconciling differences by consensus. Two interventions studied were the administration of beta-blocker, given either as a single dose or for longer duration, and the use of beta2-agonist given after the study drug.Main results: Eleven studies of single-dose treatment and 11 of treatment for longer durations, ranging from 2 days to 16 weeks, met selection criteria. Cardioselective beta-blockers, given as a single dose or for longer duration, produced no change in FEV1 or respiratory symptoms compared to placebo, and did not affect the FEV1 treatment response to beta2-agonists. Subgroup analyses revealed no significant change in results for those participants with severe chronic airways obstruction, those with a reversible obstructive component, or those with concomitant cardiovascular disease.Authors&apos; conclusions: Cardioselective beta-blockers, given to patients with COPD in the identified studies did not produce adverse respiratory effects. Given their demonstrated benefit in conditions such as heart failure, coronary artery disease and hypertension, cardioselective beta-blockers should not be routinely withheld from patients with COPD.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003566.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003566.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>753</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">753</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sanders, G. D.</style></author><author><style face="normal" font="default" size="100%">Coeytaux, R.</style></author><author><style face="normal" font="default" size="100%">Dolor, R. J.</style></author><author><style face="normal" font="default" size="100%">Hasselblad, V.</style></author><author><style face="normal" font="default" size="100%">Patel, U. D.</style></author><author><style face="normal" font="default" size="100%">Powers, B.</style></author><author><style face="normal" font="default" size="100%">Yancy Jr, W. S.</style></author><author><style face="normal" font="default" size="100%">Gray, R. N.</style></author><author><style face="normal" font="default" size="100%">Irvine, R. J.</style></author><author><style face="normal" font="default" size="100%">Kendrick, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and direct renin inhibitors for treating essential hypertension: an update (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Renin</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Healthcare Research and Quality (AHRQ)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000623</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000623/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>341</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">341</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sandli, O. K.</style></author><author><style face="normal" font="default" size="100%">Spigset, O.</style></author><author><style face="normal" font="default" size="100%">Slordal, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The polypill as cardiovascular prophylactic: clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">620-623</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [drug therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol, LDL [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014037312</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014037312/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>342</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">342</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Santschi, V.</style></author><author><style face="normal" font="default" size="100%">Chiolero, A.</style></author><author><style face="normal" font="default" size="100%">Colosimo, A. L.</style></author><author><style face="normal" font="default" size="100%">Platt, R. W.</style></author><author><style face="normal" font="default" size="100%">Taffe, P.</style></author><author><style face="normal" font="default" size="100%">Burnier, M.</style></author><author><style face="normal" font="default" size="100%">Burnand, B.</style></author><author><style face="normal" font="default" size="100%">Paradis, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e000718</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceutical Services</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014026684</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014026684/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>343</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">343</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sare, G. M.</style></author><author><style face="normal" font="default" size="100%">Gray, L. J.</style></author><author><style face="normal" font="default" size="100%">Bath, P. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of antihypertensive agents on cerebral blood flow and flow velocity in acute ischaemic stroke: systematic review of controlled studies (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1058-1064</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Flow Velocity [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebrovascular Circulation [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008105764</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008105764/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>344</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">344</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sarkhosh, K.</style></author><author><style face="normal" font="default" size="100%">Birch, D. W.</style></author><author><style face="normal" font="default" size="100%">Shi, X.</style></author><author><style face="normal" font="default" size="100%">Gill, R. S.</style></author><author><style face="normal" font="default" size="100%">Karmali, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The impact of sleeve gastrectomy on hypertension: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Obesity Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Obesity Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">832-837</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Gastroplasty [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [etiology] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Laparoscopy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity, Morbid [complications] [physiopathology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012033330</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012033330/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>345</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">345</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Savarese, G.</style></author><author><style face="normal" font="default" size="100%">Dei Cas, A.</style></author><author><style face="normal" font="default" size="100%">Rosano, G.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amore, C.</style></author><author><style face="normal" font="default" size="100%">Musella, F.</style></author><author><style face="normal" font="default" size="100%">Mosca, S.</style></author><author><style face="normal" font="default" size="100%">Reiner, M. F.</style></author><author><style face="normal" font="default" size="100%">Marchioli, R.</style></author><author><style face="normal" font="default" size="100%">Trimarco, B.</style></author><author><style face="normal" font="default" size="100%">Perrone-Filardi, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">403-410</style></pages><volume><style face="normal" font="default" size="100%">172</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Albuminuria</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014022593</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014022593/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>346</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">346</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Savarese, G.</style></author><author><style face="normal" font="default" size="100%">Musella, F.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amore, C.</style></author><author><style face="normal" font="default" size="100%">Losco, T.</style></author><author><style face="normal" font="default" size="100%">Marciano, C.</style></author><author><style face="normal" font="default" size="100%">Gargiulo, P.</style></author><author><style face="normal" font="default" size="100%">Rengo, G.</style></author><author><style face="normal" font="default" size="100%">Dellegrottaglie, S.</style></author><author><style face="normal" font="default" size="100%">Bossone, E.</style></author><author><style face="normal" font="default" size="100%">Leosco, D.</style></author><author><style face="normal" font="default" size="100%">Perrone-Filardi, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Respiratory Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Respiratory Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">414-424</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Physical Endurance</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013054785</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013054785/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>347</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">347</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Savarese, G.</style></author><author><style face="normal" font="default" size="100%">Paolillo, S.</style></author><author><style face="normal" font="default" size="100%">Costanzo, P.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amore, C.</style></author><author><style face="normal" font="default" size="100%">Cecere, M.</style></author><author><style face="normal" font="default" size="100%">Losco, T.</style></author><author><style face="normal" font="default" size="100%">Musella, F.</style></author><author><style face="normal" font="default" size="100%">Gargiulo, P.</style></author><author><style face="normal" font="default" size="100%">Marciano, C.</style></author><author><style face="normal" font="default" size="100%">Perrone-Filardi, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1192-1201</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">13</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Test</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Tolerance [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Walking [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012046071</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012046071/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>348</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">348</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schall, P.</style></author><author><style face="normal" font="default" size="100%">Wehling, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of arterial hypertension in the very elderly: a meta-analysis of clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Arzneimittel-Forschung</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arzneimittel-Forschung</style></full-title></periodical><pages><style face="normal" font="default" size="100%">221-228</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Endpoint Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [etiology] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy] [mortality] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [epidemiology] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011003406</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011003406/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>349</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">349</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scheen, A. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renin-angiotensin system inhibition prevents type 2 diabetes mellitus - part 1: a meta-analysis of randomised clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetes and Metabolism</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diabetes and Metabolism</style></full-title></periodical><pages><style face="normal" font="default" size="100%">487-496</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Captopril [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Receptor, Angiotensin, Type 1 [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005009441</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005009441/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>754</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">754</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schoonees, Anel</style></author><author><style face="normal" font="default" size="100%">Visser, Janicke</style></author><author><style face="normal" font="default" size="100%">Musekiwa, Alfred</style></author><author><style face="normal" font="default" size="100%">Volmink, Jimmy</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antioxidants [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Attention Deficit Disorder with Hyperactivity [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Erectile Dysfunction [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoids [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Osteoarthritis [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Venous Insufficiency [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Cf</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008294</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Oxidative stress has been implicated in the development of a number of conditions including cancer, arthritic disorders and cardiovascular disease. Pycnogenol®, a herbal dietary supplement derived from French maritime pine bark extract, is standardised to contain 70% procyanidin which is a powerful antioxidant. Pycnogenol® is marketed as a supplement for preventing or treating a wide range of chronic conditions.Objectives: To assess the efficacy and safety of Pycnogenol® for the treatment of chronic disorders.Search methods: We searched CENTRAL (until 18 September 2010), MEDLINE (until 18 September 2010) and EMBASE (until 13 October 2010) as well as three trial registries. We also contacted the manufacturer of Pycnogenol® and hand-searched bibliographies of included studies.Selection criteria: Randomised controlled trials evaluating the effectiveness of Pycnogenol® in adults or children with any chronic disorder were included. We assessed clinical outcomes directly related to the disorder (stratified as participant- and investigator-reported) and all-cause mortality as primary outcomes. We also assessed adverse events and biomarkers of oxidative stress.Data collection and analysis: Two authors independently assessed trial eligibility, extracted all data and assessed risk of bias. A third author additionally extracted information on outcomes and results. With three exceptions, results for outcomes across studies could not be pooled.Main results: This review includes 15 trials with a total of 791 participants that have evaluated Pycnogenol® for the treatment of seven different chronic disorders. These included asthma (two studies; N = 86), attention deficit hyperactivity disorder (one study; N = 61), chronic venous insufficiency (two studies; N = 60), diabetes mellitus (four studies; N = 201), erectile dysfunction (one study; N = 21), hypertension (two studies; N = 69) and osteoarthritis (three studies; N = 293). Two of the studies were conducted exclusively in children; the others involved adults.Due to small sample size, limited numbers of trials per condition, variation in outcomes evaluated and outcome measures used, as well as the risk of bias in the included studies, no definitive conclusions regarding the efficacy or safety of Pycnogenol® are possible.Authors&apos; conclusions: Current evidence is insufficient to support Pycnogenol® use for the treatment of any chronic disorder. Well-designed, adequately powered trials are needed to establish the value of this treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008294.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008294.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>350</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">350</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schroeder, K.</style></author><author><style face="normal" font="default" size="100%">Fahey, T.</style></author><author><style face="normal" font="default" size="100%">Ebrahim, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">How can we improve adherence to blood pressure-lowering medication in ambulatory care? (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">722-732</style></pages><volume><style face="normal" font="default" size="100%">164</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Ambulatory Care</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">dosage [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment (Health Care)</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004008265</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004008265/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>755</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">755</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schroeder, Knut</style></author><author><style face="normal" font="default" size="100%">Fahey, Tom</style></author><author><style face="normal" font="default" size="100%">Ebrahim, Shah</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Patient Compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [psychology]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004804</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Lack of adherence to blood pressure lowering medication is a major reason for poor control of hypertension worldwide. Interventions to improve adherence to antihypertensive medication have been evaluated in randomised trials but it is unclear which interventions are effective.Objectives: To determine the effectiveness of interventions aiming to increase adherence to blood pressure lowering medication in adults with high blood pressureSearch methods: All-language search of all articles (any year) in the Cochrane Controlled Trials Register (CCTR), MEDLINE, EMBASE, and CINAHL in April 2002.Selection criteria: RCTs of interventions to increase adherence to blood pressure lowering medication in adults with essential hypertension in primary care, with adherence to medication and blood pressure control as outcomesData collection and analysis: Two authors extracted data independently and in duplicate and assessed each study according to the criteria outlined by the Cochrane Collaboration Handbook.Main results: We included 38 studies testing 58 different interventions and containing data on 15519 patients. The studies were conducted in nine countries between 1975 and 2000. The duration of follow-up ranged from two to 60 months. Due to heterogeneity between studies in terms of interventions and the methods used to measure adherence, we did not pool the results. Simplifying dosing regimens increased adherence in seven out of nine studies, with a relative increase in adherence of 8 per cent to 19.6 per cent. Motivational strategies were successful in 10 out of 24 studies with generally small increases in adherence up to a maximum of 23 per cent. Complex interventions involving more than one technique increased adherence in eight out of 18 studies, ranging from 5 per cent to a maximum of 41 per cent. Patient education alone seemed largely unsuccessful.Authors&apos; conclusions: Reducing the number of daily doses appears to be effective in increasing adherence to blood pressure lowering medication and should be tried as a first line strategy, although there is less evidence of an effect on blood pressure reduction. Some motivational strategies and complex interventions appear promising, but we need more evidence on their effect through carefully designed RCTs.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004804/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004804</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">351</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sciarretta, S.</style></author><author><style face="normal" font="default" size="100%">Palano, F.</style></author><author><style face="normal" font="default" size="100%">Tocci, G.</style></author><author><style face="normal" font="default" size="100%">Baldini, R.</style></author><author><style face="normal" font="default" size="100%">Volpe, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">doi:10.1001/archinternmed.2010.427</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010007683</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010007683/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">352</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scott, R. L.</style></author><author><style face="normal" font="default" size="100%">Cummings, G. E.</style></author><author><style face="normal" font="default" size="100%">Newburn-Cook, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The feasibility and effectiveness of emergency department based hypertension screening: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Academy of Nurse Practitioners</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Academy of Nurse Practitioners</style></full-title></periodical><pages><style face="normal" font="default" size="100%">493-500</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Emergency Service, Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Health Promotion [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [epidemiology] [nursing]</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Screening [instrumentation] [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Nurse Practitioners</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">United States [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011006075</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011006075/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>353</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">353</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Semlitsch, T.</style></author><author><style face="normal" font="default" size="100%">Jeitler, K.</style></author><author><style face="normal" font="default" size="100%">Hemkens, L. G.</style></author><author><style face="normal" font="default" size="100%">Horvath, K.</style></author><author><style face="normal" font="default" size="100%">Nagele, E.</style></author><author><style face="normal" font="default" size="100%">Schuermann, C.</style></author><author><style face="normal" font="default" size="100%">Pignitter, N.</style></author><author><style face="normal" font="default" size="100%">Herrmann, K. H.</style></author><author><style face="normal" font="default" size="100%">Waffenschmidt, S.</style></author><author><style face="normal" font="default" size="100%">Siebenhofer, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increasing physical activity for the treatment of hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Sports Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sports Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1009-1023</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Motor Activity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013037640</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013037640/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>354</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">354</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sepanlou, S. G.</style></author><author><style face="normal" font="default" size="100%">Farzadfar, F.</style></author><author><style face="normal" font="default" size="100%">Jafari, E.</style></author><author><style face="normal" font="default" size="100%">Danaei, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Iranian Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Iranian Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">531-537</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Aspirin [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolytic Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Iran</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Ischemia [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Thiazides [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012046199</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012046199/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>756</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">756</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Seron, Pamela</style></author><author><style face="normal" font="default" size="100%">Lanas, Fernando</style></author><author><style face="normal" font="default" size="100%">Pardo Hernandez, Hector</style></author><author><style face="normal" font="default" size="100%">Bonfill Cosp, Xavier</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Exercise for people with high cardiovascular risk</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [blood] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol, HDL [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol, LDL [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Smoking</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009387</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: When two or more cardiovascular risk factors occur in one individual, they may interact in a multiplicative way promoting cardiovascular disease. Exercise has proven to be effective in controlling individual risk factors but its effect on overall cardiovascular risk remains uncertain.Objectives: To assess the effects of exercise training in people with increased cardiovascular risk but without a concurrent cardiovascular disease on general cardiovascular mortality, incidence of cardiovascular events, and total cardiovascular risk.Search methods: A search was conducted in CENTRAL (The Cochrane Library 2013, Issue 10 of 12), Ovid MEDLINE (1946 to week 2 November 2013), EMBASE Classic + EMBASE via Ovid (1947 to Week 47 2013), CINAHL Plus with Full Text via EBSCO (to November 2013), Science Citation Index Expanded (SCI-EXPANDED) (1970 to 22 November 2013), and Conference Proceedings Citation Index ? Science (CPCI-S) (1990 to 22 November 2013) on Web of Science (Thomson Reuters). We did not apply any date or language restrictions.Selection criteria: Randomized clinical trials comparing aerobic or resistance exercise training versus no exercise or any standard approach that does not include exercise. Participants had to be 18 years of age or older with an average 10-year Framingham risk score of 10% for cardiovascular disease over 10 years, or with two or more cardiovascular risk factors, and no history of cardiovascular disease.Data collection and analysis: The selection of studies and subsequent data collection process were conducted by two independent authors. Disagreements were solved by consensus. The results were reported descriptively. It was not possible to conduct a meta-analysis because of the high heterogeneity and high risk of bias in the included studies.Main results: A total of four studies were included that involved 823 participants, 412 in the exercise group and 411 in the control group. Follow-up of participants ranged from 16 weeks to 6 months. Overall, the included studies had a high risk of selection, detection, and attrition bias. Meta-analysis was not possible because the interventions (setting, type and intensity of exercise) and outcome measurements were not comparable, and the risk of bias in the identified studies was high. No study assessed cardiovascular or all-cause mortality or cardiovascular events as individual outcomes. One or more of the studies reported on total cardiovascular risk, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, blood pressure, body mass index, exercise capacity, and health-related quality of life but the available evidence was not sufficient to determine the effectiveness of exercise. Adverse events and smoking cessation were not assessed in the included studies.Authors&apos; conclusions: Evidence to date is entirely limited to small studies with regard to sample size, short-term follow-up, and high risk of methodological bias, which makes it difficult to derive any conclusions on the efficacy or safety of aerobic or resistance exercise on groups with increased cardiovascular risk or in individuals with two or more coexisting risk factors. Further randomized clinical trials assessing controlled exercise programmes on total cardiovascular risk in individuals are warranted.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009387.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009387.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>355</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">355</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shafiq, N.</style></author><author><style face="normal" font="default" size="100%">Reddy, S.</style></author><author><style face="normal" font="default" size="100%">Pandhi, P.</style></author><author><style face="normal" font="default" size="100%">Manoj, R.</style></author><author><style face="normal" font="default" size="100%">Talwar, K. K.</style></author><author><style face="normal" font="default" size="100%">Malhotra, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Sildenafil for pulmonary hypertension: need for evidence generation (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Clinical Pharmacology and Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Clinical Pharmacology and Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">644-651</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Atrial Function, Right [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Artery [drug effects] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Purines [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Resistance [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009101973</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009101973/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>356</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">356</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shah, K.</style></author><author><style face="normal" font="default" size="100%">Qureshi, S. U.</style></author><author><style face="normal" font="default" size="100%">Johnson, M.</style></author><author><style face="normal" font="default" size="100%">Parikh, N.</style></author><author><style face="normal" font="default" size="100%">Schulz, P. E.</style></author><author><style face="normal" font="default" size="100%">Kunik, M. E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Geriatric Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Geriatric Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">250-261</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer Disease [diet therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia, Vascular [drug therapy] [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000883</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000883/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>357</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">357</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shah, M.</style></author><author><style face="normal" font="default" size="100%">Adams-Huet, B.</style></author><author><style face="normal" font="default" size="100%">Garg, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of high-carbohydrate or high-cis-monounsaturated fat diets on blood pressure: a meta-analysis of intervention trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1251-1256</style></pages><volume><style face="normal" font="default" size="100%">85</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [diet therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Carbohydrates [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Fats, Unsaturated [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acids, Monounsaturated [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acids, Monounsaturated [chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Intervention Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Isomerism</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007005666</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007005666/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>757</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">757</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shah Prakeshkumar, S.</style></author><author><style face="normal" font="default" size="100%">Ohlsson, Arne</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Sildenafil for pulmonary hypertension in neonates</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Purines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Neonatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005494</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Persistent pulmonary hypertension in neonates (PPHN) is associated with high mortality. Currently, the therapeutic mainstay for PPHN is assisted ventilation and administration of inhaled nitric oxide (iNO). However, nitric oxide is costly and may not be appropriate in resource-poor settings. Approximately 30% of patients fail to respond to iNO. High concentrations of phosphodiesterases in the pulmonary vasculature has led to the use of phosphodiesterase inhibitors such as sildenafil or milrinone.Objectives: To assess the efficacy and safety of sildenafil in the treatment of persistent pulmonary hypertension in neonates.Search methods: The Cochrane Central Register of Controlled Trials (The Cochrane Library), MEDLINE, EMBASE, CINAHL databases were searched from their inception until December 2010; Clinicaltrials.gov web site, the reference lists of identified trials, and abstracts of meetings were searched without any language restriction.Selection criteria: Randomised or quasi-randomised controlled trials of sildenafil compared with placebo or other pulmonary vasodilators, irrespective of dose, route and duration of administration in neonates with PPHN, were included if the trial reported any of the pre-specified outcomes.Data collection and analysis: The methodological quality of the trials was assessed regarding how bias was minimized at study entry, during study intervention and at outcomes measurement. Data on relevant outcomes were extracted and the effect size was estimated and reported as relative risk (RR), risk difference (RD) and weighted mean difference (MD) as appropriate. The I-squared (I2) test of heterogeneity was applied.Main results: Three eligible trials that enrolled 77 infants were identified. The methodological quality of the studies indicated low-moderate risk of bias. All studies were performed in resource-limited settings where iNO and high frequency ventilation were not available at the time of study. There was significant reduction in mortality in the sildenafil group (typical RR 0.20, 95% CI 0.07 to 0.57; typical RD -0.38, 95% CI -0.60 to -0.16; Number needed to treat to benefit 3, 95% CI 2 to 6). Physiological parameters of oxygenation (oxygenation index, PaO2) suggested a steady improvement after the first dose of sildenafil. No clinically important side effects were identified.Authors&apos; conclusions: Sildenafil in the treatment of PPHN has significant potential especially in resource limited settings. However, a large scale randomised trial comparing sildenafil with the currently used vasodilator, inhaled nitric oxide, is needed to assess efficacy and safety.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005494.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005494.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>358</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">358</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shah, R. M.</style></author><author><style face="normal" font="default" size="100%">Singh, M.</style></author><author><style face="normal" font="default" size="100%">Bhuriya, R.</style></author><author><style face="normal" font="default" size="100%">Molnar, J.</style></author><author><style face="normal" font="default" size="100%">Arora, R. R.</style></author><author><style face="normal" font="default" size="100%">Khosla, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Favorable effects of vasodilators on left ventricular remodeling in asymptomatic patients with chronic moderate-severe aortic regurgitation and normal ejection fraction: a meta-analysis of clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">619-625</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Aortic Valve Insufficiency [drug therapy] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Confidence Intervals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Ventricles [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydralazine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Function, Left</style></keyword><keyword><style face="normal" font="default" size="100%">Ventricular Remodeling [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012049808</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012049808/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>359</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">359</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shahin, Y.</style></author><author><style face="normal" font="default" size="100%">Khan, J. A.</style></author><author><style face="normal" font="default" size="100%">Chetter, I.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Atherosclerosis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">18-33</style></pages><volume><style face="normal" font="default" size="100%">221</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Arteries [drug effects] [pathology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Elasticity [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Pulsatile Flow [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Diseases [drug therapy] [pathology] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012011028</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012011028/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>360</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">360</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shahin, Y.</style></author><author><style face="normal" font="default" size="100%">Khan, J. A.</style></author><author><style face="normal" font="default" size="100%">Samuel, N.</style></author><author><style face="normal" font="default" size="100%">Chetter, I.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Atherosclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Atherosclerosis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7-16</style></pages><volume><style face="normal" font="default" size="100%">216</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Brachial Artery [drug effects] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Vascular [drug effects] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilation [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011003183</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011003183/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>758</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">758</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shamon Sandy, D.</style></author><author><style face="normal" font="default" size="100%">Perez Marco, I.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of reserpine for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Reserpine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007655</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Many antihypertensive agents exist today for the treatment of primary hypertension (systolic blood pressure ?140 mmHg and/or diastolic blood pressure ?90 mmHg). Randomised controlled trials have been carried out to investigate the evidence for these agents.There is, for example, strong RCT evidence that thiazides reduce mortality and morbidity. Reserpine has been used as a second-line therapy in some of those trials. However, the dose-related blood pressure reduction with this agent is not known.Objectives: To investigate the dose-related effect of reserpine on blood pressure, heart rate and withdrawals due to adverse events.Search methods: The databases CENTRAL, EMBASE, and MEDLINE were searched. We also traced citations in the reference sections of the retrieved studies.Selection criteria: Included studies were truly randomised controlled trials comparing reserpine monotherapy to placebo or no treatment in patients with primary hypertension.Data collection and analysis: Methods of randomization and concealment were assessed. Data on blood pressure reduction, heart rate,and withdrawal due to adverse effects were extracted and analysed.Main results: Four RCTs (N =237) were found that met the inclusion criteria. The overall pooled effect demonstrates a statistically significant systolic blood pressure (SBP) reduction in patients taking reserpine compared to placebo (WMD -7.92, 95% CI -14.05, -1.78). Due to significant heterogeneity across trials, a significant effect in diastolic blood pressure (DBP), mean arterial pressure (MAP), and heart rate (HR) could not be found. The SBP effects were achieved with 0.5 mg/day or greater. However, the dose-response pattern could not be determined because of the small number of trials. Data from the trial that investigated Rauwiloid against placebo was not combined with reserpine data from the remaining three trials. This is because Rauwiloid is a different alkaloid extract of the plant Rauwolfia serpentina and the dose used is not comparable to reserpine. None of the included trials reported withdrawals due to adverse effects.Authors&apos; conclusions: Reserpine is effective in reducing SBP roughly to the same degree as other first-line antihypertensive drugs. However, we could not make definite conclusions regarding the dose-response pattern because of the small number of included trials. More RCTs are needed to assess the effects of reserpine on blood pressure and to determine the dose-related safety profile before the role of this drug in the treatment of primary hypertension can be established.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007655.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007655.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>759</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">759</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shan, Dan</style></author><author><style face="normal" font="default" size="100%">Wu Hong, Mei</style></author><author><style face="normal" font="default" size="100%">Yuan Qi, Yuan</style></author><author><style face="normal" font="default" size="100%">Li, Jun</style></author><author><style face="normal" font="default" size="100%">Zhou Rong, Le</style></author><author><style face="normal" font="default" size="100%">Liu Guan, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pentoxifylline for diabetic kidney disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Albuminuria [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Nephropathies [blood] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Pentoxifylline [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006800</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Diabetic kidney disease (DKD) is associated with increased morbidity and mortality, mostly relating to cardiovascular complications. The relevance of inflammation in the pathogenesis of DKD has been investigated in recent years, and it has been shown that inflammatory markers are higher in people with DKD compared with the wider population. Pentoxifylline is a methylxanthine phosphodiesterase inhibitor with favourable anti-inflammatory effects and immunoregulatory properties. The anti-inflammatory effects conferred by pentoxifylline may be beneficial in the management of DKD.Objectives: To assess the benefits and harms of pentoxifylline for treating people with DKD.Search methods: We searched the Cochrane Renal Group&apos;s specialised register (January 2012), CENTRAL (Issue 12, 2011), MEDLINE, EMBASE and four Chinese biomedical literature databases (CBM-disc, 1979 to July 2009), Chinese Science and Technique Journals Database (VIP, until July 2009), China National Knowledge Infrastructure (CNKI, until July 2009) and WanFang database (until July 2009).Selection criteria: All randomised controlled trials (RCTs) and quasi-RCTs studying the benefits and harms of pentoxifylline for DKD.Data collection and analysis: Data were extracted independently by two authors. Meta-analyses were performed when more than one study provided data on a comparable outcome in sufficiently similar patients. Results of dichotomous outcomes were expressed as risk ratios (RR) with 95% confidence intervals (CI). Mean differences (MD) were calculated to assess the effects of treatment where outcomes were expressed on continuous scales, and standardised mean differences (SMD) calculated where different scales were used. Data was pooled using the random effects model. Adverse effects were assessed using descriptive techniques and where possible, risk differences (RD) with 95% CI.Main results: We identified 17 studies that included a total of 991 participants with DKD which met our inclusion criteria. Overall, the methodological quality of included studies was low: 4/17 reported the method of randomisation, 13/17 did not; no study described the method of random allocation; 4/17 studies were considered to be at high risk of bias and 13/17 were considered to have unclear risk for incomplete outcome data reporting; 9/17 studies were at low risk bias and in 8/17 the risk of bias was unclear for selective outcome reporting.Compared with placebo, pentoxifylline significantly reduced serum creatinine (SCr) (MD -0.10 mg/dL, 95% CI -0.17 to -0.03), albuminuria (SMD -2.28, 95% CI -3.85 to -0.70) and overt proteinuria (MD -428.58 µg/min, 95% CI -661.65 to -195.50), but there was no difference in creatinine clearance (CrCl) (MD -5.18 mL/min, 95% CI -15.55 to 5.19). When compared with routine treatment alone, pentoxifylline did not significantly reduce SCr (MD 0.00 mg/dL, 95% CI -0.06 to 0.07) or blood pressure (systolic (SBP): MD -0.28 mm Hg, 95% CI -2.20 to 1.63; diastolic (DBP): MD -0.15 mm Hg, 95% CI -1.44 to 1.14), but did significantly reduce albuminuria (SMD 0.62, 95% CI 0.18 to 1.07) and proteinuria (MD 0.46 g/24 h, 95% CI 0.17 to 0.74). There was no significant difference in SCr (MD 0.00 mg/dL, 95% CI -0.08 to 0.07), albuminuria (MD -8.79 µg/min, 95% CI -27.18 to 9.59), proteinuria (MD -0.01 g/24 h, 95% CI -0.03 to 0.01) or blood pressure (SBP: MD 1.46 mm Hg, 95% CI -0.57 to 3.50; DBP: MD 1.37 mm Hg, 95% CI -0.23 to 2.98) between pentoxifylline and the active comparator (captopril or clonidine/methyldopa) for patients with type 1 and type 2 DKD. CrCl was significantly increased when pentoxifylline was compared to clonidine/methyldopa (MD 10.90 mL/min, 95% CI -1.40 to 20.40) but not with captopril (MD 3.26 mL/min, 95% CI -1.05 to 7.59). No data were available on the incidence of end-stage kidney disease (ESKD), time to ESKD, quality of life, or all-cause mortality. The adverse events of pentoxifylline were mild; no serious adverse events were reported in any of the included studies.Authors&apos; conclusions: From the available evidence, pentoxifylli e seems to offer some beneficial effects in renal function improvement and reduction in albuminuria and proteinuria, with no obvious serious adverse effects for patients with DKD. However, most studies were poorly reported, small, and methodologically flawed. Evidence to support the use of pentoxifylline for DKD was insufficient to develop recommendations for its use in this patient population. Rigorously designed, randomised, multicentre, large scale studies of pentoxifylline for DKD are needed to further assess its therapeutic effects.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006800.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006800.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>760</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">760</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharma Barjesh, Chander</style></author><author><style face="normal" font="default" size="100%">Gluud Lise, Lotte</style></author><author><style face="normal" font="default" size="100%">Sarin Shiv, Kumar</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Beta-blockers alone or with endoscopic therapy for prevention of variceal rebleeding in portal hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Liver</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006426</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:The objectives will be to assess the benefits and harms of beta-blockers alone or with endoscopic therapy for prevention of rebleeding in patients with oesophageal varices.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006426/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006426</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>361</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">361</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharma, M.</style></author><author><style face="normal" font="default" size="100%">Clark, H.</style></author><author><style face="normal" font="default" size="100%">Armour, T.</style></author><author><style face="normal" font="default" size="100%">Stotts, G.</style></author><author><style face="normal" font="default" size="100%">Cote, R.</style></author><author><style face="normal" font="default" size="100%">Hill, M. D.</style></author><author><style face="normal" font="default" size="100%">Demchuck, A. M.</style></author><author><style face="normal" font="default" size="100%">Moher, D.</style></author><author><style face="normal" font="default" size="100%">Garitty, C.</style></author><author><style face="normal" font="default" size="100%">Yazdi, F.</style></author><author><style face="normal" font="default" size="100%">Lumely-Leger, K.</style></author><author><style face="normal" font="default" size="100%">Murdock, M.</style></author><author><style face="normal" font="default" size="100%">Sampson, M.</style></author><author><style face="normal" font="default" size="100%">Barrowman, N.</style></author><author><style face="normal" font="default" size="100%">Lewin, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Acute stroke: evaluation and treatment (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">155</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Protocols</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [therapy] [diagnosis] [drug therapy] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombolytic Therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">Title to be Checked</style></publisher><accession-num><style face="normal" font="default" size="100%">DARE-12005008475</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005008475/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>761</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">761</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharma, Pawana</style></author><author><style face="normal" font="default" size="100%">Blackburn Rachel, C.</style></author><author><style face="normal" font="default" size="100%">Parke Claire, L.</style></author><author><style face="normal" font="default" size="100%">McCullough, Keith</style></author><author><style face="normal" font="default" size="100%">Marks, Angharad</style></author><author><style face="normal" font="default" size="100%">Black, Corri</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerular Filtration Rate [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Diseases [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007751</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Chronic kidney disease (CKD) is a long term condition that occurs as a result of damage to the kidneys. Early recognition of CKD is becoming increasingly common due to widespread laboratory estimated glomerular filtration rate (eGFR) reporting, raised clinical awareness, and international adoption of Kidney Disease Outcomes Quality Initiative (K/DOQI) classification. Early recognition and management of CKD affords the opportunity not only to prepare for progressive kidney impairment and impending renal replacement therapy, but also for intervening to reduce the risk of progression and cardiovascular disease. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are two classes of antihypertensive drugs that act on the renin-angiotensin-aldosterone system. Beneficial effects of ACEi and ARB on renal outcomes and survival in people with a wide range of severity of renal impairment have been reported; however, their effectiveness in the subgroup of people with early CKD (stage 1 to 3) is less certain.Objectives: This review aimed to evaluate the benefits and harms of ACEi and ARB or both in the management of people with early (stage 1 to 3) CKD who do not have diabetes mellitus.Search methods: In March 2010 we searched The Cochrane Library, including The Cochrane Renal Group&apos;s specialised register and The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE. Reference lists of review articles and relevant studies were also checked. The search was conducted using the optimally sensitive strategy developed by the Cochrane Collaboration for the identification of randomised controlled trials (RCTs) with input from an expert in trial search strategy.Selection criteria: All RCTs reporting the effect of ACEi or ARB in people with early (stage 1 to 3) CKD who did not have diabetes mellitus were selected for inclusion. Only studies of at least four weeks duration were selected. Authors, working in teams of two, independently assessed the retrieved titles and abstracts, and whenever necessary the full text of these studies were screened to determine which studies satisfied the inclusion criteria.Data collection and analysis: Data extraction was carried out by two authors, independently, using a standard data extraction form and cross checked by two other authors. Methodological quality of included studies was assessed using the Cochrane risk of bias tool. Data entry was carried out by one author and cross checked by another author. When more than one study reported similar outcomes, data were pooled using the random-effects model, but a fixed-effect model was also analysed to ensure the robustness of the model chosen and to check susceptibility to outliers. Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test. Where data permitted, subgroup analysis was used to explore possible sources of heterogeneity. The quality of the evidence was analysed.Main results: Four RCTs enrolling 2177 participants met our inclusion criteria. Of these, three compared ACEi with placebo and one compared ACEi with ARB. Two studies had an overall low risk of bias, and the other two were considered to be at moderate to high risk of bias. Low to moderate quality of evidence (from two studies representing 1906 patients) suggested that ACEi had no impact on all-cause mortality (RR 1.80, 95% CI 0.17 to 19.27, P = 0.63) or cardiovascular events (RR 0.87, 95% CI 0.66 to 1.14, P = 0.31) in people with stage 3 CKD. For all-cause mortality, there was substantial heterogeneity in the results. One study (quality assessment: low risk of bias) reported no difference in the risk of end-stage kidney disease in those with an eGFR &gt; 45 mL/min/1.74 m² treated with ACEi versus placebo (RR 1.00, 95% CI 0.09 to 1.11, P = 0.99). The (high risk of bias) study that compared ACEi with ARB reported little difference in effect between the treatments when urinary protein, blood pressure or creatinine clearance wer compared. No published studies comparing ARB with placebo or ACEi and ARB with placebo were identified.Authors&apos; conclusions: Our review demonstrated that there is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have diabetes mellitus. We have identified an area of significant uncertainty for a group of patients who account for most of those labelled as having CKD.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007751.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007751.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>762</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">762</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sheridan, S.</style></author><author><style face="normal" font="default" size="100%">Pignone, M.</style></author><author><style face="normal" font="default" size="100%">Donahue, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Screening for high blood pressure (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Screening</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Healthcare Research and Quality (AHRQ)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32003001106</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32003001106/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>362</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">362</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shetty, R.</style></author><author><style face="normal" font="default" size="100%">Biondi-Zoccai, G. G.</style></author><author><style face="normal" font="default" size="100%">Abbate, A.</style></author><author><style face="normal" font="default" size="100%">Amin, M. S.</style></author><author><style face="normal" font="default" size="100%">Jovin, I. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Percutaneous renal artery intervention versus medical therapy in patients with renal artery stenosis: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">EuroIntervention</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">EuroIntervention</style></full-title></periodical><pages><style face="normal" font="default" size="100%">844-851</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty, Balloon [adverse effects] [instrumentation]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Biological Markers [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Creatinine [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Renovascular [blood] [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction [blood] [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012000128</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012000128/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>363</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">363</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shi, K. Q.</style></author><author><style face="normal" font="default" size="100%">Fan, Y. C.</style></author><author><style face="normal" font="default" size="100%">Pan, Z. Z.</style></author><author><style face="normal" font="default" size="100%">Lin, X. F.</style></author><author><style face="normal" font="default" size="100%">Liu, W. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. P.</style></author><author><style face="normal" font="default" size="100%">Zheng, M. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Liver International</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Liver International</style></full-title></periodical><pages><style face="normal" font="default" size="100%">62-71</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Elasticity</style></keyword><keyword><style face="normal" font="default" size="100%">Elasticity Imaging Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Esophageal and Gastric Varices [diagnosis] [etiology] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal [diagnosis] [etiology] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013002608</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013002608/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>364</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">364</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shibata, M. C.</style></author><author><style face="normal" font="default" size="100%">Leon, H.</style></author><author><style face="normal" font="default" size="100%">Chatterley, T.</style></author><author><style face="normal" font="default" size="100%">Dorgan, M.</style></author><author><style face="normal" font="default" size="100%">Vandermeer, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension? (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">228-235</style></pages><volume><style face="normal" font="default" size="100%">106</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [complications] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010005880</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010005880/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>365</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">365</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shinohara, Y.</style></author><author><style face="normal" font="default" size="100%">Origasa, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Advances in Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Advances in Therapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">900-912</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia, Aspiration [complications] [ethnology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [complications] [ethnology]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013009028</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013009028/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>366</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">366</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shirani, F.</style></author><author><style face="normal" font="default" size="100%">Salehi-Abargouei, A.</style></author><author><style face="normal" font="default" size="100%">Azadbakht, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Dietary Approaches to Stop Hypertension (DASH) diet on some risk for developing type 2 diabetes: a systematic review and meta-analysis on controlled clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">939-947</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">7-8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013038159</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013038159/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>763</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">763</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shojania, K. G.</style></author><author><style face="normal" font="default" size="100%">McDonald, K. M.</style></author><author><style face="normal" font="default" size="100%">Wachter, R. M.</style></author><author><style face="normal" font="default" size="100%">Owens, D. K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Closing the quality gap: a critical analysis of quality improvement strategies. Volume 3 - hypertension care (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">98</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Quality Assurance, Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Health Care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Healthcare Research and Quality (AHRQ)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32005000078</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32005000078/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>764</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">764</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Siebenhofer, Andrea</style></author><author><style face="normal" font="default" size="100%">Jeitler, Klaus</style></author><author><style face="normal" font="default" size="100%">Berghold, Andrea</style></author><author><style face="normal" font="default" size="100%">Waltering, Andreas</style></author><author><style face="normal" font="default" size="100%">Hemkens Lars, G.</style></author><author><style face="normal" font="default" size="100%">Semlitsch, Thomas</style></author><author><style face="normal" font="default" size="100%">Pachler, Christoph</style></author><author><style face="normal" font="default" size="100%">Strametz, Reinhard</style></author><author><style face="normal" font="default" size="100%">Horvath, Karl</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-term effects of weight-reducing diets in hypertensive patients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diet, Reducing [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Loss</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008274</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: All major guidelines for antihypertensive therapy recommend weight loss. Thus dietary interventions that aim to reduce body weight might be a useful intervention to reduce blood pressure and adverse cardiovascular events associated with hypertension.Objectives: Primary objectivesTo assess the long-term effects of weight-reducing diets in hypertensive patients on-   all cause mortality -   cardiovascular morbidity -   adverse events (including total serious adverse events, withdrawal due to adverse events and total non-serious adverse events)Secondary objectivesTo assess the long-term effects of weight-reducing diets in hypertensive patients on-   change from baseline in systolic blood pressure -   change from baseline in diastolic blood pressure -   body weight reductionSearch methods: Studies were obtained from computerised searches of Ovid MEDLINE, EMBASE, CENTRAL and from searches in reference lists and systematic reviews.Selection criteria: Randomised controlled trials (RCT) in adult hypertensive patients were included if they had a study duration of at least 24 weeks and compared weight reducing dietary interventions to no dietary intervention in adult patients with primary hypertension.Data collection and analysis: Two authors independently assessed risk of bias and extracted data. Studies were pooled using fixed-effect meta-analysis. In case of moderate or larger heterogeneity as measured by Higgins I2, a random effects model was used.Main results: Eight studies involving a total of 2100 participants with high blood pressure and a mean age of 45 to 66 years met our inclusion criteria. Mean treatment duration was 6 to 36 months. No study included mortality as a pre-defined outcome. One RCT evaluated the effects of dietary weight loss on a combined endpoint, consisting of the necessity of reinstating antihypertensive therapy and severe cardiovascular complications. In this RCT weight reducing diet lowered the endpoint, hazard ratio 0.70 (95% confidence interval [CI], 0.57 to 0.87) compared to no diet. None of the studies evaluated adverse events as designated in our protocol. Blood pressure was reduced in patients assigned to weight loss diets as compared to controls: systolic blood pressure (SBP): weighted mean difference (WMD): -4.5 mm Hg; 95% CI, -7.2 to -1.8 mm Hg (3 of  8  studies included in analysis), and diastolic blood pressure (DBP): WMD -3.2 mm Hg; 95% CI, -4.8 to -1.5 mm Hg (3 of  8  studies included in analysis). Patients&apos; body weight was also reduced in dietary weight loss groups as compared to controls, WMD of -4.0 kg (95% CI: -4.8 to -3.2) (5 of  8  studies included in analysis). Two studies used withdrawal of antihypertensive medication as their primary outcome. Even though this was not considered a relevant outcome for this review, the results of these studies strengthen the finding of reduction of blood pressure by dietary weight loss interventions.Authors&apos; conclusions: In patients with primary hypertension, weight loss diets reduced body weight and blood pressure, however the magnitude of the effects are uncertain as a result of the small number of patients and studies that could be included in the analyses. It is not known whether weight loss reduces mortality and morbidity. No useful information on adverse effects was reported in the relevant trials.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008274.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008274.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>765</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">765</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Siebenhofer, Andrea</style></author><author><style face="normal" font="default" size="100%">Jeitler, Klaus</style></author><author><style face="normal" font="default" size="100%">Horvath, Karl</style></author><author><style face="normal" font="default" size="100%">Berghold, Andrea</style></author><author><style face="normal" font="default" size="100%">Siering, Ulrich</style></author><author><style face="normal" font="default" size="100%">Semlitsch, Thomas</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-term effects of weight-reducing drugs in hypertensive patients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Weight Loss</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Obesity Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cyclobutanes [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Reducing</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Lactones [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrazoles [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Safety-Based Drug Withdrawals</style></keyword><keyword><style face="normal" font="default" size="100%">Time</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007654</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: All major guidelines for antihypertensive therapy recommend weight loss; anti-obesity drugs might be a helpful option.Objectives: Primary objectives:To assess the long-term effects of pharmacologically induced reduction in body weight with orlistat, sibutramine or rimonabant on:- all cause mortality - cardiovascular morbidity - adverse eventsSecondary objectives: - changes in systolic and/or diastolic blood pressure - body weight reductioneven though sibutramine and rimonabant have been withdrawn from the market.Search methods: Studies were obtained from computerised searches of Ovid MEDLINE, EMBASE, CENTRAL and from hand searches in reference lists and systematic reviews (status as of 17th August, 2012).Selection criteria: Randomized controlled trials in adult hypertensive patients with a study duration of at least 24 weeks comparing pharmacologic interventions (orlistat, sibutramine, rimonabant) for weight loss with placebo. Data collection and analysis: Two authors independently assessed risk of bias and extracted data. Studies were pooled using fixed-effect meta-analysis in the absence of significant heterogeneity between studies (p&gt;0.1). Otherwise, we used the random effects method and investigated the cause of heterogeneity.Main results: After the updated literature search, the number of studies remained the same, with eight studies comparing orlistat or sibutramine to placebo fulfilling our inclusion criteria. No relevant studies investigating rimonabant for weight loss were identified. No study included mortality and cardiovascular morbidity as a pre-defined outcome. Incidence of gastrointestinal side effects was consistently higher in orlistat treated vs. placebo treated patients. Most frequent side effects with sibutramine were dry mouth, constipation and headache. Patients assigned to weight loss diets, orlistat or sibutramine reduced their body weight more effectively than patients in the usual care/placebo groups. Blood pressure reduction in patients treated with orlistat was for systolic blood pressure (SBP): weighted mean difference (WMD): -2.5 mm Hg; 95% CI, -4.0 to -0.9 mm Hg and for diastolic blood pressure (DBP): WMD -1.9 mm Hg; 95% CI, -3.0 to -0.9 mm Hg. Meta-analysis showed DBP increase under therapy with sibutramine: WMD +3.2 mm Hg; 95%CI +1.4 to +4.9 mm Hg.Authors&apos; conclusions: In patients with elevated blood pressure, orlistat and sibutramine reduced body weight to a similar degree. In the same trials, orlistat reduced blood pressure and sibutramine increased blood pressure. No trials investigating rimonabant in people with elevated blood pressure could be included. Long-term trials assessing the effect of orlistat, sibutramine and rimonabant on mortality and morbidity are lacking. Rimonabant and sibutramine have been withdrawn from the market for the time being.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007654.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007654.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>367</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">367</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Siebenhofer, A.</style></author><author><style face="normal" font="default" size="100%">Plank, J.</style></author><author><style face="normal" font="default" size="100%">Horvath, K.</style></author><author><style face="normal" font="default" size="100%">Berghold, A.</style></author><author><style face="normal" font="default" size="100%">Sutton, A. J.</style></author><author><style face="normal" font="default" size="100%">Sommer, R.</style></author><author><style face="normal" font="default" size="100%">Pieber, T. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetic Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diabetic Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">18-25</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Angiopathies [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Nephropathies [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004000191</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004000191/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>368</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">368</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Siervo, M.</style></author><author><style face="normal" font="default" size="100%">Lara, J.</style></author><author><style face="normal" font="default" size="100%">Ogbonmwan, I.</style></author><author><style face="normal" font="default" size="100%">Mathers, J. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">818-826</style></pages><volume><style face="normal" font="default" size="100%">143</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Beta vulgaris [chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Beverages</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">MEDLINE</style></keyword><keyword><style face="normal" font="default" size="100%">Nitrates [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Roots [adverse effects] [chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium Compounds [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013022074</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013022074/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>766</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">766</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sieswerda, Elske</style></author><author><style face="normal" font="default" size="100%">van Dalen Elvira, C.</style></author><author><style face="normal" font="default" size="100%">Postma, Aleida</style></author><author><style face="normal" font="default" size="100%">Cheuk Daniel, K. L.</style></author><author><style face="normal" font="default" size="100%">Caron Huib, N.</style></author><author><style face="normal" font="default" size="100%">Kremer Leontien, C. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anthracyclines [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotics, Antineoplastic [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Enalapril [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [chemically induced] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphocreatine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Survivors</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Childca</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008011</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can cause cardiotoxicity during and after treatment. Although several medical interventions in adults with symptomatic or asymptomatic cardiac dysfunction due to other causes are beneficial, it is not known if the same treatments are effective for childhood cancer patients and survivors with anthracycline-induced cardiotoxicity.Objectives: To compare the effect of medical interventions on anthracycline-induced cardiotoxicity in childhood cancer patients or survivors with the effect of placebo, other medical interventions or no treatment.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2011, issue 1), MEDLINE/PubMed (1949 to May 2011) and EMBASE/Ovid (1980 to May 2011) for potentially relevant articles. We additionally searched reference lists of relevant articles, conference proceedings and ongoing trial databases.Selection criteria: Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing the effectiveness of medical interventions to treat anthracycline-induced cardiotoxicity with either placebo, other medical interventions or no treatment.Data collection and analysis: Two review authors independently performed the study selection. One review author performed the data extraction and &apos;Risk of bias&apos; assessments which were checked by another review author.Main results: We identified two RCTs. One trial (135 patients) compared enalapril with placebo in childhood cancer survivors with asymptomatic anthracycline induced cardiac dysfunction. The other trial (68 patients) compared a two-week treatment of phosphocreatine with a control treatment (vitamin C, ATP, vitamin E, oral coenzyme Q10) in leukaemia patients with anthracycline-induced cardiotoxicity. Both studies had methodological limitations.The RCT on enalapril showed no (statistically) significant differences in overall survival, mortality due to heart failure, development of clinical heart failure and quality of life between treatment and control group. A post-hoc analysis showed a decrease (i.e. improvement) in one measure of cardiac function (left ventricular end systolic wall stress (LVESWS): -8.62% change) compared with placebo (+1.66% change) in the first year of treatment (P = 0.036), but not afterwards. Patients treated with enalapril had a higher risk of dizziness or hypotension (RR 7.17, 95% CI 1.71 to 30.17) and fatigue (Fisher&apos;s exact test, P = 0.013).The RCT on phosphocreatine found no differences in overall survival, mortality due to heart failure, echocardiographic cardiac function and adverse events between treatment and control group.Authors&apos; conclusions: For the effect of enalapril in childhood cancer survivors with asymptomatic cardiac dysfunction, only one RCT is available. Although there is some evidence that enalapril temporarily improves one parameter of cardiac function (LVESWS), it is unclear whether it improves clinical outcomes. Enalapril was associated with a higher risk of dizziness or hypotension and fatigue. Clinicians should weigh the possible benefits with the known side-effects of enalapril in childhood cancer survivors with asymptomatic anthracycline-induced cardiotoxicity.For the effect of phosphocreatine in childhood cancer patients with anthracycline-induced cardiotoxicity, only one RCT is available. Limited data with a high risk of bias showed no significant difference between phosphocreatine and control treatment on echocardiographic function and clinical outcomes.We did not identify any RCTs or CCTs studying other medical interventions for symptomatic or asymptomatic cardiotoxicity in childhood cancer patients or survivors.High-quality studies should be performed.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008011.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008011.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>369</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">369</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Simoni, A.</style></author><author><style face="normal" font="default" size="100%">Hardeman, W.</style></author><author><style face="normal" font="default" size="100%">Mant, J.</style></author><author><style face="normal" font="default" size="100%">Farmer, A. J.</style></author><author><style face="normal" font="default" size="100%">Kinmonth, A. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Trials to improve blood pressure through adherence to antihypertensives in stroke/TIA: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e000251</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic Attack, Transient</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013050348</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013050348/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>370</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">370</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinagra, E.</style></author><author><style face="normal" font="default" size="100%">Perricone, G.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amico, M.</style></author><author><style face="normal" font="default" size="100%">Tine, F.</style></author><author><style face="normal" font="default" size="100%">D&apos;Amico, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Alimentary Pharmacology and Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Alimentary Pharmacology and Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Carbazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">Propranolol</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014009674</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014009674/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>767</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">767</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sleilati, Gina</style></author><author><style face="normal" font="default" size="100%">Frank Robert, N.</style></author><author><style face="normal" font="default" size="100%">Mathew Milan, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure control for diabetic retinopathy</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Eyes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006127</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:1.(a) To assess the effectiveness of blood pressure control in preventing diabetic retinopathy. (b) To assess the effectiveness of blood pressure control in slowing the progression of diabetic retinopathy.2.(a) To assess the role of specific classes of antihypertensive agents in preventing diabetic retinopathy. (b) To assess the role of specific classes of antihypertensive agents in slowing the progression of diabetic retinopathy.3.(a) To assess the role of the level of blood pressure control achieved in preventing diabetic retinopathy. (b) To assess the role of the level of blood pressure control achieved in slowing the progression of diabetic retinopathy</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006127/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006127</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>768</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">768</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sloan, Derek</style></author><author><style face="normal" font="default" size="100%">Dlamini, Sipho</style></author><author><style face="normal" font="default" size="100%">Paul, Navin</style></author><author><style face="normal" font="default" size="100%">Dedicoat, Martin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acetazolamide [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Amphotericin B [supply &amp; distribution] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antifungal Agents [supply &amp; distribution] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Fluconazole [supply &amp; distribution] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Flucytosine [supply &amp; distribution] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Infections [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Health Resources [supply &amp; distribution]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Meningitis, Cryptococcal [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Hiv</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005647</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Despite the advent and increasingly wide availability of antiretroviral therapy, cryptococcal meningitis (CM) remains a significant cause of mortality and morbidity amongst individuals with HIV infection in resource-limited settings. The ideal management of CM remains unclear. The aim of this review is to assess the evidence for deciding on which antifungal regimen to use as well as other modalities of management to utilise especially resource poor settings in order to achieve the best possible outcome and enable an individual with CM to survive their acute illness and benefit from antiretroviral therapy.Objectives: To determine the most effective initial and consolidation treatment strategy for CM in HIV infected adults.Search methods: The Cochrane HIV/AIDS group search strategy was used. Key words in the search included, meningitis, cryptococcus neoformans, treatment, trial, human immunodeficiency virus, acquired immunodeficiency syndrome, antifungal agents, amphotericin, flucytosine, fluconazole, azole, lumbar puncture, cerebrospinal fluid (CSF) pressure and acetazolamide.Selection criteria: Randomised of HIV-infected adults with a first episode of CM diagnosed on CSF examination, by India ink staining, CSF culture or cryptococcal antigen testing.Data collection and analysis: Data were extracted using standardised forms and analysed using Rev Man 4.2.7 software.Main results: Six studies are included in the review. Five of the studies compared antifungal treatments and one study addressed lowering intracranial pressure. This study was stopped early due to excess adverse effects. The results of the other five studies as summarised as follows.Mayanja-Kizza 1998 compared fluconazole to fluconazole with 5 flucytosine. The dose of fluconazole used 200mg initially is lower than the recommended initial dose of 400mg. No survival advantage was found with the use of 5 flucytosine in addition to fluconazole.Two studies Brouwer 2004 and van der Horst 1997 compared Amphotericin (AmB) to AmB with 5 flucytosine. Both drugs were given at currently recommended doses for 2 weeks. No survival difference was found at 14 days or at 10 weeks (only recorded in Brouwer 2004). There were significantly more patients with sterile CSF cultures at 14 days in the group that received AmB with flucytosine.Brouwer 2004 compared AmB given alone to AmB given with flucytosine and fluconazole alone or in combination. This was a small study and no differences in mortality were noted between the groups.Bicanic 2008 compared high to standard dose AmB both with flucytosine. There was no difference in mortality between the two groups or adverse events.Leenders 1997 compared standard AmB to liposomal AmB. There was no difference in death rates between the two groups. But there were significantly fewer side effects in the group treated with liposomal AmB.Authors&apos; conclusions: The main aim of this review was to determine the best treatment for cryptococcal meningitis in resource-limited settings. In these settings usually only AmB and fluconazole are available. No studies suitable for inclusion in the review were found that compared these two drugs. Therefore we are unable to recommend either treatment as superior to the other. The recommended treatment for CM is a combination of AmB and flucytosine. The optimal dosing of AmB remains unclear. Liposomal AmB is associated with less adverse events than AmB and may be useful in selected patients where resources allow. Future research into the management of cryptococcal meningitis in resource-limited settings should focus on the most effective use of medications that are available in these settings. Flucytosine in combination with AmB leads to faster and increased sterilisation of CSF compared to using AmB alone. As Flucytosine is often not available in developing countries, policy makers and national departments of heath should consider procuring this drug for HIV treatment programmes.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005647.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005647.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>371</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">371</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Song, H. F.</style></author><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Li, H. W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of angiotensin receptor blockers in the prevention of type 2 diabetes and cardiovascular events: a meta-analysis of randomized trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Medical Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1804-1810</style></pages><volume><style face="normal" font="default" size="100%">125</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013000475</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013000475/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>372</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">372</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Souza, L. M.</style></author><author><style face="normal" font="default" size="100%">Riera, R.</style></author><author><style face="normal" font="default" size="100%">Saconato, H.</style></author><author><style face="normal" font="default" size="100%">Demathe, A.</style></author><author><style face="normal" font="default" size="100%">Atallah, A. N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Oral drugs for hypertensive urgencies: systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Sao Paulo Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sao Paulo Medical Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">366-372</style></pages><volume><style face="normal" font="default" size="100%">127</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Emergencies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010005272</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010005272/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>769</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">769</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stabler Sarah, N.</style></author><author><style face="normal" font="default" size="100%">Tejani Aaron, M.</style></author><author><style face="normal" font="default" size="100%">Huynh, Fong</style></author><author><style face="normal" font="default" size="100%">Fowkes, Claire</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Garlic for the prevention of cardiovascular morbidity and mortality in hypertensive patients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Garlic [chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Supine Position</style></keyword><keyword><style face="normal" font="default" size="100%">Triamterene [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007653</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Garlic is widely used by patients for its blood pressure lowering effects. A meta-analysis published in 2008 concluded that garlic consumption lowers blood pressure in hypertensive and normotensive patients. Therefore, it is important to review the currently available evidence to determine whether garlic may also have a beneficial role in the reduction of cardiovascular events and mortality rates in patients with hypertension.Objectives: To determine whether the use of garlic as monotherapy, in hypertensive patients, lowers the risk of cardiovascular morbidity and mortality compared to placebo.Search methods: A systematic search for trials was conducted in the Cochrane Hypertension Group Specialised Register, CENTRAL, MEDLINE, EMBASE, AGRICOLA, AMED, and CINAHL up to November 2011. A hand search of reference lists of identified reviews was conducted. Experts in the area were also contacted to identify trials not found in the electronic search. Clinicaltrials.gov was searched for ongoing trials.Selection criteria: Randomized, placebo-controlled trials of any garlic preparation versus placebo for the treatment of hypertension were included.Data collection and analysis: Two reviewers independently extracted data and assessed trial quality using the risk of bias tool. Data synthesis and analysis was performed using RevMan 5.Main results: The search identified two randomized controlled trials for inclusion. One trial included 47 hypertensive patients and showed that garlic significantly reduces mean supine systolic blood pressure by 12 mmHg (95% CI 0.56 to 23.44 mmHg, p=0.04) and mean supine diastolic blood pressure by 9 mmHg (95% CI 2.49 to 15.51 mmHg, p=0.007) versus placebo. The authors state that garlic was &quot;free from side effects&quot; and that no serious side effects were reported. There were 3 cases &quot;where a slight smell of garlic was noted.&quot;The second trial could not be meta-analysed as they did not report the number of people randomized to each treatment group. They did report that 200 mg of garlic powder given three times daily, in addition to hydrochlorothiazide-triamterene baseline therapy, produced a mean reduction of systolic blood pressure by 10-11 mmHg and of diastolic blood pressure by 6-8 mmHg versus placebo.Neither trial reported clinical outcomes and insufficient data was provided on adverse events.Authors&apos; conclusions: There is insufficient evidence to determine if garlic provides a therapeutic advantage versus placebo in terms of reducing the risk of mortality and cardiovascular morbidity in patients diagnosed with hypertension. There is also insufficient evidence to determine the difference in withdrawals due to adverse events between patients treated with garlic or placebo.Based on 2 trials in 87 hypertensive patients, it appears that garlic reduces mean supine systolic and diastolic blood pressure by approximately 10-12 mmHg and 6-9 mmHg, respectively, over and above the effect of placebo but the confidence intervals for these effect estimates are not precise and this difference in blood pressure reduction falls within the known variability in blood pressure measurements. This makes it difficult to determine the true impact of garlic on lowering blood pressure.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007653.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007653.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>373</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">373</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stainsby, D.</style></author><author><style face="normal" font="default" size="100%">Brunskill, S.</style></author><author><style face="normal" font="default" size="100%">Chapman, C. E.</style></author><author><style face="normal" font="default" size="100%">Doree, C.</style></author><author><style face="normal" font="default" size="100%">Stanworth, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Safety of blood donation from individuals with treated hypertension or non-insulin dependent type 2 diabetes: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Vox Sanguinis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Vox Sanguinis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">431-440</style></pages><volume><style face="normal" font="default" size="100%">98</style></volume><number><style face="normal" font="default" size="100%">3 Part 2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Component Removal [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Donors</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Transfusion</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Transfusion, Autologous</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [blood] [diet therapy] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiologic Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Great Britain</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [blood] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoglycemic Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Insulin [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Phlebotomy [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Syncope, Vasovagal [epidemiology] [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010004052</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010004052/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>374</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">374</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Steele, P.</style></author><author><style face="normal" font="default" size="100%">Strange, G.</style></author><author><style face="normal" font="default" size="100%">Wlodarczyk, J.</style></author><author><style face="normal" font="default" size="100%">Dalton, B.</style></author><author><style face="normal" font="default" size="100%">Stewart, S.</style></author><author><style face="normal" font="default" size="100%">Gabbay, E.</style></author><author><style face="normal" font="default" size="100%">Keogh, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy? (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Cardiovascular Disorders</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Cardiovascular Disorders</style></full-title></periodical><volume><style face="normal" font="default" size="100%">10:9</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">derivatives [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Epoprostenol [analogs &amp; derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodynamics [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Isoxazoles [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Purines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Thiophenes [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010002919</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010002919/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>375</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">375</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Strazzullo, P.</style></author><author><style face="normal" font="default" size="100%">Kerry, S. M.</style></author><author><style face="normal" font="default" size="100%">Barbato, A.</style></author><author><style face="normal" font="default" size="100%">Versiero, M.</style></author><author><style face="normal" font="default" size="100%">D&apos;Elia, L.</style></author><author><style face="normal" font="default" size="100%">Cappuccio, F. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Do statins reduce blood pressure: a meta-analysis of randomized, controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">792-798</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Diastole</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Systole</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007005383</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007005383/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>376</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">376</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Streppel, M. T.</style></author><author><style face="normal" font="default" size="100%">Arends, L. R.</style></author><author><style face="normal" font="default" size="100%">van&apos;t Veer, P.</style></author><author><style face="normal" font="default" size="100%">Grobbee, D. E.</style></author><author><style face="normal" font="default" size="100%">Geleijnse, J. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">150-156</style></pages><volume><style face="normal" font="default" size="100%">165</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Fiber</style></keyword><keyword><style face="normal" font="default" size="100%">Health Status</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005008130</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005008130/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>377</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">377</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Strippoli, G. F.</style></author><author><style face="normal" font="default" size="100%">Craig, M.</style></author><author><style face="normal" font="default" size="100%">Schena, F. P.</style></author><author><style face="normal" font="default" size="100%">Craig, J. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive agents for primary prevention of diabetic nephropathy (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Society of Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Society of Nephrology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3081-3091</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Nephropathies [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006009112</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006009112/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>770</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">770</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Strippoli Giovanni, F. M.</style></author><author><style face="normal" font="default" size="100%">Bonifati, Carmen</style></author><author><style face="normal" font="default" size="100%">Craig Maria, E.</style></author><author><style face="normal" font="default" size="100%">Navaneethan Sankar, D.</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Nephropathies [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006257</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (AIIRA) are considered to be equally effective for patients with diabetic kidney disease (DKD), but renal and not mortality outcomes have usually been considered.Objectives: To evaluate the benefits and harms ACEi and AIIRA in patients with DKD.Search methods: We searched MEDLINE (1966 to December 2005), EMBASE (1980 to December 2005), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library issue 4 2005) and contacted known investigators.Selection criteria: Studies comparing ACEi or AIIRA with placebo or each other in patients with DKD were included.Data collection and analysis: Two authors independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and results expressed as risk ratio (RR) with 95% confidence intervals (CI). Heterogeneity among studies was explored using the Cochran Q statistic and the I² test, subgroup analyses and random effects meta-regression.Main results: Forty nine studies (12,067 patients) were identified. Thirty eight compared ACEi with placebo, four compared AIIRA with placebo and seven compared ACEi and AIIRA directly. There was no significant difference in the risk of all-cause mortality for ACEi versus placebo (RR 0.91, 95% CI 0.71 to 1.17) and AIIRA versus placebo (RR 0.99, 95% CI 0.85 to 1.17). A subgroup analysis of studies using full-dose ACEi versus studies using half or less than half the maximum tolerable dose of ACEi showed a significant reduction in the risk of all-cause mortality with the use of full-dose ACEi (RR 0.78, 95% CI 0.61 to 0.98). Baseline mortality rates were similar in the ACEi and AIIRA studies. The effects of ACEi and AIIRA on renal outcomes (ESKD, doubling of creatinine, prevention of progression of micro- to macroalbuminuria, remission of micro- to normoalbuminuria) were similarly beneficial. Reliable estimates of effect of ACEi versus AIIRA could not be obtained from the three studies in which they were compared directly because of their small sample size.Authors&apos; conclusions: Although the survival benefits of ACEi are known for patients with DKD, the relative effects on survival of ACEi with AIIRA are unknown due to the lack of adequate direct comparison studies. In placebo controlled studies, only ACEi (at the maximum tolerable dose, but not lower so-called renal doses) were found to significantly reduce the risk of all-cause mortality. Renal and toxicity profiles of these two classes of agents were not significantly different.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006257/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006257</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>771</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">771</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Strippoli Giovanni, F. M.</style></author><author><style face="normal" font="default" size="100%">Navaneethan Sankar, D.</style></author><author><style face="normal" font="default" size="100%">Craig Jonathan, C.</style></author><author><style face="normal" font="default" size="100%">Palmer Suetonia, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anemia [blood] [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Erythropoietin [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hematocrit</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobin A [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [complications] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Dialysis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003967</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Anaemia affects 60% to 80% of patients with chronic kidney disease (CKD) reduces quality of life and is a risk factor for early death. Treatment options are blood transfusion, erythropoietin (EPO) and darbepoetin alfa. Recently higher haemoglobin (Hb) and haematocrit (HCT) targets have been widely advocated because of positive associations with improved survival and quality of life from observational studies.Objectives: To assess the benefits and harms of different Hb or HCT targets in CKD patients receiving any treatment for anaemia.Search methods: We searched The Cochrane Renal Group&apos;s specialised register, Cochrane Central Register of Controlled Trials (CENTRAL, in The Cochrane Library) MEDLINE (from 1966), EMBASE (from 1980) and reference lists of retrieved articles.Selection criteria: Randomised controlled trials (RCTs) and quasi-RCTs comparing different Hb/HCT targets in patients with the anaemia of CKD.Data collection and analysis: Two reviewers independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and results expressed as risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, with 95% confidence intervals (CI).Main results: Twenty two trials (3707 patients) were included. Hb ? 133 g/L was not associated with a reduction in the risk of all-cause mortality compared with 120 g/L in dialysis and pre-dialysis patients. In pre-dialysis patients, there was a significantly lower end of treatment creatinine clearance with Hb &lt; 120 g/L compared to &gt; 130 g/L (MD -4.17, 95% CI -6.33 to -2.02) but no significant difference in the risk of end-stage kidney disease (ESKD) (RR 1.05, 95% CI 0.50 to 2.22). Lower Hb targets resulted in an increased risk for seizures (RR 5.25, 95% CI 1.13 to 24.34) and a reduced risk of hypertensive episodes (RR 0.50, 95% CI 0.33 to 0.76). There were no significant differences in the risk of vascular access thrombosis.Authors&apos; conclusions: There was no significant difference in the risk of death for low (&lt; 120 g/L) versus higher Hb targets (&gt;133 g/L). Lower Hb targets were significantly associated with an increased risk for seizures but a reduced risk of hypertension. In general study quality was poor. There is a need for more adequately powered, well-designed and reported trials. Trials should be pragmatic, focusing on hard end-points (mortality, ESKD, major side effects) or outcomes which were previously not studied adequately (e.g. seizures, quality of life).</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003967.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003967.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>772</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">772</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suckling Rebecca, J.</style></author><author><style face="normal" font="default" size="100%">He Feng, J.</style></author><author><style face="normal" font="default" size="100%">MacGregor Graham, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Altered dietary salt intake for preventing and treating diabetic kidney disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 1 [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Nephropathies [diet therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride, Dietary [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006763</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: There is strong evidence that our current consumption of salt is a major factor for increased blood pressure (BP) and a modest reduction in salt intake lowers BP whether BP levels are normal or raised. Tight control of BP in diabetics lowers the risk of strokes, heart attacks and heart failure and slows the progression of diabetic kidney disease (DKD). Currently there is no consensus in restricting salt intake in diabetic patients.Objectives: To evaluate the effect of altered salt intake on BP and markers of cardiovascular disease and DKD.Search methods: In January 2010, we searched the Cochrane Renal Group&apos;s Specialised Register, CENTRAL (in The Cochrane Library), MEDLINE (from 1966) and EMBASE (from 1980) to identify appropriate articles.Selection criteria: We included all randomised controlled trials of salt reduction in individuals with type 1 and type 2 diabetes.Data collection and analysis: Two authors independently assessed studies and resolved differences by discussion with a third independent author. We calculated mean effect sizes using both the fixed-effect and random-effects models.Main results: Thirteen studies (254 individuals) met our inclusion criteria. These included 75 individuals with type 1 diabetes and 158 individuals with type 2 diabetes. The median reduction in urinary sodium was 203 mmol/24 h (11.9 g/day) in type 1 diabetes and 125 mmol/24 h (7.3 g/day) in type 2 diabetes. The median duration of salt restriction was one week in both type 1 and type 2 diabetes. BP was reduced in both type 1 and type 2 diabetes. In type 1 diabetes (56 individuals), salt restriction reduced BP by -7.11/-3.13 mm Hg (systolic/diastolic); 95% CI: systolic BP (SBP) -9.13 to -5.10; diastolic BP (DBP) -4.28 to -1.98). In type 2 diabetes (56 individuals), salt restriction reduced BP by -6.90/-2.87 mm Hg (95% CI: SBP -9.84 to -3.95; DBP -4.39 to -1.35). There was a greater reduction in BP in normotensive patients, possibly due to a larger decrease in salt intake in this group.Authors&apos; conclusions: Although the studies are not extensive, this meta-analysis shows a large fall in BP with salt restriction, similar to that of single drug therapy. All diabetics should consider reducing salt intake at least to less than 5-6 g/day in keeping with current recommendations for the general population and may consider lowering salt intake to lower levels, although further studies are needed.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006763.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006763.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>378</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">378</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suksomboon, N.</style></author><author><style face="normal" font="default" size="100%">Poolsup, N.</style></author><author><style face="normal" font="default" size="100%">Prasit, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Pharmacy and Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Pharmacy and Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">319-327</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adiponectin [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzoates [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperglycemia [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperinsulinism [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [blood] [complications] [drug therapy] [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Insulin Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">PPAR gamma [agonists]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012027880</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012027880/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>379</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">379</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, T.</style></author><author><style face="normal" font="default" size="100%">Xu, H.</style></author><author><style face="normal" font="default" size="100%">Xu, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Astragalus injection for hypertensive renal damage: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">929025</style></pages><volume><style face="normal" font="default" size="100%">2012</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Astragalus membranaceus</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012025511</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012025511/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>380</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">380</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sundstrom, J.</style></author><author><style face="normal" font="default" size="100%">Arima, H.</style></author><author><style face="normal" font="default" size="100%">Woodward, M.</style></author><author><style face="normal" font="default" size="100%">Jackson, R.</style></author><author><style face="normal" font="default" size="100%">Karmali, K.</style></author><author><style face="normal" font="default" size="100%">Lloyd-Jones, D.</style></author><author><style face="normal" font="default" size="100%">Baigent, C.</style></author><author><style face="normal" font="default" size="100%">Emberson, J.</style></author><author><style face="normal" font="default" size="100%">Rahimi, K.</style></author><author><style face="normal" font="default" size="100%">MacMahon, S.</style></author><author><style face="normal" font="default" size="100%">Patel, A.</style></author><author><style face="normal" font="default" size="100%">Perkovic, V.</style></author><author><style face="normal" font="default" size="100%">Turnbull, F.</style></author><author><style face="normal" font="default" size="100%">Neal, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">591-598</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Decision Making</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014052741</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014052741/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>381</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">381</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Taichman, D. B.</style></author><author><style face="normal" font="default" size="100%">Ornelas, J.</style></author><author><style face="normal" font="default" size="100%">Chung, L.</style></author><author><style face="normal" font="default" size="100%">Klinger, J.</style></author><author><style face="normal" font="default" size="100%">Lewis, S.</style></author><author><style face="normal" font="default" size="100%">Mandel, J.</style></author><author><style face="normal" font="default" size="100%">Palevsky, H.</style></author><author><style face="normal" font="default" size="100%">Rich, S.</style></author><author><style face="normal" font="default" size="100%">Sood, N.</style></author><author><style face="normal" font="default" size="100%">Rosenzweig, E. B.</style></author><author><style face="normal" font="default" size="100%">Trow, T.</style></author><author><style face="normal" font="default" size="100%">Yung, R.</style></author><author><style face="normal" font="default" size="100%">Elliott, C. G.</style></author><author><style face="normal" font="default" size="100%">Badesch, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacological therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">449-475</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Discovery</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Circulation</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014039176</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014039176/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>382</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">382</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Takagi, H.</style></author><author><style face="normal" font="default" size="100%">Mizuno, Y.</style></author><author><style face="normal" font="default" size="100%">Niwa, M.</style></author><author><style face="normal" font="default" size="100%">Goto, S. N.</style></author><author><style face="normal" font="default" size="100%">Umemoto, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">432-437</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013059729</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013059729/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>383</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">383</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Takagi, H.</style></author><author><style face="normal" font="default" size="100%">Mizuno, Y.</style></author><author><style face="normal" font="default" size="100%">Yamamoto, H.</style></author><author><style face="normal" font="default" size="100%">Goto, S. N.</style></author><author><style face="normal" font="default" size="100%">Umemoto, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">368-373</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amlodipine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzoates [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Confidence Intervals</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Renal [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Imidazoles [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6 [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity [complications] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Valine [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013028146</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013028146/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>384</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">384</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Takagi, H.</style></author><author><style face="normal" font="default" size="100%">Niwa, M.</style></author><author><style face="normal" font="default" size="100%">Mizuno, Y.</style></author><author><style face="normal" font="default" size="100%">Goto, S. N.</style></author><author><style face="normal" font="default" size="100%">Umemoto, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">627-633</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Benzoates</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Valine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013053080</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013053080/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>385</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">385</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Takiya, L. N.</style></author><author><style face="normal" font="default" size="100%">Peterson, A. M.</style></author><author><style face="normal" font="default" size="100%">Finley, R. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis of interventions for medication adherence to antihypertensives (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1617-1624</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">dosage [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004001739</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004001739/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>386</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">386</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Talbert, R. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Pharmacists Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Pharmacists Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e116-125</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [drug therapy] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Animals[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013044872</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013044872/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>387</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">387</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Taleb, M.</style></author><author><style face="normal" font="default" size="100%">Khuder, S.</style></author><author><style face="normal" font="default" size="100%">Tinkel, J.</style></author><author><style face="normal" font="default" size="100%">Khouri, S. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The diagnostic accuracy of Doppler echocardiography in assessment of pulmonary artery systolic pressure: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Echocardiography</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Echocardiography</style></full-title></periodical><pages><style face="normal" font="default" size="100%">258-265</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination [methods] [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Echocardiography, Doppler [methods] [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [epidemiology] [physiopathology] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Wedge Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013017423</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013017423/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>773</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">773</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tan, Aihua</style></author><author><style face="normal" font="default" size="100%">Xia, Ning</style></author><author><style face="normal" font="default" size="100%">Gao, Feng</style></author><author><style face="normal" font="default" size="100%">Mo, Zengnan</style></author><author><style face="normal" font="default" size="100%">Cao, Yunfei</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiogenesis-inhibitors for metastatic thyroid cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Pathologic [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Thyroid Neoplasms [blood supply] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Endoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007958</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Systemic cytostatic therapies for advanced, metastatic thyroid carcinomas have been poorly effective. Tumor growth and metastasis depend on blood supply and blood vessel formation (angiogenesis). Therefore, inhibition of angiogenesis may represent a promising target for cancer therapy.Objectives: To evaluate the benefits and risks of angiogenesis-inhibitors for metastatic thyroid cancer when given alone, or in combination with chemotherapy or radiotherapy.Search methods: We searched The Cochrane Library (2009, Issue 2), MEDLINE (January 2000 to May 2009) and EMBASE (January 2000 to May 2009) databases and abstracts published in annual proceedings for evidence. Attempts were made to identify studies from references in potentially relevant trials. We also searched for ongoing trials.Selection criteria: We planned to include randomized controlled trials that compared angiogenesis-inhibitors with other treatments, no treatment, or placebo in participants who had pathologically confirmed advanced thyroid cancer.Data collection and analysis: Two authors independently evaluated the search results against the selection criteria. Data extraction and risk of bias assessment were not performed because there were no studies that could be included.Main results: We did not identify any studies which met our full inclusion criteria.Authors&apos; conclusions: There is currently no reliable evidence available from randomized controlled trials regarding the bene?ts and harms of the use of angiogenesis-inhibitors for treating advanced thyroid cancer. Several trials are ongoing.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007958.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007958.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>388</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">388</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tandon, P.</style></author><author><style face="normal" font="default" size="100%">Abraldes, J. G.</style></author><author><style face="normal" font="default" size="100%">Berzigotti, A.</style></author><author><style face="normal" font="default" size="100%">Garcia-Pagan, J. C.</style></author><author><style face="normal" font="default" size="100%">Bosch, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hepatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hepatology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">273-282</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Mineralocorticoid Receptor Antagonists [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010006149</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010006149/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>389</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">389</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tang, S. H.</style></author><author><style face="normal" font="default" size="100%">Zhang, M. M.</style></author><author><style face="normal" font="default" size="100%">Wu, X. J.</style></author><author><style face="normal" font="default" size="100%">Wang, K. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A meta-analysis of the effect and safety of angiotensin II receptor blockers in treatment of portal hypertension in cirrhotic patients (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1013-1018</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver Cirrhosis [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012029530</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012029530/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>390</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">390</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tang, T. Y.</style></author><author><style face="normal" font="default" size="100%">Walsh, S. R.</style></author><author><style face="normal" font="default" size="100%">Gillard, J. H.</style></author><author><style face="normal" font="default" size="100%">Varty, K.</style></author><author><style face="normal" font="default" size="100%">Boyle, J. R.</style></author><author><style face="normal" font="default" size="100%">Gaunt, M. E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Carotid sinus nerve blockade to reduce blood pressure instability following carotid endarterectomy: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Vascular and Endovascular Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Vascular and Endovascular Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">304-311</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anesthetics, Local [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Autonomic Nerve Block</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Sinus [innervation]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Endarterectomy, Carotid [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [etiology] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypotension [etiology] [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Intraoperative Care</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007002970</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007002970/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>391</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">391</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tang, Y. H.</style></author><author><style face="normal" font="default" size="100%">Zhu, W. J.</style></author><author><style face="normal" font="default" size="100%">Wen, T. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Influence of clinically significant portal hypertension on hepatectomy for hepatocellular carcinoma: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Asian Pacific Journal of Cancer Prevention</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Asian Pacific Journal of Cancer Prevention</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1649-1654</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Carcinoma, Hepatocellular</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014020963</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014020963/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>392</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">392</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tang, Z.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Liao, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Associations of polymorphisms in the beta2-adrenergic receptor gene with essential hypertension in Han Chinese population (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular Biology Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecular Biology Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">9339-9345</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Asian Continental Ancestry Group</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Association Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Adrenergic, beta-2 [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012057860</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012057860/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>774</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">774</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Taylor, Fiona</style></author><author><style face="normal" font="default" size="100%">Huffman Mark, D.</style></author><author><style face="normal" font="default" size="100%">Macedo Ana, Filipa</style></author><author><style face="normal" font="default" size="100%">Moore Theresa, H. M.</style></author><author><style face="normal" font="default" size="100%">Burke, Margaret</style></author><author><style face="normal" font="default" size="100%">Davey Smith, George</style></author><author><style face="normal" font="default" size="100%">Ward, Kirsten</style></author><author><style face="normal" font="default" size="100%">Ebrahim, Shah</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Statins for the primary prevention of cardiovascular disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [blood] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol, HDL [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Cholesterol, LDL [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Myocardial Revascularization [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004816</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Reducing high blood cholesterol, a risk factor for cardiovascular disease (CVD) events in people with and without a past history of CVD is an important goal of pharmacotherapy. Statins are the first-choice agents. Previous reviews of the effects of statins have highlighted their benefits in people with CVD. The case for primary prevention was uncertain when the last version of this review was published (2011) and in light of new data an update of this review is required.Objectives: To assess the effects, both harms and benefits, of statins in people with no history of CVD.Search methods: To avoid duplication of effort, we checked reference lists of previous systematic reviews. The searches conducted in 2007 were updated in January 2012. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2022, Issue 4), MEDLINE OVID (1950 to December Week 4 2011) and EMBASE OVID (1980 to 2012 Week 1).There were no language restrictions.Selection criteria: We included randomised controlled trials of statins versus placebo or usual care control with minimum treatment duration of one year and follow-up of six months, in adults with no restrictions on total, low density lipoprotein (LDL) or high density lipoprotein (HDL) cholesterol levels, and where 10% or less had a history of CVD.Data collection and analysis: Two review authors independently selected studies for inclusion and extracted data. Outcomes included all-cause mortality, fatal and non-fatal CHD, CVD and stroke events, combined endpoints (fatal and non-fatal CHD, CVD and stroke events), revascularisation, change in total and LDL cholesterol concentrations, adverse events, quality of life and costs. Odds ratios (OR) and risk ratios (RR) were calculated for dichotomous data, and for continuous data, pooled mean differences (MD) (with 95% confidence intervals (CI)) were calculated. We contacted trial authors to obtain missing data.Main results: The latest search found four new trials and updated follow-up data on three trials included in the original review. Eighteen randomised control trials (19 trial arms; 56,934 participants) were included. Fourteen trials recruited patients with specific conditions (raised lipids, diabetes, hypertension, microalbuminuria). All-cause mortality was reduced by statins (OR 0.86, 95% CI 0.79 to 0.94); as was combined fatal and non-fatal CVD RR 0.75 (95% CI 0.70 to 0.81), combined fatal and non-fatal CHD events RR 0.73 (95% CI 0.67 to 0.80) and combined fatal and non-fatal stroke (RR 0.78, 95% CI 0.68 to 0.89). Reduction of revascularisation rates (RR 0.62, 95% CI 0.54 to 0.72) was also seen. Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects. There was no evidence of any serious harm caused by statin prescription. Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life. Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta-analysis indicate that these benefits are similar in people at lower (&lt; 1% per year) risk of a major cardiovascular event.Authors&apos; conclusions: Reductions in all-cause mortality, major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004816.pub5/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004816.pub5</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>393</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">393</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Taylor, R. S.</style></author><author><style face="normal" font="default" size="100%">Ashton, K. E.</style></author><author><style face="normal" font="default" size="100%">Moxham, T.</style></author><author><style face="normal" font="default" size="100%">Hooper, L.</style></author><author><style face="normal" font="default" size="100%">Ebrahim, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review) (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">843-853</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [epidemiology] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diet, Sodium-Restricted</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011004866</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011004866/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>394</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">394</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tennant, R.</style></author><author><style face="normal" font="default" size="100%">Mohammed, M. A.</style></author><author><style face="normal" font="default" size="100%">Coleman, J. J.</style></author><author><style face="normal" font="default" size="100%">Martin, U.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Monitoring patients using control charts: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal for Quality in Health Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal for Quality in Health Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">187-194</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Asthma [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Function Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring, Physiologic [methods] [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Health Care [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007006224</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007006224/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>395</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">395</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thakkar, V.</style></author><author><style face="normal" font="default" size="100%">Stevens, W. M.</style></author><author><style face="normal" font="default" size="100%">Moore, O. A.</style></author><author><style face="normal" font="default" size="100%">Nikpour, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Internal Medicine Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Internal Medicine Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">751-760</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Screening</style></keyword><keyword><style face="normal" font="default" size="100%">Scleroderma, Systemic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013022479</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013022479/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>396</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">396</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thompson, A. M.</style></author><author><style face="normal" font="default" size="100%">Hu, T.</style></author><author><style face="normal" font="default" size="100%">Eshelbrenner, C. L.</style></author><author><style face="normal" font="default" size="100%">Reynolds, K.</style></author><author><style face="normal" font="default" size="100%">He, J.</style></author><author><style face="normal" font="default" size="100%">Bazzano, L. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Jama</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Jama</style></full-title></periodical><pages><style face="normal" font="default" size="100%">913-922</style></pages><volume><style face="normal" font="default" size="100%">305</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [complications] [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Prehypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [mortality] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011002859</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011002859/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>397</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">397</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thompson, M.</style></author><author><style face="normal" font="default" size="100%">Dana, T.</style></author><author><style face="normal" font="default" size="100%">Bougatsos, C.</style></author><author><style face="normal" font="default" size="100%">Blazina, I.</style></author><author><style face="normal" font="default" size="100%">Norris, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Screening for hypertension in children and adolescents to prevent cardiovascular disease: systematic review for the US Preventive Services Task Force (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Screening</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Healthcare Research and Quality</style></publisher><accession-num><style face="normal" font="default" size="100%">DARE-12013070725</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013070725/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>775</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">775</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thompson, M.</style></author><author><style face="normal" font="default" size="100%">Dana, T.</style></author><author><style face="normal" font="default" size="100%">Bougatsos, C.</style></author><author><style face="normal" font="default" size="100%">Blazina, I.</style></author><author><style face="normal" font="default" size="100%">Norris, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Screening for hypertension in children and adolescents to prevent cardiovascular disease: systematic review for the U.S. Preventive Services Task Force (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Screening</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Healthcare Research and Quality (AHRQ)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32013000756</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000756/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>398</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">398</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thompson, M.</style></author><author><style face="normal" font="default" size="100%">Dana, T.</style></author><author><style face="normal" font="default" size="100%">Bougatsos, C.</style></author><author><style face="normal" font="default" size="100%">Blazina, I.</style></author><author><style face="normal" font="default" size="100%">Norris, S. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Screening for hypertension in children and adolescents to prevent cardiovascular disease (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">490-525</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis] [drug therapy] [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Screening [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Child[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013017332</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013017332/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>776</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">776</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tonia, Thomy</style></author><author><style face="normal" font="default" size="100%">Mettler, Annette</style></author><author><style face="normal" font="default" size="100%">Robert, Nadège</style></author><author><style face="normal" font="default" size="100%">Schwarzer, Guido</style></author><author><style face="normal" font="default" size="100%">Seidenfeld, Jerome</style></author><author><style face="normal" font="default" size="100%">Weingart, Olaf</style></author><author><style face="normal" font="default" size="100%">Hyde, Chris</style></author><author><style face="normal" font="default" size="100%">Engert, Andreas</style></author><author><style face="normal" font="default" size="100%">Bohlius, Julia</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Erythropoietin or darbepoetin for patients with cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anemia [drug therapy] [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Erythrocyte Transfusion [utilization]</style></keyword><keyword><style face="normal" font="default" size="100%">Erythropoietin [adverse effects] [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [blood] [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Recombinant Proteins [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Thromboembolism [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Haematol</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD003407</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant human erythropoiesis stimulating agents (ESAs) and red blood cell transfusions.Objectives: To assess the effects of ESAs to either prevent or treat anaemia in cancer patients.Search methods: This is an update of a Cochrane review first published in 2004. We searched the Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE and other databases. Searches were done for the periods 01/1985 to 12/2001 for the first review, 1/2002 to 04/2005 for the first update and to November 2011 for the current update. We also contacted experts in the field and pharmaceutical companies.Selection criteria: Randomised controlled trials on managing anaemia in cancer patients receiving or not receiving anti-cancer therapy that compared the use of ESAs (plus transfusion if needed).Data collection and analysis: Several review authors assessed trial quality and extracted data. One review author assessed quality assessment and extracted data, a second review author checked for correctness.Main results: This update of the systematic review includes a total of 91 trials with 20,102 participants. Use of ESAs significantly reduced the relative risk of red blood cell transfusions (risk ratio (RR) 0.65; 95% confidence interval (CI) 0.62 to 0.68, 70 trials, N = 16,093). On average, participants in the ESAs group received one unit of blood less than the control group (mean difference (MD) -0.98; 95% CI -1.17 to -0.78, 19 trials, N = 4,715). Haematological response was observed more often in participants receiving ESAs (RR 3.93; 95% CI 3.10 to 3.71, 31 trials, N = 6,413). There was suggestive evidence that ESAs may improve Quality of Life (QoL). There was strong evidence that ESAs increase mortality during active study period (hazard ratio (HR) 1.17; 95% CI 1.06 to 1.29, 70 trials, N = 15,935) and some evidence that ESAs decrease overall survival (HR 1.05; 95% CI 1.00 to 1.11, 78 trials, N = 19,003). The risk ratio for thromboembolic complications was increased in patients receiving ESAs compared to controls (RR 1.52, 95% CI 1.34 to 1.74; 57 trials, N = 15,498). ESAs may also increase the risk for hypertension (fixed-effect model: RR 1.30; 95% CI 1.08 to 1.56; random-effects model: RR 1.12; 95% CI 0.94 to 1.33, 31 trials, N = 7,228) and thrombocytopenia/haemorrhage (RR 1.21; 95% CI 1.04 to 1.42; 21 trials, N = 4,507). There was insufficient evidence to support an effect of ESA on tumour response (fixed-effect RR 1.02; 95% CI 0.98 to 1.06, 15 trials, N = 5,012).Authors&apos; conclusions: ESAs reduce the need for red blood cell transfusions but increase the risk for thromboembolic events and deaths. There is suggestive evidence that ESAs may improve QoL. Whether and how ESAs affects tumour control remains uncertain. The increased risk of death and thromboembolic events should be balanced against the potential benefits of ESA treatment taking into account each patient?s clinical circumstances and preferences. More data are needed for the effect of these drugs on quality of life and tumour progression. Further research is needed to clarify cellular and molecular mechanisms and pathways of the effects of ESAs on thrombogenesis and their potential effects on tumour growth.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003407.pub5/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD003407.pub5</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>399</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">399</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Torres, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Clinical Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1756-1765</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Multicenter Studies as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007003318</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007003318/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>400</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">400</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Touze, E.</style></author><author><style face="normal" font="default" size="100%">Trinquart, L.</style></author><author><style face="normal" font="default" size="100%">Chatellier, G.</style></author><author><style face="normal" font="default" size="100%">Mas, J. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review of the perioperative risks of stroke or death after carotid angioplasty and stenting (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e683-e693</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Angioplasty [adverse effects] [mortality] [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Artery Diseases [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Artery Disease [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Intraoperative Complications [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Postoperative Complications [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Stents [adverse effects] [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010000599</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010000599/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>777</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">777</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tran, K.</style></author><author><style face="normal" font="default" size="100%">Ho, C.</style></author><author><style face="normal" font="default" size="100%">Noorani, H. Z.</style></author><author><style face="normal" font="default" size="100%">Cimon, K.</style></author><author><style face="normal" font="default" size="100%">Hodgson, A.</style></author><author><style face="normal" font="default" size="100%">Coyle, D.</style></author><author><style face="normal" font="default" size="100%">Coyle, K.</style></author><author><style face="normal" font="default" size="100%">Myers, M. G.</style></author><author><style face="normal" font="default" size="100%">Wright, Nljm</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Thiazide diuretics as first-line treatment for hypertension: meta-analysis and economic evaluation (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><pages><style face="normal" font="default" size="100%">72</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride Symporter Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Thiazides [therapeutic use]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">Canadian Agency for Drugs and Technologies in Health (CADTH)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32008000102</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32008000102/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>401</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">401</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Treggiari, M. M.</style></author><author><style face="normal" font="default" size="100%">Walder, B.</style></author><author><style face="normal" font="default" size="100%">Suter, P. M.</style></author><author><style face="normal" font="default" size="100%">Romand, J. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Neurosurgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Neurosurgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">978-984</style></pages><volume><style face="normal" font="default" size="100%">98</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Volume</style></keyword><keyword><style face="normal" font="default" size="100%">Brain [blood supply]</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Ischemia [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Combined Modality Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hemodilution</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Vasospasm, Intracranial [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Vasospasm, Intracranial [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003001039</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003001039/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>402</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">402</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Trinquart, L.</style></author><author><style face="normal" font="default" size="100%">Mounier-Vehier, C.</style></author><author><style face="normal" font="default" size="100%">Sapoval, M.</style></author><author><style face="normal" font="default" size="100%">Gagnon, N.</style></author><author><style face="normal" font="default" size="100%">Plouin, P. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">525-532</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angioplasty, Balloon</style></keyword><keyword><style face="normal" font="default" size="100%">Fibromuscular Dysplasia [complications] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Renovascular [etiology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Artery Obstruction [etiology] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010006620</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010006620/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>403</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">403</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tropeano, A. I.</style></author><author><style face="normal" font="default" size="100%">Saleh, N.</style></author><author><style face="normal" font="default" size="100%">Hawajri, N.</style></author><author><style face="normal" font="default" size="100%">Macquin-Mavier, I.</style></author><author><style face="normal" font="default" size="100%">Maison, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Do all antihypertensive drugs improve carotid intima-media thickness? A network meta-analysis of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Fundamental and Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Fundamental and Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">395-404</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Arteries [drug effects] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Tunica Intima [drug effects] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011002898</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011002898/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>404</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">404</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turnbull, F.</style></author><author><style face="normal" font="default" size="100%">Neal, B.</style></author><author><style face="normal" font="default" size="100%">Algert, C.</style></author><author><style face="normal" font="default" size="100%">Chalmers, J.</style></author><author><style face="normal" font="default" size="100%">Chapman, N.</style></author><author><style face="normal" font="default" size="100%">Cutler, J.</style></author><author><style face="normal" font="default" size="100%">Woodward, M.</style></author><author><style face="normal" font="default" size="100%">MacMahon, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1410-1419</style></pages><volume><style face="normal" font="default" size="100%">165</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005008304</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005008304/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>405</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">405</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turnbull, F.</style></author><author><style face="normal" font="default" size="100%">Neal, B.</style></author><author><style face="normal" font="default" size="100%">Algert, C.</style></author><author><style face="normal" font="default" size="100%">Chalmers, J.</style></author><author><style face="normal" font="default" size="100%">Woodward, M.</style></author><author><style face="normal" font="default" size="100%">MacMahon, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1527-1535</style></pages><volume><style face="normal" font="default" size="100%">362</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Angiotensin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003008694</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003008694/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>406</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">406</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Turpeinen, A. M.</style></author><author><style face="normal" font="default" size="100%">Jarvenpaa, S.</style></author><author><style face="normal" font="default" size="100%">Kautiainen, H.</style></author><author><style face="normal" font="default" size="100%">Korpela, R.</style></author><author><style face="normal" font="default" size="100%">Vapaatalo, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive effects of bioactive tripeptides: a random effects meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">51-56</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Confidence Intervals</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Oligopeptides [administration &amp; dosage] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Animals[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013008804</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013008804/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>407</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">407</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tyagi, A.</style></author><author><style face="normal" font="default" size="100%">Cohen, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Yoga and hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">32-59</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Health Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Life Style</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stress, Psychological [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Yoga</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014021801</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014021801/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>778</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">778</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Uhlig, K.</style></author><author><style face="normal" font="default" size="100%">Balk, E. M.</style></author><author><style face="normal" font="default" size="100%">Patel, K.</style></author><author><style face="normal" font="default" size="100%">Ip, S.</style></author><author><style face="normal" font="default" size="100%">Kitsios, G. D.</style></author><author><style face="normal" font="default" size="100%">Obadan, N. O.</style></author><author><style face="normal" font="default" size="100%">Haynes, S. M.</style></author><author><style face="normal" font="default" size="100%">Stefan, M.</style></author><author><style face="normal" font="default" size="100%">Rao, M.</style></author><author><style face="normal" font="default" size="100%">Kong Win Chang, L.</style></author><author><style face="normal" font="default" size="100%">Gaylor, J.</style></author><author><style face="normal" font="default" size="100%">Iovin, R. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Self-measured blood pressure monitoring: comparative effectiveness (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Healthcare Research and Quality (AHRQ)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000616</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000616/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>408</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">408</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Uhlig, K.</style></author><author><style face="normal" font="default" size="100%">Patel, K.</style></author><author><style face="normal" font="default" size="100%">Ip, S.</style></author><author><style face="normal" font="default" size="100%">Kitsios, G. D.</style></author><author><style face="normal" font="default" size="100%">Balk, E. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">185-194</style></pages><volume><style face="normal" font="default" size="100%">159</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013046150</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013046150/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>779</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">779</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ulug, Pinar</style></author><author><style face="normal" font="default" size="100%">McCaslin James, E.</style></author><author><style face="normal" font="default" size="100%">Stansby, Gerard</style></author><author><style face="normal" font="default" size="100%">Powell Janet, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Endovascular versus conventional medical treatment for uncomplicated chronic type B aortic dissection</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Aneurysm, Dissecting [mortality] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Aortic Aneurysm, Thoracic [mortality] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Endovascular Procedures [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Pvd</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD006512</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Aortic dissection is a potentially life-threatening condition that occurs when a tear forms in the inner lining of the aorta. It has traditionally been treated by blood pressure control (medical treatment) or open surgery, both with high mortality rates. More recently stent-graft repair has been suggested as an alternative.Objectives: To identify the best management for uncomplicated (without rupture of the organs or malperfusion of the extremities) subacute or chronic type B aortic dissection.Search methods: The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched their Specialised Register (last searched May 2012) and CENTRAL (2012, Issue 4). Clinical trials databases were searched for ongoing or unpublished studies.Selection criteria: All randomised controlled trials designed to compare the outcome of uncomplicated (without rupture of the organs or malperfusion of the extremities) chronic (occurring more than two weeks previously) type B aortic dissection when treated by stenting adjunctive to best medical treatment versus best medical treatment alone were included.Data collection and analysis: Data on all cause and aorta-related mortality at two years was collected and analysed. In addition, secondary outcome measures were analysed, including morbidity, complications (additional endovascular or open surgery for rupture, expansion or malperfusion) and quality of life.Main results: A single trial was identified that fulfilled the inclusion criteria (INSTEAD trial). The two-year all cause survival was not statistically significantly different between study groups (95.6% ± 2.5% in the optimised medical therapy (OMT) group and 88.9% ± 3.7% in the thoracic endovascular aneurysm repair (TEVAR) + OMT group; log rank test P = 0.15).Authors&apos; conclusions: Overall, the data at two years were insufficient to make any practice recommendations. However, the data on the anatomic remodeling of dissected aortas observed after TEVAR + OMT is encouraging and future studies should follow up cases for at least five years to see if early endovascular interventions, even in stable initially uncomplicated type B patients, are of long-term benefit.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006512.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD006512.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>409</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">409</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Upadhyay, A.</style></author><author><style face="normal" font="default" size="100%">Earley, A.</style></author><author><style face="normal" font="default" size="100%">Haynes, S. M.</style></author><author><style face="normal" font="default" size="100%">Uhlig, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">541-548</style></pages><volume><style face="normal" font="default" size="100%">154</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [drug therapy] [physiopathology] [urine]</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design [standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011002403</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011002403/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>780</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">780</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Usinger, Lotte</style></author><author><style face="normal" font="default" size="100%">Reimer, Christina</style></author><author><style face="normal" font="default" size="100%">Ibsen, Hans</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Fermented milk for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cultured Milk Products [chemistry]</style></keyword><keyword><style face="normal" font="default" size="100%">Freeze Drying</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008118</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Fermented milk has been suggested to have a blood pressure lowering effect through increased content of proteins and peptides produced during the bacterial fermentation. Hypertension is one of the major risk factors for cardiovascular disease world wide and new blood pressure reducing lifestyle interventions, such as fermented milk, would be of great importance.Objectives: To investigate whether fermented milk or similar products produced by lactobacilli fermentation of milk proteins has any blood pressure lowering effect in humans when compared to no treatment or placebo.Search methods: The Cochrane Central Register of Controlled Trials (CENTRAL), English language databases, including MEDLINE (1966-2011), EMBASE (1974-2011), Cochrane Complementary Medicine Trials Register, Allied and Complementary Medicine (AMED) (1985-2011), Food science and technology abstracts (1969-2011).Selection criteria: Randomised controlled trials; cross over and parallel studies evaluating the effect on blood pressure of fermented milk in humans with an intervention period of 4 weeks or longer.Data collection and analysis: Data was extracted individually by two authors, afterwards agreement had to be obtained before imputation in the review.Main results: A modest overall effect of fermented milk on SBP was found (MD -2.45; 95% CI -4.30 to -0.60), no effect was evident on DBP (MD -0.67; 95% CI -1.48, 0.14).Authors&apos; conclusions: The review does not support an effect of fermented milk on blood pressure. Despite the positive effect on SBP the authors conclude, for several reasons, that fermented milk has no effect on blood pressure. The effect found was very modest and only on SBP, the included studies were very heterogeneous and several with weak methodology. Finally, sensitivity and subgroup analyses could not reproduce the antihypertensive effect. The results do not give notion to the use of fermented milk as treatment for hypertension or as a lifestyle intervention for pre-hypertension nor would it influence population blood pressure.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008118.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008118.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>410</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">410</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vark, L. C.</style></author><author><style face="normal" font="default" size="100%">Bertrand, M.</style></author><author><style face="normal" font="default" size="100%">Akkerhuis, K. M.</style></author><author><style face="normal" font="default" size="100%">Brugts, J. J.</style></author><author><style face="normal" font="default" size="100%">Fox, K.</style></author><author><style face="normal" font="default" size="100%">Mourad, J. J.</style></author><author><style face="normal" font="default" size="100%">Boersma, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Heart Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2088-2097</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">16</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cause of Death</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012041853</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012041853/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>411</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">411</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Varounis, C.</style></author><author><style face="normal" font="default" size="100%">Katsi, V.</style></author><author><style face="normal" font="default" size="100%">Kallikazaros, I. E.</style></author><author><style face="normal" font="default" size="100%">Tousoulis, D.</style></author><author><style face="normal" font="default" size="100%">Stefanadis, C.</style></author><author><style face="normal" font="default" size="100%">Parissis, J.</style></author><author><style face="normal" font="default" size="100%">Lekakis, J.</style></author><author><style face="normal" font="default" size="100%">Siristatidis, C.</style></author><author><style face="normal" font="default" size="100%">Manolis, A. J.</style></author><author><style face="normal" font="default" size="100%">Makris, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">195-198</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Continuous Positive Airway Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep Apnea, Obstructive</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014034087</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014034087/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>412</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">412</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vejakama, P.</style></author><author><style face="normal" font="default" size="100%">Thakkinstian, A.</style></author><author><style face="normal" font="default" size="100%">Lertrattananon, D.</style></author><author><style face="normal" font="default" size="100%">Ingsathit, A.</style></author><author><style face="normal" font="default" size="100%">Ngarmukos, C.</style></author><author><style face="normal" font="default" size="100%">Attia, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diabetologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">566-578</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2 [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Nephropathies [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012010758</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012010758/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>413</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">413</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Verberk, W. J.</style></author><author><style face="normal" font="default" size="100%">Kessels, A. G.</style></author><author><style face="normal" font="default" size="100%">Thien, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Telecare is a valuable tool for hypertension management, a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Blood Pressure Monitoring</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Blood Pressure Monitoring</style></full-title></periodical><pages><style face="normal" font="default" size="100%">149-155</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Determination [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Databases, Bibliographic</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [physiopathology] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Monitoring, Physiologic [instrumentation] [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Telemedicine [instrumentation] [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011005872</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011005872/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>414</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">414</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Verberk, W. J.</style></author><author><style face="normal" font="default" size="100%">Kroon, A. A.</style></author><author><style face="normal" font="default" size="100%">Kessels, A. G.</style></author><author><style face="normal" font="default" size="100%">Leeuw, P. W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Home blood pressure measurement: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American College of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">743-751</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure Monitoring, Ambulatory</style></keyword><keyword><style face="normal" font="default" size="100%">Home Care Services</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005001338</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005001338/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>415</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">415</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Verdecchia, P.</style></author><author><style face="normal" font="default" size="100%">Angeli, F.</style></author><author><style face="normal" font="default" size="100%">Cavallini, C.</style></author><author><style face="normal" font="default" size="100%">Gattobigio, R.</style></author><author><style face="normal" font="default" size="100%">Gentile, G.</style></author><author><style face="normal" font="default" size="100%">Staessen, J. A.</style></author><author><style face="normal" font="default" size="100%">Reboldi, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Heart Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Heart Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">679-688</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Failure [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009104925</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009104925/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>416</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">416</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vergouwen, M. D.</style></author><author><style face="normal" font="default" size="100%">Vermeulen, M.</style></author><author><style face="normal" font="default" size="100%">Haan, R. J.</style></author><author><style face="normal" font="default" size="100%">Levi, M.</style></author><author><style face="normal" font="default" size="100%">Roos, Y. B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Cerebral Blood Flow and Metabolism</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Cerebral Blood Flow and Metabolism</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1293-1308</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Dihydropyridines [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Fibrinolysis [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemia [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Subarachnoid Hemorrhage [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007002282</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007002282/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>417</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">417</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinuesa-Silva, J. M.</style></author><author><style face="normal" font="default" size="100%">Vinuesa-Silva, I.</style></author><author><style face="normal" font="default" size="100%">Pinazo-Duran, M. D.</style></author><author><style face="normal" font="default" size="100%">Soto-Alvarez, J.</style></author><author><style face="normal" font="default" size="100%">Delgado-Ortega, L.</style></author><author><style face="normal" font="default" size="100%">Diaz-Cerezo, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Conjunctival hyperemia with the use of a fixed combination of latanoprost/timolol: systematic review and meta-analysis of clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Archivos de la Sociedad Espanola de Oftalmologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archivos de la Sociedad Espanola de Oftalmologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">199-208</style></pages><volume><style face="normal" font="default" size="100%">84</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Cloprostenol [adverse effects] [analogs &amp; derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Conjunctival Diseases [chemically induced] [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">derivatives [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">dosage [adverse effects] [therapeutic use] [therapeutic use] [therapeutic use] [therapeutic use] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Glaucoma [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperemia [chemically induced] [epidemiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Ocular Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins F, Synthetic [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Quinoxalines [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfonamides [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Thiazines [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Timolol [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009107709</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009107709/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>781</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">781</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wagner Anna Dorothea, A. D. W.</style></author><author><style face="normal" font="default" size="100%">Arnold, Dirk</style></author><author><style face="normal" font="default" size="100%">Grothey Axel, A. G.</style></author><author><style face="normal" font="default" size="100%">Haerting, Johannes</style></author><author><style face="normal" font="default" size="100%">Unverzagt, Susanne</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Anti-angiogenic therapies for metastatic colorectal cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal, Humanized</style></keyword><keyword><style face="normal" font="default" size="100%">Antineoplastic Combined Chemotherapy Protocols [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Colorectal Neoplasms [blood supply] [drug therapy] [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Combined Modality Therapy [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Disease-Free Survival</style></keyword><keyword><style face="normal" font="default" size="100%">Neovascularization, Pathologic [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Phthalazines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Coloca</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005392</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Angiogenesis inhibitors have been developed to block tumour angiogenesis and target vascular endothelial cells. While some of them have already been approved by the health authorities and are successfully integrated into patient care, many others are still under development, and the clinical value of this approach has to be established.Objectives: To assess the efficacy and toxicity of targeted anti-angiogenic therapies, in addition to chemotherapy, in patients with metastatic colorectal cancer. Primary endpoints are both progression-free and overall survival. Response rates, toxicity and secondary resectability were secondary endpoints. Comparisons were first-line chemotherapy in combination with angiogenesis inhibitor, to the same chemotherapy without angiogenesis inhibitor; and second-line chemotherapy, to the same chemotherapy without angiogenesis inhibitor.Search methods: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, as well as proceedings from ECCO, ESMO and ASCO until November 2008. In addition, reference lists from trials were scanned, experts in the field and drug manufacturers were contacted to obtain further information.Selection criteria: Randomized controlled trials on targeted anti-angiogenic drugs in metastatic colorectal cancer (MCRC).Data collection and analysis: Data collection and analysis was performed, according to a previously published protocol. Because individual patient data was not provided, aggregate data had to be used for the analysis. Summary statistics for the primary endpoints were hazard ratios (HR&apos;s) and their 95% confidence intervals.Main results: At present, eligible first line trials for this meta-analysis were available for bevacizumab (5 trials including 3101 patients) and vatalanib (1 trial which included 1168 patients). The overall HR´s for PFS (0.61, 95% CI 0.45 - 0.83) and OS (0.81, 95% 0.73 - 0.90) for the comparison of first-line chemotherapy, with or without bevacizumab, confirms significant benefits in favour of the patients treated with bevacizumab. However, the effect on PFS shows significant heterogeneity. For second-line chemotherapy, with or without bevacizumab, a benefit in both PFS (HR 0.61, 95% CI 0.51 - 0.73) and OS (HR 0.75, 95% CI 0.63-0.89) was demonstrated in a single, randomized trial. While differences in treatment-related deaths and 60-day mortality were not significant, higher incidences in grade III/IV hypertension, arterial thrombembolic events and gastrointestinal perforations were observed in the patients treated with bevacizumab. For valatanib, currently available data showed a non-significant benefit in PFS and OS.Authors&apos; conclusions: The addition of bevacizumab to chemotherapy of metastatic colorectal cancer prolongs both PFS and OS in first-and second-line therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005392.pub3/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005392.pub3</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>418</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">418</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wahabi, H. A.</style></author><author><style face="normal" font="default" size="100%">Alansary, L. A.</style></author><author><style face="normal" font="default" size="100%">Al-Sabban, A. H.</style></author><author><style face="normal" font="default" size="100%">Glasziuo, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effectiveness of Hibiscus sabdariffa in the treatment of hypertension: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Phytomedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Phytomedicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">83-86</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hibiscus</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Plant Extracts [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutic Equivalency</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010001557</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010001557/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>782</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">782</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wakai, Abel</style></author><author><style face="normal" font="default" size="100%">McCabe, Aileen</style></author><author><style face="normal" font="default" size="100%">Roberts, Ian</style></author><author><style face="normal" font="default" size="100%">Schierhout, Gillian</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mannitol for acute traumatic brain injury</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries [complications] [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics, Osmotic [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Mannitol [administration &amp; dosage] [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Pentobarbital [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Saline Solution, Hypertonic [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Inj</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD001049</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Mannitol is sometimes effective in reversing acute brain swelling, but its effectiveness in the ongoing management of severe head injury remains unclear. There is evidence that, in prolonged dosage, mannitol may pass from the blood into the brain, where it might cause increased intracranial pressure.Objectives: To assess the effects of different mannitol therapy regimens, of mannitol compared to other intracranial pressure (ICP) lowering agents, and to quantify the effectiveness of mannitol administration given at other stages following acute traumatic brain injury.Search methods: We searched the Cochrane Injuries Group Specialised Register, CENTRAL (The Cochrane Library), MEDLINE (OvidSP), EMBASE (OvidSP), ISI Web of Science (SCI-EXPANDED &amp; CPCI-S) and PubMed. We checked reference lists of trials and review articles, and contacted authors of trials. The search was updated on the 20th April 2009.Selection criteria: Randomised controlled trials of mannitol, in patients with acute traumatic brain injury of any severity. The comparison group could be placebo-controlled, no drug, different dose, or different drug. We excluded cross-over trials, and trials where the intervention was started more than eight weeks after injury.Data collection and analysis: We independently rated quality of allocation concealment and extracted the data. Relative risks (RR) and 95% confidence intervals (CI) were calculated for each trial on an intention to treat basis.Main results: We identified four eligible randomised controlled trials. One trial compared ICP-directed therapy to &apos;standard care&apos; (RR for death = 0.83; 95% CI 0.47 to 1.46). One trial compared mannitol to pentobarbital (RR for death = 0.85; 95% CI 0.52 to 1.38). One trial compared mannitol to hypertonic saline (RR for death = 1.25; 95% CI 0.47 to 3.33). One trial tested the effectiveness of pre-hospital administration of mannitol against placebo (RR for death = 1.75; 95% CI 0.48 to 6.38).Authors&apos; conclusions: Mannitol therapy for raised ICP may have a beneficial effect on mortality when compared to pentobarbital treatment, but may have a detrimental effect on mortality when compared to hypertonic saline. ICP-directed treatment shows a small beneficial effect compared to treatment directed by neurological signs and physiological indicators. There are insufficient data on the effectiveness of pre-hospital administration of mannitol.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001049.pub5/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001049.pub5</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>783</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">783</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walters Julia, A. E.</style></author><author><style face="normal" font="default" size="100%">Walters, E. Haydn</style></author><author><style face="normal" font="default" size="100%">Wood-Baker, Richard</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Oral corticosteroids for stable chronic obstructive pulmonary disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenal Cortex Hormones [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary Disease, Chronic Obstructive [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD005374</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Chronic obstructive pulmonary disease (COPD) is a common chronic lung disorder, usually related to cigarette smoking, representing a major and increasing cause of morbidity and mortality. It is defined &quot;as a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases&quot;. The use of corticosteroids for their anti-inflammatory effects has been suggested.Objectives: To assess the effects of oral corticosteroids on the health status of patients with stable COPD.Search methods: Searches of the Cochrane Airways Group Specialised Register and MEDLINE were carried out in December 2003 and 2004. Review articles and bibliographies were searched.Selection criteria: Randomised controlled prospective studies in adults with stable COPD ( post-bronchodilator FEV1 &lt;80% of predicted, FEV1/FVC &lt;70%) and a history of smoking, excluding known asthmatics, in which oral steroid use was compared with placebo and use of co-interventions was matched in both groups.Data collection and analysis: Data was extracted independently by two reviewers. All trials were combined using Review Manager.Main results: From 459 titles 24 studies met the inclusion criteria. Treatment lasted three weeks or less in 19 studies, high dose oral steroid was used in 21 studies and subjects had moderate or severe COPD in 15 studies. There was a significant difference in FEV1 after two weeks treatment, WMD 53.30 ml; 95% confidence interval 22.21 to 84.39 favouring oral steroid use compared to placebo when 14 studies with available data (n=396) were combined, with no significant heterogeneity. There was a significant increase in odds for individual patient FEV1 response greater than 20% from baseline with high dose oral steroid treatment compared to placebo, OR 2.71; 95% CI 1.84 to 4.01 (9 studies) . It would be necessary to treat 7 patients (95% CI 5 to 12) with oral corticosteroids to achieve one extra case of increasing FEV1 by more than 20%, with a placebo group risk of 0.13. All differences in health-related quality of life were less than the minimum clinically important difference.There were small statistically significant advantages for functional capacity and respiratory symptom of wheeze with oral steroid treatment but no significant difference in risk of withdrawal from study due to an exacerbation or rate of serious exacerbations over 2 years with low dose oral steroid treatment. There was an increased risk of adverse effects, including increased blood glucose, adrenal suppression and reduced serum osteocalcin.Authors&apos; conclusions: There is no evidence to support the long-term use of oral steroids at doses less than 10-15 mg prednisolone though some evidence that higher doses (? 30 mg prednisolone) improve lung function over a short period. Potentially harmful adverse effects e.g.. diabetes, hypertension, osteoporosis would prevent recommending long-term use at these high doses in most patients.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005374/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD005374</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>419</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">419</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, B.</style></author><author><style face="normal" font="default" size="100%">Zhong, J.</style></author><author><style face="normal" font="default" size="100%">Lin, H.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z.</style></author><author><style face="normal" font="default" size="100%">Yan, Z.</style></author><author><style face="normal" font="default" size="100%">He, H.</style></author><author><style face="normal" font="default" size="100%">Ni, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, D.</style></author><author><style face="normal" font="default" size="100%">Zhu, Z.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetes Obesity and Metabolism</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diabetes Obesity and Metabolism</style></full-title></periodical><pages><style face="normal" font="default" size="100%">737-749</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 1 [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Glucagon-Like Peptide 1 [analogs and derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Peptides</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Glucagon [agonists]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013043594</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013043594/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>420</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">420</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Liu, K.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Lou, Y.</style></author><author><style face="normal" font="default" size="100%">Niu, Q.</style></author><author><style face="normal" font="default" size="100%">Gu, W.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Li, M.</style></author><author><style face="normal" font="default" size="100%">Zhu, X.</style></author><author><style face="normal" font="default" size="100%">Wen, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Beta1-adrenoceptor gene Arg389Gly polymorphism and essential hypertension risk in general population: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular Biology Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecular Biology Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">4055-4063</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amino Acid Substitution [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Frequency [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Adrenergic, beta-1 [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sample Size</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013020670</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013020670/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>421</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">421</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, H.</style></author><author><style face="normal" font="default" size="100%">Tang, Y.</style></author><author><style face="normal" font="default" size="100%">Rong, X.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Pan, R.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Peng, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of early blood pressure lowering on early and long-term outcomes after acute stroke: an updated meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e97917</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014034875</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014034875/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>422</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">422</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Feng, B.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chinese herbal medicine for the treatment of obesity-related hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">757540</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013041468</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013041468/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>423</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">423</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Feng, B.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Yu, G.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tianma Gouteng Yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">706125</style></pages><volume><style face="normal" font="default" size="100%">2013</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013029442</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013029442/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>424</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">424</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Feng, B.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Teng, F.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tai Chi for essential hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">215254</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Tai Ji</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013050815</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013050815/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>425</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">425</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Feng, B.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chinese herbal medicine for the treatment of prehypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">493521</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013042220</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013042220/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>426</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">426</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Acupuncture for essential hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">317-326</style></pages><volume><style face="normal" font="default" size="100%">169</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acupuncture Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013056131</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013056131/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>427</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">427</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chinese patent medicine tongxinluo capsule for hypertension: a systematic review of randomised controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">187979</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014022211</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014022211/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>428</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">428</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author><author><style face="normal" font="default" size="100%">Yang, G.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chinese herbal medicine qi ju di huang wan for the treatment of essential hypertension: a systematic review of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">262685</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013041964</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013041964/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>429</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">429</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Is it a new approach for treating senile hypertension with kidney-tonifying Chinese herbal formula? A systematic review of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">473038</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014022202</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014022202/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>430</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">430</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Feng, B.</style></author><author><style face="normal" font="default" size="100%">Qian, W.</style></author><author><style face="normal" font="default" size="100%">Fang, Z.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Chu, F.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Is yangxue qingnao granule combined with antihypertensive drugs, a new integrative medicine therapy, more effective than antihypertensive therapy alone in treating essential hypertension? (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">540613</style></pages><volume><style face="normal" font="default" size="100%">2013</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013018158</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013018158/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>431</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">431</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Yao, K.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Feng, B.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Du, X.</style></author><author><style face="normal" font="default" size="100%">Wang, P.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chinese patent medicine Liu Wei Di Huang Wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">714805</style></pages><volume><style face="normal" font="default" size="100%">2012</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013003945</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013003945/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>432</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">432</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, J. G.</style></author><author><style face="normal" font="default" size="100%">Staessen, J. A.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Bortel, L. M.</style></author><author><style face="normal" font="default" size="100%">Nawrot, T.</style></author><author><style face="normal" font="default" size="100%">Fagard, R.</style></author><author><style face="normal" font="default" size="100%">Messerli, F. H.</style></author><author><style face="normal" font="default" size="100%">Safar, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stroke</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1933-1940</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Arteries [drug effects] [pathology] [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Carotid Stenosis [pathology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control [ultrasonography]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Disease [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Complications [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperplasia</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [statistics &amp; numerical data]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Tunica Intima [drug effects] [ultrasonography] [ultrastructure]</style></keyword><keyword><style face="normal" font="default" size="100%">Tunica Media [drug effects] [ultrasonography] [ultrastructure]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006003641</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006003641/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>433</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">433</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Zhao, J. W.</style></author><author><style face="normal" font="default" size="100%">Liu, B.</style></author><author><style face="normal" font="default" size="100%">Shi, D.</style></author><author><style face="normal" font="default" size="100%">Zou, Z.</style></author><author><style face="normal" font="default" size="100%">Shi, X. Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Cardiovascular Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Cardiovascular Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">335-344</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Imidazoles [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012046379</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012046379/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>434</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">434</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, N.</style></author><author><style face="normal" font="default" size="100%">Hu, X.</style></author><author><style face="normal" font="default" size="100%">Liu, C.</style></author><author><style face="normal" font="default" size="100%">Ali, B.</style></author><author><style face="normal" font="default" size="100%">Guo, X.</style></author><author><style face="normal" font="default" size="100%">Liu, M.</style></author><author><style face="normal" font="default" size="100%">Peng, X.</style></author><author><style face="normal" font="default" size="100%">Yang, Y. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review of the diagnostic accuracy of cardiovascular magnetic resonance for pulmonary hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">455-463</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cardiac Catheterization</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Ventricles [pathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Likelihood Functions</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging, Cine</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014024336</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014024336/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>435</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">435</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, R. C.</style></author><author><style face="normal" font="default" size="100%">Jiang, F. M.</style></author><author><style face="normal" font="default" size="100%">Zheng, Q. L.</style></author><author><style face="normal" font="default" size="100%">Li, C. T.</style></author><author><style face="normal" font="default" size="100%">Peng, X. Y.</style></author><author><style face="normal" font="default" size="100%">He, C. Y.</style></author><author><style face="normal" font="default" size="100%">Luo, J.</style></author><author><style face="normal" font="default" size="100%">Liang, Z. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Respiratory Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Respiratory Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines</style></keyword><keyword><style face="normal" font="default" size="100%">Purines</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfones</style></keyword><keyword><style face="normal" font="default" size="100%">Vasodilator Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014009656</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014009656/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>436</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">436</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, X.</style></author><author><style face="normal" font="default" size="100%">Ding, X.</style></author><author><style face="normal" font="default" size="100%">Tong, Y.</style></author><author><style face="normal" font="default" size="100%">Zong, J.</style></author><author><style face="normal" font="default" size="100%">Zhao, X.</style></author><author><style face="normal" font="default" size="100%">Ren, H.</style></author><author><style face="normal" font="default" size="100%">Li, Q.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Intracranial Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Ketamine</style></keyword><keyword><style face="normal" font="default" size="100%">Narcotics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014034766</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014034766/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>784</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">784</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Yajun</style></author><author><style face="normal" font="default" size="100%">Shang, Hongcai</style></author><author><style face="normal" font="default" size="100%">Guo, Yi</style></author><author><style face="normal" font="default" size="100%">Wu, Taixiang</style></author><author><style face="normal" font="default" size="100%">Tian, Lixin</style></author><author><style face="normal" font="default" size="100%">Zhang, Junhua</style></author><author><style face="normal" font="default" size="100%">Wang, Wen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tai Chi for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009349</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To evaluate the effectiveness and safety of Tai Chi for treating hypertension.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009349/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009349</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>437</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">437</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Z.</style></author><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Nie, W.</style></author><author><style face="normal" font="default" size="100%">Huang, G.</style></author><author><style face="normal" font="default" size="100%">Tang, J.</style></author><author><style face="normal" font="default" size="100%">Guan, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">225-231</style></pages><volume><style face="normal" font="default" size="100%">70</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylurea Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013062326</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013062326/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>785</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">785</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wardle Andrew, J.</style></author><author><style face="normal" font="default" size="100%">Tulloh Robert, M. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Guanylate cyclase stimulators for pulmonary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Airways</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD011205</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the efficacy of soluble guanylate cyclase (sGC) stimulators in all aetiological types of pulmonary hypertension (PH).</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011205/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD011205</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>438</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">438</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wardt, V.</style></author><author><style face="normal" font="default" size="100%">Logan, P.</style></author><author><style face="normal" font="default" size="100%">Conroy, S.</style></author><author><style face="normal" font="default" size="100%">Harwood, R.</style></author><author><style face="normal" font="default" size="100%">Gladman, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive treatment in people with dementia (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">620-629</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Dementia</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014027721</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014027721/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">439</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Warsi, A.</style></author><author><style face="normal" font="default" size="100%">Wang, P. S.</style></author><author><style face="normal" font="default" size="100%">LaValley, M. P.</style></author><author><style face="normal" font="default" size="100%">Avorn, J.</style></author><author><style face="normal" font="default" size="100%">Solomon, D. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Self-management education programs in chronic disease: a systematic review and methodological critique of the literature (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1641-1649</style></pages><volume><style face="normal" font="default" size="100%">164</style></volume><number><style face="normal" font="default" size="100%">15</style></number><keywords><keyword><style face="normal" font="default" size="100%">Arthritis [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Asthma [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Self Care</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12004008614</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12004008614/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>440</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">440</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Webb, A. J.</style></author><author><style face="normal" font="default" size="100%">Fischer, U.</style></author><author><style face="normal" font="default" size="100%">Mehta, Z.</style></author><author><style face="normal" font="default" size="100%">Rothwell, P. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">906-915</style></pages><volume><style face="normal" font="default" size="100%">375</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [classification] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010001533</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010001533/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>786</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">786</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wegmann, M.</style></author><author><style face="normal" font="default" size="100%">Thomas, S.</style></author><author><style face="normal" font="default" size="100%">Deuber, H. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal denervation in patients with essential hypertonia (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Renal</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle Denervation</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle Hypertonia</style></keyword><keyword><style face="normal" font="default" size="100%">Sympathectomy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32011001035</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32011001035/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>441</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">441</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wen-Peng, C.</style></author><author><style face="normal" font="default" size="100%">Bing, D.</style></author><author><style face="normal" font="default" size="100%">Ling, Q.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A meta-analysis of the efficacy and safety of candesartan in Chinese patients with mild to moderate essential hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">African Journal of Pharmacy and Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">African Journal of Pharmacy and Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1012-1019</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Biphenyl Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011005956</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011005956/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>787</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">787</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">West Sarah, C.</style></author><author><style face="normal" font="default" size="100%">Tejani Aaron, M.</style></author><author><style face="normal" font="default" size="100%">Stabler Sarah, N.</style></author><author><style face="normal" font="default" size="100%">Tsang Matthew, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Eplerenone for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008996</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the effect of eplerenone as monotherapy compared to placebo in adults (of varying age and race) with essential hypertension (with and without co-morbidities) on: mortality morbidity systolic and diastolic blood pressure To determine whether eplerenone is associated with an increased incidence of withdrawals due to adverse effects compared to placebo. mortality morbidity systolic and diastolic blood pressure</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008996/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008996</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>442</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">442</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Whelton, S. P.</style></author><author><style face="normal" font="default" size="100%">Hyre, A. D.</style></author><author><style face="normal" font="default" size="100%">Pedersen, B.</style></author><author><style face="normal" font="default" size="100%">Yi, Y.</style></author><author><style face="normal" font="default" size="100%">Whelton, P. K.</style></author><author><style face="normal" font="default" size="100%">He, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">475-481</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Fiber [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12005000297</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12005000297/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>443</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">443</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">White, A. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A review of controlled trials of acupuncture for women&apos;s reproductive health care (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Family Planning and Reproductive Health Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Family Planning and Reproductive Health Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">233-236</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acupuncture Therapy [methods] [standards]</style></keyword><keyword><style face="normal" font="default" size="100%">control [therapy] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Dysmenorrhea [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Infertility, Female [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Menopause</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Women&apos;s Health</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12003006823</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12003006823/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>788</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">788</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wieland, L. Susan</style></author><author><style face="normal" font="default" size="100%">Falzon, Louise</style></author><author><style face="normal" font="default" size="100%">Sciamanna Chris, N.</style></author><author><style face="normal" font="default" size="100%">Trudeau Kimberlee, J.</style></author><author><style face="normal" font="default" size="100%">Brodney Folse, Suzanne</style></author><author><style face="normal" font="default" size="100%">Schwartz Joseph, E.</style></author><author><style face="normal" font="default" size="100%">Davidson Karina, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interactive computer-based interventions for weight loss or weight maintenance in overweight or obese people</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Weight Loss</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Overweight [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy, Computer-Assisted [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Endoc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007675</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: The World Health Organization (WHO) estimates that the number of obese or overweight individuals worldwide will increase to 1.5 billion by 2015. Chronic diseases associated with overweight or obesity include diabetes, heart disease, hypertension and stroke.Objectives: To assess the effects of interactive computer-based interventions for weight loss or weight maintenance in overweight or obese people.Search methods: We searched several electronic databases, including CENTRAL, MEDLINE, EMBASE, CINAHL, LILACS and PsycINFO, through 25 May 2011. We also searched clinical trials registries to identify studies. We scanned reference lists of included studies and relevant systematic reviews.Selection criteria: Studies were included if they were randomized controlled trials or quasi-randomized controlled trials that evaluated interactive computer-based weight loss or weight maintenance programs in adults with overweight or obesity. We excluded trials if the duration of the intervention was less than four weeks or the loss to follow-up was greater than 20% overall.Data collection and analysis: Two authors independently extracted study data and assessed risk of bias. Where interventions, control conditions, outcomes and time frames were similar between studies, we combined study data using meta-analysis.Main results: We included 14 weight loss studies with a total of 2537 participants, and four weight maintenance studies with a total of 1603 participants. Treatment duration was between four weeks and 30 months. At six months, computer-based interventions led to greater weight loss than minimal interventions (mean difference (MD) -1.5 kg; 95% confidence interval (CI) -2.1 to -0.9; two trials) but less weight loss than in-person treatment (MD 2.1 kg; 95% CI 0.8 to 3.4; one trial). At six months, computer-based interventions were superior to a minimal control intervention in limiting weight regain (MD -0.7 kg; 95% CI -1.2 to -0.2; two trials), but not superior to infrequent in-person treatment (MD 0.5 kg; 95% -0.5 to 1.6; two trials). We did not observe consistent differences in dietary or physical activity behaviors between intervention and control groups in either weight loss or weight maintenance trials. Three weight loss studies estimated the costs of computer-based interventions compared to usual care, however two of the studies were 11 and 28 years old, and recent advances in technology render these estimates unlikely to be applicable to current or future interventions, while the third study was conducted in active duty military personnel, and it is unclear whether the costs are relevant to other settings. One weight loss study reported the cost-effectiveness ratio for a weekly in-person weight loss intervention relative to a computer-based intervention as USD 7177 (EUR 5678) per life year gained (80% CI USD 3055 to USD 60,291 (EUR 2417 to EUR 47,702)). It is unclear whether this could be extrapolated to other studies. No data were identified on adverse events, morbidity, complications or health-related quality of life.Authors&apos; conclusions: Compared to no intervention or minimal interventions (pamphlets, usual care), interactive computer-based interventions are an effective intervention for weight loss and weight maintenance. Compared to in-person interventions, interactive computer-based interventions result in smaller weight losses and lower levels of weight maintenance. The amount of additional weight loss, however, is relatively small and of brief duration, making the clinical significance of these differences unclear.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007675.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007675.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>444</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">444</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wiens, M.</style></author><author><style face="normal" font="default" size="100%">Etminan, M.</style></author><author><style face="normal" font="default" size="100%">Gill, S. S.</style></author><author><style face="normal" font="default" size="100%">Takkouche, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">350-362</style></pages><volume><style face="normal" font="default" size="100%">260</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic alpha-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Fractures, Bone [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride Symporter Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12006007361</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12006007361/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>445</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">445</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wilhelm, S. M.</style></author><author><style face="normal" font="default" size="100%">Young, J.</style></author><author><style face="normal" font="default" size="100%">Kale-Pradhan, P. B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effect of bariatric surgery on hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">674-682</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bariatric Surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014021703</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014021703/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">446</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Witham, M. D.</style></author><author><style face="normal" font="default" size="100%">Nadir, M. A.</style></author><author><style face="normal" font="default" size="100%">Struthers, A. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of vitamin D on blood pressure: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1948-1954</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin D [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin D Deficiency [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamins [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009110439</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009110439/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>789</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">789</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wiysonge Charles, Shey</style></author><author><style face="normal" font="default" size="100%">Bradley Hazel, A.</style></author><author><style face="normal" font="default" size="100%">Volmink, Jimmy</style></author><author><style face="normal" font="default" size="100%">Mayosi Bongani, M.</style></author><author><style face="normal" font="default" size="100%">Mbewu, Anthony</style></author><author><style face="normal" font="default" size="100%">Opie Lionel, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Beta-blockers for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Atenolol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Disease [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Arrest [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD002003</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: This review is an update of the Cochrane Review published in 2007, which assessed the role of beta-blockade as first-line therapy for hypertension.Objectives: To quantify the effectiveness and safety of beta-blockers on morbidity and mortality endpoints in adults with hypertension.Search methods: In December 2011 we searched the Cochrane Central Register of Controlled Trials, Medline, Embase, and reference lists of previous reviews; for eligible studies published since the previous search we conducted in May 2006.Selection criteria: Randomised controlled trials (RCTs) of at least one year duration, which assessed the effects of beta-blockers compared to placebo or other drugs, as first-line therapy for hypertension, on mortality and morbidity in adults.Data collection and analysis: We selected studies and extracted data in duplicate. We expressed study results as risk ratios (RR) with 95% confidence intervals (CI) and combined them using the fixed-effects or random-effects method, as appropriate.Main results: We included 13 RCTs which compared beta-blockers to placebo (4 trials, N=23,613), diuretics (5 trials, N=18,241), calcium-channel blockers (CCBs: 4 trials, N=44,825), and renin-angiotensin system (RAS) inhibitors (3 trials, N=10,828). Three-quarters of the 40,245 participants on beta-blockers used atenolol. Most studies had a high risk of bias; resulting from various limitations in study design, conduct, and data analysis.Total mortality was not significantly different between beta-blockers and placebo (RR 0.99, 95%CI 0.88 to 1.11; I2=0%), diuretics or RAS inhibitors, but was higher for beta-blockers compared to CCBs (RR 1.07, 95%CI 1.00 to 1.14; I2=2%). Total cardiovascular disease (CVD) was lower for beta-blockers compared to placebo (RR 0.88, 95%CI 0.79 to 0.97; I2=21%). This is primarily a reflection of the significant decrease in stroke (RR 0.80, 95%CI 0.66 to 0.96; I2=0%), since there was no significant difference in coronary heart disease (CHD) between beta-blockers and placebo. There was no significant difference in withdrawals from assigned treatment due to adverse events between beta-blockers and placebo (RR 1.12, 95%CI 0.82 to 1.54; I2=66%).The effect of beta-blockers on CVD was significantly worse than that of CCBs (RR 1.18, 95%CI 1.08-1.29; I2=0%), but was not different from that of diuretics or RAS inhibitors. In addition, there was an increase in stroke in beta-blockers compared to CCBs (RR 1.24, 95%CI 1.11-1.40; I2=0%) and RAS inhibitors (RR 1.30, 95%CI 1.11 to 1.53; I2=29%). However, CHD was not significantly different between beta-blockers and diuretics, CCBs or RAS inhibitors. Participants on beta-blockers were more likely to discontinue treatment due to adverse events than those on RAS inhibitors (RR 1.41, 95% CI 1.29 to 1.54; I2=12%), but there was no significant difference with diuretics or CCBs.Authors&apos; conclusions: Initiating treatment of hypertension with beta-blockers leads to modest reductions in cardiovascular disease and no significant effects on mortality. These effects of beta-blockers are inferior to those of other antihypertensive drugs. The GRADE quality of this evidence is low, implying that the true effect of beta-blockers may be substantially different from the estimate of effects found in this review. Further research should be of high quality and should explore whether there are differences between different sub-types of beta-blockers or whether beta-blockers have differential effects on younger and elderly patients.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002003.pub4/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD002003.pub4</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>790</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">790</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wolff, T.</style></author><author><style face="normal" font="default" size="100%">Miller, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evidence for the reaffirmation of the U.S. Preventive Services Task Force recommendation on screening for high blood pressure (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [diagnosis] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Screening [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><publisher><style face="normal" font="default" size="100%">Agency for Healthcare Research and Quality (AHRQ)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32011000587</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32011000587/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>447</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">447</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wong, C. L.</style></author><author><style face="normal" font="default" size="100%">Holroyd-Leduc, J.</style></author><author><style face="normal" font="default" size="100%">Thorpe, K. E.</style></author><author><style face="normal" font="default" size="100%">Straus, S. E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Does this patient have bacterial peritonitis or portal hypertension: how do I perform a paracentesis and analyze the results? (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Jama</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Jama</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1166-1178</style></pages><volume><style face="normal" font="default" size="100%">299</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Ascitic Fluid [chemistry] [cytology] [microbiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections [blood] [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis, Differential</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrogen-Ion Concentration</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal [blood] [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Neutrophils</style></keyword><keyword><style face="normal" font="default" size="100%">Paracentesis [adverse effects] [contraindications] [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Peritoneal Cavity</style></keyword><keyword><style face="normal" font="default" size="100%">Peritonitis [blood] [diagnosis] [microbiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Serum Albumin [analysis]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008106402</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008106402/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>791</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">791</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wong Gavin, W. K.</style></author><author><style face="normal" font="default" size="100%">Boyda Heidi, N.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-1 Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007450</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Partial agonists are a subclass of beta blockers used to treat hypertension in many countries. Partial agonist act by stimulating beta receptors when they are quiescent and blocking beta receptors when they are active. The blood pressure (BP) lowering effect of partial agonist beta blockers has not been quantified.Objectives: To quantify the dose-related effects of various partial agonists beta blockers on systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate versus placebo in patients with primary hypertension.Search methods: We searched the Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, EMBASE and ClinicalTrials.gov for randomized controlled trials up to October 2014. The WHO International Clinical Trials Registry Platform (ICTRP) is searched for inclusion in the Group&apos;s Specialised Register.Selection criteria: Randomized double-blinded placebo-controlled parallel or cross-over trials. Studies must contain a partial agonist monotherapy arm with fixed dose. Patients enrolled into the studies must have primary hypertension at baseline (defined as SBP/DBP &gt; 140/90 mmHg). Duration of studies must be between three to 12 weeks.Data collection and analysis: Two authors (GW and HB) confirmed the inclusion of studies and extracted the data independently.Main results: Thirteen randomized double-blinded placebo-controlled trials that examined the blood pressure lowering efficacy of six partial agonists in 605 hypertensive patients were included in this review. Five of the included studies were parallel studies and the other eight were cross-over studies. The overall risk of bias is high in this review due to the small sample size and high risk of detection bias. Pindolol, celiprolol and alprenolol lowered SBP and DBP compared to placebo. Acebutolol lowered SBP but there was no clear evidence that it lowered DBP. There was no clear evidence that pindolol and oxprenolol lowered SBP or DBP. Other than for celiprolol, sample sizes were generally small increasing the uncertainty in findings for individual agents versus placebo. In patients with moderate to severe hypertension, partial agonists (considered as a subclass) lowered peak BP by an average of 8 mmHg systolic (95% CI, -10 to -6, very low quality evidence), 4 mmHg diastolic (95%CI, -5 to -3, very low quality evidence) and reduced heart rate by five beats per minute (95%CI, -6 to -4, very low quality evidence). Higher dose partial agonists did not appear to provide additional BP lowering effects compared to lower dose. The maximum BP lowering effect of the overall subclass occurred at the starting dose. Partial agonists reduced pulse pressure by 4 mmHg (95% CI, -5 to -2, very low evidence). Only one study reported withdrawal due to adverse effects, the risk ratio (95% confidence interval) was 0.72 (0.07, 7.67).Authors&apos; conclusions: There was very low quality evidence that in patients with moderate to severe hypertension, partial agonists lowered peak BP by an average of 8/4 mmHg and reduced heart rate by five beats per minute. There was no evidence of a greater effect at doses higher than the initial doses. This estimate was probably exaggerated as it was subject to a high risk of bias. Based on the indirect comparison of the results in this review and two Cochrane reviews on angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), which also used similar inclusion criteria as this review, the BP lowering effect appeared to be less than the effect in patients with mild to moderate elevated BP who were taking ACE inhibitors and ARBs based on an indirect comparison. Withdrawals due to adverse effects were only reported in one trial so it is impossible to assess the harm of these drugs.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007450.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007450.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>792</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">792</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wong Gavin, W. K.</style></author><author><style face="normal" font="default" size="100%">Laugerotte, Alexandra</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007449</style></accession-num><abstract><style face="normal" font="default" size="100%">: This is the protocol for a review and there is no abstract. The objectives are as follows:Primary objective: To quantify the dose-related effects of various doses and types of dual alpha and beta adrenergic receptor blockers on systolic and diastolic blood pressure versus placebo in patients with primary hypertension.Secondary objectives: To determine the effects of dual alpha and beta adrenergic receptor blockers on variability of blood pressure. To determine the effects of dual alpha and beta adrenergic receptor blockers on pulse pressure. To quantify the dose-related effects of dual alpha and beta adrenergic receptor blockers on heart rate. To quantify the effects of dual alpha and beta adrenergic receptor blockers in different doses on withdrawals due to adverse events.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007449/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007449</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>793</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">793</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wong Gavin, W. K.</style></author><author><style face="normal" font="default" size="100%">Laugerotte, Alexandra</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007451</style></accession-num><abstract><style face="normal" font="default" size="100%">: This is the protocol for a review and there is no abstract. The objectives are as follows:Primary objective: To quantify the dose-related effects of various doses and types of beta-1 selective beta adrenergic receptor blockers on systolic and diastolic blood pressure versus placebo in patients with primary hypertension.Secondary objectives: To determine the effects of beta-1 selective beta adrenergic receptor blockers on variability of blood pressure. To determine the effects of beta-1 selective beta adrenergic receptor blockers on pulse pressure. To quantify the dose-related effects of beta-1 selective beta adrenergic receptor blockers on heart rate. To quantify the effects of beta-1 selective beta adrenergic receptor blockers in different doses on withdrawals due to adverse events.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007451/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007451</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>794</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">794</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wong Gavin, W. K.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007452</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Beta-blockers are one of the classes of drugs frequently used to treat hypertension. Quantifying the blood pressure (BP) lowering effects of nonselective beta-blockers provides important information that aids clinical decision making.Objectives: To quantify the dose-related effects of nonselective beta-adrenergic receptor blockers (beta-blockers) on systolic blood pressure (SBP) and diastolic blood pressure (DBP) as compared with placebo in people with primary hypertension.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and ClinicalTrials.gov for randomized controlled trials up to October 2013.Selection criteria: Randomized, double-blind, placebo-controlled, parallel or cross-over trials. Studies had to contain a nonselective beta-blocker monotherapy arm with a fixed dose. Participants enrolled into the studies had to have primary hypertension at baseline. Duration of studies had to be between three and 12 weeks.Data collection and analysis: Two review authors (GW and AL) independently confirmed the inclusion of studies and extracted the data.Main results: We included 25 RCTs that evaluated the BP lowering effects of seven nonselective beta-blockers in 1264 people with hypertension. Among the 25 RCTs, four were parallel studies and 21 were cross-over studies. Overall, nonselective beta-blockers lowered systolic BP and diastolic BP compared with placebo. Nonselective beta-blockers, in the recommended dose range, did not showed a convincing dose-response relationship by direct comparison. The once (1x) and twice (2x) starting dose subgroups contained the largest sample size. The estimate of BP lowering efficacy for nonselective beta-blockers by combining the 1x and 2x starting dose subgroup was -10 mmHg (95% CI -11 to -8) for systolic BP and -7 mmHg (95% CI -8 to -6) for diastolic BP (low-quality evidence). Nonselective beta-blockers starting at the 1x recommended starting doses lowered heart rate by 12 beats per minute (95% CI 10 to 13) (low-quality evidence). The dose-response relationship in heart rate was evident by both direct and indirect comparison. Due to imprecision, there was no clear evidence of an effect of nonselective beta-blockers on pulse pressure in any dose subgroups except for a small reduction with the 2x starting dose (-2.2 mmHg, 95% CI -3.7 to -0.7) (very low quality evidence). The point estimates in the 1x, four times (4x) and eight times (8x) starting dose subgroups were similar to the 2x starting dose subgroup. Therefore, it would appear that if nonselective beta-blockers do lower pulse pressure, the magnitude is likely to be about 2 mmHg. There were very limited data (two studies) on withdrawals due to adverse effects (risk ratio (RR) 0.84; 95% CI 0.38 to 1.82).Authors&apos; conclusions: In people with mild-to-moderate hypertension, nonselective beta-blockers lowered peak BP by a mean of -10/-7 mmHg (systolic/diastolic) and reduced heart rate by 12 beats per minute. Propranolol and penbutolol were the two drugs that contributed to most of the data for nonselective beta-blockers. This estimate is likely exaggerated due to the presence of extreme outliers and other sources of bias. If we removed the extreme outliers from the analysis, the estimate for non-selective beta-blockers was lower (-8/-5 mmHg (systolic/diastolic)). Nonselective beta-blockers did not show a convincing graded dose-response in the recommended dose range for systolic BP and diastolic BP, while higher dose nonselective beta-blockers provided greater reduction of heart rate. Using higher dose nonselective beta-blockers might cause more side effects, such as bradycardia, without producing an additional BP lowering effect. The effect of nonselective beta-blockers on pulse pressure was likely small, at about 2 mmHg.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007452.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007452.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>795</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">795</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wright James, M.</style></author><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">First-line drugs for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic beta-Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Coronary Disease [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride Symporter Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD001841</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Sustained elevated blood pressure, unresponsive to lifestyle measures, leads to a critically important clinical question: What class of drug to use first-line? This review answers that question.Objectives: Primary objective: To quantify the benefits and harms of the major first-line anti-hypertensive drug classes: thiazides, beta-blockers, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, alpha-blockers, and angiotensin II receptor blockers (ARB).Search methods: Electronic search of MEDLINE (Jan. 1966-June 2008), EMBASE, CINAHL, the Cochrane clinical trial register, using standard search strategy of the hypertension review group with additional terms.Selection criteria: Randomized trials of at least one year duration comparing one of 6 major drug classes with a placebo or no treatment. More than 70% of people must have BP &gt;140/90 mmHg at baseline.Data collection and analysis: The outcomes assessed were mortality, stroke, coronary heart disease (CHD), cardiovascular events (CVS), decrease in systolic and diastolic blood pressure, and withdrawals due to adverse drug effects. Risk ratio (RR) and a fixed effects model were used to combine outcomes across trials.Main results: Of 57 trials identified, 24 trials with 28 arms, including 58,040 patients met the inclusion criteria. Thiazides (19 RCTs) reduced mortality (RR 0.89, 95% CI 0.83, 0.96), stroke (RR 0.63, 95% CI 0.57, 0.71), CHD (RR 0.84, 95% CI 0.75, 0.95) and CVS (RR 0.70, 95% CI 0.66, 0.76). Low-dose thiazides (8 RCTs) reduced CHD (RR 0.72, 95% CI 0.61, 0.84), but high-dose thiazides (11 RCTs) did not (RR 1.01, 95% CI 0.85, 1.20). Beta-blockers (5 RCTs) reduced stroke (RR 0.83, 95% CI 0.72, 0.97) and CVS (RR 0.89, 95% CI 0.81, 0.98) but not CHD (RR 0.90, 95% CI 0.78, 1.03) or mortality (RR 0.96, 95% CI 0.86, 1.07). ACE inhibitors (3 RCTs) reduced mortality (RR 0.83, 95% CI 0.72-0.95), stroke (RR 0.65, 95% CI 0.52-0.82), CHD (RR 0.81, 95% CI 0.70-0.94) and CVS (RR 0.76, 95% CI 0.67-0.85). Calcium-channel blocker (1 RCT) reduced stroke (RR 0.58, 95% CI 0.41, 0.84) and CVS (RR 0.71, 95% CI 0.57, 0.87) but not CHD (RR 0.77 95% CI 0.55, 1.09) or mortality (RR 0.86 95% CI 0.68, 1.09). No RCTs were found for ARBs or alpha-blockers.Authors&apos; conclusions: First-line low-dose thiazides reduce all morbidity and mortality outcomes. First-line ACE inhibitors and calcium channel blockers may be similarly effective but the evidence is less robust. First-line high-dose thiazides and first-line beta-blockers are inferior to first-line low-dose thiazides.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001841.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001841.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>448</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">448</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, F. B.</style></author><author><style face="normal" font="default" size="100%">Zhan, M.</style></author><author><style face="normal" font="default" size="100%">Tang, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Irbesartan for hypertensive patients with hyperuricaemia: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1290-1294</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Biphenyl Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperuricemia</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012000081</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012000081/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>449</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">449</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, H. D.</style></author><author><style face="normal" font="default" size="100%">Xu, G. L.</style></author><author><style face="normal" font="default" size="100%">Qin, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis on effectiveness and safety of irbesarten/hydrochlorothiazide combination therapy in treatment of essential hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Jilin University (Medicine Edition)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Jilin University (Medicine Edition)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">517-522</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Biphenyl Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011004262</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011004262/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">450</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, H. Y.</style></author><author><style face="normal" font="default" size="100%">Huang, J. W.</style></author><author><style face="normal" font="default" size="100%">Lin, H. J.</style></author><author><style face="normal" font="default" size="100%">Liao, W. C.</style></author><author><style face="normal" font="default" size="100%">Peng, Y. S.</style></author><author><style face="normal" font="default" size="100%">Hung, K. Y.</style></author><author><style face="normal" font="default" size="100%">Wu, K. D.</style></author><author><style face="normal" font="default" size="100%">Tu, Y. K.</style></author><author><style face="normal" font="default" size="100%">Chien, K. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Bmj</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bmj</style></full-title></periodical><pages><style face="normal" font="default" size="100%">f6008</style></pages><volume><style face="normal" font="default" size="100%">347</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adrenergic Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Bayes Theorem</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channels [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Creatinine [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Angiopathies [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic Nephropathies [complications] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Failure, Chronic [complications] [mortality]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013061330</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013061330/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>451</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">451</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, S.</style></author><author><style face="normal" font="default" size="100%">Chen, J. J.</style></author><author><style face="normal" font="default" size="100%">Kudelka, A.</style></author><author><style face="normal" font="default" size="100%">Lu, J.</style></author><author><style face="normal" font="default" size="100%">Zhu, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet Oncology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet Oncology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">117-123</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiogenesis Inhibitors [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antineoplastic Agents [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzenesulfonates [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Niacinamide [analogs &amp; derivatives]</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylurea Compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Pyridines [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008009289</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008009289/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>452</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">452</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, S. H.</style></author><author><style face="normal" font="default" size="100%">Ho, S. C.</style></author><author><style face="normal" font="default" size="100%">Zhong, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of vitamin D supplementation on blood pressure (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Southern Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Southern Medical Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">729-737</style></pages><volume><style face="normal" font="default" size="100%">103</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Diastole [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Systole [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin D [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010006322</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010006322/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>453</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">453</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, X.</style></author><author><style face="normal" font="default" size="100%">Jiang, X.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Systematic review and meta analysis of randomized controlled trials on Tianmagouteng decoction in treatment of primary hypertension with liver Yang hyperactivity syndrome (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Traditional Chinese Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Traditional Chinese Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">15-18</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Yin-Yang</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013022343</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013022343/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>454</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">454</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, X.</style></author><author><style face="normal" font="default" size="100%">Yang, T.</style></author><author><style face="normal" font="default" size="100%">Zhou, Q.</style></author><author><style face="normal" font="default" size="100%">Li, S.</style></author><author><style face="normal" font="default" size="100%">Huang, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Heart Failure</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Heart Failure</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Heart Failure, Systolic</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphodiesterase 5 Inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014009613</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014009613/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>455</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">455</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xi, G. L.</style></author><author><style face="normal" font="default" size="100%">Cheng, J. W.</style></author><author><style face="normal" font="default" size="100%">Lu, G. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">546-552</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzoates [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Losartan [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008104212</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008104212/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>456</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">456</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xia, Z. Q.</style></author><author><style face="normal" font="default" size="100%">Dong, B. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of different doses of metoprolol in the treatment of primary hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">802-809</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Metoprolol [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007004187</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007004187/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>457</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">457</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xing, X. Q.</style></author><author><style face="normal" font="default" size="100%">Han, B.</style></author><author><style face="normal" font="default" size="100%">Wu, X. W.</style></author><author><style face="normal" font="default" size="100%">Xiao, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, S. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of prostacyclins therapy in pulmonary arterial hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">African Journal of Pharmacy and Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">African Journal of Pharmacy and Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2199-2208</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">20</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins I</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012000025</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012000025/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>458</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">458</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xiong, X.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Feng, B.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Moxibustion for essential hypertension (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Complementary Therapies in Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Complementary Therapies in Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">187-195</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Moxibustion</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014015800</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014015800/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>459</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">459</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xiong, X.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Feng, B.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Duan, L.</style></author><author><style face="normal" font="default" size="100%">Gao, A.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Du, X.</style></author><author><style face="normal" font="default" size="100%">Li, N.</style></author><author><style face="normal" font="default" size="100%">Wang, P.</style></author><author><style face="normal" font="default" size="100%">Su, K.</style></author><author><style face="normal" font="default" size="100%">Chu, F.</style></author><author><style face="normal" font="default" size="100%">Zhang, G.</style></author><author><style face="normal" font="default" size="100%">Li, X.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Zhen gan xi feng decoction, a traditional chinese herbal formula, for the treatment of essential hypertension: a systematic review of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">982380</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013020945</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013020945/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>460</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">460</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xiong, X.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Feng, B.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Du, X.</style></author><author><style face="normal" font="default" size="100%">Wang, P.</style></author><author><style face="normal" font="default" size="100%">Chu, F.</style></author><author><style face="normal" font="default" size="100%">Li, J.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Banxia baizhu tianma decoction for essential hypertension: a systematic review of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-Based Complementary and Alternative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">271462</style></pages><volume><style face="normal" font="default" size="100%">2012</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013003300</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013003300/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>461</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">461</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xiong, X. J.</style></author><author><style face="normal" font="default" size="100%">Liu, W.</style></author><author><style face="normal" font="default" size="100%">Yang, X. C.</style></author><author><style face="normal" font="default" size="100%">Feng, B.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y. Q.</style></author><author><style face="normal" font="default" size="100%">Li, S. J.</style></author><author><style face="normal" font="default" size="100%">Li, X. K.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ginkgo biloba extract for essential hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1131-1136</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Ginkgo biloba</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014036410</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014036410/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>462</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">462</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, F. Y.</style></author><author><style face="normal" font="default" size="100%">Yang, B.</style></author><author><style face="normal" font="default" size="100%">Shi, D.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Zou, Z.</style></author><author><style face="normal" font="default" size="100%">Shi, X. Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">195-205</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acrylates [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Imidazoles [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Thiophenes [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012011997</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012011997/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>463</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">463</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, G.</style></author><author><style face="normal" font="default" size="100%">Wu, H.</style></author><author><style face="normal" font="default" size="100%">Du, B.</style></author><author><style face="normal" font="default" size="100%">Qin, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The efficacy and safety of cilnidipine on mild to moderate essential hypertension: a systematic review and meta-analysis of randomized controlled trials in Chinese patients (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Cardiovascular and Hematological Disorders Drug Targets</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cardiovascular and Hematological Disorders Drug Targets</style></full-title></periodical><pages><style face="normal" font="default" size="100%">56-62</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Dihydropyridines [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic [standards]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012050789</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012050789/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>464</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">464</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, J.</style></author><author><style face="normal" font="default" size="100%">Qin, L.</style></author><author><style face="normal" font="default" size="100%">Want, P.</style></author><author><style face="normal" font="default" size="100%">Li, W.</style></author><author><style face="normal" font="default" size="100%">Chang, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">933-940</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects] [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Diastole</style></keyword><keyword><style face="normal" font="default" size="100%">dosage [pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [diet therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Milk Proteins [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Systole</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Aged[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009102458</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009102458/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>465</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">465</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xu, L. J.</style></author><author><style face="normal" font="default" size="100%">Meng, Q.</style></author><author><style face="normal" font="default" size="100%">He, S. W.</style></author><author><style face="normal" font="default" size="100%">Yin, X. L.</style></author><author><style face="normal" font="default" size="100%">Tang, Z. L.</style></author><author><style face="normal" font="default" size="100%">Bo, H. Y.</style></author><author><style face="normal" font="default" size="100%">Lan, X. Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effects of health education on patients with hypertension in China: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Education Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Education Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">137-149</style></pages><volume><style face="normal" font="default" size="100%">73</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014016422</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014016422/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>796</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">796</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xue, Hao</style></author><author><style face="normal" font="default" size="100%">Lu, Zhuang</style></author><author><style face="normal" font="default" size="100%">Tang Wen, Lu</style></author><author><style face="normal" font="default" size="100%">Pang Lu, Wei</style></author><author><style face="normal" font="default" size="100%">Wang Gan, Mi</style></author><author><style face="normal" font="default" size="100%">Wong Gavin, W. K.</style></author><author><style face="normal" font="default" size="100%">Wright James, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008170</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Renin-angiotensin system (RAS) inhibitors are widely prescribed for treatment of hypertension, especially for diabetic patients on the basis of postulated advantages for the reduction of diabetic nephropathy and cardiovascular morbidity and mortality. Despite widespread use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for hypertension in both diabetic and non-diabetic patients, the efficacy and safety of RAS inhibitors compared to other antihypertensive drug classes remains unclear.Objectives: To evaluate the benefits and harms of first-line RAS inhibitors compared to other first-line antihypertensive drugs in patients with hypertension.Search methods: We searched the Cochrane Hypertension Group&apos;s Specialised Register, MEDLINE, MEDLINE In-Process, EMBASE and ClinicalTrials.gov for randomized controlled trials up to November 19, 2014 and the Cochrane Central Register of Controlled Trials (CENTRAL) up to October 19, 2014. The WHO International Clinical Trials Registry Platform (ICTRP) is searched for inclusion in the Cochrane Hypertension Group&apos;s Specialised Register.Selection criteria: We included randomized, active-controlled, double-blinded studies with at least six months follow-up in people with primary elevated blood pressure (?130/85 mmHg), which compared first-line RAS inhibitors with other first-line antihypertensive drug classes and reported morbidity and mortality or blood pressure outcomes. Patients with proven secondary hypertension were excluded.Data collection and analysis: Two authors independently selected the included trials, evaluated the risk of bias and entered the data for analysis.Main results: We included 42 studies, involving 65,733 participants, with a mean age of 66 years. Much of the evidence for our key outcomes is dominated by a small number of large studies at a low risk of bias for most sources of bias. Imbalances in the added second-line antihypertensive drugs in some of the studies were important enough for us to downgrade the quality of the evidence.Primary outcomes were all-cause death, fatal and non-fatal stroke, fatal and non-fatal myocardial infarction (MI), fatal and non-fatal congestive heart failure (CHF) requiring hospitalization, total cardiovascular (CV) events (consisted of fatal and non-fatal stroke, fatal and non-fatal MI and fatal and non-fatal CHF requiring hospitalizations), and ESRF. Secondary outcomes were systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR).Compared with first-line calcium channel blockers (CCBs), we found moderate quality evidence that first-line RAS inhibitors decreased heart failure (HF) (35,143 participants in 5 RCTs, RR 0.83, 95% CI 0.77 to 0.90, ARR 1.2%), and moderate quality evidence that they increased stroke (34,673 participants in 4 RCTs, RR 1.19, 95% CI 1.08 to 1.32, ARI 0.7%). They had similar effects on all-cause death (35,226 participants in 5 RCTs, RR 1.03, 95% CI 0.98 to 1.09; moderate quality evidence), total CV events (35,223 participants in 6 RCTs, RR 0.98, 95% CI 0.93 to 1.02; moderate quality evidence), total MI (35,043 participants in 5 RCTs, RR 1.01, 95% CI 0.93 to 1.09; moderate quality evidence). The results for ESRF do not exclude potentially important differences (19,551 participants in 4 RCTs, RR 0.88, 95% CI 0.74 to 1.05; low quality evidence).Compared with first-line thiazides, we found moderate quality evidence that first-line RAS inhibitors increased HF (24,309 participants in 1 RCT, RR 1.19, 95% CI 1.07 to 1.31, ARI 1.0%), and increased stroke (24,309 participants in 1 RCT, RR 1.14, 95% CI 1.02 to 1.28, ARI 0.6%). They had similar effects on all-cause death (24,309 participants in 1 RCT, RR 1.00, 95% CI 0.94 to 1.07; moderate quality evidence), total CV events (24,379 participants in 2 RCTs, RR 1.05, 95% CI 1.00 to 1.11; moderate quality evidence), and total MI (24,379 participants in 2 RCTs, RR 0.93, 95% CI 0.86 to 1.01; moderate quality evidence). Results for ESRF do not exclude potentially important differences (24,309 particip nts in 1 RCT, RR 1.10, 95% CI 0.88 to 1.37; low quality evidence).Compared with first-line beta-blockers, we found low quality evidence that first-line RAS inhibitors decreased total CV events (9239 participants in 2 RCTs, RR 0.88, 95% CI 0.80 to 0.98, ARR 1.7%), and low quality evidence that they decreased stroke (9193 participants in 1 RCT, RR 0.75, 95% CI 0.63 to 0.88, ARR 1.7% ). Our analyses do not exclude potentially important differences between first-line RAS inhibitors and beta-blockers on all-cause death (9193 participants in 1 RCT, RR 0.89, 95% CI 0.78 to 1.01; low quality evidence), HF (9193 participants in 1 RCT, RR 0.95, 95% CI 0.76 to 1.18; low quality evidence), and total MI (9239 participants in 2 RCTs, RR 1.05, 95% CI 0.86 to 1.27; low quality evidence).Blood pressure comparisons between RAS inhibitors and other classes showed either no differences or small differences that did not necessarily correlate with the differences in the morbidity outcomes.In the protocol, we identified non-fatal serious adverse events (SAE) as a primary outcome. However, when we extracted the data from included studies, none of them reported total SAE in a manner that could be used in the review. Therefore, there is no information about SAE in the review.Authors&apos; conclusions: We found predominantly moderate quality evidence that all-cause mortality is similar when first-line RAS inhibitors are compared to other first-line antihypertensive agents. First-line thiazides caused less HF and stroke than first-line RAS inhibitors. The quality of the evidence comparing first-line beta-blockers and first-line RAS inhibitors was low and the lower risk of total CV events and stroke seen with RAS inhibitors may change with the publication of additional trials. Compared with first-line CCBs, first-line RAS inhibitors reduced HF but increased stroke. The magnitude of the reduction in HF exceeded the increase in stroke. The small differences in effect on blood pressure between the different classes of drugs did not correlate with the differences in the primary outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008170.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008170.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>797</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">797</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Jie</style></author><author><style face="normal" font="default" size="100%">Feng, Yue</style></author><author><style face="normal" font="default" size="100%">Ying, Li</style></author><author><style face="normal" font="default" size="100%">Liu Guan, J.</style></author><author><style face="normal" font="default" size="100%">Chen, Jiao</style></author><author><style face="normal" font="default" size="100%">Ren, Yu-lan</style></author><author><style face="normal" font="default" size="100%">Liang, Fan-rong</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Acupuncture for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008821</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To quantify the blood pressure lowering effects of acupuncture in adults with primary hypertension.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008821/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008821</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>798</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">798</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Jie</style></author><author><style face="normal" font="default" size="100%">Liu, Ming</style></author><author><style face="normal" font="default" size="100%">Zhou, Junshan</style></author><author><style face="normal" font="default" size="100%">Zhang, Shihong</style></author><author><style face="normal" font="default" size="100%">Lin, Sen</style></author><author><style face="normal" font="default" size="100%">Zhao, Hongdong</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Edaravone for acute intracerebral haemorrhage</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antipyrine [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral Hemorrhage [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Free Radical Scavengers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Stroke</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD007755</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Intracerebral haemorrhage (ICH) causes significant morbidity and mortality. Prognosis for ICH patients is poor. Edaravone may be safe and effective in reducing the risk of early death and improving long-term functional outcomes in survivors.Objectives: To assess the safety and efficacy of edaravone for acute ICH.Search methods: We searched the Cochrane Stroke Group Trials Register (March 2010), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 2 2010), the Chinese Stroke Trials Register (August 2010), MEDLINE (1950 to August 2010), EMBASE (1980 to March 2010) and 12 Chinese databases (August 2010). We also searched ongoing trials registers, reference lists, relevant conference proceedings and contacted companies manufacturing edaravone.Selection criteria: Randomised controlled trials (RCTs) in which edaravone was compared with placebo, or edaravone plus routine treatment was compared with routine treatment alone, in patients with acute ICH.Data collection and analysis: Two review authors independently assessed trial quality and extracted data, collected adverse events data and contacted trialists for missing information.Main results: We included 10 RCTs involving 768 participants; quality was generally poor. For all trials, the control group was usual care/routine therapy (not placebo), treatment allocation and outcome evaluations were not blinded or not described, and the primary outcome (death or dependency at the end of long-term follow-up) was not reported. Only one trial reported deaths, indicating that edaravone treatment did not decrease the number of deaths significantly either during the scheduled treatment (RR 0.62, 95% CI 0.11 to 3.50) or at three month follow-up (RR 0.93, 95% CI 0.20 to 4.32). Four studies assessed activities of daily living (ADL) but ADL score was not improved significantly (MD 21.65, 95% CI -6.98 to 50.28) at the end of long-term follow-up. Combining data from all studies, edaravone treatment did increase the rate of improvement of neurological impairment (RR 1.48, 95% CI 1.29 to 1.69) until the end of the scheduled treatment, but it is not clear that this translates to any longer-term bene?t of clinical importance. Reported adverse events with edaravone were mild and were common (9%), but there was no significant difference in adverse effect between the two groups (RR 2.09, 95% CI 0.71 to 6.19).Authors&apos; conclusions: All 10 studies were inconclusive in finding a beneficial or deleterious effect provided by edaravone for the treatment of ICH. Further high quality, large scale RCTs are required.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007755.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD007755.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>466</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">466</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Xiong, X.</style></author><author><style face="normal" font="default" size="100%">Yang, G.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effectiveness of stimulation of acupoint KI 1 by (Moxa) for the Treatment of Essential Hypertension: A Systematic Review of Randomized Controlled Trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">187484</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acupuncture Points</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisia</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014027886</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014027886/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>467</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">467</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Zhao, H.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Chinese massage (Tuina) for the treatment of essential hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">541-548</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Massage</style></keyword><keyword><style face="normal" font="default" size="100%">Medicine, Chinese Traditional</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014038676</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014038676/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>468</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">468</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, X. C.</style></author><author><style face="normal" font="default" size="100%">Xiong, X. J.</style></author><author><style face="normal" font="default" size="100%">Yang, G. Y.</style></author><author><style face="normal" font="default" size="100%">Wang, H. R.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Songling Xuemaikang capsule for primary hypertension: a systematic review of randomized controlled trials (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Integrative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Integrative Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Captopril</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014017068</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014017068/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>469</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">469</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Wei, R. B.</style></author><author><style face="normal" font="default" size="100%">Xing, Y.</style></author><author><style face="normal" font="default" size="100%">Tang, L.</style></author><author><style face="normal" font="default" size="100%">Zheng, X. Y.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. C.</style></author><author><style face="normal" font="default" size="100%">Gao, Y. W.</style></author><author><style face="normal" font="default" size="100%">Li, M. X.</style></author><author><style face="normal" font="default" size="100%">Chen, X. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Metabolism: Clinical and Experimental</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Metabolism: Clinical and Experimental</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1858-1866</style></pages><volume><style face="normal" font="default" size="100%">62</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Glucose</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Insulin Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013056303</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013056303/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>470</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">470</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Z.</style></author><author><style face="normal" font="default" size="100%">Han, G.</style></author><author><style face="normal" font="default" size="100%">Wu, Q.</style></author><author><style face="normal" font="default" size="100%">Ye, X.</style></author><author><style face="normal" font="default" size="100%">Jin, Z.</style></author><author><style face="normal" font="default" size="100%">Yin, Z.</style></author><author><style face="normal" font="default" size="100%">Qi, X.</style></author><author><style face="normal" font="default" size="100%">Bai, M.</style></author><author><style face="normal" font="default" size="100%">Wu, K.</style></author><author><style face="normal" font="default" size="100%">Fan, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Gastroenterology and Hepatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Gastroenterology and Hepatology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1718-1725</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hepatic Encephalopathy [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal [mortality] [surgery]</style></keyword><keyword><style face="normal" font="default" size="100%">Polytetrafluoroethylene</style></keyword><keyword><style face="normal" font="default" size="100%">Portasystemic Shunt, Transjugular Intrahepatic [instrumentation] [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Stents</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Patency</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010007986</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010007986/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>471</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">471</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yano, Y.</style></author><author><style face="normal" font="default" size="100%">Briasoulis, A.</style></author><author><style face="normal" font="default" size="100%">Bakris, G. L.</style></author><author><style face="normal" font="default" size="100%">Hoshide, S.</style></author><author><style face="normal" font="default" size="100%">Wang, J. G.</style></author><author><style face="normal" font="default" size="100%">Shimada, K.</style></author><author><style face="normal" font="default" size="100%">Kario, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA) (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Society of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Society of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">epub</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013064171</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013064171/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>472</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">472</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yeh, G. Y.</style></author><author><style face="normal" font="default" size="100%">Wang, C.</style></author><author><style face="normal" font="default" size="100%">Wayne, P. M.</style></author><author><style face="normal" font="default" size="100%">Phillips, R. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effect of Tai Chi exercise on blood pressure: a systematic review (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Preventive Cardiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Preventive Cardiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">82-89</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Tai Ji</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009109018</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009109018/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>473</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">473</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yi, H. G.</style></author><author><style face="normal" font="default" size="100%">Huang, G. Z.</style></author><author><style face="normal" font="default" size="100%">Liu, G. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of levoamlodipine besylate for essential hypertension: a systematic review (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Evidence-Based Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">543-550</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amlodipine</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12008104708</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12008104708/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>474</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">474</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yin, L.</style></author><author><style face="normal" font="default" size="100%">Liu, H.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Rong, W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The surgical treatment for portal hypertension: a systematic review and meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">ISRN Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ISRN Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">464053</style></pages><volume><style face="normal" font="default" size="100%">2013</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Esophageal and Gastric Varices</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Portal</style></keyword><keyword><style face="normal" font="default" size="100%">Portasystemic Shunt, Surgical</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Surgical Procedures</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013016855</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013016855/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">475</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yoon, C.</style></author><author><style face="normal" font="default" size="100%">Yang, H. S.</style></author><author><style face="normal" font="default" size="100%">Jeon, I.</style></author><author><style face="normal" font="default" size="100%">Chang, Y.</style></author><author><style face="normal" font="default" size="100%">Park, S. M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">CMAJ: Canadian Medical Association Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CMAJ: Canadian Medical Association Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">E1073-e1084</style></pages><volume><style face="normal" font="default" size="100%">183</style></volume><number><style face="normal" font="default" size="100%">14</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiologic Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Esophageal Neoplasms [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Neoplasms [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011007031</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011007031/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>476</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">476</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yu, C.</style></author><author><style face="normal" font="default" size="100%">Longfei, L.</style></author><author><style face="normal" font="default" size="100%">Long, W.</style></author><author><style face="normal" font="default" size="100%">Feng, Z.</style></author><author><style face="normal" font="default" size="100%">Jiping, N.</style></author><author><style face="normal" font="default" size="100%">Mao, L.</style></author><author><style face="normal" font="default" size="100%">Lin, Q.</style></author><author><style face="normal" font="default" size="100%">Hequn, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review and meta-analysis of new onset hypertension after extracorporeal shock wave lithotripsy (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">International Urology and Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Urology and Nephrology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">719-725</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Lithotripsy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013064076</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013064076/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>799</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">799</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zechmeister-Koss, I.</style></author><author><style face="normal" font="default" size="100%">Reichel, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Renal denervation in patients with essential hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Technology Assessment Database</style></full-title></periodical><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blood Pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Catheter Ablation</style></keyword><keyword><style face="normal" font="default" size="100%">Denervation</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA)</style></publisher><accession-num><style face="normal" font="default" size="100%">HTA-32012000782</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32012000782/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>477</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">477</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, F.</style></author><author><style face="normal" font="default" size="100%">Yang, Y.</style></author><author><style face="normal" font="default" size="100%">Hu, D.</style></author><author><style face="normal" font="default" size="100%">Lei, H.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Lack of an association between TSC gene Arg904Gln polymorphisms and essential hypertension risk based on a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Genetics and Molecular Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Genetics and Molecular Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3511-3517</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style face="normal" font="default" size="100%">Amino Acid Substitution [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Bias (Epidemiology)</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Confidence Intervals</style></keyword><keyword><style face="normal" font="default" size="100%">Genes, Dominant [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Association Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single Nucleotide [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Drug [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium Chloride Symporters [genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013012020</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013012020/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>800</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">800</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang Hong, Wei</style></author><author><style face="normal" font="default" size="100%">Tong, Juan</style></author><author><style face="normal" font="default" size="100%">Zhou, Guangming</style></author><author><style face="normal" font="default" size="100%">Jia, Haizhong</style></author><author><style face="normal" font="default" size="100%">Jiang Johnny, Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tianma Gouteng Yin Formula for treating primary hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Chinese Herbal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD008166</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Tianma Gouteng Yin Formula (TGYF) is widely used to treat hypertension-related symptoms in clinical practice in East Asia. It has been shown to have a blood pressure lowering effect, reducing total cholesterol, improving clinical symptoms and quality of life, and preventing the occurrence of stroke in hypertensive patients. Understanding the effect of Tianma Gouteng Yin Formula on blood pressure, quality of life and cardiovascular risk factors could be valuable for the management of high blood pressure.Objectives: To assess the efficacy and safety of Tianma Gouteng Yin Formula for treating primary hypertension compared to placebo or no treatment.Search methods: English databases including Cochrane Central (CCTR), MEDLINE, EMBASE, AMED, CINAHL, IPA, and the Hypertension Group Specialised Register were searched up to July 2011. Chinese databases including Chinese Biomedical Database, TCMonline , Chinese Dissertation Database, CMAC and the Index to Chinese Periodical Literature were searched up to April 2010.Selection criteria: Randomised and quasi-randomised controlled trials that compared TGYF with no treatment or placebo for primary hypertension.Data collection and analysis: No study was identified which met the inclusion criteria for this review.Main results: No study was identified which met the inclusion criteria for this review.Authors&apos; conclusions: As no trials could be identified, no conclusions can be made about the role of TGYF in the treatment of primary hypertension. Well-designed randomized controlled studies need to be conducted and published.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008166.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008166.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>801</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">801</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang Kevin, L.</style></author><author><style face="normal" font="default" size="100%">Kim, Junghoo</style></author><author><style face="normal" font="default" size="100%">Wong Gavin, W. K.</style></author><author><style face="normal" font="default" size="100%">Musini Vijaya, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Time course for blood pressure lowering of beta one selective blockers</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD010077</style></accession-num><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the temporal blood pressure lowering effects of beta one selective blockers for adult patients with primary hypertension.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010077/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010077</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>802</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">802</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Ling</style></author><author><style face="normal" font="default" size="100%">Zeng, Xiaoxi</style></author><author><style face="normal" font="default" size="100%">Fu, Ping</style></author><author><style face="normal" font="default" size="100%">Wu Hong, Mei</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Renal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD009120</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are widely used in peritoneal dialysis (PD) patients, yet controversy exists about their impact on residual kidney function.Objectives: This review aimed to evaluate the benefits and harms of ACEis and ARBs for preserving residual kidney function in PD patients.Search methods: The Cochrane Renal Group&apos;s specialised register, Cochrane Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE (OvidSP interface), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI) and other resources were searched by applying a prespecified comprehensive search strategy. Date of last search: 01 May 2014.Selection criteria: Randomised controlled trials (RCTs) and quasi-RCTs comparing ACEis or ARBs with placebo, other antihypertensive drugs or each other in PD patients were included.Data collection and analysis: Screening, selection, data extraction and quality assessments for each retrieved article were carried out by two authors using standardised forms. Authors were contacted when published data were incomplete. Statistical analyses were performed using the random effects model and results expressed as risk ratio (RR) with 95% confidence intervals (CI). Heterogeneity among studies was explored using the Cochran Q statistic and the I² test, subgroup analyses and random effects meta-regression.Main results: Six open-label studies (257 patients) were identified. One study compared ACEi with other antihypertensive drugs, three compared ARBs with other antihypertensive drugs, and two studies compared an ARB with an ACEi. Long-term use (? 12 months) of an ARB showed significantly benefit of preserving residual kidney function in continuous ambulatory PD (CAPD) patients (MD 1.11 mL/min/1.73 m², 95% CI 0.38 to 1.83), although there was no significant benefit when an ARB were used short-term (? six months). One study showed that compared with other antihypertensive drugs, long-term use (12 months) of the ACEi ramipril showed a significant reduction in the decline of residual kidney function in patients on CAPD (MD -0.93 mL/min/1.73m², 95% CI -0.75 to -0.11), and delayed the progression to complete anuria (RR 0.64, 95% CI 0.41 to 0.99). There was no significant difference in serum potassium, urinary protein excretion, Kt/V, weekly creatinine clearance and blood pressure for ARBs versus other antihypertensive drugs. Compared with other antihypertensive drugs, ramipril showed no difference in mortality and cardiovascular events. Compared with an ACEi, ARBs did not show any difference in residual kidney function.The selection bias assessment was low in four studies and unclear in two. Five studies were open-label; however the primary outcome (residual kidney function) was obtained objectively from laboratory tests, and were not likely to be influenced by the lack of blinding. Reporting bias was unclear in all six studies.Authors&apos; conclusions: Compared with other antihypertensive drugs, long-term use (? 12 months) of ACEis or ARBs showed additional benefits of preserving residual kidney function in CAPD patients. There was no significant difference on residual kidney function preservation between ARBs and ACEis. However, limited by the small number of RCTs enrolling small number of participants, there is currently insufficient evidence to support the use of an ACEi or an ARB as first line antihypertensive therapy in PD patients.</style></abstract><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009120.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD009120.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>478</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">478</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, R. F.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author><author><style face="normal" font="default" size="100%">Ma, G. F.</style></author><author><style face="normal" font="default" size="100%">Shao, F. C.</style></author><author><style face="normal" font="default" size="100%">Wu, X. H.</style></author><author><style face="normal" font="default" size="100%">Ying, K. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Diagnostic value of transthoracic Doppler echocardiography in pulmonary hypertension: a meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1261-1264</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Echocardiography, Doppler</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [diagnosis]</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011001736</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001736/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>479</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">479</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Wu, Y. M.</style></author><author><style face="normal" font="default" size="100%">Wu, Y. B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review: the effects of T-type CCB or ACEI/ARB for hypertensive patients with chronic kidney disease (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Database of Abstracts of Reviews of Effects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1965-1969</style></pages><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Renal Insufficiency, Chronic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12014016192</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014016192/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>803</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">803</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhao, Ping</style></author><author><style face="normal" font="default" size="100%">Xu, Ping</style></author><author><style face="normal" font="default" size="100%">Wan, Chaomin</style></author><author><style face="normal" font="default" size="100%">Wang, Zhengrong</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evening versus morning dosing regimen drug therapy for hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [physiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Circadian Rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Htn</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><publisher><style face="normal" font="default" size="100%">John Wiley &amp; Sons, Ltd</style></publisher><accession-num><style face="normal" font="default" size="100%">CD004184</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Variation in blood pressure levels display circadian rhythms. The morning surge in blood pressure is known to increase the risk of myocardial events in the first several hours post awakening. A systematic review of the administration-time-related-effects of evening versus morning dosing regimen of antihypertensive drugs in the management of patients with primary hypertension has not been conducted.Objectives: To evaluate the administration-time-related-effects of antihypertensive drugs administered as once daily monotherapy in the evening versus morning administration regimen on all cause mortality, cardiovascular morbidity and reduction of blood pressure in patients with primary hypertension.Search methods: We searched Cochrane CENTRAL on Ovid (4th Quarter 2009), Ovid MEDLINE (1950 to October 2009), EMBASE (1974 to October 2009), the Chinese Biomedical literature database (1978 to 2009) and the reference lists of relevant articles. No language restrictions were applied.Selection criteria: Randomized controlled trials comparing the administration-time-related effects of evening with morning dosing monotherapy regimens in patients with primary hypertension were included. Patients with known secondary hypertension, shift workers or white coat hypertension were excluded.Data collection and analysis: Two authors independently extracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Data synthesis and analysis were done using RevMan 5.1. Random effects meta-analysis and sensitivity analysis were conducted.Main results: 21 randomized controlled trials (RCTs) in 1,993 patients with primary hypertension met the inclusion criteria for this review - ACEIs (5 trials), CCBs (7 trials), ARBs (6 trials), diuretics (2 trials), alpha-blockers (1 trial), and beta-blockers (1 trial). Meta-analysis showed significant heterogeneity across trials.No RCT reported on all cause mortality, cardiovascular mortality, cardiovascular morbidity and serious adverse events.There was no statistically significant difference for overall adverse events (RR=0.78, 95%CI: 0.37 to 1.65) and withdrawals due to adverse events (RR=0.53, 95%CI: 0.26 to 1.07).No significant differences were noted for morning SBP (-1.62 mm Hg, 95% CI: -4.19 to 0.95) and morning DBP (-1.21 mm Hg, 95% CI: -3.28 to 0.86); but 24-hour BP (SBP: -1.71 mm Hg, 95% CI: -2.78 to -0.65; DBP: -1.38 mm Hg, 95% CI: -2.13 to -0.62) showed a statistically significant difference.Authors&apos; conclusions: No RCT reported on clinically relevant outcome measures - all cause mortality, cardiovascular morbidity and morbidity. There were no significant differences in overall adverse events and withdrawals due to adverse events among the evening versus morning dosing regimens. In terms of BP lowering efficacy, for 24-hour SBP and DBP, the data suggests that better blood pressure control was achieved with bedtime dosing than morning administration of antihypertensive medication, the clinical significance of which is not known.</style></abstract><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004184.pub2/abstract</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD004184.pub2</style></electronic-resource-num></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>480</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">480</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, G. Q.</style></author><author><style face="normal" font="default" size="100%">Zhao, Z. M.</style></author><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Gu, Y.</style></author><author><style face="normal" font="default" size="100%">Li, Y.</style></author><author><style face="normal" font="default" size="100%">Chen, X. M.</style></author><author><style face="normal" font="default" size="100%">Fu, S. P.</style></author><author><style face="normal" font="default" size="100%">Shen, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-analysis of scalp acupuncture for acute hypertensive intracerebral hemorrhage (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Alternative and Complementary Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Alternative and Complementary Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">293-299</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acupuncture Therapy [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Intracranial Hemorrhage, Hypertensive [complications] [mortality] [therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases [etiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Scalp</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011002861</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011002861/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>481</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">481</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, Y.</style></author><author><style face="normal" font="default" size="100%">Yang, T.</style></author><author><style face="normal" font="default" size="100%">Chen, G.</style></author><author><style face="normal" font="default" size="100%">Hu, E.</style></author><author><style face="normal" font="default" size="100%">Gu, Q.</style></author><author><style face="normal" font="default" size="100%">Xiong, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">13-21</style></pages><volume><style face="normal" font="default" size="100%">70</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Inhalation</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12013053378</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013053378/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>482</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">482</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, Z.</style></author><author><style face="normal" font="default" size="100%">Lin, S.</style></author><author><style face="normal" font="default" size="100%">Shi, H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review and meta-analysis of telmisartan vs valsartan in the management of essential hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">414-421</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzoates [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Confidence Intervals</style></keyword><keyword><style face="normal" font="default" size="100%">Diastole [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Diuretics [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrochlorothiazide [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Renin-Angiotensin System [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Systole [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Valine [adverse effects] [analogs &amp; derivatives] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12010005902</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12010005902/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>483</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">483</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, Z.</style></author><author><style face="normal" font="default" size="100%">Shi, H.</style></author><author><style face="normal" font="default" size="100%">Jia, J.</style></author><author><style face="normal" font="default" size="100%">Li, D.</style></author><author><style face="normal" font="default" size="100%">Lin, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the Renin-Angiotensin-Aldosterone System</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the Renin-Angiotensin-Aldosterone System</style></full-title></periodical><pages><style face="normal" font="default" size="100%">102-112</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amides [administration &amp; dosage] [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin Receptor Antagonists [administration &amp; dosage] [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage] [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Fumarates [administration &amp; dosage] [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011003857</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011003857/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>484</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">484</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, Z.</style></author><author><style face="normal" font="default" size="100%">Shi, H.</style></author><author><style face="normal" font="default" size="100%">Jia, J.</style></author><author><style face="normal" font="default" size="100%">Li, D.</style></author><author><style face="normal" font="default" size="100%">Lin, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the Renin-Angiotensin-Aldosterone System</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the Renin-Angiotensin-Aldosterone System</style></full-title></periodical><pages><style face="normal" font="default" size="100%">365-374</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Pressure [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Losartan [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Publication Bias</style></keyword><keyword><style face="normal" font="default" size="100%">Regression Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazoles [adverse effects] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011005984</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011005984/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>485</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">485</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhu, B.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">Sun, L.</style></author><author><style face="normal" font="default" size="100%">Cao, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis (Provisional abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Cardiovascular Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Cardiovascular Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">342-346</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [administration &amp; dosage] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Tolerance [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension, Pulmonary [drug therapy] [physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphodiesterase 5 Inhibitors [administration &amp; dosage] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Prostaglandins [administration &amp; dosage] [pharmacology] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, Endothelin [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12012050617</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12012050617/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>486</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">486</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhu, X.</style></author><author><style face="normal" font="default" size="100%">Wu, S.</style></author><author><style face="normal" font="default" size="100%">Dahut, W. L.</style></author><author><style face="normal" font="default" size="100%">Parikh, C. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Kidney Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Kidney Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">186-193</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antibodies, Monoclonal [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria [chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria [epidemiology]</style></keyword><keyword><style face="normal" font="default" size="100%">Proteinuria [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A [antagonists &amp; inhibitors]</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A [immunology]</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A [metabolism]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12007000784</style></accession-num><notes><style face="normal" font="default" size="100%">Exclude</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12007000784/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>487</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">487</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zou, Z.</style></author><author><style face="normal" font="default" size="100%">Xi, G. L.</style></author><author><style face="normal" font="default" size="100%">Yuan, H. B.</style></author><author><style face="normal" font="default" size="100%">Zhu, Q. F.</style></author><author><style face="normal" font="default" size="100%">Shi, X. Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">339-349</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Angiotensin-Converting Enzyme Inhibitors [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Angiotensin II Type 1 Receptor Blockers [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzimidazoles [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Benzoates [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Enalapril [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Lisinopril [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Perindopril [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Ramipril [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12009105786</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12009105786/frame.html</style></url></related-urls></urls></record><record><database name="Cochrane Library CDSR HTA DARE.enl" path="C:\Users\jrathbon\Dropbox\John - Shared folder\Coverage of SR across Bio-med databases\January 2015 searches\15 January 2015 all search results\Cochrane Library CDSR HTA DARE.enl">Cochrane Library CDSR HTA DARE.enl</database><source-app name="EndNote" version="17.2">EndNote</source-app><rec-number>488</rec-number><foreign-keys><key app="EN" db-id="f22zstr5sde09qep5zg5zp2wsr5tdzstpx5z">488</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zou, Z.</style></author><author><style face="normal" font="default" size="100%">Xu, F. Y.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">An, M. M.</style></author><author><style face="normal" font="default" size="100%">Zhang, H.</style></author><author><style face="normal" font="default" size="100%">Shi, X. Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials (Structured abstract)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Human Hypertension</style></full-title></periodical><pages><style face="normal" font="default" size="100%">203-210</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Albuminuria [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Antihypertensive Agents [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">control</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination [adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension [complications] [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Indoles [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Diseases [etiology] [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Verapamil [adverse effects] [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Female[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Male[checkword]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged[checkword]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">DARE-12011001711</style></accession-num><notes><style face="normal" font="default" size="100%">Include</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12011001711/frame.html</style></url></related-urls></urls></record></records></xml>